
<html lang="en"     class="pb-page"  data-request-id="0bcafc65-7bb6-4ff3-b9af-da3c1b2d4ff3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.9b00017;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-20;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms" /></meta><meta name="dc.Creator" content="Junting  Zhou" /></meta><meta name="dc.Creator" content="Xueyang  Jiang" /></meta><meta name="dc.Creator" content="Siyu  He" /></meta><meta name="dc.Creator" content="Hongli  Jiang" /></meta><meta name="dc.Creator" content="Feng  Feng" /></meta><meta name="dc.Creator" content="Wenyuan  Liu" /></meta><meta name="dc.Creator" content="Wei  Qu" /></meta><meta name="dc.Creator" content="Haopeng  Sun" /></meta><meta name="dc.Description" content="Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit satisfactory efficacy. Recently, increasing evidence indicates that simultaneous modulation of multiple t..." /></meta><meta name="Description" content="Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit satisfactory efficacy. Recently, increasing evidence indicates that simultaneous modulation of multiple t..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 13, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00017" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00017" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00017" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00017" /></link>
        
    
    

<title>Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00017" /></meta><meta property="og:title" content="Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0033.jpeg" /></meta><meta property="og:description" content="Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit satisfactory efficacy. Recently, increasing evidence indicates that simultaneous modulation of multiple targets may improve both therapeutic safety and efficacy, compared with single-target drugs. However, few multitarget drugs are on market or in clinical trials, despite the best efforts of medicinal chemists. This article discusses the systematic establishment of target combination, lead generation, and optimization of multitarget-directed ligands (MTDLs). Moreover, we analyze some MTDLs research cases for several complex diseases in recent years and the physicochemical properties of 117 clinical multitarget drugs, with the aim to reveal the trends and insights of the potential use of MTDLs." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit satisfactory efficacy. Recently, increasing evidence indicates that simultaneous modulation of multiple targets may improve both therapeutic safety and efficacy, compared with single-target drugs. However, few multitarget drugs are on market or in clinical trials, despite the best efforts of medicinal chemists. This article discusses the systematic establishment of target combination, lead generation, and optimization of multitarget-directed ligands (MTDLs). Moreover, we analyze some MTDLs research cases for several complex diseases in recent years and the physicochemical properties of 117 clinical multitarget drugs, with the aim to reveal the trends and insights of the potential use of MTDLs." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0033.jpeg" /></meta><meta name="twitter:title" content="Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00017"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00017">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00017&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00017&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00017&amp;href=/doi/10.1021/acs.jmedchem.9b00017" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 8881-8914</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b00179" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Junting Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Junting Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, People’s Republic of China</div><div class="loa-info-affiliations-info">Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Junting++Zhou">Junting Zhou</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xueyang Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xueyang Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, People’s Republic of China</div><div class="loa-info-affiliations-info">Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xueyang++Jiang">Xueyang Jiang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Siyu He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Siyu He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Siyu++He">Siyu He</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongli Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongli Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, People’s Republic of China</div><div class="loa-info-affiliations-info">Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongli++Jiang">Hongli Jiang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Feng Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Feng Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, People’s Republic of China</div><div class="loa-info-affiliations-info">Jiangsu Food and Pharmaceutical Science College, Huaian 223003, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Feng">Feng Feng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenyuan Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenyuan Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Analytical Chemistry, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenyuan++Liu">Wenyuan Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Qu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Qu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>W.Q.: e-mail, <a href="/cdn-cgi/l/email-protection#b8c8d7c8d7c9c2d0f8898a8e96dbd7d5"><span class="__cf_email__" data-cfemail="f5859a859a848f9db5c4c7c3db969a98">[email protected]</span></a>; phone, +86-13852294378.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Qu">Wei Qu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Haopeng Sun</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haopeng Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>H.S.: e-mail, <a href="/cdn-cgi/l/email-protection#760503181e171906131811364740455815191b"><span class="__cf_email__" data-cfemail="cbb8bea5a3aaa4bbaea5ac8bfafdf8e5a8a4a6">[email protected]</span></a>; phone, +86-13951934235.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haopeng++Sun">Haopeng Sun</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5109-0304" title="Orcid link">http://orcid.org/0000-0002-5109-0304</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00017&amp;href=/doi/10.1021%2Facs.jmedchem.9b00017" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 8881–8914</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 13, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 January 2019</li><li><span class="item_label"><b>Published</b> online</span>13 May 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 October 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00017" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00017</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8881%26pageCount%3D34%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJunting%2BZhou%252C%2BXueyang%2BJiang%252C%2BSiyu%2BHe%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D20%26contentID%3Dacs.jmedchem.9b00017%26title%3DRational%2BDesign%2Bof%2BMultitarget-Directed%2BLigands%253A%2BStrategies%2Band%2BEmerging%2BParadigms%26numPages%3D34%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8914%26publicationDate%3DOctober%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00017"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5065</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">59</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00017" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Junting&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Xueyang&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Siyu&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Hongli&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Wenyuan&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Qu&quot;},{&quot;first_name&quot;:&quot;Haopeng&quot;,&quot;last_name&quot;:&quot;Sun&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;8881-8914&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00017&quot;},&quot;abstract&quot;:&quot;Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit satisfactory efficacy. Recently, increasing evidence indicates that simultaneous modulation of multiple targets may improve both therapeutic safety and efficacy, compared with single-target drugs. However, few multitarget drugs are on market or in clinical trials, despite the best efforts of medicinal chemists. This article discusses the systematic establishment of target combination, lead generation, and optimization of multitarget-directed ligands (MTDLs). Moreover, we analyze some MTDLs research cases for several complex diseases in recent years and the physicochemical properties of 117 clinical multitarget drugs, with the aim to reveal the trends and insights of the potential use of MTDLs.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00017&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00017" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00017&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00017" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00017&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00017" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00017&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00017&amp;href=/doi/10.1021/acs.jmedchem.9b00017" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00017" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00017" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00017%26sid%3Dliteratum%253Aachs%26pmid%3D31082225%26genre%3Darticle%26aulast%3DZhou%26date%3D2019%26atitle%3DRational%2BDesign%2Bof%2BMultitarget-Directed%2BLigands%253A%2BStrategies%2Band%2BEmerging%2BParadigms%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D20%26spage%3D8881%26epage%3D8914%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290663" title="Pharmacophores">Pharmacophores</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292202" title="Drug discovery">Drug discovery</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/20" title="Go to Volume 62, Issue 20"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/jmcmar.2019.62.issue-20/20191024/jmcmar.2019.62.issue-20.largecover.jpg" alt="Go to Volume 62, Issue 20"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0033.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit satisfactory efficacy. Recently, increasing evidence indicates that simultaneous modulation of multiple targets may improve both therapeutic safety and efficacy, compared with single-target drugs. However, few multitarget drugs are on market or in clinical trials, despite the best efforts of medicinal chemists. This article discusses the systematic establishment of target combination, lead generation, and optimization of multitarget-directed ligands (MTDLs). Moreover, we analyze some MTDLs research cases for several complex diseases in recent years and the physicochemical properties of 117 clinical multitarget drugs, with the aim to reveal the trends and insights of the potential use of MTDLs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02282" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02282" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The doctrine of “one molecule, one target, one disease” dominated the pharmaceutical industry in the 20th century.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Plenty of successful selective drugs have been developed from this doctrine, which will predominate for certain diseases in the future.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> However, for multifactorial diseases such as cancer,<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a> neurodegenerative disease,<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> cardiovascular disease<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> and infection,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> the initiation and progression involve multiple receptors or signaling pathways. For multifactorial diseases, manipulating a single target does not always lead to satisfactory efficacy, despite the best research efforts.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Hence, there is an increasing interest in developing therapeutics which simultaneously manipulate multiple targets for improving therapeutic efficacy and (or) safety.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">There are two approaches of multitarget therapeutics: the first approach is a mixture of monotherapies, including drug cocktail (combinations of drugs with a single active ingredient, respectively) and combination drug (one formula includes multiple active ingredients), whereas the second approach is multitarget-directed ligands (MTDLs, one tablet, one active ingredient).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The former approach may provide better dose flexibility and lower treatment cost. However, it often suffered from adverse effects and poor patient compliance.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> For instance, the combination of venlafaxine and fluoxetine for depression therapy may cause severe anticholinergic adverse effects.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Furthermore, it often leads to undesired effects such as dose-limiting toxicities, drug–drug interactions, and complex and unpredictable pharmacokinetic (PK)/pharmacodynamic (PD) profiles.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Since 2004, Morphy et al. started to systematically review strategies for multifunctional ligands development.<a onclick="showRef(event, 'ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21 ref22">(18−22)</a> MTDLs are agents that treat multifactorial diseases by interacting with multiple targets involved in pathogenesis.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This strategy could avoid many pitfalls.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> In <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the advantages and disadvantages of the above two approaches are discussed.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Comparison of the Advantages and Disadvantages of Two Multitarget Therapeutics<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">mixture of monotherapies</th><th class="colsep0 rowsep0" align="center">multiple ligands</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="center">Advantages</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1. Can offer better dose flexibility by directly adjust ratio of drugs in mixture.</td><td class="colsep0 rowsep0" align="left">1. They are new chemical entity.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2. Can achieve sequenced administration or adjusting target exposure.</td><td class="colsep0 rowsep0" align="left">2. The programs of development and regulatory approval are standard, same as the single target drugs.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3. Clinical trials may be faster due to clinical experience, and the treatment cost may be lower.</td><td class="colsep0 rowsep0" align="left">3. As a single active component, the PK/PD properties are easier to formulate compared with a mixture.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4. Therapeutic efficacy may increase through synergies even at low dosages.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5. Reduced adverse effects enable wider therapeutic windows.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="center">Disadvantages</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1. “Combination versus parts” factorial trial might be conducted.</td><td class="colsep0 rowsep0" align="left">1. Achieving balanced and multiselective potency toward multiple targets is challenging.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2. Should align PK/PD properties of the multiple components.</td><td class="colsep0 rowsep0" align="left">2. Difficult to achieve sequenced administration at the targets.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3. More likely to cause drug–drug interaction.</td></tr></tbody></table></div></div><div class="NLM_p">To date, some outstanding MTDLs have been in clinical trial stage or approved by regulatory agencies.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> However, many of them were found by serendipity, such as imatinib (a multitarget kinase inhibitor).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The “simple” strategy of making MTDLs by linking two active ligands together usually resulted in very large molecular weight (MW).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> For example, many research studies have published about hybrids of tacrine and other active ligands, which were obtained in linked pharmacophore approach.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Moreover, some lead compounds discovered through phenotypic screening lack definite targets, with high promiscuity and severe adverse effects.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> These problems explain the failures of many MTDLs.</div><div class="NLM_p last">Thus, we believe that multitarget drugs should be designed in a more rational and holistic view of target combination, ligands selection, and the balance of desired activities to maximize developability, efficacy, and safety. In this review, we discuss the above critical issues, analyze the physicochemical properties of 117 clinical multitarget drugs, and go over important references about MTDLs published in recent years to provide a comprehensive compendium of the rational design of MTDLs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  Rational Combination of Multiple Targets for MTDLs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77221" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77221" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The design and validation of target combination is crucial for MTDLs discovery; ideal target combination may provide superior therapeutic efficacy through synergies. It is generally easier to design multitarget ligands for highly related targets in the same superfamily.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> If targets belong to different superfamilies, their endogenous ligand had better be similar or even identical (often a monoamine or an eicosanoid).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> If so, the binding sites of multiple targets are more likely to accommodate a shared ligand frame.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Interestingly, there are also some rare examples whose targets come from different superfamilies, and endogenous ligands are also unrelated.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> In this case, the realistic method could be combining pharmacophores via exploiting the tolerant positions of each component.</div><div class="NLM_p">Nonetheless, for highly similar targets, achieving multiple activities is easy, but formulating optimized selectivity at closely related but undesired targets is the challenge.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Theoretically, undesired but relevant targets had better be as few as possible. But a few examples showed that it was not impossible.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.1.  Target Combination Based on Clinical Observations</h3><div class="NLM_p">Combination therapies such as drug cocktails are common topics of clinical studies, but the issues of complex PK profiles, drug–drug interaction often limit their clinical applications.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> However, the increasing knowledge of enhanced efficacy suggests that the target combination (validated by drug cocktails) may be possible.<a onclick="showRef(event, 'ref26 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref26 ref38 ref39">(26,38,39)</a></div><div class="NLM_p last">A typical example of target combination based on clinical observations is antipsychotic. Initially, the antipsychotics targeting dopamine D<sub>2</sub>-like receptors often cause considerable adverse effects, for example, the extrapyramidal motor symptoms.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The following clinical research found that additional inclusion of antiserotonergic 5-HT<sub>2A</sub> led to improved treatment effect and reduced adverse effects.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Subsequently, the adjustment of potencies toward multiple targets, including agonism on one receptor and partial agonism on another was achieved.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> Such multitarget design driven by clinical observation significantly improved efficacy and reduced adverse effects, and antipsychotic drugs such as cariprazine and aripiprazole are the successful examples.<a onclick="showRef(event, 'ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46">(44−46)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2.  Target Combination Based on Phenotypic Screening</h3><div class="NLM_p">Phenotypic screening is another approach for target combination.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> Cellular, tissue, and animal models can all be used for screening large numbers of compound combinations for synergies.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> But high throughput of putative compounds or target combination requires tremendous animal experiments. Although only a few compounds are tested, different dose combinations would require large animal sample sizes. Therefore, genetic knockdown or knockout of one target is a feasible approach to reduce animal usage, due to the absence of dose combinations.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> For instance, a study used diclofenac (a COX inhibitor) in an inflammatory model using FAAH (−/−) mice to validate the synergistic effect of these two targets.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><div class="NLM_p last">Biological assays that generate multidimensional readouts are usually known as high-content screening, which are valuable approaches for MTDLs discovery.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> If the screening systems are more complex, entire animals may be employed, enabling sophisticated readouts including even behavioral changes.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> For example, fruit fly or zebrafish can be used for the complex screening system.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.3.  Target Combination Based on in Silico Technique</h3><div class="NLM_p last">In silico technique is also a feasible approach for screening suitable target combination.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Many in silico methods<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> are available, such as analysis of biological target networks via machine learning.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The network pharmacology method by analyzing signaling networks is especially valuable.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> However, the hypothetic target combination predicted by computational approaches needs wet-lab validation to confirm its biological foundation and feasibility. For example, the target combination of insulin-like growth factor 1 receptor (IGF1R) and cyclin-dependent kinase 4 (CDK4) was predicted by computational modeling and validated to be synergistic drug targets for DDL in dedifferentiated liposarcoma (DDL)-derived cells.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">3.  Lead Generation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30658" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30658" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">For exploring MTDL lead compounds, there are generally two approaches: screening approaches and knowledge-based approaches.<a onclick="showRef(event, 'ref19 ref20 ref59'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref59">(19,20,59)</a> They usually analyze information in the literature or patent.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.1.  Knowledge-Based Approach</h3><div class="NLM_p">Knowledge-based approach is also known as pharmacophore-based approach, which is currently the predominant method for generating MTDLs.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> This approach combines pharmacophores of selective ligands for multiple targets into a single compound, which integrates the activities of these ligands. In the order of pharmacophore overlap incrementation, the MTDLs are classified into linked, fused, and merged types (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Actually, the level of overlap of the pharmacophores forms a continuum: one extreme is the linked MTDLs with high MW and lengthy linker, whereas the other extreme is the merged MTDLs, which is the result of a high degree of overlap of pharmacophores and obtains smaller MW and simpler structure.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0031.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Multitarget drug design strategy based on pharmacophore.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In linked MTDLs, the pharmacophores are connected by stable or biodegradable linkers. In fused MTDLs, the pharmacophores are attached directly. In merged MTDLs, the pharmacophores are merged together.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">3.1.1.  Linked Pharmacophores</h4><div class="NLM_p">A linked MTDL typically contains underlying pharmacophores separated by a linker that does not exist in any one of the original ligands.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Although this is a straightforward strategy, the position, length, and composition of linkers can be designed to retain the activity of the template scaffolds.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> For instance, the linker should not join a ligand at the position with steric effect. Sometimes, the linker itself works as a pharmacophore by interacting with the target. Therefore, linkers should be tailored so as to enhance interactions between the targets and linkers.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> According to the property of linkers, the linked MTDLs are further divided into two categories: cleavable or noncleavable.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p">However, linked MTDLs are usually too large for favorable bioavailability or accessing intracellular compartments. Moreover, the linker may hinder the interaction between targets and ligands.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Recently, linked pharmacophores become a popular concept: a targeting ligand (e.g., the antibody) is linked to an active molecule, then the targeting ligand delivers the active ligand to a desired target to exert efficacy.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div><div class="NLM_p">The cleavable MTDLs employ a linker that can be degraded to release ligands for corresponding targets, respectively.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In most cases, cleavable MTDLs have an ester linker that can be degraded by plasma esterase, as shown in the example in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>A. Although cleavage might make the PK/PD relationship complex, cleavable MTDLs are regarded as a single active ingredient in the stage of administration. This is one advantage compared with cocktails and multicomponent drugs.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Two Categories of Linked MTDLs: Cleavable MTDLs and Noncleavable MTDLs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Compound <b>3</b> is a cleavable MTDL, with an ester linker that can be hydrolyzed in vivo.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> (B) Compound <b>6</b> is a noncleavable MTDL, the linker of which is stable in vivo.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></p></p></figure><div class="NLM_p">Compound <b>3</b> was reported as a new multitarget therapeutic candidate, which incorporated the pharmacophores of cinnamic acids <b>1</b> (lipoxygenase inhibitors, antioxidants, and anti-inflammatories)<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> and paracetamol <b>2</b> (a nonsteroidal anti-inflammatory drug)<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> via an ester linker. Compound <b>3</b> showed high analgesic activity (91%) suggesting the application in treating peripheral nerve injuries<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>A). This kind of MTDL may be referred to as “mutual prodrug”: after degradation of ester linker, the released ligands will elicit therapeutic effects in distinct pathways.</div><div class="NLM_p">Most reported linked MTDLs are actually noncleavable MTDLs, whose linker is stable in vivo. As single active ingredients, noncleavable MTDLs are able to interact multiple targets and responsible for corresponding activity.</div><div class="NLM_p last">Compound <b>6</b> is a pharmacological hybrid combining H<sub>1</sub> receptor (H<sub>1</sub>R) and H<sub>2</sub>R antagonistic activities. It was designed through linking roxatidine-type H<sub>2</sub>R antagonist (<b>5</b>) pharmacophore with mepyramine-type H<sub>1</sub>R antagonist (<b>4</b>) motif.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> The <i>N</i>-desmethylmepyramine was linked by a polymethylene linker to form the cyanoguanidine motif that was the “urea equivalent” of the H<sub>2</sub>R antagonist moiety. Compound <b>6</b> was the most potent hybrid with p<i>K</i><sub>b</sub> values of 8.42 for H<sub>1</sub>R and 6.43 for H<sub>2</sub>R<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B).</div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">3.1.2.  Fused Pharmacophores</h4><div class="NLM_p">The MTDLs with partially overlapped pharmacophores are classified as fused MTDLs.</div><div class="NLM_p">Compound <b>9</b> was designed by fusing the phenyl from rivastigming (<b>7</b>) and the dihydroindene ring from rasagiline (<b>8</b>). Compound <b>9</b> exhibited both acetylcholinesterase (AChE) and monoamine oxidases (MAOs) activities simultaneously (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>A).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Compound <b>12</b> is a hybrid of curcumin <b>10</b> and melatonin <b>11</b>, two well-studied natural products in Alzheimer’s disease (AD) models. Hybrid <b>12</b> was discovered to exhibit significant neuroprotection and antioxidative activities<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>B).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Structures of Fused Pharmacophores<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>The two pharmacophores are in blue and red; purple illustrates the fused/merged pharmacophore from two selective ligands. (A) Dual cholinesterase/MAO-B inhibitor (<b>9</b>).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> (B) Neuroprotection/antioxidative bisfunctional agent (<b>12</b>).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Both compounds <b>9</b> and <b>12</b> are the products of fused pharmacophores approach.</p></p></figure></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">3.1.3.  Merged Pharmacophores</h4><div class="NLM_p">The MTDLs with merged pharmacophores have the highest level of pharmacophore overlapping. By identification of the “tolerant region” for each receptor and taking advantage of commonalities in each framework of the template ligands, the pharmacophores are highly integrated to obtain smaller MW and simpler structures with optimized physicochemical profiles.</div><div class="NLM_p">Through incorporating the pharmacophore of 3-hydroxy-4-pydinone (for metal chelation) from deferiprone and aminopropoxyphenyl scaffold from a H<sub>3</sub>R antagonist into one molecule, compound <b>16</b> was designed, synthesized, and biologically characterized.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> It shows excellent selective H<sub>3</sub>R antagonism (from compound <b>13</b>), amyloid-β (Aβ) aggregation inhibition (from compound <b>14</b>), metal ion chelation, and radical scavenging (from compound <b>15</b>)<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>A). A site-activated multifunctional candidate for treating AD was reported.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> This research integrated their newly developed bifunctional chelator HLA20 (<b>17</b>) and two marketed drugs, rivastigmine (<b>7</b>) and donepezil (<b>18</b>, an AChE inhibitor). Three moieties (phenyl, carbamyl, and ethylmethylamino moieties) of rivastigmine bound to the active site of AChE; meanwhile, the pharmacophore [(5, 6-dimethoxy-1-indanon-2-yl)methylpiperidine] from donepezil interacted with the middle of AChE gorge and the PAS. The above moieties were merged into the scaffold of <b>17</b>. Compound <b>19</b> showed less cytotoxicity than <b>17</b> and negligible affinity to metal ions, unless it inhibited BuChE and AChE (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>B).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Representative Structures of Merged Pharmacophores<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Multifunctional agent (<b>16</b>) is designed by merging the pharmacophores of the aminopropoxyphenyl scaffolds from compounds <b>13</b>, <b>14</b>, and <b>15</b>.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> (B) Bisfunctional compound <b>19</b> is designed via merging the pharmacophores from chelator HLA20 (<b>17</b>), rivastigmine (<b>7</b>), and donepezil (<b>18</b>).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></p></p></figure></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">3.2.  Screening Approach</h3><div class="NLM_p">The screening approach is another commonly reported strategy for MTDL lead generation.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Actually, focused screening is the main-stream screening strategy instead of “irrational” high throughput screening (HTS). In focused screening, compound classes already identified to be effective toward one of the targets of interest are subsequently screened for another one. It is a favorable approach for targets that are kinases: MTDLs are often identified via cross-screening of compounds in kinase panel profiling.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div><div class="NLM_p">MTDLs produced by screening methods may obtain all activities toward both targets of interest (A and B).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> But the resulting MTDLs are highly unlikely to possess the balanced affinity to multiple targets; therefore, the affinity would need to be optimized on all targets (cf. <a class="ref internalNav" href="#sec4_3" aria-label="section 4.3">section 4.3</a>). Moreover, the lead may also have activity toward undesired targets, which must be “design-out” during optimization (cf. <a class="ref internalNav" href="#sec4_2" aria-label="section 4.2">section 4.2</a>) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0032.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. The screening of compounds libraries may generate a lead compound that obtains all activities toward both targets of interest (A and B). (a) But a single compound may be unlikely to have balanced affinity to all targets; therefore its activities should be optimized. (b) In another case, the lead compound also has activity toward undesired targets, which must be “designed out” during optimization.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">4.  Lead Optimization</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43570" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43570" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">After the lead generation phase, the next challenge is to optimize the lead ligand for balanced activities and better physicochemical profiles. In this lead optimization phase, there are mainly two approaches: the design-in and design-out approaches.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">4.1.  Design-In Approach</h3><div class="NLM_p">In design-in approach, the pharmacophore of one ligand is designed into the other according to molecular architecture and functional groups important for interacting with the biological targets.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Preferably, the two selective lead compounds share sufficient similarity. The challenge of this approach lies in enhancing affinity to one target while retaining the affinity to the other target. Therefore, systematic structure–activity relationship (SAR) of substitution for multiple potencies should be modeled.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> The SAR data of selective template ligands may provide many hints for the optimization of the hybrid, e.g., whether scaffold hopping is workable and whether substituents are feasible, etc. Of note, instead of two distinctly separated approaches, the rational generation of merged pharmacophores and the design-in approach can be referred to as a common strategy.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Using design-in approach, Woo et al.<a onclick="showRef(event, 'ref72 ref73 ref74 ref75 ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref72 ref73 ref74 ref75 ref76 ref77">(72−77)</a> designed a phenol sulfamate moiety from compound <b>21</b> into the scaffold of compound <b>20</b>. The phenol sulfamate moiety of compound <b>21</b> is responsible for irreversible steroid sulfatase (STS) inhibition, and the scaffold of <b>20</b> is for aromatase inhibition. The initial optimization relied on molecular docking and cocrystals studies that created the hybrid compound <b>22</b>. Further SAR research and scaffold hopping developed several chemotypes of MTDLs, among which the compound <b>23</b> targeted both enzymes with activities down to picomolar values (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Representative Example of Design-In Strategy<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Based on design-in approach, the pharmacophore of <b>20</b> is designed into that of <b>21</b>, according to molecular docking and cocrystals information.<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75,76)</a></p></p></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">4.2.  Design-Out Approach</h3><div class="NLM_p">Generally, design-out approach begins with a compound that simultaneously acts on all targets of interest, involving undesired ones. By reduction of the affinity to undesired targets, selectivity to the targets of interest will be improved.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Compared with design-in and merged pharmacophores approaches, this approach may benefit more from X-ray structure analysis because it starts from a single ligand which already modulates with all desired targets.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The binding mode of the lead compound toward undesired targets can be characterized via cocrystal structures analysis. The identification of the binding mode differences between desired and undesired targets paves the way for the disruption of the potency on the “off-target(s)”.</div><div class="NLM_p">Such approach is less common due to the rarity of available leads with multitarget activities. However, it is still attractive if the number of targets of interest exceeds two because every additional target may exponentially increase the challenges of design-in approach.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">The design-out approach has been applied successfully to develop MTDLs. For instance, Reichard et al.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> designed a neurokinin 1 (NK<sub>1</sub>)/NK<sub>2</sub> dual antagonist in this approach. Compound <b>24</b> is a broad-spectrum NK antagonist. Its <i>K</i><sub>i</sub> values are 1.3 nM, 0.4 nM, and 0.3 nM for NK<sub>1</sub>, NK<sub>2</sub>, and NK<sub>3</sub>, respectively. However, NK<sub>3</sub> receptor may have a critical impact on androgen/secretion/gonadotrophin production. Targeting NK<sub>3</sub> may lead to an anti-androgen therapy, but their intention was to develop a NK<sub>1</sub>/NK<sub>2</sub> dual antagonist for asthma. Therefore, they minimized NK<sub>3</sub> binding affinity of the lead to avoid potential NK<sub>3</sub>-mediated effects. By application of a stereosimplification strategy, a strict SAR study of piperidine pharmacophore from <b>24</b> was carried out via an efficient synthesis of substituted cyclic urea, which resulted in the development of compound <b>25</b>, which showed selective NK<sub>1</sub>/NK<sub>2</sub> affinity (the <i>K</i><sub>i</sub> values were 1.9, 4.1, and 945 nM for NK<sub>1</sub>, NK<sub>2</sub>, and NK<sub>3</sub>, respectively) (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Representative Example of Design-Out Approach<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>In the design-out approach, compound <b>25</b> is obtained by reducing the affinity to the undesired target NK<sub>3</sub>, meanwhile retaining the affinities on NK<sub>1</sub> and NK<sub>2</sub>.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></p></p></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">4.3.  Balancing of Activities</h3><div class="NLM_p">Establishing the optimal ratio of affinities to multiple targets via in vitro assays is critical: ideally, each target should be modulated to a suitable level in vivo at similar brain or plasma concentrations to maximize clinical relevance.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> For a MTDL with large difference in affinities in vitro toward multiple targets, it may well only exert multiple effects at high doses. However, it often causes side effects that limit the dosage upper limit.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> However, recent examples showed the feasibility of balancing activities through synergistic effect with differences in in vitro activities.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> So the phenotypic experiments in vivo activity validations are necessary.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In most cases, the goal is to balance in vitro activities within an order of magnitude for multiple targets, under the presumption that it may achieve similar degrees of in vivo receptor occupancy. However, the biodistribution of compound, the level of receptor occupancy for each target, receptor and (or) enzyme densities are different in various tissues.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Therefore, clinical knowledge and input are very important for optimizing in vitro activities. If clinical knowledge or input is insufficient, animal pathological models may be helpful to find the optimal balanced ratio.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p last">Ideally, the template ligands to be integrated should contain similar physicochemical profiles and in vivo activities at the same order of magnitude because it is hard to obtain a workable MTDL if the template ligands are completely different from each other in terms of PK/PD profiles and activities.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">5.  MTDL Synthesis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61802" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61802" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since MTDLs are often hybrids integrated by two or more selective ligands, their synthesis will be undoubtedly be more difficult than traditional small molecule drugs. Moreover, the generation of effective molecules as MTDLs relies on the nature of template ligands, linkage site, linker length, etc. Therefore, developing efficient synthetic strategies for MTDLs is crucial for MTDLs development. For linked MTDLs, the linker may be the key in designing leads because the length, position, and structure of linkers may influence the activity. In some cases, linkers can participate in target binding and even work as pharmacophores.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div class="NLM_p">The click chemistry paradigm<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> has been quickly applied to medicinal chemistry because it meets three important criteria to be an ideal reaction: versatility, selectivity, and efficiency. Recent application of click chemistry mainly focused on copper-catalyzed azide–alkyne cycloaddition (CuAAC), the thiol–yne click reaction (TYC)/thiol–ene click reaction (TEC), and the Diels–Alder (DA) reaction.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div><div class="NLM_p">Among them, CuAAC reactions are most widely applied in MTDLs synthesis (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>A). The simplicity and tolerance of CuAAC reaction, with the relatively inertial triazole ring, suggested its capability of linking two or more ligands. For instance, a “click chemistry” method was described for the efficient synthesis of proteosis-targeting chimera (PROTAC).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> This reaction was applied in linking the bromodomain and extra-terminal domain 4 (BRD4) ligand, and ligase binders targeting Von Hippel–Lindau (VHL) and cereblon (CRBN) proteins (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>B).</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. General Scheme and Representative Example of CuAAC Reaction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) 1,3-Dipolar cycloaddition between alkynes and azides; (B) representative example of CuAAC reaction.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></p></p></figure><div class="NLM_p">Furthermore, the structures of 1,2,3-triazoles formed through CuAAC reaction not only contribute to linking entities but also work as biologically active pharmacophores in treating cancer,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> acquired immune deficiency syndrome epidemic,<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> tuberculosis,<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> fungal infections.<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89,90)</a> However, few 1,2,3-triazole-bearing therapeutics are on market or in clinical trials. Hopefully, we will witness the emergence of them on market as the click reactions are used more and more widely.</div><div class="NLM_p">Compared with CuAAC reaction, TEC/TYC and DA reactions are less applied in the synthesis of MTDLs. DA reaction can be applied between a substituted alkene (usually termed the dienophile) and a conjugated diene,<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> to form a substituted cyclohexene derivative (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>A). On the basis of merged pharmacophores approach, Arepalli et al.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> designed a series of novel 1,3-diphenylbenzo[<i>f</i>][1,7]benzonaphthyrdines as potent cytotoxic agents and topoisomerase IIα inhibitors, through one-pot intermolecular imino DA reaction (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>C). This reaction has many advantages, such as being economical, having atom-economy, being a multicomponent reaction, being region-selective, and having broad substrate scope.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> TEC/TYC reaction only has a few applications in the synthesis of MTDLs (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>B).</div><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. General Schemes and Representative Example of DA and Thiol–Ene/Yne Click Reaction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Diels–Alder (DA) reaction; (B) TEC reaction (top) and the TYC reaction (bottom); (C) representative example of DA reaction.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></p></p></figure><div class="NLM_p">Apart from the click chemistry, cross-coupling reactions are emerging as an effective method of organic transformations with diverse applications in the systhesis of carbon–carbon (or carbon–heteroatom) bonds.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> They have enabled synthesizing complex organic molecules, with extensive applications in the preparation of MTDLs.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Such reactions have several advantages: (i) mild conditions; (ii) high yields; (iii) easy application under both aqueous and heterogeneous conditions; (iv) toleration of a broad range of functional groups; (v) robustness to steric hindrance.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> The high predictability, operational-simplicity, and superb functional group tolerance of cross-coupling reactions may contribute to efficient strategies development for MTDLs synthesis.</div><div class="NLM_p">The Suzuki cross-coupling represents the most powerful C–C bond forming reaction in organic synthesis.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Traditional Suzuki cross-coupling contains the coupling of an aryl halide (pseudohalide) and an organoboron reagent and is most commonly employed for the synthesis of biaryls by a C(sp<sup>2</sup>)–C(sp<sup>2</sup>) disconnection using a nickel or palladium catalyst (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>A). Acyl Suzuki cross-coupling contains the coupling of an acyl electrophile (acyl halide, anhydride, ester, amide) and an organoboron reagent (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>B). Hou et al.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> developed an efficient and convenient protocol for synthesizing ABT-869 (a MTDL for receptor tyrosine kinases), and the Suzuki coupling reaction was applied in the key step of ABT-869 synthesis (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>C). The synthetic process was more suitable for industrial production due to the advantages of simplicity, high yield, and purity.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. General Scheme and Representative Example of Suzuki Reaction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Aryl Suzuki reaction: C(sp<sup>2</sup>–sp<sup>2</sup>) cross-coupling. (B) Acyl Suzuki reaction: C(acyl-sp<sup>2</sup>) cross-coupling. (C) Representative example of Suzuki reaction.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></p></p></figure><div class="NLM_p">The cross-coupling reaction of organic electrophiles with organostannanes is usually referred to as the Stille reaction (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>A). The process of Stille reaction is mild, and it can tolerate of a broad range of functional groups, which is therefore widely applied in the synthesis of complex molecules.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Further, organostannanes are generally insensitive to oxygen and moisture, are tolerant to harsher conditions, and can be achieved through various methods.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> The R<sub>1</sub> group attached to the trialkyltin is generally sp<sup>2</sup>-hybridized, involving aryl and alkenes groups, but conditions have been designed to incorporate both sp<sup>3</sup>-hybridized groups, such as benzylic and allylic substituents, and sp-hybridized alkynes. X is generally a halide (such as Cl, Br, or I), but pseudo-halides (such as triflates), sulfonates, and phosphates can also be used.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Rasolofonjatovo et al.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> designed a series of hybrids through merging combretastatin A-4 and isocombretastatin A-4 cores. The Stille reaction was applied in the key synthesis progress (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>B).</div><figure id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. General Scheme and Representative Example of Stille Reaction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Stille reaction; (B) representative example of Stille reaction.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></p></p></figure><div class="NLM_p">The palladium catalyzed C–C bond formation, which couples a sp<sup>s</sup> carbon of an aryl or vinyl halide (or triflate) with a terminal sp hybridized carbon (from an alkyne), is generally referred to as Sonogashira cross-coupling reaction (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>A). It is one of the most frequently used for sp<sup>2</sup>–sp C–C bond construction, widely applied in natural products synthesis, dendrimers, heterocycles, and conjugated polymers.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Khatyr et al.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> obtained the multitarget ligands through chemioselective palladium-catalyzed Sonogashira reaction (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>B). The main advantage of this method is adaptability and synthetic versatility for synthesizing multitopic metal-binding ligands with various bridging units and phenyl substituents.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><figure id="sch10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. General Scheme and Representative Example of Sonogashira Reaction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Sonogashira reaction; (B) representative example of Sonogashira reaction.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></p></p></figure><div class="NLM_p">The Heck reaction is the reaction of an alkene with an unsaturated halide (or triflate), which was catalyzed by a palladium or palladium nanomaterial, to create a substituted alkene (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>A).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> It is attractive in terms of synthesis because high chemoselectivity and mild conditions are associated with low cost of the reagents and low toxicity.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> On the basis of fused pharmacophores approach, Palem et al.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> reported a novel quinazolinones with allylphenylquinoxaline hybrid designed for antiproliferative activity, utilizing palladium-catalyzed Heck reaction in the final synthesis step (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>B).</div><figure id="sch11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0011.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. General Scheme and Representative Example of Heck Reaction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Heck reaction; (B) representative example of Heck reaction.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></p></p></figure><div class="NLM_p last">The synthesis of MTDLs is generally more difficult than single-target ligands. The synthetic reactions discussed above are all efficient and mild methods for MTDLs synthesis. What is more, they all have high product yields and are tolerant of a broad range of functional groups. Thus, these efficient reactions may enable convenient synthesis of MTDLs.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">6.  Developability and Physicochemical Challenges</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41655" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41655" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Many factors contribute to the developability of MTDLs, particularly the physicochemical properties relevant to the molecular size and complexity.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Physicochemical properties will further influence the PK profiles and oral bioavailability, which is the most favorable route of administration.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In general, optimizing the PK profiles while keeping a balanced activity is the most difficult challenge in the lead optimizing phase. As a result of a combination of selective ligands, MTDLs may be more lipophilic and have higher molecular weight than approved drugs on market.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Many MTDLs have MW > 500 and cLogP > 5,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> which are major challenges to developability.</div><div class="NLM_p">A database of 117 MTDLs on market or in clinical trials was compiled by searching the Web site <a href="https://integrity.thomson-pharma.com" class="extLink">https://integrity.thomson-pharma.com</a>. According to the classification on this Web site, the full database was divided into subsets by therapeutic fields. For each MTDL, seven physicochemical properties were calculated: MW, cLogP, the number of hydrogen bond acceptors (HBA), the number of hydrogen bond donors (HBD), polar surface area (PSA), the number of rotatable bonds (RB), and the number of heteroatoms.<a onclick="showRef(event, 'ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref106 ref107">(106,107)</a> The mean and median values of the above seven properties for the full set and each subset are shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Physicochemical Properties Data of MTDLs on Market or in Clinical Trails<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">therapeutic field</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">cancer</th><th class="colsep0 rowsep0" align="center">nervous system disease</th><th class="colsep0 rowsep0" align="center">cardiovascular disease</th><th class="colsep0 rowsep0" align="center">infectious disease</th><th class="colsep0 rowsep0" align="center">full MTDL set</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MW</td><td class="colsep0 rowsep0" align="left">476.51 (471.26)</td><td class="colsep0 rowsep0" align="left">335.06 (314.91)</td><td class="colsep0 rowsep0" align="left">408.08 (391.98)</td><td class="colsep0 rowsep0" align="left">407.90 (324.34)</td><td class="colsep0 rowsep0" align="left">385.96 (371.54)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP</td><td class="colsep0 rowsep0" align="left">3.81 (4.43)</td><td class="colsep0 rowsep0" align="left">3.16 (3.51)</td><td class="colsep0 rowsep0" align="left">3.27 (3.29)</td><td class="colsep0 rowsep0" align="left">2.58 (2.48)</td><td class="colsep0 rowsep0" align="left">3.22 (3.39)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HBA</td><td class="colsep0 rowsep0" align="left">6.18 (6.00)</td><td class="colsep0 rowsep0" align="left">3.75 (3.00)</td><td class="colsep0 rowsep0" align="left">5.20 (5.00)</td><td class="colsep0 rowsep0" align="left">5.95 (4.00)</td><td class="colsep0 rowsep0" align="left">4.81 (4.00)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HBD</td><td class="colsep0 rowsep0" align="left">1.95 (2.00)</td><td class="colsep0 rowsep0" align="left">1.35 (1.00)</td><td class="colsep0 rowsep0" align="left">2.50 (2.00)</td><td class="colsep0 rowsep0" align="left">3.00 (3.00)</td><td class="colsep0 rowsep0" align="left">1.93 (2.00)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PSA</td><td class="colsep0 rowsep0" align="left">99.06 (94.00)</td><td class="colsep0 rowsep0" align="left">62.27 (54.64)</td><td class="colsep0 rowsep0" align="left">102.11 (93.89)</td><td class="colsep0 rowsep0" align="left">115.91 (96.79)</td><td class="colsep0 rowsep0" align="left">84.70 (77.23)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RB</td><td class="colsep0 rowsep0" align="left">6.32 (6.00)</td><td class="colsep0 rowsep0" align="left">5.46 (5.00)</td><td class="colsep0 rowsep0" align="left">8.20 (7.50)</td><td class="colsep0 rowsep0" align="left">6.84 (5.00)</td><td class="colsep0 rowsep0" align="left">6.32 (5.00)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">heteroatom</td><td class="colsep0 rowsep0" align="left">9.36 (9.50)</td><td class="colsep0 rowsep0" align="left">5.41 (5.00)</td><td class="colsep0 rowsep0" align="left">7.25 (6.50)</td><td class="colsep0 rowsep0" align="left">8.68 (8.00)</td><td class="colsep0 rowsep0" align="left">7.00 (6.00)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">approved drug number</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sample number</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">56</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">117</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The values outside the parentheses represent the mean values, and the inside ones represent the median values.</p></div></div></div><div class="NLM_p">We found significant differences in physicochemical properties among the MTDLs in the four therapeutic fields. For instance, the mean (median) values of MW are 335.06 (314.91) for MTDLs in the field of nervous system disease and 476.51 (471.26) for MTDLs in the field of cancer. It is remarkable that nervous system disease cluster occupied the lowest mean (median) values of all seven properties, especially the MW and lipophilicity, which are critical for blood–brain barrier (BBB) permeability. It is consistent with the fact that few MTDLs in the field of neurodegenerative diseases (especially for AD) reached clinical trial stage or on market, though many research studies have been conducted. Through a literature search, we found that the MTDLs for AD in basic research had significant different targets (such as AChE and Aβ aggregation inhibition). Most of these MTDLs have MW > 500 Da, which may raise concerns on their oral bioavailability and the ability to cross BBB. For instance, many research studies have been published about hybrids generated simply via linking active pharmacophore to tacrine.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Except for a few exceptions, most of MTDLs in basic research studies for AD have never been tested for the ability to cross the BBB or oral bioavailability. If tests to address these problems were conducted, they were confined to in vitro experiments by the parallel artificial membrane permeability assay (PAMPA). However, PAMPA which is based on an artificial membrane-mimic system is just a passive model for testing BBB permeability, whose results may not agree with actual in vivo situation.</div><div class="NLM_p">Conversely, the mean (median) values for MTDLs in the field of cancer are all higher than or equal to that of full MTDL set. Furthermore, the MTDLs in the field of cancer have the highest MW, cLogP, HBA, and heteroatom mean (median) values, consistent with the structure complexity of targets involved in cancers. So far, many MTDLs for cancer treatment are on market or in clinical trial stage; however, only a few of them were originally designed as multitarget drugs, such as axitinib<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> and lapatinib,<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> whereas the rest are just serendipity:<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> the multiple activities were discovered during kinase activity profiling, or they were designed for other therapeutic areas. In other words, they were designed for single targets but actually act on multiple targets. The discovery of imatinib is a typical example.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> From the successful case of imatinib, high throughput in vitro screening may facilitate discovering more MTDLs ever considered as single-target drug candidate.</div><div class="NLM_p">Regarding the MTDLs in the fields of cardiovascular and infectious diseases, the mean (median) values are generally higher than that of full MTDL set (except for the cLogP median values of cardiovascular disease). This also indicates to some extent the complexity of the multitarget drugs for cardiovascular disease and infectious disease.</div><div class="NLM_p">Therefore, as a general principle of MTDL design, the complexity and size of the template ligands had better be minimized, and the pharmacophores overlap had better be maximized. Removing functionality and rotatable bonds to simplify structures has often been required in lead optimization.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> If the pharmacophores are completely different, it may be impossible to integrate into a compact compound, and a high MW may be unavoidable. In this case, the high MW will be one of the main reasons for failure in clinical settings. Therefore, similar targets, in terms of possessing identical or highly similar endogenous ligand or being from the same superfamily, are preferred to rationally design multiple ligands. On the other hand, where possible, the template ligands are highly desirable with favorable physicochemical profiles because it is hard to obtain a worthy MTDL if the template ligands suffer physicochemical liabilities. Moreover, it is easier to discover high-quality lead compounds by taking screening and pharmacophore combination approaches simultaneously because the lead compounds obtained by screening usually have small molecular size and more favorable physicochemical profiles.</div><div class="NLM_p last">If a drug candidate is given via intravenous administration or the aim is to discover pharmacological tools to explore the feasibility of novel target combination, the oral bioavailability is less of an issue.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">7.  Recent Progress of MTDLs in Drug Discovery Campaign</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17824" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17824" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A full description of recently discovered MTDLs is beyond the scope of this article. So we just discuss the MTDLs’ application in some common multifactorial diseases to provide better insights of translational research.</div><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">7.1.  MTDLs for Cancer</h3><div class="NLM_p">Currently, cancer is the focus of MTDL discovery because of the multifactorial nature and frequently developed resistance to chemotherapy.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> The synergistic activities of MTDLs may contribute to higher therapeutic efficacy and delayed resistance development.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a></div><div id="sec7_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34">7.1.1.  MTDLs Targeting Histone Deacetylase and Other Targets</h4><div class="NLM_p">Histone deacetylase (HDAC) is an epigenetic enzyme associated with tumorigenesis and development. HDAC is therefore regarded as an important target for cancer therapy.<a onclick="showRef(event, 'ref114 ref115'); return false;" href="javascript:void(0);" class="ref ref114 ref115">(114,115)</a> Generally, HDAC inhibitors (HDACi) consist of three parts: (i) a zinc binding group (ZBG) to chelate the catalytic zinc ion; (ii) a hydrophobic linker to occupy the tunnel of the active site; (iii) a surface cap to recognize the amino acid residues around the entrance of the active site.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></div><div class="NLM_p">So far, four HDACi have been approved, including vorinostat (SAHA),<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> belinostat (PXD101),<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> romidepsin (FK228),<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> and panobinostat (LBH589).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> However, HDACi only demonstrated the efficacy in hematologic malignancies but not solid tumors.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Hopefully, combination therapies would lead to more clinical applications of HDACi, and emerging interest was drawn to this field.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Moreover, the HDACi pharmacophores can tolerate diverse cap groups to enable MTDLs strategies. Currently, HDACi have been combined with a variety of anticancer drugs in clinical studies, and the target combination selection of HDACi-based multitarget drug candidates was mainly based on these clinical experience.<a onclick="showRef(event, 'ref123 ref124 ref125 ref126'); return false;" href="javascript:void(0);" class="ref ref123 ref124 ref125 ref126">(123−126)</a></div><div class="NLM_p">Proteasome inhibitor (PI) bortezomib<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> was applied in combination with HDACi panobinostat in clinical studies to induce simultaneous blockage of the aggresome pathways and ubiquitin degradation. Bhatia et al.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> reported a first-in-class dual HDAC-proteasome inhibitor. Rather than covalent binders, they focused on noncovalent scaffolds of PIs in order to avoid the pitfalls of insufficient specificity, insufficient stability, excessive reactivity, as well as chemical incompatibilities due to highly reactive electrophilic warheads.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> The high affinity of compound <b>26</b> was mainly due to a P3-neopentyl-Asn residue (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>A).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Moreover, the available crystal structures of proteasome and corresponding peptidic ligands reveal that the bulky residue, as an excellent side chain, can occupy the whole S3 specificity pocket in the chymotrypsin-like site of the 20S core particle. So they utilized compound <b>26</b> as template to design and synthesize dual-HDAC-PIs. The X-ray structure of <b>26</b> revealed the exposure of P4 residue to the solvent. So they decided to incorporate the HDACi part in the P4 position (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>A). On the other hand, the most effective synergy was derived from the combination of PIs and HDAC6. Compound <b>27</b> is a representative selective HDAC6 inhibitor on the basis of an <i>N</i>-dydroxybenzamide scaffold which provided HDAC6 selectivity. They replaced the solvent-exposed 4-picolyl scaffold by a methyl group in the P2 position to reduce MW. The above hybridization strategy led to the HDAC-proteasome inhibitor compound <b>28</b>. Biochemical assays, cellular assays, and X-ray crystal structures analysis (HDAC6 and 20S proteasome complexed with compound <b>28</b>) confirmed that compound <b>28</b> inhibited both targets simultaneously. Compound <b>28</b> was tested for the activity of proteasome inhibition. While ricolinostat (HDAC6 inhibitor) and vorinostat (pan-HDAC inhibitor) were the negative controls, bortezomib was the positive control. Furthermore, compound <b>28</b> can block the activity of chymotrypsin-like proteasome in selected leukemic cell lines (HL-60, SUP-B15r, and SEM), while vorinostat and ricolinostat cannot (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biological Activities of MTDLs Targeting HDAC and Proteasome<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">HDAC6</th><th class="colsep0 rowsep0" align="center">HL60</th><th class="colsep0 rowsep0" align="center">SEM</th><th class="colsep0 rowsep0" align="center">SUP-B15r</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">0.27 ± 0.01</td><td class="colsep0 rowsep0" align="left">260.70 ± 3.12</td><td class="colsep0 rowsep0" align="left">394.20 ± 9.85</td><td class="colsep0 rowsep0" align="left">820.50 ± 13.94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bortezomib</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6.67 ± 0.16</td><td class="colsep0 rowsep0" align="left">4.43 ± 0.13</td><td class="colsep0 rowsep0" align="left">28.09 ± 1.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ricolinostat</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>25000</td><td class="colsep0 rowsep0" align="left">>25000</td><td class="colsep0 rowsep0" align="left">>25000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vornostat</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>25000</td><td class="colsep0 rowsep0" align="left">>25000</td><td class="colsep0 rowsep0" align="left">>25000</td></tr></tbody></table></div></div><figure id="sch12" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0012.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. MTDLs Targeting HDAC and Other Targets<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Most HDACi consist of three parts: a ZBG, a hydrophobic linker, and a surface cognition cap.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The HDACi pharmacophores can tolerate diverse cap groups, enabling MTDLs strategies.</p></p></figure><div class="NLM_p">Regarding to the fused-pharmacophores strategy, He et al.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> have reported novel HDACs and p53-human murine double minute 2 (MDM2) interaction dual-inhibitors (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>B). The interaction with MDM2 protein is a major inhibitory mechanism of of p53.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Blocking the interaction of p53 and MDM2 can reactivate the function of p53 and is therefore believed to be a promising strategy for cancer therapy. By analyzing the binding models of known MDM2 inhibitors and HDACs, they found that three functional groups on the imidazole scaffold of compound <b>29</b> can mimick Phe19, Leu26, and Trp23 residues in p53, which stretched into the binding pocket of MDM2. Therefore, they used the SAHA (<b>30</b>) and <b>29</b> as templates to design and synthesize MDM2-HDAC dual inhibitors. The N3 substitution of <b>29</b> exposed to the solvent was designed to introduce a linker (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>B). The resulting compound <b>31</b> showed remarkable selectivity for HDAC6 and high affinity to MDM2 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Moreover, it exhibited superb in vivo antitumor efficacy in A549 xenograft model (tumor growth inhibition (TGI) = 74.5%) and was orally available.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Biological Activities of MTDLs Targeting HDAC and MDM2<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">MDM2</th><th class="colsep0 rowsep0" align="center">HDAC1</th><th class="colsep0 rowsep0" align="center">HDAC6</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b>, nutlin-3</td><td class="colsep0 rowsep0" align="left">0.14 ± 0.04</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b>, SAHA</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">45.0 ± 3.1</td><td class="colsep0 rowsep0" align="left">16.3 ± 1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">0.11 ± 0.03</td><td class="colsep0 rowsep0" align="left">821 ± 12</td><td class="colsep0 rowsep0" align="left">17.5 ± 1.5</td></tr></tbody></table></div></div><div class="NLM_p">The combination of pazopanib<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> (a multiple vascular endothelial growth factor receptor (VEGFR) inhibitor for advanced renal cell carcinoma treatment) and HDACi exhibited good preclinical results.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Therefore, another series of dual HDAC-VEGFR inhibitor were designed down the road.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Zang et al.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> incorporated pazopanib (<b>32</b>) into the surface recognition cap of HDACi pharmacophore from MS-275 (<b>33</b>, an HDACi) (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>C) to overcome developed drug resistance in almost all patients treated with VEGFR inhibitors.<a onclick="showRef(event, 'ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref133 ref134">(133,134)</a> Vascular endothelial growth factor (VEGF)/VEGFR signaling pathway is regarded as the main antiangiogenesis target for cancer therapy.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> They selected pazopanib as a template based on promising preclinical study results of combination of pazopanib and HDACi.<a onclick="showRef(event, 'ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref124 ref125">(124,125)</a> To decide which site of compound <b>32</b> can be substituted without losing the affinity to VEGFR-2, they analyzed the binding pattern of compound <b>32</b> within the ATP pocket of VEGFR-2. They found that the 2-aminopyrimidine scaffold of <b>32</b> formed two critical hydrogen bonds with the Cys917 residue in the hinge region, and the indazole moiety inserted into the inner pocket of VEGFR-2. Therefore, they kept these two important scaffolds without modification. They figured out that the solvent-exposed benzenesulfonamide moiety could be modified with the HDACi motif without compromising the VEGFR-2 inhibition. Therefore, they conjugated two privileged ZBGs (ortho-aminoanilide and hydroxamic acid) to the solvent-exposed phenyl group straightway or by diverse linkers, resulting in a series of dual HDAC-VEGFR-2 inhibitors. The resulting compound <b>34</b> showed HDACs inhibition comparable to entinostat (an HDACi in phase III) and uncompromised antiangiogenic activities compared with pazopanib (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Moreover, compound <b>34</b> has ideal PK profiles, up to 72% oral bioavailability in SD rats, and desirable in vivo antitumor efficacy in HT-29 xenograft model (TGI = 40%).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Biological Activities of MTDLs Targeting HDAC and VEGFR-2<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center" char=".">VEGFR-2</th><th class="colsep0 rowsep0" align="center" char=".">HDAC</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">Inh % (0.2 μM)</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b>, pazopanib</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b>, MS-275</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">0.13</td></tr></tbody></table></div></div><div class="NLM_p">The combination of Janus kinases 2 (JAK2) and HDAC inhibitors has been reported in clinical studies.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> On this basis, Huang et al.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> reported designing dual JAK2-HDAC inhibitors for invasive fungal infections (IFIs) and leukemia treatment simultaneously (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>D). JAK2 is a validated target for multiple cancers, including hematological malignancies.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> But the application of JAK2 inhibitors has been in compliance with drug resistance and the complication of IFIs.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> In general, a JAK2 inhibitor consists of three parts: two hydrophobic groups, hinge-region binder (typically an aminopyrimidine), and a solvent-exposed motif. The aminopyrimidine proved to be an important motif for JAK2 inhibition. The first series were designed via merging of the central motif of the template compound <b>35</b> with the ZBG group from compound <b>30</b> (benzamide or hydroxamic acid) by diverse linkers.</div><div class="NLM_p">Since <i>N</i>-phenylmethanesulfonamide derivatives of compound <b>35</b> showed similar activity for JAK2 inhibition, the second series were designed and synthesized with the <i>N</i>-cyanomethylbenzamide/<i>N</i>-phenylmethanesulfonamide substitution. A minor substitution in the hydrophobic area of compound <b>35</b> could be tolerated; thus benzamide or hydroxamic acid was introduced in this position. The optimized compound <b>36</b> in the second series showed highly selective JAK2/HDAC6 inhibition (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Importantly, compound <b>36</b> had shown efficacy in several in vivo models, such as human embryonic lung fibroblasts (HEL) xenograft model.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Biological Activities of MTDLs Targeting HDAC and JAK2<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">JAK2</th><th class="colsep0 rowsep0" align="center">HDAC1</th><th class="colsep0 rowsep0" align="center">HDAC6</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b>, SAHA</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">40 ± 9</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">41 ± 5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">8.4 ± 0.7</td><td class="colsep0 rowsep0" align="left">250 ± 25</td><td class="colsep0 rowsep0" align="left">46 ± 1.7</td></tr></tbody></table></div></div></div><div id="sec7_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40">7.1.2.  MTDLs Targeting Src and MEK Kinases</h4><div class="NLM_p">As a non-receptor type tyrosine kinase, Src regulates many activities of cancer cells, such as proliferation, migration, and invasion.<a onclick="showRef(event, 'ref139 ref140'); return false;" href="javascript:void(0);" class="ref ref139 ref140">(139,140)</a> Therefore, Src is believed to be a valuable target to treat cancer. On the other hand, MEK kinase can influence mitogen-activated protein kinase (MAPK) signaling pathway and regulate apoptosis and oncogenic transformation<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> and is therefore another important anticancer target. Unfortunately, merely 22% patients in the presence of the BRAF gene mutations can be treated with MEK inhibitor (trametinib) for melanoma in clinical trials.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> There is a need to apply combination therapies to improve the clinical response.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Recent clinical research showed that the simultaneous inhibition of MEK and Src led to improved efficacy in cancer patients.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></div><div class="NLM_p">In previous work, Cui et al.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> found that acridine derivatives OA (<b>37</b>) exhibited inhibition on Src. But the inhibition of <b>37</b> on Src is weak, likely because there is merely one hydrogen-bond interaction between <b>37</b> and the hinge of Src protein. In addition, studies have shown that molecules that bear a moiety can improve the affinity of kinase inhibition obviously, such as urea bonds which had the ability to bind the DFG-out conformation of c-Src.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> For examples, some kinase inhibitors approved or in clinical trial stage, such as imatinib,<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> ponatinib,<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> and regorafenib,<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> all have amido or urea moieties capable of forming hydrogen bonds with the amino acid residues of the DFG-out pocket of kinases.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Taking these into considerations, they introduced the phenylurea moieties to the 9-anilinoacridine substituents by fused-pharmacophores approach (<a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>). Among the derivatives, compound <b>39</b> inhibited 59.67% of Src activity and exhibited inhibition rates on MEK and PI3K of 43.23% and 44.41% at 10 μM, respectively. The antiproliferative activity of <b>39</b> was determined on HepG-2 and K562 cells using MTT assay, and imatinib was the positive control. For compounds <b>37</b> and <b>39</b>, the IC<sub>50</sub> of antiproliferative activities on HepG-2 and K562 cells were shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. Compound <b>39</b> is a novel MTDL for dual Src and MEK inhibition and can induce cancer cell apoptosis.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></div><figure id="sch13" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0013.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. MTDLs Targeting Src and MEK Kinases<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Biological Activities of MTDLs Targeting Src and MEK Kinases<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">Src</th><th class="colsep0 rowsep0" align="center">MEK</th><th class="colsep0 rowsep0" align="center">K562</th><th class="colsep0 rowsep0" align="center">HepG-2</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Inh %</th><th class="colsep0 rowsep0" align="center">Inh %</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">8.02 at 50 μM</td><td class="colsep0 rowsep0" align="left">44.03 at 50 μM</td><td class="colsep0 rowsep0" align="left">5.8</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">59.67 at 10 μM</td><td class="colsep0 rowsep0" align="left">43.23 at 10 μM</td><td class="colsep0 rowsep0" align="left">4.08</td><td class="colsep0 rowsep0" align="left">9.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">imatinib</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.53</td><td class="colsep0 rowsep0" align="left">>25</td></tr></tbody></table></div></div></div><div id="sec7_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43">7.1.3.  MTDLs Targeting ERα and VEGFR-2</h4><div class="NLM_p">In breast cancer, estrogen receptor α (ERα) is charge of estrogen-induced proliferation.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> VEGFR-2 is also considered as a dominant receptor in the angiogenesis pathway.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> However, VEGFR-2 inhibitors have limited efficacy as monotherapy.<a onclick="showRef(event, 'ref152 ref153'); return false;" href="javascript:void(0);" class="ref ref152 ref153">(152,153)</a> A combination of tamoxifen (<b>41</b>, a selective estrogen receptor modulator (SERM)) and only low doses of brivanib alaninate (a VEGFR-2 inhibitor) was able to improve therapeutic efficacy and at the same time prevent SERM resistant tumor growth.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Furthermore, VEGFR-2 inhibitors that contain an indol-2-one scaffold share some structural similarities with SERMs, such as YM231146 (<b>42</b>) and sunitinib.</div><div class="NLM_p">Hereby, Tang et al.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> designed and synthesized a series of dual-target inhibitors toward VEGFR-2 and ERα through linked-pharmacophore approach. They integrated the 2<i>H</i>-1-benzopyran pharmacophore form acolbifene (<b>40</b>) with functional groups capable of inhibiting VEGFR-2 selectively (<a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>). Among the ERα/VEGFR-2 dual inhibitors, compound <b>43</b> had the highest level of inhibitory activities for ERα and VEGFR-2 (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). Following studies demonstrated potential antiproliferation activity of compound <b>43</b> on MCF-7 breast cancer cells, as well as good in vivo antiangiogenesis activity.</div><figure id="sch14" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0014.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. MTDLs Targeting ERα and VEGFR-2<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Biological Activities of MTDLs Targeting ERα and VEGFR-2<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">ERα</th><th class="colsep0 rowsep0" align="center">MCF-7</th><th class="colsep0 rowsep0" align="center">VEGFR-2</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Inh % (0.1 mg/mL)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">Inh % (0.1 mg/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">99.89</td><td class="colsep0 rowsep0" align="left">2.73</td><td class="colsep0 rowsep0" align="left">100.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">7.2 μM<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">0.099 μM<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b>, tamoxifen</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">1.89</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sunitinib</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">100 (0.14 μM<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a>)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">The value represents the IC<sub>50</sub> values for ERα inhibition.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">The value represents the IC<sub>50</sub> values for VEGFR-2 inhibition.</p></div></div></div><div class="NLM_p last">In pursuit of diverse scaffolds as MTDLs for ERα and VEGFR-2 inhibition, they further designed a series of 6-arylindenoisoquinolone analogues containing side chains.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Compound <b>44</b> contained two hydroxyl groups, which mimicked estradiol to form two hydrogen-bond interactions with ERα. Compound <b>44</b> was also tested for inhibitory activity of human breast cancer cell lines MCF-7 (ER+). Compound <b>44</b> proved to be an ERα/VEGFR-2 dual inhibitor, and its IC<sub>50</sub> values are shown in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. This work identified a novel approach to design multitarget drugs with pharmacophores from two families’ targets.</div></div><div id="sec7_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46">7.1.4.  MTDLs Targeting Microtubule and Tyrosine Kinase (RTK)</h4><div class="NLM_p">Combination chemotherapy with cytotoxic and antiangiogenic drug (especially RTK inhibitors) has shown promising results in clinical studies.<a onclick="showRef(event, 'ref157 ref158 ref159'); return false;" href="javascript:void(0);" class="ref ref157 ref158 ref159">(157−159)</a> Compound <b>46</b> is a dual inhibitor for VEGFR-2 and platelet-derived growth factor receptor β (PDGFR-β), with furo[2,3-<i>d</i>]pyrimidine scaffold.<a onclick="showRef(event, 'ref160 ref161'); return false;" href="javascript:void(0);" class="ref ref160 ref161">(160,161)</a> Furthermore, 6-methylcyclopenta fused pyrimidines <b>45</b> showed strong tubulin depolymerization activity, as well as both in vitro and in vivo anticancer activities.<a onclick="showRef(event, 'ref162 ref163 ref164'); return false;" href="javascript:void(0);" class="ref ref162 ref163 ref164">(162−164)</a></div><div class="NLM_p">As an initial research study, Zhang et al.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> tried to integrate tubulin inhibitory activity of compound <b>45</b> into the existing RTK inhibitor compound <b>46</b>. They replaced the 5-substitution onto the 4-NH moiety of compound <b>48</b> and placed a 6-CH<sub>3</sub> group on compound <b>46</b> to generate a hybrid furo[2,3-<i>d</i>]pyrimidine scaffold (<a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>). This scaffold has antitubulin activity compared to compound <b>45</b>, and it can also access the hydrophobic region on the basic pharmacophore for RTKs (VEGFR-2 and PDGFR-β). Among the derivatives generated by the 2-substitution, the 2-methyl-group-substituted compound <b>47</b> showed EC<sub>50</sub> value of 3.9 μM for angiogenesis inhibition. The inhibitory efficiency of compound <b>47</b> was 9-fold higher than erlotinib and approximately equals half of sunitinib. Moreover, <b>47</b> was the most active compound as tubulin depolymerizer and for EGFR, VEGFR-2, and PDGFR-β inhibition (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). SAR analysis of this compound series indicated that the <i>N</i>-alkyl group is the key for microtubule depolymerization activity. In order to explore the bioactive conformation, they further designed a series of 4-substituted 2,6-dimethylfuro[2,3-<i>d</i>]pyrimidines that were conformationally restricted. Compared with compound <b>47</b>, optimized compound <b>48</b> exhibited a remarkable improved inhibitory efficiency on RTKs and microtubule assembly.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div><figure id="sch15" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0015.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. MTDLs Targeting Tyrosine Kinase and Microtubule<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Biological Activities of MTDLs Targeting RTKs and Microtubule<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">PDGFR-β</th><th class="colsep0 rowsep0" align="center">VEGFR-2</th><th class="colsep0 rowsep0" align="center">microtubule depolymerization</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">22.8 ± 4.9</td><td class="colsep0 rowsep0" align="left">19.1 ± 3.0</td><td class="colsep0 rowsep0" align="left">103</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">58.2 ± 8.0</td><td class="colsep0 rowsep0" align="left">33.2 ± 5.0</td><td class="colsep0 rowsep0" align="left">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sunitinib</td><td class="colsep0 rowsep0" align="left">83.1 ± 10.1</td><td class="colsep0 rowsep0" align="left">18.9 ± 2.7</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">combretastatin A-4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">9.8</td></tr></tbody></table></div></div></div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49">7.2.  MTDLs for Central Nervous System Diseases</h3><div class="NLM_p">Owing to the complex etiology of central nervous system diseases, development of new multifunctional drugs in this therapeutic field has become more attractive in recent years.<a onclick="showRef(event, 'ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref167 ref168">(167,168)</a></div><div id="sec7_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50">7.2.1.  MTDLs Targeting Glycogen Synthase Kinase 3β and Tau-Aggregation for AD</h4><div class="NLM_p">In 2018, Gandini et al.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> developed 2,4-thiazolidinedione derivatives with dual inhibitory activities on the glycogen synthase kinase 3β (GSK-3β, a phosphorylating tau kinase) and tau aggregation process (<a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a>). It is not easy to design a ligand binding two targets which shared no binding site similarity, as in the cases of tau protein and GSK-3β.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Moreover, combining molecular skeletons from two different molecules in one small molecule could be very challenging for PK optimization.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></div><figure id="sch16" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0016.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. MTDLs Targeting GSK-3β and Tau-Aggregation for AD<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Initially, they found some known GSK-3β inhibitors had common five-membered heterocyclic fragments with hydrogen bond donor and acceptor functionalities.<a onclick="showRef(event, 'ref172 ref173'); return false;" href="javascript:void(0);" class="ref ref172 ref173">(172,173)</a> Thiadiazolidinedione (TDZD) is the first class reported non-ATP competitive inhibitor of GSK-3β,<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> and tideglusib (<b>49</b>) is currently under clinical development.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Interestingly, thiohydantoin, hydantoin, and rhodanine were discovered as effective scaffolds to inhibit tau antiaggregation.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Thus, they speculated that the cross-talk of the above scaffolds may be applied for the two selected targets. They did not select rhodanine as lead due to the pan-assay interference compounds (PAINS) behavior.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Conversely, they selected the 2,4-thiazolidinedione (TZD) fragment without PAINS (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>),<a onclick="showRef(event, 'ref178 ref179'); return false;" href="javascript:void(0);" class="ref ref178 ref179">(178,179)</a> even though TZD scaffold has never been explored as either GSK-3β or tau antiaggregation fragment. Previous works showed that (i) 5-arylidene substitution could improve efficacy of the 2-iminothiazolidin-4-one GSK-3β inhibitors and (ii) their volume and size did not fit in similar regions of homologous kinases, suggesting that selectivity for GSK-3β could be optimized.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Thus, they modified position 5 using diverse heteroaromatic and aromatic substituents and obtained series of 5-arylidene-2,4-thiazolidinediones. The resulting compounds <b>50</b> and <b>51</b> exhibited (i) micromolar IC<sub>50</sub> values for GSK-3β (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>) and increased the cell viability in cell model induced by okadaic acid, (ii) PAMPA-BBB permeability and suitable cellular safety profile, and (iii) satisfactory PK properties and balanced activities with low MW.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Biological Activities of MTDLs Targeting GSK-3β and Tau Aggregation<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">GSK-3β</th><th class="colsep0 rowsep0" align="center">tau K18 self-aggregation</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">Inh % (10 μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">4.93 ± 0.66</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">0.89 ± 0.21</td><td class="colsep0 rowsep0" align="left">35<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b>, tideglusib</td><td class="colsep0 rowsep0" align="left">0.69 ± 0.09</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">Compared to tau K18 self-aggregation alone.</p></div></div></div></div><div id="sec7_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53">7.2.2.  MTDLs Targeting ChE and Other Targets for AD</h4><div class="NLM_p">Tacrine is an acetylcholinesterase inhibitor (AChEI) approved by the FDA,<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> but its hepatotoxicity limited further clinical applications. Nowadays, tacrine is widely used as a template for designing MTDLs for AD therapy.<a onclick="showRef(event, 'ref181 ref182'); return false;" href="javascript:void(0);" class="ref ref181 ref182">(181,182)</a> It is worth mentioning that many of tacrine hybrids have decreased toxicity.</div><div class="NLM_p">Neurofibrillary tangles (NFTs) represent one of the most relevant histopathological hallmarks of AD. According to the tau hypothesis, GSK-3β is a multifunctional serine/threonine kinase that regulates tau phosphorylation and precipitation as NFTs. On the basis of linked-pharmacophore strategy, our group designed a series of GSK-3β/AChE dual inhibitors.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> The hybrid compound <b>54</b> exhibited the promising profile: (i) the IC<sub>50</sub> values for hAChE and hGSK-3β inhibition are 6.5 nM and 66 nM, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>); (ii) in vivo studies indicated that compound <b>54</b> effectively improved the learning and memory of scopolamine-treated ICR mice; (iii) it had lower hepatotoxicity compared with tacrine. The research identified a novel approach for developing dual GSK-3β/AChE inhibitors as drug candidates for AD therapy (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>).</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Biological Activities of MTDLs Targeting GSK-3β and ChE<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">hGSK-3β</th><th class="colsep0 rowsep0" align="center">hAChE</th><th class="colsep0 rowsep0" align="center">hBuChE</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b>, tacrine</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">230 ± 31</td><td class="colsep0 rowsep0" align="left">40 ± 3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">66 ± 6.2</td><td class="colsep0 rowsep0" align="left">6.4 ± 0.3</td><td class="colsep0 rowsep0" align="left">260 ± 32</td></tr></tbody></table></div></div><figure id="sch17" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0017.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. MTDLs Targeting ChE and Other Targets for AD<a onclick="showRef(event, 'ref183 ref187 ref190'); return false;" href="javascript:void(0);" class="ref ref183 ref187 ref190">(183,187,190)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Melatonin (<b>55</b>) is a pineal neurohormone, and its level decreases with age, notably in AD patients. Studies have shown that melatonin had strong antioxidant activities and could eliminate various reactive oxygen species.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Furthermore, it can protect microglial cells from Aβ-induced apoptosis and improve cognitive disorders in rats.<a onclick="showRef(event, 'ref185 ref186'); return false;" href="javascript:void(0);" class="ref ref185 ref186">(185,186)</a> Rodriguez-Franco et al.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> developed novel melatonin-tacrine hybrids based on the linked-pharmacophore approach. They linked the two pharmacophores with different length of linkers, which can be stretched into the enzyme cavity (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>). Compound <b>56</b> was the strongest inhibitor for hAChE with 40 000-fold inhibitory efficiency of tacrine. Interestingly, it showed high selectivity of 1000-fold on AChE over hBuChE. Moreover, compound <b>56</b> had 2.5-fold higher oxygen radical absorbance capacity than trolox (a vitamin E analogue) (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>).</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Biological Activities of MTDLs Targeting ChE and Oxidation<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">hAChE</th><th class="colsep0 rowsep0" align="center">hBuChE</th><th class="colsep0 rowsep0" align="center">trolox</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">equiv<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b>, tacrine</td><td class="colsep0 rowsep0" align="left">350 ± 10</td><td class="colsep0 rowsep0" align="left">40 ± 2</td><td class="colsep0 rowsep0" align="left"><0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.3 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">0.008 ± 0.0004</td><td class="colsep0 rowsep0" align="left">7.8 ± 0.4</td><td class="colsep0 rowsep0" align="left">2.5 ± 0.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup><sup>a</sup></sup><p class="last">Data are expressed as μmol of trolox equivalent/μmol of tested compound.</p></div></div></div><div class="NLM_p">MAOs are considered to be valuable targets for AD therapy because its high expression level leads to oxidative damage.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> Selegiline<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> (<b>57</b>) is a selective and irreversible MAO-B inhibitor and shows neuroprotective effect in in vitro and in vivo AD models. On the basis of linked-pharmacophore approach, Lu et al.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> designed series of selegiline–tacrine hybrids through linking of the two pharmacophores using carbon spacers with different lengths (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>). Compound <b>58</b> showed balanced activities toward all the targets (<a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a></a>).</div><div class="NLM_table-wrap" id="tbl13"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 13. Biological Activities of MTDLs Targeting ChE and MAO<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">AChE</th><th class="colsep0 rowsep0" align="center">BuChE</th><th class="colsep0 rowsep0" align="center">hMAO-A</th><th class="colsep0 rowsep0" align="center">hMAO-B</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b>, tacrine</td><td class="colsep0 rowsep0" align="left">110.2 ± 7.30</td><td class="colsep0 rowsep0" align="left">21.6 ± 1.77</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="left">22.6 ± 3.04</td><td class="colsep0 rowsep0" align="left">9.37 ± 0.75</td><td class="colsep0 rowsep0" align="left">0.3724 ± 0.0249</td><td class="colsep0 rowsep0" align="left">0.1810 ± 0.0300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">clorgyline</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.0041 ± 0.0002</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pargyline</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.1180 ± 0.0160</td></tr></tbody></table></div></div><div class="NLM_p">Recent studies suggested that depression present in nearly 40% of dementia patients<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> can be treated with serotonin transporter (SERT) inhibitors.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> Nowadays, fluoxetine (<b>59</b>, an antidepressant)<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> and paroxetine<a onclick="showRef(event, 'ref194 ref195'); return false;" href="javascript:void(0);" class="ref ref194 ref195">(194,195)</a> are two of the most widely used SERT inhibitors without anticholinergic adverse effects.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Thus, the combination of AChE and SERT inhibition might have great benefits: cognitive impairment might be reduced, and dose-related side effects due to undue AChE inhibition might be avoided.<a onclick="showRef(event, 'ref195 ref196'); return false;" href="javascript:void(0);" class="ref ref195 ref196">(195,196)</a> To design such a MTDL, a hypothetical model of AChE active center was constructed based on crystal structure of AChE and donepezil.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Rivastigmine (<b>7</b>), a marketed AChE inhibitor, was chosen as the template. They speculated that there were three parts of rivastigmine responsible for binding to AChE in hypothetic binding sites: (i) a carbamate for catalytic triad site; (ii) an aryl for hydrophobic binding site A; (iii) an amine for the ionic site.</div><div class="NLM_p">Compound <b>59</b> was selected as the element to access the hydrophobic binding site of AChE. Moreover, fluoxetine can inhibit SERT activity strongly and has an ethylamine group to overlap with rivastigmine (<a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>). Therefore, a novel dual AChE-SERT inhibitor compound <b>60</b> with balanced AChE-SERT inhibitory activities was developed. The conformationally restricted compound <b>61</b> was further designed and synthesized to improve the inhibition efficiency (<a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a></a>).</div><figure id="sch18" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0018.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. MTDLs Targeting AChE and SERT for AD<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl14"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 14. Biological Activities of MTDLs Targeting AChE and SERT<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center" char=".">AChE</th><th class="colsep0 rowsep0" align="center" char=".">SERT</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b>, rivastigmine</td><td class="colsep0 rowsep0" align="char" char=".">11000</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b>, donepezil</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b>, fluoxetine</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">180</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="char" char=".">101</td><td class="colsep0 rowsep0" align="char" char=".">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr></tbody></table></div></div></div><div id="sec7_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60">7.2.3.  MTDLs Targeting Metal Chelation, Aβ, Metal-Aβ, and ROS for AD</h4><div class="NLM_p">Lee et al.<a onclick="showRef(event, 'ref197 ref198'); return false;" href="javascript:void(0);" class="ref ref197 ref198">(197,198)</a> first reported a single molecule that inhibited multiple pathologic mechanisms of AD, involving metal-induced Aβ aggregation, metal-free, toxicity induced by Aβ and metal-Aβ, free radical reaction, and ROS generation (<a class="ref internalNav" href="#sch19" aria-label="Scheme 19">Scheme 19</a>). To block metal chelation and Aβ/metal-Aβ interactions, the hybrid was designed via merging compound <b>63</b>, a known Aβ imaging tool,<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> with compound <b>62</b>, a molecule targeting metal-Aβ,<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> and compound <b>64</b>, a metal chelator.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> Nitrogen and oxygen donor atoms, as well as a hydroxyl group, were introduced to form a tetradentate hybrid to increase metal binding ability. In this conformation, the ligand can inhibit ROS generation by disrupting the favorable tetrahedral geometry of Cu(I). Substituents (such as phenolic and quinoline groups)<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> as validated antioxidants were introduced into hybrid for antioxidation. Finally, polar groups (such as amino and hydroxyl groups) were added to improve water solubility. Series of chemical studies indicated that hybrid <b>65</b> targeted metal free and metal-Aβ, inhibited in vitro Aβ aggregation, as well as reduced the toxicity caused by Aβ. Moreover, compound <b>65</b> was water-soluble with potential BBB permeability and regulated the formation and presence of free radicals (<a class="ref showTableEvent internalNav" data-ID="tbl15" href="#tbl15">Table <a class="ref showTableEvent internalNav" data-ID="tbl15" href="#tbl15">15</a></a>).</div><figure id="sch19" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0019.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. MTDLs Targeting Metal Chelation, Aβ, Metal-Aβ, and ROS for AD<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl15"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 15. Biological Activities of MTDLs Targeting Metal Chelation, Aβ, Metal-Aβ, and ROS<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">multiple activities of <b>65</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aβ and metal-Aβ</td><td class="colsep0 rowsep0" align="left"><b>65</b> can bind to Aβ40 and Aβ42.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>65</b> stoichiometry and can bind to metal-Aβ42 and chelate Cu(II) from Aβ42 competitively.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aβ42 fibers</td><td class="colsep0 rowsep0" align="left"><b>65</b> can interact with Aβ42 fibers and bind to Zn(II)-Aβ42 fibers.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Metal</td><td class="colsep0 rowsep0" align="left"><b>65</b> can bind to Cu(II) and Zn(II) selectively and chelate metal ions surrounded by soluble Aβ.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Early oligomerization of Aβ</td><td class="colsep0 rowsep0" align="left"><b>65</b> can inhibit the formation of dodecamer and hexamer.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Metal-associated Aβ-induced toxicity</td><td class="colsep0 rowsep0" align="left"><b>65</b> may regulate Aβ/metal-Aβ-induced toxicity.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ROS formation</td><td class="colsep0 rowsep0" align="left"><b>65</b> may control Cu-triggered formation of hydroxyl radicals.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Oxidation</td><td class="colsep0 rowsep0" align="left"><b>65</b> can scavenge free radicals more effectively than trolox (1.41 ± 0.15 for <b>65</b>; 1.00 ± 0.08 for trolox) by the TEAC assay.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BBB permeability</td><td class="colsep0 rowsep0" align="left"><b>65</b> may cross the BBB in PAMPA assay.</td></tr></tbody></table></div></div></div><div id="sec7_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63">7.2.4.  MTDLs Targeting MAO-B and Other Targets for Parkinson’s Disease</h4><div class="NLM_p">Parkinson’s disease (PD) is a well-known nervous system disease. MAOs plays an important role in neurotransmitter degradation. In the human brain, the MAO-B mainly degrades dopamine and therefore serves as a target for PD.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> The human histamine H<sub>3</sub> receptor (hH<sub>3</sub>R) is mainly expressed in the central nervous system (CNS). The activation of presynaptic H<sub>3</sub>R might reduce the release neurotransmitters including dopamine,<a onclick="showRef(event, 'ref204 ref205'); return false;" href="javascript:void(0);" class="ref ref204 ref205">(204,205)</a> indicating its value as a promising target for PD. Compounds <b>68</b> and <b>69</b> are potent and selective reversible MAO-B inhibitors. Ciproxifan (<b>66</b>) is a H<sub>3</sub>R inverse agonist with simultaneous MAO-B inhibitory activity.</div><div class="NLM_p">In the linked-pharmacophore approach, Affini et al.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> designed and synthesized MAO-B/H<sub>3</sub>R dual-target ligands for PD therapy. The alkyloxyphenyl linker of compound <b>66</b> was kept, whereas the imidazole moiety was replaced by piperidine (from UCL2190, <b>67</b>) which fits the H<sub>3</sub>R pharmacophore more favorably. Series I was designed by introduction of the H<sub>3</sub>R pharmacophore to the C5 or C6 position of the indanone scaffold of compound <b>68</b>. Series II was designed by introducing the H<sub>3</sub>R motif to the C5 or C6 position of the more lipophilic 2-benzylideneindanone derivative <b>69</b>. Series III was designed by introducing the H<sub>3</sub>R motif to the benzylidene ring B at the C4′ position (<a class="ref internalNav" href="#sch20" aria-label="Scheme 20">Scheme 20</a>). Extensive SAR studies generated various chemotypes of dual MAO-B/hH<sub>3</sub>R inhibitors. Compound <b>70</b> (from series III) showed strong activities on MAO-B and hH<sub>3</sub>R, as well as selectivity on MAO-B over A (SI > 36) (<a class="ref showTableEvent internalNav" data-ID="tbl16" href="#tbl16">Table <a class="ref showTableEvent internalNav" data-ID="tbl16" href="#tbl16">16</a></a>). Thus, indanone-substituted derivatives are potent lead compounds for MAO-B/hH<sub>3</sub>R dual-target candidates for the treatment of PD.</div><figure id="sch20" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0020.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. MTDLs Targeting MAO-B and H<sub>3</sub>R for PD<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl16"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 16. Biological Activities of MTDLs Targeting MAO-B and H<sub>3</sub>R<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">MAO-A</th><th class="colsep0 rowsep0" align="center">MAO-B</th><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">SI<a class="ref internalNav" href="#t16fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">H<sub>3</sub>R</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b>, ciproxifan</td><td class="colsep0 rowsep0" align="left">2100</td><td class="colsep0 rowsep0" align="left">11000</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="left">46–180</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b>, UCL2190</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="left">>1000000</td><td class="colsep0 rowsep0" align="left">9.2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">276</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t16fn1"><div class="footnote" id="t16fn1"><sup><sup>a</sup></sup><p class="last">Selectivity index (SI) = IC<sub>50</sub>(MAO-A)/IC<sub>50</sub>(MAO-B).</p></div></div></div><div class="NLM_p">Among the validated targets for PD treatment, A<sub>2A</sub> adenosine receptor (AR) and MAO-B are two most important ones.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> Combined with levodopa, MAO-B inhibitors can inhibit dopamine metabolism in the brain and therefore increase the levels of dopamine. Compound <b>71</b> is a strong A<sub>2A</sub> antagonist.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> Caffeine (<b>72</b>) is a nonselective AR antagonists with cognitive enhancer efficacy in treating PD and AD.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> In 2014, the first compound is reported to inhibit all three targets of interest, A<sub>1</sub>, A<sub>2A</sub>ARs, and MAO-B.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> In 2016, Brunschweiger et al.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> further developed a series of novel derivatives based on compound <b>71</b> via SAR investigation. The benzyl group of compound <b>71</b> was substituted by diverse aromatic groups, and there substituent groups were introduced directly or through various linkers to the N8 of the pyrazinopurine scaffold (<a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>). Among these compounds, compound <b>73</b> showed comparable inhibitory activities on A<sub>1</sub>, A<sub>2A</sub>ARs, and MAO-B (<a class="ref showTableEvent internalNav" data-ID="tbl17" href="#tbl17">Table <a class="ref showTableEvent internalNav" data-ID="tbl17" href="#tbl17">17</a></a>).</div><figure id="sch21" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0021.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. MTDLs Targeting MAO-B and A<sub>1</sub>/A<sub>2A</sub> AR for PD<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl17"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 17. Biological Activities of MTDLs Targeting MAO-B and A<sub>1</sub>/A<sub>2A</sub> AR<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">A<sub>1</sub>AR</th><th class="colsep0 rowsep0" align="center">A<sub>2A</sub>AR</th><th class="colsep0 rowsep0" align="center">hMAO-A</th><th class="colsep0 rowsep0" align="center">hMAO-B</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="left">0.265 ± 0.068</td><td class="colsep0 rowsep0" align="left">1.06 ± 0.30</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>10.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left">44.9</td><td class="colsep0 rowsep0" align="left">23.4</td><td class="colsep0 rowsep0" align="left">>50.0</td><td class="colsep0 rowsep0" align="left">>50.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>73</b></td><td class="colsep0 rowsep0" align="left">0.393 ± 0.101</td><td class="colsep0 rowsep0" align="left">0.595 ± 0.051</td><td class="colsep0 rowsep0" align="left">>10.0</td><td class="colsep0 rowsep0" align="left">0.210 ± 0.041</td></tr></tbody></table></div></div></div><div id="sec7_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68">7.2.5.  MTDLs Targeting SERT/5-HT<sub>1A</sub>/5-HT<sub>7</sub> for Depression</h4><div class="NLM_p">Depression is one of the leading causes of disability in the world.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> However, there are still significant challenges for depression treatment, such as limited patient response rate and tremendous adverse effects.<a onclick="showRef(event, 'ref213 ref214'); return false;" href="javascript:void(0);" class="ref ref213 ref214">(213,214)</a> The combination of SERT and 5-HT receptor inhibition may be an effective strategy for treating depression.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> Recent research indicated that pindolol could enhance selective serotonin reuptake inhibitors (SSRIs) effects and simultaneously target 5-HT<sub>1A</sub>.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> Additionally, the combination of selective 5-HT<sub>7</sub> receptor antagonist with even a low dose of SSRI was effective in depression models. Hence, MTDLs toward SERT/5-HT<sub>1A</sub>/5-HT<sub>7</sub> may be valuable for treating depression.</div><div class="NLM_p">The benzofuran derivative <b>77</b> showed high binding affinity to the 5-HT<sub>1A</sub> receptor and SERT.<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> 2-Biphenylpiperazine derivatives <b>74</b>–<b>76</b> exhibited high affinity to 5-HT<sub>1A</sub> as well as 5-HT<sub>7</sub> receptors.<a onclick="showRef(event, 'ref218 ref219 ref220'); return false;" href="javascript:void(0);" class="ref ref218 ref219 ref220">(218−220)</a> On the basis of the knowledge above, Gu et al.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> reported a series of novel aralkylpiperazine compounds in a merged-pharmacophore approach. To explore the affinity to 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> receptors, the N1 position was introduced by diverse aromatic groups. And they tested if replacing the benzofuran scaffold with indole scaffold could enhance serotonin reuptake inhibition (<a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>). Among the series of compounds, compound <b>78</b> exhibited high affinity to 5-HT<sub>1A</sub>/5-HT<sub>7</sub> and strong serotonin reuptake inhibition (RUI) (<a class="ref showTableEvent internalNav" data-ID="tbl18" href="#tbl18">Table <a class="ref showTableEvent internalNav" data-ID="tbl18" href="#tbl18">18</a></a>).</div><figure id="sch22" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0022.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. MTDLs Targeting SERT/5-HT<sub>1A</sub>/5-HT<sub>7</sub> for Depression<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl18"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 18. Biological Activities of MTDLs Targeting SERT/5-HT<sub>1A</sub>/5-HT<sub>7</sub><a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">5-HT<sub>1A</sub></th><th class="colsep0 rowsep0" align="center">5-HT<sub>7</sub></th><th class="colsep0 rowsep0" align="center">SERT</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>74</b></td><td class="colsep0 rowsep0" align="left">60.9</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>75</b></td><td class="colsep0 rowsep0" align="left">188</td><td class="colsep0 rowsep0" align="left">0.58</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>76</b></td><td class="colsep0 rowsep0" align="left">99</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>77</b></td><td class="colsep0 rowsep0" align="left">1.94</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">25.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">25</td></tr></tbody></table></div></div></div><div id="sec7_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71">7.2.6.  MTDLs Targeting Dopamine D<sub>2</sub> Receptor and Serotonin Reuptake for Schizophrenia</h4><div class="NLM_p">Schizophrenia is an overwhelming mental disease.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> Though typical antipsychotics show improvement in mitigating positive symptoms by blocking dopamine D<sub>2</sub> receptors (D<sub>2</sub>Rs),<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> they may also lead to extrapyramidal symptoms (EPS) like PD and tardive dyskinesia.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> The combination of a neuroleptic together with a SSRI showed improved efficacy for schizophrenia, at the same time a decrease in depression, without exacerbating EPS.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> Therefore, Smid et al.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> designed hybrids based on the templates of a well-known dopamine D<sub>2</sub> receptor inhibitor (eltoprazine,<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a><b>80</b>) and a serotonin reuptake (SR) inhibitor (indalpine, <b>79</b>) (<a class="ref internalNav" href="#sch23" aria-label="Scheme 23">Scheme 23</a>). They took some factors into consideration for receptor affinity: (i) the length of the alkyl linker between the aryl and indole piperazine groups; (ii) the substitution pattern of the indole scaffold; (iii) the bicyclic heteroaryl structure. Some key candidates showed potent in vitro and in vivo pharmacological activities, especially compound <b>81</b>. Molecular docking also indicated that compound <b>81</b> can adopt two different conformations, which fit the SR pharmacophore and dopamine D<sub>2</sub> receptor pharmacophore, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl19" href="#tbl19">Table <a class="ref showTableEvent internalNav" data-ID="tbl19" href="#tbl19">19</a></a>).</div><figure id="sch23" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0023.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. MTDLs Targeting Dopamine D<sub>2</sub> Receptor and Serotonin Reuptake for Schizophrenia<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl19"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 19. Biological Activities of MTDLs Targeting Dopamine D<sub>2</sub> Receptor and Serotonin Reuptake<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">in vitro</th><th class="rowsep1 colsep0" colspan="2" align="center">in vivo</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">hD<sub>2</sub></th><th class="colsep0 rowsep0" align="center">rSR</th><th class="colsep0 rowsep0" align="center">APO<a class="ref internalNav" href="#t19fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">5-HTP<a class="ref internalNav" href="#t19fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (mg/kg)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>79</b>, indalpine</td><td class="colsep0 rowsep0" align="left">2.0 ± 0.1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>80</b>, eltoprazine</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.0 ± 0.1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>81</b></td><td class="colsep0 rowsep0" align="left">6.9 ± 1.8</td><td class="colsep0 rowsep0" align="left">0.2 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" align="left">0.15</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t19fn1"><div class="footnote" id="t19fn1"><sup><sup>a</sup></sup><p class="last">Antagonizing apomorphine induced climbing behavior in mice (po).</p></div><div class="footnote" id="t19fn2"><sup><sup>b</sup></sup><p class="last">5-HTP induced serotonin syndrome like behavior in mice (po).</p></div></div></div></div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74">7.3.  MTDLs for Cardiovascular Diseases</h3><div class="NLM_p">Cardiovascular diseases are the leading causes of death in humans,<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> the pathological process of which is multifactorial.<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> The development of MTDLs may bring great benefits for cardiovascular disease patients.<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(229)</a></div><div id="sec7_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75">7.3.1.  MTDLs Targeting AT<sub>1</sub> and ET<sub>A</sub> for Hypertension</h4><div class="NLM_p">In the renin–angiotensin–aldosterone system (RAAS), angiotensin II (Ang II) binds to two G-protein-coupled receptors (GPCRs), angiotensin II type 1 (AT<sub>1</sub>) and AT<sub>2</sub>, leading to vasoconstriction and the release of vasopressin and aldosterone.<a onclick="showRef(event, 'ref230 ref231'); return false;" href="javascript:void(0);" class="ref ref230 ref231">(230,231)</a> Therefore, an antagonist for AT<sub>1</sub> and AT<sub>2</sub> might be useful for treating cardiovascular diseases.<a onclick="showRef(event, 'ref9 ref232'); return false;" href="javascript:void(0);" class="ref ref9 ref232">(9,232)</a> The endothelin receptors ET<sub>A</sub> and ET<sub>B</sub> are also potential targets for cardiovascular diseases.<a onclick="showRef(event, 'ref233 ref234'); return false;" href="javascript:void(0);" class="ref ref233 ref234">(233,234)</a> ET<sub>A</sub> regulates vasoconstriction, whereas ET<sub>B</sub> counteracts these effects by facilitating the synthesis of vasodilators prostacycline and nitric oxide.<a onclick="showRef(event, 'ref235 ref236'); return false;" href="javascript:void(0);" class="ref ref235 ref236">(235,236)</a></div><div class="NLM_p">In merged-pharmacophore approach, Murugesan et al.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> reported a dual-target AT<sub>1</sub> and ET<sub>A</sub> antagonist. Compound <b>82</b> (a known ET<sub>A</sub> antagonist) was selected as the template. Irbesartan (compound <b>83)</b> is an AT<sub>1</sub> antagonist approved by many regulatory agencies. They merged the pharmacophores of <b>82</b> (a biphenylsulfonamide attached to a 5-isoxazole) and <b>83</b> (a biphenylimidazolone). Moreover, the 5-isoxazole was replaced by a 3-isoxazole to improve the metabolic stability (<a class="ref internalNav" href="#sch24" aria-label="Scheme 24">Scheme 24</a>). The resulting compound <b>84</b> exhibited balanced activities for the two targets (<a class="ref showTableEvent internalNav" data-ID="tbl20" href="#tbl20">Table <a class="ref showTableEvent internalNav" data-ID="tbl20" href="#tbl20">20</a></a>). PK profiles such as oral bioavailability, <i>C</i><sub>max</sub>/<i>T</i><sub>max</sub> and half-life in plasma were also tested. Compared to <b>82</b> and <b>83</b>, <b>84</b> exhibited further decreased blood pressure in rats and more durable effects.</div><figure id="sch24" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0024.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. MTDLs Targeting AT<sub>1</sub> and ET<sub>A</sub> for Hypertension<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl20"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 20. Biological Activities of MTDLs Targeting AT<sub>1</sub> and ET<sub>A</sub><a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a><sup>,</sup><a class="ref internalNav" href="#t20fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">ET<sub>A</sub></th><th class="colsep0 rowsep0" align="center">AT<sub>1</sub></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>83</b>, irbesartan</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>84</b></td><td class="colsep0 rowsep0" align="left">9.3</td><td class="colsep0 rowsep0" align="left">0.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t20fn1"><div class="footnote" id="t20fn1"><sup><sup>a</sup></sup><p class="last">The maximal efficacy of darglitazone in the PPARγ activation assay was defined as 100%.</p></div></div></div></div><div id="sec7_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78">7.3.2.  MTDLs Targeting PPARγ and AT<sub>2</sub> for Cardiovascular Disease</h4><div class="NLM_p">The peroxisome proliferator-activated receptor γ (PPARγ), as a critical target for the prevention of diabetes, is an intracellular nuclear hormone receptor regulating insulin and glucose metabolism.<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(237)</a> The American Heart Association indicated that there’s a strong association between cardiovascular diseases and diabetes; patients with one disease are prone to suffer from the other.<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(238)</a> Therefore, a drug candidate with dual activities to AT<sub>1</sub> and PPARγ may potentially treat symptoms that are cardiovascular risk factors, e.g., hypertension, insulin resistance, and hypertriglyceridemia.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a></div><div class="NLM_p">In merged-pharmacophore approach, Casimiro-Garcia et al.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> developed a dual-active PPARγ agonist and AT<sub>1</sub> antagonist. Telmisartan (compound <b>85)</b> is an approved AT<sub>1</sub> antagonist, and compound <b>86</b> is a PPARγ agonist. A general pharmacophore to address two targets was identified by cross-screening: an acidic head group, a hydrophobic tail, and a nonpolar phenyl linker (<a class="ref internalNav" href="#sch25" aria-label="Scheme 25">Scheme 25</a>). The carboxylic acid was substituted with bioisostere tetrazole ring with a large size to fully occupy the binding pocket and keep the favorable interactions. Further, they complemented the biphenyl linker of compound <b>85</b> with a cyclopentyl group to reduce polarity. The template benzimidazole was substituted with a pyridine imidazole to enhance the interactions with the charged binding site (<a class="ref internalNav" href="#sch25" aria-label="Scheme 25">Scheme 25</a>). Among the 15 synthesized molecules, compound <b>87</b> has optimal activity profile on both targets (<a class="ref showTableEvent internalNav" data-ID="tbl21" href="#tbl21">Table <a class="ref showTableEvent internalNav" data-ID="tbl21" href="#tbl21">21</a></a>). In two in vivo models, compound <b>87</b> also reduced blood pressure for a longer duration compared with the approved drug telmisartan.</div><figure id="sch25" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0025.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Design of Multitargeted Agents Targeting PPARγ and AT<sub>1</sub> for Hypertension<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl21"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 21. Biological Activities of MTDLs Targeting PPARγ and AT<sub>1</sub><a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center" char=".">AT<sub>1</sub></th><th class="colsep0 rowsep0" align="center" char=".">hPPARγ</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM) (% max)<a class="ref internalNav" href="#t21fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b>, telmisartan</td><td class="colsep0 rowsep0" align="char" char=".">0.49</td><td class="colsep0 rowsep0" align="char" char=".">1520</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pioglitazone</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1280</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>87</b></td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">212</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t21fn1"><div class="footnote" id="t21fn1"><sup><sup>a</sup></sup><p class="last">The maximal efficacy of darglitazone in the PPARγ activation assay was defined as 100%.</p></div></div></div></div><div id="sec7_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81">7.3.3.  MTDLs Targeting ACE and DPP4 for Hypertension and Diabetes, Respectively</h4><div class="NLM_p">It has been estimated that about 70% of patients with type 2 diabetes are hypertensive.<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(240)</a> On the other hand, the risk of suffering from type 2 diabetes is far higher in patients with hypertension.<a onclick="showRef(event, 'ref241'); return false;" href="javascript:void(0);" class="ref ref241">(241)</a> For the patients with both hypertension and diabetes, taking angiotensin converting enzyme (ACE) inhibitors and dipeptidyl peptidase 4 (DPP4) inhibitors is the common practice. However, the combinations of multiple prescription drugs could be challenging for patient compliance. Therefore, dual-target inhibitors for ACE and DPP4 may further improve the treatment of cardiovascular disease.</div><div class="NLM_p">In 2017, Sattigeri et al.<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a> reported a new series of dual inhibitors for ACE and DPP4. Initially, they analyzed ligand-ACE and ligand-DPP4 cocrystal structures to orient the design of dual inhibitors.<a onclick="showRef(event, 'ref243 ref244 ref245 ref246'); return false;" href="javascript:void(0);" class="ref ref243 ref244 ref245 ref246">(243−246)</a> Thus, ACE inhibitors need a carboxy group, a zinc chelating group (SH or COOH), and a hydrophobic group to occupy the pocket of ACE. DPP4 inhibitors typically need a hydrophobic moiety (such as trifluorophenyl to interact with a serine) and a basic amine (such as amino to form a salt bridge with glutamic acid). The structure analysis of fosinoprilat (<b>89</b>) and zofenopril (<b>90</b>) suggested that the proline ring of enalaprilat (<b>88</b>) can be further substituted. A similar analysis of DPP4 inhibitors (<b>91</b> and <b>92</b>) suggested that the pocket of DDP4 was large enough to accommodate certain substitutions, and ACE ligand can be merged at the triazolopiperidine ring of compound <b>91</b> (<a class="ref internalNav" href="#sch26" aria-label="Scheme 26">Scheme 26</a>A). Thus, they removed the triazolopiperidine motif of compound <b>91</b> and incorporated all necessary scaffolds for ACE and DPP4 inhibitionvia an amide (<a class="ref internalNav" href="#sch26" aria-label="Scheme 26">Scheme 26</a>B). Among the hybrids, compound <b>93</b> was the strongest dual inhibitor of DPP4 and ACE (<a class="ref showTableEvent internalNav" data-ID="tbl22" href="#tbl22">Table <a class="ref showTableEvent internalNav" data-ID="tbl22" href="#tbl22">22</a></a>) and showed good PK properties in plasma (AUC = 23.49 μg·h/mL, <i>C</i><sub>max</sub> = 2.51 μg/mL).</div><figure id="sch26" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0026.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. MTDLs Targeting ACE and DPP4 for Hypertension and Diabetes<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Representative scaffold of ACE and DPP4 inhibitors.<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a> (B) ACE/DPP4 dual inhibitors merged by enalaprilat <b>82</b> and sitagliptin <b>85</b>.</p></p></figure><div class="NLM_table-wrap" id="tbl22"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 22. Biological Activities of MTDLs Targeting ACE and DPP4<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">ACE inhibiton,<a class="ref internalNav" href="#t22fn1" aria-label="a">a</a> IC<sub>50</sub> (nM)</th><th class="rowsep1 colsep0" colspan="3" align="center">DPP4 inhibiton,<a class="ref internalNav" href="#t22fn1" aria-label="a">a</a> IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>88</b>, enalaprilat</td><td class="colsep0 rowsep0" align="left">9.6</td><td class="colsep0 rowsep0" align="left">11.5</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>100 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>91</b>, sitagliptin</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">11 μM</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>93</b></td><td class="colsep0 rowsep0" align="left">2800</td><td class="colsep0 rowsep0" align="left">2210</td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left">1230</td><td class="colsep0 rowsep0" align="left">7170</td><td class="colsep0 rowsep0" align="left">102</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t22fn1"><div class="footnote" id="t22fn1"><sup><sup>a</sup></sup><p class="last">Plasma from Wistar rat, <i>ob</i>/<i>ob</i> mouse, and human was used as source of ACE and DPP4 enzymes.</p></div></div></div></div></div><div id="sec7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84">7.4.  MTDLs for Infectious Disease</h3><div id="sec7_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85">7.4.1.  MTDLs Targeting Integrase and Reverse Transcriptase for AIDS</h4><div class="NLM_p">Human immunodeficiency virus (HIV) is the pathogen of acquired immunodeficiency syndrome (AIDS). Integrase (IN) and reverse transcriptase (RT) are two enzymes for indispensable HIV-1 replication.<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a> IN integrates viral DNA into the host genome, whereas RT transcribes single-stranded RNA viral genome into double-stranded DNA.<a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a> Recently, designing MTDLs for IN and RT dual inhibition is emerging for anti-HIV research.<a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a></div><div class="NLM_p">Wang et al.<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a> provided the first IN/RT dual inhibitors. TNK-651 (<b>94</b>) is a strong non-nucleoside RT inhibitor, whose N-1 substituent group stretches from the NNRTI binding site to the protein/solvent interface<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a> (<a class="ref internalNav" href="#sch27" aria-label="Scheme 27">Scheme 27</a>). It would tolerate the integration of another pharmacophore for IN.<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a> GS-9137 (<b>95</b>)<a onclick="showRef(event, 'ref252'); return false;" href="javascript:void(0);" class="ref ref252">(252)</a> is a very strong IN inhibitor with a quinolone carboxylic acid core. Therefore, linking quinolone pharmacophore and pyrimidine generated IN/RT dual inhibitors, e.g., compound <b>96</b> (<a class="ref showTableEvent internalNav" data-ID="tbl23" href="#tbl23">Table <a class="ref showTableEvent internalNav" data-ID="tbl23" href="#tbl23">23</a></a>).</div><figure id="sch27" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0027.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. MTDLs Targeting IN and RT for AIDS<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl23"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 23. Biological Activities of MTDLs Targeting IN and RT<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">IN</th><th class="colsep0 rowsep0" align="center">RT</th><th class="colsep0 rowsep0" align="center">HIV</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>94</b>, TNK-651</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">0.057</td><td class="colsep0 rowsep0" align="left">0.033</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>95</b>, GS-9137</td><td class="colsep0 rowsep0" align="left">0.0072</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.0009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>96</b></td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="left">0.22</td></tr></tbody></table></div></div><div class="NLM_p">Subsequently, they reported another IN/RT inhibitor<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a> (<a class="ref internalNav" href="#sch28" aria-label="Scheme 28">Scheme 28</a>). In a similar way, through crystallographic analysis, they found that the methylsulfonamide motif at position C-5 of delavirdine (<b>98</b>, an RT inhibitor)<a onclick="showRef(event, 'ref253'); return false;" href="javascript:void(0);" class="ref ref253">(253)</a> was located on the protein/solvent interface, which can tolerate functional substituent groups. Therefore, they substituted the sulfonamide group with a diketoacid (DKA) group (from compound <b>97</b> ) and obtained IN/RTdual inhibitors. Except for a DKA type of metal-chelating functionality, IN binding also needs a hydrophobic aromatic ring adjacent to the chelator that can be satisfied by the indole ring of the hybrid. These hybrids all strongly inhibited both IN and RT enzymatic activities and HIV proliferation in a cell assay. Compound <b>99</b> had the strongest activities among these hybrids (<a class="ref showTableEvent internalNav" data-ID="tbl24" href="#tbl24">Table <a class="ref showTableEvent internalNav" data-ID="tbl24" href="#tbl24">24</a></a>).</div><figure id="sch28" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0028.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. MTDLs Targeting IN and RT for AIDS<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl24"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 24. Biological Activities of MTDLs Targeting IN and RT<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">IN</th><th class="colsep0 rowsep0" align="center">RT</th><th class="colsep0 rowsep0" align="center">HIV</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>97</b></td><td class="colsep0 rowsep0" align="left">0.093</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">0.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>98</b>, delavirdine</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">0.036</td><td class="colsep0 rowsep0" align="left">0.021</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>99</b></td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">0.059</td><td class="colsep0 rowsep0" align="left">0.52</td></tr></tbody></table></div></div></div><div id="sec7_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90">7.4.2.  MTDLs Targeting PfATP6 and Host Hemoglobin Digestion for Malaria</h4><div class="NLM_p">Malaria is a severe disease that leads to over one million deaths per year. More seriously, the parasite has developed resistance to the majority of monotherapy.<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a> For this reason, combination chemotherapy of artemisinin (<b>100</b>) with other antimalarials like quinine (<b>101</b>)<a onclick="showRef(event, 'ref255'); return false;" href="javascript:void(0);" class="ref ref255">(255)</a> is recommended.<a onclick="showRef(event, 'ref256'); return false;" href="javascript:void(0);" class="ref ref256">(256)</a> Quinine can effectively inhibit the asexual erythrocytic forms of malaria, possibly due to the interference with host hemoglobin digestion.<a onclick="showRef(event, 'ref257'); return false;" href="javascript:void(0);" class="ref ref257">(257)</a> A Fe<sup>2+</sup>-activated artemisinin has strong PfATP6 (a critical parasite Ca<sup>2+</sup> transporter) inhibitory activity.<a onclick="showRef(event, 'ref256'); return false;" href="javascript:void(0);" class="ref ref256">(256)</a> On the basis of the knowledge above, Walsh et al.<a onclick="showRef(event, 'ref256'); return false;" href="javascript:void(0);" class="ref ref256">(256)</a> designed a artemisinin–quinine hybrid that was linked covalently (<b>102</b>) (<a class="ref internalNav" href="#sch29" aria-label="Scheme 29">Scheme 29</a>). The vinyl group from quinine was modified for the introduction from artemisinin. This novel hybrid had strong in vitro activity on the (drug-resistant) FcB1 and 3D7 strains of <i>Plasmodium falciparum</i>. The activity was better than quinine alone, artemisinin alone, or a 1:1 mixture of quinine and artemisinin (<a class="ref showTableEvent internalNav" data-ID="tbl25" href="#tbl25">Table <a class="ref showTableEvent internalNav" data-ID="tbl25" href="#tbl25">25</a></a>).</div><figure id="sch29" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0029.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. MTDLs Targeting PfATP6 and Host Hemoglobin Digestion for Malaria</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl25"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 25. Biological Activities of MTDLs Targeting PfATP6 and Host Haemoglobin Digestion<a onclick="showRef(event, 'ref256'); return false;" href="javascript:void(0);" class="ref ref256">(256)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">3D7 (48 h)</th><th class="colsep0 rowsep0" align="center">3D7 (72 h)</th><th class="colsep0 rowsep0" align="center">FcB1 (48 h)</th><th class="colsep0 rowsep0" align="center">FcB1 (72 h)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>100</b>, artemisinin</td><td class="colsep0 rowsep0" align="left">49.4</td><td class="colsep0 rowsep0" align="left">45.5</td><td class="colsep0 rowsep0" align="left">50.0</td><td class="colsep0 rowsep0" align="left">55.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>101</b>, quinine</td><td class="colsep0 rowsep0" align="left">149</td><td class="colsep0 rowsep0" align="left">73.5</td><td class="colsep0 rowsep0" align="left">96.8</td><td class="colsep0 rowsep0" align="left">75.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>102</b></td><td class="colsep0 rowsep0" align="left">8.95</td><td class="colsep0 rowsep0" align="left">10.4</td><td class="colsep0 rowsep0" align="left">9.59</td><td class="colsep0 rowsep0" align="left">10.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">quinine + artemisinin<a class="ref internalNav" href="#t25fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">31.8</td><td class="colsep0 rowsep0" align="left">28.6</td><td class="colsep0 rowsep0" align="left">27.9</td><td class="colsep0 rowsep0" align="left">26.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t25fn1"><div class="footnote" id="t25fn1"><sup><sup>a</sup></sup><p class="last">Values represent concentrations of each of quinine and artemisinin in a 1:1 ratio.</p></div></div></div></div></div><div id="sec7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93">7.5.  MTDLs Targeting 15-LOX and COX-2 for Inflammation</h3><div class="NLM_p">MTDLs comprising various targets for inflammation exhibited good therapeutic potentials.<a onclick="showRef(event, 'ref258'); return false;" href="javascript:void(0);" class="ref ref258">(258)</a> The activation of lipoxygenases (LOXs) and cyclooxygenases (COXs) are both crucial for generating multiple downstream mediators for inflammation.<a onclick="showRef(event, 'ref259'); return false;" href="javascript:void(0);" class="ref ref259">(259)</a> Overexpression of 15-LOX is related to some inflammatory diseases due to downstream production of 15(<i>S</i>)-hydroxyeicosatetraenoic acid (15-HETE) and eoxins.<a onclick="showRef(event, 'ref260'); return false;" href="javascript:void(0);" class="ref ref260">(260)</a> As for COX, it has two isoforms: COX-1 and COX-2.<a onclick="showRef(event, 'ref261'); return false;" href="javascript:void(0);" class="ref ref261">(261)</a> COX-1 participates in the prostaglandins synthesis, which is important for normal physiology of some organs, such as gastrointestinal tract and kidney, whereas COX-2 mainly participates in the process of inflammation.<a onclick="showRef(event, 'ref262'); return false;" href="javascript:void(0);" class="ref ref262">(262)</a></div><div class="NLM_p">Omar et al.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> reported an anti-inflammatory MTDL for 15-LOX and COX-2 dual inhibition. They surmised that the hybridization of the pharmacophores 4-thiazolidinone (from <b>103</b>, a 15-LOX inhibitor) and 1,3,4-thiadiazole (from <b>104</b>, a COX-2 inhibitor) could strongly inhibit inflammation with minimal adverse effects. Merging both scaffolds was expected to provide better selectivity on COX-2 over COX-1 because the large size of the hybrid compound may not fit in the COX-1 binding pocket, which is smaller than COX-2 (<a class="ref internalNav" href="#sch30" aria-label="Scheme 30">Scheme 30</a>).<a onclick="showRef(event, 'ref263'); return false;" href="javascript:void(0);" class="ref ref263">(263)</a> Adopting a fused-pharmacophore approach, compound <b>105</b> showed activities against COX-2 and 15-LOX (<a class="ref showTableEvent internalNav" data-ID="tbl26" href="#tbl26">Table <a class="ref showTableEvent internalNav" data-ID="tbl26" href="#tbl26">26</a></a>). Additionally, it showed in vitro inhibitory activity on LOX significantly higher than zileuton and was well tolerated in animal models (<a class="ref showTableEvent internalNav" data-ID="tbl26" href="#tbl26">Table <a class="ref showTableEvent internalNav" data-ID="tbl26" href="#tbl26">26</a></a>).</div><figure id="sch30" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0030.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 30. MTDLs Targeting 15-LOX and COX-2 for Inflammation<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl26"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 26. Biological Activities of MTDLs Targeting 15-LOX and COX-2<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">compd</th><th class="colsep0 rowsep0" align="center">15-LOX</th><th class="colsep0 rowsep0" align="center">COX-1</th><th class="colsep0 rowsep0" align="center">COX-2</th><th class="colsep0 rowsep0" rowspan="2" align="center" valign="middle">SI<a class="ref internalNav" href="#t26fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>103</b></td><td class="colsep0 rowsep0" align="left">8.24</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>104</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8.94</td><td class="colsep0 rowsep0" align="left">0.33</td><td class="colsep0 rowsep0" align="left">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>105</b></td><td class="colsep0 rowsep0" align="left">11.87</td><td class="colsep0 rowsep0" align="left">15.42</td><td class="colsep0 rowsep0" align="left">0.07</td><td class="colsep0 rowsep0" align="left">220.29</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t26fn1"><div class="footnote" id="t26fn1"><sup><sup>a</sup></sup><p class="last">Selectivity index (SI) = IC<sub>50</sub>(COX-1)/IC<sub>50</sub>(COX-2).</p></div></div></div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">8.  Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14756" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14756" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the past few decades, the “one molecule, one target, one disease” paradigm dominated the pharmaceutical industry. But the increasing research studies indicate that perhaps we are entering an exciting new era of systematic discovery of MTDLs.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> So far, the major challenges for rational design of MTDLs are target selection, achieving appropriate ratio of desired activities, and optimizing the PK profiles. Thus, future rational, successful MTDLs discovery calls for a holistic view rather than the reductionistic approach.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">This review provided an overview of recent development of MTDLs for the treatment of multifactorial diseases. The identification and validation of novel target combination in disease relevance and developability perspectives will be critical for success. Balancing the multitarget activities, optimizing the physicochemical and PK profiles, and achieving high selectivity over undesired targets are the most challenging aspects.</div><div class="NLM_p">In addition to the methods discussed above, there are many other computational methods for rational drug design, e.g., the field of quantitative systems pharmacology, a computer-based methodology that combines preclinical neurophysiology, neuropharmacology, and available clinical information, enabling testing of combinations in virtual patients.<a onclick="showRef(event, 'ref264'); return false;" href="javascript:void(0);" class="ref ref264">(264)</a> QSAR methodology has been used to identify molecular factors for target interaction and to propose the best molecules for the following studies.<a onclick="showRef(event, 'ref265'); return false;" href="javascript:void(0);" class="ref ref265">(265)</a> Virtual screening methods have been applied to identify leads in huge in silico libraries of compounds.<a onclick="showRef(event, 'ref266'); return false;" href="javascript:void(0);" class="ref ref266">(266)</a> On the basis of molecular docking, dynamic studies may evaluate the stability of the ligand–protein complexes and determine important interactions in the binding patterns of the ligands.<a onclick="showRef(event, 'ref267'); return false;" href="javascript:void(0);" class="ref ref267">(267)</a></div><div class="NLM_p">Apart from the typical MTDLs inhibiting or activating two or more targets simultaneously, it may be possible to further develop dual functional molecules targeting different systems of the body. For instance, the antibody–drug conjugates (ADCs), hydrophobic tag (HyT), PROTAC are emerging technologies, which are structurally characterized by bifunctionality. For a typical MTDL, it acts on two (or more) different targets to exert additive or synergistic effects. Different from typical MTDLs, molecules designed with the above three technologies can recruit protein of interest (POI), then induce protein–protein interaction (PPI) and POI degradation. ADCs consist of recombinant monoclonal antibodies (mAbs) and cytotoxic chemicals (known as payloads) by linkers.<a onclick="showRef(event, 'ref268'); return false;" href="javascript:void(0);" class="ref ref268">(268)</a> The mAb binds to specific antigens or receptors on cancer cell, then the whole ADC is internalized into the cancer cell, where the payloads exert cytotoxic effects.<a onclick="showRef(event, 'ref269'); return false;" href="javascript:void(0);" class="ref ref269">(269)</a> After about 50 years of research, several ADCs have been approved: trastuzumab emtansine<a onclick="showRef(event, 'ref270'); return false;" href="javascript:void(0);" class="ref ref270">(270)</a> and brentuximab vedotin<a onclick="showRef(event, 'ref271'); return false;" href="javascript:void(0);" class="ref ref271">(271)</a> have paved the way for clinical trials of more ADCs. Hydrophobic tags technology is a small molecule that mimics a misfolded protein conformation. The synthetic hydrophobic groups (such as adamantane, a bulky hydrocarbon) form a covalent bond to the surface of target proteins, inducing their degradation via the proteasomes.<a onclick="showRef(event, 'ref272'); return false;" href="javascript:void(0);" class="ref ref272">(272)</a> An example is fluvestrant<a onclick="showRef(event, 'ref273'); return false;" href="javascript:void(0);" class="ref ref273">(273)</a> approved by the FDA in 2002. Moreover, the PROTAC technology is another strategy for protein degradation. PROTAC is a special kind of MTDL that integrates a target-binding ligand and an E3 ligase ligand into one molecule via a linker. By accessing rather than inhibiting active E3 ligases, PROTAC induces ubiquitination and degradation of the target protein by the proteasome.<a onclick="showRef(event, 'ref274 ref275'); return false;" href="javascript:void(0);" class="ref ref274 ref275">(274,275)</a> Therefore, we can see that the future application of MTDL will become even more diversified.</div><div class="NLM_p last">Therefore, we foresee that the new generation of MTDLs, characterized by the chemical, biological, and theoretical level, provides a road to treat complex diseases effectively.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i97"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00017" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00017" class="ext-link">10.1021/acs.jmedchem.9b00017</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Name, indication, MW, cLogP, PSA, HBA, HBD, RB, number of heteroatoms, and clinical phase of 117 MTDLs on market or in clinical trails (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00017/suppl_file/jm9b00017_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00017/suppl_file/jm9b00017_si_002.pdf">jm9b00017_si_002.pdf (778.3 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00017" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63774" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63774" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Qu</span> - <span class="hlFld-Affiliation affiliation">Department
of Natural Medicinal Chemistry, China Pharmaceutical
University, Nanjing, 211198, People’s Republic
of China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a2d2cdd2cdd3d8cae29390948cc1cdcf"><span class="__cf_email__" data-cfemail="f888978897898290b8c9caced69b9795">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haopeng Sun</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, China Pharmaceutical
University, Nanjing 211198, People’s Republic
of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5109-0304" title="Orcid link">http://orcid.org/0000-0002-5109-0304</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6112140f09000e11040f06215057524f020e0c"><span class="__cf_email__" data-cfemail="3a494f54525b554a5f545d7a0b0c0914595557">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Junting Zhou</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, China Pharmaceutical
University, Nanjing 211198, People’s Republic
of China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Natural Medicinal Chemistry, China Pharmaceutical
University, Nanjing, 211198, People’s Republic
of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xueyang Jiang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, China Pharmaceutical
University, Nanjing 211198, People’s Republic
of China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Natural Medicinal Chemistry, China Pharmaceutical
University, Nanjing, 211198, People’s Republic
of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Siyu He</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, China Pharmaceutical
University, Nanjing 211198, People’s Republic
of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongli Jiang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, China Pharmaceutical
University, Nanjing 211198, People’s Republic
of China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Natural Medicinal Chemistry, China Pharmaceutical
University, Nanjing, 211198, People’s Republic
of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Feng</span> - <span class="hlFld-Affiliation affiliation">Department
of Natural Medicinal Chemistry, China Pharmaceutical
University, Nanjing, 211198, People’s Republic
of China</span>; 
    <span class="hlFld-Affiliation affiliation">Jiangsu
Food and Pharmaceutical Science College, Huaian 223003, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenyuan Liu</span> - <span class="hlFld-Affiliation affiliation">Department
of Analytical Chemistry, China Pharmaceutical
University, Nanjing 210009, People’s Republic
of China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>H.S., W.Q., and J.Z. were responsible for writing this manuscript. All authors have participated in the checking and revision of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38552" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38552" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Junting Zhou</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=BIO-d7e5497-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Junting Zhou</b> received her Bachelor’s degree from China Pharmaceutical University in 2016. She is currently a postgraduate student at the Department of Natural Medicinal Chemistry (China Pharmaceutical University) under the supervision of Prof. Feng Feng. Her main research focuses on the discovery, synthesis, and biological evaluation of designed multiple ligands targeting Alzheimer’s disease.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Xueyang Jiang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=BIO-d7e5502-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xueyang Jiang</b> studied Pharmacy at Anhui University of Chinese Medicine and received his Bachelor’s degree in 2013. He is pursuing his doctorate in nature medicinal chemistry at China Pharmaceutical University under the supervision of Prof. Feng Feng. His research is focused on the structural optimization and mechanism study of the natural product in the field of Alzheimer disease.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Siyu He</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=BIO-d7e5507-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Siyu He</b> received her Bachelor’s degree from China Pharmaceutical University in 2016. She is currently a postgraduate student at the Department of Medicinal Chemistry (China Pharmaceutical University) under the supervision of Associate Prof. Haopeng Sun. Her research mainly focuses on the discovery, synthesis, and biological evaluation of small molecules targeting autophagy machinery.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Hongli Jiang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=BIO-d7e5512-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hongli Jiang</b> received her Bachelor’s degree from China Pharmaceutical University in 2017. She is currently a postgraduate student at the Department of Natural Medicinal Chemistry (China Pharmaceutical University) under the supervision of Associate Prof. Wei Qu. Her research mainly focuses on the design, synthesis, and biological evaluation of small molecules for AD therapy.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Feng Feng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=BIO-d7e5517-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Feng Feng</b> graduated in Chemistry at Shaanxi Normal University in 1991. He received his Ph.D. in 2001 in Pharmacy, with a thesis about natural products with antitumor activities supervised by Prof. S. X. Zhao. He studied at the University of California, Irvine as Visiting Scholar in 2005. In 2010, he was promoted to Professor of Natural Medicinal Chemistry at China Pharmaceutical University. So far, he has published more than 70 papers in journals indexed by Science Citation Index. His major research interests include extraction and isolation of chemical constituents from natural medicines, structural modification of active compositions, and drug analysis in vivo. In addition, he is focusing on the prevention and treatment of cancer and neurodegenerative agents.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Wenyuan Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=BIO-d7e5522-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wenyuan Liu</b> graduated in Chemistry at Shaanxi Normal University in 1991. She received her Ph.D. in 2004 in Pharmaceutical Analysis, supervised by Prof. Z. X. Zhang. She studied in the University of California, San Diego as Visiting Scholar in 2008. In 2010, she was promoted to Professor of Pharmaceutical Analysis at China Pharmaceutical University. So far, she has published more than 50 research papers in <i>Journal of Chromatography A</i>, <i>Journal of Chromatography B</i>, <i>Journal of Pharmaceutical and Biomedical Analysis</i>, and others. Her major research interests include the analysis of pharmaceutical instruments.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Wei Qu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=BIO-d7e5536-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wei Qu</b> graduated in Traditional Chinese Pharmacy at the China Pharmaceutical University in 2004. She received her Ph.D. in 2009 in Natural Medicinal Chemistry, with a thesis about natural products with antitumor activities supervised by Prof. J. Y. Liang. In 2016, she was promoted to Associate Professor of Natural Medicinal Chemistry at China Pharmaceutical University. Her current research interests are focused on design, synthesis, and biological evaluation of natural compounds and active chemical constituents from natural medicines, in particular, agents targeting neurodegenerative diseases and cancer.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Haopeng Sun</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=BIO-d7e5541-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Haopeng Sun</b> graduated in Pharmacy at the China Pharmaceutical University in 2006. He received his Ph.D. in 2011 in Medicinal Chemistry, with a thesis about the structural optimization and mechanism study of the natural product, with Advisor Prof. Q. D. You. In 2014, he was promoted to Associate Professor of Medicinal Chemistry at China Pharmaceutical University. So far, he has published more than 110 papers in peer-review journals indexed by Science Citation Index. His major research interests include the design, synthesis, and biological evaluation of small molecule bioactive compounds, in particular, agents targeting neurodegenerative diseases. In addition, he is focusing in the field of anticancer and anti-inflammatory agents.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i107">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53458" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53458" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully thank the support from National Natural Science Foundation of China (Grants 81573281 and 81830105). We also thank the support from “Double First-Class” initiative innovation team project of China Pharmaceutical University (Grants CPU2018GF11 and CPU2018GY34). We also appreciate the support from the Joint Laboratory of China Pharmaceutical University and Taian City Central Hospital.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">MTDL</td><td class="NLM_def"><p class="first last">multitarget-directed ligand</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">AChE</td><td class="NLM_def"><p class="first last">acetylcholinesterase</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">DDL</td><td class="NLM_def"><p class="first last">dedifferentiated liposarcoma</p></td></tr><tr><td class="NLM_term">H<sub>1</sub>R</td><td class="NLM_def"><p class="first last">H<sub>1</sub> receptor</p></td></tr><tr><td class="NLM_term">IGF1R</td><td class="NLM_def"><p class="first last">insulin-like growth factor 1 receptor</p></td></tr><tr><td class="NLM_term">CDK4</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase 4</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">NK</td><td class="NLM_def"><p class="first last">neurokinin</p></td></tr><tr><td class="NLM_term">CuAAC</td><td class="NLM_def"><p class="first last">cycloaddition</p></td></tr><tr><td class="NLM_term">TEC</td><td class="NLM_def"><p class="first last">thiol–ene click reaction</p></td></tr><tr><td class="NLM_term">TYC</td><td class="NLM_def"><p class="first last">thiol–yne click reaction</p></td></tr><tr><td class="NLM_term">DA</td><td class="NLM_def"><p class="first last">Diels–Alder reaction</p></td></tr><tr><td class="NLM_term">BRD4</td><td class="NLM_def"><p class="first last">extra-terminal domain 4</p></td></tr><tr><td class="NLM_term">VHL</td><td class="NLM_def"><p class="first last">Von Hippel–Lindau</p></td></tr><tr><td class="NLM_term">CRBN</td><td class="NLM_def"><p class="first last">cereblon</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">RB</td><td class="NLM_def"><p class="first last">rotatable bond</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen bond donor</p></td></tr><tr><td class="NLM_term">HBA</td><td class="NLM_def"><p class="first last">hydrogen bond acceptor</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HDACi</td><td class="NLM_def"><p class="first last">histone deacetylases inhibitor</p></td></tr><tr><td class="NLM_term">ZBG</td><td class="NLM_def"><p class="first last">zinc binding group</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">proteasome inhibitor</p></td></tr><tr><td class="NLM_term">MDM2</td><td class="NLM_def"><p class="first last">murine double minute 2</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">IFI</td><td class="NLM_def"><p class="first last">invasive fungal infection</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">ERα</td><td class="NLM_def"><p class="first last">estrogen receptor α</p></td></tr><tr><td class="NLM_term">SERM</td><td class="NLM_def"><p class="first last">selective estrogen receptor modulator</p></td></tr><tr><td class="NLM_term">PDGFR-β</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor β</p></td></tr><tr><td class="NLM_term">TDZD</td><td class="NLM_def"><p class="first last">thiadiazolidinedione</p></td></tr><tr><td class="NLM_term">PAINS</td><td class="NLM_def"><p class="first last">pan assay interference compounds</p></td></tr><tr><td class="NLM_term">TZD</td><td class="NLM_def"><p class="first last">thiazolidinedione</p></td></tr><tr><td class="NLM_term">Aβ</td><td class="NLM_def"><p class="first last">amyloid-β</p></td></tr><tr><td class="NLM_term">NFT</td><td class="NLM_def"><p class="first last">neurofibrillary tangle</p></td></tr><tr><td class="NLM_term">ACh</td><td class="NLM_def"><p class="first last">acetylcholine</p></td></tr><tr><td class="NLM_term">AChEI</td><td class="NLM_def"><p class="first last">acetylcholinesterase inhibitor</p></td></tr><tr><td class="NLM_term">GSK-3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase 3β</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">hH<sub>3</sub>R</td><td class="NLM_def"><p class="first last">human histamine H<sub>3</sub> receptor</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">adenosine receptor</p></td></tr><tr><td class="NLM_term">SSRI</td><td class="NLM_def"><p class="first last">selective serotonin reuptake inhibitor</p></td></tr><tr><td class="NLM_term">RUI</td><td class="NLM_def"><p class="first last">reuptake inhibition</p></td></tr><tr><td class="NLM_term">D<sub>2</sub>R</td><td class="NLM_def"><p class="first last">dopamine D<sub>2</sub> receptor</p></td></tr><tr><td class="NLM_term">Ang II</td><td class="NLM_def"><p class="first last">angiotensin II</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">PPARγ</td><td class="NLM_def"><p class="first last">proliferator-activated receptor γ</p></td></tr><tr><td class="NLM_term">DPP4</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase 4</p></td></tr><tr><td class="NLM_term">ACE</td><td class="NLM_def"><p class="first last">angiotensin converting enzyme</p></td></tr><tr><td class="NLM_term">COX</td><td class="NLM_def"><p class="first last">cyclooxygenase</p></td></tr><tr><td class="NLM_term">LOX</td><td class="NLM_def"><p class="first last">lipoxygenase</p></td></tr><tr><td class="NLM_term">15-HETE</td><td class="NLM_def"><p class="first last">15(<i>S</i>)-hydroxyeicosatetraenoic acid</p></td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody–drug conjugate</p></td></tr><tr><td class="NLM_term">HyT</td><td class="NLM_def"><p class="first last">hydrophobic tag</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteosis-targeting chimera</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">protein–protein interaction</p></td></tr><tr><td class="NLM_term">POI</td><td class="NLM_def"><p class="first last">protein of interest</p></td></tr><tr><td class="NLM_term">mAbs</td><td class="NLM_def"><p class="first last">monoclonal antibodies</p></td></tr><tr><td class="NLM_term">BED4</td><td class="NLM_def"><p class="first last">bromodomain and extra-terminal domain 4</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">STS</td><td class="NLM_def"><p class="first last">steroid sulfatase</p></td></tr><tr><td class="NLM_term">EPS</td><td class="NLM_def"><p class="first last">extrapyramidal symptom</p></td></tr><tr><td class="NLM_term">SR</td><td class="NLM_def"><p class="first last">serotonin reuptake</p></td></tr><tr><td class="NLM_term">AT<sub>1</sub></td><td class="NLM_def"><p class="first last">angiotensin II type 1</p></td></tr><tr><td class="NLM_term">HEL</td><td class="NLM_def"><p class="first last">human embryonic lung fibroblast</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i109">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00326" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00326" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 275 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giulianotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welmaker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghten, R. A.</span></span> <span> </span><span class="NLM_article-title">Shifting from the Single to the Multitarget Paradigm in Drug Discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">9–10</span>),  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2013.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23340113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC3szhsV2rsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=495-501&issue=9%E2%80%9310&author=J.+L.+Medina-Francoauthor=M.+A.+Giulianottiauthor=G.+S.+Welmakerauthor=R.+A.+Houghten&title=Shifting+from+the+Single+to+the+Multitarget+Paradigm+in+Drug+Discovery&doi=10.1016%2Fj.drudis.2013.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Shifting from the single to the multitarget paradigm in drug discovery</span></div><div class="casAuthors">Medina-Franco Jose L; Giulianotti Marc A; Welmaker Gregory S; Houghten Richard A</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">495-501</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increasing evidence that several drug compounds exert their effects through interactions with multiple targets is boosting the development of research fields that challenge the data reductionism approach.  In this article, we review and discuss the concepts of drug repurposing, polypharmacology, chemogenomics, phenotypic screening and high-throughput in vivo testing of mixture-based libraries in an integrated manner.  These research fields offer alternatives to the current paradigm of drug discovery, from a one target-one drug model to a multiple-target approach.  Furthermore, the goals of lead identification are being expanded accordingly to identify not only 'key' compounds that fit with a single-target 'lock', but also 'master key' compounds that favorably interact with multiple targets (i.e. operate a set of desired locks to gain access to the expected clinical effects).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOFtVP-kWcL7qxQ2mb9Pu8fW6udTcc2eZ65j1YJfHt2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szhsV2rsQ%253D%253D&md5=b4f8c7d1ebbbf32ed4c6c87500baf66f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26aulast%3DGiulianotti%26aufirst%3DM.%2BA.%26aulast%3DWelmaker%26aufirst%3DG.%2BS.%26aulast%3DHoughten%26aufirst%3DR.%2BA.%26atitle%3DShifting%2520from%2520the%2520Single%2520to%2520the%2520Multitarget%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26issue%3D9%25E2%2580%259310%26spage%3D495%26epage%3D501%26doi%3D10.1016%2Fj.drudis.2013.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A.</span></span> <span> </span><span class="NLM_article-title">Network Pharmacology: The Next Paradigm in Drug Discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&issue=11&author=A.+Hopkins&title=Network+Pharmacology%3A+The+Next+Paradigm+in+Drug+Discovery&doi=10.1038%2Fnchembio.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0lg7zEMUepnoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%26atitle%3DNetwork%2520Pharmacology%253A%2520The%2520Next%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26issue%3D11%26spage%3D682%26epage%3D690%26doi%3D10.1038%2Fnchembio.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D. F.</span></span> <span> </span><span class="NLM_article-title">Designing Multi-Targeted Agents: An Emerging Anticancer Drug Discovery Paradigm</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2017.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28494256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=195-211&author=R.+G.+Fuauthor=Y.+Sunauthor=W.+B.+Shengauthor=D.+F.+Liao&title=Designing+Multi-Targeted+Agents%3A+An+Emerging+Anticancer+Drug+Discovery+Paradigm&doi=10.1016%2Fj.ejmech.2017.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm</span></div><div class="casAuthors">Fu, Rong-geng; Sun, Yuan; Sheng, Wen-bing; Liao, Duan-fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195-211</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is to design ligands with max. selectivity to act on individual drug targets.  With the target-based approach, many new chem. entities have been discovered, developed, and further approved as drugs.  However, there are a large no. of complex diseases such as cancer that cannot be effectively treated or cured only with one medicine to modulate the biol. function of a single target.  As simultaneous intervention of two (or multiple) cancer progression relevant targets has shown improved therapeutic efficacy, the innovation of multi-targeted drugs has become a promising and prevailing research topic and numerous multi-targeted anticancer agents are currently at various developmental stages.  However, most multi-pharmacophore scaffolds are usually discovered by serendipity or screening, while rational design by combining existing pharmacophore scaffolds remains an enormous challenge.  In this review, four types of multi-pharmacophore modes are discussed, and the examples from literature will be used to introduce attractive lead compds. with the capability of simultaneously interfering with different enzyme or signaling pathway of cancer progression, which will reveal the trends and insights to help the design of the next generation multi-targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGjXR-zscrArVg90H21EOLACvtfcHk0lg7zEMUepnoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D&md5=511561bd2cd186d5dafa905b7257bf32</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DR.%2BG.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DW.%2BB.%26aulast%3DLiao%26aufirst%3DD.%2BF.%26atitle%3DDesigning%2520Multi-Targeted%2520Agents%253A%2520An%2520Emerging%2520Anticancer%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D136%26spage%3D195%26epage%3D211%26doi%3D10.1016%2Fj.ejmech.2017.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valabrega, G.</span></span> <span> </span><span class="NLM_article-title">Multitarget Drugs: The Present and the Future of Cancer Therapy</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1517/14656560902781907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1517%2F14656560902781907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19284362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtF2mu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=589-600&issue=4&author=A.+Petrelliauthor=G.+Valabrega&title=Multitarget+Drugs%3A+The+Present+and+the+Future+of+Cancer+Therapy&doi=10.1517%2F14656560902781907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget drugs: the present and the future of cancer therapy</span></div><div class="casAuthors">Petrelli, Annalisa; Valabrega, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-600</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Target therapies for the treatment of human cancers have revolutionized the concept of oncol. medicine.  This type of therapeutic approach is directed to the inhibition of mol. targets that play a pivotal role in tumor progression - such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival - mainly by means of compds. able to block their activity.  In the beginning, the aim of target therapies was specifically to hit a single mol. expressed in neoplastic cells.  Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease.  Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different mols.  This review summarizes the mol. basis of multitarget therapies and the most relevant results obtained in different cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSM1xsRJGBX7Vg90H21EOLACvtfcHk0lg7zEMUepnoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtF2mu70%253D&md5=c84e048407e6d9354a1f4a595fb4a468</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F14656560902781907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560902781907%26sid%3Dliteratum%253Aachs%26aulast%3DPetrelli%26aufirst%3DA.%26aulast%3DValabrega%26aufirst%3DG.%26atitle%3DMultitarget%2520Drugs%253A%2520The%2520Present%2520and%2520the%2520Future%2520of%2520Cancer%2520Therapy%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26issue%3D4%26spage%3D589%26epage%3D600%26doi%3D10.1517%2F14656560902781907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghavendra, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pingili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadasi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S. V. U. M.</span></span> <span> </span><span class="NLM_article-title">Dual or Multi-Targeting Inhibitors: The Next Generation Anticancer Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1277</span>– <span class="NLM_lpage">1300</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2017.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29126724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslyrt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1277-1300&author=N.+M.+Raghavendraauthor=D.+Pingiliauthor=S.+Kadasiauthor=A.+Mettuauthor=S.+V.+U.+M.+Prasad&title=Dual+or+Multi-Targeting+Inhibitors%3A+The+Next+Generation+Anticancer+Agents&doi=10.1016%2Fj.ejmech.2017.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dual or multi-targeting inhibitors: The next generation anticancer agents</span></div><div class="casAuthors">Raghavendra, Nulgumnalli Manjunathaiah; Pingili, Divya; Kadasi, Sundeep; Mettu, Akhila; Prasad, S. V. U. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1277-1300</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Dual-targeting/Multi-targeting of oncoproteins by a single drug mol. represents an efficient, logical and alternative approach to drug combinations.  An increasing interest in this approach is indicated by a steady upsurge in the no. of articles on targeting dual/multi proteins published in the last 5 years.  Combining different inhibitors that destiny specific single target is the std. treatment for cancer.  A new generation of dual or multi-targeting drugs is emerging, where a single chem. entity can act on multiple mol. targets.  Dual/Multi-targeting agents are beneficial for solving limited efficiencies, poor safety and resistant profiles of an individual target.  Designing dual/multi-target inhibitors with predefined biol. profiles present a challenge.  The latest advances in bioinformatic tools and the availability of detailed structural information of target proteins have shown a way of discovering multi-targeting mols.  This neoteric artifice that amalgamates the mol. docking of small mols. with protein-based common pharmacophore to design multi-targeting inhibitors is gaining great importance in anticancer drug discovery.  Current review focus on the discoveries of dual targeting agents in cancer therapy using rational, computational, proteomic, bioinformatics and polypharmacol. approach that enables the discovery and rational design of effective and safe multi-target anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVpBUpxW1okLVg90H21EOLACvtfcHk0lhtiHCH3oP73g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslyrt7jO&md5=a14783194c23f7dc5f200cf6eabf9269</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DRaghavendra%26aufirst%3DN.%2BM.%26aulast%3DPingili%26aufirst%3DD.%26aulast%3DKadasi%26aufirst%3DS.%26aulast%3DMettu%26aufirst%3DA.%26aulast%3DPrasad%26aufirst%3DS.%2BV.%2BU.%2BM.%26atitle%3DDual%2520or%2520Multi-Targeting%2520Inhibitors%253A%2520The%2520Next%2520Generation%2520Anticancer%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1277%26epage%3D1300%26doi%3D10.1016%2Fj.ejmech.2017.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Co-Targeting Cancer Drug Escape Pathways Confers Clinical Advantage for Multi-Target Anticancer Drugs</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2015.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.phrs.2015.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=26438971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ShtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=123-131&author=L.+Taoauthor=F.+Zhuauthor=F.+Xuauthor=Z.+Chenauthor=Y.+Y.+Jiangauthor=Y.+Z.+Chen&title=Co-Targeting+Cancer+Drug+Escape+Pathways+Confers+Clinical+Advantage+for+Multi-Target+Anticancer+Drugs&doi=10.1016%2Fj.phrs.2015.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs</span></div><div class="casAuthors">Tao, Lin; Zhu, Feng; Xu, Feng; Chen, Zhe; Jiang, Yu Yang; Chen, Yu Zong</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123-131</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent investigations have suggested that anticancer therapeutics may be enhanced by co-targeting the primary anticancer target and the corresponding drug escape pathways.  Whether this strategy confers statistically significant clin. advantage has not been systematically investigated.  This question was probed by the evaluation of the clin. status and the multiple targets of 23 approved and 136 clin. trial multi-target anticancer drugs with particular focus on those co-targeting EGFR, HER2, Abl, VEGFR2, mTOR, PI3K, Alk, MEK, KIT, and DNA topoisomerase, and some of the 14, 7, 13, 20, 6, 5, 7, 2, 4 and 10 cancer drug escape pathways resp.  Most of the approved (73.9%) and phase III (75.0%), the majority of the Phase II (62.8%) and I (53.6%), and the minority of the discontinued (35.3%) multi-target drugs were found to co-target cancer drug escape pathways.  This suggests that co-targeting anticancer targets and drug escape pathways confer significant clin. advantage and such strategy can be more extensively explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZKuYkoBNEebVg90H21EOLACvtfcHk0lhtiHCH3oP73g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ShtbnM&md5=8596b0d20f94e8e4ec7d74f6cb5c618a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26atitle%3DCo-Targeting%2520Cancer%2520Drug%2520Escape%2520Pathways%2520Confers%2520Clinical%2520Advantage%2520for%2520Multi-Target%2520Anticancer%2520Drugs%26jtitle%3DPharmacol.%2520Res.%26date%3D2015%26volume%3D102%26spage%3D123%26epage%3D131%26doi%3D10.1016%2Fj.phrs.2015.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Multi-Target-Directed Ligands To Combat Neurodegenerative Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1021/jm7009364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&issue=3&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-Target-Directed+Ligands+To+Combat+Neurodegenerative+Diseases&doi=10.1021%2Fjm7009364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0lhtiHCH3oP73g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-Target-Directed%2520Ligands%2520To%2520Combat%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D3%26spage%3D347%26epage%3D372%26doi%3D10.1021%2Fjm7009364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
der Schyf, C. J.</span></span> <span> </span><span class="NLM_article-title">The Use of Multi-Target Drugs in the Treatment of Neurodegenerative Diseases</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1586/ecp.11.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1586%2Fecp.11.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22114774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFGgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=293-298&issue=3&author=C.+J.+Van%0Ader+Schyf&title=The+Use+of+Multi-Target+Drugs+in+the+Treatment+of+Neurodegenerative+Diseases&doi=10.1586%2Fecp.11.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The use of multi-target drugs in the treatment of neurodegenerative diseases</span></div><div class="casAuthors">Van der Schyf, Cornelis J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">293-298</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative disorders lead to increased mortality and morbidity in older patients, and are a great burden on society, where there is currently no approved treatment to prevent the progression of these diseases.  Many clinicians and basic scientists have become persuaded that a strategy aimed at the simultaneous targeting of multiple proteins (and therefore etiologies) involved in the development of a disease should be more beneficial than the currently accepted 'silver bullet' approach.  Select examples of multi-target drug candidates currently under investigation for neurodegenerative diseases are shown.  Importantly, such transition from a 'magic bullet' to a 'magic shotgun' approach may be key in designing future treatment regimens for neurodegenerative diseases and assocd. cognitive decline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAwTj0XbQk3LVg90H21EOLACvtfcHk0lhryqFb-PUJAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFGgsrk%253D&md5=7aa001180af3e144548f7f617aa12c2d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1586%2Fecp.11.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.11.13%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520Use%2520of%2520Multi-Target%2520Drugs%2520in%2520the%2520Treatment%2520of%2520Neurodegenerative%2520Diseases%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D4%26issue%3D3%26spage%3D293%26epage%3D298%26doi%3D10.1586%2Fecp.11.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belluti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampa, A.</span></span> <span> </span><span class="NLM_article-title">Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1759</span>– <span class="NLM_lpage">1782</span>, <span class="refDoi"> DOI: 10.2174/0929867311320130012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F0929867311320130012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23410171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2juro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1759-1782&issue=13&author=A.+Bisiauthor=S.+Gobbiauthor=F.+Bellutiauthor=A.+Rampa&title=Design+of+Multifunctional+Compounds+for+Cardiovascular+Disease%3A+From+Natural+Scaffolds+to+%E2%80%9CClassical%E2%80%9D+Multitarget+Approach&doi=10.2174%2F0929867311320130012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Design of multifunctional compounds for cardiovascular disease: from natural scaffolds to "classical" multitarget approach</span></div><div class="casAuthors">Bisi, A.; Gobbi, S.; Belluti, F.; Rampa, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1759-1782</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cardiovascular disease represents the main cause of death worldwide.  Novel therapies to reduce elevated blood pressure and treat resistant hypertension, to consequently reduce the assocd. cardiovascular risk factors, are still required.  Among the different strategies commonly used in medicinal chem. to develop new mols., the synthesis of multitarget/hybrid compds. combining two or more pharmacophore groups targeting simultaneously selected factors involved in cardiovascular diseases, has gained increasing interest.  This review will focus on the most recent literature on multifunctional cardiovascular drugs, paying particular attention on hybrid compds. bearing natural scaffolds, considering that compds. derived from medicinal exts. are generally appealing for the medicinal chemist as they often bear the so-called "privileged structures".  Moreover, taking into account many excellent reviews dealing with multitarget cardiovascular drugs published in the last few years, mainly devoted to RAAS inhibition and/or NO donors hybrid drugs, herein the most significant results obtained and the benefits and limitations of these approaches will be highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBZAxoIKJrM7Vg90H21EOLACvtfcHk0lhryqFb-PUJAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2juro%253D&md5=0d6cdd19a2850a461b8b4c576caabd2f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130012%26sid%3Dliteratum%253Aachs%26aulast%3DBisi%26aufirst%3DA.%26aulast%3DGobbi%26aufirst%3DS.%26aulast%3DBelluti%26aufirst%3DF.%26aulast%3DRampa%26aufirst%3DA.%26atitle%3DDesign%2520of%2520Multifunctional%2520Compounds%2520for%2520Cardiovascular%2520Disease%253A%2520From%2520Natural%2520Scaffolds%2520to%2520%25E2%2580%259CClassical%25E2%2580%259D%2520Multitarget%2520Approach%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D13%26spage%3D1759%26epage%3D1782%26doi%3D10.2174%2F0929867311320130012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gattrell, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, M.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands in Metabolic Disease Research: From Concept to Platform</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">15–16</span>),  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2013.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23454344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVertL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=692-696&issue=15%E2%80%9316&author=W.+Gattrellauthor=C.+Johnstoneauthor=S.+Patelauthor=C.+S.+Smithauthor=A.+Scheelauthor=M.+Schindler&title=Designed+Multiple+Ligands+in+Metabolic+Disease+Research%3A+From+Concept+to+Platform&doi=10.1016%2Fj.drudis.2013.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Designed multiple ligands in metabolic disease research: from concept to platform</span></div><div class="casAuthors">Gattrell, W.; Johnstone, C.; Patel, S.; Smith, C. Sambrook; Scheel, A.; Schindler, M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15-16</span>),
    <span class="NLM_cas:pages">692-696</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Type 2 diabetes mellitus (T2DM) is a multifactorial disease, and drug monotherapy typically results in unsatisfactory treatment outcomes for patients.  Even when used in combination, existing therapies lack efficacy in the long term.  Designed multiple ligands (DMLs) are compds. developed to modulate multiple targets relevant to a disease.  DMLs offer the potential to yield greater efficacy over monotherapies, either by modulating different biol. pathways, or by boosting a single one.  However, examples of DMLs progressing into clin. trials, or onto the market are rare; DML drug discovery is challenging, and perceived by some to be almost impossible.  Nevertheless, with the judicious selection of biol. targets, both from a biol. and chem. perspective, it is possible to develop drug-like DMLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqsRea2XH7-7Vg90H21EOLACvtfcHk0lhryqFb-PUJAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVertL8%253D&md5=56204a6c37b64ee11d3f6bd617cad00b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DGattrell%26aufirst%3DW.%26aulast%3DJohnstone%26aufirst%3DC.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DC.%2BS.%26aulast%3DScheel%26aufirst%3DA.%26aulast%3DSchindler%26aufirst%3DM.%26atitle%3DDesigned%2520Multiple%2520Ligands%2520in%2520Metabolic%2520Disease%2520Research%253A%2520From%2520Concept%2520to%2520Platform%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26issue%3D15%25E2%2580%259316%26spage%3D692%26epage%3D696%26doi%3D10.1016%2Fj.drudis.2013.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grivennikov, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greten, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span> <span> </span><span class="NLM_article-title">Immunity, Inflammation, and Cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.01.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.cell.2010.01.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20303878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVSgu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=883-899&issue=6&author=S.+I.+Grivennikovauthor=F.+R.+Gretenauthor=M.+Karin&title=Immunity%2C+Inflammation%2C+and+Cancer&doi=10.1016%2Fj.cell.2010.01.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Immunity, inflammation, and cancer</span></div><div class="casAuthors">Grivennikov, Sergei I.; Greten, Florian R.; Karin, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">883-899</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Inflammatory responses play decisive roles at different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis.  Inflammation also affects immune surveillance and responses to therapy.  Immune cells that infiltrate tumors engage in an extensive and dynamic crosstalk with cancer cells, and some of the mol. events that mediate this dialog have been revealed.  This review outlines the principal mechanisms that govern the effects of inflammation and immunity on tumor development and discusses attractive new targets for cancer therapy and prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSKC7HKir8HLVg90H21EOLACvtfcHk0liPgE05bsfnPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVSgu7g%253D&md5=5d554f70b26c479b72d934a462ac2086</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.01.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.01.025%26sid%3Dliteratum%253Aachs%26aulast%3DGrivennikov%26aufirst%3DS.%2BI.%26aulast%3DGreten%26aufirst%3DF.%2BR.%26aulast%3DKarin%26aufirst%3DM.%26atitle%3DImmunity%252C%2520Inflammation%252C%2520and%2520Cancer%26jtitle%3DCell%26date%3D2010%26volume%3D140%26issue%3D6%26spage%3D883%26epage%3D899%26doi%3D10.1016%2Fj.cell.2010.01.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands: Basic Research vs Clinical Outcomes</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3387</span>, <span class="refDoi"> DOI: 10.2174/092986712801215883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F092986712801215883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22680630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOhtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=3353-3387&issue=20&author=L.+Costantinoauthor=D.+Barlocco&title=Designed+Multiple+Ligands%3A+Basic+Research+vs+Clinical+Outcomes&doi=10.2174%2F092986712801215883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Designed multiple ligands: basic research vs clinical outcomes</span></div><div class="casAuthors">Costantino, L.; Barlocco, D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3353-3387</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The clin. treatment of multifactorial pathologies (e.g. cancer, Alzheimer's disease, psychiatric disorders), is still a major challenge.  Many researches have been published dealing with the design of multiple ligands, able to act at the same time towards several targets relevant for a given pathol.  In the present review, the clin. results about these compds. have been reported, together with the design strategy adopted, in order to allow a crit. evaluation of the outcomes of these efforts.  What is emerging is that several effective design strategies of multitarget compds. are available, and the choice among these appears to be dependent on the therapeutic area considered.  However, at present, besides multitarget drugs discovered during optimization efforts by means of phenotypic assays, drug coadministrations or fixed dose formulations appear to be more useful therapeutic options than designed multiple ligands; this scenario will change when systems biol. will be able to select crit. targets, i.e. nodal proteins that should be inhibited in order to obtain a therapeutic action; at this point, the design of multiple ligands will allow a renaissance of medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobv_P2UM6L_7Vg90H21EOLACvtfcHk0liPgE05bsfnPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOhtrrN&md5=82123bbafc10a19c65a0bc0c5be72546</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F092986712801215883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712801215883%26sid%3Dliteratum%253Aachs%26aulast%3DCostantino%26aufirst%3DL.%26aulast%3DBarlocco%26aufirst%3DD.%26atitle%3DDesigned%2520Multiple%2520Ligands%253A%2520Basic%2520Research%2520vs%2520Clinical%2520Outcomes%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26issue%3D20%26spage%3D3353%26epage%3D3387%26doi%3D10.2174%2F092986712801215883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology in a Single Drug: Multitarget Drugs</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.2174/0929867311320130004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F0929867311320130004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23410164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1639-1645&issue=13&author=M.+L.+Bolognesi&title=Polypharmacology+in+a+Single+Drug%3A+Multitarget+Drugs&doi=10.2174%2F0929867311320130004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology in a single drug: multitarget drugs</span></div><div class="casAuthors">Bolognesi, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1639-1645</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases.  It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these.  Polypharmacol. can involve combinations and/or multitarget drugs (MTD).  Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations.  This review article focuses on MTDs from a medicinal chem. perspective.  I will explore their use in current clin. practice, their likely application in the future, and the challenges to be overcome to achieve this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeSnmeFeRpMrVg90H21EOLACvtfcHk0liPgE05bsfnPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D&md5=0e69395566711e018db8a61b1ae0f56e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130004%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DPolypharmacology%2520in%2520a%2520Single%2520Drug%253A%2520Multitarget%2520Drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D13%26spage%3D1639%26epage%3D1645%26doi%3D10.2174%2F0929867311320130004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehár, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Therapeutics: When the Whole Is Greater Than the Sum of the Parts</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&issue=1&author=G.+R.+Zimmermannauthor=J.+Leh%C3%A1rauthor=C.+T.+Keith&title=Multi-Target+Therapeutics%3A+When+the+Whole+Is+Greater+Than+the+Sum+of+the+Parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2ebR1EiQt5grVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-Target%2520Therapeutics%253A%2520When%2520the%2520Whole%2520Is%2520Greater%2520Than%2520the%2520Sum%2520of%2520the%2520Parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D1%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitznagel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybeck, T. R.</span></span> <span> </span><span class="NLM_article-title">The Effect of Prescribed Daily Dose Frequency on Patient Medication Compliance</span>. <i>Arch. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>150</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1881</span>– <span class="NLM_lpage">1884</span>, <span class="refDoi"> DOI: 10.1001/archinte.1990.00390200073014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1001%2Farchinte.1990.00390200073014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=2102668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADyaK3czmsFGltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=1990&pages=1881-1884&issue=9&author=S.+A.+Eisenauthor=D.+K.+Millerauthor=R.+S.+Woodwardauthor=E.+Spitznagelauthor=T.+R.+Przybeck&title=The+Effect+of+Prescribed+Daily+Dose+Frequency+on+Patient+Medication+Compliance&doi=10.1001%2Farchinte.1990.00390200073014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of prescribed daily dose frequency on patient medication compliance</span></div><div class="casAuthors">Eisen S A; Miller D K; Woodward R S; Spitznagel E; Przybeck T R</div><div class="citationInfo"><span class="NLM_cas:title">Archives of internal medicine</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1881-4</span>
        ISSN:<span class="NLM_cas:issn">0003-9926</span>.
    </div><div class="casAbstract">The objective of this study was to determine the relationship between prescribed daily dose frequency and patient medication compliance.  The medication compliance of 105 patients receiving antihypertensive medications was monitored by analyzing data obtained from special pill containers that electronically record the date and time of medication removal.  Inaccurate compliance estimates derived using the simple pill count method were thereby avoided.  Compliance was defined as the percent of days during which the prescribed number of doses were removed.  Compliance improved from 59.0% on a three-time daily regimen to 83.6% on a once-daily regimen.  Thus, compliance improves dramatically as prescribed dose frequency decreases.  Probably the single most important action that health care providers can take to improve compliance is to select medications that permit the lowest daily prescribed dose frequency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ77B5mAT4PZMRAV4D_Ins_fW6udTcc2eYZqZ8qllJMTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3czmsFGltg%253D%253D&md5=83afa34a4f1dafc6e0ab4bc87c33026c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1001%2Farchinte.1990.00390200073014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchinte.1990.00390200073014%26sid%3Dliteratum%253Aachs%26aulast%3DEisen%26aufirst%3DS.%2BA.%26aulast%3DMiller%26aufirst%3DD.%2BK.%26aulast%3DWoodward%26aufirst%3DR.%2BS.%26aulast%3DSpitznagel%26aufirst%3DE.%26aulast%3DPrzybeck%26aufirst%3DT.%2BR.%26atitle%3DThe%2520Effect%2520of%2520Prescribed%2520Daily%2520Dose%2520Frequency%2520on%2520Patient%2520Medication%2520Compliance%26jtitle%3DArch.%2520Intern.%2520Med.%26date%3D1990%26volume%3D150%26issue%3D9%26spage%3D1881%26epage%3D1884%26doi%3D10.1001%2Farchinte.1990.00390200073014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benazzi, F.</span></span> <span> </span><span class="NLM_article-title">Severe Anticholinergic Side Effects with Venlafaxine-Fluoxetine Combination</span>. <i>Can. J. Psychiat.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">980</span>– <span class="NLM_lpage">981</span>, <span class="refDoi"> DOI: 10.1177/070674379704200916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1177%2F070674379704200916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=9429070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADyaK1c%252FptVOlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1997&pages=980-981&issue=9&author=F.+Benazzi&title=Severe+Anticholinergic+Side+Effects+with+Venlafaxine-Fluoxetine+Combination&doi=10.1177%2F070674379704200916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Severe anticholinergic side effects with venlafaxine-fluoxetine combination</span></div><div class="casAuthors">Benazzi F</div><div class="citationInfo"><span class="NLM_cas:title">Canadian journal of psychiatry. Revue canadienne de psychiatrie</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">980-1</span>
        ISSN:<span class="NLM_cas:issn">0706-7437</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOuldGgM09iwHqQV89nF-2fW6udTcc2eYZqZ8qllJMTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252FptVOlug%253D%253D&md5=851586ec8f23a093b7ed9a172f855ad8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1177%2F070674379704200916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F070674379704200916%26sid%3Dliteratum%253Aachs%26aulast%3DBenazzi%26aufirst%3DF.%26atitle%3DSevere%2520Anticholinergic%2520Side%2520Effects%2520with%2520Venlafaxine-Fluoxetine%2520Combination%26jtitle%3DCan.%2520J.%2520Psychiat.%26date%3D1997%26volume%3D42%26issue%3D9%26spage%3D980%26epage%3D981%26doi%3D10.1177%2F070674379704200916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&issue=2&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+Design%3A+A+Medicinal+Chemist%E2%80%99s+Perspective+on+Multitargeting+Compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0liTzQBbrUVESA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520Design%253A%2520A%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Perspective%2520on%2520Multitargeting%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D2%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry Approaches for Multitarget Drugs</span>. <i>Burger’s Med. Chem. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1002/0471266949.bmc124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2F0471266949.bmc124" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=249-274&author=R.+Morphyauthor=Z.+Rankovic&title=Medicinal+Chemistry+Approaches+for+Multitarget+Drugs&doi=10.1002%2F0471266949.bmc124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2F0471266949.bmc124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471266949.bmc124%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DMedicinal%2520Chemistry%2520Approaches%2520for%2520Multitarget%2520Drugs%26jtitle%3DBurger%25E2%2580%2599s%2520Med.%2520Chem.%2520Drug%2520Discovery%26date%3D2010%26spage%3D249%26epage%3D274%26doi%3D10.1002%2F0471266949.bmc124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">From Magic Bullets to Designed Multiple Ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&issue=15&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+Magic+Bullets+to+Designed+Multiple+Ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0ljPEQmi9GfLuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520Magic%2520Bullets%2520to%2520Designed%2520Multiple%2520Ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D15%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designing Multiple Ligands - Medicinal Chemistry Strategies and Challenges</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.2174/138161209787315594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F138161209787315594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19199984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=587-600&issue=6&author=R.+Morphyauthor=Z.+Rankovic&title=Designing+Multiple+Ligands+-+Medicinal+Chemistry+Strategies+and+Challenges&doi=10.2174%2F138161209787315594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multiple ligands - medicinal chemistry strategies and challenges</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been widely recognized over the recent years that parallel modulation of multiple biol. targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease.  In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a no. of illustrative example are given.  Designing multiple ligands is frequently a challenging endeavor for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets while obtaining physicochem. and pharmacokinetic properties that are consistent with the administration of an oral drug.  Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUo6NjoK5D-LVg90H21EOLACvtfcHk0ljPEQmi9GfLuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D&md5=fa34039be6e9c3b489f530fc74fd0346</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F138161209787315594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315594%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigning%2520Multiple%2520Ligands%2520-%2520Medicinal%2520Chemistry%2520Strategies%2520and%2520Challenges%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26issue%3D6%26spage%3D587%26epage%3D600%26doi%3D10.2174%2F138161209787315594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Fragments, Network Biology and Designing Multiple Ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2006.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17275736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=156-160&issue=3&author=R.+Morphyauthor=Z.+Rankovic&title=Fragments%2C+Network+Biology+and+Designing+Multiple+Ligands&doi=10.1016%2Fj.drudis.2006.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Fragments, network biology and designing multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3&4</span>),
    <span class="NLM_cas:pages">156-160</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Modulating multiple protein targets simultaneously can be beneficial for treating complex diseases.  The redundancy that exists within biol. networks means that modulating single proteins might not be sufficient to produce the desired efficacy while, at the same time, minimizing adverse effects.  Designing multi-target drugs can be challenging for medicinal chemists, with current lead-discovery strategies often producing large, complex mols. with low ligand efficiency and poor oral bioavailability.  Paradoxically, analyses of the relationship between the selectivity of biol. active compds. and their mol. size suggest that promiscuous compds. should typically be smaller than target-selective compds.  A fragment-based approach to multi-target drug discovery could lead to a new generation of compds. with improved physicochem. and pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXRYwI33BCNLVg90H21EOLACvtfcHk0ljPEQmi9GfLuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D&md5=64a3c7e8c3280db166dda799a77d689a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFragments%252C%2520Network%2520Biology%2520and%2520Designing%2520Multiple%2520Ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D3%26spage%3D156%26epage%3D160%26doi%3D10.1016%2Fj.drudis.2006.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands. An Emerging Drug Discovery Paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&issue=21&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+Multiple+Ligands.+An+Emerging+Drug+Discovery+Paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lgdzKYm_X7McQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520Multiple%2520Ligands.%2520An%2520Emerging%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D21%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valgimigli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Multi-Target-Directed Drug Design Strategy: From a Dual Binding Site Acetylcholinesterase Inhibitor to a Trifunctional Compound against Alzheimer’s Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">6446</span>– <span class="NLM_lpage">6449</span>, <span class="refDoi"> DOI: 10.1021/jm701225u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701225u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOgsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6446-6449&issue=26&author=M.+L.+Bolognesiauthor=A.+Cavalliauthor=L.+Valgimigliauthor=M.+Bartoliniauthor=M.+Rosiniauthor=V.+Andrisanoauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-Target-Directed+Drug+Design+Strategy%3A+From+a+Dual+Binding+Site+Acetylcholinesterase+Inhibitor+to+a+Trifunctional+Compound+against+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fjm701225u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-directed drug design strategy: From a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease</span></div><div class="casAuthors">Bolognesi, Maria Laura; Cavalli, Andrea; Valgimigli, Luca; Bartolini, Manuela; Rosini, Michela; Andrisano, Vincenza; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">6446-6449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A design strategy to convert a dual-binding site AChE inhibitor into triple functional compds. with promising in vitro profile against multifactorial syndromes, such as Alzheimer's disease, is proposed.  The lead compd. bis(7)-tacrine was properly modified to confer to the new mols. the ability of chelating metals, involved in the neurodegenerative process.  The multifunctional compds. show activity against human AChE, are able to inhibit the AChE-induced amyloid-β aggregation, and chelate metals, such as iron and copper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEt8652LxJMbVg90H21EOLACvtfcHk0lgdzKYm_X7McQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOgsr7O&md5=07a8b5a6495b9759256a36d2bfebbd29</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm701225u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701225u%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DValgimigli%26aufirst%3DL.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-Target-Directed%2520Drug%2520Design%2520Strategy%253A%2520From%2520a%2520Dual%2520Binding%2520Site%2520Acetylcholinesterase%2520Inhibitor%2520to%2520a%2520Trifunctional%2520Compound%2520against%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D26%26spage%3D6446%26epage%3D6449%26doi%3D10.1021%2Fjm701225u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lötsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span> <span> </span><span class="NLM_article-title">Low-Dose Drug Combinations Along Molecular Pathways Could Maximize Therapeutic Effectiveness While Minimizing Collateral Adverse Effects</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2011.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22016087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FjtVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=1001-1006&issue=23&author=J.+L%C3%B6tschauthor=G.+Geisslinger&title=Low-Dose+Drug+Combinations+Along+Molecular+Pathways+Could+Maximize+Therapeutic+Effectiveness+While+Minimizing+Collateral+Adverse+Effects&doi=10.1016%2Fj.drudis.2011.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects</span></div><div class="casAuthors">Lotsch Jorn; Geisslinger Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">1001-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increasing knowledge of molecular signaling processes has enabled the identification of drug targets that synergistically address multifactorial symptoms along several contributing pathways.  The idea behind 'polypills' is that minor doses of pharmacodynamically interacting drugs would selectively achieve intended clinical effects.  Analogously, monofactorial symptoms could be addressed vertically along their main pathway.  Clinical selectivity follows from successive incomplete inhibitions of the pathological pathway at several steps.  Here, we discuss and exemplify of how successive inhibitions in the prostaglandin E2 (PGE(2)) signaling pathway could achieve anti-inflammatory and analgesic effects while preserving physiological PGE(2) signaling in organs of major toxicity.  Intentionally using intelligent low-dose drug combinations might provide an innovative therapeutic concept that directs combined small-drug effects towards a large, selective clinical effect with minor collateral damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRu7M3C_0-j-dfST00W0BcfW6udTcc2eYUqL23rdoHb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FjtVygtg%253D%253D&md5=f88337f88016a3736e13e493dc064089</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6tsch%26aufirst%3DJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26atitle%3DLow-Dose%2520Drug%2520Combinations%2520Along%2520Molecular%2520Pathways%2520Could%2520Maximize%2520Therapeutic%2520Effectiveness%2520While%2520Minimizing%2520Collateral%2520Adverse%2520Effects%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D23%26spage%3D1001%26epage%3D1006%26doi%3D10.1016%2Fj.drudis.2011.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&issue=19&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+Opportunities+in+Drug+Discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0ljQAx0f0-8z7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520Opportunities%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D19%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Strategies for Modern Biomarker and Drug Development in Oncology</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1186/s13045-014-0070-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1186%2Fs13045-014-0070-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25277503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=70-85&issue=1&author=A.+D.+Smithauthor=D.+Rodaauthor=T.+A.+Yap&title=Strategies+for+Modern+Biomarker+and+Drug+Development+in+Oncology&doi=10.1186%2Fs13045-014-0070-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for modern biomarker and drug development in oncology</span></div><div class="casAuthors">Smith, Alan D.; Roda, Desam; Yap, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">70/1-70/16</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Technol. advancements in the mol. characterization of cancers have enabled researchers to identify an increasing no. of key mol. drivers of cancer progression.  These discoveries have led to multiple novel anticancer therapeutics, and clin. benefit in selected patient populations.  Despite this, the identification of clin. relevant predictive biomarkers of response continues to lag behind.  In this review, we discuss strategies for the mol. characterization of cancers and the importance of biomarkers for the development of novel antitumor therapeutics.  We also review crit. successes and failures in oncol., and detail the lessons learnt, which may aid in the acceleration of anticancer drug development and biomarker discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWNEkFi4M0pLVg90H21EOLACvtfcHk0ljQAx0f0-8z7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVOrsQ%253D%253D&md5=735ba9bd2f866b407057dd5cb89e839f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1186%2Fs13045-014-0070-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-014-0070-8%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BD.%26aulast%3DRoda%26aufirst%3DD.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DStrategies%2520for%2520Modern%2520Biomarker%2520and%2520Drug%2520Development%2520in%2520Oncology%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2014%26volume%3D7%26issue%3D1%26spage%3D70%26epage%3D85%26doi%3D10.1186%2Fs13045-014-0070-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, A.</span></span> <span> </span><span class="NLM_article-title">Glivec (STI571, Imatinib), a Rationally Developed, Targeted Anticancer Drug</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1038/nrd839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&issue=7&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+Imatinib%29%2C+a+Rationally+Developed%2C+Targeted+Anticancer+Drug&doi=10.1038%2Fnrd839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0ljQAx0f0-8z7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520Imatinib%2529%252C%2520a%2520Rationally%2520Developed%252C%2520Targeted%2520Anticancer%2520Drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D7%26spage%3D493%26epage%3D502%26doi%3D10.1038%2Fnrd839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
los Ríos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iriepa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gálvez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarroya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Inhibitory Activity of Cholinesterases, and Neuroprotective Profile of Novel 1,8-Naphthyridine Derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5129</span>– <span class="NLM_lpage">5143</span>, <span class="refDoi"> DOI: 10.1021/jm901902w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901902w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVKqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5129-5143&issue=14&author=C.+De%0Alos+R%C3%ADosauthor=J.+Egeaauthor=J.+Marco-Contellesauthor=R.+Le%C3%B3nauthor=A.+Samadiauthor=I.+Iriepaauthor=I.+Moraledaauthor=E.+G%C3%A1lvezauthor=A.+G.+Garc%C3%ADaauthor=M.+G.+L%C3%B3pezauthor=M.+Villarroyaauthor=A.+Romero&title=Synthesis%2C+Inhibitory+Activity+of+Cholinesterases%2C+and+Neuroprotective+Profile+of+Novel+1%2C8-Naphthyridine+Derivatives&doi=10.1021%2Fjm901902w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Inhibitory Activity of Cholinesterases, and Neuroprotective Profile of Novel 1,8-Naphthyridine Derivatives</span></div><div class="casAuthors">de los Rios, Cristobal; Egea, Javier; Marco-Contelles, Jose; Leon, Rafael; Samadi, Abdelouahid; Iriepa, Isabel; Moraleda, Ignacio; Galvez, Enrique; Garcia, Antonio G.; Lopez, Manuela G.; Villarroya, Mercedes; Romero, Alejandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5129-5143</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1,8-Naphthyridine derivs. related to neuroprotective compd. I (ITH4012) have been synthesized.  In general, they have shown better inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) than most related tacrine derivs.  The compds. presented an interesting neuroprotective profile in SH-SY5Y neuroblastoma cells stressed with rotenone/oligomycin A.  Moreover, compd. II also caused protection in cells stressed with okadaic acid (OA) or amyloid β 1-42 peptide (Aβ1-42).  Interestingly, compd. II prevented the OA-induced PP2A inhibition, one of the enzymes implicated in τ dephosphorylation.  This compd. also exhibited neuroprotection against neurotoxicity elicited by oxygen and glucose deprivation in hippocampal slices.  Because these stressors caused neuronal damage related to physiopathol. hallmarks found in the brain of Alzheimer's disease (AD) patients, we conclude that compd. II deserves further in vivo studies in AD models to test its therapeutic potential in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn990-FK7y87Vg90H21EOLACvtfcHk0ljQAx0f0-8z7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVKqsbg%253D&md5=92d0cf582eb9816f03c72a2f8344883f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm901902w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901902w%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2Blos%2BR%25C3%25ADos%26aufirst%3DC.%26aulast%3DEgea%26aufirst%3DJ.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DLe%25C3%25B3n%26aufirst%3DR.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DG%25C3%25A1lvez%26aufirst%3DE.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25B3pez%26aufirst%3DM.%2BG.%26aulast%3DVillarroya%26aufirst%3DM.%26aulast%3DRomero%26aufirst%3DA.%26atitle%3DSynthesis%252C%2520Inhibitory%2520Activity%2520of%2520Cholinesterases%252C%2520and%2520Neuroprotective%2520Profile%2520of%2520Novel%25201%252C8-Naphthyridine%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D14%26spage%3D5129%26epage%3D5143%26doi%3D10.1021%2Fjm901902w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de los Ríos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huertas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Franco, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">do Carmo Carreiras, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarroya, M.</span></span> <span> </span><span class="NLM_article-title">Tacripyrines, the First Tacrine-Dihydropyridine Hybrids, as Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2724</span>– <span class="NLM_lpage">2732</span>, <span class="refDoi"> DOI: 10.1021/jm801292b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801292b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkslCqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2724-2732&issue=9&author=J.+Marco-Contellesauthor=R.+Le%C3%B3nauthor=C.+de+los+R%C3%ADosauthor=A.+Samadiauthor=M.+Bartoliniauthor=V.+Andrisanoauthor=O.+Huertasauthor=X.+Barrilauthor=F.+J.+Luqueauthor=M.+I.+Rodr%C3%ADguez-Francoauthor=B.+L%C3%B3pezauthor=M.+G.+L%C3%B3pezauthor=A.+G.+Garc%C3%ADaauthor=M.+do+Carmo+Carreirasauthor=M.+Villarroya&title=Tacripyrines%2C+the+First+Tacrine-Dihydropyridine+Hybrids%2C+as+Multitarget-Directed+Ligands+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fjm801292b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Tacripyrines, the First Tacrine-Dihydropyridine Hybrids, as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Marco-Contelles, Jose; Leon, Rafael; de los Rios, Cristobal; Samadi, Abdelouahid; Bartolini, Manuela; Andrisano, Vincenza; Huertas, Oscar; Barril, Xavier; Luque, F. Javier; Rodriguez-Franco, Maria I.; Lopez, Beatriz; Lopez, Manuela G.; Garcia, Antonio G.; Carreiras, Maria do Carmo; Villarroya, Mercedes</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2724-2732</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tacripyrines (1-14) have been designed by combining an AChE inhibitor (tacrine) with a calcium antagonist such as nimodipine and are targeted to develop a multitarget therapeutic strategy to confront AD.  Tacripyrines are selective and potent AChE inhibitors in the nanomolar range.  The mixed type inhibition of hAChE activity of compd. 11 (IC50 105 ± 15 nM) is assocd. to a 30.7 ± 8.6% inhibition of the proaggregating action of AChE on the Aβ and a moderate inhibition of Aβ self-aggregation (34.9 ± 5.4%).  Mol. modeling indicates that binding of compd. 11 to the AChE PAS mainly involves the (R)-11 enantiomer, which also agrees with the noncompetitive inhibition mechanism exhibited by p-methoxytacripyrine 11.  Tacripyrines are neuroprotective agents, show moderate Ca2+ channel blocking effect, and cross the blood-brain barrier, emerging as lead candidates for treating AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrz5BaASigkrVg90H21EOLACvtfcHk0ljK0NAe64WixQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkslCqtL4%253D&md5=ca6ad88e3ac305a398654c26e936cf5e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm801292b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801292b%26sid%3Dliteratum%253Aachs%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DLe%25C3%25B3n%26aufirst%3DR.%26aulast%3Dde%2Blos%2BR%25C3%25ADos%26aufirst%3DC.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DHuertas%26aufirst%3DO.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DRodr%25C3%25ADguez-Franco%26aufirst%3DM.%2BI.%26aulast%3DL%25C3%25B3pez%26aufirst%3DB.%26aulast%3DL%25C3%25B3pez%26aufirst%3DM.%2BG.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DA.%2BG.%26aulast%3Ddo%2BCarmo%2BCarreiras%26aufirst%3DM.%26aulast%3DVillarroya%26aufirst%3DM.%26atitle%3DTacripyrines%252C%2520the%2520First%2520Tacrine-Dihydropyridine%2520Hybrids%252C%2520as%2520Multitarget-Directed%2520Ligands%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D9%26spage%3D2724%26epage%3D2732%26doi%3D10.1021%2Fjm801292b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Priest, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdemli, G.</span></span> <span> </span><span class="NLM_article-title">Phenotypic Screening in the 21st Century</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.3389/fphar.2014.00264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3389%2Ffphar.2014.00264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25520660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC2MvgvVKqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=264-265&author=B.+T.+Priestauthor=G.+Erdemli&title=Phenotypic+Screening+in+the+21st+Century&doi=10.3389%2Ffphar.2014.00264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening in the 21st century</span></div><div class="casAuthors">Priest Birgit T; Erdemli Gul</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">264</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOCl0Oo1R-_MSzjBFCN0BJfW6udTcc2ea9vISxPAIlxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvgvVKqtw%253D%253D&md5=d9f314f46f7272d0cb6c43d50eccce87</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00264%26sid%3Dliteratum%253Aachs%26aulast%3DPriest%26aufirst%3DB.%2BT.%26aulast%3DErdemli%26aufirst%3DG.%26atitle%3DPhenotypic%2520Screening%2520in%2520the%252021st%2520Century%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D264%26epage%3D265%26doi%3D10.3389%2Ffphar.2014.00264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seshacharyulu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponnusamy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haridas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganti, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, S. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the EGFR Signaling Pathway in Cancer Therapy</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1517/14728222.2011.648617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1517%2F14728222.2011.648617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22239438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Wksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=15-31&issue=1&author=P.+Seshacharyuluauthor=M.+P.+Ponnusamyauthor=D.+Haridasauthor=M.+Jainauthor=A.+K.+Gantiauthor=S.+K.+Batra&title=Targeting+the+EGFR+Signaling+Pathway+in+Cancer+Therapy&doi=10.1517%2F14728222.2011.648617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the EGFR signaling pathway in cancer therapy</span></div><div class="casAuthors">Seshacharyulu, Parthasarathy; Ponnusamy, Moorthy P.; Haridas, Dhanya; Jain, Maneesh; Ganti, Apar K.; Batra, Surinder K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-31</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Cancer is a devastating disease; however, several therapeutic advances have recently been made, wherein EGFR and its family members have emerged as useful biomarkers and therapeutic targets.  EGFR, a transmembrane glycoprotein is a member of the ERBB receptor tyrosine kinase superfamily.  EGFR binds to its cognate ligand EGF, which further induces tyrosine phosphorylation and receptor dimerization with other family members leading to enhanced uncontrolled proliferation.  Several anti-EGFR therapies such as monoclonal antibodies and tyrosine kinase inhibitors have been developed, which has enabled clinicians to identify and treat specific patient cohorts.Areas covered: This review covers the basic mechanism of EGFR activation and the role of EGFR signaling in cancer progression.  Furthermore, current developments made toward targeting the EGFR signaling pathway for the treatment of epithelial cancers and a summary of the various anti-EGFR therapeutic agents that are currently in use are also presented in this review.Expert opinion: EGFR signaling is a part of a complex network that has been the target of effective cancer therapies.  However, a further understanding of the system is required to develop an effective anticancer regimen.  A combination therapy that comprises an anti-EGFR and a chemotherapeutic/chemopreventive agent will exhibit a multi-pronged approach that can be developed into a highly attractive and specific mol. oriented remedy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDi_-cVSomx7Vg90H21EOLACvtfcHk0ljK0NAe64WixQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Wksw%253D%253D&md5=91357f1fb76bd06c03d4269f90ad907a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.648617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.648617%26sid%3Dliteratum%253Aachs%26aulast%3DSeshacharyulu%26aufirst%3DP.%26aulast%3DPonnusamy%26aufirst%3DM.%2BP.%26aulast%3DHaridas%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DM.%26aulast%3DGanti%26aufirst%3DA.%2BK.%26aulast%3DBatra%26aufirst%3DS.%2BK.%26atitle%3DTargeting%2520the%2520EGFR%2520Signaling%2520Pathway%2520in%2520Cancer%2520Therapy%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2012%26volume%3D16%26issue%3D1%26spage%3D15%26epage%3D31%26doi%3D10.1517%2F14728222.2011.648617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Läubli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amico, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashyap, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zippelius, A.</span></span> <span> </span><span class="NLM_article-title">The Multi-Receptor Inhibitor Axitinib Reverses Tumor-Induced Immunosuppression and Potentiates Treatment with Immune-Modulatory Antibodies in Preclinical Murine Models</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">824</span>, <span class="refDoi"> DOI: 10.1007/s00262-018-2136-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1007%2Fs00262-018-2136-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29487979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktVyru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2018&pages=815-824&issue=5&author=H.+L%C3%A4ubliauthor=P.+M%C3%BCllerauthor=L.+D%E2%80%99Amicoauthor=M.+Buchiauthor=A.+S.+Kashyapauthor=A.+Zippelius&title=The+Multi-Receptor+Inhibitor+Axitinib+Reverses+Tumor-Induced+Immunosuppression+and+Potentiates+Treatment+with+Immune-Modulatory+Antibodies+in+Preclinical+Murine+Models&doi=10.1007%2Fs00262-018-2136-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models</span></div><div class="casAuthors">Laubli, Heinz; Muller, Philipp; D'Amico, Lucia; Buchi, Melanie; Kashyap, Abhishek S.; Zippelius, Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">815-824</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cancer immunotherapies have significantly improved the prognosis of cancer patients.  Despite the clin. success of targeting inhibitory checkpoint receptors, including PD-1 and/or CTLA-4 on T cells, only a minority of patients derive benefit from these therapies.  New strategies to improve cancer immunotherapy are therefore needed.  Combination therapy of checkpoint inhibitors with targeted agents has promisingly shown to increase the efficacy of immunotherapy.  Here, we analyzed the immunomodulatory effects of the multi-receptor tyrosine kinase inhibitor axitinib and its efficacy in combination with immunotherapies.  In different syngeneic murine tumor models, axitinib showed therapeutic efficacy that was not only mediated by VEGF-VEGFR inhibition, but also through the induction of anti-cancer immunity.  Mechanistically, a significant redn. of immune-suppressive cells, including a decrease of tumor-promoting mast cells and tumor-assocd. macrophages was obsd. upon axitinib treatment.  Inhibition of mast cells by axitinib as well as their exptl. depletion led to reduced tumor growth.  Of note, treatment with axitinib led to an improved T cell response, while the latter was pivotal for the therapeutic efficacy.  Combination with immune checkpoint inhibitors anti-PD-1 and anti-TIM-3 and/or agonistic engagement of the activating receptor CD137 resulted in a synergistic therapeutic efficacy.  This demonstrates non-redundant immune activation induced by axitinib via modulation of myeloid and mast cells.  These findings provide important mechanistic insights into axitinib-mediated anti-cancer immunity and provide rationale for clin. combinations of axitinib with different immunotherapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCLQVx7zMMu7Vg90H21EOLACvtfcHk0ljuMS7YD3ZAwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktVyru74%253D&md5=0cc2cfdc9c7caf2da9f9854705ca9e94</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs00262-018-2136-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-018-2136-x%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25A4ubli%26aufirst%3DH.%26aulast%3DM%25C3%25BCller%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Amico%26aufirst%3DL.%26aulast%3DBuchi%26aufirst%3DM.%26aulast%3DKashyap%26aufirst%3DA.%2BS.%26aulast%3DZippelius%26aufirst%3DA.%26atitle%3DThe%2520Multi-Receptor%2520Inhibitor%2520Axitinib%2520Reverses%2520Tumor-Induced%2520Immunosuppression%2520and%2520Potentiates%2520Treatment%2520with%2520Immune-Modulatory%2520Antibodies%2520in%2520Preclinical%2520Murine%2520Models%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2018%26volume%3D67%26issue%3D5%26spage%3D815%26epage%3D824%26doi%3D10.1007%2Fs00262-018-2136-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balancon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berton, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genicot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberty, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallemand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirlot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quere, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talaga, P.</span></span> <span> </span><span class="NLM_article-title">First Dual NK<sub>1</sub> Antagonists-Serotonin Reuptake Inhibitors: Synthesis and SAR of a New Class of Potential Antidepressants</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00727-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0960-894X%2801%2900727-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11755367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsV2i" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=261-261&issue=2&author=T.+Ryckmansauthor=L.+Balanconauthor=O.+Bertonauthor=C.+Genicotauthor=Y.+Lambertyauthor=B.+Lallemandauthor=P.+Pasauauthor=N.+Pirlotauthor=L.+Quereauthor=P.+Talaga&title=First+Dual+NK1+Antagonists-Serotonin+Reuptake+Inhibitors%3A+Synthesis+and+SAR+of+a+New+Class+of+Potential+Antidepressants&doi=10.1016%2FS0960-894X%2801%2900727-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">First dual NK1 antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants</span></div><div class="casAuthors">Ryckmans, Thomas; Balancon, Laurent; Berton, Olivier; Genicot, Christophe; Lamberty, Yves; Lallemand, Benedicte; Pasau, Patrick; Pirlot, Nathalie; Quere, Luc; Talaga, Patrice</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">261-264</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Compds. combining NK1 antagonism and serotonin reuptake inhibition are described, and potentially represent a new generation of antidepressants.  Compd. I displays good affinities for both the NK1 receptor and the serotonin reuptake site (32 and 25 nM, resp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgto-S8efa1rVg90H21EOLACvtfcHk0ljuMS7YD3ZAwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsV2i&md5=c0b66a90c6d86e650fd1782409ea4976</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900727-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900727-2%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DBalancon%26aufirst%3DL.%26aulast%3DBerton%26aufirst%3DO.%26aulast%3DGenicot%26aufirst%3DC.%26aulast%3DLamberty%26aufirst%3DY.%26aulast%3DLallemand%26aufirst%3DB.%26aulast%3DPasau%26aufirst%3DP.%26aulast%3DPirlot%26aufirst%3DN.%26aulast%3DQuere%26aufirst%3DL.%26aulast%3DTalaga%26aufirst%3DP.%26atitle%3DFirst%2520Dual%2520NK1%2520Antagonists-Serotonin%2520Reuptake%2520Inhibitors%253A%2520Synthesis%2520and%2520SAR%2520of%2520a%2520New%2520Class%2520of%2520Potential%2520Antidepressants%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26issue%3D2%26spage%3D261%26epage%3D261%26doi%3D10.1016%2FS0960-894X%2801%2900727-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, T.</span></span> <span> </span><span class="NLM_article-title">Approach to Dual-Acting Platelet Activating Factor (PAF) Receptor Antagonist/Thromboxane Synthase Inhibitor (TxSI) Based on the Link of Paf Antagonists and TxSIs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00731-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0960-894X%2801%2900731-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11814792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslKlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=341-344&issue=3&author=M.+Fujitaauthor=T.+Sekiauthor=H.+Inadaauthor=K.+Shimizuauthor=A.+Takahamaauthor=T.+Sano&title=Approach+to+Dual-Acting+Platelet+Activating+Factor+%28PAF%29+Receptor+Antagonist%2FThromboxane+Synthase+Inhibitor+%28TxSI%29+Based+on+the+Link+of+Paf+Antagonists+and+TxSIs&doi=10.1016%2FS0960-894X%2801%2900731-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs</span></div><div class="casAuthors">Fujita, Masakazu; Seki, Taketsugu; Inada, Haruaki; Shimizu, Kazuhiro; Takahama, Akane; Sano, Tetsuro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-344</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of compds. which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxSIs, such as ridogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5EjkkdRo9orVg90H21EOLACvtfcHk0ljuMS7YD3ZAwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslKlug%253D%253D&md5=7fb11467ba0f5afff9ff1c7ed37a0263</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900731-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900731-4%26sid%3Dliteratum%253Aachs%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DInada%26aufirst%3DH.%26aulast%3DShimizu%26aufirst%3DK.%26aulast%3DTakahama%26aufirst%3DA.%26aulast%3DSano%26aufirst%3DT.%26atitle%3DApproach%2520to%2520Dual-Acting%2520Platelet%2520Activating%2520Factor%2520%2528PAF%2529%2520Receptor%2520Antagonist%252FThromboxane%2520Synthase%2520Inhibitor%2520%2528TxSI%2529%2520Based%2520on%2520the%2520Link%2520of%2520Paf%2520Antagonists%2520and%2520TxSIs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26issue%3D3%26spage%3D341%26epage%3D344%26doi%3D10.1016%2FS0960-894X%2801%2900731-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarcsay, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span> <span> </span><span class="NLM_article-title">Contributions of Molecular Properties to Drug Promiscuity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1795</span>, <span class="refDoi"> DOI: 10.1021/jm301514n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301514n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXns1ehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1789-1795&issue=5&author=%C3%81.+Tarcsayauthor=G.+M.+Keseru&title=Contributions+of+Molecular+Properties+to+Drug+Promiscuity&doi=10.1021%2Fjm301514n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Contributions of Molecular Properties to Drug Promiscuity</span></div><div class="casAuthors">Tarcsay, Akos; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1789-1795</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In contrast to designed polypharmacol. that can result in efficient drugs for complex disorders, unintended drug promiscuity has detrimental contribution to side effects and toxicol.  Characterization of promiscuous compds. enhances the understanding of complex interaction patterns and aids the design of compds. with broader selectivity against off-targets that has a major impact on medicinal chem. outcome.  In this Miniperspective we provide insights to the effect of physicochem. parameters on promiscuity.  Information collected from recent, large-scale in vitro studies enabled us to discuss the relationships between physicochem. properties and promiscuity in detail.  In light of these data, lipophilicity and basic character have the highest influence.  On the basis of the accumulated knowledge, we propose the extensive use of pre- and postsynthesis metrics, as well as strict control of physicochem. properties during medicinal chem. optimizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf1J_jqkK3DrVg90H21EOLACvtfcHk0lj3uHY2Cw-FoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXns1ehug%253D%253D&md5=c5763ee1aed897ff19e5a2344b95b9c1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm301514n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301514n%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3D%25C3%2581.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DContributions%2520of%2520Molecular%2520Properties%2520to%2520Drug%2520Promiscuity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D5%26spage%3D1789%26epage%3D1795%26doi%3D10.1021%2Fjm301514n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Omar, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdu-Allah, A. A.H. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Moty, S. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Biological Evaluation and Docking Study of 1,3,4-Thiadiazole-Thiazolidinone Hybrids as Anti-Inflammatory Agents with Dual Inhibition of COX-2 and 15-LOX</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bioorg.2018.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29986191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yrs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2018&pages=461-471&author=Y.+M.+Omarauthor=A.+A.H.+H.+M.+Abdu-Allahauthor=S.+G.+Abdel-Moty&title=Synthesis%2C+Biological+Evaluation+and+Docking+Study+of+1%2C3%2C4-Thiadiazole-Thiazolidinone+Hybrids+as+Anti-Inflammatory+Agents+with+Dual+Inhibition+of+COX-2+and+15-LOX&doi=10.1016%2Fj.bioorg.2018.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation and docking study of 1,3,4-thiadiazole-thiazolidinone hybrids as anti-inflammatory agents with dual inhibition of COX-2 and 15-LOX</span></div><div class="casAuthors">Omar, Yasser M.; Abdu-Allah, Hajjaj H. M.; Abdel-Moty, Samia G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">461-471</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present study describes the synthesis, full characterization and biol. evaluation of a series of thiadiazole-thiazolidinone hybrids bearing 5-alk/arylidene as dual inhibitors of these enzymes.  The design was based on merging pharmacophores that exhibit potent anti-inflammatory activities in one mol. frame.  5-(4-Hydroxyphenyl)-1,3,4-thiadiazol-2-amine was efficiently synthesized, chloroacetylated and cyclized to give the key 4-thiazolidinone.  Knoevenagel condensation of the above compd. with different aldehydes afforded 1,3,4-thiadiazole-thiazolidinone hybrids I (R = Ph, pyridin-3-yl, styryl, etc.).  These compds. were subjected to in vitro COX-1/COX-2, 15-LOX inhibition assays.  Few compds. with promising potency (IC50 = 70-100 nM) and selectivity index (SI = 220-55) were further tested for in vivo anti-inflammatory activity and effect on gastric mucosa.  The most promising compd. I (R = 3,4-(Cl)2C6H3) inhibits COX-2 enzyme at a nanomolar concn. (IC50 = 70 nM, SI = 220) with simultaneous inhibition of 15-LOX (IC50 = 11 μM).  These results are comparable to the potency and selectivity of the std. drugs of both enzymes; celecoxib (COX-2 IC50 = 49 nM, SI = 308) and zileuton (15-LOX IC50 = 15 μM) in one construct.  Interestingly three compds. exhibited equiv. to or even higher activity than that of celecoxib in vivo anti-inflammatory activity at 3 h interval with good GIT safety profile.  Mol. docking study conferred binding sites of these compds. on COX-2 and 15-LOX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxsqbJIO0ZSbVg90H21EOLACvtfcHk0lj3uHY2Cw-FoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yrs7bF&md5=063987e9bc07741542e788826add193c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DOmar%26aufirst%3DY.%2BM.%26aulast%3DAbdu-Allah%26aufirst%3DA.%2BA.H.%2BH.%2BM.%26aulast%3DAbdel-Moty%26aufirst%3DS.%2BG.%26atitle%3DSynthesis%252C%2520Biological%2520Evaluation%2520and%2520Docking%2520Study%2520of%25201%252C3%252C4-Thiadiazole-Thiazolidinone%2520Hybrids%2520as%2520Anti-Inflammatory%2520Agents%2520with%2520Dual%2520Inhibition%2520of%2520COX-2%2520and%252015-LOX%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D80%26spage%3D461%26epage%3D471%26doi%3D10.1016%2Fj.bioorg.2018.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadnis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baska, R. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monshizadegan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowala, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">Dual Angiotensin II and Endothelin a Receptor Antagonists: Synthesis of 2’-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1021/jm049548x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049548x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyltrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=171-179&issue=1&author=N.+Murugesanauthor=Z.+Guauthor=L.+Fadnisauthor=J.+E.+Tellewauthor=R.+A.+F.+Baskaauthor=Y.+Yangauthor=S.+M.+Beyerauthor=H.+Monshizadeganauthor=K.+E.+Dickinsonauthor=M.+T.+Valentineauthor=W.+G.+Humphreysauthor=S.-J.+Lanauthor=W.+R.+Ewingauthor=K.+E.+Carlsonauthor=M.+C.+Kowalaauthor=R.+Zahlerauthor=J.+E.+Macor&title=Dual+Angiotensin+II+and+Endothelin+a+Receptor+Antagonists%3A+Synthesis+of+2%E2%80%99-Substituted+N-3-Isoxazolyl+Biphenylsulfonamides+with+Improved+Potency+and+Pharmacokinetics&doi=10.1021%2Fjm049548x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2'-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics</span></div><div class="casAuthors">Murugesan, Natesan; Gu, Zhengxiang; Fadnis, Leena; Tellew, John E.; Baska, Rose Ann F.; Yang, Yifan; Beyer, Sophie M.; Monshizadegan, Hossain; Dickinson, Kenneth E.; Valentine, Maria T.; Humphreys, W. Griffith; Lan, Shih-Jung; Ewing, William R.; Carlson, Kenneth E.; Kowala, Mark C.; Zahler, Robert; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a previous report its was demonstrated that merging together key structural elements present in an AT1 receptor antagonist (irbesartan) with key structural elements in a biphenylsulfonamide ETA receptor antagonist followed by addnl. optimization provided a product which is a dual-action receptor antagonist (DARA), which potently blocked both AT1 and ETA receptors.  Described herein are our efforts directed toward improving both the pharmacokinetic profile as well as the AT1 and ETA receptor potency of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-2-sulfonamide (I).  Efforts centered on modifying the 2'-side chain of I and examg. the (isoxazolyl)sulfonamide moiety in I.  This effort resulted in the discovery of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)[1,1'-biphenyl]-2-sulfonamide (II) as a highly potent second-generation DARA.  This compd. also showed substantially improved pharmacokinetic properties compared to I.  In rats, DARA II reduced blood pressure elevations caused by i.v. infusion of Ang II or big ET-1 to a greater extent and with longer duration than DARA I or AT1 or ETA receptor antagonists alone.  II clearly demonstrated superiority over irbesartan (an AT1 receptor antagonist) in the normal SHR model of hypertension in a dose-dependent manner, demonstrating the synergy of AT1 and ETA receptor blockade in a single mol.  The crystal and mol. structures of II were reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2G8_AfjEVOrVg90H21EOLACvtfcHk0lj3uHY2Cw-FoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyltrzO&md5=d4e66dc82cd65970cde8ca8f3094c8c6</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm049548x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049548x%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DFadnis%26aufirst%3DL.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DBaska%26aufirst%3DR.%2BA.%2BF.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DBeyer%26aufirst%3DS.%2BM.%26aulast%3DMonshizadegan%26aufirst%3DH.%26aulast%3DDickinson%26aufirst%3DK.%2BE.%26aulast%3DValentine%26aufirst%3DM.%2BT.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DLan%26aufirst%3DS.-J.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DKowala%26aufirst%3DM.%2BC.%26aulast%3DZahler%26aufirst%3DR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DDual%2520Angiotensin%2520II%2520and%2520Endothelin%2520a%2520Receptor%2520Antagonists%253A%2520Synthesis%2520of%25202%25E2%2580%2599-Substituted%2520N-3-Isoxazolyl%2520Biphenylsulfonamides%2520with%2520Improved%2520Potency%2520and%2520Pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D1%26spage%3D171%26epage%3D179%26doi%3D10.1021%2Fjm049548x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poornima, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blunder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efferth, T.</span></span> <span> </span><span class="NLM_article-title">Network Pharmacology of Cancer: From Understanding of Complex Interactomes to the Design of Multi-Target Specific Therapeutics from Nature</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.phrs.2016.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27329331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFShsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=290-302&author=P.+Poornimaauthor=J.+D.+Kumarauthor=Q.+Zhaoauthor=M.+Blunderauthor=T.+Efferth&title=Network+Pharmacology+of+Cancer%3A+From+Understanding+of+Complex+Interactomes+to+the+Design+of+Multi-Target+Specific+Therapeutics+from+Nature&doi=10.1016%2Fj.phrs.2016.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature</span></div><div class="casAuthors">Poornima, Paramasivan; Kumar, Jothi Dinesh; Zhao, Qiaoli; Blunder, Martina; Efferth, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">290-302</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite massive investments in drug research and development, the significant decline in the no. of new drugs approved or translated to clin. use raises the question, whether single targeted drug discovery is the right approach.  To combat complex systemic diseases that harbor robust biol. networks such as cancer, single target intervention is proved to be ineffective.  In such cases, network pharmacol. approaches are highly useful, because they differ from conventional drug discovery by addressing the ability of drugs to target numerous proteins or networks involved in a disease.  Pleiotropic natural products are one of the promising strategies due to their multi-targeting and due to lower side effects.  In this review, we discuss the application of network pharmacol. for cancer drug discovery.  We provide an overview of the current state of knowledge on network pharmacol., focus on different tech. approaches and implications for cancer therapy (e.g. polypharmacol. and synthetic lethality), and illustrate the therapeutic potential with selected examples green tea polyphenolics, Eleutherococcus senticosus, Rhodiola rosea, and Schisandra chinensis.  Finally, we present future perspectives on their plausible applications for diagnosis and therapy of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwqqjqEH_wtrVg90H21EOLACvtfcHk0ljYlrqTQA6qPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFShsr%252FM&md5=be3757ac287f3b90ebbcb69016a9410c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DPoornima%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DJ.%2BD.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DBlunder%26aufirst%3DM.%26aulast%3DEfferth%26aufirst%3DT.%26atitle%3DNetwork%2520Pharmacology%2520of%2520Cancer%253A%2520From%2520Understanding%2520of%2520Complex%2520Interactomes%2520to%2520the%2520Design%2520of%2520Multi-Target%2520Specific%2520Therapeutics%2520from%2520Nature%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D290%26epage%3D302%26doi%3D10.1016%2Fj.phrs.2016.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jørgensen, J. T.</span></span> <span> </span><span class="NLM_article-title">The Importance of Predictive Biomarkers in Oncology Drug Development</span>. <i>Expert Rev. Mol. Diagn.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">807</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1080/14737159.2016.1199962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1080%2F14737159.2016.1199962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27282189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FosVChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=807-809&issue=8&author=J.+T.+J%C3%B8rgensen&title=The+Importance+of+Predictive+Biomarkers+in+Oncology+Drug+Development&doi=10.1080%2F14737159.2016.1199962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The importance of predictive biomarkers in oncology drug development</span></div><div class="casAuthors">Jorgensen Jan Trost</div><div class="citationInfo"><span class="NLM_cas:title">Expert review of molecular diagnostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">807-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpjsop5xOrXENoizSOkG_FfW6udTcc2eZLu7gHzVcDNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FosVChug%253D%253D&md5=a98aabac63825ef0d86e882456e73061</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1080%2F14737159.2016.1199962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737159.2016.1199962%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520Importance%2520of%2520Predictive%2520Biomarkers%2520in%2520Oncology%2520Drug%2520Development%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Diagn.%26date%3D2016%26volume%3D16%26issue%3D8%26spage%3D807%26epage%3D809%26doi%3D10.1080%2F14737159.2016.1199962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeep, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choonara, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillay, V.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Therapeutics for Neuropsychiatric and Neurodegenerative Disorders</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1886</span>– <span class="NLM_lpage">1914</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27506871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaiu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1886-1914&issue=12&author=P.+Bawaauthor=P.+Pradeepauthor=P.+Kumarauthor=Y.+E.+Choonaraauthor=G.+Modiauthor=V.+Pillay&title=Multi-Target+Therapeutics+for+Neuropsychiatric+and+Neurodegenerative+Disorders&doi=10.1016%2Fj.drudis.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders</span></div><div class="casAuthors">Bawa, Priya; Pradeep, Priyamvada; Kumar, Pradeep; Choonara, Yahya E.; Modi, Girish; Pillay, Viness</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1886-1914</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Historically, neuropsychiatric and neurodegenerative disease treatments focused on the 'magic bullet' concept; however multi-targeted strategies are increasingly attractive gauging from the escalating research in this area.  Because these diseases are typically co-morbid, multi-targeted drugs capable of interacting with multiple targets will expand treatment to the co-morbid disease condition.  Despite their theor. efficacy, there are significant impediments to clin. success (e.g., difficulty titrating individual aspects of the drug and inconclusive pathophysiol. mechanisms).  The new and revised diagnostic frameworks along with studies detailing the endophenotypic characteristics of the diseases promise to provide the foundation for the circumvention of these impediments.  This review serves to evaluate the various marketed and nonmarketed multi-targeted drugs with particular emphasis on their design strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaUcziq8vK_bVg90H21EOLACvtfcHk0ljYlrqTQA6qPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaiu7rL&md5=47734b25b4b55be4f04f3ef936dfa313</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DBawa%26aufirst%3DP.%26aulast%3DPradeep%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DChoonara%26aufirst%3DY.%2BE.%26aulast%3DModi%26aufirst%3DG.%26aulast%3DPillay%26aufirst%3DV.%26atitle%3DMulti-Target%2520Therapeutics%2520for%2520Neuropsychiatric%2520and%2520Neurodegenerative%2520Disorders%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26issue%3D12%26spage%3D1886%26epage%3D1914%26doi%3D10.1016%2Fj.drudis.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E. H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarazi, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahid, M.</span></span> <span> </span><span class="NLM_article-title">The Effectiveness of Multi-Target Agents in Schizophrenia and Mood Disorders: Relevance of Receptor Signature to Clinical Action</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>126</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2010.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.pharmthera.2010.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20171983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksF2qur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=173-185&issue=2&author=E.+H.+F.+Wongauthor=F.+I.+Taraziauthor=M.+Shahid&title=The+Effectiveness+of+Multi-Target+Agents+in+Schizophrenia+and+Mood+Disorders%3A+Relevance+of+Receptor+Signature+to+Clinical+Action&doi=10.1016%2Fj.pharmthera.2010.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action</span></div><div class="casAuthors">Wong, Erik H. F.; Tarazi, Frank I.; Shahid, Mohammed</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-185</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Schizophrenia, bipolar disorder and unipolar depression are multi-dimensional and severely disabling psychiatric diseases with a strong need for improved pharmacotherapies with better adherence, long-term outcome and patient functionality.  Progress has been achieved with the emergence of tailored multi-target agents (MTAs), such as second-generation antipsychotics for schizophrenia, with expanding clin. utility in bipolar disorder and depression.  Better understanding of how these MTAs exert their beneficial and undesirable clin. effects in terms of receptor interaction remains an area for further elucidation, which may provide insight towards a new generation of individualized, and optimized therapies.  This review explores to what extent the receptor signature of MTAs informs about their clin. action and therapeutic utility.  Compelling clin. validation exists only for a limited no. of mol. targets (e.g. D2 receptor blockade, serotonin transport inhibition), indicating overall high attrition and poor translation of predictive preclin. pharmacol.  Nevertheless, recent advances have identified promising novel approaches for schizophrenia, bipolar disorder and depression that require further clin. validation.  It is hoped that the expanding clin. and mechanistic knowledge garnered from the use of existing MTAs will provide addnl. opportunities for "reverse translation" and towards target validation.  There is considerable scope for further developing and applying the knowledge linking receptor signature to clin. activity to drive stronger target validation, and ultimately support rational development of the next generation of MTAs for the improved treatment of schizophrenia and mood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprA36orGSrq7Vg90H21EOLACvtfcHk0lhowxXKaC6HxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksF2qur8%253D&md5=3ecf4d69c5847b205e004f5379bf3b1a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DE.%2BH.%2BF.%26aulast%3DTarazi%26aufirst%3DF.%2BI.%26aulast%3DShahid%26aufirst%3DM.%26atitle%3DThe%2520Effectiveness%2520of%2520Multi-Target%2520Agents%2520in%2520Schizophrenia%2520and%2520Mood%2520Disorders%253A%2520Relevance%2520of%2520Receptor%2520Signature%2520to%2520Clinical%2520Action%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D126%26issue%3D2%26spage%3D173%26epage%3D185%26doi%3D10.1016%2Fj.pharmthera.2010.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroeze, W. K.</span></span> <span> </span><span class="NLM_article-title">Magic Shotguns Versus Magic Bullets: Selectively Non-Selective Drugs for Mood Disorders and Schizophrenia</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1038/nrd1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&issue=4&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+Shotguns+Versus+Magic+Bullets%3A+Selectively+Non-Selective+Drugs+for+Mood+Disorders+and+Schizophrenia&doi=10.1038%2Fnrd1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0lhowxXKaC6HxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520Shotguns%2520Versus%2520Magic%2520Bullets%253A%2520Selectively%2520Non-Selective%2520Drugs%2520for%2520Mood%2520Disorders%2520and%2520Schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D4%26spage%3D353%26epage%3D359%26doi%3D10.1038%2Fnrd1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeshima, M.</span></span> <span> </span><span class="NLM_article-title">Treating Mixed Mania/Hypomania: A Review and Synthesis of the Evidence</span>. <i>CNS Spectrums.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1017/S1092852916000845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1017%2FS1092852916000845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28004626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FnsVKksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=177-185&issue=2&author=M.+Takeshima&title=Treating+Mixed+Mania%2FHypomania%3A+A+Review+and+Synthesis+of+the+Evidence&doi=10.1017%2FS1092852916000845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Treating mixed mania/hypomania: a review and synthesis of the evidence</span></div><div class="casAuthors">Takeshima Minoru</div><div class="citationInfo"><span class="NLM_cas:title">CNS spectrums</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-185</span>
        ISSN:<span class="NLM_cas:issn">1092-8529</span>.
    </div><div class="casAbstract">The DSM-5 incorporates a broad concept of mixed states and captured ≥3 nonoverlapping symptoms of the opposite polarity using a "with mixed features" specifier to be applied to manic/hypomanic and major depressive episodes.  Pharmacotherapy of mixed states is challenging because of the necessity to treat both manic/hypomanic and depressive symptoms concurrently.  High-potency antipsychotics used to treat manic symptoms and antidepressants can potentially deteriorate symptoms of the opposite polarity.  This review aimed to provide a synthesis of the current evidence for pharmacotherapy of mixed states with an emphasis on mixed mania/hypomania.  A PubMed search was conducted for randomized controlled trials (RCTs) that were at least moderately sized, included a placebo arm, and contained information on acute-phase and maintenance treatments of adult patients with mixed episodes or mania/hypomania with significant depressive symptoms.  Most studies were post-hoc subgroup and pooled analyses of the data from RCTs for acute manic and mixed episodes of bipolar I disorder; only two prospectively examined efficacy for mixed mania/hypomania specifically.  Aripiprazole, asenapine, carbamazepine, olanzapine, and ziprasidone showed the strongest evidence of efficacy in acute-phase treatment.  Quetiapine and divalproex/valproate were also efficacious.  Combination therapies with these atypical antipsychotics and mood stabilizers can be considered in severe cases.  Olanzapine and quetiapine (alone or in combination with lithium/divalproex) showed the strongest evidence of efficacy in maintenance treatment.  Lithium and lamotrigine may be beneficial given their preventive effects on suicide and depressive relapse.  Further prospective studies primarily focusing on mixed states are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5cBz8zkyS2Nj_Vg2vObihfW6udTcc2ebe4AAGFmSbj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FnsVKksQ%253D%253D&md5=87a4b1fe530051dc37c3aa50eb1b8e00</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1017%2FS1092852916000845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1092852916000845%26sid%3Dliteratum%253Aachs%26aulast%3DTakeshima%26aufirst%3DM.%26atitle%3DTreating%2520Mixed%2520Mania%252FHypomania%253A%2520A%2520Review%2520and%2520Synthesis%2520of%2520the%2520Evidence%26jtitle%3DCNS%2520Spectrums.%26date%3D2017%26volume%3D22%26issue%3D2%26spage%3D177%26epage%3D185%26doi%3D10.1017%2FS1092852916000845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuplin, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holahan, M. R.</span></span> <span> </span><span class="NLM_article-title">Aripiprazole, a Drug That Displays Partial Agonism and Functional Selectivity</span>. <i>Curr. Neuropharnacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1192</span>– <span class="NLM_lpage">1207</span>, <span class="refDoi"> DOI: 10.2174/1570159X15666170413115754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F1570159X15666170413115754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28412910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFens7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=1192-1207&issue=8&author=E.+W.+Tuplinauthor=M.+R.+Holahan&title=Aripiprazole%2C+a+Drug+That+Displays+Partial+Agonism+and+Functional+Selectivity&doi=10.2174%2F1570159X15666170413115754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity</span></div><div class="casAuthors">Tuplin, Erin W.; Holahan, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1192-1207</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: The treatment of schizophrenia is challenging due to the wide range of symptoms (pos., neg., cognitive) assocd. with the disease.  Typical antipsychotics that antagonize D2 receptors are effective in treating pos. symptoms, but extrapyramidal side-effects (EPS) are a common occurrence.  Atypical antipsychotics targeting 5-HT2A and D2 receptors are more effective at treating cognitive and neg. symptoms compared to typical antipsychotics, but these drugs also result in side-effects such as metabolic syndromes.  Objective: To identify evidence in the literature that elucidates the pharmacol. profile of aripiprazole.s.  Methods: We searched PubMed for peer reviewed articles on aripiprazole and its clin. efficacy, side-effects, pharmacol., and effects in animal models of schizophrenia symptoms.  Results: Aripiprazole is a newer atypical antipsychotic that displays a unique pharmacol. profile, including partial D2 agonism and functionally selective properties.  Aripiprazole is effective at treating the pos. symptoms of schizophrenia and has the potential to treat neg. and cognitive symptoms at least as well as other atypical antipsychotics.  The drug has a favorable side-effect profile and has a low propensity to result in EPS or metabolic syndromes.  Animal models of schizophrenia have been used to det. the efficacy of aripiprazole in symptom management.  In these instances, aripiprazole resulted in the reversal of deficits in extinction, pre-pulse inhibition, and social withdrawal.  Because aripiprazole requires a greater than 90% occupancy rate at D2 receptors to be clin. active and does not produce EPS, this suggests a functionally selective effect on intracellular signaling pathways.  Conclusion: A combination of factors such as dopamine system stabilization via partial agonism, functional selectivity at D2 receptors, and serotonin-dopamine system interaction may contribute to the ability of aripiprazole to successfully manage schizophrenia symptoms.  This review examines these mechanisms of action to further clarify the pharmacol. actions of aripiprazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiNaT3zwOCzLVg90H21EOLACvtfcHk0ljctI_MGWemGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFens7vM&md5=a3e01bec5ee707325ac14bcee420a4d2</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.2174%2F1570159X15666170413115754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X15666170413115754%26sid%3Dliteratum%253Aachs%26aulast%3DTuplin%26aufirst%3DE.%2BW.%26aulast%3DHolahan%26aufirst%3DM.%2BR.%26atitle%3DAripiprazole%252C%2520a%2520Drug%2520That%2520Displays%2520Partial%2520Agonism%2520and%2520Functional%2520Selectivity%26jtitle%3DCurr.%2520Neuropharnacol.%26date%3D2017%26volume%3D15%26issue%3D8%26spage%3D1192%26epage%3D1207%26doi%3D10.2174%2F1570159X15666170413115754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caraci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggio, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drago, F.</span></span> <span> </span><span class="NLM_article-title">New Drugs in Psychiatry: Focus on New Pharmacological Targets</span>. <i>F1000Research</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.12688/f1000research.10233.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.12688%2Ff1000research.10233.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28408985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnslOhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=397-405&author=F.+Caraciauthor=G.+M.+Leggioauthor=S.+Salomoneauthor=F.+Drago&title=New+Drugs+in+Psychiatry%3A+Focus+on+New+Pharmacological+Targets&doi=10.12688%2Ff1000research.10233.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">New drugs in psychiatry: focus on new pharmacological targets</span></div><div class="casAuthors">Caraci Filippo; Caraci Filippo; Leggio Gian Marco; Salomone Salvatore; Drago Filippo</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">397</span>
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    </div><div class="casAbstract">The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years.  To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications.  In this report, we detail drug candidates being examined as treatments for psychiatric disorders.  Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer's disease.  All of the compounds considered were recently approved for human use or are in advanced clinical trials.  Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression.  New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine.  As for Alzheimer's disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQm8I_QiD3OJNhSDZx9hyjKfW6udTcc2eYszjvnmfNZo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnslOhsw%253D%253D&md5=a49356e1ef4094435d21d838138a120f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.10233.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.10233.1%26sid%3Dliteratum%253Aachs%26aulast%3DCaraci%26aufirst%3DF.%26aulast%3DLeggio%26aufirst%3DG.%2BM.%26aulast%3DSalomone%26aufirst%3DS.%26aulast%3DDrago%26aufirst%3DF.%26atitle%3DNew%2520Drugs%2520in%2520Psychiatry%253A%2520Focus%2520on%2520New%2520Pharmacological%2520Targets%26jtitle%3DF1000Research%26date%3D2017%26volume%3D6%26spage%3D397%26epage%3D405%26doi%3D10.12688%2Ff1000research.10233.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huhn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider-Thoma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bighelli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolakopoulou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leucht, S.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic Drugs for Patients with Schizophrenia and Predominant or Prominent Negative Symptoms: A Systematic Review and Meta-Analysis</span>. <i>Eur. Arch. Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>268</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1007/s00406-018-0869-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1007%2Fs00406-018-0869-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29368205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC1MvktFensg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=2018&pages=625-639&issue=7&author=M.+Krauseauthor=Y.+Zhuauthor=M.+Huhnauthor=J.+Schneider-Thomaauthor=I.+Bighelliauthor=A.+Nikolakopoulouauthor=S.+Leucht&title=Antipsychotic+Drugs+for+Patients+with+Schizophrenia+and+Predominant+or+Prominent+Negative+Symptoms%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1007%2Fs00406-018-0869-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis</span></div><div class="casAuthors">Krause Marc; Zhu Yikang; Huhn Maximilian; Schneider-Thoma Johannes; Bighelli Irene; Leucht Stefan; Krause Marc; Zhu Yikang; Nikolakopoulou Adriani</div><div class="citationInfo"><span class="NLM_cas:title">European archives of psychiatry and clinical neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">625-639</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Negative symptoms are the core of schizophrenia, but whether antipsychotics are efficacious for their treatment is unclear.  Moreover, there is debate whether patients in relevant trials should have predominant negative symptoms or whether prominent negative symptoms are also acceptable.  METHODS:  We systematically reviewed randomised, blinded antipsychotic drug trials in patients with schizophrenia and either predominant or prominent negative symptoms (last search Dec 12, 2017).  Separate pairwise meta-analyses were conducted in these two populations.  The primary outcome was negative symptoms.  Depressive, symptoms, positive symptoms, and extrapyramidal side-effects were analysed as causes of secondary negative symptoms.  FINDINGS:  We included 21 randomized-controlled trials with 3451 participants which revealed the following significant differences in the primary outcome: in patients with predominant negative symptoms amisulpride was superior to placebo (N = 4; n = 590, SMD 0.47, CI 0.23, 0.71), olanzapine was superior to haloperidol in a small trial (n = 35) and cariprazine outperformed risperidone (N = 1, n = 456, SMD - 0.29, CI - 0.48, - 0.11).  In patients with prominent negative symptoms, olanzapine and quetiapine were superior to risperidone in single trials.  Overall, studies in prominent negative symptoms were potentially more confounded by improvements of secondary negative symptoms.  INTERPRETATION:  Amisulpride is the only antipsychotic that outperformed placebo in the treatment of predominant negative symptoms, but there was a parallel reduction of depression.  Cariprazine was better than risperidone in a large trial that was well-controlled for secondary negative symptoms, but the trial was sponsored by its manufacturer.  Future trials should apply scientifically developed definitions such as the deficit syndrome and the persistent negative symptoms concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwQM34mV101rBItaL1WaVAfW6udTcc2eYszjvnmfNZo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvktFensg%253D%253D&md5=240bd56132a816c7282544f143ba983a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs00406-018-0869-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-018-0869-3%26sid%3Dliteratum%253Aachs%26aulast%3DKrause%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DHuhn%26aufirst%3DM.%26aulast%3DSchneider-Thoma%26aufirst%3DJ.%26aulast%3DBighelli%26aufirst%3DI.%26aulast%3DNikolakopoulou%26aufirst%3DA.%26aulast%3DLeucht%26aufirst%3DS.%26atitle%3DAntipsychotic%2520Drugs%2520for%2520Patients%2520with%2520Schizophrenia%2520and%2520Predominant%2520or%2520Prominent%2520Negative%2520Symptoms%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DEur.%2520Arch.%2520Psychiatry%2520Clin.%2520Neurosci.%26date%3D2018%26volume%3D268%26issue%3D7%26spage%3D625%26epage%3D639%26doi%3D10.1007%2Fs00406-018-0869-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koutsoukas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchmair, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitmore, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span> <span> </span><span class="NLM_article-title">From in Silico Target Prediction to Multi-Target Drug Design: Current Databases, Methods and Applications</span>. <i>J. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2554</span>– <span class="NLM_lpage">2574</span>, <span class="refDoi"> DOI: 10.1016/j.jprot.2011.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.jprot.2011.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21621023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2011&pages=2554-2574&issue=12&author=A.+Koutsoukasauthor=B.+Simmsauthor=J.+Kirchmairauthor=P.+J.+Bondauthor=A.+V.+Whitmoreauthor=S.+Zimmerauthor=M.+P.+Youngauthor=J.+L.+Jenkinsauthor=M.+Glickauthor=R.+C.+Glenauthor=A.+Bender&title=From+in+Silico+Target+Prediction+to+Multi-Target+Drug+Design%3A+Current+Databases%2C+Methods+and+Applications&doi=10.1016%2Fj.jprot.2011.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">From in silico target prediction to multi-target drug design: Current databases, methods and applications</span></div><div class="casAuthors">Koutsoukas, Alexios; Simms, Benjamin; Kirchmair, Johannes; Bond, Peter J.; Whitmore, Alan V.; Zimmer, Steven; Young, Malcolm P.; Jenkins, Jeremy L.; Glick, Meir; Glen, Robert C.; Bender, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2554-2574</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Given the tremendous growth of bioactivity databases, the use of computational tools to predict protein targets of small mols. has been gaining importance in recent years.  Applications span a wide range, from the designed polypharmacol.' of compds. to mode-of-action anal.  In this review, we firstly survey databases that can be used for ligand-based target prediction and which have grown tremendously in size in the past.  We furthermore outline methods for target prediction that exist, both based on the knowledge of bioactivities from the ligand side and methods that can be applied in situations when a protein structure is known.  Applications of successful in silico target identification attempts are discussed in detail, which were based partly or in whole on computational target predictions in the first instance.  This includes the authors' own experience using target prediction tools, in this case considering phenotypic antibacterial screens and the anal. of high-throughput screening data.  Finally, we will conclude with the prospective application of databases to not only predict, retrospectively, the protein targets of a small mol., but also how to design ligands with desired polypharmacol. in a prospective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQAhthzL8wiLVg90H21EOLACvtfcHk0lj8yBzgUVszeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE&md5=3fd699639ef3faf347537ef400030dd9</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2011.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2011.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DKoutsoukas%26aufirst%3DA.%26aulast%3DSimms%26aufirst%3DB.%26aulast%3DKirchmair%26aufirst%3DJ.%26aulast%3DBond%26aufirst%3DP.%2BJ.%26aulast%3DWhitmore%26aufirst%3DA.%2BV.%26aulast%3DZimmer%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DM.%2BP.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DBender%26aufirst%3DA.%26atitle%3DFrom%2520in%2520Silico%2520Target%2520Prediction%2520to%2520Multi-Target%2520Drug%2520Design%253A%2520Current%2520Databases%252C%2520Methods%2520and%2520Applications%26jtitle%3DJ.%2520Proteomics%26date%3D2011%26volume%3D74%26issue%3D12%26spage%3D2554%26epage%3D2574%26doi%3D10.1016%2Fj.jprot.2011.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, D.</span></span> <span> </span><span class="NLM_article-title">Phenotypic Screening in Cancer Drug Discovery—Past, Present and Future</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1038/nrd4366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd4366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25033736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=588-602&issue=8&author=J.+G.+Moffatauthor=J.+Rudolphauthor=D.+Bailey&title=Phenotypic+Screening+in+Cancer+Drug+Discovery%E2%80%94Past%2C+Present+and+Future&doi=10.1038%2Fnrd4366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening in cancer drug discovery - past, present and future</span></div><div class="casAuthors">Moffat, John G.; Rudolph, Joachim; Bailey, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">588-602</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches.  Given that oncol. is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncol. drug discovery by analyzing the origins of all new small-mol. cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clin. development.  Although the majority of these drugs originated from target-based discovery, we identified a significant no. whose discovery depended on phenotypic screening approaches.  We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes.  However, tech. and biol. advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTWtoTIgWqvbVg90H21EOLACvtfcHk0lj8yBzgUVszeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L&md5=0e8efed90e5bc4b47f959b83a6ab5b96</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrd4366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4366%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DD.%26atitle%3DPhenotypic%2520Screening%2520in%2520Cancer%2520Drug%2520Discovery%25E2%2580%2594Past%252C%2520Present%2520and%2520Future%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D8%26spage%3D588%26epage%3D602%26doi%3D10.1038%2Fnrd4366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H. J.</span></span> <span> </span><span class="NLM_article-title">Identification and Validation of Bioactive Small Molecule Target through Phenotypic Screening</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1922</span>– <span class="NLM_lpage">1928</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.11.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2011.11.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22153994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlOmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1922-1928&issue=6&author=Y.+S.+Choauthor=H.+J.+Kwon&title=Identification+and+Validation+of+Bioactive+Small+Molecule+Target+through+Phenotypic+Screening&doi=10.1016%2Fj.bmc.2011.11.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and validation of bioactive small molecule target through phenotypic screening</span></div><div class="casAuthors">Cho, Yoon Sun; Kwon, Ho Jeong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1922-1928</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">For effective bioactive small mol. discovery and development into new therapeutic drug, a systematic screening and target protein identification is required.  Different from the conventional screening system, herein phenotypic screening in combination with multi-omics-based target identification and validation (MOTIV) is introduced.  First, phenotypic screening provides visual effect of bioactive small mols. in the cell or organism level.  It is important to know the effect on the cell or organism level since small mols. affect not only a single target but the entire cellular mechanism within a cell or organism.  Secondly, MOTIV provides systemic approach to discover the target protein of bioactive small mol.  With the chem. genomics and proteomics approach of target identification methods, various target protein candidates are identified.  Then network anal. and validations of these candidates result in identifying the biol. relevant target protein and cellular mechanism.  Overall, the combination of phenotypic screening and MOTIV will provide an effective approach to discover new bioactive small mols. and their target protein and mechanism identification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRmAssvm8bYbVg90H21EOLACvtfcHk0lj8yBzgUVszeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlOmsr8%253D&md5=29ba512d59e1dab3832572d39713dd4b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.11.021%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DY.%2BS.%26aulast%3DKwon%26aufirst%3DH.%2BJ.%26atitle%3DIdentification%2520and%2520Validation%2520of%2520Bioactive%2520Small%2520Molecule%2520Target%2520through%2520Phenotypic%2520Screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26issue%3D6%26spage%3D1922%26epage%3D1928%26doi%3D10.1016%2Fj.bmc.2011.11.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mett, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydon, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, P.</span></span> <span> </span><span class="NLM_article-title">Phenylamino-Pyrimidine (PAP) - Derivatives: A New Class of Potent and Highly Selective PDGF -Receptor Autophosphorylation Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1226</span>, <span class="refDoi"> DOI: 10.1016/0960-894X(96)00197-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2F0960-894X%2896%2900197-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK28Xjs1ykt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=1221-1226&issue=11&author=J.+Zimmermannauthor=E.+Buchdungerauthor=H.+Mettauthor=T.+Meyerauthor=N.+B.+Lydonauthor=P.+Traxler&title=Phenylamino-Pyrimidine+%28PAP%29+-+Derivatives%3A+A+New+Class+of+Potent+and+Highly+Selective+PDGF+-Receptor+Autophosphorylation+Inhibitors&doi=10.1016%2F0960-894X%2896%2900197-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">(Phenylamino)pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors</span></div><div class="casAuthors">Zimmermann, Juerg; Buchdunger, Elisabeth; Mett, Helmut; Meyer, Thomas; Lydon, Nicholas B.; Traxler, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1221-1226</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">(Phenylamino)pyrimidines represent a novel class of inhibitors of the PDGF-receptor autophosphorylation with a high degree of selectivity vs. other tyrosine and serine/threonine kinases.  Optimum activity of ca 10 nM (IC50) was obsd. when the phenylamino-group which is attached to the pyrimidine carries a benzamide-moiety with a lipophilic substituent in 4-position.  The target compds. were derivs. of 4-methyl-N3-[4-(3-pyridinyl)-2-pyrimidinyl]-1,3-benzenediamine I (R2 = H, Me; R3 = H, benzoyl, Me, etc.; R4 = H, benzoyl, etc.).  A 2-thienyl analog of I was also prepd. and tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU5f-7b9Q_77Vg90H21EOLACvtfcHk0lj8yBzgUVszeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjs1ykt70%253D&md5=0c35d8248e2e396caaf518b2abb62835</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2896%2900197-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252896%252900197-7%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26aulast%3DTraxler%26aufirst%3DP.%26atitle%3DPhenylamino-Pyrimidine%2520%2528PAP%2529%2520-%2520Derivatives%253A%2520A%2520New%2520Class%2520of%2520Potent%2520and%2520Highly%2520Selective%2520PDGF%2520-Receptor%2520Autophosphorylation%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26issue%3D11%26spage%3D1221%26epage%3D1226%26doi%3D10.1016%2F0960-894X%2896%2900197-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlik, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moxham, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomandl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sall, D. J.</span></span> <span> </span><span class="NLM_article-title">Modern Phenotypic Drug Discovery is a Viable, Neoclassic Pharma Strategy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4527</span>– <span class="NLM_lpage">4538</span>, <span class="refDoi"> DOI: 10.1021/jm201649s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201649s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1OitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4527-4538&issue=10&author=J.+A.+Leeauthor=M.+T.+Uhlikauthor=C.+M.+Moxhamauthor=D.+Tomandlauthor=D.+J.+Sall&title=Modern+Phenotypic+Drug+Discovery+is+a+Viable%2C+Neoclassic+Pharma+Strategy&doi=10.1021%2Fjm201649s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy</span></div><div class="casAuthors">Lee, Jonathan A.; Uhlik, Mark T.; Moxham, Christopher M.; Tomandl, Dirk; Sall, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4527-4538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmaceutical industry (Pharma) is currently facing unprecedented challenges.  In addn. to strategic patent expirations, the rate of drug launches has been essentially const. for 60 years with overall productivity falling since the 1970s.  Similarly, the appearance of novel targets to FDA approved drugs, a measure of industry innovation, has not dramatically improved since the 1980s.  Although Pharma productivity is a multifaceted problem, detailed analyses of comprehensive, industry-wide data indicate that late stage clin. failures are a major contributor that has been attributed to poor target validation (TV) and the lack of predictive biomarkers that translate to the clinic.  In the spirit of "reinventing innovation" Pharma needs to introspectively identify areas for improvement.  This communication considers how choices in drug screening strategies may relate to target validation issues and influence the probability of identifying novel medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8CcODiYYNgLVg90H21EOLACvtfcHk0ljobj4uEUjW_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1OitLs%253D&md5=1937641b632e348d7566c016ca4cf51d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm201649s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201649s%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BA.%26aulast%3DUhlik%26aufirst%3DM.%2BT.%26aulast%3DMoxham%26aufirst%3DC.%2BM.%26aulast%3DTomandl%26aufirst%3DD.%26aulast%3DSall%26aufirst%3DD.%2BJ.%26atitle%3DModern%2520Phenotypic%2520Drug%2520Discovery%2520is%2520a%2520Viable%252C%2520Neoclassic%2520Pharma%2520Strategy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D10%26spage%3D4527%26epage%3D4538%26doi%3D10.1021%2Fjm201649s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mccarroll, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendelev, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokel, D.</span></span> <span> </span><span class="NLM_article-title">Leveraging Large-Scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00800</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00800" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=842-849&issue=4&author=M.+N.+Mccarrollauthor=L.+Gendelevauthor=M.+J.+Keiserauthor=D.+Kokel&title=Leveraging+Large-Scale+Behavioral+Profiling+in+Zebrafish+to+Explore+Neuroactive+Polypharmacology&doi=10.1021%2Facschembio.5b00800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology</span></div><div class="casAuthors">McCarroll, Matthew N.; Gendelev, Leo; Keiser, Michael J.; Kokel, David</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-849</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Many psychiatric drugs modulate the nervous system through multitarget mechanisms.  However, systematic identification of multitarget compds. has been difficult using traditional in vitro screening assays.  New approaches to phenotypic profiling in zebrafish can help researchers identify novel compds. with complex polypharmacol.  For example, large-scale behavior-based chem. screens can rapidly identify large nos. of structurally diverse and phenotype-related compds.  Once these compds. have been identified, a systems-level anal. of their structures may help to identify statistically enriched target pathways.  Together, systematic behavioral profiling and multitarget predictions may help researchers identify new behavior-modifying pathways and CNS therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3QN11t7PEEbVg90H21EOLACvtfcHk0ljobj4uEUjW_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSlsL8%253D&md5=6d69351d9c3e6c711881947aac517e75</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00800%26sid%3Dliteratum%253Aachs%26aulast%3DMccarroll%26aufirst%3DM.%2BN.%26aulast%3DGendelev%26aufirst%3DL.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DKokel%26aufirst%3DD.%26atitle%3DLeveraging%2520Large-Scale%2520Behavioral%2520Profiling%2520in%2520Zebrafish%2520to%2520Explore%2520Neuroactive%2520Polypharmacology%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3D842%26epage%3D849%26doi%3D10.1021%2Facschembio.5b00800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonoshita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scopton, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, P. M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Real, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagan, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A. C.</span></span> <span> </span><span class="NLM_article-title">A Whole-Animal Platform to Advance a Clinical Kinase Inhibitor into New Disease Space</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnchembio.2556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29355849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=291-298&issue=3&author=M.+Sonoshitaauthor=A.+P.+Scoptonauthor=P.+M.+U.+Ungauthor=M.+A.+Murrayauthor=L.+Silberauthor=A.+Y.+Maldonadoauthor=A.+Realauthor=A.+Schlessingerauthor=R.+L.+Caganauthor=A.+C.+Dar&title=A+Whole-Animal+Platform+to+Advance+a+Clinical+Kinase+Inhibitor+into+New+Disease+Space&doi=10.1038%2Fnchembio.2556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A whole-animal platform to advance a clinical kinase inhibitor into new disease space</span></div><div class="casAuthors">Sonoshita, Masahiro; Scopton, Alex P.; Ung, Peter M. U.; Murray, Matthew A.; Silber, Lisa; Maldonado, Andres Y.; Real, Alexander; Schlessinger, Avner; Cagan, Ross L.; Dar, Arvin C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-298</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Synthetic tailoring of approved drugs for new indications is often difficult, as the most appropriate targets may not be readily apparent, and therefore few roadmaps exist to guide chem.  Here, we report a multidisciplinary approach for accessing novel target and chem. space starting from an FDA-approved kinase inhibitor.  By combining chem. and genetic modifier screening with computational modeling, we identify distinct kinases that strongly enhance ('pro-targets') or limit ('anti-targets') whole-animal activity of the clin. kinase inhibitor sorafenib in a Drosophila medullary thyroid carcinoma (MTC) model.  We demonstrate that RAF-the original intended sorafenib target-and MKNK kinases function as pharmacol. liabilities because of inhibitor-induced transactivation and neg. feedback, resp.  Through progressive synthetic refinement, we report a new class of 'tumor calibrated inhibitors' with unique polypharmacol. and strongly improved therapeutic index in fly and human MTC xenograft models.  This platform provides a rational approach to creating new high-efficacy and low-toxicity drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokPGDBCxqaILVg90H21EOLACvtfcHk0ljobj4uEUjW_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2msrk%253D&md5=54fd159e29ffa581e7c53983d92dd134</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2556%26sid%3Dliteratum%253Aachs%26aulast%3DSonoshita%26aufirst%3DM.%26aulast%3DScopton%26aufirst%3DA.%2BP.%26aulast%3DUng%26aufirst%3DP.%2BM.%2BU.%26aulast%3DMurray%26aufirst%3DM.%2BA.%26aulast%3DSilber%26aufirst%3DL.%26aulast%3DMaldonado%26aufirst%3DA.%2BY.%26aulast%3DReal%26aufirst%3DA.%26aulast%3DSchlessinger%26aufirst%3DA.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26aulast%3DDar%26aufirst%3DA.%2BC.%26atitle%3DA%2520Whole-Animal%2520Platform%2520to%2520Advance%2520a%2520Clinical%2520Kinase%2520Inhibitor%2520into%2520New%2520Disease%2520Space%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26issue%3D3%26spage%3D291%26epage%3D298%26doi%3D10.1038%2Fnchembio.2556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span> <span> </span><span class="NLM_article-title">In-Silico Approaches to Multi-Target Drug Discovery</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1007/s11095-010-0065-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1007%2Fs11095-010-0065-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20221898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVWrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2010&pages=739-749&issue=5&author=X.+H.+Maauthor=Z.+Shiauthor=C.+Tanauthor=Y.+Jiangauthor=M.+L.+Goauthor=B.+C.+Lowauthor=Y.+Z.+Chen&title=In-Silico+Approaches+to+Multi-Target+Drug+Discovery&doi=10.1007%2Fs11095-010-0065-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">In-Silico Approaches to Multi-target Drug Discovery - Computer Aided Multi-target Drug Design, Multi-target Virtual Screening</span></div><div class="casAuthors">Ma, Xiao Hua; Shi, Zhe; Tan, Chunyan; Jiang, Yuyang; Go, Mei Lin; Low, Boon Chuan; Chen, Yu Zong</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">739-749</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Multi-target drugs against selective multiple targets improve therapeutic efficacy, safety and resistance profiles by collective regulations of a primary therapeutic target together with compensatory elements and resistance activities.  Efforts have been made to employ in-silico methods for facilitating the search and design of selective multi-target agents.  These methods have shown promising potential in facilitating drug discovery directed at selective multiple targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob4gKJy9MUFLVg90H21EOLACvtfcHk0lgiORsndsMPpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVWrsbc%253D&md5=c530372ddbcce5e35f52984d5f6e32e2</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs11095-010-0065-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-010-0065-2%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%2BH.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DGo%26aufirst%3DM.%2BL.%26aulast%3DLow%26aufirst%3DB.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26atitle%3DIn-Silico%2520Approaches%2520to%2520Multi-Target%2520Drug%2520Discovery%26jtitle%3DPharm.%2520Res.%26date%3D2010%26volume%3D27%26issue%3D5%26spage%3D739%26epage%3D749%26doi%3D10.1007%2Fs11095-010-0065-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span> <span> </span><span class="NLM_article-title">Advances in Computational Approaches in Identifying Synergistic Drug Combinations</span>. <i>Briefings Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1172</span>– <span class="NLM_lpage">1182</span>, <span class="refDoi"> DOI: 10.1093/bib/bbx047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1093%2Fbib%2Fbbx047" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=1172-1182&issue=6&author=Z.+Shengauthor=Y.+Sunauthor=Z.+Yinauthor=K.+Tangauthor=Z.+Cao&title=Advances+in+Computational+Approaches+in+Identifying+Synergistic+Drug+Combinations&doi=10.1093%2Fbib%2Fbbx047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1093%2Fbib%2Fbbx047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbib%252Fbbx047%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DZ.%26atitle%3DAdvances%2520in%2520Computational%2520Approaches%2520in%2520Identifying%2520Synergistic%2520Drug%2520Combinations%26jtitle%3DBriefings%2520Bioinf.%26date%3D2017%26volume%3D19%26issue%3D6%26spage%3D1172%26epage%3D1182%26doi%3D10.1093%2Fbib%2Fbbx047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chua, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker-Kellogg, L.</span></span> <span> </span><span class="NLM_article-title">Synergistic Target Combination Prediction from Curated Signaling Networks: Machine Learning Meets Systems Biology and Pharmacology</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.ymeth.2017.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ymeth.2017.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28552265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsVKjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=60-80&author=H.+E.+Chuaauthor=S.+S.+Bhowmickauthor=L.+Tucker-Kellogg&title=Synergistic+Target+Combination+Prediction+from+Curated+Signaling+Networks%3A+Machine+Learning+Meets+Systems+Biology+and+Pharmacology&doi=10.1016%2Fj.ymeth.2017.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic target combination prediction from curated signaling networks: Machine learning meets systems biology and pharmacology</span></div><div class="casAuthors">Chua, Huey Eng; Bhowmick, Sourav S.; Tucker-Kellogg, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Methods (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-80</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Given a signaling network, the target combination prediction problem aims to predict efficacious and safe target combinations for combination therapy.  State-of-the-art in silico methods use Monte Carlo simulated annealing (MCSA) to modify a candidate soln. stochastically, and use the Metropolis criterion to accept or reject the proposed modifications.  However, such stochastic modifications ignore the impact of the choice of targets and their activities on the combination's therapeutic effect and off-target effects, which directly affect the soln. quality.  In this paper, we present MASCOT, a method that addresses this limitation by leveraging two addnl. heuristic criteria to minimize off-target effects and achieve synergy for candidate modification.  Specifically, off-target effects measure the unintended response of a signaling network to the target combination and is often assocd. with toxicity.  Synergy occurs when a pair of targets exerts effects that are greater than the sum of their individual effects, and is generally a beneficial strategy for maximizing effect while minimizing toxicity. MASCOT leverages on a machine learning-based target prioritization method which prioritizes potential targets in a given disease-assocd. network to select more effective targets (better therapeutic effect and/or lower off-target effects); and on Loewe additivity theory from pharmacol. which assesses the non-additive effects in a combination drug treatment to select synergistic target activities.  Our exptl. study on two disease-related signaling networks demonstrates the superiority of MASCOT in comparison to existing approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0NdKdd4aa5rVg90H21EOLACvtfcHk0ljesAu8SC8bSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsVKjur0%253D&md5=aeb07b7c7c6a58e6c4e7e70418e6fdec</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2017.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2017.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DChua%26aufirst%3DH.%2BE.%26aulast%3DBhowmick%26aufirst%3DS.%2BS.%26aulast%3DTucker-Kellogg%26aufirst%3DL.%26atitle%3DSynergistic%2520Target%2520Combination%2520Prediction%2520from%2520Curated%2520Signaling%2520Networks%253A%2520Machine%2520Learning%2520Meets%2520Systems%2520Biology%2520and%2520Pharmacology%26jtitle%3DMethods%26date%3D2017%26volume%3D129%26spage%3D60%26epage%3D80%26doi%3D10.1016%2Fj.ymeth.2017.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Network Pharmacology: The Next Paradigm in Drug Discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&issue=11&author=A.+L.+Hopkins&title=Network+Pharmacology%3A+The+Next+Paradigm+in+Drug+Discovery&doi=10.1038%2Fnchembio.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0ljesAu8SC8bSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520Pharmacology%253A%2520The%2520Next%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26issue%3D11%26spage%3D682%26epage%3D690%26doi%3D10.1038%2Fnchembio.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinelli, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korkut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crago, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span> <span> </span><span class="NLM_article-title">Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">294</span>), <span class="NLM_elocation-id">ra85</span> <span class="refDoi"> DOI: 10.1126/scisignal.2004014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1126%2Fscisignal.2004014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24065146" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&issue=294&author=M.+L.+Millerauthor=E.+J.+Molinelliauthor=J.+S.+Nairauthor=T.+Sheikhauthor=R.+Samyauthor=X.+Jingauthor=Q.+Heauthor=A.+Korkutauthor=A.+M.+Cragoauthor=S.+Singerauthor=G.+K.+Schwartzauthor=C.+Sander&title=Drug+Synergy+Screen+and+Network+Modeling+in+Dedifferentiated+Liposarcoma+Identifies+CDK4+and+IGF1R+as+Synergistic+Drug+Targets&doi=10.1126%2Fscisignal.2004014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004014%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DMolinelli%26aufirst%3DE.%2BJ.%26aulast%3DNair%26aufirst%3DJ.%2BS.%26aulast%3DSheikh%26aufirst%3DT.%26aulast%3DSamy%26aufirst%3DR.%26aulast%3DJing%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DKorkut%26aufirst%3DA.%26aulast%3DCrago%26aufirst%3DA.%2BM.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DSander%26aufirst%3DC.%26atitle%3DDrug%2520Synergy%2520Screen%2520and%2520Network%2520Modeling%2520in%2520Dedifferentiated%2520Liposarcoma%2520Identifies%2520CDK4%2520and%2520IGF1R%2520as%2520Synergistic%2520Drug%2520Targets%26jtitle%3DSci.%2520Signaling%26date%3D2013%26volume%3D6%26issue%3D294%26doi%3D10.1126%2Fscisignal.2004014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">Can We Rationally Design Promiscuous Drugs?</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2006.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&issue=1&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can+We+Rationally+Design+Promiscuous+Drugs%3F&doi=10.1016%2Fj.sbi.2006.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0ljesAu8SC8bSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan%2520We%2520Rationally%2520Design%2520Promiscuous%2520Drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26issue%3D1%26spage%3D127%26epage%3D136%26doi%3D10.1016%2Fj.sbi.2006.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savelieff, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span> <span> </span><span class="NLM_article-title">Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1322</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00138</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00138" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOis7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=1221-1322&author=M.+G.+Savelieffauthor=G.+Namauthor=J.+Kangauthor=H.+J.+Leeauthor=M.+Leeauthor=M.+H.+Lim&title=Development+of+Multifunctional+Molecules+as+Potential+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Parkinson%E2%80%99s+Disease%2C+and+Amyotrophic+Lateral+Sclerosis+in+the+Last+Decade&doi=10.1021%2Facs.chemrev.8b00138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade</span></div><div class="casAuthors">Savelieff, Masha G.; Nam, Geewoo; Kang, Juhye; Lee, Hyuck Jin; Lee, Misun; Lim, Mi Hee</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1221-1322</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative diseases pose a substantial socioeconomic burden on society.  Unfortunately, the aging world population and lack of effective cures foreshadow a neg. outlook.  Although a large amt. of research has been dedicated to elucidating the pathologies of neurodegenerative diseases, their principal causes remain elusive.  Metal ion dyshomeostasis, proteopathy, oxidative stress, and neurotransmitter deficiencies are pathol. features shared across multiple neurodegenerative disorders.  In addn., these factors are proposed to be interrelated upon disease progression.  Thus, the development of multifunctional compds. capable of simultaneously interacting with several pathol. components has been suggested as a soln. to undertake the complex pathologies of neurodegenerative diseases.  In this review, the authors outline and discuss possible therapeutic targets in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis and mols., previously designed or discovered as potential drug candidates for these disorders with emphasis on multifunctionality.  In addn., underrepresented areas of research are discussed to indicate new directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeYBpXrefkZbVg90H21EOLACvtfcHk0lhlZHCi5ob55Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOis7jL&md5=ee3763784767afe96c57e10439183f82</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00138%26sid%3Dliteratum%253Aachs%26aulast%3DSavelieff%26aufirst%3DM.%2BG.%26aulast%3DNam%26aufirst%3DG.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DM.%2BH.%26atitle%3DDevelopment%2520of%2520Multifunctional%2520Molecules%2520as%2520Potential%2520Therapeutic%2520Candidates%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%252C%2520Parkinson%25E2%2580%2599s%2520Disease%252C%2520and%2520Amyotrophic%2520Lateral%2520Sclerosis%2520in%2520the%2520Last%2520Decade%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D1221%26epage%3D1322%26doi%3D10.1021%2Facs.chemrev.8b00138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetsch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvaïa, N.</span></span> <span> </span><span class="NLM_article-title">Strategies and Challenges for the Next Generation of Antibody-Drug Conjugates</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd.2016.268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28303026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=315-337&issue=5&author=A.+Beckauthor=L.+Goetschauthor=C.+Dumontetauthor=N.+Corva%C3%AFa&title=Strategies+and+Challenges+for+the+Next+Generation+of+Antibody-Drug+Conjugates&doi=10.1038%2Fnrd.2016.268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies and challenges for the next generation of antibody-drug conjugates</span></div><div class="casAuthors">Beck, Alain; Goetsch, Liliane; Dumontet, Charles; Corvaia, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-337</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncol. therapeutics.  After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clin. trials that are evaluating more than 60 further ADC candidates.  The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody.  Furthermore, lessons learned during the past decade are now being used in the development of third-generation ADCs.  In this Review, we discuss strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues.  The selection and engineering of antibodies for site-specific drug conjugation, which will result in higher homogeneity and increased stability, as well as the quest for new conjugation chemistries and mechanisms of action, are priorities in ADC research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP7lV63Ws8rbVg90H21EOLACvtfcHk0lhlZHCi5ob55Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D&md5=7358b6080dd1aed1d21e98c078cd9ef1</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.268%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DGoetsch%26aufirst%3DL.%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DCorva%25C3%25AFa%26aufirst%3DN.%26atitle%3DStrategies%2520and%2520Challenges%2520for%2520the%2520Next%2520Generation%2520of%2520Antibody-Drug%2520Conjugates%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D5%26spage%3D315%26epage%3D337%26doi%3D10.1038%2Fnrd.2016.268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peperidou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoukranidou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontogiorgis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadjipavlou-Litina, D.</span></span> <span> </span><span class="NLM_article-title">Multitarget Molecular Hybrids of Cinnamic Acids</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">20197</span>– <span class="NLM_lpage">20226</span>, <span class="refDoi"> DOI: 10.3390/molecules191220197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3390%2Fmolecules191220197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25474291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOksL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=20197-20226&issue=12&author=A.+Peperidouauthor=D.+Kapoukranidouauthor=C.+Kontogiorgisauthor=D.+Hadjipavlou-Litina&title=Multitarget+Molecular+Hybrids+of+Cinnamic+Acids&doi=10.3390%2Fmolecules191220197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target molecular hybrids of cinnamic acids</span></div><div class="casAuthors">Peperidou, Aikaterini; Kapoukranidou, Dorothea; Kontogiorgis, Christos; Hadjipavlou-Litina, Dimitra</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">20197-20226, 30 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The synthesis of 11 potential multi-target hybrids incorporating cinnamic acids and paracetamol/4-hydroxycoumarin/7-hydroxycoumarin/benzocaine/p-aminophenol/m-aminophenol, e.g., I (R = 4-AcNHC6H4, coumarin-4-yl, coumarin-7-yl, etc.), II (R = 4-AcNHC6H4, 4-methylcoumarin-7-yl) and III was reported.  Four hybrids I [R = 4-AcNHC6H4 (IV), 3-AcNHC6H4 (V)], II [R = 4-methylcoumarin-7-yl (VI)] and III were found to be multifunctional biol. agents.  Hybrid V showed the highest lipoxygenase (LOX) inhibition (IC50 = 0.34 μM) and analgesic activity (98.1%), whereas hybrid VI exhibited good LOX inhibitory activity (IC50 = 50 μM) and the highest anti-proteolytic activity (IC50 = 5 μM).  Hybrid IV showed high analgesic activity (91%) and appeared to be a promising agent for treating peripheral nerve injuries.  Hybrid III presented an interesting combination of anti-LOX and anti-proteolytic activity.  The 2D-structure-activity relationship studies showed that both steric and electronic parameters played major roles in the activity of these compds. while mol. docking studies pointed to the fact that allosteric interactions may govern the LOX-inhibitor binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvjS082qO0-rVg90H21EOLACvtfcHk0lhlZHCi5ob55Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOksL%252FP&md5=d4983b67b6842066139bc56e2ef8a490</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.3390%2Fmolecules191220197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules191220197%26sid%3Dliteratum%253Aachs%26aulast%3DPeperidou%26aufirst%3DA.%26aulast%3DKapoukranidou%26aufirst%3DD.%26aulast%3DKontogiorgis%26aufirst%3DC.%26aulast%3DHadjipavlou-Litina%26aufirst%3DD.%26atitle%3DMultitarget%2520Molecular%2520Hybrids%2520of%2520Cinnamic%2520Acids%26jtitle%3DMolecules%26date%3D2014%26volume%3D19%26issue%3D12%26spage%3D20197%26epage%3D20226%26doi%3D10.3390%2Fmolecules191220197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertolini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerzoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tacchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, S.</span></span> <span> </span><span class="NLM_article-title">Paracetamol: New Vistas of an Old Drug</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3–4</span>),  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2006.00250.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1111%2Fj.1527-3458.2006.00250.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17227290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=250-275&issue=3%E2%80%934&author=A.+Bertoliniauthor=A.+Ferrariauthor=A.+Ottaniauthor=S.+Guerzoniauthor=R.+Tacchiauthor=S.+Leone&title=Paracetamol%3A+New+Vistas+of+an+Old+Drug&doi=10.1111%2Fj.1527-3458.2006.00250.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Paracetamol: new vistas of an old drug</span></div><div class="casAuthors">Bertolini, Alfio; Ferrari, Anna; Ottani, Alessandra; Guerzoni, Simona; Tacchi, Raffaella; Leone, Sheila</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">250-275</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  Paracetamol (acetaminophen) is one of the most popular and widely used drugs for the treatment of pain and fever.  It occupies a unique position among analgesic drugs.  Unlike NSAIDs it is almost unanimously considered to have no antiinflammatory activity and does not produce gastrointestinal damage or untoward cardiorenal effects.  Unlike opiates it is almost ineffective in intense pain and has no depressant effect on respiration.  Although paracetamol has been used clin. for more than a century, its mode of action has been a mystery until about one year ago, when two independent groups (Zygmunt and colleagues and Bertolini and colleagues) produced exptl. data unequivocally demonstrating that the analgesic effect of paracetamol is due to the indirect activation of cannabinoid CB1 receptors.  In brain and spinal cord, paracetamol, following deacetylation to its primary amine (p-aminophenol), is conjugated with arachidonic acid to form N-arachidonoylphenolamine, a compd. already known (AM404) as an endogenous cannabinoid.  The involved enzyme is fatty acid amide hydrolase.  N-arachidonoylphenolamine is an agonist at TRPV1 receptors and an inhibitor of cellular anandamide uptake, which leads to increased levels of endogenous cannabinoids; moreover, it inhibits cyclooxygenases in the brain, albeit at concns. that are probably not attainable with analgesic doses of paracetamol.  CB1 receptor antagonist, at a dose level that completely prevents the analgesic activity of a selective CB1 receptor agonist, completely prevents the analgesic activity of paracetamol.  Thus, paracetamol acts as a pro-drug, the active one being a cannabinoid.  These findings finally explain the mechanism of action of paracetamol and the peculiarity of its effects, including the behavioral ones.  Curiously, just when the first CB1 agonists are being introduced for pain treatment, it comes out that an indirect cannabinomimetic had been extensively used (and sometimes overused) for more than a century.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoYiJbYPLTT7Vg90H21EOLACvtfcHk0lhlZHCi5ob55Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSmtbk%253D&md5=41135b8ce21cff099651a01af348b98b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2006.00250.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2006.00250.x%26sid%3Dliteratum%253Aachs%26aulast%3DBertolini%26aufirst%3DA.%26aulast%3DFerrari%26aufirst%3DA.%26aulast%3DOttani%26aufirst%3DA.%26aulast%3DGuerzoni%26aufirst%3DS.%26aulast%3DTacchi%26aufirst%3DR.%26aulast%3DLeone%26aufirst%3DS.%26atitle%3DParacetamol%253A%2520New%2520Vistas%2520of%2520an%2520Old%2520Drug%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2006%26volume%3D12%26issue%3D3%25E2%2580%25934%26spage%3D250%26epage%3D275%26doi%3D10.1111%2Fj.1527-3458.2006.00250.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alisch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elz, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Dual Histamine H<sub>1</sub> and H<sub>2</sub> Receptor Antagonist Activity of Cyanoguanidine Derivatives</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">14186</span>– <span class="NLM_lpage">14202</span>, <span class="refDoi"> DOI: 10.3390/molecules181114186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3390%2Fmolecules181114186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24248146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFamu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=14186-14202&issue=11&author=B.+Sadekauthor=R.+Alischauthor=A.+Buschauerauthor=S.+Elz&title=Synthesis+and+Dual+Histamine+H1+and+H2+Receptor+Antagonist+Activity+of+Cyanoguanidine+Derivatives&doi=10.3390%2Fmolecules181114186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and dual histamine H1 and H2 receptor antagonist activity of cyanoguanidine derivatives</span></div><div class="casAuthors">Sadek, Bassem; Alisch, Rudi; Buschauer, Armin; Elz, Sigurd</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">14186-14202, 17 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Aiming at pharmacol. hybrids combining H1R and H2R antagonistic activity a series of cyanoguanidines I (R1 = OCH3, F; n = 2, 3, 4, etc.) was synthesized by linking mepyramine-type H1R antagonist substructures with roxatidine- tiotidine- or ranitidine-type H2R antagonist moieties.  N-desmethylmepyramine was connected via a poly-methylene spacer to a cyanoguanidine group as the "urea equiv." of the H2R antagonist moiety.  The title compds. were screened for histamine antagonistic activity at the isolated ileum (H1R) and the isolated spontaneously beating right atrium (H2R) of the guinea pig.  The results indicate that depending on the nature of the H2R antagonist partial structure the highest H1R antagonist potency resided in roxatidine-type compds. with spacers of six methylene groups in length (compd. I (R1 = OCH3 n = 6)) and tiotidine-type compds. irresp. of the alkyl chain length (compds. I (R1 = F; n = 3), I (R1 = OCH3; n = 6), I (R1 = F; n = 6)) N-cyano-N'-[2-[[(2-guanidino-4-thiazolyl)methyl]thio]ethyl]-N&quot;-[2-[N-[2-[N-(4-methoxybenzyl)-N-(pyridyl)-amino] ethyl]-N-methylamino]ethyl] guanidine I (R1 = OCH3; n = 2) pKB values: 8.05 (H1R, ileum) and 7.73 (H2R, atrium) and the homolog with the mepyramine moiety connected by a six-membered chain to the tiotidine-like partial structure (compd. I (R1 = OCH3; n = 6)) pKB values: 8.61 (H1R) and 6.61 (H2R) were among the most potent hybrid compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCNbcDkpmgQbVg90H21EOLACvtfcHk0ljLPePtihCItw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFamu70%253D&md5=3844b36899c180423eb4281c6900c923</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3390%2Fmolecules181114186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules181114186%26sid%3Dliteratum%253Aachs%26aulast%3DSadek%26aufirst%3DB.%26aulast%3DAlisch%26aufirst%3DR.%26aulast%3DBuschauer%26aufirst%3DA.%26aulast%3DElz%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520Dual%2520Histamine%2520H1%2520and%2520H2%2520Receptor%2520Antagonist%2520Activity%2520of%2520Cyanoguanidine%2520Derivatives%26jtitle%3DMolecules%26date%3D2013%26volume%3D18%26issue%3D11%26spage%3D14186%26epage%3D14202%26doi%3D10.3390%2Fmolecules181114186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sterling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzig, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkelstein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miskolczi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molnar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rantal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagyva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zekany, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krais, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, M.</span></span> <span> </span><span class="NLM_article-title">Novel Dual Inhibitors of Ache and Mao Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer’s Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">5260</span>– <span class="NLM_lpage">5279</span>, <span class="refDoi"> DOI: 10.1021/jm020120c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020120c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVymsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=5260-5279&issue=24&author=J.+Sterlingauthor=Y.+Herzigauthor=T.+Gorenauthor=N.+Finkelsteinauthor=D.+Lernerauthor=W.+Goldenbergauthor=I.+Miskolcziauthor=S.+Molnarauthor=F.+Rantalauthor=T.+Tamasauthor=G.+Tothauthor=A.+Zagyvaauthor=A.+Zekanyauthor=G.+Lavianauthor=A.+Grossauthor=R.+Friedmanauthor=M.+Razinauthor=W.+Huangauthor=B.+Kraisauthor=M.+Chorevauthor=M.+B.+Youdimauthor=M.+Weinstock&title=Novel+Dual+Inhibitors+of+Ache+and+Mao+Derived+from+Hydroxy+Aminoindan+and+Phenethylamine+as+Potential+Treatment+for+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fjm020120c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer's Disease</span></div><div class="casAuthors">Sterling, Jeffrey; Herzig, Yaacov; Goren, Tamar; Finkelstein, Nina; Lerner, David; Goldenberg, Willy; Miskolczi, Istvan; Molnar, Sandor; Rantal, Ferenc; Tamas, Tivadar; Toth, Gyorgy; Zagyva, Adela; Zekany, Andras; Lavian, Gila; Gross, Aviva; Friedman, Rachel; Razin, Michal; Huang, Wei; Krais, Boris; Chorev, Michael; Youdim, Moussa B.; Weinstock, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5260-5279</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Carbamate derivs. of N-propargylaminoindanes (Series I) and N-propargylphenethylamines (Series II) were synthesized via multistep procedures from the corresponding hydroxy precursors.  The resp. rasagiline- and selegiline-related series were designed to combine inhibitory activities of both acetylcholine esterase (AChE) and monoamine oxidase (MAO) by virtue of their carbamoyl and propargylamine pharmacophores.  Each compd. was tested for these activities in vitro in order to find mols. with similar potencies against each enzyme.  Compds. with such dual AChE and MAO inhibitory activities are expected to have potential for the treatment of Alzheimer's disease.  The obsd. SAR also offers insight into the requirements of the active sites on these enzymes.  A carbamate moiety was found to be essential for AChE inhibition, which was absent in the corresponding hydroxy precursors.  The propargyl group caused 2-70-fold decrease in AChE inhibitory activity (depending on the position of the carbamoyl group) of Series I, but had little or no effect in Series II.  Thus, the 6- and 7-carbamyloxyphenyls in Series I were either equipotent to, or slightly (2- to 5-fold) less active as AChE inhibitors than, the corresponding compds. in Series II, while the 4-carbamyloxyphenyls were more potent.  The presence of the carbamate moiety in 6- and 7-carbamyloxyphenyls of Series I, considerably decreased MAO-A and -B inhibitory activity, compared to that of the parent hydroxy analogs, while the opposite was true for Series II.  Thus, the 6- and 7-carbamyloxyphenyls in Series I were 2-3 orders of magnitude weaker MAO inhibitors while the 4- carbamyloxyphenyls were equipotent with the corresponding compds. in Series II.  In both series, N-methylation of the propargylamine enhanced the MAO (A and B equally) inhibitory activities and decreased the AChE inhibitory activity.  Two candidates belonging to the indan and tetralin ring systems (HCl salts of I and II) and one phenethylamine (mesylate salt of III) were identified as possible leads for further development based on the following criteria: (a) comparable AChE and MAO-B inhibitory activities, (b) good to moderate AChE inhibitory activity, and (c) lack of strong MAO-A selectivity.  However, it is likely that these compds. will be metabolized to the corresponding phenols, with inhibitory activities against AChE and/or MAO-A or -B, different from those of the parent carbamates.  Thus, the apparent enzyme inhibition will be a result of the combined inhibition of all of these individual metabolites.  The results of our ongoing in vivo screening programs will be published elsewhere.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0RScteajUEbVg90H21EOLACvtfcHk0ljLPePtihCItw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVymsLg%253D&md5=62136a48889ce0fe28a76aa70e577eb9</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm020120c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020120c%26sid%3Dliteratum%253Aachs%26aulast%3DSterling%26aufirst%3DJ.%26aulast%3DHerzig%26aufirst%3DY.%26aulast%3DGoren%26aufirst%3DT.%26aulast%3DFinkelstein%26aufirst%3DN.%26aulast%3DLerner%26aufirst%3DD.%26aulast%3DGoldenberg%26aufirst%3DW.%26aulast%3DMiskolczi%26aufirst%3DI.%26aulast%3DMolnar%26aufirst%3DS.%26aulast%3DRantal%26aufirst%3DF.%26aulast%3DTamas%26aufirst%3DT.%26aulast%3DToth%26aufirst%3DG.%26aulast%3DZagyva%26aufirst%3DA.%26aulast%3DZekany%26aufirst%3DA.%26aulast%3DLavian%26aufirst%3DG.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DR.%26aulast%3DRazin%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DKrais%26aufirst%3DB.%26aulast%3DChorev%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DWeinstock%26aufirst%3DM.%26atitle%3DNovel%2520Dual%2520Inhibitors%2520of%2520Ache%2520and%2520Mao%2520Derived%2520from%2520Hydroxy%2520Aminoindan%2520and%2520Phenethylamine%2520as%2520Potential%2520Treatment%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26issue%3D24%26spage%3D5260%26epage%3D5279%26doi%3D10.1021%2Fjm020120c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chojnacki, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toldo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Franco, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halquist, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-(4-Hydroxy-Phenyl)-3-oxo-Pentanoic Acid [2-(5-Methoxy-1H-indol-3-yl)-ethyl]-amide as a Potential Neuroprotectant for Alzheimer’s Disease by Hybridization of Curcumin and Melatonin</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1021/cn500081s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn500081s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=690-699&issue=8&author=J.+E.+Chojnackiauthor=K.+Liuauthor=X.+Yanauthor=S.+Toldoauthor=T.+Seldenauthor=M.+Estradaauthor=M.+I.+Rodr%C3%ADguez-Francoauthor=M.+S.+Halquistauthor=D.+Yeauthor=S.+Zhang&title=Discovery+of+5-%284-Hydroxy-Phenyl%29-3-oxo-Pentanoic+Acid+%5B2-%285-Methoxy-1H-indol-3-yl%29-ethyl%5D-amide+as+a+Potential+Neuroprotectant+for+Alzheimer%E2%80%99s+Disease+by+Hybridization+of+Curcumin+and+Melatonin&doi=10.1021%2Fcn500081s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-(4-Hydroxyphenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1H-indol-3-yl)-ethyl]-amide as a Neuroprotectant for Alzheimer's Disease by Hybridization of Curcumin and Melatonin</span></div><div class="casAuthors">Chojnacki, Jeremy E.; Liu, Kai; Yan, Xing; Toldo, Stefano; Selden, Tyler; Estrada, Martin; Rodriguez-Franco, Maria Isabel; Halquist, Matthew S.; Ye, Dexian; Zhang, Shijun</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">690-699</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our effort to develop effective neuroprotectants as potential treatments for Alzheimer's disease (AD), hybrid compds. of curcumin and melatonin, two natural products that have been extensively studied in various AD models, were designed, synthesized, and biol. characterized.  A lead hybrid compd. (7) was discovered to show significant neuroprotection with nanomolar potency (EC50 = 27.60 ± 9.4 nM) in MC65 cells, a cellular AD model.  Multiple in vitro assay results established that 7 exhibited moderate inhibitory effects on the prodn. of amyloid-β oligomers (AβOs) in MC65 cells, but not on the aggregation of Aβ species.  It also exhibited significant antioxidative properties.  Further mechanistic studies demonstrated that 7's antioxidant effects correlate well with its neuroprotective potency for MC65 cells, and these effects might be due to its interference with the interactions of AβOs within the mitochondria of MC65 cells.  Furthermore, 7 was confirmed to cross the blood-brain barrier (BBB) and deliver a sufficient amt. to brain tissue after oral administration.  Collectively, these results strongly support the hybridization approach as an efficient strategy to help identify novel scaffolds with a desired pharmacol., and strongly encourage further optimization of 7 to develop more potent neuroprotectants for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJVho5ZWpCabVg90H21EOLACvtfcHk0lj7aoz1_oHNdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSntb0%253D&md5=0d01ae996fd26e64c03457fc74a271b3</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fcn500081s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn500081s%26sid%3Dliteratum%253Aachs%26aulast%3DChojnacki%26aufirst%3DJ.%2BE.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DToldo%26aufirst%3DS.%26aulast%3DSelden%26aufirst%3DT.%26aulast%3DEstrada%26aufirst%3DM.%26aulast%3DRodr%25C3%25ADguez-Franco%26aufirst%3DM.%2BI.%26aulast%3DHalquist%26aufirst%3DM.%2BS.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%25205-%25284-Hydroxy-Phenyl%2529-3-oxo-Pentanoic%2520Acid%2520%255B2-%25285-Methoxy-1H-indol-3-yl%2529-ethyl%255D-amide%2520as%2520a%2520Potential%2520Neuroprotectant%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%2520by%2520Hybridization%2520of%2520Curcumin%2520and%2520Melatonin%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26issue%3D8%26spage%3D690%26epage%3D699%26doi%3D10.1021%2Fcn500081s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Novel 1-Phenyl-3-Hydroxy-4-Pyridinone Derivatives as Multifunctional Agents for the Therapy of Alzheimer’s Disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00224</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00224" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OhurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=69-81&issue=1&author=R.+Shengauthor=L.+Tangauthor=L.+Jiangauthor=L.+Hongauthor=Y.+Shiauthor=N.+Zhouauthor=Y.+Hu&title=Novel+1-Phenyl-3-Hydroxy-4-Pyridinone+Derivatives+as+Multifunctional+Agents+for+the+Therapy+of+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Facschemneuro.5b00224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 1-Phenyl-3-hydroxy-4-pyridinone Derivatives as Multifunctional Agents for the Therapy of Alzheimer's Disease</span></div><div class="casAuthors">Sheng, Rong; Tang, Li; Jiang, Liu; Hong, Lingjuan; Shi, Ying; Zhou, Naiming; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-81</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 1-phenyl-3-hydroxy-4-pyridinone derivs. were designed and synthesized as multifunctional agents for Alzheimer's disease (AD) therapy through incorporation of 3-hydroxy-4-pyridinone moiety from deferiprone into the scaffold of H3 receptor antagonists.  Most of these new compds. displayed designed quadruple functions, H3 receptor antagonism, Aβ aggregation inhibition, metal ion chelation, and radical scavenging.  Esp., the most promising compd. I displayed nanomolar IC50 values in H3 receptor antagonism with high selectivity, efficient capability to interrupt the formation of Aβ1-42 fibrils, good copper and iron chelating properties, and more potent 2,2'-azino-bis(3-ethyl-benzothiazoline-6-sulfonic acid) radical cation (ABTS•+) scavenging activity than Trolox.  Further biol. evaluation revealed that it did not show obvious cytotoxicity and hERG potassium channel inhibition at micromolar concn.  In addn., compd. I demonstrated suitable pharmacokinetic properties and acceptable blood-brain barrier permeability in vivo.  All these results indicate that compd. I is a potential multifunctional candidate for AD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOIWDXJyxn1bVg90H21EOLACvtfcHk0lj7aoz1_oHNdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OhurnJ&md5=66c8440d6a02d18c7cbbd948f5b97540</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00224%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DHong%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DNovel%25201-Phenyl-3-Hydroxy-4-Pyridinone%2520Derivatives%2520as%2520Multifunctional%2520Agents%2520for%2520the%2520Therapy%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26issue%3D1%26spage%3D69%26epage%3D81%26doi%3D10.1021%2Facschemneuro.5b00224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridkin, M.</span></span> <span> </span><span class="NLM_article-title">Site-Activated Multifunctional Chelator with Acetylcholinesterase and Neuroprotective-Neurorestorative Moieties for Alzheimer’s Therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4095</span>– <span class="NLM_lpage">4098</span>, <span class="refDoi"> DOI: 10.1021/jm900504c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900504c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1entLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4095-4098&issue=14&author=H.+Zhengauthor=M.+B.+H.+Youdimauthor=M.+Fridkin&title=Site-Activated+Multifunctional+Chelator+with+Acetylcholinesterase+and+Neuroprotective-Neurorestorative+Moieties+for+Alzheimer%E2%80%99s+Therapy&doi=10.1021%2Fjm900504c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Site-Activated Multifunctional Chelator with Acetylcholinesterase and Neuroprotective-Neurorestorative Moieties for Alzheimer's Therapy</span></div><div class="casAuthors">Zheng, Hailin; Youdim, Moussa B. H.; Fridkin, Mati</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4095-4098</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel strategy to develop site-activated multifunctional chelators for targeting multiple etiologies of Alzheimer's disease is reported.  The novel prochelator HLA20A with improved cytotoxicity shows little affinity for metal ions until it is activated by binding and inhibiting acetylcholinesterase (AChE), releasing an active chelator HLA20 that modulates amyloid precursor protein (APP) regulation and β-amyloid (Aβ) redn., suppresses oxidative stress, and passivates excess metal ions (Fe, Cu, and Zn) in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAebTKcHHU_LVg90H21EOLACvtfcHk0lj7aoz1_oHNdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1entLg%253D&md5=aa0826ea6d65e7cffb171e5aaf27a141</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm900504c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900504c%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DFridkin%26aufirst%3DM.%26atitle%3DSite-Activated%2520Multifunctional%2520Chelator%2520with%2520Acetylcholinesterase%2520and%2520Neuroprotective-Neurorestorative%2520Moieties%2520for%2520Alzheimer%25E2%2580%2599s%2520Therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D14%26spage%3D4095%26epage%3D4098%26doi%3D10.1021%2Fjm900504c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jenwitheesuk, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samudrala, R.</span></span> <span> </span><span class="NLM_article-title">Novel Paradigms for Drug Discovery: Computational Multitarget Screening</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2007.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.tips.2007.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18190973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslOjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=62-71&issue=2&author=E.+Jenwitheesukauthor=J.+A.+Horstauthor=K.+L.+Rivasauthor=W.+C.+Van+Voorhisauthor=R.+Samudrala&title=Novel+Paradigms+for+Drug+Discovery%3A+Computational+Multitarget+Screening&doi=10.1016%2Fj.tips.2007.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Novel paradigms for drug discovery: computational multitarget screening</span></div><div class="casAuthors">Jenwitheesuk, Ekachai; Horst, Jeremy A.; Rivas, Kasey L.; Van Voorhis, Wesley C.; Samudrala, Ram</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">62-71</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  An established paradigm in current drug development is (i) to identify a single protein target whose inhibition is likely to result in the successful treatment of a disease of interest; (ii) to assay exptl. large libraries of small-mol. compds. in vitro and in vivo to identify promising inhibitors in model systems; and (iii) to det. whether the findings are extensible to humans.  This complex process, which is largely based on trial and error, is risk-, time- and cost-intensive.  Computational (virtual) screening of drug-like compds. simultaneously against the at. structures of multiple protein targets, taking into account protein-inhibitor dynamics, might help to identify lead inhibitors more efficiently, particularly for complex drug-resistant diseases.  Here we discuss the potential benefits of this approach, using HIV-1 and Plasmodium falciparum infections as examples.  We propose a virtual drug discovery pipeline' that will not only identify lead inhibitors efficiently, but also help minimize side-effects and toxicity, thereby increasing the likelihood of successful therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcA1qFl-hV8bVg90H21EOLACvtfcHk0lj7aoz1_oHNdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslOjsLo%253D&md5=0dd3e34e8bf4a9799194d7add9ff7343</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DJenwitheesuk%26aufirst%3DE.%26aulast%3DHorst%26aufirst%3DJ.%2BA.%26aulast%3DRivas%26aufirst%3DK.%2BL.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DSamudrala%26aufirst%3DR.%26atitle%3DNovel%2520Paradigms%2520for%2520Drug%2520Discovery%253A%2520Computational%2520Multitarget%2520Screening%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26issue%3D2%26spage%3D62%26epage%3D71%26doi%3D10.1016%2Fj.tips.2007.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Virtual Screening of Selective Multitarget Kinase Inhibitors by Combinatorial Support Vector Machines</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.1021/mp100179t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp100179t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVKrtrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=1545-1560&issue=5&author=X.+H.+Maauthor=R.+Wangauthor=C.+Y.+Tanauthor=Y.+Y.+Jiangauthor=T.+Luauthor=H.+B.+Raoauthor=X.+Y.+Liauthor=M.+L.+Goauthor=B.+C.+Lowauthor=Y.+Z.+Chen&title=Virtual+Screening+of+Selective+Multitarget+Kinase+Inhibitors+by+Combinatorial+Support+Vector+Machines&doi=10.1021%2Fmp100179t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening of Selective Multitarget Kinase Inhibitors by Combinatorial Support Vector Machines</span></div><div class="casAuthors">Ma, X. H.; Wang, R.; Tan, C. Y.; Jiang, Y. Y.; Lu, T.; Rao, H. B.; Li, X. Y.; Go, M. L.; Low, B. C.; Chen, Y. Z.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1545-1560</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitarget agents have been increasingly explored for enhancing efficacy and reducing counter-target activities and toxicities.  Efficient virtual screening (VS) tools for searching selective multitarget agents are desired.  Combinatorial support vector machines (C-SVM) were tested as VS tools for searching dual-inhibitors of 11 combinations of 9 anticancer kinase targets (EGFR, VEGFR, PDGFR, Src, FGFR, Lck, CDK1, CDK2, GSK3).  C-SVM trained on 233-1,316 non-dual-inhibitors correctly identified 26.8%-57.3% (majority >36%) of the 56-230 intra-kinase-group dual-inhibitors (equiv. to the 50-70% yields of two independent individual target VS tools), and 12.2% of the 41 inter-kinase-group dual-inhibitors.  C-SVM were fairly selective in misidentifying as dual-inhibitors 3.7%-48.1% (majority <20%) of the 233-1,316 non-dual-inhibitors of the same kinase pairs and 0.98%-4.77% of the 3,971-5,180 inhibitors of other kinases.  C-SVM produced low false-hit rates in misidentifying as dual-inhibitors 1,746-4,817 (0.013%-0.036%) of the 13.56 M PubChem compds., 12-175 (0.007%-0.104%) of the 168 K MDDR compds., and 0-84 (0.0%-2.9%) of the 19,495-38,483 MDDR compds. similar to the known dual-inhibitors.  C-SVM was compared to other VS methods Surflex-Dock, DOCK Blaster, kNN and PNN against the same sets of kinase inhibitors and the full set or subset of the 1.02 M Zinc clean-leads data set.  C-SVM produced comparable dual-inhibitor yields, slightly better false-hit rates for kinase inhibitors, and significantly lower false-hit rates for the Zinc clean-leads data set.  Combinatorial SVM showed promising potential for searching selective multitarget agents against intra-kinase-group kinases without explicit knowledge of multitarget agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKJ6MMCBxMtrVg90H21EOLACvtfcHk0lh0tj_QpIB1Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVKrtrjE&md5=83803384463f5a03a9f3d7a0e2c9b594</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fmp100179t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp100179t%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%2BH.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DC.%2BY.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DRao%26aufirst%3DH.%2BB.%26aulast%3DLi%26aufirst%3DX.%2BY.%26aulast%3DGo%26aufirst%3DM.%2BL.%26aulast%3DLow%26aufirst%3DB.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26atitle%3DVirtual%2520Screening%2520of%2520Selective%2520Multitarget%2520Kinase%2520Inhibitors%2520by%2520Combinatorial%2520Support%2520Vector%2520Machines%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2010%26volume%3D7%26issue%3D5%26spage%3D1545%26epage%3D1560%26doi%3D10.1021%2Fmp100179t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favia, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">The Role of Fragment-Based and Computational Methods in Polypharmacology</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2011.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21864710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns12gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=23-34&issue=1&author=G.+Bottegoniauthor=A.+D.+Faviaauthor=M.+Recanatiniauthor=A.+Cavalli&title=The+Role+of+Fragment-Based+and+Computational+Methods+in+Polypharmacology&doi=10.1016%2Fj.drudis.2011.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The role of fragment-based and computational methods in polypharmacology</span></div><div class="casAuthors">Bottegoni, Giovanni; Favia, Angelo D.; Recanatini, Maurizio; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">23-34</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol.-based strategies are gaining increased attention as a novel approach to obtaining potentially innovative medicines for multifactorial diseases.  However, some within the pharmaceutical community have resisted these strategies because they can be resource-hungry in the early stages of the drug discovery process.  Here, we report on fragment-based and computational methods that might accelerate and optimize the discovery of multitarget drugs.  In particular, we illustrate that fragment-based approaches can be particularly suited for polypharmacol., owing to the inherent promiscuous nature of fragments.  In parallel, we explain how computer-assisted protocols can provide invaluable insights into how to unveil compds. theor. able to bind to more than one protein.  Furthermore, several pragmatic aspects related to the use of these approaches are covered, thus offering the reader practical insights on multitarget-oriented drug discovery projects.  We report on fragment-based and computational approaches as possible ways to accelerate and optimize the discovery of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqX_beZ_hY17Vg90H21EOLACvtfcHk0lh0tj_QpIB1Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns12gtw%253D%253D&md5=c774326a467a2b8fef62c6e1224c2a78</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DThe%2520Role%2520of%2520Fragment-Based%2520and%2520Computational%2520Methods%2520in%2520Polypharmacology%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D1%26spage%3D23%26epage%3D34%26doi%3D10.1016%2Fj.drudis.2011.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahon, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V.</span></span> <span> </span><span class="NLM_article-title">Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1423</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fcmdc.201100145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21608133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptFKrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1423-1438&issue=8&author=P.+M.+Woodauthor=L.+W.+Wooauthor=M.+P.+Thomasauthor=M.+F.+Mahonauthor=A.+Purohitauthor=B.+V.+Potter&title=Aromatase+and+Dual+Aromatase-Steroid+Sulfatase+Inhibitors+from+the+Letrozole+and+Vorozole+Templates&doi=10.1002%2Fcmdc.201100145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates</span></div><div class="casAuthors">Wood, Paul M.; Woo, L. W. Lawrence; Thomas, Mark P.; Mahon, Mary F.; Purohit, Atul; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1423-1438</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Concurrent inhibition of aromatase and steroid sulfatase (STS) may provide a more effective treatment for hormone-dependent breast cancer than monotherapy against individual enzymes, and several dual aromatase-sulfatase inhibitors (DASIs) have been reported.  Three aromatase inhibitors with sub-nanomolar potency, better than the benchmark agent letrozole, were designed.  To further explore the DASI concept, a new series of letrozole-derived sulfamates and a vorozole-based sulfamate were designed and biol. evaluated in JEG-3 cells to reveal structure-activity relationships.  Amongst achiral and racemic compds., 2-bromo-4-(2-(4-cyanophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)phenyl sulfamate is the most potent DASI (aromatase: IC50=0.87 nM; STS: IC50=593 nM).  The enantiomers of the phenolic precursor to this compd. were sepd. by chiral HPLC and their abs. configuration detd. by X-ray crystallog.  Following conversion to their corresponding sulfamates, the S-(+)-enantiomer was found to inhibit aromatase and sulfatase most potently (aromatase: IC50=0.52 nM; STS: IC50=280 nM).  The docking of each enantiomer and other ligands into the aromatase and sulfatase active sites was also investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq91XsDqvKlHrVg90H21EOLACvtfcHk0lh0tj_QpIB1Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptFKrtrw%253D&md5=94dae7013fdf874ffe1540b8d31122c5</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100145%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DP.%2BM.%26aulast%3DWoo%26aufirst%3DL.%2BW.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DB.%2BV.%26atitle%3DAromatase%2520and%2520Dual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%2520from%2520the%2520Letrozole%2520and%2520Vorozole%2520Templates%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26issue%3D8%26spage%3D1423%26epage%3D1438%26doi%3D10.1002%2Fcmdc.201100145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1021/ml100273k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100273k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ags7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=243-247&issue=3&author=L.+W.+L.+Wooauthor=C.+Bubertauthor=A.+Purohitauthor=B.+V.+L.+Potter&title=Hybrid+Dual+Aromatase-Steroid+Sulfatase+Inhibitors+with+Exquisite+Picomolar+Inhibitory+Activity&doi=10.1021%2Fml100273k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity</span></div><div class="casAuthors">Woo, L. W. Lawrence; Bubert, Christian; Purohit, Atul; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-247</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Single agents against multiple drug targets are highly topical.  Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS), and several dual aromatase-sulfatase inhibitors (DASIs) have been recently reported.  The best compds. from two leading classes of DASI, 3 and 9, are low nanomolar inhibitors.  In search of a novel class of DASI, core motifs of two leading classes were combined to give a series of hybrid structures, with several compds. showing markedly improved dual inhibitory activities in the picomolar range in JEG-3 cells.  Thus, DASIs 14 (I, IC50: aromatase, 15 pM; STS, 830 pM) and 15 (IC50: aromatase, 18 pM; STS, 130 pM) are the first examples of an exceptional new class of highly potent dual inhibitor that should encourage further development toward multitargeted therapeutic intervention in HDBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_WoO0V3JbF7Vg90H21EOLACvtfcHk0liYbPayC_0ANg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ags7zK&md5=2805cabcf0c8210afec7bf65825b24c7</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fml100273k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100273k%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DHybrid%2520Dual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%2520with%2520Exquisite%2520Picomolar%2520Inhibitory%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26issue%3D3%26spage%3D243%26epage%3D247%26doi%3D10.1021%2Fml100273k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-Triazol-4-YL)amino]methyl}phenyl sulfamate</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fcmdc.201300015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23495205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVentLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=779-799&issue=5&author=L.+W.+L.+Wooauthor=P.+M.+Woodauthor=C.+Bubertauthor=M.+P.+Thomasauthor=A.+Purohitauthor=B.+V.+L.+Potter&title=Synthesis+and+Structure-Activity+Relationship+Studies+of+Derivatives+of+the+Dual+Aromatase-Sulfatase+Inhibitor+4-%7B%5B%284-Cyanophenyl%29%284H-1%2C2%2C4-Triazol-4-YL%29amino%5Dmethyl%7Dphenyl+sulfamate&doi=10.1002%2Fcmdc.201300015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship studies of derivatives of the dual aromatase-sulfatase inhibitor 4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate</span></div><div class="casAuthors">Woo, L. W. Lawrence; Wood, Paul M.; Bubert, Christian; Thomas, Mark P.; Purohit, Atul; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">779-799</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivs. are first-generation dual aromatase and sulfatase inhibitors (DASIs).  Structure-activity relationship studies were performed on these compds., and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group.  The most potent in vitro DASI discovered is an imidazole deriv. with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell prepn. of 0.2 and 2.5 nM, resp.  The parent phenol of this compd. inhibits aromatase with an IC50 value of 0.028 nM in the same assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDg_Fo94VkELVg90H21EOLACvtfcHk0liYbPayC_0ANg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVentLo%253D&md5=2d34b5f5c7e29c46c959dabd15c441e5</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300015%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DWood%26aufirst%3DP.%2BM.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationship%2520Studies%2520of%2520Derivatives%2520of%2520the%2520Dual%2520Aromatase-Sulfatase%2520Inhibitor%25204-%257B%255B%25284-Cyanophenyl%2529%25284H-1%252C2%252C4-Triazol-4-YL%2529amino%255Dmethyl%257Dphenyl%2520sulfamate%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26issue%3D5%26spage%3D779%26epage%3D799%26doi%3D10.1002%2Fcmdc.201300015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahon, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Dual Aromatase-Steroid Sulfatase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3540</span>– <span class="NLM_lpage">3560</span>, <span class="refDoi"> DOI: 10.1021/jm061462b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061462b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1CjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3540-3560&issue=15&author=L.+W.+L.+Wooauthor=C.+Bubertauthor=O.+B.+Sutcliffeauthor=A.+Smithauthor=S.+K.+Chanderauthor=M.+F.+Mahonauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+L.+Potter&title=Dual+Aromatase-Steroid+Sulfatase+Inhibitors&doi=10.1021%2Fjm061462b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Aromatase-Steroid Sulfatase Inhibitors</span></div><div class="casAuthors">Woo, L. W. Lawrence; Bubert, Christian; Sutcliffe, Oliver B.; Smith, Andrew; Chander, Surinder K.; Mahon, Mary F.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3540-3560</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By introducing the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated.  Two best DASIs (I and II) in vitro (JEG-3 cells) had IC50(aromatase) = 0.82 nM; IC50(sulfatase) = 39 nM, and IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM, resp.  X-ray crystallog. of I, and docking studies of selected compds. into an aromatase homol. model and the steroid sulfatase crystal structure are presented.  Both I and II inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose.  Almost complete dual inhibition is obsd. for I but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h.  DASI I did not inhibit aldosterone synthesis.  The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPvCTamzS0qbVg90H21EOLACvtfcHk0liYbPayC_0ANg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1CjtLs%253D&md5=69641aaecd430daad1c2f8074be4b436</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm061462b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061462b%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DSutcliffe%26aufirst%3DO.%2BB.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DDual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D15%26spage%3D3540%26epage%3D3560%26doi%3D10.1021%2Fjm061462b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V.</span></span> <span> </span><span class="NLM_article-title">Highly Potent First Examples of Dual Aromatase-Steroid Sulfatase Inhibitors Based on a Biphenyl Template</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2155</span>– <span class="NLM_lpage">2170</span>, <span class="refDoi"> DOI: 10.1021/jm901705h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901705h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFKit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2155-2170&issue=5&author=L.+W.+L.+Wooauthor=T.+Jacksonauthor=A.+Puteyauthor=G.+Cozierauthor=P.+Leonardauthor=K.+R.+Acharyaauthor=S.+K.+Chanderauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+Potter&title=Highly+Potent+First+Examples+of+Dual+Aromatase-Steroid+Sulfatase+Inhibitors+Based+on+a+Biphenyl+Template&doi=10.1021%2Fjm901705h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Potent First Examples of Dual Aromatase-Steroid Sulfatase Inhibitors based on a Biphenyl Template</span></div><div class="casAuthors">Woo, L. W. Lawrence; Jackson, Toby; Putey, Aurelien; Cozier, Gyles; Leonard, Philip; Acharya, K. Ravi; Chander, Surinder K.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2155-2170</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hormone-dependent breast cancer may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS).  Therefore, an aromatase inhibitory pharmacophore was introduced into a known biphenyl STS inhibitor to give a series of novel dual aromatase-sulfatase inhibitors (DASIs).  Several compds. were good aromatase or STS inhibitors and DASI I (R = H) (IC50: aromatase, 2.0 nM; STS, 35 nM) and its chlorinated congener I (R = Cl) (IC50: aromatase, 0.5 nM; STS, 5.5 nM) were examples that showed exceptional dual potency in JEG-3 cells.  At 1 mg/kg po, I (R = H, Cl) strongly reduced plasma estradiol levels and inhibited liver STS activity potently in vivo.  DASI I (R = Cl) was non-estrogenic and potently inhibited carbonic anhydrase II (hCAII) (IC50 86 nM).  A complex of I (R = Cl) and hCAII was crystd. and its structure solved by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMz59lyRAt-rVg90H21EOLACvtfcHk0lisGmL5RaQHUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFKit70%253D&md5=3cdf0a54b96c189fd18cae4361f3338e</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm901705h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901705h%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DJackson%26aufirst%3DT.%26aulast%3DPutey%26aufirst%3DA.%26aulast%3DCozier%26aufirst%3DG.%26aulast%3DLeonard%26aufirst%3DP.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%26atitle%3DHighly%2520Potent%2520First%2520Examples%2520of%2520Dual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%2520Based%2520on%2520a%2520Biphenyl%2520Template%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D5%26spage%3D2155%26epage%3D2170%26doi%3D10.1021%2Fjm901705h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">First Dual Aromatase-Steroid Sulfatase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3193</span>– <span class="NLM_lpage">3196</span>, <span class="refDoi"> DOI: 10.1021/jm034033b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034033b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksFWjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3193-3196&issue=15&author=L.+W.+L.+Wooauthor=O.+B.+Sutcliffeauthor=C.+Bubertauthor=A.+Grassoauthor=S.+K.+Chanderauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+L.+Potter&title=First+Dual+Aromatase-Steroid+Sulfatase+Inhibitors&doi=10.1021%2Fjm034033b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">First Dual Aromatase-Steroid Sulfatase Inhibitors</span></div><div class="casAuthors">Woo, L. W. Lawrence; Sutcliffe, Oliver B.; Bubert, Christian; Grasso, Anna; Chander, Surinder K.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3193-3196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aromatase inhibitors in clin. use block the biosynthesis of estrogens.  Hydrolysis of estrone 3-sulfate by steroid sulfatase is an important addnl. source of tumor estrogen, and blockade of both enzymes should provide a more effective endocrine therapy.  Sulfamoylated derivs. of the aromatase inhibitor YM511 inhibited sulfatase and aromatase in JEG-3 cells with resp. IC50 values of 20-227 and 0.82-100 nM (cf. letrozole, 0.89 nM).  One dual inhibitor was potent against both enzymes in vivo, validating the concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOq7z9wm030LVg90H21EOLACvtfcHk0lisGmL5RaQHUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksFWjsrk%253D&md5=b487f4b92cab559a36f69b7aaebeb9d1</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fjm034033b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034033b%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DSutcliffe%26aufirst%3DO.%2BB.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DGrasso%26aufirst%3DA.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DFirst%2520Dual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D15%26spage%3D3193%26epage%3D3196%26doi%3D10.1021%2Fjm034033b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, J.
R.</span></span> <span> </span><span class="NLM_article-title">Chapter 10:The Challenges of Multi-Target Lead Optimization</span>. <i>Designing Multi-Target Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1039/9781849734912-00141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1039%2F9781849734912-00141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=141-154&author=J.%0AR.+Morphy&title=Chapter+10%3AThe+Challenges+of+Multi-Target+Lead+Optimization&doi=10.1039%2F9781849734912-00141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1039%2F9781849734912-00141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252F9781849734912-00141%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26atitle%3DChapter%252010%253AThe%2520Challenges%2520of%2520Multi-Target%2520Lead%2520Optimization%26jtitle%3DDesigning%2520Multi-Target%2520Drugs%26date%3D2012%26spage%3D141%26epage%3D154%26doi%3D10.1039%2F9781849734912-00141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reichard, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grice, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majmundar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthes, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Oxime Dual NK<sub>1</sub>/NK<sub>2</sub> Antagonists with Reduced NK Affinity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2355</span>– <span class="NLM_lpage">2358</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)00462-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0960-894X%2802%2900462-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=12161132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvVGju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=2355-2358&issue=17&author=G.+A.+Reichardauthor=C.+A.+Griceauthor=N.+Y.+Shihauthor=J.+Spitlerauthor=S.+Majmundarauthor=S.+D.+Wangauthor=S.+Paliwalauthor=J.+C.+Anthesauthor=J.+J.+Piwinski&title=Preparation+of+Oxime+Dual+NK1%2FNK2+Antagonists+with+Reduced+NK+Affinity&doi=10.1016%2FS0960-894X%2802%2900462-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of oxime dual NK1/NK2 antagonists with reduced NK3 affinity</span></div><div class="casAuthors">Reichard, Gregory A.; Grice, Cheryl A.; Shih, Neng-Yang; Spitler, James; Majmundar, Sapna; Wang, Steven D.; Paliwal, Sunil; Anthes, John C.; Piwinski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2355-2358</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">By employing a stereosimplification approach, a thorough SAR exploration of the piperidine region of Sch 206272 was possible through a practical and efficient synthesis of substituted cyclic ureas.  This SAR study led to the identification of a benzimidazolinone series of compds. which display single digit nanomolar NK1/NK2 affinity and near micromolar binding for the NK3 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpoegeWv2YvbVg90H21EOLACvtfcHk0lisGmL5RaQHUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvVGju7g%253D&md5=3271156060eeb818bd5b7823196b5ec3</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900462-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900462-6%26sid%3Dliteratum%253Aachs%26aulast%3DReichard%26aufirst%3DG.%2BA.%26aulast%3DGrice%26aufirst%3DC.%2BA.%26aulast%3DShih%26aufirst%3DN.%2BY.%26aulast%3DSpitler%26aufirst%3DJ.%26aulast%3DMajmundar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%2BD.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DAnthes%26aufirst%3DJ.%2BC.%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26atitle%3DPreparation%2520of%2520Oxime%2520Dual%2520NK1%252FNK2%2520Antagonists%2520with%2520Reduced%2520NK%2520Affinity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26issue%3D17%26spage%3D2355%26epage%3D2358%26doi%3D10.1016%2FS0960-894X%2802%2900462-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entsuah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, R. L.</span></span> <span> </span><span class="NLM_article-title">Comparative Efficacy between Venlafaxine and SSRIs: A Pooled Analysis of Patients with Depression</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1166</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/S0006-3223(02)01425-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0006-3223%2802%2901425-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=12488062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsFSqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2002&pages=1166-1174&issue=12&author=S.+M.+Stahlauthor=R.+Entsuahauthor=R.+L.+Rudolph&title=Comparative+Efficacy+between+Venlafaxine+and+SSRIs%3A+A+Pooled+Analysis+of+Patients+with+Depression&doi=10.1016%2FS0006-3223%2802%2901425-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression</span></div><div class="casAuthors">Stahl, Stephen M.; Entsuah, Richard; Rudolph, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1166-1174</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Serotonergic and adrenergic enhancement may be synergistic and more effective than serotonergic enhancement alone in treating depression.  The dual serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine is a dual reuptake inhibitor that may therefore offer greater efficacy than selective serotonin reuptake inhibitors (SSRIs).  Data from eight randomized, double-blind, controlled studies were pooled to compare efficacy in depressed patients receiving venlafaxine/venlafaxine extended release (XR), SSRIs, or placebo for ≤8 wk.  The mean changes from baseline in the 21-item Hamilton Rating Scale for Depression (HAM-D21), Montgomery-Asberg Depression Rating Scale (MADRS), and Clin. Global Impressions-Global Improvement (CGI-I) and CGI-Severity of Illness (CGI-S) item scores were compared, as were response rates derived from these scales.  Statistically significant differences in mean HAM-D21 score decrease between venlafaxine (14.5) and SSRIs (12.6) and between the active treatments and placebo (11.3) were obsd.  Venlafaxine significantly decreased the mean MADRS scores more than SSRIs (17.8 vs. 15.9), and both treatments were significantly better than placebo (12.9).  The same pattern of significance for CGI-I, HAM-D21, and MADRS response rates between venlafaxine (71%, 64%, and 67%, resp.), SSRIs (64%, 57%, and 59%, resp.), and placebo (50%, 42%, and 41%, resp.) was obsd.  Thus, venlafaxine was significantly more effective than SSRIs in improving depression, perhaps due to enhancing both serotonin and norepinephrine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRCMEi9kcN7bVg90H21EOLACvtfcHk0ljEkbWXsI9TOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsFSqur4%253D&md5=0fb286dab5f16acb4e0074c547ae2e6c</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2802%2901425-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252802%252901425-7%26sid%3Dliteratum%253Aachs%26aulast%3DStahl%26aufirst%3DS.%2BM.%26aulast%3DEntsuah%26aufirst%3DR.%26aulast%3DRudolph%26aufirst%3DR.%2BL.%26atitle%3DComparative%2520Efficacy%2520between%2520Venlafaxine%2520and%2520SSRIs%253A%2520A%2520Pooled%2520Analysis%2520of%2520Patients%2520with%2520Depression%26jtitle%3DBiol.%2520Psychiatry%26date%3D2002%26volume%3D52%26issue%3D12%26spage%3D1166%26epage%3D1174%26doi%3D10.1016%2FS0006-3223%2802%2901425-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic-Nikolic, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uliassi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">A Perspective on Multi-Target Drug Discovery and Design for Complex Diseases</span>. <i>Clini. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1186/s40169-017-0181-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1186%2Fs40169-017-0181-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29318404" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=1-14&issue=3&author=R.+R.+Ramsayauthor=M.+R.+Popovic-Nikolicauthor=K.+Nikolicauthor=E.+Uliassiauthor=M.+L.+Bolognesi&title=A+Perspective+on+Multi-Target+Drug+Discovery+and+Design+for+Complex+Diseases&doi=10.1186%2Fs40169-017-0181-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1186%2Fs40169-017-0181-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40169-017-0181-2%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DPopovic-Nikolic%26aufirst%3DM.%2BR.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DUliassi%26aufirst%3DE.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DA%2520Perspective%2520on%2520Multi-Target%2520Drug%2520Discovery%2520and%2520Design%2520for%2520Complex%2520Diseases%26jtitle%3DClini.%2520Transl.%2520Med.%26date%3D2018%26volume%3D7%26issue%3D3%26spage%3D1%26epage%3D14%26doi%3D10.1186%2Fs40169-017-0181-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurkauf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieltyka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodbeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Primus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasley, J.</span></span> <span> </span><span class="NLM_article-title">Indoline and Piperazine Containing Derivatives as a Novel Class of Mixed D<sub>2</sub>/D<sub>4</sub> Receptor Antagonists. Part 2: Asymmetric Synthesis and Biological Evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">3111</span>– <span class="NLM_lpage">3115</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)00656-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0960-894X%2802%2900656-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=12372513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38Xns1Ogs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=3111-3115&issue=21&author=H.+Zhaoauthor=X.+A.+Heauthor=A.+Thurkaufauthor=D.+Hoffmanauthor=A.+Kieltykaauthor=R.+Brodbeckauthor=R.+Primusauthor=J.+Wasley&title=Indoline+and+Piperazine+Containing+Derivatives+as+a+Novel+Class+of+Mixed+D2%2FD4+Receptor+Antagonists.+Part+2%3A+Asymmetric+Synthesis+and+Biological+Evaluation&doi=10.1016%2FS0960-894X%2802%2900656-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 2: Asymmetric synthesis and biological evaluation</span></div><div class="casAuthors">Zhao, He; He, Xiaoshu; Thurkauf, Andrew; Hoffman, Diane; Kieltyka, Andrzej; Brodbeck, Robbin; Primus, Renee; Wasley, Jan W. F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3111-3115</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of chiral benzylpiperazinyl-1-(2,3-dihydroindol-1-yl)ethanone derivs. were prepd. and examd. for their affinity at dopamine D2 and D4 receptors.  Three compds. having D2/D4 affinity ratios approximating that found for the atypical neuroleptic clozapine were further evaluated in behavioral tests of antipsychotic efficacy and motor side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEiDLTvWdcp7Vg90H21EOLACvtfcHk0ljEkbWXsI9TOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xns1Ogs7s%253D&md5=7f84a80314abed56ceb2ff61b9dd8477</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900656-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900656-X%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DX.%2BA.%26aulast%3DThurkauf%26aufirst%3DA.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DKieltyka%26aufirst%3DA.%26aulast%3DBrodbeck%26aufirst%3DR.%26aulast%3DPrimus%26aufirst%3DR.%26aulast%3DWasley%26aufirst%3DJ.%26atitle%3DIndoline%2520and%2520Piperazine%2520Containing%2520Derivatives%2520as%2520a%2520Novel%2520Class%2520of%2520Mixed%2520D2%252FD4%2520Receptor%2520Antagonists.%2520Part%25202%253A%2520Asymmetric%2520Synthesis%2520and%2520Biological%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26issue%3D21%26spage%3D3111%26epage%3D3115%26doi%3D10.1016%2FS0960-894X%2802%2900656-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agalave, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maujan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pore, V. S.</span></span> <span> </span><span class="NLM_article-title">Click Chemistry: 1,2,3-Triazoles as Pharmacophores</span>. <i>Chem. - Asian J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2696</span>– <span class="NLM_lpage">2718</span>, <span class="refDoi"> DOI: 10.1002/asia.201100432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fasia.201100432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21954075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSjur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=2696-2718&issue=10&author=S.+G.+Agalaveauthor=S.+R.+Maujanauthor=V.+S.+Pore&title=Click+Chemistry%3A+1%2C2%2C3-Triazoles+as+Pharmacophores&doi=10.1002%2Fasia.201100432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Click Chemistry: 1,2,3-Triazoles as Pharmacophores</span></div><div class="casAuthors">Agalave, Sandip G.; Maujan, Suleman R.; Pore, Vandana S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - An Asian Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2696-2718</span>CODEN:
                <span class="NLM_cas:coden">CAAJBI</span>;
        ISSN:<span class="NLM_cas:issn">1861-4728</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The copper(I)-catalyzed 1,2,3-triazole-forming reaction between azides and terminal alkynes has become the gold std. of click chem.' due to its reliability, specificity, and biocompatibility.  Applications of click chem. are increasingly found in all aspects of drug discovery; they range from lead finding through combinatorial chem. and target-templated in vitro chem., to proteomics and DNA research by using bioconjugation reactions.  The triazole products are more than just passive linkers; they readily assoc. with biol. targets, through hydrogen-bonding and dipole interactions.  The present review will focus mainly on the recent literature for applications of this reaction in the field of medicinal chem., in particular on use of the 1,2,3-triazole moiety as pharmacophore.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUyLcfL241V7Vg90H21EOLACvtfcHk0ljEkbWXsI9TOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSjur7P&md5=73631df03b9b2e58c7870e7239bb2548</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fasia.201100432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fasia.201100432%26sid%3Dliteratum%253Aachs%26aulast%3DAgalave%26aufirst%3DS.%2BG.%26aulast%3DMaujan%26aufirst%3DS.%2BR.%26aulast%3DPore%26aufirst%3DV.%2BS.%26atitle%3DClick%2520Chemistry%253A%25201%252C2%252C3-Triazoles%2520as%2520Pharmacophores%26jtitle%3DChem.%2520-%2520Asian%2520J.%26date%3D2011%26volume%3D6%26issue%3D10%26spage%3D2696%26epage%3D2718%26doi%3D10.1002%2Fasia.201100432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span> <span> </span><span class="NLM_article-title">Click Chemistry: Diverse Chemical Function from a Few Good Reactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2004</span>– <span class="NLM_lpage">2021</span>, <span class="refDoi"> DOI: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksVOis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=2004-2021&issue=11&author=H.+C.+Kolbauthor=M.+G.+Finnauthor=K.+B.+Sharpless&title=Click+Chemistry%3A+Diverse+Chemical+Function+from+a+Few+Good+Reactions&doi=10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Click chemistry: diverse chemical function from a few good reactions</span></div><div class="casAuthors">Kolb, Hartmuth C.; Finn, M. G.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2004-2021</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">Review with > 88 refs.  Examn. of nature's favorite mols. reveals a striking preference for making carbon-heteroatom bonds over carbon-carbon bonds - surely no surprise given that carbon dioxide is nature's starting material and that most reactions are performed in water.  Nucleic acids, proteins, and polysaccharides are condensation polymers of small subunits stitched together by carbon-heteroatom bonds.  Even the 35 or so building blocks from which these crucial mols. are made each contain, at most, six contiguous C-C bonds, except for the three arom. amino acids.  Taking a cue from nature's approach, the development of a set of powerful, highly reliable, and selective reactions for the rapid synthesis of useful new compds. and combinatorial libraries through heteroatom links (C-X-C), an approach called "click chem." is addressed.  Click chem. is at once defined, enabled, and constrained by a handful of nearly perfect "spring-loaded" reactions.  The stringent criteria for a process to earn click chem. status are described along with examples of the mol. frameworks that are easily made using this spartan, but powerful, synthetic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptrjo9nxXNRrVg90H21EOLACvtfcHk0lhEHkdp8QnEYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksVOis78%253D&md5=61c28b416c42c87821bc8a5bc2fdec36</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3773%252820010601%252940%253A11%253C2004%253A%253AAID-ANIE2004%253E3.0.CO%253B2-5%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DClick%2520Chemistry%253A%2520Diverse%2520Chemical%2520Function%2520from%2520a%2520Few%2520Good%2520Reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2001%26volume%3D40%26issue%3D11%26spage%3D2004%26epage%3D2021%26doi%3D10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellamaggiore, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mccarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipford, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span> <span> </span><span class="NLM_article-title">A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01781</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01781" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=453-461&issue=2&author=R.+P.+Wurzauthor=K.+Dellamaggioreauthor=H.+Douauthor=N.+Javierauthor=M.+C.+Loauthor=J.+D.+Mccarterauthor=D.+Mohlauthor=C.+Sastriauthor=J.+R.+Lipfordauthor=V.+J.+Cee&title=A+%E2%80%9CClick+Chemistry+Platform%E2%80%9D+for+the+Rapid+Synthesis+of+Bispecific+Molecules+for+Inducing+Protein+Degradation&doi=10.1021%2Facs.jmedchem.6b01781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation</span></div><div class="casAuthors">Wurz, Ryan P.; Dellamaggiore, Ken; Dou, Hannah; Javier, Noelle; Lo, Mei-Chu; McCarter, John D.; Mohl, Dane; Sastri, Christine; Lipford, J. Russell; Cee, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">453-461</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Proteolysis targeting chimeras (PROTACs) are bispecific mols. contg. a target protein binder and an ubiquitin ligase binder connected by a linker.  By recruiting an ubiquitin ligase to a target protein, PROTACs promote ubiquitination and proteasomal degrdn. of the target protein.  The generation of effective PROTACs depends on the nature of the protein/ligase ligand pair, linkage site, linker length, and linker compn., all of which have been difficult to address in a systematic way.  Herein, the authors describe a "click chem." approach for the synthesis of PROTACs.  The authors demonstrate the utility of this approach with the bromodomain and extra terminal domain-4 (BRD4) ligand JQ-1 (3) and ligase binders targeting cereblon (CRBN) and Von Hippel-Lindau (VHL) proteins.  An AlphaScreen proximity assay was used to det. the ability of PROTACs to form the ternary ligase-PROTAC-target protein complex and a MSD assay to measure cellular degrdn. of the target protein promoted by PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpooapLJ2Zln7Vg90H21EOLACvtfcHk0lhEHkdp8QnEYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7w%253D&md5=090c569ae1f079ab6504348aabec8909</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01781%26sid%3Dliteratum%253Aachs%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DDellamaggiore%26aufirst%3DK.%26aulast%3DDou%26aufirst%3DH.%26aulast%3DJavier%26aufirst%3DN.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DMccarter%26aufirst%3DJ.%2BD.%26aulast%3DMohl%26aufirst%3DD.%26aulast%3DSastri%26aufirst%3DC.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26atitle%3DA%2520%25E2%2580%259CClick%2520Chemistry%2520Platform%25E2%2580%259D%2520for%2520the%2520Rapid%2520Synthesis%2520of%2520Bispecific%2520Molecules%2520for%2520Inducing%2520Protein%2520Degradation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D2%26spage%3D453%26epage%3D461%26doi%3D10.1021%2Facs.jmedchem.6b01781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laplante, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fader, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandrick, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandrick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hucke, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. J.</span></span> <span> </span><span class="NLM_article-title">Assessing Atropisomer Axial Chirality in Drug Discovery and Development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">7005</span>– <span class="NLM_lpage">7022</span>, <span class="refDoi"> DOI: 10.1021/jm200584g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200584g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7005-7022&issue=20&author=S.+R.+Laplanteauthor=L.+D.+Faderauthor=K.+R.+Fandrickauthor=D.+R.+Fandrickauthor=O.+Huckeauthor=R.+Kemperauthor=S.+P.+Millerauthor=P.+J.+Edwards&title=Assessing+Atropisomer+Axial+Chirality+in+Drug+Discovery+and+Development&doi=10.1021%2Fjm200584g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing Atropisomer Axial Chirality in Drug Discovery and Development</span></div><div class="casAuthors">LaPlante, Steven R.; Fader, Lee D.; Fandrick, Keith R.; Fandrick, Daniel R.; Hucke, Oliver; Kemper, Ray; Miller, Stephen P. F.; Edwards, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7005-7022</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ8uS-SDx68bVg90H21EOLACvtfcHk0liNzqIAcd3gfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFygu7zN&md5=6b44135b3871d2460fba4b3246b899e3</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjm200584g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200584g%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DS.%2BR.%26aulast%3DFader%26aufirst%3DL.%2BD.%26aulast%3DFandrick%26aufirst%3DK.%2BR.%26aulast%3DFandrick%26aufirst%3DD.%2BR.%26aulast%3DHucke%26aufirst%3DO.%26aulast%3DKemper%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DS.%2BP.%26aulast%3DEdwards%26aufirst%3DP.%2BJ.%26atitle%3DAssessing%2520Atropisomer%2520Axial%2520Chirality%2520in%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D20%26spage%3D7005%26epage%3D7022%26doi%3D10.1021%2Fjm200584g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elder, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokin, V. V.</span></span> <span> </span><span class="NLM_article-title">Rapid Discovery and Structure-Activity Profiling of Novel Inhibitors of Human Immunodeficiency Virus Type 1 Protease Enabled by the Copper(I)-Catalyzed Synthesis of 1,2,3-Triazoles and Their Further Functionalization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">7697</span>– <span class="NLM_lpage">7710</span>, <span class="refDoi"> DOI: 10.1021/jm060754+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060754%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GjsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7697-7710&issue=26&author=M.+Whitingauthor=J.+C.+Trippauthor=Y.+C.+Linauthor=W.+Lindstromauthor=A.+J.+Olsonauthor=J.+H.+Elderauthor=K.+B.+Sharplessauthor=V.+V.+Fokin&title=Rapid+Discovery+and+Structure-Activity+Profiling+of+Novel+Inhibitors+of+Human+Immunodeficiency+Virus+Type+1+Protease+Enabled+by+the+Copper%28I%29-Catalyzed+Synthesis+of+1%2C2%2C3-Triazoles+and+Their+Further+Functionalization&doi=10.1021%2Fjm060754%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Discovery and Structure-Activity Profiling of Novel Inhibitors of Human Immunodeficiency Virus Type 1 Protease Enabled by the Copper(I)-Catalyzed Synthesis of 1,2,3-Triazoles and Their Further Functionalization</span></div><div class="casAuthors">Whiting, Matthew; Tripp, Jonathan C.; Lin, Ying-Chuan; Lindstrom, William; Olson, Arthur J.; Elder, John H.; Sharpless, K. Barry; Fokin, Valery V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7697-7710</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Building from the results of a computational screen of a range of triazole-contg. compds. for binding efficiency to human immunodeficiency virus type 1 protease (HIV-1-Pr), a novel series of potent inhibitors has been developed.  The copper(I)-catalyzed azide-alkyne cycloaddn. (CuAAC), which provides ready access to 1,4-disubstituted-1,2,3-triazoles, was used to unite a focused library of azide-contg. fragments with a diverse array of functionalized alkyne-contg. building blocks.  In combination with direct screening of the crude reaction products, this method led to the rapid identification of a lead structure and readily enabled optimization of both azide and alkyne fragments.  Replacement of the triazole with a range of alternative linkers led to greatly reduced protease inhibition; however, further functionalization of the triazoles at the 5-position gave a series of compds. with increased activity, exhibiting Ki values as low as 8 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxP4sXbJdAZbVg90H21EOLACvtfcHk0liNzqIAcd3gfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GjsbjL&md5=252fb639055fb8e55a1e1a0eb0842853</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm060754%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060754%252B%26sid%3Dliteratum%253Aachs%26aulast%3DWhiting%26aufirst%3DM.%26aulast%3DTripp%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DY.%2BC.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26aulast%3DElder%26aufirst%3DJ.%2BH.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26aulast%3DFokin%26aufirst%3DV.%2BV.%26atitle%3DRapid%2520Discovery%2520and%2520Structure-Activity%2520Profiling%2520of%2520Novel%2520Inhibitors%2520of%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Protease%2520Enabled%2520by%2520the%2520Copper%2528I%2529-Catalyzed%2520Synthesis%2520of%25201%252C2%252C3-Triazoles%2520and%2520Their%2520Further%2520Functionalization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D26%26spage%3D7697%26epage%3D7710%26doi%3D10.1021%2Fjm060754%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somu, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, C. C.</span></span> <span> </span><span class="NLM_article-title">Rationally Designed Nucleoside Antibiotics That Inhibit Siderophore Biosynthesis of Mycobacterium Tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1021/jm051060o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051060o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht12rtbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=31-34&issue=1&author=R.+V.+Somuauthor=H.+Boshoffauthor=C.+Qiaoauthor=E.+M.+Bennettauthor=C.+E.+Barryauthor=C.+C.+Aldrich&title=Rationally+Designed+Nucleoside+Antibiotics+That+Inhibit+Siderophore+Biosynthesis+of+Mycobacterium+Tuberculosis&doi=10.1021%2Fjm051060o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed Nucleoside Antibiotics That Inhibit Siderophore Biosynthesis of Mycobacterium tuberculosis</span></div><div class="casAuthors">Somu, Ravindranadh V.; Boshoff, Helena; Qiao, Chunhua; Bennett, Eric M.; Barry, Clifton E., III; Aldrich, Courtney C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-34</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A rationally designed nucleoside inhibitor of Mycobacterium tuberculosis growth (MIC99 = 0.19 μM) that disrupts siderophore biosynthesis was identified.  The activity is due to inhibition of the adenylate-forming enzyme MbtA which is involved in biosynthesis of the mycobactins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGothJgh0PSwprVg90H21EOLACvtfcHk0li7rT_DCEvE9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht12rtbjO&md5=48a498dce7210655779519d534dff088</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm051060o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051060o%26sid%3Dliteratum%253Aachs%26aulast%3DSomu%26aufirst%3DR.%2BV.%26aulast%3DBoshoff%26aufirst%3DH.%26aulast%3DQiao%26aufirst%3DC.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DAldrich%26aufirst%3DC.%2BC.%26atitle%3DRationally%2520Designed%2520Nucleoside%2520Antibiotics%2520That%2520Inhibit%2520Siderophore%2520Biosynthesis%2520of%2520Mycobacterium%2520Tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D1%26spage%3D31%26epage%3D34%26doi%3D10.1021%2Fjm051060o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aher, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pore, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, M. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antifungal Activity of 1,2,3-Triazole Containing Fluconazole Analogues</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmcl.2008.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19110424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2isLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=759-763&issue=3&author=N.+G.+Aherauthor=V.+S.+Poreauthor=N.+N.+Mishraauthor=A.+Kumarauthor=P.+K.+Shuklaauthor=A.+Sharmaauthor=M.+K.+Bhat&title=Synthesis+and+Antifungal+Activity+of+1%2C2%2C3-Triazole+Containing+Fluconazole+Analogues&doi=10.1016%2Fj.bmcl.2008.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antifungal activity of 1,2,3-triazole containing fluconazole analogues</span></div><div class="casAuthors">Aher, Nilkanth G.; Pore, Vandana S.; Mishra, Nripendra N.; Kumar, Awanit; Shukla, Praveen K.; Sharma, Aanchal; Bhat, Manoj K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">759-763</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fluconazole based mimics contg. 1,2,3-triazole were designed and synthesized as antifungal agents.  Their antifungal activities were evaluated in vitro by measuring the minimal inhibitory concns. (MICs).  Three compds. were found to be more potent against Candida fungal pathogens than control drugs fluconazole and amphotericin B.  The studies presented here provide structural modification of fluconazole to give 1,2,3-triazole contg. mols.  Furthermore, these mols. were evaluated in vivo against Candida albicans i.v. challenge in Swiss mice and antiproliferative activities were tested against human hepatocellular carcinoma Hep3B and human epithelial carcinoma A431.  It was found that compd. I resulted in 97.4% redn. in fungal load in mice and did not show any profound proliferative effect at lower dose (0.001 mg/mL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSEDdN0gVgG7Vg90H21EOLACvtfcHk0li7rT_DCEvE9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2isLs%253D&md5=2f36e9db134f3f849482a359de94b525</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DAher%26aufirst%3DN.%2BG.%26aulast%3DPore%26aufirst%3DV.%2BS.%26aulast%3DMishra%26aufirst%3DN.%2BN.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DShukla%26aufirst%3DP.%2BK.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DBhat%26aufirst%3DM.%2BK.%26atitle%3DSynthesis%2520and%2520Antifungal%2520Activity%2520of%25201%252C2%252C3-Triazole%2520Containing%2520Fluconazole%2520Analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D3%26spage%3D759%26epage%3D763%26doi%3D10.1016%2Fj.bmcl.2008.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pore, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, P. K.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Fluconazole/Bile Acid Conjugate Using Click Reaction</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">11178</span>– <span class="NLM_lpage">11186</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2006.09.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.tet.2006.09.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWjtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=11178-11186&issue=48&author=V.+S.+Poreauthor=N.+G.+Aherauthor=M.+Kumarauthor=P.+K.+Shukla&title=Design+and+Synthesis+of+Fluconazole%2FBile+Acid+Conjugate+Using+Click+Reaction&doi=10.1016%2Fj.tet.2006.09.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of fluconazole/bile acid conjugate using click reaction</span></div><div class="casAuthors">Pore, Vandana S.; Aher, Nilkanth G.; Kumar, Manish; Shukla, Praveen K.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">11178-11186</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Novel fluconazole/bile acid conjugates I (R1 = H, OH) and II (R2 = H, OH) were designed and their regioselective synthesis was achieved in very high yield via Cu(I) catalyzed intermol. 1,3-dipolar cycloaddn.  These new mols. showed good antifungal activity against Candida species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKpCIH_kQb1bVg90H21EOLACvtfcHk0lhHxEyX1AxGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWjtLfO&md5=404c12ebd37361363d759143d0138ba8</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2006.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2006.09.021%26sid%3Dliteratum%253Aachs%26aulast%3DPore%26aufirst%3DV.%2BS.%26aulast%3DAher%26aufirst%3DN.%2BG.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DShukla%26aufirst%3DP.%2BK.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Fluconazole%252FBile%2520Acid%2520Conjugate%2520Using%2520Click%2520Reaction%26jtitle%3DTetrahedron%26date%3D2006%26volume%3D62%26issue%3D48%26spage%3D11178%26epage%3D11186%26doi%3D10.1016%2Fj.tet.2006.09.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, C. M.</span></span> <span> </span><span class="NLM_article-title">What Makes a Neutral Imino Dieneophile Undergo a Thermal, Non-Catalysed, Diels-Alder Reaction?</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6035</span>– <span class="NLM_lpage">6050</span>, <span class="refDoi"> DOI: 10.1016/S0040-4020(98)00284-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0040-4020%2898%2900284-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK1cXjsFSjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=6035-6050&issue=22&author=A.+Whitingauthor=C.+M.+Windsor&title=What+Makes+a+Neutral+Imino+Dieneophile+Undergo+a+Thermal%2C+Non-Catalysed%2C+Diels-Alder+Reaction%3F&doi=10.1016%2FS0040-4020%2898%2900284-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">What makes a neutral imino dieneophile undergo a thermal, non-catalyzed, Diels-Alder reaction?</span></div><div class="casAuthors">Whiting, Andrew; Windsor, Carl M.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6035-6050</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Ab initio calcns. have been carried out at the MP2/6-31G* level of theory on the aza-Diels-Alder reaction of a range electron deficient imines (with sulfonyl and/or carbonyl substituents) with buta-1,3-diene.  In all cases but one, an early cyclic transition-state could be located in which most often, the forming N-C bond was more fully formed than the forming C-C bond.  However, examples were found in which this order of bond formation was reversed.  Examn. of HOMO-LUMO energy levels show that aza-Diels-Alder reactions are HOMO (diene)-LUMO (dienophile) controlled and that the most electron deficient imines should be more reactive than simple alkyl or aryl imines and imines possessing less electron withdrawing groups.  Evidence is also found for exo-lone pair effects, but these effects become obscured by other stereoelectronic effects as electron withdrawing substituents are added to the imine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO3WeQiHMFM7Vg90H21EOLACvtfcHk0lhHxEyX1AxGRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjsFSjsrw%253D&md5=36f7cead30efcaf6f537fc098a8634a9</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2898%2900284-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252898%252900284-1%26sid%3Dliteratum%253Aachs%26aulast%3DWhiting%26aufirst%3DA.%26aulast%3DWindsor%26aufirst%3DC.%2BM.%26atitle%3DWhat%2520Makes%2520a%2520Neutral%2520Imino%2520Dieneophile%2520Undergo%2520a%2520Thermal%252C%2520Non-Catalysed%252C%2520Diels-Alder%2520Reaction%253F%26jtitle%3DTetrahedron%26date%3D1998%26volume%3D54%26issue%3D22%26spage%3D6035%26epage%3D6050%26doi%3D10.1016%2FS0040-4020%2898%2900284-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arepalli, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of 1,3-Diphenylbenzo[F][1,7]Naphthyrdines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5586</span>– <span class="NLM_lpage">5597</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.08.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2017.08.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28870801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVertL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=5586-5597&issue=20&author=S.+K.+Arepalliauthor=B.+Parkauthor=K.+Leeauthor=H.+Joauthor=K.+Y.+Junauthor=Y.+Kwonauthor=J.+S.+Kangauthor=J.+K.+Jungauthor=H.+Lee&title=Design%2C+Synthesis+and+Biological+Evaluation+of+1%2C3-Diphenylbenzo%5BF%5D%5B1%2C7%5DNaphthyrdines&doi=10.1016%2Fj.bmc.2017.08.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 1,3-diphenylbenzo[f][1,7]naphthyrdines</span></div><div class="casAuthors">Arepalli, Sateesh Kumar; Park, Byeongwoo; Lee, Kiho; Jo, Hyunji; Jun, Kyu-Yeon; Kwon, Youngjoo; Kang, Jong-Soon; Jung, Jae-Kyung; Lee, Heesoon</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5586-5597</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel twenty 1,3-diphenylbenzo[f][1,7]benzonaphthyrdine derivs. I [R = H, Me; R1 = 2-thienyl, 4-BrC6H4, 1-naphthyl, etc.] were designed and synthesized through intermol. imino Diels-Alder reaction.  Their in vitro cytotoxic activities were evaluated against six human cancer cell lines (NCIH23, HCT15, NUGC-3, ACHN, PC-3, and MDA-MB-231).  Majority of synthesized compds. exhibited significant cytotoxic activities against all tested human cancer cell lines.  Among them I [R = H; R1 = 4-Me2NC6H4, 4-ClC6H4, 3-CNC6H4] derivs. exhibited most promising cytotoxic activities.  Furthermore these compds. were evaluated against human topoisomerase IIα inhibition, out of which the compd. I [R = H; R1 = 4-Me2NC6H4] exhibited 1.3 and 1.2 times more potent human topoisomerase IIα inhibition than the ref. drug etoposide in both 100 μM and 20 μM concns. resp.  Mol. docking studies for the compd. I [R = H; R1 = 4-Me2NC6H4] have also been executed by sybyl X-2.1 in which it revealed that it's binding site with topo IIα DNA cleavage site where etoposide was situated.  The benzo[f][1,7]naphthyridine ring was stacked between the DNA bases of the cleavage site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUsjR1RS3bd7Vg90H21EOLACvtfcHk0ljWRq4SBz2MiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVertL3E&md5=aa64050fe197fda2887e901ef0b25ae8</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.08.030%26sid%3Dliteratum%253Aachs%26aulast%3DArepalli%26aufirst%3DS.%2BK.%26aulast%3DPark%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DJo%26aufirst%3DH.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DJung%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25201%252C3-Diphenylbenzo%255BF%255D%255B1%252C7%255DNaphthyrdines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D20%26spage%3D5586%26epage%3D5597%26doi%3D10.1016%2Fj.bmc.2017.08.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span> <span> </span><span class="NLM_article-title">Transition Metal-Catalyzed Decarboxylative Cross-Coupling Reactions</span>. <i>Sci. China: Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1670</span>– <span class="NLM_lpage">1687</span>, <span class="refDoi"> DOI: 10.1007/s11426-011-4381-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1007%2Fs11426-011-4381-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVamtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1670-1687&issue=11&author=R.+Shangauthor=L.+Liu&title=Transition+Metal-Catalyzed+Decarboxylative+Cross-Coupling+Reactions&doi=10.1007%2Fs11426-011-4381-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Transition metal-catalyzed decarboxylative cross-coupling reactions</span></div><div class="casAuthors">Shang, Rui; Liu, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Science China: Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1670-1687</span>CODEN:
                <span class="NLM_cas:coden">SCCCCS</span>;
        ISSN:<span class="NLM_cas:issn">1869-1870</span>.
    
            (<span class="NLM_cas:orgname">Science China Press</span>)
        </div><div class="casAbstract">A review.  Transition metal-catalyzed decarboxylative cross-coupling reactions recently emerged as a new and important category of org. transformations that find versatile applications in the construction of carbon-carbon and carbon-heteroatom bonds.  The use of relatively cheap and stable carboxylic acids to replace organometallic reagents enables the decarboxylative cross-coupling reactions to proceed with good selectivities and functional group tolerance.  The present review summarized the various types of decarboxylative cross-coupling reactions catalyzed by different transition metal complexes.  The scope and applications of these reactions were described.  The challenges and opportunities in the field were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2w4ggGiGk17Vg90H21EOLACvtfcHk0ljWRq4SBz2MiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVamtb3J&md5=8724384faf443545d40c0e78e4ad844c</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1007%2Fs11426-011-4381-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11426-011-4381-0%26sid%3Dliteratum%253Aachs%26aulast%3DShang%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DL.%26atitle%3DTransition%2520Metal-Catalyzed%2520Decarboxylative%2520Cross-Coupling%2520Reactions%26jtitle%3DSci.%2520China%253A%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D11%26spage%3D1670%26epage%3D1687%26doi%3D10.1007%2Fs11426-011-4381-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stüer, R.</span></span> <span> </span><span class="NLM_article-title">Metal-Catalyzed Cross-Coupling Reactions</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>347</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1002/adsc.200404362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fadsc.200404362" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2005&pages=197-197&issue=1&author=R.+St%C3%BCer&title=Metal-Catalyzed+Cross-Coupling+Reactions&doi=10.1002%2Fadsc.200404362"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2Fadsc.200404362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.200404362%26sid%3Dliteratum%253Aachs%26aulast%3DSt%25C3%25BCer%26aufirst%3DR.%26atitle%3DMetal-Catalyzed%2520Cross-Coupling%2520Reactions%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2005%26volume%3D347%26issue%3D1%26spage%3D197%26epage%3D197%26doi%3D10.1002%2Fadsc.200404362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span> <span> </span><span class="NLM_article-title">Cross-Coupling Reactions of Organoboranes: An Easy Method for C-C Bonding</span>. <i>Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">894</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.1246/cl.2011.894</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1246%2Fcl.2011.894" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1CjurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=894-901&issue=9&author=A.+Suzukiauthor=Y.+Yamamoto&title=Cross-Coupling+Reactions+of+Organoboranes%3A+An+Easy+Method+for+C-C+Bonding&doi=10.1246%2Fcl.2011.894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-coupling reactions of organoboranes: an easy method for C-C bonding</span></div><div class="casAuthors">Suzuki, Akira; Yamamoto, Yasunori</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">894-901</span>CODEN:
                <span class="NLM_cas:coden">CMLTAG</span>;
        ISSN:<span class="NLM_cas:issn">0366-7022</span>.
    
            (<span class="NLM_cas:orgname">Chemical Society of Japan</span>)
        </div><div class="casAbstract">A review was given on cross-coupling reactions of organoboranes.  The Pd-catalyzed cross-coupling reaction between different types of organoboron compds. and various org. halides or triflates in the presence of base provides a powerful and general methodol. for the formation of C-C bonds.  C(sp2)-B compds. (such as aryl- and 1-alkenylborons) and C(sp3)-B compds. (alkylborons) readily cross-couple with org. electrophiles to give coupled products selectively in high yields.  Recently, C(sp)-B compds. (1-alkynylborons) were also obsd. to react with org. electrophiles to produce expected cross-coupled products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBPWtZI9vbx7Vg90H21EOLACvtfcHk0ljWRq4SBz2MiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1CjurfP&md5=608c14749c275d669f66bddd1fae4f3b</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1246%2Fcl.2011.894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.2011.894%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DY.%26atitle%3DCross-Coupling%2520Reactions%2520of%2520Organoboranes%253A%2520An%2520Easy%2520Method%2520for%2520C-C%2520Bonding%26jtitle%3DChem.%2520Lett.%26date%3D2011%26volume%3D40%26issue%3D9%26spage%3D894%26epage%3D901%26doi%3D10.1246%2Fcl.2011.894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyaura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2457</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.1021/cr00039a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&issue=7&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-Catalyzed+Cross-Coupling+Reactions+of+Organoboron+Compounds&doi=10.1021%2Fcr00039a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0lhClDTCoWigsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-Catalyzed%2520Cross-Coupling%2520Reactions%2520of%2520Organoboron%2520Compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26issue%3D7%26spage%3D2457%26epage%3D2483%26doi%3D10.1021%2Fcr00039a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a Multiple Target Receptor Tyrosine Kinase Inhibitors ABT-869</span>. <i>Youji Huaxue</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1196</span>– <span class="NLM_lpage">1200</span>, <span class="refDoi"> DOI: 10.6023/cjoc201402025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.6023%2Fcjoc201402025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVent7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=1196-1200&issue=6&author=X.+Houauthor=J.+Zhangauthor=H.+Liu&title=Synthesis+of+a+Multiple+Target+Receptor+Tyrosine+Kinase+Inhibitors+ABT-869&doi=10.6023%2Fcjoc201402025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a multiple target receptor tyrosine kinase inhibitors ABT-869</span></div><div class="casAuthors">Hou, Xuehui; Zhang, Jingyu; Liu, Hongmin</div><div class="citationInfo"><span class="NLM_cas:title">Youji Huaxue</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1196-1200</span>CODEN:
                <span class="NLM_cas:coden">YCHHDX</span>;
        ISSN:<span class="NLM_cas:issn">0253-2786</span>.
    
            (<span class="NLM_cas:orgname">Youji Huaxue Bianjibu</span>)
        </div><div class="casAbstract">An efficient and convenient protocol for the synthesis of ABT-869, which is a multiple target receptor tyrosine kinase inhibitors with novel structure and high inhibitory activity, was developed in seven steps from cheap and com. available of 3-fluoroaniline.  The target mol. was obtained in 42.3% overall yield without any traditional purifn. (column chromatog. or crystn.).  Ultrasonic reaction technol. was introduced in the Suzuki coupling reaction which is the key step of the prepn. of ABT-869.  The synthetic process was more suitable for industrialized prodn. due to the advantages of available starting material, simplicity and cheapness, well yield and purity (HPLC > 99.0%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6tge5jRoMfLVg90H21EOLACvtfcHk0lhClDTCoWigsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVent7zK&md5=0f6ffc16b507eb01bd320a4b41e197f9</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.6023%2Fcjoc201402025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6023%252Fcjoc201402025%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520a%2520Multiple%2520Target%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%2520ABT-869%26jtitle%3DYouji%2520Huaxue%26date%3D2014%26volume%3D34%26issue%3D6%26spage%3D1196%26epage%3D1200%26doi%3D10.6023%2Fcjoc201402025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cordovilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolomé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Ilarduya, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinet, P.</span></span> <span> </span><span class="NLM_article-title">The Stille Reaction, 38 Years Later</span>. <i>ACS Catal.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">3040</span>– <span class="NLM_lpage">3053</span>, <span class="refDoi"> DOI: 10.1021/acscatal.5b00448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscatal.5b00448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslWjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=3040-3053&issue=5&author=C.+Cordovillaauthor=C.+Bartolom%C3%A9author=J.+M.+Mart%C3%ADnez-Ilarduyaauthor=P.+Espinet&title=The+Stille+Reaction%2C+38+Years+Later&doi=10.1021%2Facscatal.5b00448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">The Stille Reaction, 38 Years Later</span></div><div class="casAuthors">Cordovilla, Carlos; Bartolome, Camino; Martinez-Ilarduya, Jesus Ma; Espinet, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">ACS Catalysis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3040-3053</span>CODEN:
                <span class="NLM_cas:coden">ACCACS</span>;
        ISSN:<span class="NLM_cas:issn">2155-5435</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This review concs. on the mechanistic new knowledge and on important aspects such as the revolution with the use of bulky phosphines, the bimetallic alternative of the Stille reaction, the enantioselectivity in Stille and palladium-free Stille processes, the meaning of copper effect, or the possible approaches to make Stille coupling a greener process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Ha3gQr1-3LVg90H21EOLACvtfcHk0liC9zIII-HPiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslWjtLw%253D&md5=290571217e0fad67940a22ec95ede583</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facscatal.5b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscatal.5b00448%26sid%3Dliteratum%253Aachs%26aulast%3DCordovilla%26aufirst%3DC.%26aulast%3DBartolom%25C3%25A9%26aufirst%3DC.%26aulast%3DMart%25C3%25ADnez-Ilarduya%26aufirst%3DJ.%2BM.%26aulast%3DEspinet%26aufirst%3DP.%26atitle%3DThe%2520Stille%2520Reaction%252C%252038%2520Years%2520Later%26jtitle%3DACS%2520Catal.%26date%3D2015%26volume%3D5%26issue%3D5%26spage%3D3040%26epage%3D3053%26doi%3D10.1021%2Facscatal.5b00448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echavarren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R.</span></span> <span> </span><span class="NLM_article-title">Discussion Addendum For: 4-Methoxy-4′-Nitrophenyl. Recent Advances in the Stille Biaryl Coupling Reaction and Applications in Complex Natural Products Synthesis</span>. <i>Org. Synth.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>88</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1002/0471264229.os088.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2F0471264229.os088.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21960729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1ertr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2011&pages=197-201&issue=3&author=R.+M.+Williamsauthor=J.+Stilleauthor=A.+Echavarrenauthor=J.+Hendrixauthor=B.+Albrechtauthor=R.+Williams&title=Discussion+Addendum+For%3A+4-Methoxy-4%E2%80%B2-Nitrophenyl.+Recent+Advances+in+the+Stille+Biaryl+Coupling+Reaction+and+Applications+in+Complex+Natural+Products+Synthesis&doi=10.1002%2F0471264229.os088.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Discussion addendum for: 4-methoxy-4'-nitrophenyl. Recent advances in the Stille biaryl coupling reaction and applications in complex natural products synthesis</span></div><div class="casAuthors">Williams, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Syntheses</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">197-201</span>CODEN:
                <span class="NLM_cas:coden">ORSYAT</span>;
        ISSN:<span class="NLM_cas:issn">0078-6209</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Addendum to an original article published by Stille, J., Echavarren, A., Hendrix, J., Albrecht, B., Williams, R., Org. Synth. 1993, 71, 97.  Recent advances in the application of the Stille coupling reaction were discussed.  This cross-coupling reaction was applied to the synthesis of TMC-95A, TMC-95B, chloropeptin, himastatin [i.e., (2S,2'S,3aR,3'aR,8aS,8'aS)-1,1',2,2',3,3',3a,3'a,8,8',8a,8'a-dodecahydro-3a,3'a-dihydroxy[5,5'-bipyrrolo[2,3-b]indole]-2,2'-dicarbonylbis[D-valyl-(2S)-2-hydroxy-3-methylbutanoyl-(3R,5R)-hexahydro-5-hydroxy-3-pyridazinecarbonyl-L-leucyl-D-threonine] (6→11),(6'→11')-dilactam].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF9mqwrGRaDLVg90H21EOLACvtfcHk0liC9zIII-HPiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1ertr8%253D&md5=33eb5ec5bfbe1cea4d470477a7fd5e90</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1002%2F0471264229.os088.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471264229.os088.18%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DR.%2BM.%26aulast%3DStille%26aufirst%3DJ.%26aulast%3DEchavarren%26aufirst%3DA.%26aulast%3DHendrix%26aufirst%3DJ.%26aulast%3DAlbrecht%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DR.%26atitle%3DDiscussion%2520Addendum%2520For%253A%25204-Methoxy-4%25E2%2580%25B2-Nitrophenyl.%2520Recent%2520Advances%2520in%2520the%2520Stille%2520Biaryl%2520Coupling%2520Reaction%2520and%2520Applications%2520in%2520Complex%2520Natural%2520Products%2520Synthesis%26jtitle%3DOrg.%2520Synth.%26date%3D2011%26volume%3D88%26issue%3D3%26spage%3D197%26epage%3D201%26doi%3D10.1002%2F0471264229.os088.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasolofonjatovo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provot, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brion, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alami, M.</span></span> <span> </span><span class="NLM_article-title">Regioselective Hydrostannation of Diarylalkynes Directed by a Labile Ortho Bromine Atom: An Easy Access to Stereodefined Triarylolefins, Hybrids of Combretastatin A-4 and Isocombretastatin A-4</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3617</span>– <span class="NLM_lpage">3626</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2010.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2010.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20627378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=3617-3626&issue=9&author=E.+Rasolofonjatovoauthor=O.+Provotauthor=A.+Hamzeauthor=J.+Bignonauthor=S.+Thoretauthor=J.+D.+Brionauthor=M.+Alami&title=Regioselective+Hydrostannation+of+Diarylalkynes+Directed+by+a+Labile+Ortho+Bromine+Atom%3A+An+Easy+Access+to+Stereodefined+Triarylolefins%2C+Hybrids+of+Combretastatin+A-4+and+Isocombretastatin+A-4&doi=10.1016%2Fj.ejmech.2010.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective hydrostannation of diarylalkynes directed by a labile ortho bromine atom: An easy access to stereodefined triarylolefins, hybrids of combretastatin A-4 and isocombretastatin A-4</span></div><div class="casAuthors">Rasolofonjatovo, Evelia; Provot, Olivier; Hamze, Abdallah; Bignon, Jerome; Thoret, Sylviane; Brion, Jean-Daniel; Alami, Mouad</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3617-3626</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of triarylolefins bearing the combretastatin A-4 and the isocombretastatin A-4 cores, e.g. I, were synthesized and evaluated.  The cooperative ortho-effect of a labile bromine atom in the regioselective hydrostannation of unsym. diarylalkynes leading to stereodefined triarylolefins is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_b9lfH7fywbVg90H21EOLACvtfcHk0ljQTSqnSfNLqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKiurs%253D&md5=0d9cbc3112ce1bc9946b28341294cf37</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DRasolofonjatovo%26aufirst%3DE.%26aulast%3DProvot%26aufirst%3DO.%26aulast%3DHamze%26aufirst%3DA.%26aulast%3DBignon%26aufirst%3DJ.%26aulast%3DThoret%26aufirst%3DS.%26aulast%3DBrion%26aufirst%3DJ.%2BD.%26aulast%3DAlami%26aufirst%3DM.%26atitle%3DRegioselective%2520Hydrostannation%2520of%2520Diarylalkynes%2520Directed%2520by%2520a%2520Labile%2520Ortho%2520Bromine%2520Atom%253A%2520An%2520Easy%2520Access%2520to%2520Stereodefined%2520Triarylolefins%252C%2520Hybrids%2520of%2520Combretastatin%2520A-4%2520and%2520Isocombretastatin%2520A-4%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26issue%3D9%26spage%3D3617%26epage%3D3626%26doi%3D10.1016%2Fj.ejmech.2010.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chinchilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najera, C.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in Sonogashira Reactions</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">5084</span>– <span class="NLM_lpage">5121</span>, <span class="refDoi"> DOI: 10.1039/c1cs15071e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1039%2Fc1cs15071e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21655588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=5084-5121&issue=10&author=R.+Chinchillaauthor=C.+Najera&title=Recent+Advances+in+Sonogashira+Reactions&doi=10.1039%2Fc1cs15071e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in Sonogashira reactions</span></div><div class="casAuthors">Chinchilla, Rafael; Najera, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5084-5121</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review with 352 refs. discusses the Sonogashira reaction of alkynes and aryl halides to yield aryl alkynes and, in particular, the development of catalysts for Sonogashira reactions.  The mechanism of the Sonogashira reaction, the use of supported and unsupported palladium complexes with phosphines, nitrogen-contg. (imine and pyridine) ligands, ligands contg. phosphorus, nitrogen, and oxygen, and N-heterocyclic carbenes as catalysts, the use of palladacycles, ligand-free palladium species, and palladium nanoparticles as catalysts, and the use of other metals as catalysts or cocatalysts for Sonogashira coupling reactions are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRRxM3DrQgRrVg90H21EOLACvtfcHk0ljQTSqnSfNLqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtbvE&md5=daa28257436731bf1fc800f0d1ce46f3</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1039%2Fc1cs15071e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cs15071e%26sid%3Dliteratum%253Aachs%26aulast%3DChinchilla%26aufirst%3DR.%26aulast%3DNajera%26aufirst%3DC.%26atitle%3DRecent%2520Advances%2520in%2520Sonogashira%2520Reactions%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2011%26volume%3D40%26issue%3D10%26spage%3D5084%26epage%3D5121%26doi%3D10.1039%2Fc1cs15071e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khatyr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziessel, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Quasi-Linear and Segmented Bis- to Penta-2, 2′-Bipyridine Polytopic Ligands Built Via a Convergent Approach</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7814</span>– <span class="NLM_lpage">7824</span>, <span class="refDoi"> DOI: 10.1021/jo000836k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo000836k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1OisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2000&pages=7814-7824&issue=23&author=A.+Khatyrauthor=R.+Ziessel&title=Synthesis+of+Quasi-Linear+and+Segmented+Bis-+to+Penta-2%2C+2%E2%80%B2-Bipyridine+Polytopic+Ligands+Built+Via+a+Convergent+Approach&doi=10.1021%2Fjo000836k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Quasi-Linear and Segmented Bis- to Penta-2,2'-bipyridine Polytopic Ligands Built via a Convergent Approach</span></div><div class="casAuthors">Khatyr, Abderrahim; Ziessel, Raymond</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7814-7824</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reliable and practical routes for the prepn. of segmented oligomeric 2,2'-bipyridine-based ligands possessing rigid and conjugated spacers are presented.  The first series of ligands bears a single alkyne function as a bridge and has been built by Pd(0)-catalyzed cross-coupling reactions between ethynylated and bromo-substituted derivs. of 2,2'-bipyridine (bipy).  These new ligands provide access to numerous hexameric, octameric, and decameric pyridine-based materials.  Optimum conditions were found with [Pd(PPh3)4] (6 mol %) in benzene contg. diisopropylamine at 80 °C.  The second series of sol. ligands was synthesized around a 1,4-diethynyl-2,5-didodecyloxybenzene bridging unit.  The synthesis required a protection/deprotection methodol., as well as a chemoselective palladium-catalyzed Sonogashira-Hagihara cross-coupling protocol to obtain the target multitopic ligands.  Within this strategy, the pivotal intermediates bearing one or two bipy and Ph units are required and such entities were isolated in excellent yield.  The products are highly sol. and photostable.  In each case, the final step involves a double cross-coupling reaction between the appropriate constituents, with the best preparative conditions involving [Pd(PPh3)4] (6 mol %) in propylamine at 70 °C.  The main advantage of this methodol. lies in its synthetic versatility and adaptability for creating multitopic metal-binding scaffolds with a potentially large variety of bridging units and Ph substituents.  Spectroscopic data for the new oligomers show a steady decrease in optical energy with an increasing degree of oligomerization.  The different results obtained with these ligands highlight the importance of the rigid 1,4-diethynylphenyl linker in directing the outcome of the nanosized mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZX0Q5T4wJF7Vg90H21EOLACvtfcHk0ljQTSqnSfNLqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1OisLg%253D&md5=945e70b53725a438b67d828c26567983</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fjo000836k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo000836k%26sid%3Dliteratum%253Aachs%26aulast%3DKhatyr%26aufirst%3DA.%26aulast%3DZiessel%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520Quasi-Linear%2520and%2520Segmented%2520Bis-%2520to%2520Penta-2%252C%25202%25E2%2580%25B2-Bipyridine%2520Polytopic%2520Ligands%2520Built%2520Via%2520a%2520Convergent%2520Approach%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2000%26volume%3D65%26issue%3D23%26spage%3D7814%26epage%3D7824%26doi%3D10.1021%2Fjo000836k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cabri, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candiani, I.</span></span> <span> </span><span class="NLM_article-title">Recent Developments and New Perspectives in the Heck Reaction</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1021/ar00049a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar00049a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK2MXjtF2rs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1995&pages=2-7&issue=1&author=W.+Cabriauthor=I.+Candiani&title=Recent+Developments+and+New+Perspectives+in+the+Heck+Reaction&doi=10.1021%2Far00049a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Developments and New Perspectives in the Heck Reaction</span></div><div class="casAuthors">Cabri, Walter; Candiani, Ilaria</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-7</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with ∼34 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCqeZaru8_x7Vg90H21EOLACvtfcHk0li1F-SLpsch1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtF2rs78%253D&md5=5cb0bb6cf962e1573c70cfb1a895bba1</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Far00049a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far00049a001%26sid%3Dliteratum%253Aachs%26aulast%3DCabri%26aufirst%3DW.%26aulast%3DCandiani%26aufirst%3DI.%26atitle%3DRecent%2520Developments%2520and%2520New%2520Perspectives%2520in%2520the%2520Heck%2520Reaction%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1995%26volume%3D28%26issue%3D1%26spage%3D2%26epage%3D7%26doi%3D10.1021%2Far00049a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morazzoni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrangolini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bombardelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabri, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riva, A.</span></span> <span> </span><span class="NLM_article-title">Samital®: A New Botanical Drug for the Treatment of Mucositis Induced by Oncological Therapies</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1717</span>– <span class="NLM_lpage">1725</span>, <span class="refDoi"> DOI: 10.2217/fon.13.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2217%2Ffon.13.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24156331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KktbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=1717-1725&issue=11&author=P.+Morazzoniauthor=G.+Petrangoliniauthor=E.+Bombardelliauthor=M.+Ronchiauthor=W.+Cabriauthor=A.+Riva&title=Samital%C2%AE%3A+A+New+Botanical+Drug+for+the+Treatment+of+Mucositis+Induced+by+Oncological+Therapies&doi=10.2217%2Ffon.13.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">SAMITAL: a new botanical drug for the treatment of mucositis induced by oncological therapies</span></div><div class="casAuthors">Morazzoni, Paolo; Petrangolini, Giovanna; Bombardelli, Ezio; Ronchi, Massimo; Cabri, Walter; Riva, Antonella</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1717-1725</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  SAMITAL (Indena SpA, Milan, Italy) is a new multicomponent and multiacting botanical formulation rationally designed for the relief of oral mucositis induced by chemotherapy and/or radiotherapy in oncol. patients.  Each of the individual botanical constituents of SAMITAL-standardized exts. of Vaccinium myrtillus, Macleaya cordata and Echinacea angustifolia have a long history of clin. use that corroborates their safety and activity in SAMITAL.  A no. of pilot trials in oncol. patients demonstrated that SAMITAL has good clin. efficacy and tolerability as evidenced by its significant effects in terms of redn. of mucositis, pain and a general improvement in patient quality of life.  Importantly, the use of this botanical formulation had the added benefit that patients were able to complete their chemotherapy/radiotherapy regimen.  Phase II trials with SAMITAL as part of an overall clin. development program are currently ongoing in Italy and are planned in the USA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRBNaXYekUgbVg90H21EOLACvtfcHk0li1F-SLpsch1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KktbbN&md5=0a0398f115ba24462c6c041f33f40d56</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.2217%2Ffon.13.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.13.165%26sid%3Dliteratum%253Aachs%26aulast%3DMorazzoni%26aufirst%3DP.%26aulast%3DPetrangolini%26aufirst%3DG.%26aulast%3DBombardelli%26aufirst%3DE.%26aulast%3DRonchi%26aufirst%3DM.%26aulast%3DCabri%26aufirst%3DW.%26aulast%3DRiva%26aufirst%3DA.%26atitle%3DSamital%25C2%25AE%253A%2520A%2520New%2520Botanical%2520Drug%2520for%2520the%2520Treatment%2520of%2520Mucositis%2520Induced%2520by%2520Oncological%2520Therapies%26jtitle%3DFuture%2520Oncol.%26date%3D2013%26volume%3D9%26issue%3D11%26spage%3D1717%26epage%3D1725%26doi%3D10.2217%2Ffon.13.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palem, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alugubelli, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarapu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polepalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manga, V.</span></span> <span> </span><span class="NLM_article-title">Quinazolinones-Phenylquinoxaline Hybrids with Unsaturation/Saturation Linkers as Novel Anti-Proliferative Agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3014</span>– <span class="NLM_lpage">3018</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmcl.2016.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27209232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28Xotleju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3014-3018&issue=13&author=J.+D.+Palemauthor=G.+R.+Alugubelliauthor=R.+Bantuauthor=L.+Nagarapuauthor=S.+Polepalliauthor=S.+N.+Jainauthor=R.+Bathiniauthor=V.+Manga&title=Quinazolinones-Phenylquinoxaline+Hybrids+with+Unsaturation%2FSaturation+Linkers+as+Novel+Anti-Proliferative+Agents&doi=10.1016%2Fj.bmcl.2016.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Quinazolinones-Phenylquinoxaline hybrids with unsaturation/saturation linkers as novel anti-proliferative agents</span></div><div class="casAuthors">Palem, Jyothsna Devi; Alugubelli, Gopi Reddy; Bantu, Rajashaker; Nagarapu, Lingaiah; Polepalli, Sowjanya; Jain, S. Nishanth; Bathini, Raju; Manga, Vijjulatha</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3014-3018</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of novel quinazolinones with allylphenyl quinoxaline hybrids were efficiently synthesized in good yields by the reaction of 3-allyl-2-methylquinazolin-4(3H)-one with bromophenyl quinoxaline utilizing Pd catalyzed Heck-cross coupling and evaluated for anti-proliferative activity against four cancer cell lines such as HeLa (cervical), MIAPACA (pancreatic), MDA-MB-231 (breast) and IMR32 (neuroblastoma).  Compds. I (R = Ph, 4-OMeC6H4, 4-MeC6H4, 2,4-OMeC6H3) exhibited promising anti-proliferative activity with GI50 values ranging from 0.06 to 0.2 μM against four cell lines, while compds. I (R = 4-OMeC6H4, 4-CF3C6H4) showed significant activity against HeLa and MIAPACA cell lines and compds. I (R = 4-ClC6H4, 2,4-MeC6H3, 2,3,4-OMeC6H2,2-F-4-OMeC6H3) showed selective potency against IMR32 and MDA-MB-231 cell lines.  This is the first report on the synthesis and in vitro anti-proliferative evaluation of E-2-(4-substituted)-3-(3-(4-(quinoxalin-2-yl)phenyl)allyl)quinazolin-4(3H)-ones.  Docking results indicate a sign of good correlation between exptl. activity and calcd. binding affinity (dock score), suggesting that these compds. could act as promising DNA intercalates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZP6Vaf976VbVg90H21EOLACvtfcHk0liUF1SmAHx7UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xotleju74%253D&md5=652d3865f9dadec257c7f894e90e39ba</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DPalem%26aufirst%3DJ.%2BD.%26aulast%3DAlugubelli%26aufirst%3DG.%2BR.%26aulast%3DBantu%26aufirst%3DR.%26aulast%3DNagarapu%26aufirst%3DL.%26aulast%3DPolepalli%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DS.%2BN.%26aulast%3DBathini%26aufirst%3DR.%26aulast%3DManga%26aufirst%3DV.%26atitle%3DQuinazolinones-Phenylquinoxaline%2520Hybrids%2520with%2520Unsaturation%252FSaturation%2520Linkers%2520as%2520Novel%2520Anti-Proliferative%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D13%26spage%3D3014%26epage%3D3018%26doi%3D10.1016%2Fj.bmcl.2016.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, z.</span></span> <span> </span><span class="NLM_article-title">The Physicochemical Challenges of Designing Multiple Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&issue=16&author=R.+Morphyauthor=z.+Rankovic&title=The+Physicochemical+Challenges+of+Designing+Multiple+Ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0liUF1SmAHx7UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3Dz.%26atitle%3DThe%2520Physicochemical%2520Challenges%2520of%2520Designing%2520Multiple%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D16%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostrom, J.</span></span> <span> </span><span class="NLM_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9442</span>– <span class="NLM_lpage">9468</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00675</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00675" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9442-9468&issue=21&author=D.%0AG.+Brownauthor=J.+Bostrom&title=Where+Do+Recent+Small+Molecule+Clinical+Development+Candidates+Come+From%3F&doi=10.1021%2Facs.jmedchem.8b00675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9442-9468</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An anal. of 66 published clin. candidates from Journal of Medicinal Chem. has been conducted to shed light on which lead generation strategies are most frequently employed in identifying drug candidates.  The most frequent lead generation strategy (producing a drug candidate) was based on starting points derived from previously known compds. (43%) followed by random high throughput screening (29%).  The remainder of approaches included focused screening, structure-based drug design (SBDD), fragment-based lead generation (FBLG), and DNA-encoded library screening (DEL).  An anal. of physicochem. properties on the hit-to-clin. pairs shows an av. increase in mol. wt. (ΔMW = +85) but no change in lipophilicity (ΔclogP = -0.2), although exceptions are noted.  The majority (>50%) of clin. candidates were found to be structurally very different from their starting point and were more complex.  Finally, several reports of noncovalent scaffolds modified by a covalent warhead using SBDD approaches are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKVZOYYj87bLVg90H21EOLACvtfcHk0liUF1SmAHx7UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F&md5=211341fa12156e9512650d3352893a5e</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostrom%26aufirst%3DJ.%26atitle%3DWhere%2520Do%2520Recent%2520Small%2520Molecule%2520Clinical%2520Development%2520Candidates%2520Come%2520From%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468%26doi%3D10.1021%2Facs.jmedchem.8b00675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sameem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeedi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahdavi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafiee, A.</span></span> <span> </span><span class="NLM_article-title">A Review on Tacrine-Based Scaffolds as Multi-Target Drugs (MTDLs) for Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.10.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2016.10.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27876467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFait77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2017&pages=332-345&author=B.+Sameemauthor=M.+Saeediauthor=M.+Mahdaviauthor=A.+Shafiee&title=A+Review+on+Tacrine-Based+Scaffolds+as+Multi-Target+Drugs+%28MTDLs%29+for+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2016.10.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease</span></div><div class="casAuthors">Sameem, Bilqees; Saeedi, Mina; Mahdavi, Mohammad; Shafiee, Abbas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">332-345</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a multifactorial neurol. disorder among elderly people and combinatorial factors such as genetic, lifestyle, and environmental are involved in onset and disease progression.  It has been demonstrated that loss of cholinergic transmission is one of the most significant causes of AD.  One strategy currently being investigated for the development of new therapeutics relates to the enhancement of cholinergic system through several ways.  At this juncture, anticholinesterase inhibitors have absorbed lots of attention and different marketed drugs such as donepezil, rivastigmine, tacrine, and galantamine have been developed. 9-Amino-1,2,3,4-tetrahydroacridine known as tacrine was introduced in 1945 as an efficient anticholinesterase agent.  The mechanism of action of tacrine was proved to inhibit the metab. of acetylcholine and therefore extending its activity and raising levels in the cerebral cortex.  However, extensive use of tacrine was limited since it showed various side effects and toxicity.  Thus, lots of efforts were carried out to prep. tacrine analogs to overcome the related adverse effects.  This review describes differently synthesized tacrine-based scaffolds as cholinesterase inhibitors to manage Alzheimer's disease (AD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrURdMfJvk17bVg90H21EOLACvtfcHk0ljS7TvFbYvE8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFait77F&md5=2462b18c5601b6491dfe553452268f40</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.10.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.10.060%26sid%3Dliteratum%253Aachs%26aulast%3DSameem%26aufirst%3DB.%26aulast%3DSaeedi%26aufirst%3DM.%26aulast%3DMahdavi%26aufirst%3DM.%26aulast%3DShafiee%26aufirst%3DA.%26atitle%3DA%2520Review%2520on%2520Tacrine-Based%2520Scaffolds%2520as%2520Multi-Target%2520Drugs%2520%2528MTDLs%2529%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D128%26spage%3D332%26epage%3D345%26doi%3D10.1016%2Fj.ejmech.2016.10.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stacchiotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Vullo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morosi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barisella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaffaroni, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagrada, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, P. G.</span></span> <span> </span><span class="NLM_article-title">Activity of Axitinib in Progressive Advanced Solitary Fibrous Tumour: Results from an Exploratory, Investigator-Driven Phase 2 Clinical Study</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2018.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejca.2018.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=30528807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlKmur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2019&pages=225-233&author=S.+Stacchiottiauthor=N.+Simeoneauthor=S.+Lo+Vulloauthor=C.+Morosiauthor=F.+G.+Grecoauthor=A.+Gronchiauthor=M.+Barisellaauthor=P.+Colliniauthor=N.+Zaffaroniauthor=G.+P.+Dagradaauthor=A.+M.+Frezzaauthor=L.+Marianiauthor=P.+G.+Casali&title=Activity+of+Axitinib+in+Progressive+Advanced+Solitary+Fibrous+Tumour%3A+Results+from+an+Exploratory%2C+Investigator-Driven+Phase+2+Clinical+Study&doi=10.1016%2Fj.ejca.2018.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study</span></div><div class="casAuthors">Stacchiotti, S.; Simeone, N.; Lo Vullo, S.; Morosi, C.; Greco, F. G.; Gronchi, A.; Barisella, M.; Collini, P.; Zaffaroni, N.; Dagrada, G. P.; Frezza, A. M.; Mariani, L.; Casali, P. G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">225-233</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To explore the activity of axitinib in advanced solitary fibrous tumor (SFT).In this investigator-driven phase II study on axitinib in advanced and progressive SFT, patients received axitinib, 5 mg bis in day (BID), until progression or limiting toxicity.  Pathol. diagnosis was centrally reviewed, distinguishing malignant SFT (M-SFT) and high-grade/dedifferentiated SFT (HG/D-SFT) subtypes.  The primary end-point was the overall response rate (ORR) by Choi criteria (Choi).  Secondary end-points were response by Response Evaluation Criteria in Solid Tumors (RECIST), progression-free survival (PFS) and overall survival (OS).From Apr. 2015 and Oct. 2017, 17 eligible patients entered the study (metastatic: 17; SFT subtype: 13 M-SFT, 4 HG/D-SFT; prior treatment: 9 antiangiogenics, 5 cytotoxics).  All patients were evaluable for response.  The best Choi response was seven partial response (PR) (ORR, 41.2%), six stable disease (SD) and four progressions.  Choi-ORR was 54% (7/13) when only M-SFTs were considered.  Four of seven responsive patients were pretreated with pazopanib.  No responses were detected in HG/D-SFT.  Best RECIST response was one PR (5.9%), 14 SD and two progressions.  Toxicity was as expected.  Median Choi-PFS was 5.1 (interquartile range [IQR]: 2.5-14.8) months.  Median Choi-PFS was 14.8 (IQR: 5.1-18.0) and 2.8 (IQR: 2.0-5.9) months for patients responsive and non-responsive by Choi, resp. (p = 0.0416).  At a 14.4-mo median follow-up, median OS was 25.3 mo.This study showed that axitinib is active in progressive advanced SFT.  One-half of patients carrying the malignant variant of the disease responded, with a >12-mo median progression arrest.  Responses were better detected with Choi and seen even in patients resistant to other antiangiogenics.  Tolerability was good.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp513UQk09o87Vg90H21EOLACvtfcHk0ljS7TvFbYvE8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlKmur%252FI&md5=98003e74d221bf4eea3fca05e06672fe</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2018.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2018.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DStacchiotti%26aufirst%3DS.%26aulast%3DSimeone%26aufirst%3DN.%26aulast%3DLo%2BVullo%26aufirst%3DS.%26aulast%3DMorosi%26aufirst%3DC.%26aulast%3DGreco%26aufirst%3DF.%2BG.%26aulast%3DGronchi%26aufirst%3DA.%26aulast%3DBarisella%26aufirst%3DM.%26aulast%3DCollini%26aufirst%3DP.%26aulast%3DZaffaroni%26aufirst%3DN.%26aulast%3DDagrada%26aufirst%3DG.%2BP.%26aulast%3DFrezza%26aufirst%3DA.%2BM.%26aulast%3DMariani%26aufirst%3DL.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DActivity%2520of%2520Axitinib%2520in%2520Progressive%2520Advanced%2520Solitary%2520Fibrous%2520Tumour%253A%2520Results%2520from%2520an%2520Exploratory%252C%2520Investigator-Driven%2520Phase%25202%2520Clinical%2520Study%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2019%26volume%3D106%26spage%3D225%26epage%3D233%26doi%3D10.1016%2Fj.ejca.2018.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konecny, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegram, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Untch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spehar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podratz, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D. J.</span></span> <span> </span><span class="NLM_article-title">Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1630</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-1182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1158%2F0008-5472.CAN-05-1182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16452222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVemsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1630-1639&issue=3&author=G.+E.+Konecnyauthor=M.+D.+Pegramauthor=N.+Venkatesanauthor=R.+Finnauthor=G.+Yangauthor=M.+Rahmehauthor=M.+Untchauthor=D.+W.+Rusnakauthor=G.+Speharauthor=R.+J.+Mullinauthor=B.+R.+Keithauthor=T.+M.+Gilmerauthor=M.+Bergerauthor=K.+C.+Podratzauthor=D.+J.+Slamon&title=Activity+of+the+Dual+Kinase+Inhibitor+Lapatinib+%28GW572016%29+against+HER-2-Overexpressing+and+Trastuzumab-Treated+Breast+Cancer+Cells&doi=10.1158%2F0008-5472.CAN-05-1182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells</span></div><div class="casAuthors">Konecny, Gottfried E.; Pegram, Mark D.; Venkatesan, Natarajan; Finn, Richard; Yang, Guorong; Rahmeh, Martina; Untch, Michael; Rusnak, David W.; Spehar, Glenn; Mullin, Robert J.; Keith, Barry R.; Gilmer, Tona M.; Berger, Mark; Podratz, Karl C.; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1630-1639</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases.  Here, we explore the therapeutic potential of lapatinib by testing its effect on tumor cell growth in a panel of 31 characterized human breast cancer cell lines, including trastuzumab-conditioned HER-2-pos. cell lines.  We further characterize its activity in combination with trastuzumab and analyze whether EGFR and HER-2 expression or changes induced in the activation of EGFR, HER-2, Raf, AKT, or extracellular signal-regulated kinase (ERK) are markers of drug activity.  We report that concn.-dependent antiproliferative effects of lapatinib were seen in all breast cancer cell lines tested but varied significantly between individual cell lines with up to 1,000-fold difference in the IC50s (range, 0.010-18.6 μmol/L).  Response to lapatinib was significantly correlated with HER-2 expression and its ability to inhibit HER-2, Raf, AKT, and ERK phosphorylation.  Long-term in vivo lapatinib studies were conducted with human breast cancer xenografts in athymic mice.  Treatment over 77 days resulted in a sustained and significant redn. in xenograft vol. compared with untreated controls.  For the combination of lapatinib plus trastuzumab, synergistic drug interactions were obsd. in four different HER-2-overexpressing cell lines.  Moreover, lapatinib retained significant in vitro activity against cell lines selected for long-term outgrowth (>9 mo) in trastuzumab-contg. (100 μg/mL) culture medium.  These observations provide a clear biol. rationale to test lapatinib as a single agent or in combination with trastuzumab in HER-2-overexpressing breast cancer and in patients with clin. resistance to trastuzumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1QJyAqugZmLVg90H21EOLACvtfcHk0lhikX4TPoUwNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVemsg%253D%253D&md5=f81c4f6671403021fce2df854c07e8c9</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-1182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-1182%26sid%3Dliteratum%253Aachs%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26aulast%3DPegram%26aufirst%3DM.%2BD.%26aulast%3DVenkatesan%26aufirst%3DN.%26aulast%3DFinn%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DRahmeh%26aufirst%3DM.%26aulast%3DUntch%26aufirst%3DM.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DSpehar%26aufirst%3DG.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DPodratz%26aufirst%3DK.%2BC.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DActivity%2520of%2520the%2520Dual%2520Kinase%2520Inhibitor%2520Lapatinib%2520%2528GW572016%2529%2520against%2520HER-2-Overexpressing%2520and%2520Trastuzumab-Treated%2520Breast%2520Cancer%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D3%26spage%3D1630%26epage%3D1639%26doi%3D10.1158%2F0008-5472.CAN-05-1182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doak, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobritzsch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span> <span> </span><span class="NLM_article-title">How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2312</span>– <span class="NLM_lpage">2327</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Cgu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2312-2327&issue=6&author=B.+C.+Doakauthor=J.+Zhengauthor=D.+Dobritzschauthor=J.+Kihlberg&title=How+Beyond+Rule+of+5+Drugs+and+Clinical+Candidates+Bind+to+Their+Targets&doi=10.1021%2Facs.jmedchem.5b01286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets</span></div><div class="casAuthors">Doak, Bradley C.; Zheng, Jie; Dobritzsch, Doreen; Kihlberg, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2312-2327</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve discovery of drugs for difficult targets, the opportunities of chem. space beyond the rule of 5 (bRo5) were examd. by retrospective anal. of a comprehensive set of structures for complexes between drugs and clin. candidates and their targets.  The anal. illustrates the potential of compds. far beyond rule of 5 space to modulate novel and difficult target classes that have large, flat, and groove-shaped binding sites.  However, ligand efficiencies are significantly reduced for flat- and groove-shape binding sites, suggesting that adjustments of how to use such metrics are required.  Ligands bRo5 appear to benefit from an appropriate balance between rigidity and flexibility to bind with sufficient affinity to their targets, with macrocycles and nonmacrocycles being found to have similar flexibility.  However, macrocycles were more disk- and spherelike, which may contribute to their superior binding to flat sites, while rigidification of nonmacrocycles lead to rodlike ligands that bind well to groove-shaped binding sites.  These insights should contribute to altering perceptions of what targets are considered "druggable" and provide support for drug design in beyond rule of 5 space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZD-h9VodiPLVg90H21EOLACvtfcHk0lhikX4TPoUwNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Cgu77F&md5=a417b605d1a3ffbc7ee84706401f01f4</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01286%26sid%3Dliteratum%253Aachs%26aulast%3DDoak%26aufirst%3DB.%2BC.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DDobritzsch%26aufirst%3DD.%26aulast%3DKihlberg%26aufirst%3DJ.%26atitle%3DHow%2520Beyond%2520Rule%2520of%25205%2520Drugs%2520and%2520Clinical%2520Candidates%2520Bind%2520to%2520Their%2520Targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D6%26spage%3D2312%26epage%3D2327%26doi%3D10.1021%2Facs.jmedchem.5b01286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basten, J. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dinther, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boeckel, C. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boom, J. H.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of a Novel Synthetic Napap-Penta-Saccharide Conjugate Displaying a Dual Antithrombotic Action</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2013</span>– <span class="NLM_lpage">2018</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(99)00320-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0960-894X%2899%2900320-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10450972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK1MXltVChtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=2013-2018&issue=14&author=R.+C.+Buijsmanauthor=J.+E.+M.+Bastenauthor=T.+G.+van+Dintherauthor=G.+A.+van+der+Marelauthor=C.+A.+A.+van+Boeckelauthor=J.+H.+van+Boom&title=Design+and+Synthesis+of+a+Novel+Synthetic+Napap-Penta-Saccharide+Conjugate+Displaying+a+Dual+Antithrombotic+Action&doi=10.1016%2FS0960-894X%2899%2900320-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of a novel synthetic NAPAP-pentasaccharide conjugate displaying a dual antithrombotic action</span></div><div class="casAuthors">Buijsman, Rogier C.; Basten, Jan E. M.; Van Dinther, Theo G.; Van der Marel, Gijsbert A.; Van Boeckel, Constant A. A.; Van Boom, Jacques H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2013-2018</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The synthesis of a novel antithrombotic consisting of a heparin pentasaccharide conjugated to the active site inhibitor N-(2-naphtalenesulfonyl)-glycyl-(D)-4-aminophenyl-alanyl-piperidine (NAPAP) (I) is reported.  This conjugate shows a unique pharmacol. profile both in vitro and in vivo having direct anti-thrombin and ATIII-mediated anti-Xa activity.  Furthermore, conjugate I has a prolonged in vivo half-life compared to NAPAP (1.5 h vs 9 min.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp03SwXZa8FfrVg90H21EOLACvtfcHk0liOHYioKTC0sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVChtb0%253D&md5=617ef74eba7661c4dc883c76dac2b91d</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900320-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900320-0%26sid%3Dliteratum%253Aachs%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DBasten%26aufirst%3DJ.%2BE.%2BM.%26aulast%3Dvan%2BDinther%26aufirst%3DT.%2BG.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3Dvan%2BBoeckel%26aufirst%3DC.%2BA.%2BA.%26aulast%3Dvan%2BBoom%26aufirst%3DJ.%2BH.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520a%2520Novel%2520Synthetic%2520Napap-Penta-Saccharide%2520Conjugate%2520Displaying%2520a%2520Dual%2520Antithrombotic%2520Action%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26issue%3D14%26spage%3D2013%26epage%3D2018%26doi%3D10.1016%2FS0960-894X%2899%2900320-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, A.</span></span> <span> </span><span class="NLM_article-title">From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.2174/092986708783503212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F092986708783503212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18288997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVyisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=422-432&issue=5&author=S.+Giordanoauthor=A.+Petrelli&title=From+Single-+to+Multi-Target+Drugs+in+Cancer+Therapy%3A+When+Aspecificity+Becomes+an+Advantage&doi=10.2174%2F092986708783503212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">From single- to multi-target drugs in cancer therapy: when a specificity becomes an advantage</span></div><div class="casAuthors">Petrelli, A.; Giordano, S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">422-432</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeted therapies by means of compds. that inhibit a specific target mol. represent a new perspective in the treatment of cancer.  In contrast to conventional chemotherapy which acts on all dividing cells generating toxic effects and damage of normal tissues, targeted drugs allow to hit, in a more specific manner, subpopulations of cells directly involved in tumor progression.  Mols. controlling cell proliferation and death, such as Tyrosine Kinase Receptors (RTKs) for growth factors, are among the best targets for this type of therapeutic approach.  Two classes of compds. targeting RTKs are currently used in clin. practice: monoclonal antibodies and tyrosine kinase inhibitors.  The era of targeted therapy began with the approval of Trastuzumab, a monoclonal antibody against HER2, for treatment of metastatic breast cancer, and Imatinib, a small tyrosine kinase inhibitor targeting BCR-Abl, in Chronic Myeloid Leukemia.  Despite the initial enthusiasm for the efficacy of these treatments, clinicians had to face soon the problem of relapse, as almost invariably cancer patients developed drug resistance, often due to the activation of alternative RTKs pathways.  In this view, the rationale at the basis of targeting drugs is radically shifting.  In the past, the main effort was aimed at developing highly specific inhibitors acting on single RTKs.  Now, there is a general agreement that mols. interfering simultaneously with multiple RTKs might be more effective than single target agents.  With the recent approval by FDA of Sorafenib and Sunitinib - targeting VEGFR, PDGFR, FLT-3 and c-Kit - a different scenario has been emerging, where a new generation of anti-cancer drugs, able to inhibit more than one pathway, would probably play a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8AXb2ROTStLVg90H21EOLACvtfcHk0liOHYioKTC0sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVyisL0%253D&md5=d90df6a670921b6fad58caa46db01fa5</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.2174%2F092986708783503212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708783503212%26sid%3Dliteratum%253Aachs%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DPetrelli%26aufirst%3DA.%26atitle%3DFrom%2520Single-%2520to%2520Multi-Target%2520Drugs%2520in%2520Cancer%2520Therapy%253A%2520When%2520Aspecificity%2520Becomes%2520an%2520Advantage%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26issue%3D5%26spage%3D422%26epage%3D432%26doi%3D10.2174%2F092986708783503212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S.</span></span> <span> </span><span class="NLM_article-title">Targeting the Cancer Epigenome for Therapy</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">630</span>– <span class="NLM_lpage">641</span>, <span class="refDoi"> DOI: 10.1038/nrg.2016.93</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrg.2016.93" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27629931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWiu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=630-641&author=P.+A.+Jonesauthor=J.+P.+J.+Issaauthor=S.+Baylin&title=Targeting+the+Cancer+Epigenome+for+Therapy&doi=10.1038%2Fnrg.2016.93"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer epigenome for therapy</span></div><div class="casAuthors">Jones, Peter A.; Issa, Jean-Pierre J.; Baylin, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">630-641</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Next-generation sequencing has revealed that more than 50% of human cancers harbor mutations in enzymes that are involved in chromatin organization.  Tumor cells not only are activated by genetic and epigenetic alterations, but also routinely use epigenetic processes to ensure their escape from chemotherapy and host immune surveillance.  Hence, a growing emphasis of recent drug discovery efforts has been on targeting the epigenome, including DNA methylation and histone modifications, with several new drugs being tested and some already approved by the US Food and Drug Administration (FDA).  The future will see the increasing success of combining epigenetic drugs with other therapies.  As epigenetic drugs target the epigenome as a whole, these true 'genomic medicines' lessen the need for precision approaches to individualized therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5pfbPOnZMtbVg90H21EOLACvtfcHk0liT-dxHrDRcew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWiu77O&md5=22d98e58a4637d61af34a382e92adace</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1038%2Fnrg.2016.93&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg.2016.93%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%2BA.%26aulast%3DIssa%26aufirst%3DJ.%2BP.%2BJ.%26aulast%3DBaylin%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520Cancer%2520Epigenome%2520for%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2016%26volume%3D17%26spage%3D630%26epage%3D641%26doi%3D10.1038%2Fnrg.2016.93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+Deacetylases+and+Their+Inhibitors+in+Cancer%2C+Neurological+Diseases+and+Immune+Disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0liT-dxHrDRcew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520Deacetylases%2520and%2520Their%2520Inhibitors%2520in%2520Cancer%252C%2520Neurological%2520Diseases%2520and%2520Immune%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezzeldin, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diasio, R. B.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1934</span>, <span class="refDoi"> DOI: 10.2165/11315680-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2165%2F11315680-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19747008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOrsLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1911-1934&issue=14&author=X.+Maauthor=H.+H.+Ezzeldinauthor=R.+B.+Diasio&title=Histone+Deacetylase+Inhibitors&doi=10.2165%2F11315680-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: current status and overview of recent clinical trials</span></div><div class="casAuthors">Ma, Xujun; Ezzeldin, Hany H.; Diasio, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1934</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are a new group of anticancer agents that have a potential role in the regulation of gene expression, induction of cell death, apoptosis and cell cycle arrest of cancer cells by altering the acetylation status of chromatin and other non-histone proteins.  In clin. trials, HDAC inhibitors have demonstrated promising antitumor activity as monotherapy in cutaneous T-cell lymphoma and other haematol. malignancies.  In solid tumors, several HDAC inhibitors have been shown to be efficacious as single agents; however, results of most clin. trials were in favor of using HDAC inhibitors either prior to the initiation of chemotherapy or in combination with other treatments.  Currently, the mol. basis of response to HDAC inhibitors in patients is not fully understood.  In this review, we summarize the current status of HDAC inhibitors, as single agents or in combination with other agents in different phases of clin. trials.  In most of the clin. trials, HDAC inhibitors were tolerable and exerted biol. or antitumor activity.  HDAC inhibitors have been studied in phase I, II and III clin. trials with variable efficacy.  The combination of HDAC inhibitors with other anticancer agents including epigenetic or chemotherapeutic agents demonstrated favorable clin. outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdv-nIzRilyLVg90H21EOLACvtfcHk0ljzxPuAjPtOKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOrsLbI&md5=7bffcf6f0627d58907d0e98085f4bdf5</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.2165%2F11315680-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11315680-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%26aulast%3DEzzeldin%26aufirst%3DH.%2BH.%26aulast%3DDiasio%26aufirst%3DR.%2BB.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%26jtitle%3DDrugs%26date%3D2009%26volume%3D69%26issue%3D14%26spage%3D1911%26epage%3D1934%26doi%3D10.2165%2F11315680-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Vorinostat</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/nrd2227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd2227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17269160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=21-22&author=S.+Grantauthor=C.+Easleyauthor=P.+Kirkpatrick&title=Vorinostat&doi=10.1038%2Fnrd2227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat</span></div><div class="casAuthors">Grant, Steven; Easley, Chris; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-22</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYtFgooxRrcbVg90H21EOLACvtfcHk0ljzxPuAjPtOKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfK&md5=4017dcf775971088e24fca37e8a369af</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fnrd2227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2227%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DEasley%26aufirst%3DC.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DVorinostat%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D21%26epage%3D22%26doi%3D10.1038%2Fnrd2227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poole, R. M.</span></span> <span> </span><span class="NLM_article-title">Belinostat: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0275-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1007%2Fs40265-014-0275-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25134672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtl2nsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1543-1554&issue=13&author=R.+M.+Poole&title=Belinostat%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0275-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Belinostat: First Global Approval</span></div><div class="casAuthors">Poole, Raewyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1543-1554</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Belinostat [Beleodaq (US)], a small-mol. hydroxamate-type inhibitor of class I, II and IV histone deacetylase (HDAC) enzymes, has been developed by TopoTarget and Spectrum Pharmaceuticals for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).  Belinostat has received its first global approval as monotherapy for this indication in the US, under the Food and Drug Administration's accelerated approval program.  This article summarizes the milestones in the development of belinostat leading to this first approval for the treatment of PTCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm9C6yBRy7Q7Vg90H21EOLACvtfcHk0ljzxPuAjPtOKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtl2nsrzL&md5=b8bc6efe62e7fd78d6a9d022a8d96559</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0275-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0275-8%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%2BM.%26atitle%3DBelinostat%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26issue%3D13%26spage%3D1543%26epage%3D1554%26doi%3D10.1007%2Fs40265-014-0275-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vandermolen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberlies, N. H.</span></span> <span> </span><span class="NLM_article-title">Romidepsin (Istodax, NSC 630176, FR901228, FK228, Depsipeptide): A Natural Product Recently Approved for Cutaneous T-Cell Lymphoma</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1038/ja.2011.35</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fja.2011.35" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21587264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC3MjptFWqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2011&pages=525-531&author=K.+M.+Vandermolenauthor=W.+McCullochauthor=C.+J.+Pearceauthor=N.+H.+Oberlies&title=Romidepsin+%28Istodax%2C+NSC+630176%2C+FR901228%2C+FK228%2C+Depsipeptide%29%3A+A+Natural+Product+Recently+Approved+for+Cutaneous+T-Cell+Lymphoma&doi=10.1038%2Fja.2011.35"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma</span></div><div class="casAuthors">VanderMolen Karen M; McCulloch William; Pearce Cedric J; Oberlies Nicholas H</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of antibiotics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">525-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Romidepsin (Istodax), a selective inhibitor of histone deacetylases (HDACs), was approved for the treatment of cutaneous T-cell lymphoma in November 2009 by the US Food and Drug Administration.  This unique natural product was discovered from cultures of Chromobacterium violaceum, a Gram-negative bacterium isolated from a Japanese soil sample.  This bicyclic compound acts as a prodrug, its disulfide bridge being reduced by glutathione on uptake into the cell, allowing the free thiol groups to interact with Zn ions in the active site of class I and II HDAC enzymes.  Due to the synthetic complexity of the compound, as well as the low yield from the producing organism, analogs are sought to create synthetically accessible alternatives.  As a T-cell lymphoma drug, romidepsin offers a valuable new treatment for diseases with few effective therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6-aG7G4t02v69nzq6467DfW6udTcc2eY2wLHlXRkBALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjptFWqtg%253D%253D&md5=7d9d400857a6cf11cfe1f58acf5c1558</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fja.2011.35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2011.35%26sid%3Dliteratum%253Aachs%26aulast%3DVandermolen%26aufirst%3DK.%2BM.%26aulast%3DMcCulloch%26aufirst%3DW.%26aulast%3DPearce%26aufirst%3DC.%2BJ.%26aulast%3DOberlies%26aufirst%3DN.%2BH.%26atitle%3DRomidepsin%2520%2528Istodax%252C%2520NSC%2520630176%252C%2520FR901228%252C%2520FK228%252C%2520Depsipeptide%2529%253A%2520A%2520Natural%2520Product%2520Recently%2520Approved%2520for%2520Cutaneous%2520T-Cell%2520Lymphoma%26jtitle%3DJ.%2520Antibiot.%26date%3D2011%26volume%3D64%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fja.2011.35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floresta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monciino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span> <span> </span><span class="NLM_article-title">The Search for Potent, Small-Molecule Hdacis in Cancer Treatment: A Decade after Vorinostat</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1373</span>– <span class="NLM_lpage">1428</span>, <span class="refDoi"> DOI: 10.1002/med.21437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fmed.21437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28181261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1373-1428&issue=6&author=C.+Zagniauthor=G.+Florestaauthor=G.+Monciinoauthor=A.+Rescifina&title=The+Search+for+Potent%2C+Small-Molecule+Hdacis+in+Cancer+Treatment%3A+A+Decade+after+Vorinostat&doi=10.1002%2Fmed.21437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat</span></div><div class="casAuthors">Zagni Chiara; Floresta Giuseppe; Monciino Giulia; Rescifina Antonio; Floresta Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1373-1428</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression.  In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases.  Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T-cell lymphoma.  This review provides an overview of current knowledge, progress, and molecular mechanisms of HDACIs, covering a period from 2011 until 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPT4s_HXWveWmbXvSEQle5fW6udTcc2eY2wLHlXRkBALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D&md5=79f4fe123e5ee6ba072e9147536fab67</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1002%2Fmed.21437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21437%26sid%3Dliteratum%253Aachs%26aulast%3DZagni%26aufirst%3DC.%26aulast%3DFloresta%26aufirst%3DG.%26aulast%3DMonciino%26aufirst%3DG.%26aulast%3DRescifina%26aufirst%3DA.%26atitle%3DThe%2520Search%2520for%2520Potent%252C%2520Small-Molecule%2520Hdacis%2520in%2520Cancer%2520Treatment%253A%2520A%2520Decade%2520after%2520Vorinostat%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26issue%3D6%26spage%3D1373%26epage%3D1428%26doi%3D10.1002%2Fmed.21437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaempf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rofelty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolosky, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span> <span> </span><span class="NLM_article-title">Molecularly Targeted Drug Combinations Demonstrate Selective Effectiveness for Myeloid- and Lymphoid-Derived Hematologic Malignancies</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">E7554</span>– <span class="NLM_lpage">E7563</span>, <span class="refDoi"> DOI: 10.1073/pnas.1703094114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1073%2Fpnas.1703094114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28784769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yku7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=E7554-E7563&issue=36&author=S.+E.+Kurtzauthor=C.+A.+Eideauthor=A.+Kaempfauthor=V.+Khannaauthor=S.+L.+Savageauthor=A.+Rofeltyauthor=I.+Englishauthor=H.+Hoauthor=R.+Pandyaauthor=W.+J.+Boloskyauthor=H.+Poonauthor=M.+W.+Deiningerauthor=R.+Collinsauthor=R.+T.+Swordsauthor=J.+Wattsauthor=D.+A.+Pollyeaauthor=B.+C.+Medeirosauthor=E.+Traerauthor=C.+E.+Tognonauthor=M.+Moriauthor=B.+J.+Drukerauthor=J.+W.+Tyner&title=Molecularly+Targeted+Drug+Combinations+Demonstrate+Selective+Effectiveness+for+Myeloid-+and+Lymphoid-Derived+Hematologic+Malignancies&doi=10.1073%2Fpnas.1703094114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies</span></div><div class="casAuthors">Kurtz, Stephen E.; Eide, Christopher A.; Kaempf, Andy; Khanna, Vishesh; Savage, Samantha L.; Rofelty, Angela; English, Isabel; Ho, Hibery; Pandya, Ravi; Bolosky, William J.; Poon, Hoifung; Deininger, Michael W.; Collins, Robert; Swords, Ronan T.; Watts, Justin; Pollyea, Daniel A.; Medeiros, Bruno C.; Traer, Elie; Tognon, Cristina E.; Mori, Motomi; Druker, Brian J.; Tyner, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">E7554-E7563</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Translating the genetic and epigenetic heterogeneity underlying human cancers into therapeutic strategies is an ongoing challenge.  Large-scale sequencing efforts have uncovered a spectrum of mutations in many hematol. malignancies, including acute myeloid leukemia (AML), suggesting that combinations of agents will be required to treat these diseases effectively.  Combinatorial approaches will also be crit. for combating the emergence of genetically heterogeneous subclones, rescue signals in the microenvironment, and tumor-intrinsic feedback pathways that all contribute to disease relapse.  To identify novel and effective drug combinations, the authors performed ex vivo sensitivity profiling of 122 primary patient samples from a variety of hematol. malignancies against a panel of 48 drug combinations.  The combinations were designed as drug pairs that target nonoverlapping biol. pathways and comprise drugs from different classes, preferably with Food and Drug Administration approval.  A combination ratio (CR) was derived for each drug pair, and CRs were evaluated with respect to diagnostic categories as well as against genetic, cytogenetic, and cellular phenotypes of specimens from the two largest disease categories: AML and chronic lymphocytic leukemia (CLL).  Nearly all tested combinations involving a BCL2 inhibitor showed addnl. benefit in patients with myeloid malignancies, whereas select combinations involving PI3K, CSF1R, or bromodomain inhibitors showed preferential benefit in lymphoid malignancies.  Expanded analyses of patients with AML and CLL revealed specific patterns of ex vivo drug combination efficacy that were assocd. with select genetic, cytogenetic, and phenotypic disease subsets, warranting further evaluation.  These findings highlight the heuristic value of an integrated functional genomic approach to the identification of novel treatment strategies for hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS5BseZMmHHrVg90H21EOLACvtfcHk0liKQLpZKnqVIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yku7jI&md5=1a8ece4125f7a943cffe2066b4d9b0ed</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1703094114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1703094114%26sid%3Dliteratum%253Aachs%26aulast%3DKurtz%26aufirst%3DS.%2BE.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DKaempf%26aufirst%3DA.%26aulast%3DKhanna%26aufirst%3DV.%26aulast%3DSavage%26aufirst%3DS.%2BL.%26aulast%3DRofelty%26aufirst%3DA.%26aulast%3DEnglish%26aufirst%3DI.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DPandya%26aufirst%3DR.%26aulast%3DBolosky%26aufirst%3DW.%2BJ.%26aulast%3DPoon%26aufirst%3DH.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DWatts%26aufirst%3DJ.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26aulast%3DTraer%26aufirst%3DE.%26aulast%3DTognon%26aufirst%3DC.%2BE.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26atitle%3DMolecularly%2520Targeted%2520Drug%2520Combinations%2520Demonstrate%2520Selective%2520Effectiveness%2520for%2520Myeloid-%2520and%2520Lymphoid-Derived%2520Hematologic%2520Malignancies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26issue%3D36%26spage%3DE7554%26epage%3DE7563%26doi%3D10.1073%2Fpnas.1703094114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamand, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butrynski, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornicek, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Phase 1 Study of Oral Abexinostat, a Histone Deacetylase Inhibitor, in Combination with Doxorubicin in Patients with Metastatic Sarcoma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1223</span>– <span class="NLM_lpage">1230</span>, <span class="refDoi"> DOI: 10.1002/cncr.29175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fcncr.29175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25536954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlCmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=1223-1230&issue=8&author=E.+Choyauthor=Y.+Flamandauthor=S.+Balasubramanianauthor=J.+E.+Butrynskiauthor=D.+C.+Harmonauthor=S.+Georgeauthor=G.+M.+Coteauthor=A.+J.+Wagnerauthor=J.+A.+Morganauthor=M.+Sirisawadauthor=C.+Maniauthor=F.+J.+Hornicekauthor=Z.+Duanauthor=G.+D.+demetri&title=Phase+1+Study+of+Oral+Abexinostat%2C+a+Histone+Deacetylase+Inhibitor%2C+in+Combination+with+Doxorubicin+in+Patients+with+Metastatic+Sarcoma&doi=10.1002%2Fcncr.29175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma</span></div><div class="casAuthors">Choy, Edwin; Flamand, Yael; Balasubramanian, Sriram; Butrynski, James E.; Harmon, David C.; George, Suzanne; Cote, Gregory M.; Wagner, Andrew J.; Morgan, Jeffrey A.; Sirisawad, Mint; Mani, Chitra; Hornicek, Francis J.; Duan, Zhenfeng; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1223-1230</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : It has been demonstrated that several inhibitors of histone deacetylase (HDAC) can enhance chemotherapy-induced apoptosis and reduce sarcoma tumor vol. in preclin. models.  The authors sought to det. the max. tolerated dose, pharmacokinetics/pharmacodynamics, safety, and toxicity of the HDAC inhibitor abexinostat (PCI-24781) when administered with doxorubicin to patients with metastatic sarcomas.  METHODS : Participants were enrolled in a std., phase 1, 3 + 3, dose-escalation study design.  Abexinostat was administered on days 1 through 5 with 75 mg/m2 of doxorubicin administered on day 4 of every 21-day cycle until patients developed disease progression or drug intolerance or reached a cumulative lifetime doxorubicin dose of 450 mg/m2.  Granulocyte-colony-stimulating factor (G-CSF) support was provided at physician discretion on arm A and was provided to all participants in arm B. From 3 to 6 participants initially received abexinostat 30 mg/m2 twice daily, and subsequent cohorts were administered doses of 15 mg/m2, 45 mg/m2, or 60 mg/m2 twice daily.  All patients without progressive disease after receiving a cumulative lifetime doxorubicin dose of 450 mg/m2 were given the option to continue with abexinostat as a single agent until they developed disease progression.  RESULTS : In total, 22 participants (10 who had previously experienced tumor growth after doxorubicin therapy) were enrolled (6 in arm A, 14 in arm B), 20 were evaluable for dose-limiting toxicity (DLT), and 17 were evaluable for radiol. response.  In arm A, participants received abexinostat 15 mg/m2 or 30 mg/m2 twice daily.  DLTs of grade 3 and 4 neutropenia were obsd. in 2 of 3 participants who received abexinostat 30 mg/m2 twice daily.  Neither of those patients received G-CSF prophylaxis.  In arm B, participants received abexinostat at doses of 30 mg/m2, 45 mg/m2, or 60 mg/m2 twice daily, all with mandated G-CSF support.  Two DLTs were obsd. at the 60 mg/m2 twice-daily dose (grade 3 infection, grade 4 thrombocytopenia).  The pharmacokinetics of abexinostat were not affected by doxorubicin.  HDAC activity, as measured by histone acetylation in peripheral blood mononuclear cells, was maximally inhibited at the abexinostat 30 mg/m2 twice-daily dose.  Of the 17 participants who were evaluable for radiol. response, 1 patient had a partial response, 9 patients had stable disease, and 7 patients had progressive disease as their best response; and 8 patients completed ≥5 cycles.  Three of those participants had stable disease as their most recent disease status when the current report was written.  Four participants who continued on monotherapy remained in stable disease for a median of 9.8 wk after completing doxorubicin.  The most common toxicities were fatigue, thrombocytopenia, and anemia.  No study-related deaths were obsd.  CONCLUSIONS : The max. tolerated dose for abexinostat was 45 mg/m2 twice daily administered on days 1 through 5 when patients received doxorubicin 75 mg/m2 on day 4 of a 3-wk cycle and G-CSF support was mandated.  Toxicities were manageable, and tumor responses were obsd.  Addnl. studies are needed to further define the specific contributions of HDAC inhibition in patients who receive doxorubicin for the treatment of metastatic sarcoma.  Cancer 2015;121:1223-1230. cpr 2014 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXHVb_DjNZbVg90H21EOLACvtfcHk0liKQLpZKnqVIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlCmt7w%253D&md5=f07b212088bc2e919656a3737feee3ef</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29175%26sid%3Dliteratum%253Aachs%26aulast%3DChoy%26aufirst%3DE.%26aulast%3DFlamand%26aufirst%3DY.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DButrynski%26aufirst%3DJ.%2BE.%26aulast%3DHarmon%26aufirst%3DD.%2BC.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DCote%26aufirst%3DG.%2BM.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DMani%26aufirst%3DC.%26aulast%3DHornicek%26aufirst%3DF.%2BJ.%26aulast%3DDuan%26aufirst%3DZ.%26aulast%3Ddemetri%26aufirst%3DG.%2BD.%26atitle%3DPhase%25201%2520Study%2520of%2520Oral%2520Abexinostat%252C%2520a%2520Histone%2520Deacetylase%2520Inhibitor%252C%2520in%2520Combination%2520with%2520Doxorubicin%2520in%2520Patients%2520with%2520Metastatic%2520Sarcoma%26jtitle%3DCancer%26date%3D2015%26volume%3D121%26issue%3D8%26spage%3D1223%26epage%3D1230%26doi%3D10.1002%2Fcncr.29175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2034</span>– <span class="NLM_lpage">2042</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1158%2F1535-7163.MCT-11-0433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22072815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2034-2042&issue=11&author=T.+Hideshimaauthor=P.+G.+Richardsonauthor=K.+C.+Anderson&title=Mechanism+of+Action+of+Proteasome+Inhibitors+and+Deacetylase+Inhibitors+and+the+Biological+Basis+of+Synergy+in+Multiple+Myeloma&doi=10.1158%2F1535-7163.MCT-11-0433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma</span></div><div class="casAuthors">Hideshima, Teru; Richardson, Paul G.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2034-2042</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Novel agents, including the proteasome inhibitor bortezomib, have significantly improved the response and survival of patients with multiple myeloma over the last decade.  Despite these advances, many patients relapse or do not benefit from the currently available therapies; thus, multiple myeloma remains an incurable disease.  Deacetylase inhibitors (DACi), including panobinostat and vorinostat, have recently emerged as novel agents being evaluated in the treatment of multiple myeloma.  Deacetylases are a group of enzymes with effects on various intracellular proteins, including histones, transcription factors, and mol. chaperones.  Although DACi inhibit cell growth and induce apoptosis in multiple myeloma cells as a single agent, synergistic activity has been obsd. when they were used in combination with bortezomib.  The mechanistic basis of synergy is multifactorial and includes disruption of protein degrdn. and inhibition of the interaction of multiple myeloma cells with the tumor microenvironment.  This review summarizes recent advancements in the understanding of the mechanism of action of proteasome inhibitors and DACi in multiple myeloma and examines the biol. basis of their synergistic effects.  Data from the studies summarized here have been used as the rationale for the implementation of phase II and III clin. trials of DACi, alone and combined with bortezomib, in relapsed and refractory multiple myeloma.  Mol Cancer Ther; 10(11); 2034-42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWTic1RyTJsbVg90H21EOLACvtfcHk0lgfbulZIfsZzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbJ&md5=741285acef164545c3388037dc42f73f</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0433%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DMechanism%2520of%2520Action%2520of%2520Proteasome%2520Inhibitors%2520and%2520Deacetylase%2520Inhibitors%2520and%2520the%2520Biological%2520Basis%2520of%2520Synergy%2520in%2520Multiple%2520Myeloma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26issue%3D11%26spage%3D2034%26epage%3D2042%26doi%3D10.1158%2F1535-7163.MCT-11-0433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Booth, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poklepovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, P.</span></span> <span> </span><span class="NLM_article-title">The HDAC Inhibitor Ar42 Interacts with Pazopanib to Kill Trametinib/Dabrafenib-Resistant Melanoma Cells in Vitro and in Vivo</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">16367</span>– <span class="NLM_lpage">16386</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.18632%2Foncotarget.14829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28146421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC1c3hs1ensg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=16367-16386&issue=10&author=L.+Boothauthor=J.+L.+Robertsauthor=C.+Sanderauthor=J.+Leeauthor=J.+M.+Kirkwoodauthor=A.+Poklepovicauthor=P.+Dent&title=The+HDAC+Inhibitor+Ar42+Interacts+with+Pazopanib+to+Kill+Trametinib%2FDabrafenib-Resistant+Melanoma+Cells+in+Vitro+and+in+Vivo&doi=10.18632%2Foncotarget.14829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo</span></div><div class="casAuthors">Booth Laurence; Roberts Jane L; Dent Paul; Sander Cindy; Kirkwood John M; Lee John; Poklepovic Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">16367-16386</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Studies focused on the killing of activated B-RAF melanoma cells by the histone deacetylase (HDAC) inhibitor AR42.  Compared to other tumor cell lines, PDX melanoma isolates were significantly more sensitive to AR42-induced killing.  AR42 and the multi-kinase inhibitor pazopanib interacted to activate: an eIF2α-Beclin1 pathway causing autophagosome formation; an eIF2α-DR4/DR5/CD95 pathway; and an eIF2α-dependent reduction in the expression of c-FLIP-s, MCL-1 and BCL-XL.  AR42 did not alter basal chaperone activity but increased the ability of pazopanib to inhibit HSP90, HSP70 and GRP78.  AR42 and pazopanib caused HSP90/HSP70 dissociation from RAF-1 and B-RAF that resulted in reduced 'RAF' expression.  The drug combination activated a DNA-damage-ATM-AMPK pathway that was associated with: NFκB activation; reduced mTOR S2448 and ULK-1 S757 phosphorylation; and increased ULK-1 S317 and ATG13 S318 phosphorylation.  Knock down of PERK, eIF2α, Beclin1, ATG5 or AMPKα, or expression of IκB S32A S36A, ca-mTOR or TRX, reduced cell killing.  AR42, via lysosomal degradation, reduced the protein expression of HDACs 2/5/6/10/11.  In vivo, a 3-day exposure of dabrafenib/trametinib resistant melanoma cells to the AR42 pazopanib combination reduced tumor growth and enhanced survival from ~25 to ~40 days.  Tumor cells that had adapted through therapy exhibited elevated HGF expression and the c-MET inhibitor crizotinib enhanced AR42 pazopanib lethality in this evolved drug-resistant population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnL7dhQ2F3lw8IxFYvehhofW6udTcc2eZMyIUzi7hrRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3hs1ensg%253D%253D&md5=c3f08fc94db5e44b13b903fb366ec656</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14829%26sid%3Dliteratum%253Aachs%26aulast%3DBooth%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DJ.%2BL.%26aulast%3DSander%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DPoklepovic%26aufirst%3DA.%26aulast%3DDent%26aufirst%3DP.%26atitle%3DThe%2520HDAC%2520Inhibitor%2520Ar42%2520Interacts%2520with%2520Pazopanib%2520to%2520Kill%2520Trametinib%252FDabrafenib-Resistant%2520Melanoma%2520Cells%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D10%26spage%3D16367%26epage%3D16386%26doi%3D10.18632%2Foncotarget.14829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavallai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamed, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poklepovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, P.</span></span> <span> </span><span class="NLM_article-title">Pazopanib and HDAC Inhibitors Interact to Kill Sarcoma Cells</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.4161/cbt.28163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.4161%2Fcbt.28163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24556916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC2cvmvVWkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=578-585&issue=5&author=S.+Tavallaiauthor=H.+A.+Hamedauthor=S.+Grantauthor=A.+Poklepovicauthor=P.+Dent&title=Pazopanib+and+HDAC+Inhibitors+Interact+to+Kill+Sarcoma+Cells&doi=10.4161%2Fcbt.28163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Pazopanib and HDAC inhibitors interact to kill sarcoma cells</span></div><div class="casAuthors">Tavallai Seyedmehrad; Hamed Hossein A; Dent Paul; Grant Steven; Poklepovic Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer biology & therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">578-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The present studies were to determine whether the multi-kinase inhibitor pazopanib interacted with histone deacetylase inhibitors (HDACI: valproate, vorinostat) to kill sarcoma cells.  In multiple sarcoma cell lines, at clinically achievable doses, pazopanib and HDACI interacted in an additive to greater than additive fashion to cause tumor cell death.  The drug combination increased the numbers of LC3-GFP and LC3-RFP vesicles.  Knockdown of Beclin1 or ATG5 significantly suppressed drug combination lethality.  Expression of c-FLIP-s, and to a lesser extent BCL-XL or dominant negative caspase 9 reduced drug combination toxicity; knock down of FADD or CD95 was protective.  Expression of both activated AKT and activated MEK1 was required to strongly suppress drug combination lethality.  The drug combination inactivated mTOR and expression of activated mTOR strongly suppressed drug combination lethality.  Treatment of animals carrying sarcoma tumors with pazopanib and valproate resulted in a greater than additive reduction in tumor volume compared with either drug individually.  As both pazopanib and HDACIs are FDA-approved agents, our data argue for further determination as to whether this drug combination is a useful sarcoma therapy in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKYvhlH_G7rdXdcedVHT5tfW6udTcc2ebAEDpg_csFi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvmvVWkug%253D%253D&md5=b9875edef70fd1197911c61095330466</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.4161%2Fcbt.28163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.28163%26sid%3Dliteratum%253Aachs%26aulast%3DTavallai%26aufirst%3DS.%26aulast%3DHamed%26aufirst%3DH.%2BA.%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DPoklepovic%26aufirst%3DA.%26aulast%3DDent%26aufirst%3DP.%26atitle%3DPazopanib%2520and%2520HDAC%2520Inhibitors%2520Interact%2520to%2520Kill%2520Sarcoma%2520Cells%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2014%26volume%3D15%26issue%3D5%26spage%3D578%26epage%3D585%26doi%3D10.4161%2Fcbt.28163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2059</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1158%2F1078-0432.CCR-13-0279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24583800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2051-2059&issue=8&author=S.+C.+Meyerauthor=R.+L.+Levine&title=Molecular+Pathways%3A+Molecular+Basis+for+Sensitivity+and+Resistance+to+JAK+Kinase+Inhibitors&doi=10.1158%2F1078-0432.CCR-13-0279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span></div><div class="casAuthors">Meyer, Sara C.; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2059</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.  Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is assocd. with hematol. malignancies, autoimmune disorders, and immune-deficient conditions.  Genetic alterations of JAK2 occur in the majority of patients with myeloproliferative neoplasms and occur in a subset of patients with acute leukemias.  JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes.  Hyperactive JAK at the apex of these potent oncogenic signaling pathways therefore represents an important target for small-mol. kinase inhibitors in different disease states.  The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, resp., and addnl. ATP-competitive JAK inhibitors are in clin. development.  Although these agents show clin. activity, the ability of these JAK inhibitors to induce clin./mol. remissions in hematol. malignancies seems limited and resistance upon chronic drug exposure is seen.  Alternative modes of targeting JAK2 such as allosteric kinase inhibition or HSP90 inhibition are under evaluation, as is the use of histone deacetylase inhibitors.  Combination therapy approaches integrating inhibition of STAT, PI3K/Akt, and MAPK pathways with JAK kinase inhibitors might be crit. to overcome malignancies characterized by dysregulated JAK signaling.  Clin Cancer Res; 20(8); 2051-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgmYqhJDI07Vg90H21EOLACvtfcHk0lj-1fenXAzjFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D&md5=7c7ad00b5c8020fd660d86c057827eb2</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0279%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMolecular%2520Pathways%253A%2520Molecular%2520Basis%2520for%2520Sensitivity%2520and%2520Resistance%2520to%2520JAK%2520Kinase%2520Inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D8%26spage%3D2051%26epage%3D2059%26doi%3D10.1158%2F1078-0432.CCR-13-0279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ressing, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkhardt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span> <span> </span><span class="NLM_article-title">Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10299</span>– <span class="NLM_lpage">10309</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWrur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10299-10309&issue=22&author=S.+Bhatiaauthor=V.+Kriegerauthor=M.+Grollauthor=J.+D.+Oskoauthor=N.+Ressingauthor=H.+Ahlertauthor=A.+Borkhardtauthor=T.+Kurzauthor=D.+W.+Christiansonauthor=J.+Hauerauthor=F.+K.+Hansen&title=Discovery+of+the+First-in-Class+Dual+Histone+Deacetylase-Proteasome+Inhibitor&doi=10.1021%2Facs.jmedchem.8b01487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor</span></div><div class="casAuthors">Bhatia, Sanil; Krieger, Viktoria; Groll, Michael; Osko, Jeremy D.; Ressing, Nina; Ahlert, Heinz; Borkhardt, Arndt; Kurz, Thomas; Christianson, David W.; Hauer, Julia; Hansen, Finn K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10299-10309</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual- or multitarget drugs have emerged as a promising alternative to combination therapies.  Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase (HDAC) inhibitors due to the simultaneous blockage of the ubiquitin degrdn. and aggresome pathways.  Here, the authors present the design, synthesis, binding modes, and anticancer properties of RTS-V5 as the first-in-class dual HDAC-proteasome ligand.  The inhibition of both targets was confirmed by biochem. and cellular assays as well as x-ray crystal structures of the 20S proteasome and HDAC6 complexed with RTS-V5.  Cytotoxicity assays with leukemia and multiple myeloma cell lines as well as therapy refractory primary patient-derived leukemia cells demonstrated that RTS-V5 possesses potent and selective anticancer activity.  The results will thus guide the structure-based optimization of dual HDAC-proteasome inhibitors for the treatment of hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwJMqcDlzXA7Vg90H21EOLACvtfcHk0liqlBN4PB-b0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWrur7K&md5=7d47e664bd77ac1bc5ebd39ea6eed02a</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01487%26sid%3Dliteratum%253Aachs%26aulast%3DBhatia%26aufirst%3DS.%26aulast%3DKrieger%26aufirst%3DV.%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DRessing%26aufirst%3DN.%26aulast%3DAhlert%26aufirst%3DH.%26aulast%3DBorkhardt%26aufirst%3DA.%26aulast%3DKurz%26aufirst%3DT.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DHauer%26aufirst%3DJ.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26atitle%3DDiscovery%2520of%2520the%2520First-in-Class%2520Dual%2520Histone%2520Deacetylase-Proteasome%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D22%26spage%3D10299%26epage%3D10309%26doi%3D10.1021%2Facs.jmedchem.8b01487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallastegui, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arciniega, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillebrand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">Hydroxyureas as Noncovalent Proteasome Inhibitors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1002/anie.201106010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fanie.201106010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2rurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=247-249&issue=1&author=N.+Gallasteguiauthor=P.+Beckauthor=M.+Arciniegaauthor=R.+Huberauthor=S.+Hillebrandauthor=M.+Groll&title=Hydroxyureas+as+Noncovalent+Proteasome+Inhibitors&doi=10.1002%2Fanie.201106010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxyureas as Noncovalent Proteasome Inhibitors</span></div><div class="casAuthors">Gallastegui, Nerea; Beck, Philipp; Arciniega, Marcelino; Huber, Robert; Hillebrand, Stefan; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">247-249</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Inhibitors with a new mechanism of action are needed for 20S proteasome (CP) inhibition owing to the ineffectiveness of current market drugs against some types of solid tumors.  A novel class of nonpeptidic CP inhibitors has been developed, which display reversible and noncovalent binding.  The structure-based design of these highly active and site-specific inhibitors revealed unexplored binding subpockets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV0vwa018n0rVg90H21EOLACvtfcHk0liqlBN4PB-b0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2rurfI&md5=22dcc1101f70a3d4920f467240add238</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1002%2Fanie.201106010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201106010%26sid%3Dliteratum%253Aachs%26aulast%3DGallastegui%26aufirst%3DN.%26aulast%3DBeck%26aufirst%3DP.%26aulast%3DArciniega%26aufirst%3DM.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DHillebrand%26aufirst%3DS.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3DHydroxyureas%2520as%2520Noncovalent%2520Proteasome%2520Inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26issue%3D1%26spage%3D247%26epage%3D249%26doi%3D10.1002%2Fanie.201106010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigstad, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sappal, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J. L.</span></span> <span> </span><span class="NLM_article-title">Characterization of a New Series of Non-Covalent Proteasome Inhibitors with Exquisite Potency and Selectivity for the 20Sβ5-Subunit</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>430</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1042/BJ20100383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1042%2FBJ20100383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20632995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=461-476&issue=3&author=C.+Blackburnauthor=K.+M.+Gigstadauthor=P.+Halesauthor=K.+Garciaauthor=M.+Jonesauthor=F.+J.+Bruzzeseauthor=C.+Barrettauthor=J.+X.+Liuauthor=T.+A.+Soucyauthor=D.+S.+Sappalauthor=N.+Bumpauthor=E.+J.+Olhavaauthor=P.+Flemingauthor=L.+R.+Dickauthor=C.+Tsuauthor=M.+D.+Sintchakauthor=J.+L.+Blank&title=Characterization+of+a+New+Series+of+Non-Covalent+Proteasome+Inhibitors+with+Exquisite+Potency+and+Selectivity+for+the+20S%CE%B25-Subunit&doi=10.1042%2FBJ20100383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit</span></div><div class="casAuthors">Blackburn, Christopher; Gigstad, Kenneth M.; Hales, Paul; Garcia, Khristofer; Jones, Matthew; Bruzzese, Frank J.; Barrett, Cynthia; Liu, Jane X.; Soucy, Teresa A.; Sappal, Darshan S.; Bump, Nancy; Olhava, Edward J.; Fleming, Paul; Dick, Lawrence R.; Tsu, Christopher; Sintchak, Michael D.; Blank, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-476</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The mammalian 26S proteasome is a 2500 kDa multi-catalytic complex involved in intracellular protein degrdn.  The authors describe the synthesis and properties of a novel series of non-covalent di-peptide inhibitors of the proteasome based on a capped tripeptide that was first identified by high-throughput screening of a library of approx. 350000 compds. for inhibitors of the ubiquitin-proteasome system in cells.  It is shown that these compds. are entirely selective for the β5 (chymotrypsin-like) site over the β1 (caspase-like) and β2 (trypsin-like) sites of the 20S core particle of the proteasome, and over a panel of less closely related proteases.  Compd. optimization, guided by x-ray crystallog. of the liganded 20S core particle, confirmed their non-covalent binding mode and provided a structural basis for their enhanced in vitro and cellular potencies.  The authors demonstrate that such compds. show low nanomolar IC50 values for the human 20S β5 site in vitro, and that pharmacol. inhibition of this site in cells is sufficient to potently inhibit the degrdn. of a tetra-ubiquitin-luciferase reporter, activation of NFκB (nuclear factor κB) in response to TNF-α (tumor necrosis factor-α) and the proliferation of cancer cells.  Finally, the authors identified capped dipeptides that show differential selectivity for the β5 site of the constitutively expressed proteasome and immunoproteasome in vitro and in B-cell lymphomas.  Collectively, these studies describe the synthesis, activity and binding mode of a new series of non-covalent proteasome inhibitors with unprecedented potency and selectivity for the β5 site, and which can discriminate between the constitutive proteasome and immunoproteasome in vitro and in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodAundpO9R0LVg90H21EOLACvtfcHk0lgdWUXLtrnRrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtb3O&md5=de750c60263f0ec83961326ae2b94445</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1042%2FBJ20100383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100383%26sid%3Dliteratum%253Aachs%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DGigstad%26aufirst%3DK.%2BM.%26aulast%3DHales%26aufirst%3DP.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DBarrett%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%2BX.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DSappal%26aufirst%3DD.%2BS.%26aulast%3DBump%26aufirst%3DN.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DBlank%26aufirst%3DJ.%2BL.%26atitle%3DCharacterization%2520of%2520a%2520New%2520Series%2520of%2520Non-Covalent%2520Proteasome%2520Inhibitors%2520with%2520Exquisite%2520Potency%2520and%2520Selectivity%2520for%2520the%252020S%25CE%25B25-Subunit%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26issue%3D3%26spage%3D461%26epage%3D476%26doi%3D10.1042%2FBJ20100383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small Molecules Simultaneously Inhibiting P53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7245</span>– <span class="NLM_lpage">7260</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00664</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00664" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlykur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7245-7260&issue=16&author=S.+Heauthor=G.+Dongauthor=S.+Wuauthor=K.+Fangauthor=Z.+Miaoauthor=W.+Wangauthor=C.+Sheng&title=Small+Molecules+Simultaneously+Inhibiting+P53-Murine+Double+Minute+2+%28MDM2%29+Interaction+and+Histone+Deacetylases+%28HDACs%29%3A+Discovery+of+Novel+Multitargeting+Antitumor+Agents&doi=10.1021%2Facs.jmedchem.8b00664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Wu, Shanchao; Fang, Kun; Miao, Zhenyuan; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7245-7260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P53-Murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important targets in antitumor drug development.  Inspired by the synergistic effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors were identified, which showed excellent activities against both targets.  In particular, compd. 14d was proven to be a potent and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms were validated in cancer cells.  Compd. 14d showed excellent in vivo antitumor potency in the A549 xenograft model, providing a promising lead compd. for the development of novel antitumor agents.  Also, this proof-of-concept study offers a novel and efficient strategy for multitargeting antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx94Uvm3pP8bVg90H21EOLACvtfcHk0lgdWUXLtrnRrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlykur3L&md5=68871e41ecb786e135b01742e59eec85</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00664%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520Molecules%2520Simultaneously%2520Inhibiting%2520P53-Murine%2520Double%2520Minute%25202%2520%2528MDM2%2529%2520Interaction%2520and%2520Histone%2520Deacetylases%2520%2528HDACs%2529%253A%2520Discovery%2520of%2520Novel%2520Multitargeting%2520Antitumor%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D16%26spage%3D7245%26epage%3D7260%26doi%3D10.1021%2Facs.jmedchem.8b00664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vousden, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D. P.</span></span> <span> </span><span class="NLM_article-title">P53 in Health and Disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1038/nrm2147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrm2147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17380161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtlygsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=275-283&issue=4&author=K.+H.+Vousdenauthor=D.+P.+Lane&title=P53+in+Health+and+Disease&doi=10.1038%2Fnrm2147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">p53 in health and disease</span></div><div class="casAuthors">Vousden, Karen H.; Lane, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">275-283</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  As a component of the response to acute stress, p53 has a well established role in protecting against cancer development.  However, it is now becoming clear that p53 can have a much broader role and can contribute to the development, life expectancy and overall fitness of an organism.  Although the function of p53 as a tumor suppressor ensures that we can't live without it, an integrated view of p53 suggests that not all of its functions are conducive to a long and healthy life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoND8MaF-_GGbVg90H21EOLACvtfcHk0lirBXVmSL5Yhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtlygsr0%253D&md5=c39c719e12d6cb436786acb162101b28</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1038%2Fnrm2147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2147%26sid%3Dliteratum%253Aachs%26aulast%3DVousden%26aufirst%3DK.%2BH.%26aulast%3DLane%26aufirst%3DD.%2BP.%26atitle%3DP53%2520in%2520Health%2520and%2520Disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26issue%3D4%26spage%3D275%26epage%3D283%26doi%3D10.1038%2Fnrm2147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5304</span>– <span class="NLM_lpage">5322</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00384</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00384" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5304-5322&issue=12&author=J.+Zangauthor=X.+Liangauthor=Y.+Huangauthor=Y.+Jiaauthor=X.+Liauthor=W.+Xuauthor=C.+J.+Chouauthor=Y.+Zhang&title=Discovery+of+Novel+Pazopanib-Based+HDAC+and+VEGFR+Dual+Inhibitors+Targeting+Cancer+Epigenetics+and+Angiogenesis+Simultaneously&doi=10.1021%2Facs.jmedchem.8b00384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously</span></div><div class="casAuthors">Zang, Jie; Liang, Xuewu; Huang, Yongxue; Jia, Yuping; Li, Xiaoyang; Xu, Wenfang; Chou, C. James; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5304-5322</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein a novel series of pazopanib hybrids as polypharmacol. antitumor agents were developed based on the crosstalk between histone deacetylases (HDACs) and vascular endothelial growth factor (VEGF) pathway.  Among them, one ortho-aminoanilide 6d and one hydroxamic acid 13f exhibited considerable total HDACs and VEGFR-2 inhibitory activities.  The HDAC inhibitory activities endowed 6d and 13f with potent antiproliferative activities, which was not obsd. in the approved VEGFR inhibitor pazopanib.  Compds. 6d and 13f possessed comparable HDAC isoform selectivity profiles to the clin. class I HDAC inhibitor MS-275 and the approved pan-HDAC inhibitor SAHA, resp. 6d and 13f also exhibited uncompromised multiple tyrosine kinases inhibitory activities relative to pazopanib.  The intracellular dual inhibition to HDAC and VEGFR of 6d and 13f was validated by Western blot anal.  In both HUVECs tube formation assay and rat thoracic aorta rings assay, 6d and 13f showed comparable antiangiogenic potencies to pazopanib.  What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpmz6rwKiKSbVg90H21EOLACvtfcHk0lirBXVmSL5Yhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D&md5=437da0a6cca1ec211219aef87a6ddbc5</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Novel%2520Pazopanib-Based%2520HDAC%2520and%2520VEGFR%2520Dual%2520Inhibitors%2520Targeting%2520Cancer%2520Epigenetics%2520and%2520Angiogenesis%2520Simultaneously%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D12%26spage%3D5304%26epage%3D5322%26doi%3D10.1021%2Facs.jmedchem.8b00384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vyse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broncel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhamra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P. H.</span></span> <span> </span><span class="NLM_article-title">Quantitative Phosphoproteomic Analysis of Acquired Cancer Drug Resistance to Pazopanib and Dasatinib</span>. <i>J. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1016/j.jprot.2017.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.jprot.2017.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28842319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKgu7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2018&pages=130-140&author=S.+Vyseauthor=F.+McCarthyauthor=M.+Broncelauthor=A.+Paulauthor=J.+P.+Wongauthor=A.+Bhamraauthor=P.+H.+Huang&title=Quantitative+Phosphoproteomic+Analysis+of+Acquired+Cancer+Drug+Resistance+to+Pazopanib+and+Dasatinib&doi=10.1016%2Fj.jprot.2017.08.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib</span></div><div class="casAuthors">Vyse, Simon; McCarthy, Frank; Broncel, Malgorzata; Paul, Angela; Wong, Jocelyn P.; Bhamra, Amandeep; Huang, Paul H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">130-140</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acquired drug resistance impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy.  The lack of clin. effective therapies to overcome resistance represents an unmet need.  Understanding the signalling that drives drug resistance will facilitate the development of new salvage therapies to treat patients with secondary TKI resistance.  In this study, we utilize mass spectrometry to characterize the global phosphoproteomic alterations that accompany the acquisition of resistance to two FDA-approved TKIs, pazopanib and dasatinib, in the A204 rhabdoid tumor cell line.  Our anal. finds that only 6% and 9.7% of the quantified phosphoproteome is altered upon the acquisition of pazopanib and dasatinib resistance, resp.  Pazopanib resistant cells display elevated phosphorylation in cytoskeletal regulatory pathways while dasatinib resistant cells show an upregulation of the insulin receptor/IGF-1R signalling pathway.  Drug response profiling rediscovers several previously reported vulnerabilities assocd. with pazopanib and dasatinib resistance and identifies a new dependency to the second generation HSP90 inhibitor NVP-AUY-922.  This study provides a useful resource detailing the candidate signalling determinants of acquired TKI resistance; and reveals a therapeutic approach of inhibiting HSP90 function as a means of salvage therapy to overcome pazopanib and dasatinib resistance.  Pazopanib and dasatinib are tyrosine kinase inhibitors (TKIs) approved for the treatment of multiple cancer types.  Patients who are treated with these drugs are prone to the development of drug resistance and consequently tumor relapse.  Here we use quant. phosphoproteomics to characterize the signalling pathways which are enriched in cells that have acquired resistance to these two drugs.  Furthermore, targeted drug screens were used to identify salvage therapies capable of overcoming pazopanib and dasatinib resistance.  This data advances our understanding of the mechanisms of TKI resistance and highlights candidate targets for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYFjUX3bTf-bVg90H21EOLACvtfcHk0lh0Mp5uGMQJBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKgu7rK&md5=b659908784eff089023d81c1a1c98436</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2017.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2017.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DVyse%26aufirst%3DS.%26aulast%3DMcCarthy%26aufirst%3DF.%26aulast%3DBroncel%26aufirst%3DM.%26aulast%3DPaul%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DJ.%2BP.%26aulast%3DBhamra%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DP.%2BH.%26atitle%3DQuantitative%2520Phosphoproteomic%2520Analysis%2520of%2520Acquired%2520Cancer%2520Drug%2520Resistance%2520to%2520Pazopanib%2520and%2520Dasatinib%26jtitle%3DJ.%2520Proteomics%26date%3D2018%26volume%3D170%26spage%3D130%26epage%3D140%26doi%3D10.1016%2Fj.jprot.2017.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezeli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelemen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vegvari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tisza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laszlo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helbich, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegedus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klikovits, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoda, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klepetko, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paku, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marko-Varga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dome, B.</span></span> <span> </span><span class="NLM_article-title">Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.7150/thno.16767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.7150%2Fthno.16767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28042343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtVGktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=400-412&issue=2&author=S.+Torokauthor=M.+Rezeliauthor=O.+Kelemenauthor=A.+Vegvariauthor=K.+Watanabeauthor=Y.+Sugiharaauthor=A.+Tiszaauthor=T.+Martonauthor=I.+Kovacsauthor=J.+Tovariauthor=V.+Laszloauthor=T.+H.+Helbichauthor=B.+Hegedusauthor=T.+Klikovitsauthor=M.+A.+Hodaauthor=W.+Klepetkoauthor=S.+Pakuauthor=G.+Marko-Vargaauthor=B.+Dome&title=Limited+Tumor+Tissue+Drug+Penetration+Contributes+to+Primary+Resistance+against+Angiogenesis+Inhibitors&doi=10.7150%2Fthno.16767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Limited tumor tissue drug penetration contributes to primary resistance against angiogenesis inhibitors</span></div><div class="casAuthors">Torok, Szilvia; Rezeli, Melinda; Kelemen, Olga; Vegvari, Akos; Watanabe, Kenichi; Sugihara, Yutaka; Tisza, Anna; Marton, Timea; Kovacs, Ildiko; Tovari, Jozsef; Laszlo, Viktoria; Helbich, Thomas H.; Hegedus, Balazs; Klikovits, Thomas; Hoda, Mir Alireza; Klepetko, Walter; Paku, Sandor; Marko-Varga, Gyorgy; Dome, Balazs</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">400-412</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Resistance mechanisms against antiangiogenic drugs are unclear.  Here, we correlated the antitumor and antivascular properties of five different antiangiogenic receptor tyrosine kinase inhibitors (RTKIs) (motesanib, pazopanib, sorafenib, sunitinib, vatalanib) with their intratumoral distribution data obtained by matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI).  In the first mouse model, only sunitinib exhibited broad-spectrum antivascular and antitumor activities by simultaneously suppressing vascular endothelial growth factor receptor-2 (VEGFR2) and desmin expression, and by increasing intratumoral hypoxia and inhibiting both tumor growth and vascularisation significantly.  Importantly, the highest and most homogeneous intratumoral drug concns. have been found in sunitinib-treated animals.  In another animal model, where in contrast to the first model vatalanib was detectable at homogeneously high intratumoral concns., the drug significantly reduced tumor growth and angiogenesis.  In conclusion, the tumor tissue penetration and thus the antiangiogenic and antitumor potential of antiangiogenic RTKIs vary among the tumor models and our study demonstrates the potential of MALDI-MSI to predict the efficacy of unlabeled small mol. antiangiogenic drugs in malignant tissue.  Our approach is thus a major tech. and preclin. advance demonstrating that primary resistance to angiogenesis inhibitors involves limited tumor tissue drug penetration.  We also conclude that MALDI-MSI may significantly contribute to the improvement of antivascular cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjaQn-h68CBbVg90H21EOLACvtfcHk0lh0Mp5uGMQJBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtVGktr0%253D&md5=39e01c9ae14fc2251309c23d39027e90</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.7150%2Fthno.16767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.16767%26sid%3Dliteratum%253Aachs%26aulast%3DTorok%26aufirst%3DS.%26aulast%3DRezeli%26aufirst%3DM.%26aulast%3DKelemen%26aufirst%3DO.%26aulast%3DVegvari%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DSugihara%26aufirst%3DY.%26aulast%3DTisza%26aufirst%3DA.%26aulast%3DMarton%26aufirst%3DT.%26aulast%3DKovacs%26aufirst%3DI.%26aulast%3DTovari%26aufirst%3DJ.%26aulast%3DLaszlo%26aufirst%3DV.%26aulast%3DHelbich%26aufirst%3DT.%2BH.%26aulast%3DHegedus%26aufirst%3DB.%26aulast%3DKlikovits%26aufirst%3DT.%26aulast%3DHoda%26aufirst%3DM.%2BA.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DPaku%26aufirst%3DS.%26aulast%3DMarko-Varga%26aufirst%3DG.%26aulast%3DDome%26aufirst%3DB.%26atitle%3DLimited%2520Tumor%2520Tissue%2520Drug%2520Penetration%2520Contributes%2520to%2520Primary%2520Resistance%2520against%2520Angiogenesis%2520Inhibitors%26jtitle%3DTheranostics%26date%3D2017%26volume%3D7%26issue%3D2%26spage%3D400%26epage%3D412%26doi%3D10.7150%2Fthno.16767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musumeci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span> <span> </span><span class="NLM_article-title">Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">10797</span>– <span class="NLM_lpage">10822</span>, <span class="refDoi"> DOI: 10.1021/jm301085w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301085w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10797-10822&issue=24&author=F.+Musumeciauthor=M.+Radiauthor=C.+Brulloauthor=S.+Schenone&title=Vascular+Endothelial+Growth+Factor+%28VEGF%29+Receptors%3A+Drugs+and+New+Inhibitors&doi=10.1021%2Fjm301085w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors</span></div><div class="casAuthors">Musumeci, Francesca; Radi, Marco; Brullo, Chiara; Schenone, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10797-10822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these agents and the importance of the research in the field of angiogenesis inhibitors for future oncol. therapy.  In this Perspective we briefly report the inhibitors that are in clin. use, while we dedicate two wider sections to the compds. that are in clin. trials and to the new derivs. appearing in the literature.  We esp. consider the medicinal chem. aspect of the topic and report the structure-activity relationship studies and the binding mode of some inhibitors as well as the biol. data of the compds. discovered in the past 5 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP5ioBH5ZGAbVg90H21EOLACvtfcHk0lhT_XEl39TUOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbvL&md5=d995df9120c8f56c1ab142b1aea8dfbc</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Fjm301085w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301085w%26sid%3Dliteratum%253Aachs%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DRadi%26aufirst%3DM.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DVascular%2520Endothelial%2520Growth%2520Factor%2520%2528VEGF%2529%2520Receptors%253A%2520Drugs%2520and%2520New%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D24%26spage%3D10797%26epage%3D10822%26doi%3D10.1021%2Fjm301085w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6074</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6056-6074&issue=14&author=Y.+Huangauthor=G.+Dongauthor=H.+Liauthor=N.+Liuauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+Janus+Kinase+2+%28JAK2%29+and+Histone+Deacetylase+%28HDAC%29+Dual+Inhibitors+as+a+Novel+Strategy+for+the+Combinational+Treatment+of+Leukemia+and+Invasive+Fungal+Infections&doi=10.1021%2Facs.jmedchem.8b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span></div><div class="casAuthors">Huang, Yahui; Dong, Guoqiang; Li, Huanqiu; Liu, Na; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6056-6074</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin., leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens.  Herein, a novel therapeutic strategy was developed in which a small mol. can simultaneously treat leukemia and invasive fungal infections (IFIs).  Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematol. cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections.  In particular, compd. I, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections.  This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_ii7EQG1qLVg90H21EOLACvtfcHk0lhT_XEl39TUOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN&md5=ba7cf74761120f0526ab520196e3dded</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Janus%2520Kinase%25202%2520%2528JAK2%2529%2520and%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Dual%2520Inhibitors%2520as%2520a%2520Novel%2520Strategy%2520for%2520the%2520Combinational%2520Treatment%2520of%2520Leukemia%2520and%2520Invasive%2520Fungal%2520Infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D14%26spage%3D6056%26epage%3D6074%26doi%3D10.1021%2Facs.jmedchem.8b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, M.</span></span> <span> </span><span class="NLM_article-title">Targeting JAK Kinase in Solid Tumors: Emerging Opportunities and Challenges</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1038/onc.2015.150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fonc.2015.150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25982279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVOns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=939-951&issue=8&author=M.+Buchertauthor=C.+J.+Burnsauthor=M.+Ernst&title=Targeting+JAK+Kinase+in+Solid+Tumors%3A+Emerging+Opportunities+and+Challenges&doi=10.1038%2Fonc.2015.150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting JAK kinase in solid tumors: emerging opportunities and challenges</span></div><div class="casAuthors">Buchert, M.; Burns, C. J.; Ernst, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">939-951</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Various human malignancies are characterized by excessive activation of the Janus family of cytoplasmic tyrosine kinases (JAK) and their assocd. transcription factors STAT3 and STAT5.  In the majority of solid tumors, this occurs in response to increased abundance of inflammatory cytokines in the tumor microenvironment prominently produced by infiltrating innate immune cells.  Many of these cytokines share common receptor subunits and belong to the interleukin (IL)-6/IL-11, IL-10/IL-22 and IL-12/IL-23 families.  Therapeutic inhibition of the JAK/STAT3 pathway potentially offers considerable benefit owing to the capacity of JAK/STAT3 signaling to promote cancer hallmarks in the tumor and its environment, including proliferation, survival, angiogenesis, tumor metab. while suppressing antitumor immunity.  This is further emphasized by the current successful clin. applications of JAK-specific small mol. inhibitors for the treatment of inflammatory disorders and hematopoietic malignancies.  Here we review current preclin. applications for JAK inhibitors for the treatment of solid cancers in mice, with a focus on the most common malignancies emanating from oncogenic transformation of the epithelial mucosa in the stomach and colon.  Emerging data with small mol. JAK-specific ATP-binding analogs corroborate genetic findings and suggest that interference with the JAK/STAT3 pathway may suppress the growth of the most common forms of sporadic colon cancers that arise from mutations of the APC tumor suppressor gene.  Likewise inhibition of cytokine-dependent activation of the JAK/STAT3 pathway may also afford orthogonal treatment opportunities for other oncogene-addicted cancer cells that have gained drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ogRfeEyKErVg90H21EOLACvtfcHk0lifA0UU4ys3TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVOns7s%253D&md5=fd63866700ca096c476f1942157deccc</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1038%2Fonc.2015.150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2015.150%26sid%3Dliteratum%253Aachs%26aulast%3DBuchert%26aufirst%3DM.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DErnst%26aufirst%3DM.%26atitle%3DTargeting%2520JAK%2520Kinase%2520in%2520Solid%2520Tumors%253A%2520Emerging%2520Opportunities%2520and%2520Challenges%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26issue%3D8%26spage%3D939%26epage%3D951%26doi%3D10.1038%2Fonc.2015.150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offidani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fianchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picardi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chierichini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramatti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Invernizzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lint, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcucci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentini, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girmenia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosari, A.</span></span> <span> </span><span class="NLM_article-title">The Epidemiology of Fungal Infections in Patients with Hematologic Malignancies: The SEIFEM-2004 Study</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1068</span>– <span class="NLM_lpage">1075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16885047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BD28vmtFyiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2006&pages=1068-1075&issue=8&author=L.+Paganoauthor=M.+Cairaauthor=A.+Candoniauthor=M.+Offidaniauthor=L.+Fianchiauthor=B.+Martinoauthor=D.+Pastoreauthor=M.+Picardiauthor=A.+Boniniauthor=A.+Chierichiniauthor=R.+Fanciauthor=C.+Caramattiauthor=R.+Invernizziauthor=D.+Matteiauthor=M.+E.+Mitraauthor=L.+Melilloauthor=F.+Aversaauthor=M.+T.+Van+Lintauthor=P.+Falcucciauthor=C.+G.+Valentiniauthor=C.+Girmeniaauthor=A.+Nosari&title=The+Epidemiology+of+Fungal+Infections+in+Patients+with+Hematologic+Malignancies%3A+The+SEIFEM-2004+Study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study</span></div><div class="casAuthors">Pagano Livio; Caira Morena; Candoni Anna; Offidani Massimo; Fianchi Luana; Martino Bruno; Pastore Domenico; Picardi Marco; Bonini Alessandro; Chierichini Anna; Fanci Rosa; Caramatti Cecilia; Invernizzi Rosangela; Mattei Daniele; Mitra Maria Enza; Melillo Lorella; Aversa Franco; Van Lint Maria Teresa; Falcucci Paolo; Valentini Caterina Giovanna; Girmenia Corrado; Nosari Annamaria</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1068-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND OBJECTIVES:  The aim of this study was to evaluate the incidence and outcome of invasive fungal infections (IFI) in patients with hematologic malignancies.  DESIGN AND METHODS:  This was a retrospective cohort study of patients admitted between 1999 and 2003 to 18 hematology wards in Italy.  Each participating center provided information on all patients with newly diagnosed hematologic malignancies admitted during the survery period and on all episodes of IFI experienced by these patients.  RESULTS:  The cohort was formed of 11,802 patients with hematologic malignacies: acute leukemia (myeloid 3012, lymphoid 1173), chronic leukemia (myeloid 596, lymphoid 1104), lymphoma (Hodgkin's 844, non-Hodgkin's 3457), or multiple myeloma (1616).  There were 538 proven or probable IFI (4.6%); 373 (69%) occurred in patients with acute myeloid leukemia.  Over half (346/538) were caused by molds (2.9%), in most cases Aspergillus spp. (310/346).  The 192 yeast infections (1.6%) included 175 cases of candidemia.  Overall and IFI-attributable mortality rates were 2% (209/11802) and 39% (209/538), respectively.  The highest IFI-attributable mortality rates were associated with zygomycosis (64%) followed by fusariosis (53%), aspergillosis (42%), and candidemia (33%).  INTERPRETATION AND CONCLUSIONS:  Patients with hematologic malignancies are currently at higher risk of IFI caused by molds than by yeasts, and the incidence of IFI is highest among patients with acute myeloid leukemia.  Aspergillus spp are still the most common pathogens, followed by Candida spp.  Other agents are rare.  The attributable mortality rate for aspergillosis has dropped from 60-70% to approximately 40%.  Candidemia-related mortality remains within the 30-40% range reported in literature although the incidence has decreased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjYIQsWCoicbZpSb_XWfMrfW6udTcc2eYJntDi_k3qsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vmtFyiug%253D%253D&md5=a892c750b021aed0db557d66852aaabc</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPagano%26aufirst%3DL.%26aulast%3DCaira%26aufirst%3DM.%26aulast%3DCandoni%26aufirst%3DA.%26aulast%3DOffidani%26aufirst%3DM.%26aulast%3DFianchi%26aufirst%3DL.%26aulast%3DMartino%26aufirst%3DB.%26aulast%3DPastore%26aufirst%3DD.%26aulast%3DPicardi%26aufirst%3DM.%26aulast%3DBonini%26aufirst%3DA.%26aulast%3DChierichini%26aufirst%3DA.%26aulast%3DFanci%26aufirst%3DR.%26aulast%3DCaramatti%26aufirst%3DC.%26aulast%3DInvernizzi%26aufirst%3DR.%26aulast%3DMattei%26aufirst%3DD.%26aulast%3DMitra%26aufirst%3DM.%2BE.%26aulast%3DMelillo%26aufirst%3DL.%26aulast%3DAversa%26aufirst%3DF.%26aulast%3DVan%2BLint%26aufirst%3DM.%2BT.%26aulast%3DFalcucci%26aufirst%3DP.%26aulast%3DValentini%26aufirst%3DC.%2BG.%26aulast%3DGirmenia%26aufirst%3DC.%26aulast%3DNosari%26aufirst%3DA.%26atitle%3DThe%2520Epidemiology%2520of%2520Fungal%2520Infections%2520in%2520Patients%2520with%2520Hematologic%2520Malignancies%253A%2520The%2520SEIFEM-2004%2520Study%26jtitle%3DHaematologica%26date%3D2006%26volume%3D91%26issue%3D8%26spage%3D1068%26epage%3D1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aleshin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span> <span> </span><span class="NLM_article-title">Src: A Century of Science Brought to the Clinic</span>. <i>Neoplasia.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1593/neo.10328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1593%2Fneo.10328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20689754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVClsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=599-607&issue=8&author=A.+Aleshinauthor=R.+S.+Finn&title=Src%3A+A+Century+of+Science+Brought+to+the+Clinic&doi=10.1593%2Fneo.10328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">SRC: a century of science brought to the clinic</span></div><div class="casAuthors">Aleshin, Alexey; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">599-607</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">A review.  The SRC family kinases are the largest family of nonreceptor tyrosine kinases and one of the best-studied targets for cancer therapy.  SRC, arguably the oldest oncogene, has been implicated in pathways regulating proliferation, angiogenesis, invasion and metastasis, and bone metab.  More recently, researchers have proposed that the transforming ability of SRC is linked to its ability to activate key signaling mols. in these pathways, rather than through direct activity.  It has been hypothesized that blocking SRC activation may inhibit these pathways, resulting in antitumor activity.  However, successfully targeting SRC in a clin. setting remains a challenge, and SRC inhibitors have only recently begun to move through clin. development.  Preclin. studies have identified specific mol. "subgroups" and histologies that may be more sensitive to SRC inhibition.  In addn., other studies have demonstrated synergistic interactions between SRC inhibitors and other targeted therapies and cytotoxics.  In this review, we summarize SRC biol. and how it has been applied to the clin. development of SRC inhibitors.  The status of SRC inhibitors, including dasatinib, saracatinib, and bosutinib, which are in phase 1, 2, and 3 trials, is highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_g3wyg6sIcLVg90H21EOLACvtfcHk0lgsnMimZcy92A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVClsrs%253D&md5=4eaa783194fb3abb0a8234f4e16d5af4</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1593%2Fneo.10328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.10328%26sid%3Dliteratum%253Aachs%26aulast%3DAleshin%26aufirst%3DA.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DSrc%253A%2520A%2520Century%2520of%2520Science%2520Brought%2520to%2520the%2520Clinic%26jtitle%3DNeoplasia.%26date%3D2010%26volume%3D12%26issue%3D8%26spage%3D599%26epage%3D607%26doi%3D10.1593%2Fneo.10328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westhoff, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fincham, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N. O.</span></span> <span> </span><span class="NLM_article-title">Src-Mediated Phosphorylation of Focal Adhesion Kinase Couples Actin and Adhesion Dynamics to Survival Signaling</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8113</span>, <span class="refDoi"> DOI: 10.1128/MCB.24.18.8113-8133.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1128%2FMCB.24.18.8113-8133.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15340073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnslCrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=8113&issue=18&author=M.+A.+Westhoffauthor=B.+Serrelsauthor=V.+J.+Finchamauthor=M.+C.+Frameauthor=N.+O.+Carragher&title=Src-Mediated+Phosphorylation+of+Focal+Adhesion+Kinase+Couples+Actin+and+Adhesion+Dynamics+to+Survival+Signaling&doi=10.1128%2FMCB.24.18.8113-8133.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Src-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling</span></div><div class="casAuthors">Westhoff, M. A.; Serrels, B.; Fincham, V. J.; Frame, M. C.; Carragher, N. O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8113-8133</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Integrin-assocd. focal adhesions not only provide adhesive links between cellular actin and extracellular matrix but also are sites of signal transmission into the cell interior.  Many cell responses signal through focal adhesion kinase (FAK), often by integrin-induced autophosphorylation of FAK or phosphorylation by Src family kinases.  Here, we used an interfering FAK mutant (4-9F-FAK) to show that Src-dependent FAK phosphorylation is required for focal adhesion turnover and cell migration, by controlling assembly of a calpain 2/FAK/Src/p42ERK complex, calpain activation, and proteolysis of FAK.  Expression of 4-9F-FAK in FAK-deficient fibroblasts also disrupts F-actin assembly assocd. with normal adhesion and spreading.  In addn., we found that FAK's ability to regulate both assembly and disassembly of the actin and adhesion networks may be linked to regulation of the protease calpain.  Surprisingly, we also found that the same interfering 4-9F-FAK mutant protein causes apoptosis of serum-deprived, transformed cells and suppresses anchorage-independent growth.  These data show that Src-mediated phosphorylation of FAK acts as a pivotal regulator of both actin and adhesion dynamics and survival signaling, which, in turn, control apparently distinct processes such as cell migration and anchorage-independent growth.  This also highlights that dynamic regulation of actin and adhesions (which include the integrin matrix receptors) is crit. to signaling output and biol. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2pNhJXdyh1bVg90H21EOLACvtfcHk0lgsnMimZcy92A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnslCrsbw%253D&md5=d5cc89848c8147fcb46299ce04c5c72c</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.18.8113-8133.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.18.8113-8133.2004%26sid%3Dliteratum%253Aachs%26aulast%3DWesthoff%26aufirst%3DM.%2BA.%26aulast%3DSerrels%26aufirst%3DB.%26aulast%3DFincham%26aufirst%3DV.%2BJ.%26aulast%3DFrame%26aufirst%3DM.%2BC.%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26atitle%3DSrc-Mediated%2520Phosphorylation%2520of%2520Focal%2520Adhesion%2520Kinase%2520Couples%2520Actin%2520and%2520Adhesion%2520Dynamics%2520to%2520Survival%2520Signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26issue%3D18%26spage%3D8113%26doi%3D10.1128%2FMCB.24.18.8113-8133.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagemann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J. L.</span></span> <span> </span><span class="NLM_article-title">The UPS and Downs of MEK Kinase Interactions</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">875</span>, <span class="refDoi"> DOI: 10.1016/S0898-6568(01)00220-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0898-6568%2801%2900220-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11728826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXos1Cmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2001&pages=863-875&issue=12&author=C.+Hagemannauthor=J.+L.+Blank&title=The+UPS+and+Downs+of+MEK+Kinase+Interactions&doi=10.1016%2FS0898-6568%2801%2900220-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">The ups and downs of MEK kinase interactions</span></div><div class="casAuthors">Hagemann, Carsten; Blank, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">863-875</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 107 refs.  MEK kinases (MEKKs) comprise a family of related serine-threonine protein kinases that regulate MAP kinase (MAPK) signaling pathways leading to c-Jun N-terminal kinase (JNK) and p38 activation, induced by cellular stress (e.g., UV and γ-irradn., osmotic stress, heat shock, protein synthesis inhibitors), inflammatory cytokines [e.g., tumor necrosis factor-α (TNFα) and interleukin-1 (IL1), and G protein-coupled receptor agonists (e.g., thrombin)].  These stress-activated kinases have been implicated in apoptosis, oncogenic transformation, and inflammatory responses in various cell types.  At present, the signaling events involving MEKKs are not well understood.  This review summarizes the current knowledge concerning the regulation and function of MEKK family members, with particular emphasis on those factors capable of directly interacting with distinct MEKK isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBlpNKGd09WrVg90H21EOLACvtfcHk0lhVOwxcFRaXBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXos1Cmsr0%253D&md5=9e469d562cc1610a71cb200404032931</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2FS0898-6568%2801%2900220-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0898-6568%252801%252900220-0%26sid%3Dliteratum%253Aachs%26aulast%3DHagemann%26aufirst%3DC.%26aulast%3DBlank%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520UPS%2520and%2520Downs%2520of%2520MEK%2520Kinase%2520Interactions%26jtitle%3DCell.%2520Signalling%26date%3D2001%26volume%3D13%26issue%3D12%26spage%3D863%26epage%3D875%26doi%3D10.1016%2FS0898-6568%2801%2900220-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciombor, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekaii-Saab, T.</span></span> <span> </span><span class="NLM_article-title">Selumetinib for the Treatment of Cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.982275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1517%2F13543784.2015.982275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25385055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=111-123&issue=1&author=K.+K.+Ciomborauthor=T.+Bekaii-Saab&title=Selumetinib+for+the+Treatment+of+Cancer&doi=10.1517%2F13543784.2015.982275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">selumetinib for the treatment of cancer</span></div><div class="casAuthors">Ciombor, Kristen Keon; Bekaii-Saab, Tanios</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-123</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: The MAPK pathway is essential for regulation of cellular proliferation, differentiation and survival.  Multiple human cancers have demonstrated activation of Raf-mitogen-activated kinase kinase (MEK)-extracellular signal-related kinase signaling, a hallmark of these tumors.  Efforts to inhibit various protein kinases in this pathway have led to the development of MEK inhibitors. is one such drug, functioning as an oral, selective non-ATP-competitive MEK1/2 inhibitor.  Areas covered: In this article, the authors discuss the underlying biol. of MEK inhibition and its rationale in cancer treatment.  Furthermore, the authors summarize the clin. development of selumetinib in various tumor types, from initial Phase I studies to randomized Phase II studies, both as monotherapy or in combination with other chemotherapeutics.  Expert opinion: Given the frequency of activated MAPK signaling in multiple tumor types, the potent MEK inhibitor selumetinib had strong preclin. and early clin. rationale, particularly in those tumors harboring KRAS or BRAF mutations.  While efficacy signals have been seen in various tumor types treated with selumetinib, better biomarkers are needed to select patients most likely to respond favorably to this agent.  Furthermore, combinatorial therapy with selumetinib and other targeted agents can likely be optimized to maximize the antitumor effect of inhibiting RAS/MAPK signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzukRIrAMzm7Vg90H21EOLACvtfcHk0lhVOwxcFRaXBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCls7rL&md5=7f1a1a192f5c0f22cddda91dc21c753b</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.982275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.982275%26sid%3Dliteratum%253Aachs%26aulast%3DCiombor%26aufirst%3DK.%2BK.%26aulast%3DBekaii-Saab%26aufirst%3DT.%26atitle%3DSelumetinib%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26issue%3D1%26spage%3D111%26epage%3D123%26doi%3D10.1517%2F13543784.2015.982275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sill, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaker, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcguire, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotmensch, J.</span></span> <span> </span><span class="NLM_article-title">A Phase II Evaluation of Selumetinib (AZD6244, ARRY-142886), a Selective MEK-1/2 Inhibitor in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ygyno.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25887099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslGitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2015&pages=30-35&issue=1&author=R.+L.+Colemanauthor=M.+W.+Sillauthor=P.+H.+Thakerauthor=D.+P.+Benderauthor=D.+Streetauthor=W.+Mcguireauthor=C.+M.+Johnstonauthor=J.+Rotmensch&title=A+Phase+II+Evaluation+of+Selumetinib+%28AZD6244%2C+ARRY-142886%29%2C+a+Selective+MEK-1%2F2+Inhibitor+in+the+Treatment+of+Recurrent+or+Persistent+Endometrial+Cancer%3A+An+NRG+Oncology%2FGynecologic+Oncology+Group+Study&doi=10.1016%2Fj.ygyno.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study</span></div><div class="casAuthors">Coleman, Robert L.; Sill, Michael W.; Thaker, Premal H.; Bender, David P.; Street, Daron; McGuire, William P.; Johnston, Carolyn M.; Rotmensch, Jacob</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-35</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Activation of the mitogen activated protein kinase pathway plays a pivotal role in cell proliferation and is frequently activated in endometrial cancer.  We sought to evaluate the efficacy/safety of selumetinib, a selective MEK-1/2 inhibitor in women with recurrent endometrial cancer.This was a phase II, single-arm, open-label study evaluating response and 6-mo event-free survival (EFS) as primary endpoints.  Eligible patients had measurable disease, 1-2 prior cytotoxic regimens, and performance status 0-2.  Selumetinib 75 mg PO BID was administered daily until progression or intolerance.  One cycle was 28 days.Fifty-four patients were enrolled; 2 were excluded due to improper pre-study treatment (1) and never treated (1), leaving 52 evaluable for efficacy/safety.  Median age was 62; histol. included endometrioid (58%), serous (17%) and mixed (23%).  Seventeen patients (33%) had 2 prior cytotoxic regimens.  The median no. of cycles administered was 2 (1-34).  Three (6%) patients had objective response (1 CR, 2 PR); 13 had SD as best response.  The proportion of patients with 6-mo EFS was 12%.  Median EFS, progression-free and overall survival was 2.1, 2.3, and 8.5 mo, resp.  Drug-attributed grade 3/4 adverse events were obsd. (≥ 5%) were fatigue (15%), anemia (10%), pain (10%), extremity edema (8%), and dyspnea (6%).  There was 1 grade 4 infection (renal), 1 grade 4 anemia, and 1 death due to hemorrhage (rectum).Selumetinib was tolerable in this population but did not meet pre-trial specifications for clin. efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvnX9fLy0Bw7Vg90H21EOLACvtfcHk0liSqqsZLtZevg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslGitbs%253D&md5=2736b28e137c79ec23cffb3ff05d4782</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DSill%26aufirst%3DM.%2BW.%26aulast%3DThaker%26aufirst%3DP.%2BH.%26aulast%3DBender%26aufirst%3DD.%2BP.%26aulast%3DStreet%26aufirst%3DD.%26aulast%3DMcguire%26aufirst%3DW.%26aulast%3DJohnston%26aufirst%3DC.%2BM.%26aulast%3DRotmensch%26aufirst%3DJ.%26atitle%3DA%2520Phase%2520II%2520Evaluation%2520of%2520Selumetinib%2520%2528AZD6244%252C%2520ARRY-142886%2529%252C%2520a%2520Selective%2520MEK-1%252F2%2520Inhibitor%2520in%2520the%2520Treatment%2520of%2520Recurrent%2520or%2520Persistent%2520Endometrial%2520Cancer%253A%2520An%2520NRG%2520Oncology%252FGynecologic%2520Oncology%2520Group%2520Study%26jtitle%3DGynecol.%2520Oncol.%26date%3D2015%26volume%3D138%26issue%3D1%26spage%3D30%26epage%3D35%26doi%3D10.1016%2Fj.ygyno.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arozarena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellbrock, C.</span></span> <span> </span><span class="NLM_article-title">Combination of MEK and Src Inhibition Suppresses Melanoma Cell Growth and Invasion</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1038/onc.2012.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fonc.2012.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22310287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFCq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=86-96&issue=1&author=J.+Fergusonauthor=I.+Arozarenaauthor=M.+Ehrhardtauthor=C.+Wellbrock&title=Combination+of+MEK+and+Src+Inhibition+Suppresses+Melanoma+Cell+Growth+and+Invasion&doi=10.1038%2Fonc.2012.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion</span></div><div class="casAuthors">Ferguson, J.; Arozarena, I.; Ehrhardt, M.; Wellbrock, C.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-96</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The RAS-RAF-MEK-ERK pathway is deregulated in over 90% of malignant melanomas, and targeting MEK as a central kinase of this pathway is currently tested in clin. trials.  However, dose-limiting side effects are obsd., and MEK inhibitors that sufficiently reduce ERK activation in patients show a low clin. response.  Apart from dose limitations, a reason for the low response to MEK targeting drugs is thought to be the upregulation of counteracting signalling cascades as a direct response to MEK inhibition.  Therefore, understanding the biol. of melanoma cells and the effects of MEK inhibition on these cells will help to identify new combinatorial approaches that are more potent and allow for lower concns. of the drug being used.  We have discovered that in melanoma cells MEK inhibition by selumetinib (AZD6244, ARRY-142886) or PD184352, while efficiently suppressing proliferation, stimulates increased invasiveness.  Inhibition of MEK suppresses actin-cortex contraction and increases integrin-mediated adhesion.  Most importantly, and surprisingly, MEK inhibition results in a significant increase in matrix metalloproteases (MMP)-2 and membrane-type 1-MMP expression.  All together, MEK inhibition in melanoma cells induces a mesenchymal' phenotype that is characterised by protease-driven invasion.  This mode of invasion is dependent on integrin-mediated adhesion, and because SRC kinases are the main regulators of this process, the SRC kinase inhibitor, saracatinib (AZD0530), completely abolished the MEK inhibitor-induced invasion.  Moreover, the combination of saracatinib and selumetinib effectively suppressed the growth and invasion of melanoma cells in a 3D environment, suggesting that combined inhibition of MEK and SRC is a promising approach to improve the efficacy of targeting the ERK/MAP kinase pathway in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4HItW1RDTErVg90H21EOLACvtfcHk0liSqqsZLtZevg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFCq&md5=d95e45d305f634cd19ea354fb8546871</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.25%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DJ.%26aulast%3DArozarena%26aufirst%3DI.%26aulast%3DEhrhardt%26aufirst%3DM.%26aulast%3DWellbrock%26aufirst%3DC.%26atitle%3DCombination%2520of%2520MEK%2520and%2520Src%2520Inhibition%2520Suppresses%2520Melanoma%2520Cell%2520Growth%2520and%2520Invasion%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26issue%3D1%26spage%3D86%26epage%3D96%26doi%3D10.1038%2Fonc.2012.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Evaluation of Acridine Derivatives as Multi-Target Src and Mek Kinase Inhibitors for Anti-Tumor Treatment</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2015.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=26707846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKju7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=261-269&issue=2&author=Z.+Cuiauthor=X.+Liauthor=L.+Liauthor=B.+Zhangauthor=C.+Gaoauthor=Y.+Chenauthor=C.+Tanauthor=H.+Liuauthor=W.+Xieauthor=T.+Yangauthor=Y.+Jiang&title=Design%2C+Synthesis+and+Evaluation+of+Acridine+Derivatives+as+Multi-Target+Src+and+Mek+Kinase+Inhibitors+for+Anti-Tumor+Treatment&doi=10.1016%2Fj.bmc.2015.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment</span></div><div class="casAuthors">Cui, Zhishan; Li, Xi; Li, Lulu; Zhang, Bin; Gao, Chunmei; Chen, Yuzong; Tan, Chunyan; Liu, Hongxia; Xie, Weiyi; Yang, Ti; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">261-269</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Clin. studies have shown enhanced anticancer effects of combined inhibition of Src and MEK kinases.  Development of multi-target drugs against Src and MEK is of potential therapeutic advantage against cancers.  As a follow-up of our previous studies, and by using mol. docking method, we designed and synthesized a new series of 9-anilinoacridines contg. phenyl-urea moieties as potential novel dual Src and MEK inhibitors.  The anti-proliferative assays against K562 and HepG-2 tumor cells showed that most of the derivs. displayed good cytotoxicity in vitro.  In particular, kinase inhibition assays showed that compd. 8m inhibited Src (59.67%) and MEK (43.23%) at 10 μM, and displayed moderate inhibitory activity against ERK and AKT, the downstream effectors of both Src and MEK.  Moreover, compd. 8m was found to induce K562 cells apoptosis.  Structure-activity relationships of these derivs. were analyzed.  Our study suggested that acridine scaffold, particularly compd. 8m, is of potential interest for developing novel multi-target Src and MEK kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL1R3KFWycz7Vg90H21EOLACvtfcHk0ljqTZ0Nus0ihQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKju7%252FJ&md5=27d5f1427be1e73781816f5e6a046da9</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Evaluation%2520of%2520Acridine%2520Derivatives%2520as%2520Multi-Target%2520Src%2520and%2520Mek%2520Kinase%2520Inhibitors%2520for%2520Anti-Tumor%2520Treatment%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D2%26spage%3D261%26epage%3D269%26doi%3D10.1016%2Fj.bmc.2015.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Recognition of C-Src Via the Imatinib-Binding Conformation</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2008.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.chembiol.2008.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18940662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KmsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1015-1022&issue=10&author=A.+C.+Darauthor=M.+S.+Lopezauthor=K.+M.+Shokat&title=Small+Molecule+Recognition+of+C-Src+Via+the+Imatinib-Binding+Conformation&doi=10.1016%2Fj.chembiol.2008.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation</span></div><div class="casAuthors">Dar, Arvin C.; Lopez, Michael S.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The cancer drug, Imatinib, is a selective Abl kinase inhibitor that does not inhibit the closely related kinase c-Src.  This one drug and its ability to selectively inhibit Abl over c-Src has been a guiding principle in virtually all kinase drug discovery efforts in the last 15 years.  A prominent hypothesis explaining the selectivity of Imatinib is that Abl has an intrinsic ability to adopt an inactive conformation (termed DFG-out), whereas c-Src appears to pay a high intrinsic energetic penalty for adopting this conformation, effectively excluding Imatinib from its ATP pocket.  This explanation of the difference in binding affinity of Imatinib for Abl vs. c-Src makes the striking prediction that it would not be possible to design an inhibitor that binds to the DFG-out conformation of c-Src with high affinity.  The authors report the discovery of a series of such inhibitors.  The authors use structure-activity relationships and x-ray crystallog. to confirm the authors' findings.  These studies suggest that small mols. are capable of inducing the generally unfavorable DFG-out conformation in c-Src.  Structural comparison between c-Src in complex with these inhibitors allows the authors to speculate on the differential selectivity of Imatinib for c-Src and Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgbxnfmxtR-LVg90H21EOLACvtfcHk0ljqTZ0Nus0ihQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KmsrfP&md5=f1047f4a56359511939164a3c2604cb6</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2008.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2008.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DLopez%26aufirst%3DM.%2BS.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DSmall%2520Molecule%2520Recognition%2520of%2520C-Src%2520Via%2520the%2520Imatinib-Binding%2520Conformation%26jtitle%3DChem.%2520Biol.%26date%3D2008%26volume%3D15%26issue%3D10%26spage%3D1015%26epage%3D1022%26doi%3D10.1016%2Fj.chembiol.2008.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J. J.</span></span> <span> </span><span class="NLM_article-title">Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1021/jm0608107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0608107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=409-424&issue=3&author=J.+J.+Liao&title=Molecular+Recognition+of+Protein+Kinase+Binding+Pockets+for+Design+of+Potent+and+Selective+Kinase+Inhibitors&doi=10.1021%2Fjm0608107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many kinase inhibitors have failed in preclin. or clin. development because of the lack of such selectivity that induces intolerable side effects, mostly because the catalytic cleft is highly conserved in sequence and conformation.  Systematic anal. of the crystal structures of protein kinases can offer insight into the design of highly selective kinase inhibitors to overcome these effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroDTl2SBUfbbVg90H21EOLACvtfcHk0lj0_aLNFDcV3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D&md5=77542d3ba589bd834a0d2b97a24eea05</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fjm0608107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608107%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.%26atitle%3DMolecular%2520Recognition%2520of%2520Protein%2520Kinase%2520Binding%2520Pockets%2520for%2520Design%2520of%2520Potent%2520and%2520Selective%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D3%26spage%3D409%26epage%3D424%26doi%3D10.1021%2Fjm0608107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriaux, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramoorthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snodgrass, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commodore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span> <span> </span><span class="NLM_article-title">AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ccr.2009.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19878872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&issue=5&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.+S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+Pan-BCR-ABL+Inhibitor+for+Chronic+Myeloid+Leukemia%2C+Potently+Inhibits+the+T315I+Mutant+and+Overcomes+Mutation-Based+Resistance&doi=10.1016%2Fj.ccr.2009.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span></div><div class="casAuthors">O'Hare, Thomas; Shakespeare, William C.; Zhu, Xiaotian; Eide, Christopher A.; Rivera, Victor M.; Wang, Frank; Adrian, Lauren T.; Zhou, Tianjun; Huang, Wei-Sheng; Xu, Qihong; Metcalf, Chester A., III; Tyner, Jeffrey W.; Loriaux, Marc M.; Corbin, Amie S.; Wardwell, Scott; Ning, Yaoyu; Keats, Jeffrey A.; Wang, Yihan; Sundaramoorthi, Raji; Thomas, Mathew; Zhou, Dong; Snodgrass, Joseph; Commodore, Lois; Sawyer, Tomi K.; Dalgarno, David C.; Deininger, Michael W. N.; Druker, Brian J.; Clackson, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">401-412</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib.  Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compd. mutants selected on sequential inhibitor therapy remain major clin. challenges.  We report design and preclin. evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants.  AP24534 inhibited all tested BCR-ABL mutants in cellular and biochem. assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.  Our work supports clin. evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3g7ZYNXwLbVg90H21EOLACvtfcHk0lj0_aLNFDcV3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N&md5=62a383734fc345b97647ba71aa7aee04</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520Pan-BCR-ABL%2520Inhibitor%2520for%2520Chronic%2520Myeloid%2520Leukemia%252C%2520Potently%2520Inhibits%2520the%2520T315I%2520Mutant%2520and%2520Overcomes%2520Mutation-Based%2520Resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26issue%3D5%26spage%3D401%26epage%3D412%26doi%3D10.1016%2Fj.ccr.2009.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staab, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmanová, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hawari, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisiela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wsol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maser, E.</span></span> <span> </span><span class="NLM_article-title">Studies on Reduction of S-Nitrosoglutathione by Human Carbonyl Reductases 1 and 3</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2011.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.cbi.2011.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21256830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFaisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2011&pages=95-103&issue=1&author=C.+A.+Staabauthor=T.+Hartmanov%C3%A1author=Y.+El-Hawariauthor=B.+Ebertauthor=M.+Kisielaauthor=V.+Wsolauthor=H.+J.+Martinauthor=E.+Maser&title=Studies+on+Reduction+of+S-Nitrosoglutathione+by+Human+Carbonyl+Reductases+1+and+3&doi=10.1016%2Fj.cbi.2011.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3</span></div><div class="casAuthors">Staab, Claudia A.; Hartmanova, Tereza; El-Hawari, Yasser; Ebert, Bettina; Kisiela, Michael; Wsol, Vladimir; Martin, Hans-Joerg; Maser, Edmund</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">95-103</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Human carbonyl reductases 1 and 3 (CBR1 and CBR3) are monomeric NADPH-dependent enzymes of the short-chain dehydrogenase/reductase superfamily.  Despite 72% identity in primary structure they exhibit substantial differences in substrate specificity.  Recently, the endogenous low mol. wt. S-nitrosothiol S-nitrosoglutathione (GSNO) has been added to the broad substrate spectrum of CBR1.  The current study initially addressed whether CBR3 could equally reduce GSNO which was not the case.  Neither the introduction of residues which contribute to glutathione binding in CBR1, i.e. K106Q and S97V/D98A, nor the exchange C143S, which prevents a theor. disulfide bond with C227 in CBR3, could engender activity towards GSNO.  However, exchanging amino acids 236-244 in CBR3 to correspond to CBR1 was sufficient to engender catalytic activity towards GSNO.  Catalytic efficiency was further improved by the exchanges Q142M, C143S, P230W and H270S.  Hence, the same residues previously reported as important for redn. of carbonyl compds. appear to be key to CBR1-mediated redn. of GSNO.  Furthermore, for CBR1-mediated redn. of GSNO, considerable substrate inhibition at concns. >5 K m was obsd.  Treatment of CBR1 with GSNO followed by removal of low mol. wt. compds. decreased the GSNO reducing activity, suggesting a covalent modification.  Treatment with dithiothreitol, but not with ascorbic acid, could rescue the activity, indicating S-glutathionylation rather than S-nitrosation as the underlying mechanism.  As C227 has previously been identified as the reactive cysteine in CBR1, the variant CBR1 C227S was generated, which, in comparison to the wild-type protein, displayed a similar k cat, but a 30-fold higher K m, and did not show substrate inhibition.  Collectively, the results clearly argue for a physiol. role of CBR1, but not for CBR3, in GSNO redn. and thus ultimately in regulation of NO signaling.  Furthermore, at higher concns., GSNO appears to work as a suicide inhibitor for CBR1, probably through glutathionylation of C227.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Vd97BSeEd7Vg90H21EOLACvtfcHk0ljoQu5443F8QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFaisLw%253D&md5=697b17c7e676aa0b081d6a2afc29d87e</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2011.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2011.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DStaab%26aufirst%3DC.%2BA.%26aulast%3DHartmanov%25C3%25A1%26aufirst%3DT.%26aulast%3DEl-Hawari%26aufirst%3DY.%26aulast%3DEbert%26aufirst%3DB.%26aulast%3DKisiela%26aufirst%3DM.%26aulast%3DWsol%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DH.%2BJ.%26aulast%3DMaser%26aufirst%3DE.%26atitle%3DStudies%2520on%2520Reduction%2520of%2520S-Nitrosoglutathione%2520by%2520Human%2520Carbonyl%2520Reductases%25201%2520and%25203%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2011%26volume%3D191%26issue%3D1%26spage%3D95%26epage%3D103%26doi%3D10.1016%2Fj.cbi.2011.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranjitkar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maly, D. J.</span></span> <span> </span><span class="NLM_article-title">Affinity Reagents That Target a Specific Inactive Form of Protein Kinases</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.chembiol.2010.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20189109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1WksLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=195-206&issue=2&author=P.+Ranjitkarauthor=A.+M.+Brockauthor=D.+J.+Maly&title=Affinity+Reagents+That+Target+a+Specific+Inactive+Form+of+Protein+Kinases&doi=10.1016%2Fj.chembiol.2010.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Affinity reagents that target a specific inactive form of protein kinases</span></div><div class="casAuthors">Ranjitkar, Pratistha; Brock, Amanda M.; Maly, Dustin J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A no. of small-mol. inhibitors have been developed that target the catalytic domains of protein kinases that are not in an active conformation.  An inactive form that has been obsd. in several kinases is the DFG-out conformation.  This conformation is characterized by an almost 180° rotation of the conserved Asp-Phe-Gly (DFG) motif in the ATP-binding cleft relative to the active form.  However, the sequence and structural determinants that allow a kinase to stably adopt the DFG-out conformation are not known.  Here, we characterize a series of inhibitors based on a general pharmacophore for this inactive form.  We demonstrate that modified versions of these inhibitors can be used to study the thermodn. and kinetics of ligand binding to DFG-out-adopting kinases and for enriching these kinases from complex protein mixts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5wAdraHMJRLVg90H21EOLACvtfcHk0ljoQu5443F8QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1WksLo%253D&md5=63d0140c2cb16eb8cf8b4e4052b57013</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DRanjitkar%26aufirst%3DP.%26aulast%3DBrock%26aufirst%3DA.%2BM.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26atitle%3DAffinity%2520Reagents%2520That%2520Target%2520a%2520Specific%2520Inactive%2520Form%2520of%2520Protein%2520Kinases%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26issue%3D2%26spage%3D195%26epage%3D206%26doi%3D10.1016%2Fj.chembiol.2010.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S. A.</span></span> <span> </span><span class="NLM_article-title">Estrogen Receptor and Breast Cancer</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1006/scbi.2001.0389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1006%2Fscbi.2001.0389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11562176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmvVGgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=339-352&issue=5&author=S.+Sommerauthor=S.+A.+Fuqua&title=Estrogen+Receptor+and+Breast+Cancer&doi=10.1006%2Fscbi.2001.0389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor and breast cancer</span></div><div class="casAuthors">Sommer, Stephanie; Fuqua, Suzanne A. W.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">339-352</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review.  Breast cancer, the most common malignancy in women, was already known to be assocd. with the steroid hormone estrogen more than a century ago.  The discovery of the estrogen receptor (ER) provided not only a powerful predictive and prognostic marker, but also an efficient target for the treatment of hormone-dependent breast cancer with antiestrogens.  In this paper the authors will sketch the important role of ER in the development, progression, and treatment of the disease, which is complicated by the receptor's interaction with co-regulatory proteins, its cross-talk with other signal transduction pathways, and its involvement in the development of antiestrogen resistance.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosLN8VQ1UX_bVg90H21EOLACvtfcHk0lgMhfqmWWraEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmvVGgtro%253D&md5=6681648d7604b4c3c3404e6782888818</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1006%2Fscbi.2001.0389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fscbi.2001.0389%26sid%3Dliteratum%253Aachs%26aulast%3DSommer%26aufirst%3DS.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%26atitle%3DEstrogen%2520Receptor%2520and%2520Breast%2520Cancer%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2001%26volume%3D11%26issue%3D5%26spage%3D339%26epage%3D352%26doi%3D10.1006%2Fscbi.2001.0389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D. J.</span></span> <span> </span><span class="NLM_article-title">Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7471</span>– <span class="NLM_lpage">7478</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-1070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1158%2F1078-0432.CCR-09-1070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20008847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGgur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=7471-7478&issue=24&author=L.+M.+Ellisauthor=D.+J.+Hicklin&title=Resistance+to+Targeted+Therapies%3A+Refining+Anticancer+Therapy+in+the+Era+of+Molecular+Oncology&doi=10.1158%2F1078-0432.CCR-09-1070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology</span></div><div class="casAuthors">Ellis, Lee M.; Hicklin, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7471-7478</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The advent of targeted therapy for treatment of human cancers has added significantly to our armamentarium as we strive to prolong patient survival while minimizing toxicity.  In cancers driven by a dominant oncogene, targeted therapies have led to remarkable improvements in response and survival, whereas in others the outcome has been more modest.  One key aspect toward realizing the potential of targeted therapies is a better understanding of the intrinsic or acquired resistance mechanisms that limit their efficacy.  The articles in this CCR Focus provide insights into mol. mechanisms of resistance to targeted therapy.  Recent discoveries of the mol. pathways that mediate intrinsic resistance to targeted therapy have led to the identification of predictive biomarkers that allow for better patient selection for front line treatment.  Equally important, the identification of mechanisms of acquired resistance following front line therapy has led to the discovery of novel agents that overcome these resistance mechanisms.  Improving the efficacy of targeted therapies in the future will require expanding our understanding of resistance mechanisms, the development of new generations of rationally designed targeted agents, and translating this information to the clinic to select patients for appropriate therapy. (Clin Cancer Res 2009;15(24):7471-8).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriS0Jdxl1tIrVg90H21EOLACvtfcHk0lgMhfqmWWraEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGgur3E&md5=e439319776b37225d3b6b6d7062753c1</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1070%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DL.%2BM.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26atitle%3DResistance%2520to%2520Targeted%2520Therapies%253A%2520Refining%2520Anticancer%2520Therapy%2520in%2520the%2520Era%2520of%2520Molecular%2520Oncology%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26issue%3D24%26spage%3D7471%26epage%3D7478%26doi%3D10.1158%2F1078-0432.CCR-09-1070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fratto, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imperatori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincenzi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, G.</span></span> <span> </span><span class="NLM_article-title">New Perspectives: Role of Sunitinib in Breast Cancer</span>. <i>Clin. Ter.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21717054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC3MnksFGhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2011&pages=251-257&issue=3&author=M.+E.+Frattoauthor=M.+Imperatoriauthor=B.+Vincenziauthor=F.+Tomaoauthor=D.+Santiniauthor=G.+Tonini&title=New+Perspectives%3A+Role+of+Sunitinib+in+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">New perspectives: role of Sunitinib in breast cancer</span></div><div class="casAuthors">Fratto M E; Imperatori M; Vincenzi B; Tomao F; Santini D; Tonini G</div><div class="citationInfo"><span class="NLM_cas:title">La Clinica terapeutica</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">251-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sunitinib malate (SU11248) is a multitarget oral tyrosine kinase receptor (RTKs) inhibitor which was approved by FDA in renal cells carcinoma (RCC) and imatinib-resistant or imatinib-intollerant gastro-intestinal stromal tumour (GIST).  Sunitinib is able to inhibit RTKs such as receptors for platelet-derived growth factor (PDGF-Rα and β) and for vascular endothelial growth factor (VEGFRs).  It is able to inhibit KIT receptor, colony stimulating factor type 1 receptor (CSF-1R), glial cell line neutrophic factor receptor (RET), fms-like tyrosine kinase receptor-3 (FLT-3 or CD135), signal transducer and activator of transcription 3 (STAT3) and AKT (protein kinase B) in tumour cells.  Many Sunitinib targets play important roles in growth and survival of human breast cancer (BC).  The "rationale" of Sunitinib in BC (with or without others antiagiogenetic therapy) is its ability to block simultaneously intracellular portion of RTKs inhibiting many downstream signals.  We overviewed the most relevant studies concerning Sunitinib in metastatic BC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtkJeUsPHMgOvW160gIxP_fW6udTcc2eaXlmdeC7fcnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnksFGhsw%253D%253D&md5=eef9a27b4e853f725fad134dfd9ec055</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFratto%26aufirst%3DM.%2BE.%26aulast%3DImperatori%26aufirst%3DM.%26aulast%3DVincenzi%26aufirst%3DB.%26aulast%3DTomao%26aufirst%3DF.%26aulast%3DSantini%26aufirst%3DD.%26aulast%3DTonini%26aufirst%3DG.%26atitle%3DNew%2520Perspectives%253A%2520Role%2520of%2520Sunitinib%2520in%2520Breast%2520Cancer%26jtitle%3DClin.%2520Ter.%26date%3D2011%26volume%3D162%26issue%3D3%26spage%3D251%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinszanto, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oseni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargnoli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">Experimental Treatment of Estrogen Receptor (ER) Positive Breast Cancer with Tamoxifen and Brivanib Alaninate, a VEGFR-2/FGFR-1 Kinase Inhibitor: A Potential Clinical Application of Angiogenesis Inhibitors</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1537</span>– <span class="NLM_lpage">1553</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2010.02.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejca.2010.02.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20303261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslersrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=1537-1553&issue=9&author=R.+R.+Patelauthor=S.+Senguptaauthor=H.+R.+Kimauthor=A.+J.+Kleinszantoauthor=J.+R.+Pyleauthor=F.+Zhuauthor=T.+Liauthor=E.+A.+Rossauthor=S.+Oseniauthor=J.+Fargnoliauthor=V.+C.+Jordan&title=Experimental+Treatment+of+Estrogen+Receptor+%28ER%29+Positive+Breast+Cancer+with+Tamoxifen+and+Brivanib+Alaninate%2C+a+VEGFR-2%2FFGFR-1+Kinase+Inhibitor%3A+A+Potential+Clinical+Application+of+Angiogenesis+Inhibitors&doi=10.1016%2Fj.ejca.2010.02.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors</span></div><div class="casAuthors">Patel, Roshani R.; Sengupta, Surojeet; Kim, Helen R.; Klein-Szanto, Andres J.; Pyle, Jennifer R.; Zhu, Fang; Li, Tianyu; Ross, Eric A.; Oseni, Salewa; Fargnoli, Joseph; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1537-1553</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Purpose: Tamoxifen, a selective estrogen receptor modulator (SERM), and brivanib alaninate, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, are two target specific agents that result in a substantial decrease in tumor growth when given alone.  Tamoxifen activates SERM stimulated breast and endometrial tumor growth.  Tamoxifen and brivanib alaninate have side-effects that can affect therapeutic outcomes.  The primary goal of the current study was to evaluate the therapeutic effects of lower doses of both agents when given in combination to mice with SERM sensitive, estrogen stimulated tumor xenografts (MCF-7 E2 tumors).  Expts. were conducted to evaluate the response of SERM stimulated breast (MCF-7 Tam, MCF-7 Ral) and endometrial tumors (EnCa 101) to demonstrate the activity of brivanib alaninate in SERM resistant models.  Exptl. design: In the current study, tumor xenografts were minced and bi-transplanted into the mammary fat pads of athymic, ovariectomized mice.  Preliminary expts. were conducted to det. an effective oral dose of tamoxifen and brivanib alaninate that had minimal effect on tumor growth.  Doses of 125 μg of tamoxifen and 0.05 mg/g of brivanib alaninate were evaluated.  An expt. was designed to evaluate the effect of the two agents together when started at the time of tumor implantation.  An addnl. expt. was done in which tumors were already established and then treated, to obtain enough tumor tissue for mol. anal.  Results: Brivanib alaninate was effective at inhibiting tumor growth in SERM sensitive (MCF-7 E2) and SERM stimulated (EnCa 101, MCF-7 Ral, MCF-7 Tam) models.  The effect of the low dose drug combination as an anti-tumor strategy for SERM sensitive (MCF-7 E2) in early treatment was as effective as higher doses of either drug used alone.  In established tumors, the combination is successful at decreasing tumor growth, while neither agent alone is effective.  Mol. anal. revealed a decreased phosphorylation of VEGFR-2 in tumors that were treated with brivanib alaninate and an increase in VEGFA transcription to compensate for the blockade of VEGFR-2 by increasing the transcription of VEGFA.  Tamoxifen increases the phosphorylation of VEGFR-2 and this effect is abrogated by brivanib alaninate.  There was also increased necrosis in tumors treated with brivanib alaninate.  Conclusion: Historically, tamoxifen has a role in blocking angiogenesis as well as the blockade of the ER.  Tamoxifen and a low dose of an angiogenesis inhibitor, brivanib alaninate, can potentially be combined not only to maximise therapeutic efficacy but also to retard SERM resistant tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofVr791Q6E_7Vg90H21EOLACvtfcHk0ljwuFMNzpczwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslersrc%253D&md5=7e9196684220a65879aefa14b1ca5e67</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2010.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2010.02.018%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DR.%2BR.%26aulast%3DSengupta%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DKleinszanto%26aufirst%3DA.%2BJ.%26aulast%3DPyle%26aufirst%3DJ.%2BR.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DRoss%26aufirst%3DE.%2BA.%26aulast%3DOseni%26aufirst%3DS.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DExperimental%2520Treatment%2520of%2520Estrogen%2520Receptor%2520%2528ER%2529%2520Positive%2520Breast%2520Cancer%2520with%2520Tamoxifen%2520and%2520Brivanib%2520Alaninate%252C%2520a%2520VEGFR-2%252FFGFR-1%2520Kinase%2520Inhibitor%253A%2520A%2520Potential%2520Clinical%2520Application%2520of%2520Angiogenesis%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26issue%3D9%26spage%3D1537%26epage%3D1553%26doi%3D10.1016%2Fj.ejca.2010.02.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of 2,3-Diaryl Isoquinolinone Derivatives as Anti-Breast Cancer Agents Targeting ERα and VEGFR-2</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2133</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.03.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmcl.2014.03.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24721727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvVSnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2129-2133&issue=9&author=Z.+Tangauthor=S.+Niuauthor=F.+Liuauthor=K.+Laoauthor=J.+Miaoauthor=J.+Jiauthor=X.+Wangauthor=M.+Yanauthor=L.+Zhangauthor=Q.+Youauthor=H.+Xiaoauthor=H.+Xiang&title=Synthesis+and+Biological+Evaluation+of+2%2C3-Diaryl+Isoquinolinone+Derivatives+as+Anti-Breast+Cancer+Agents+Targeting+ER%CE%B1+and+VEGFR-2&doi=10.1016%2Fj.bmcl.2014.03.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2</span></div><div class="casAuthors">Tang, Zhichao; Niu, Shaoxiong; Liu, Fei; Lao, Kejing; Miao, Jingshan; Ji, Jinzi; Wang, Xiang; Yan, Ming; Zhang, Luyong; You, Qidong; Xiao, Hong; Xiang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2129-2133</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The estrogen receptor α is recognized as important pharmaceutical target for breast cancer therapy, and vascular endothelial growth factor receptors (VEGFRs) play important roles in tumor angiogenesis including breast cancer.  A series of 2,3-diaryl isoquinolinone derivs. were designed and synthesized targeting both estrogen receptor α (ERα) and VEGFR-2.  Bioactivity evaluation showed that compds. I, II and III exhibited significant anti-proliferative and anti-angiogenesis activities via ERα and VEGFR-2 dependent mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrej5jO0H8Cg7Vg90H21EOLACvtfcHk0lj27J6yh0KCPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvVSnu7w%253D&md5=7317c65c33d0b516403d0b0f6ea0eaf0</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.03.042%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DNiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DLao%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYou%26aufirst%3DQ.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DXiang%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%25202%252C3-Diaryl%2520Isoquinolinone%2520Derivatives%2520as%2520Anti-Breast%2520Cancer%2520Agents%2520Targeting%2520ER%25CE%25B1%2520and%2520VEGFR-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D9%26spage%3D2129%26epage%3D2133%26doi%3D10.1016%2Fj.bmcl.2014.03.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muyaba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Evaluation of 6-Aryl-Indenoisoquinolone Derivatives Dual Targeting ERα and VEGFR-2 as Anti-Breast Cancer Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.04.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2016.04.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27176944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnslarsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2016&pages=328-339&author=Z.+Tangauthor=C.+Wuauthor=T.+Wangauthor=K.+Laoauthor=Y.+Wangauthor=L.+Liuauthor=M.+Muyabaauthor=P.+Xuauthor=C.+Heauthor=G.+Luoauthor=Z.+Qianauthor=S.+Niuauthor=L.+Wangauthor=Y.+Wangauthor=H.+Xiaoauthor=Q.+Youauthor=H.+Xiang&title=Design%2C+Synthesis+and+Evaluation+of+6-Aryl-Indenoisoquinolone+Derivatives+Dual+Targeting+ER%CE%B1+and+VEGFR-2+as+Anti-Breast+Cancer+Agents&doi=10.1016%2Fj.ejmech.2016.04.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents</span></div><div class="casAuthors">Tang, Zhichao; Wu, Chengzhe; Wang, Tianlin; Lao, Kejing; Wang, Yejun; Liu, Linyi; Muyaba, Moses; Xu, Pei; He, Conghui; Luo, Guoshun; Qian, Zhouyang; Niu, Shaoxiong; Wang, Lijun; Wang, Ying; Xiao, Hong; You, Qidong; Xiang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">328-339</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The estrogen receptors have played important roles in breast cancer development and progression.  Selective estrogen receptor modulators, such as Tamoxifen, have showed great benefits in the treatment and prevention of breast cancer.  But the disadvantages of induction of endometrial cancer and drug resistance have limited their use.  Multiple ligand which act at multiple biomol. targets may exert favorable advantages of improved efficacy with lower incidence of side effects.  In this work, we described the synthesis and evaluation of a series of 6-aryl-indenoisoquinolone derivs. as dual ERα and VEGFR-2 inhibitors.  These compds. presented good ERα binding affinity and ERα antagonistic activity, as well as potent VEGFR-2 inhibitory potency.  They also possessed excellent anti-proliferative activities against MCF-7, MDA-MB-231, Ishikawa and HUVEC cell lines.  Further investigation of selective compd. I showed that it was able to inhibit the activation of VEGFR-2 and the signaling transduction of Raf-1/MAPK/ERK pathway in MCF-7 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8cPcZlnhWCrVg90H21EOLACvtfcHk0lj27J6yh0KCPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnslarsbk%253D&md5=00cc7ead9649299f9692143a91ac01fa</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.04.029%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLao%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMuyaba%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DNiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DYou%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Evaluation%2520of%25206-Aryl-Indenoisoquinolone%2520Derivatives%2520Dual%2520Targeting%2520ER%25CE%25B1%2520and%2520VEGFR-2%2520as%2520Anti-Breast%2520Cancer%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D118%26spage%3D328%26epage%3D339%26doi%3D10.1016%2Fj.ejmech.2016.04.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cesca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bizzaro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavazzi, R.</span></span> <span> </span><span class="NLM_article-title">Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">259</span>, <span class="refDoi"> DOI: 10.3389/fonc.2013.00259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3389%2Ffonc.2013.00259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24102047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC2cfltlWguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=259&author=M.+Cescaauthor=F.+Bizzaroauthor=M.+Zucchettiauthor=R.+Giavazzi&title=Tumor+Delivery+of+Chemotherapy+Combined+with+Inhibitors+of+Angiogenesis+and+Vascular+Targeting+Agents&doi=10.3389%2Ffonc.2013.00259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents</span></div><div class="casAuthors">Cesca Marta; Bizzaro Francesca; Zucchetti Massimo; Giavazzi Raffaella</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">259</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Numerous angiogenesis-vascular targeting agents have been admitted to the ranks of cancer therapeutics; most are used in polytherapy regimens.  This review looks at recent progress and our own preclinical experience in combining angiogenesis inhibitors, mainly acting on VEGF/VEGFR pathways, and vascular targeting agents with conventional chemotherapy, discussing the factors that determine the outcome of these treatments.  Molecular and morphological modifications of the tumor microenvironment associated with drug distribution and activity are reviewed.  Modalities to improve drug delivery and strategies for optimizing combination therapy are examined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0YQxum6hoa77NkxioyDXTfW6udTcc2eZNGIyoER5mg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfltlWguw%253D%253D&md5=18d08759e91e0baf80e6471b7514a115</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00259%26sid%3Dliteratum%253Aachs%26aulast%3DCesca%26aufirst%3DM.%26aulast%3DBizzaro%26aufirst%3DF.%26aulast%3DZucchetti%26aufirst%3DM.%26aulast%3DGiavazzi%26aufirst%3DR.%26atitle%3DTumor%2520Delivery%2520of%2520Chemotherapy%2520Combined%2520with%2520Inhibitors%2520of%2520Angiogenesis%2520and%2520Vascular%2520Targeting%2520Agents%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D259%26doi%3D10.3389%2Ffonc.2013.00259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, D. J.</span></span> <span> </span><span class="NLM_article-title">Combination of Antiangiogenesis with Chemotherapy for More Effective Cancer Treatment</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3670</span>– <span class="NLM_lpage">3684</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1158%2F1535-7163.MCT-08-0715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19074844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2iurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=3670-3684&issue=12&author=J.+Maauthor=D.+J.+Waxman&title=Combination+of+Antiangiogenesis+with+Chemotherapy+for+More+Effective+Cancer+Treatment&doi=10.1158%2F1535-7163.MCT-08-0715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of antiangiogenesis with chemotherapy for more effective cancer treatment</span></div><div class="casAuthors">Ma, Jie; Waxman, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3670-3684</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is a hallmark of tumor development and metastasis and is now a validated target for cancer treatment.  However, the survival benefits of antiangiogenic drugs have thus far been rather modest, stimulating interest in developing more effective ways to combine antiangiogenic drugs with established chemotherapies.  This review discusses recent progress and emerging challenges in this field; interactions between antiangiogenic drugs and conventional chemotherapeutic agents are examd., and strategies for the optimization of combination therapies are discussed.  Antiangiogenic drugs such as the anti-vascular endothelial growth factor antibody bevacizumab can induce a functional normalization of the tumor vasculature that is transient and can potentiate the activity of coadministered chemoradiotherapies.  However, chronic angiogenesis inhibition typically reduces tumor uptake of coadministered chemotherapeutics, indicating a need to explore new approaches, including intermittent treatment schedules and provascular strategies to increase chemotherapeutic drug exposure.  In cases where antiangiogenesis-induced tumor cell starvation augments the intrinsic cytotoxic effects of a conventional chemotherapeutic drug, combination therapy may increase antitumor activity despite a decrease in cytotoxic drug exposure.  As new angiogenesis inhibitors enter the clinic, reliable surrogate markers are needed to monitor the progress of antiangiogenic therapies and to identify responsive patients.  New targets for antiangiogenesis continue to be discovered, increasing the opportunities to interdict tumor angiogenesis and circumvent resistance mechanisms that may emerge with chronic use of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFuKsU4WlEmLVg90H21EOLACvtfcHk0lhH48yHOyumHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2iurnN&md5=187b65f71cce4580756ae01973ca758f</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0715%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWaxman%26aufirst%3DD.%2BJ.%26atitle%3DCombination%2520of%2520Antiangiogenesis%2520with%2520Chemotherapy%2520for%2520More%2520Effective%2520Cancer%2520Treatment%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26issue%3D12%26spage%3D3670%26epage%3D3684%26doi%3D10.1158%2F1535-7163.MCT-08-0715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolhouse, M. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chasetopping, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dan, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornell, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilesmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenfell, B. T.</span></span> <span> </span><span class="NLM_article-title">Dynamics of the 2001 UK Foot and Mouth Epidemic: Stochastic Dispersal in a Heterogeneous Landscape</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>294</i></span> (<span class="NLM_issue">5543</span>),  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1126/science.1065973</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1126%2Fscience.1065973" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11679661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotVCitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2001&pages=813-817&issue=5543&author=M.+J.+Keelingauthor=M.+E.+J.+Woolhouseauthor=D.+J.+Shawauthor=L.+Matthewsauthor=M.+Chasetoppingauthor=T.+H.+Danauthor=S.+J.+Cornellauthor=J.+Kappeyauthor=J.+Wilesmithauthor=B.+T.+Grenfell&title=Dynamics+of+the+2001+UK+Foot+and+Mouth+Epidemic%3A+Stochastic+Dispersal+in+a+Heterogeneous+Landscape&doi=10.1126%2Fscience.1065973"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamics of the 2001 UK foot and mouth epidemic: stochastic dispersal in a heterogeneous landscape</span></div><div class="casAuthors">Keeling, Matt J.; Woolhouse, Mark E. J.; Shaw, Darren J.; Matthews, Louise; Chase-Topping, Margo; Haydon, Dan T.; Cornell, Stephen J.; Kappey, Jens; Wilesmith, John; Grenfell, Bryan T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">5543</span>),
    <span class="NLM_cas:pages">813-817</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Foot-and-mouth is one of the world's most economically important livestock diseases.  We developed an individual farm-based stochastic model of the current UK epidemic.  The fine grain of the epidemiol. data reveals the infection dynamics at an unusually high spatiotemporal resoln.  We show that the spatial distribution, size, and species compn. of farms all influence the obsd. pattern and regional variability of outbreaks.  The other key dynamical component is long-tailed stochastic dispersal of infection, combining frequent local movements with occasional long jumps.  We assess the history and possible duration of the epidemic, the performance of control strategies, and general implications for disease dynamics in space and time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxMSVeBiOn9rVg90H21EOLACvtfcHk0lhH48yHOyumHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotVCitLc%253D&md5=13431effc8446e7c510108765616f51b</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1126%2Fscience.1065973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1065973%26sid%3Dliteratum%253Aachs%26aulast%3DKeeling%26aufirst%3DM.%2BJ.%26aulast%3DWoolhouse%26aufirst%3DM.%2BE.%2BJ.%26aulast%3DShaw%26aufirst%3DD.%2BJ.%26aulast%3DMatthews%26aufirst%3DL.%26aulast%3DChasetopping%26aufirst%3DM.%26aulast%3DDan%26aufirst%3DT.%2BH.%26aulast%3DCornell%26aufirst%3DS.%2BJ.%26aulast%3DKappey%26aufirst%3DJ.%26aulast%3DWilesmith%26aufirst%3DJ.%26aulast%3DGrenfell%26aufirst%3DB.%2BT.%26atitle%3DDynamics%2520of%2520the%25202001%2520UK%2520Foot%2520and%2520Mouth%2520Epidemic%253A%2520Stochastic%2520Dispersal%2520in%2520a%2520Heterogeneous%2520Landscape%26jtitle%3DScience%26date%3D2001%26volume%3D294%26issue%3D5543%26spage%3D813%26epage%3D817%26doi%3D10.1126%2Fscience.1065973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnke, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisliuk, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. T.</span></span> <span> </span><span class="NLM_article-title">Novel 5-Substituted, 2,4-Diaminofuro[2,3-D]Pyrimidines as Multireceptor Tyrosine Kinase and Dihydrofolate Reductase Inhibitors with Antiangiogenic and Antitumor Activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5475</span>– <span class="NLM_lpage">5491</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.04.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2005.04.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16039863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnslyjsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=5475-5491&issue=18&author=A.+Gangjeeauthor=Y.+Zengauthor=M.+Ihnatauthor=L.+A.+Warnkeauthor=D.+W.+Greenauthor=R.+L.+Kisliukauthor=F.+T.+Lin&title=Novel+5-Substituted%2C+2%2C4-Diaminofuro%5B2%2C3-D%5DPyrimidines+as+Multireceptor+Tyrosine+Kinase+and+Dihydrofolate+Reductase+Inhibitors+with+Antiangiogenic+and+Antitumor+Activity&doi=10.1016%2Fj.bmc.2005.04.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity</span></div><div class="casAuthors">Gangjee, Aleem; Zeng, Yibin; Ihnat, Michael; Warnke, Linda A.; Green, Dixy W.; Kisliuk, Roy L.; Lin, Fu-Tyan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5475-5491</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent evidence suggests that combination therapy of cancer with receptor tyrosine kinase (RTK) inhibitors, which are usually cytostatic, with conventional chemotherapeutic agents, which are usually cytotoxic, provide an improved treatment option.  The authors have designed, synthesized, and evaluated a series of novel 2,4-diamino-5-substituted furo[2,3-d]pyrimidines with RTK and dihydrofolate reductase (DHFR) inhibitory activity in single mols., as potential cytostatic and cytotoxic agents with antitumor activity.  These compds. were synthesized from 2,4-diamino-5-chloromethyl furo[2,3-d]pyrimidine and aryl Me ketones using the Wittig reaction to afford the C-8-C-9 unsatd. analogs followed by catalytic redn. to the corresponding satd. compds.  The satd. and unsatd. C-8-C-9 bridged compds. were evaluated as inhibitors of vascular endothelial growth factor receptor (VEGFR-2, Flk, KDR), epidermal growth factor receptor, and platelet-derived growth factor receptor-β (PDGFR-β).  Selected analogs were also evaluated as antiangiogenic agents in the chicken embryo chorioallantoic membrane (CAM) assay.  The compds. were also evaluated as inhibitors of human (h) DHFR and Toxoplasma gondii (tg) DHFR.  In each evaluation, a known std. compd. was used as a comparison.  Of the compds. evaluated, compd. (I) was as potent as the std. compds. against VEGFR-2 and PDGFR-β, showing dual inhibitory activity against RTK.  This analog was also highly effective in the CAM assay.  A second analog (II) also demonstrated dual VEGFR-2 and PDGFR-β inhibitory activity as well as potent antiangiogenic activity in the CAM assay.  Four addnl. analogs were also effective against PDGFR-β and in the CAM assay.  An unsatd. C-8-C-9 moiety was necessary for RTK inhibitory activity.  Compd. I also showed inhibitory activity against hDHFR and tgDHFR, illustrating the multitarget inhibitory potential of these analogs.  The biol. activity of these analogs also suggests the necessity of an unsatd. C-8-C-9 bridge for dual RTK and DHFR inhibitory activity.  Compds. II and I were also evaluated in a B16 melanoma mouse model and were found to be more active as antitumor agents than methotrexate.  In addn., both II and I were also active in decreasing lung metastases in a mouse model of B16 melanomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMnkWI8AhnqrVg90H21EOLACvtfcHk0lhIv4ImR2WFkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnslyjsro%253D&md5=055bcb04b9e0e6d6d10e3e65cab44ccd</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.04.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.04.087%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DWarnke%26aufirst%3DL.%2BA.%26aulast%3DGreen%26aufirst%3DD.%2BW.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26aulast%3DLin%26aufirst%3DF.%2BT.%26atitle%3DNovel%25205-Substituted%252C%25202%252C4-Diaminofuro%255B2%252C3-D%255DPyrimidines%2520as%2520Multireceptor%2520Tyrosine%2520Kinase%2520and%2520Dihydrofolate%2520Reductase%2520Inhibitors%2520with%2520Antiangiogenic%2520and%2520Antitumor%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26issue%3D18%26spage%3D5475%26epage%3D5491%26doi%3D10.1016%2Fj.bmc.2005.04.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnke, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cody, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queener, S. F.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and X-Ray Crystal Structures of 2,4-Diaminofuro[2,3-D]Pyrimidines as Multireceptor Tyrosine Kinase and Dihydrofolate Reductase Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">7324</span>– <span class="NLM_lpage">7336</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.08.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2009.08.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19748785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ais7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=7324-7336&issue=20&author=A.+Gangjeeauthor=W.+Liauthor=L.+Linauthor=Y.+Zengauthor=M.+Ihnatauthor=L.+A.+Warnkeauthor=D.+W.+Greenauthor=V.+Codyauthor=J.+Paceauthor=S.+F.+Queener&title=Design%2C+Synthesis%2C+and+X-Ray+Crystal+Structures+of+2%2C4-Diaminofuro%5B2%2C3-D%5DPyrimidines+as+Multireceptor+Tyrosine+Kinase+and+Dihydrofolate+Reductase+Inhibitors&doi=10.1016%2Fj.bmc.2009.08.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors</span></div><div class="casAuthors">Gangjee, Aleem; Li, Wei; Lin, Lu; Zeng, Yibin; Ihnat, Michael; Warnke, Linda A.; Green, Dixy W.; Cody, Vivian; Pace, Jim; Queener, Sherry F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7324-7336</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To optimize dual receptor tyrosine kinase (RTK) and dihydrofolate reductase (DHFR) inhibition, the E- and Z-isomers of 5-[2-(2-methoxyphenyl)prop-1-en-1-yl]furo[2,3-d]pyrimidine-2,4-diamines (I and II) were sepd. by HPLC and the X-ray crystal structures (2.0 and 1.4 Å, resp.) with mouse DHFR and NADPH as well as with human DHFR (1.5 Å) were detd.  The E- and Z-isomers adopt different binding modes when bound to mouse DHFR.  A series of 2,4-diaminofuro[2,3-d]pyrimidines were designed and synthesized using the X-ray crystal structures of I and II with DHFR to increase their DHFR inhibitory activity.  Wittig reactions of appropriate 2-methoxyphenyl ketones with 2,4-diamino-6-chloromethyl furo[2,3-d]pyrimidine afforded the C8-C9 unsatd. compds. and catalytic redn. gave the satd.  Homologation of the C9-Me analog maintains DHFR inhibitory activity.  In addn., inhibition of EGFR and PDGFR-β were discovered for satd. C9-homologated analogs that were absent in the satd. C9-Me analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ_LlusYVT1rVg90H21EOLACvtfcHk0lhIv4ImR2WFkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ais7nK&md5=d19a1a3934dff94664163160733695a4</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.08.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.08.044%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DWarnke%26aufirst%3DL.%2BA.%26aulast%3DGreen%26aufirst%3DD.%2BW.%26aulast%3DCody%26aufirst%3DV.%26aulast%3DPace%26aufirst%3DJ.%26aulast%3DQueener%26aufirst%3DS.%2BF.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520X-Ray%2520Crystal%2520Structures%2520of%25202%252C4-Diaminofuro%255B2%252C3-D%255DPyrimidines%2520as%2520Multireceptor%2520Tyrosine%2520Kinase%2520and%2520Dihydrofolate%2520Reductase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26issue%3D20%26spage%3D7324%26epage%3D7336%26doi%3D10.1016%2Fj.bmc.2009.08.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risinger, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Discovery of Water Soluble Microtubule Targeting Agents That Bind to the Colchicine Site on Tubulin and Circumvent Pgp Mediated Resistance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8116</span>– <span class="NLM_lpage">8128</span>, <span class="refDoi"> DOI: 10.1021/jm101010n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101010n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlens77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8116-8128&issue=22&author=A.+Gangjeeauthor=Y.+Zhaoauthor=L.+Linauthor=S.+Raghavanauthor=E.+G.+Robertsauthor=A.+L.+Risingerauthor=E.+Hamelauthor=S.+L.+Mooberry&title=Synthesis+and+Discovery+of+Water+Soluble+Microtubule+Targeting+Agents+That+Bind+to+the+Colchicine+Site+on+Tubulin+and+Circumvent+Pgp+Mediated+Resistance&doi=10.1021%2Fjm101010n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Discovery of Water-Soluble Microtubule Targeting Agents that Bind to the Colchicine Site on Tubulin and Circumvent Pgp Mediated Resistance</span></div><div class="casAuthors">Gangjee, Aleem; Zhao, Ying; Lin, Lu; Raghavan, Sudhir; Roberts, Elizabeth G.; Risinger, April L.; Hamel, Ernest; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8116-8128</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two classes of mols. were designed and synthesized based on a 6-CH3 cyclopenta[d]pyrimidine scaffold and a pyrrolo[2,3-d]pyrimidine scaffold.  The pyrrolo[2,3-d]pyrimidines were synthesized by reacting Et 2-cyano-4,4-diethoxybutanoate and acetamidine, which in turn was chlorinated and reacted with the appropriate anilines to afford pyrrolopyrimidines I (R = Me, H).  The cyclopenta[d]pyrimidines were obtained from 3-methyladapic acid, followed by reaction with acetamidine to afford the cyclopenta[d]pyrimidine scaffold.  Chlorination and reaction with appropriate anilines afforded cyclopentapyrimidines, II (R = 4-MeO, 3-MeO, 2-MeO, H).  Pyrimidines I (R = Me)(III) and II (R = 4-MeO)(IV) had potent antiproliferative activities in the nanomolar range.  Cyclopentapyrimidine IV is significantly more potent than pyrrolopyrimidine III.  Mechanistic studies showed that III and IV cause loss of cellular microtubules, inhibit the polymn. of purified tubulin, and inhibit colchicine binding.  Modeling studies show interactions of these compds. within the colchicine site.  The identification of these new inhibitors that can also overcome clin. relevant mechanisms of drug resistance provides new scaffolds for colchicine site agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc5L05H-4Yj7Vg90H21EOLACvtfcHk0ljahhRd8n6vvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlens77M&md5=8a0bd50260d069a868762389f24d5399</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Fjm101010n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101010n%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DE.%2BG.%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DSynthesis%2520and%2520Discovery%2520of%2520Water%2520Soluble%2520Microtubule%2520Targeting%2520Agents%2520That%2520Bind%2520to%2520the%2520Colchicine%2520Site%2520on%2520Tubulin%2520and%2520Circumvent%2520Pgp%2520Mediated%2520Resistance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D22%26spage%3D8116%26epage%3D8128%26doi%3D10.1021%2Fjm101010n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Activities of (R)- and (S)-N-(4-Methoxy-Phenyl)-N,2,6-Trimethyl-6,7-Dihydro-5h-Cyclopenta[D]Pyrimidin-4-Aminium Chloride as Potent Cytotoxic Antitubulin Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6151</span>– <span class="NLM_lpage">6155</span>, <span class="refDoi"> DOI: 10.1021/jm2007722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVWlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6151-6155&issue=17&author=A.+Gangjeeauthor=Y.+Zhaoauthor=E.+Hamelauthor=C.+Westbrookauthor=S.+L.+Mooberry&title=Synthesis+and+Biological+Activities+of+%28R%29-+and+%28S%29-N-%284-Methoxy-Phenyl%29-N%2C2%2C6-Trimethyl-6%2C7-Dihydro-5h-Cyclopenta%5BD%5DPyrimidin-4-Aminium+Chloride+as+Potent+Cytotoxic+Antitubulin+Agents&doi=10.1021%2Fjm2007722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium Chloride as Potent Cytotoxic Antitubulin Agents</span></div><div class="casAuthors">Gangjee, Aleem; Zhao, Ying; Hamel, Ernest; Westbrook, Cara; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6151-6155</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(R,S)-I is a potent antimitotic compd.  (R)-I·HCl and (S)-I·HCl were synthesized from (R)- and (S)-3-methyladipic acid.  Both enantiomers were potent inhibitors of cell proliferation and caused cellular microtubule loss and mitotic arrest.  They inhibited purified tubulin assembly and the binding of [3H]colchicine to tubulin, with (S)-I being about twice as potent.  Cytotoxicity against 60 tumor cell lines, however, indicated that the (S)-isomer was 10- to 88-fold more potent than the (R)-isomer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreGCYMkdEFH7Vg90H21EOLACvtfcHk0ljahhRd8n6vvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVWlsrk%253D&md5=7a657154e09ef127e57dc648936bcd2b</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Fjm2007722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007722%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DWestbrook%26aufirst%3DC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DSynthesis%2520and%2520Biological%2520Activities%2520of%2520%2528R%2529-%2520and%2520%2528S%2529-N-%25284-Methoxy-Phenyl%2529-N%252C2%252C6-Trimethyl-6%252C7-Dihydro-5h-Cyclopenta%255BD%255DPyrimidin-4-Aminium%2520Chloride%2520as%2520Potent%2520Cytotoxic%2520Antitubulin%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D17%26spage%3D6151%26epage%3D6155%26doi%3D10.1021%2Fjm2007722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span> <span> </span><span class="NLM_article-title">Structure Activity-Relationship and in Vitro and in Vivo Evaluation of the Potent Cytotoxic Anti-Microtubule Agent N-(4-Methoxyphenyl)-N,2,6-Trimethyl-6,7-Dihydro-5h-Cyclopenta[D]Pyrimidin-4-Aminium Chloride and Its Analogues as Antitumor Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6829</span>– <span class="NLM_lpage">6844</span>, <span class="refDoi"> DOI: 10.1021/jm400639z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400639z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOltrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6829-6844&issue=17&author=A.+Gangjeeauthor=Y.+Zhaoauthor=S.+Raghavanauthor=C.+Rohenaauthor=S.+L.+Mooberryauthor=E.+Hamel&title=Structure+Activity-Relationship+and+in+Vitro+and+in+Vivo+Evaluation+of+the+Potent+Cytotoxic+Anti-Microtubule+Agent+N-%284-Methoxyphenyl%29-N%2C2%2C6-Trimethyl-6%2C7-Dihydro-5h-Cyclopenta%5BD%5DPyrimidin-4-Aminium+Chloride+and+Its+Analogues+as+Antitumor+Agents&doi=10.1021%2Fjm400639z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship and in Vitro and in Vivo Evaluation of the Potent Cytotoxic Anti-microtubule Agent N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium Chloride and Its Analogues As Antitumor Agents</span></div><div class="casAuthors">Gangjee, Aleem; Zhao, Ying; Raghavan, Sudhir; Rohena, Cristina C.; Mooberry, Susan L.; Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6829-6844</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 21 substituted cyclopenta-[d]-pyrimidines were synthesized as an extension of authors' discovery of the parent compd. (±)-I·HCl as an anti-microtubule agent.  The structure-activity relationship indicates that the N-Me and a 4N-methoxy groups appear important for potent activity.  In addn., the 6-substituent in the parent analog is not necessary for activity.  The most potent compd. II·HCl was a one to two digit nanomolar inhibitor of most tumor cell proliferations and was up to 7-fold more potent than the parent compd. (±)-I·HCl.  In addn., II·HCl inhibited cancer cell proliferation regardless of Pgp or βIII-tubulin status, both of which are known to cause clin. resistance to several anti-tubulin agents.  In vivo efficacy of II·HCl was demonstrated against a triple neg. breast cancer xenograft mouse model.  Compd. II·HCl is water-sol. and easily synthesized and serves as a lead compd. for further preclin. evaluation as an antitumor agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy75OVrLjyoLVg90H21EOLACvtfcHk0ljsb2dY9Zfqkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOltrjL&md5=22222571e2f3a3a9ddb0b25bdbfc7236</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Fjm400639z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400639z%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DRohena%26aufirst%3DC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DStructure%2520Activity-Relationship%2520and%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520the%2520Potent%2520Cytotoxic%2520Anti-Microtubule%2520Agent%2520N-%25284-Methoxyphenyl%2529-N%252C2%252C6-Trimethyl-6%252C7-Dihydro-5h-Cyclopenta%255BD%255DPyrimidin-4-Aminium%2520Chloride%2520and%2520Its%2520Analogues%2520as%2520Antitumor%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D17%26spage%3D6829%26epage%3D6844%26doi%3D10.1021%2Fjm400639z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey-Downs, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dybdal-Hargreaves, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohena, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">The Design and Discovery of Water Soluble 4-Substituted-2,6-Dimethylfuro[2,3-D]Pyrimidines as Multitargeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3753</span>– <span class="NLM_lpage">3772</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2014.04.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24890652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=3753-3772&issue=14&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=J.+E.+Thorpeauthor=B.+C.+Dischauthor=A.+Bastianauthor=L.+C.+Bailey-Downsauthor=N.+F.+Dybdal-Hargreavesauthor=C.+C.+Rohenaauthor=E.+Hamelauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+Design+and+Discovery+of+Water+Soluble+4-Substituted-2%2C6-Dimethylfuro%5B2%2C3-D%5DPyrimidines+as+Multitargeted+Receptor+Tyrosine+Kinase+Inhibitors+and+Microtubule+Targeting+Antitumor+Agents&doi=10.1016%2Fj.bmc.2014.04.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents</span></div><div class="casAuthors">Zhang, Xin; Raghavan, Sudhir; Ihnat, Michael; Thorpe, Jessica E.; Disch, Bryan C.; Bastian, Anja; Bailey-Downs, Lora C.; Dybdal-Hargreaves, Nicholas F.; Rohena, Cristina C.; Hamel, Ernest; Mooberry, Susan L.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3753-3772</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The design, synthesis and biol. evaluations of fourteen 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines are reported.  Four compds. inhibit vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor β (PDGFR-β), and target tubulin leading to cytotoxicity.  Compd. I has nanomolar potency, comparable to sunitinib and semaxinib, against tumor cell lines overexpressing VEGFR-2 and PDGFR-β.  Further, I binds at the colchicine site on tubulin, depolymerizes cellular microtubules and inhibits purified tubulin assembly and overcomes both βIII-tubulin and P-glycoprotein-mediated drug resistance, and initiates mitotic arrest leading to apoptosis.  In vivo, its HCl salt, I·HCl, reduced tumor size and vascularity in xenograft and allograft murine models and was superior to docetaxel and sunitinib, without overt toxicity.  Thus I·HCl affords potential combination chemotherapy in a single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz0a4q7mfRm7Vg90H21EOLACvtfcHk0ljsb2dY9Zfqkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCns78%253D&md5=b35cd4ed7f053ea14d7ef5ee33828b38</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DDisch%26aufirst%3DB.%2BC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DBailey-Downs%26aufirst%3DL.%2BC.%26aulast%3DDybdal-Hargreaves%26aufirst%3DN.%2BF.%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520Design%2520and%2520Discovery%2520of%2520Water%2520Soluble%25204-Substituted-2%252C6-Dimethylfuro%255B2%252C3-D%255DPyrimidines%2520as%2520Multitargeted%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%2520and%2520Microtubule%2520Targeting%2520Antitumor%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26issue%3D14%26spage%3D3753%26epage%3D3772%26doi%3D10.1016%2Fj.bmc.2014.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zammiello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">The Design, Synthesis and Biological Evaluation of Conformationally Restricted 4-Substituted-2,6-Dimethylfuro[2,3-D]Pyrimidines as Multi-Targeted Receptor Tyrosine Kinase and Microtubule Inhibitors as Potential Antitumor Agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2423</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2015.03.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25882519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1Gmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2408-2423&issue=10&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=E.+Hamelauthor=C.+Zammielloauthor=A.+Bastianauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+Design%2C+Synthesis+and+Biological+Evaluation+of+Conformationally+Restricted+4-Substituted-2%2C6-Dimethylfuro%5B2%2C3-D%5DPyrimidines+as+Multi-Targeted+Receptor+Tyrosine+Kinase+and+Microtubule+Inhibitors+as+Potential+Antitumor+Agents&doi=10.1016%2Fj.bmc.2015.03.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents</span></div><div class="casAuthors">Zhang, Xin; Raghavan, Sudhir; Ihnat, Michael; Hamel, Ernest; Zammiello, Cynthia; Bastian, Anja; Mooberry, Susan L.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2408-2423</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of eleven conformationally restricted, 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines was designed to explore the bioactive conformation required for dual inhibition of microtubule assembly and receptor tyrosine kinases (RTKs), and their biol. activities are reported.  All three rotatable single bonds in the lead compd. were sequentially restricted to address the role of each in SAR for microtubule and RTK inhibitory effects.  Several compds. showed microtubule depolymg. activity comparable to or better than the lead compd., some with nanomolar EC50 values.  One compd. had no effect on microtubules, others showed potent RTK inhibition with nanomolar IC50s.  These compds. confirm that the bioactive conformation for RTK inhibition is different from that for tubulin inhibition.  A tetrahydroquinoline analog showed the most potent dual tubulin inhibitors (i.e., tubulin polymn. inhibitors, microtubule-disrupting agents) and RTK inhibitory activities [i.e., low nanomolar inhibition of epidermal growth factor receptors (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived growth factor receptor β (PDGFR-β)].  The tetrahydroquinoline analog has highly potent activity against many NCI cancer cell lines, including several chemo-resistant cell lines, and could serve as a lead for further preclin. studies.  The synthesis of the target compds. was achieved by a reaction of 4-chloro-2,6-dimethylfuro[2,3-d]pyrimidine with amine derivs., such as benzenamine derivs., benzofuranamine derivs., tetrahydroquinoline derivs., indole derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3IUVQLu9YarVg90H21EOLACvtfcHk0lgL635ipyn2kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1Gmu78%253D&md5=4a6d65424606155db3ab4ec5751ad213</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.061%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DZammiello%26aufirst%3DC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520Design%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Conformationally%2520Restricted%25204-Substituted-2%252C6-Dimethylfuro%255B2%252C3-D%255DPyrimidines%2520as%2520Multi-Targeted%2520Receptor%2520Tyrosine%2520Kinase%2520and%2520Microtubule%2520Inhibitors%2520as%2520Potential%2520Antitumor%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26issue%3D10%26spage%3D2408%26epage%3D2423%26doi%3D10.1016%2Fj.bmc.2015.03.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derrick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehrani, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruotolo, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span> <span> </span><span class="NLM_article-title">Structure-Mechanism-Based Engineering of Chemical Regulators Targeting Distinct Pathological Factors in Alzheimer’s Disease</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13115</span>– <span class="NLM_lpage">13127</span>, <span class="refDoi"> DOI: 10.1038/ncomms13115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fncomms13115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27734843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSitb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13115-13127&author=M.+W.+Beckauthor=J.+S.+Derrickauthor=R.+A.+Kerrauthor=S.+B.+Ohauthor=W.+J.+Choauthor=S.+J.+Leeauthor=Y.+Jiauthor=J.+Hanauthor=Z.+A.+Tehraniauthor=N.+Suhauthor=S.+Kimauthor=S.+D.+Larsenauthor=K.+S.+Kimauthor=J.+Y.+Leeauthor=B.+T.+Ruotoloauthor=M.+H.+Lim&title=Structure-Mechanism-Based+Engineering+of+Chemical+Regulators+Targeting+Distinct+Pathological+Factors+in+Alzheimer%E2%80%99s+Disease&doi=10.1038%2Fncomms13115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-mechanism-based engineering of chemical regulators targeting distinct pathological factors in Alzheimer's disease</span></div><div class="casAuthors">Beck, Michael W.; Derrick, Jeffrey S.; Kerr, Richard A.; Oh, Shin Bi; Cho, Woo Jong; Lee, Shin Jung C.; Ji, Yonghwan; Han, Jiyeon; Tehrani, Zahra Aliakbar; Suh, Nayoung; Kim, Sujeong; Larsen, Scott D.; Kim, Kwang S.; Lee, Joo-Yong; Ruotolo, Brandon T.; Lim, Mi Hee</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13115</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The absence of effective therapeutics against Alzheimer's disease (AD) is a result of the limited understanding of its multifaceted etiol.  Because of the lack of chem. tools to identify pathol. factors, investigations into AD pathogenesis have also been insubstantial.  Here we report chem. regulators that demonstrate distinct specificity towards targets linked to AD pathol., including metals, amyloid-β (Aβ), metal-Aβ, reactive oxygen species, and free org. radicals.  We obtained these chem. regulators through a rational structure-mechanism-based design strategy.  We performed structural variations of small mols. for fine-tuning their electronic properties, such as ionization potentials and mechanistic pathways for reactivity towards different targets.  We established in vitro and/or in vivo efficacies of the regulators for modulating their targets' reactivities, ameliorating toxicity, reducing amyloid pathol., and improving cognitive deficits.  Our chem. tools show promise for deciphering AD pathogenesis and discovering effective drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4uSKnEfAtfrVg90H21EOLACvtfcHk0lgL635ipyn2kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSitb3P&md5=c92d00abedc661f493e496ba21f20879</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1038%2Fncomms13115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13115%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DM.%2BW.%26aulast%3DDerrick%26aufirst%3DJ.%2BS.%26aulast%3DKerr%26aufirst%3DR.%2BA.%26aulast%3DOh%26aufirst%3DS.%2BB.%26aulast%3DCho%26aufirst%3DW.%2BJ.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DTehrani%26aufirst%3DZ.%2BA.%26aulast%3DSuh%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLarsen%26aufirst%3DS.%2BD.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DRuotolo%26aufirst%3DB.%2BT.%26aulast%3DLim%26aufirst%3DM.%2BH.%26atitle%3DStructure-Mechanism-Based%2520Engineering%2520of%2520Chemical%2520Regulators%2520Targeting%2520Distinct%2520Pathological%2520Factors%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13115%26epage%3D13127%26doi%3D10.1038%2Fncomms13115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derrick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earnest, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozbil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korshavn, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merino, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shearer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruotolo, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span> <span> </span><span class="NLM_article-title">A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates: In Vitro and in Vivo Efficacy and Molecular Mechanisms</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">14785</span>– <span class="NLM_lpage">14797</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b10043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b10043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVGmt7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=14785-14797&issue=46&author=J.+S.+Derrickauthor=R.+A.+Kerrauthor=Y.+Namauthor=S.+B.+Ohauthor=H.+J.+Leeauthor=K.+G.+Earnestauthor=N.+Suhauthor=K.+L.+Peckauthor=M.+Ozbilauthor=K.+J.+Korshavnauthor=A.+Ramamoorthyauthor=R.+Prabhakarauthor=E.+J.+Merinoauthor=J.+Shearerauthor=J.+Y.+Leeauthor=B.+T.+Ruotoloauthor=M.+H.+Lim&title=A+Redox-Active%2C+Compact+Molecule+for+Cross-Linking+Amyloidogenic+Peptides+into+Nontoxic%2C+Off-Pathway+Aggregates%3A+In+Vitro+and+in+Vivo+Efficacy+and+Molecular+Mechanisms&doi=10.1021%2Fjacs.5b10043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates: In Vitro and In Vivo Efficacy and Molecular Mechanisms</span></div><div class="casAuthors">Derrick, Jeffrey S.; Kerr, Richard A.; Nam, Younwoo; Oh, Shin Bi; Lee, Hyuck Jin; Earnest, Kaylin G.; Suh, Nayoung; Peck, Kristy L.; Ozbil, Mehmet; Korshavn, Kyle J.; Ramamoorthy, Ayyalusamy; Prabhakar, Rajeev; Merino, Edward J.; Shearer, Jason; Lee, Joo-Yong; Ruotolo, Brandon T.; Lim, Mi Hee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">14785-14797</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chem. reagents targeting and controlling amyloidogenic peptides have received much attention for helping identify their roles in the pathogenesis of protein-misfolding disorders.  Herein, the authors report a novel strategy for redirecting amyloidogenic peptides into nontoxic, off-pathway aggregates, which utilizes redox properties of a small mol. (DMPD, N,N-dimethyl-p-phenylenediamine) to trigger covalent adduct formation with the peptide.  In addn., for the first time, biochem., biophys., and mol. dynamics simulation studies have been performed to demonstrate a mechanistic understanding for such an interaction between a small mol. (DMPD) and amyloid-β (Aβ) and its subsequent anti-amyloidogenic activity, which, upon its transformation, generates ligand-peptide adducts via primary amine-dependent intramol. crosslinking correlated with structural compaction.  Furthermore, in vivo efficacy of DMPD toward amyloid pathol. and cognitive impairment was evaluated employing 5xFAD mice of Alzheimer's disease (AD).  Such a small mol. (DMPD) is indicated to noticeably reduce the overall cerebral amyloid load of sol. Aβ forms and amyloid deposits as well as significantly improve cognitive defects in the AD mouse model.  Overall, the authors' in vitro and in vivo studies of DMPD toward Aβ with the first mol.-level mechanistic investigations present the feasibility of developing new, innovative approaches that employ redox-active compds. without the structural complexity as next-generation chem. tools for amyloid management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVgBBoRUmXObVg90H21EOLACvtfcHk0lgC9Esx5RtvrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVGmt7fL&md5=f95a3cad02c9a2752ea0389e69820943</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b10043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b10043%26sid%3Dliteratum%253Aachs%26aulast%3DDerrick%26aufirst%3DJ.%2BS.%26aulast%3DKerr%26aufirst%3DR.%2BA.%26aulast%3DNam%26aufirst%3DY.%26aulast%3DOh%26aufirst%3DS.%2BB.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DEarnest%26aufirst%3DK.%2BG.%26aulast%3DSuh%26aufirst%3DN.%26aulast%3DPeck%26aufirst%3DK.%2BL.%26aulast%3DOzbil%26aufirst%3DM.%26aulast%3DKorshavn%26aufirst%3DK.%2BJ.%26aulast%3DRamamoorthy%26aufirst%3DA.%26aulast%3DPrabhakar%26aufirst%3DR.%26aulast%3DMerino%26aufirst%3DE.%2BJ.%26aulast%3DShearer%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DRuotolo%26aufirst%3DB.%2BT.%26aulast%3DLim%26aufirst%3DM.%2BH.%26atitle%3DA%2520Redox-Active%252C%2520Compact%2520Molecule%2520for%2520Cross-Linking%2520Amyloidogenic%2520Peptides%2520into%2520Nontoxic%252C%2520Off-Pathway%2520Aggregates%253A%2520In%2520Vitro%2520and%2520in%2520Vivo%2520Efficacy%2520and%2520Molecular%2520Mechanisms%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26issue%3D46%26spage%3D14785%26epage%3D14797%26doi%3D10.1021%2Fjacs.5b10043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gandini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gonzalez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaldivar-Diez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccheri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petralla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legname, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7640</span>– <span class="NLM_lpage">7656</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00610</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00610" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVChu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7640-7656&issue=17&author=A.+Gandiniauthor=M.+Bartoliniauthor=D.+Tedescoauthor=L.+Martinez-Gonzalezauthor=C.+Rocaauthor=N.+E.+Campilloauthor=J.+Zaldivar-Diezauthor=C.+Perezauthor=G.+Zuccheriauthor=A.+Mitiauthor=A.+Feoliauthor=S.+Castellanoauthor=S.+Petrallaauthor=B.+Montiauthor=M.+Rossiauthor=F.+Modaauthor=G.+Legnameauthor=A.+Martinezauthor=M.+L.+Bolognesi&title=Tau-Centric+Multitarget+Approach+for+Alzheimer%E2%80%99s+Disease%3A+Development+of+First-in-Class+Dual+Glycogen+Synthase+Kinase+3%CE%B2+and+Tau-Aggregation+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors</span></div><div class="casAuthors">Gandini, Annachiara; Bartolini, Manuela; Tedesco, Daniele; Martinez-Gonzalez, Loreto; Roca, Carlos; Campillo, Nuria E.; Zaldivar-Diez, Josefa; Perez, Concepcion; Zuccheri, Giampaolo; Miti, Andrea; Feoli, Alessandra; Castellano, Sabrina; Petralla, Sabrina; Monti, Barbara; Rossi, Martina; Moda, Fabio; Legname, Giuseppe; Martinez, Ana; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7640-7656</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several findings propose the altered tau protein network as an important target for Alzheimer's disease (AD).  Particularly, two points of pharmacol. intervention can be envisaged: inhibition of phosphorylating tau kinase GSK-3β and tau aggregation process.  On the basis of this consideration and on the authors' interest in multitarget paradigms in AD, the authors report on the discovery of 2,4-thiazolidinedione derivs. endowed with such a profile. 28 and 30 displayed micromolar IC50 values toward GSK-3β, together with the capacity of inhibiting AcPHF6 aggregation of 60% and 80% at 10 μM, resp.  In addn., they showed PAMPA-BBB permeability, together with a suitable cellular safety profile. 30 also displayed inhibition of both K18 and full-length tau aggregations.  Finally, both compds. were able to improve cell viability in an okadaic acid-induced neurodegeneration cell model.  To the best of the authors' knowledge, 28 and 30 are the first balanced, nontoxic, dual-acting compds. hitting tau cascade at two different hubs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6bQV6XoAhyrVg90H21EOLACvtfcHk0lhX2BBjPLCEKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVChu7%252FL&md5=34b7e2f2556f3e96c768dd87fb3f0e6d</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00610%26sid%3Dliteratum%253Aachs%26aulast%3DGandini%26aufirst%3DA.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DTedesco%26aufirst%3DD.%26aulast%3DMartinez-Gonzalez%26aufirst%3DL.%26aulast%3DRoca%26aufirst%3DC.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DZaldivar-Diez%26aufirst%3DJ.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DZuccheri%26aufirst%3DG.%26aulast%3DMiti%26aufirst%3DA.%26aulast%3DFeoli%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DS.%26aulast%3DPetralla%26aufirst%3DS.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DRossi%26aufirst%3DM.%26aulast%3DModa%26aufirst%3DF.%26aulast%3DLegname%26aufirst%3DG.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DTau-Centric%2520Multitarget%2520Approach%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Development%2520of%2520First-in-Class%2520Dual%2520Glycogen%2520Synthase%2520Kinase%25203%25CE%25B2%2520and%2520Tau-Aggregation%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7640%26epage%3D7656%26doi%3D10.1021%2Facs.jmedchem.8b00610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duran-Frigola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siragusa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruppin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruciani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aloy, P.</span></span> <span> </span><span class="NLM_article-title">Detecting Similar Binding Pockets to Enable Systems Polypharmacology</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e1005522</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1005522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1371%2Fjournal.pcbi.1005522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28662117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1agurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=e1005522&issue=6&author=M.+Duran-Frigolaauthor=L.+Siragusaauthor=E.+Ruppinauthor=X.+Barrilauthor=G.+Crucianiauthor=P.+Aloy&title=Detecting+Similar+Binding+Pockets+to+Enable+Systems+Polypharmacology&doi=10.1371%2Fjournal.pcbi.1005522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Detecting similar binding pockets to enable systems polypharmacology</span></div><div class="casAuthors">Duran-Frigola, Miquel; Siragusa, Lydia; Ruppin, Eytan; Barril, Xavier; Cruciani, Gabriele; Aloy, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1005522/1-e1005522/18</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In the era of systems biol., multi-target pharmacol. strategies hold promise for tackling disease-related networks.  In this regard, drug promiscuity may be leveraged to interfere with multiple receptors: the so-called polypharmacol. of drugs can be anticipated by analyzing the similarity of binding sites across the proteome.  Here, we perform a pairwise comparison of 90,000 putative binding pockets detected in 3,700 proteins, and find that 23,000 pairs of proteins have at least one similar cavity that could, in principle, accommodate similar ligands.  By inspecting these pairs, we demonstrate how the detection of similar binding sites expands the space of opportunities for the rational design of drug polypharmacol.  Finally, we illustrate how to leverage these opportunities in protein-protein interaction networks related to several therapeutic classes and tumor types, and in a genome-scale metabolic model of leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrncR4y_CryxbVg90H21EOLACvtfcHk0lhX2BBjPLCEKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1agurnE&md5=568e97aa21976360c76610cdfd4dbfd7</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005522%26sid%3Dliteratum%253Aachs%26aulast%3DDuran-Frigola%26aufirst%3DM.%26aulast%3DSiragusa%26aufirst%3DL.%26aulast%3DRuppin%26aufirst%3DE.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DAloy%26aufirst%3DP.%26atitle%3DDetecting%2520Similar%2520Binding%2520Pockets%2520to%2520Enable%2520Systems%2520Polypharmacology%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D6%26spage%3De1005522%26doi%3D10.1371%2Fjournal.pcbi.1005522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">466</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.3390/molecules21040466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3390%2Fmolecules21040466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27070562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWktLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=466-477&issue=4&author=F.+Pratiauthor=A.+Cavalliauthor=M.+L.+Bolognesi&title=Navigating+the+Chemical+Space+of+Multitarget-Directed+Ligands%3A+From+Hybrids+to+Fragments+in+Alzheimer%E2%80%99s+Disease&doi=10.3390%2Fmolecules21040466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Navigating the chemical space of multitarget-directed ligands: from hybrids to fragments in Alzheimer's disease</span></div><div class="casAuthors">Prati, Federica; Cavalli, Andrea; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">466/1-466/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Multitarget drug discovery is one of the hottest topics and most active fields in the search for new mols. against Alzheimer's disease (AD).  Over the last 20 years, many promising multitarget-directed ligands (MTDLs) have been identified and developed at a pre-clin. level.  However, how to design them in a rational way remains the most fundamental challenge of medicinal chemists.  This is related to the foundational question of achieving an optimized activity towards multiple targets of interest, while preserving drug-like properties.  In this respect, large hybrid mols. and small fragments are poles apart.  In this review article, our aim is to appraise what we have accomplished in the development of both hybrid- and fragment-like mols. directed to diverse AD targets (i.e., acetylcholinesterase, NMDA receptors, metal chelation, BACE-1 and GSK-3β).  In addn., we attempt to highlight what are the persistent needs that deserve to be improved and cared for, with the ultimate goal of moving an MTDL to AD clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAXsoof4raqbVg90H21EOLACvtfcHk0lhX2BBjPLCEKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWktLjI&md5=3653a0ef6b41711663e8d2f2d4ae74f6</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21040466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21040466%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DNavigating%2520the%2520Chemical%2520Space%2520of%2520Multitarget-Directed%2520Ligands%253A%2520From%2520Hybrids%2520to%2520Fragments%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26issue%3D4%26spage%3D466%26epage%3D477%26doi%3D10.3390%2Fmolecules21040466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanfar, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaddoumi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Sayed, K. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel GSK-3β Inhibitors with Potent in Vitro and in Vivo Activities and Excellent Brain Permeability Using Combined Ligand- and Structure-Based Virtual Screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">8534</span>– <span class="NLM_lpage">8545</span>, <span class="refDoi"> DOI: 10.1021/jm100941j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100941j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8534-8545&issue=24&author=M.+A.+Khanfarauthor=R.+A.+Hillauthor=A.+Kaddoumiauthor=K.+A.+El+Sayed&title=Discovery+of+Novel+GSK-3%CE%B2+Inhibitors+with+Potent+in+Vitro+and+in+Vivo+Activities+and+Excellent+Brain+Permeability+Using+Combined+Ligand-+and+Structure-Based+Virtual+Screening&doi=10.1021%2Fjm100941j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel GSK-3β Inhibitors with Potent in Vitro and in Vivo Activities and Excellent Brain Permeability Using Combined Ligand- and Structure-Based Virtual Screening</span></div><div class="casAuthors">Khanfar, Mohammad A.; Hill, Ronald A.; Kaddoumi, Amal; El Sayed, Khalid A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8534-8545</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulation of glycogen synthase kinase (GSK-3β) is implicated in the pathophysiol. of many diseases, including type-2 diabetes, stroke, Alzheimer's, and others.  A multistage virtual screening strategy designed to overcome known caveats arising from the considerable flexibility of GSK-3β yielded, from among compds. in our inhouse database and two com. databases, new GSK-3β inhibitors with novel scaffold structures.  The two most potent and selective validated hits, a 2-anilino-5-phenyl-1,3,4-oxadiazole (24) and a phenylmethylene hydantoin (28), both exhibited nanomolar affinity and selectivity over CDK2 and were potent enough for direct in vivo validation.  Both were able to cause significant increases in liver glycogen accumulation in dose-dependent fashion.  One also exhibited excellent blood-brain barrier permeability, the other adequate for a lead compd.  Analogs of the oxadiazole 24 were synthesized to exptl. corroborate or rule out ligand-bound structures arising from docking studies.  SAR results supported one docking study among a no. of alternatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonQs-nSeLYcrVg90H21EOLACvtfcHk0lgSsYl1emnyAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksb%252FF&md5=c58e912dea590063241a5a6554639009</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Fjm100941j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100941j%26sid%3Dliteratum%253Aachs%26aulast%3DKhanfar%26aufirst%3DM.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BA.%26aulast%3DKaddoumi%26aufirst%3DA.%26aulast%3DEl%2BSayed%26aufirst%3DK.%2BA.%26atitle%3DDiscovery%2520of%2520Novel%2520GSK-3%25CE%25B2%2520Inhibitors%2520with%2520Potent%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Activities%2520and%2520Excellent%2520Brain%2520Permeability%2520Using%2520Combined%2520Ligand-%2520and%2520Structure-Based%2520Virtual%2520Screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D24%26spage%3D8534%26epage%3D8545%26doi%3D10.1021%2Fjm100941j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arfeen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborti, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharatam, P. V.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of 5-Benzylidene-2-Iminothiazolidin-4-Ones as Selective GSK-3β Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.04.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2016.04.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27423119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtF2hs7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=727-736&author=M.+Arfeenauthor=S.+Bhagatauthor=R.+Patelauthor=S.+Prasadauthor=I.+Royauthor=A.+K.+Chakrabortiauthor=P.+V.+Bharatam&title=Design%2C+Synthesis+and+Biological+Evaluation+of+5-Benzylidene-2-Iminothiazolidin-4-Ones+as+Selective+GSK-3%CE%B2+Inhibitors&doi=10.1016%2Fj.ejmech.2016.04.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors</span></div><div class="casAuthors">Arfeen, Minhajul; Bhagat, Shweta; Patel, Rahul; Prasad, Shivcharan; Roy, Ipsita; Chakraborti, Asit K.; Bharatam, Prasad V.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">727-736</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, iminothiazolidin-4-one derivs. were explored as selective GSK-3β inhibitors.  Mol. docking anal. was carried to design a series of compds., which were synthesized using substituted thioureas, Et chloroacetate and benzaldehydes.  Out of the twenty five compds. synthesized during this work, the in vitro evaluation against GSK-3 led to the identification of nine compds. with activity in lower nano-molar range (2-85 nM).  Further, in vitro evaluation against CDK-2 showed five compds. to be selective towards GSK-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquv-FRHRtwRbVg90H21EOLACvtfcHk0lgSsYl1emnyAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtF2hs7vJ&md5=fae12d7afdb57bf8512a0f8fbe481056</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.04.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.04.075%26sid%3Dliteratum%253Aachs%26aulast%3DArfeen%26aufirst%3DM.%26aulast%3DBhagat%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DI.%26aulast%3DChakraborti%26aufirst%3DA.%2BK.%26aulast%3DBharatam%26aufirst%3DP.%2BV.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25205-Benzylidene-2-Iminothiazolidin-4-Ones%2520as%2520Selective%2520GSK-3%25CE%25B2%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D727%26epage%3D736%26doi%3D10.1016%2Fj.ejmech.2016.04.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, F. J.</span></span> <span> </span><span class="NLM_article-title">First Non-ATP Competitive Glycogen Synthase Kinase 3β(GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer’s Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1292</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1021/jm011020u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm011020u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFCgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1292-1299&issue=6&author=A.+Martinezauthor=M.+Alonsoauthor=A.+Castroauthor=C.+P%C3%A9rezauthor=F.+J.+Moreno&title=First+Non-ATP+Competitive+Glycogen+Synthase+Kinase+3%CE%B2%28GSK-3%CE%B2%29+Inhibitors%3A+Thiadiazolidinones+%28TDZD%29+as+Potential+Drugs+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fjm011020u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">First Non-ATP Competitive Glycogen Synthase Kinase 3β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Martinez, Ana; Alonso, Mercedes; Castro, Ana; Perez, Concepcion; Moreno, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1292-1299</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3β (GSK-3β) has a central role in Alzheimer's disease (AD).  Selective inhibitors which avoid τ hyperphosphorylation may represent an effective therapeutic approach to the pharmacotherapy of AD and other neurodegenerative disorders.  The synthesis, biol. evaluation, and SAR of some thiadiazolidinones (TDZD) as the first non-ATP competitive inhibitor of GSK-3β.  Their synthesis is based on the reactivity of sulfenyl chlorides.  In GSK-3β assays, TDZD derivs. showed IC50 values in the micromolar range, whereas in other protein kinase assays they were devoid of any inhibitory activity.  SAR studies allowed the identification of the key structural features.  Finally, a possible enzymic binding mode is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofQZkRe2BHh7Vg90H21EOLACvtfcHk0lhEgTHQOOeY9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFCgu70%253D&md5=a364133d1035bee183c58ad30ac140f8</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Fjm011020u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm011020u%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DCastro%26aufirst%3DA.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DF.%2BJ.%26atitle%3DFirst%2520Non-ATP%2520Competitive%2520Glycogen%2520Synthase%2520Kinase%25203%25CE%25B2%2528GSK-3%25CE%25B2%2529%2520Inhibitors%253A%2520Thiadiazolidinones%2520%2528TDZD%2529%2520as%2520Potential%2520Drugs%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26issue%3D6%26spage%3D1292%26epage%3D1299%26doi%3D10.1021%2Fjm011020u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palomo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Muela, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Garcia, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Castillo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timchenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span> <span> </span><span class="NLM_article-title">Subtly Modulating Glycogen Synthase Kinase 3β: Allosteric Inhibitors Development and Their Potential for the Treatment of Chronic Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4983</span>– <span class="NLM_lpage">5001</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00395</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00395" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1SgurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4983-5001&issue=12&author=V.+Palomoauthor=D.+I.+P%C3%A9rezauthor=C.+Rocaauthor=C.+Andersonauthor=N.+Rodriguez-Muelaauthor=C.+P%C3%A9rezauthor=J.+A.+Morales-Garciaauthor=J.+A.+Reyesauthor=N.+E.+Campilloauthor=A.+M.+P%C3%A9rez-Castilloauthor=L.+L.+Rubinauthor=L.+Timchenkoauthor=C.+Gilauthor=A.+Martinez&title=Subtly+Modulating+Glycogen+Synthase+Kinase+3%CE%B2%3A+Allosteric+Inhibitors+Development+and+Their+Potential+for+the+Treatment+of+Chronic+Diseases&doi=10.1021%2Facs.jmedchem.7b00395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases</span></div><div class="casAuthors">Palomo, Valle; Perez, Daniel I.; Roca, Carlos; Anderson, Cara; Rodriguez-Muela, Natalia; Perez, Concepcion; Morales-Garcia, Jose A.; Reyes, Julio A.; Campillo, Nuria E.; Perez-Castillo, Ana M.; Rubin, Lee L.; Timchenko, Lubov; Gil, Carmen; Martinez, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4983-5001</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3β (GSK-3β) is a central target in several unmet diseases.  To increase the specificity of GSK-3β inhibitors in chronic treatments, we developed small mols. allowing subtle modulation of GSK-3β activity.  Design synthesis, structure-activity relationships, and binding mode of quinoline-3-carbohydrazide derivs. as allosteric modulators of GSK-3β are presented here.  Furthermore, we show how allosteric binders may overcome the β-catenin side effects assocd. with strong GSK-3β inhibition.  The therapeutic potential of some of these modulators has been tested in human samples from patients with congenital myotonic dystrophy type 1 (CDM1) and spinal muscular atrophy (SMA) patients.  We found that compd. I (R1 = 6-Br, R2 = Et, R3 = C11H23) improves delayed myogenesis in CDM1 myoblasts, while compds. I (R1 = H, 6-Br, R2 = Et, R3 = C11H23) have neuroprotective properties in SMA-derived cells.  These findings suggest that the allosteric modulators of GSK-3β may be used for future development of drugs for DM1, SMA, and other chronic diseases where GSK-3β inhibition exhibits therapeutic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGottlg1vBoPw7Vg90H21EOLACvtfcHk0lhEgTHQOOeY9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1SgurY%253D&md5=858ba99deb166b43a488c1141c40ff63</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00395%26sid%3Dliteratum%253Aachs%26aulast%3DPalomo%26aufirst%3DV.%26aulast%3DP%25C3%25A9rez%26aufirst%3DD.%2BI.%26aulast%3DRoca%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DC.%26aulast%3DRodriguez-Muela%26aufirst%3DN.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DMorales-Garcia%26aufirst%3DJ.%2BA.%26aulast%3DReyes%26aufirst%3DJ.%2BA.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DP%25C3%25A9rez-Castillo%26aufirst%3DA.%2BM.%26aulast%3DRubin%26aufirst%3DL.%2BL.%26aulast%3DTimchenko%26aufirst%3DL.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DSubtly%2520Modulating%2520Glycogen%2520Synthase%2520Kinase%25203%25CE%25B2%253A%2520Allosteric%2520Inhibitors%2520Development%2520and%2520Their%2520Potential%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D12%26spage%3D4983%26epage%3D5001%26doi%3D10.1021%2Facs.jmedchem.7b00395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khlistunova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biernat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span> <span> </span><span class="NLM_article-title">Rhodanine-Based Tau Aggregation Inhibitors in Cell Models of Tauopathy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">9215</span>– <span class="NLM_lpage">9219</span>, <span class="refDoi"> DOI: 10.1002/anie.200704051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fanie.200704051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BD2sjjtlSltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=9215-9219&issue=48&author=B.+Bulicauthor=M.+Pickhardtauthor=I.+Khlistunovaauthor=J.+Biernatauthor=E.-M.+Mandelkowauthor=E.+Mandelkowauthor=H.+Waldmann&title=Rhodanine-Based+Tau+Aggregation+Inhibitors+in+Cell+Models+of+Tauopathy&doi=10.1002%2Fanie.200704051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Rhodanine-based tau aggregation inhibitors in cell models of tauopathy</span></div><div class="casAuthors">Bulic Bruno; Pickhardt Marcus; Khlistunova Inna; Biernat Jacek; Mandelkow Eva-Maria; Mandelkow Eckhard; Waldmann Herbert</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">9215-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScsfK7C2PCgf6xYuD7tu2XfW6udTcc2ebc44OR2p-3BLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjjtlSltg%253D%253D&md5=9948b3054bae5ce9e52d0ce3d4635788</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1002%2Fanie.200704051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200704051%26sid%3Dliteratum%253Aachs%26aulast%3DBulic%26aufirst%3DB.%26aulast%3DPickhardt%26aufirst%3DM.%26aulast%3DKhlistunova%26aufirst%3DI.%26aulast%3DBiernat%26aufirst%3DJ.%26aulast%3DMandelkow%26aufirst%3DE.-M.%26aulast%3DMandelkow%26aufirst%3DE.%26aulast%3DWaldmann%26aufirst%3DH.%26atitle%3DRhodanine-Based%2520Tau%2520Aggregation%2520Inhibitors%2520in%2520Cell%2520Models%2520of%2520Tauopathy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2007%26volume%3D46%26issue%3D48%26spage%3D9215%26epage%3D9219%26doi%3D10.1002%2Fanie.200704051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendgen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C. D.</span></span> <span> </span><span class="NLM_article-title">Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">743</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1021/jm201243p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201243p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGkt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=743-753&issue=2&author=T.+Mendgenauthor=C.+Steuerauthor=C.+D.+Klein&title=Privileged+Scaffolds+or+Promiscuous+Binders%3A+A+Comparative+Study+on+Rhodanines+and+Related+Heterocycles+in+Medicinal+Chemistry&doi=10.1021%2Fjm201243p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry</span></div><div class="casAuthors">Mendgen, Thomas; Steuer, Christian; Klein, Christian D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">743-753</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rhodanines and related five-membered heterocycles with multiple heteroatoms have recently gained a reputation of being unselective compds. that appear as "frequent hitters" in screening campaigns and therefore have little value in drug discovery.  However, this judgment appears to be based mostly on anecdotal evidence.  Having identified various rhodanines and related compds. in screening campaigns, we decided to perform a systematic study on their promiscuity.  An amt. of 163 rhodanines, hydantoins, thiohydantoins, and thiazolidinediones were synthesized and tested against several targets.  The compds. were also characterized with respect to aggregation and electrophilic reactivity, and the binding modes of rhodanines and related compds. in published x-ray cocrystal structures were analyzed.  The results indicate that the exocyclic, double bonded sulfur atom in rhodanines and thiohydantoins, in addn. to other structural features, offers a particularly high d. of interaction sites for polar interactions and hydrogen bonds.  This causes a promiscuous behavior at concns. in the "screening range" but should not be regarded as a general knockout criterion that excludes such screening hits from further development.  It is suggested that special criteria for target affinity and selectivity are applied to these classes of compds. and that their exceptional and potentially valuable biomol. binding properties are consequently exploited in a useful way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLzna8Pcz1iLVg90H21EOLACvtfcHk0lgB9_lFbdUDZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGkt7nN&md5=6a94d097f44bdbaaec9a56fd6b371521</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Fjm201243p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201243p%26sid%3Dliteratum%253Aachs%26aulast%3DMendgen%26aufirst%3DT.%26aulast%3DSteuer%26aufirst%3DC.%26aulast%3DKlein%26aufirst%3DC.%2BD.%26atitle%3DPrivileged%2520Scaffolds%2520or%2520Promiscuous%2520Binders%253A%2520A%2520Comparative%2520Study%2520on%2520Rhodanines%2520and%2520Related%2520Heterocycles%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D2%26spage%3D743%26epage%3D753%26doi%3D10.1021%2Fjm201243p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J.</span></span> <span> </span><span class="NLM_article-title">Seven Year Itch. Pan-Assay Interference Compounds (Pains) in 2017 - Utility and Limitations</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00903</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00903" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=36-44&issue=1&author=J.+B.+Baellauthor=J.+Nissink&title=Seven+Year+Itch.+Pan-Assay+Interference+Compounds+%28Pains%29+in+2017+-+Utility+and+Limitations&doi=10.1021%2Facschembio.7b00903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations</span></div><div class="casAuthors">Baell, Jonathan B.; Nissink, J. Willem M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on all necessary considerations for the appropriate use of PAINs filters formulated to process hundreds and thousands of compds. in seconds, and identify PAINS in order to exclude them from further anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocZ7E_j7zxfbVg90H21EOLACvtfcHk0liiQhRQGE-J9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bK&md5=051115704137d6a91b8271702c619682</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00903%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DNissink%26aufirst%3DJ.%26atitle%3DSeven%2520Year%2520Itch.%2520Pan-Assay%2520Interference%2520Compounds%2520%2528Pains%2529%2520in%25202017%2520-%2520Utility%2520and%2520Limitations%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D1%26spage%3D36%26epage%3D44%26doi%3D10.1021%2Facschembio.7b00903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeanmart, S.</span></span> <span> </span><span class="NLM_article-title">Pan Assay Interference Compounds (Pains) and Other Promiscuous Compounds in Antifungal Research</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00361</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00361" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=497-503&issue=2&author=M.+Pouliotauthor=S.+Jeanmart&title=Pan+Assay+Interference+Compounds+%28Pains%29+and+Other+Promiscuous+Compounds+in+Antifungal+Research&doi=10.1021%2Facs.jmedchem.5b00361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research</span></div><div class="casAuthors">Pouliot, Martin; Jeanmart, Stephane</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">497-503</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Every week, articles disclosing new antifungal leads reported as promising starting points for optimization projects are published.  In many cases, the mechanism that accounts for their antifungal activity has not been fully elucidated.  More significantly, the detrimental impact that could result from certain embedded chem. features has been underestimated or even overlooked.  In the course of the authors' research in the agrochem. area, the authors have concluded that in many cases such leads are actually nonoptimizable because they either contain what are now recognized as pan assay interference compds. (PAINS) or other promiscuous groups.  This article is aimed at highlighting the pitfalls the authors have encountered and hopefully to steer other research groups away from them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqURFxdfKNQIbVg90H21EOLACvtfcHk0liiQhRQGE-J9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7rE&md5=af11fcafd47de435fcc5fdf05080023a</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00361%26sid%3Dliteratum%253Aachs%26aulast%3DPouliot%26aufirst%3DM.%26aulast%3DJeanmart%26aufirst%3DS.%26atitle%3DPan%2520Assay%2520Interference%2520Compounds%2520%2528Pains%2529%2520and%2520Other%2520Promiscuous%2520Compounds%2520in%2520Antifungal%2520Research%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D2%26spage%3D497%26epage%3D503%26doi%3D10.1021%2Facs.jmedchem.5b00361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giacobini, E.</span></span> <span> </span><span class="NLM_article-title">Invited Review Cholinesterase Inhibitors for Alzheimer’s Disease Therapy: From Tacrine to Future Applications</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">5–6</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1016/S0197-0186(97)00124-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0197-0186%2897%2900124-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=9676739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK1cXksFSmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1998&pages=413-419&issue=5%E2%80%936&author=E.+Giacobini&title=Invited+Review+Cholinesterase+Inhibitors+for+Alzheimer%E2%80%99s+Disease+Therapy%3A+From+Tacrine+to+Future+Applications&doi=10.1016%2FS0197-0186%2897%2900124-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications</span></div><div class="casAuthors">Giacobini, Ezio</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">413-419</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with 41 refs., beginning with a historical background of the pharmacol. development of tacrine almost 50 yr ago (1949).  Tacrine was the 1st drug to be tested, clin., on a large scale and to be registered (1993) for treatment of Alzheimer's disease.  Clin. results of four 2nd-generation cholinesterase inhibitors (ChEI) (donepezil, ENA 713, eptastigmine and metrifonate) are reviewed and compared with those of other ChEI such as tacrine, physostigmine and galanthamine.  Data based on >6000 patients show that the 2nd-generation drugs are well tolerated and give evidence of clin. efficacy.  Differences are mainly due to frequency of side effects, no. of dropouts and percentage of improved patients.  These results also demonstrate the presence of clin. efficacy for all ChEI tested so far.  Clin. mechanism of action, levels of efficacy and differences among various ChEI are discussed.  Future potential indications are suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmjB6TkRL8E7Vg90H21EOLACvtfcHk0liiQhRQGE-J9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksFSmurg%253D&md5=0677cf6d7c497974f146b40fd1602aab</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2FS0197-0186%2897%2900124-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0197-0186%252897%252900124-1%26sid%3Dliteratum%253Aachs%26aulast%3DGiacobini%26aufirst%3DE.%26atitle%3DInvited%2520Review%2520Cholinesterase%2520Inhibitors%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Therapy%253A%2520From%2520Tacrine%2520to%2520Future%2520Applications%26jtitle%3DNeurochem.%2520Int.%26date%3D1998%26volume%3D32%26issue%3D5%25E2%2580%25936%26spage%3D413%26epage%3D419%26doi%3D10.1016%2FS0197-0186%2897%2900124-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolezal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabelova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruba, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedlacek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepovimova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spilovska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musilek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opletalova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepsova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span> <span> </span><span class="NLM_article-title">7-Meota-Donepezil Like Compounds as Cholinesterase Inhibitors: Synthesis, Pharmacological Evaluation, Molecular Modeling and QSAR Studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.05.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2014.05.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24929293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVCqu7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=426-438&author=J.+Korabecnyauthor=R.+Dolezalauthor=P.+Cabelovaauthor=A.+Horovaauthor=E.+Hrubaauthor=J.+Ricnyauthor=L.+Sedlacekauthor=E.+Nepovimovaauthor=K.+Spilovskaauthor=M.+Andrsauthor=K.+Musilekauthor=V.+Opletalovaauthor=V.+Sepsovaauthor=D.+Ripovaauthor=K.+Kuca&title=7-Meota-Donepezil+Like+Compounds+as+Cholinesterase+Inhibitors%3A+Synthesis%2C+Pharmacological+Evaluation%2C+Molecular+Modeling+and+QSAR+Studies&doi=10.1016%2Fj.ejmech.2014.05.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">7-MEOTA-donepezil like compounds as cholinesterase inhibitors: Synthesis, pharmacological evaluation, molecular modeling and QSAR studies</span></div><div class="casAuthors">Korabecny, Jan; Dolezal, Rafael; Cabelova, Pavla; Horova, Anna; Hruba, Eva; Ricny, Jan; Sedlacek, Lukas; Nepovimova, Eugenie; Spilovska, Katarina; Andrs, Martin; Musilek, Kamil; Opletalova, Veronika; Sepsova, Vendula; Ripova, Daniela; Kuca, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">426-438</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Methoxytetrahydroacridinylethylpiperazines I•3 HCl [R = ArCH2, Ph(CH2)n, 1-naphthylmethyl, 2-naphthylmethyl, 2-(1-naphthyl)ethyl, cyclohexylmethyl, HC≡CCH2; Ar = Ph, 4-BrC6H4, 4-MeC6H4, 3,5-Me2C6H3, 4-O2NC6H4, 4-NCC6H4, 4-MeO2CC6H4, 4-F3CC6H4, 3-MeC6H4, 2-MeC6H4, 4-i-PrC6H4, 4-MeSC6H4, 3-BrC6H4, 2-BrC6H4], hybrids of 7-methoxytacrine and donepezil, were prepd. as inhibitors of acetylcholinesterase and butyrylcholinesterase.  I were nonselective inhibitors of cholinesterases of different origins with IC50 values of 0.8->200 μM.  I showed mixed inhibition of both the peripheral and cationic anionic sites of acetylcholinesterase as detd. by kinetic anal.  Mol. modeling and QSAR studies were performed to rationalize the obsd. in vitro activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpisi1Zh6iob7Vg90H21EOLACvtfcHk0lj7Qj2EKuIzmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVCqu7zI&md5=c7482dac3cf66a61e7dcdf00865fe157</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.05.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.05.066%26sid%3Dliteratum%253Aachs%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DDolezal%26aufirst%3DR.%26aulast%3DCabelova%26aufirst%3DP.%26aulast%3DHorova%26aufirst%3DA.%26aulast%3DHruba%26aufirst%3DE.%26aulast%3DRicny%26aufirst%3DJ.%26aulast%3DSedlacek%26aufirst%3DL.%26aulast%3DNepovimova%26aufirst%3DE.%26aulast%3DSpilovska%26aufirst%3DK.%26aulast%3DAndrs%26aufirst%3DM.%26aulast%3DMusilek%26aufirst%3DK.%26aulast%3DOpletalova%26aufirst%3DV.%26aulast%3DSepsova%26aufirst%3DV.%26aulast%3DRipova%26aufirst%3DD.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3D7-Meota-Donepezil%2520Like%2520Compounds%2520as%2520Cholinesterase%2520Inhibitors%253A%2520Synthesis%252C%2520Pharmacological%2520Evaluation%252C%2520Molecular%2520Modeling%2520and%2520QSAR%2520Studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D82%26spage%3D426%26epage%3D438%26doi%3D10.1016%2Fj.ejmech.2014.05.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeřábek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uliassi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidotti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepsova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabinova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena-Altamira, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petralla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Tacrine-Resveratrol Fused Hybrids as Multi-Target-Directed Ligands against Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.12.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2016.12.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28064079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=250-262&author=J.+Je%C5%99%C3%A1bekauthor=E.+Uliassiauthor=L.+Guidottiauthor=J.+Korabecnyauthor=O.+Soukupauthor=V.+Sepsovaauthor=M.+Hrabinovaauthor=K.+Kucaauthor=M.+Bartoliniauthor=L.+E.+Pena-Altamiraauthor=S.+Petrallaauthor=B.+Montiauthor=M.+Robertiauthor=M.+L.+Bolognesi&title=Tacrine-Resveratrol+Fused+Hybrids+as+Multi-Target-Directed+Ligands+against+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2016.12.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease</span></div><div class="casAuthors">Jerabek, Jakub; Uliassi, Elisa; Guidotti, Laura; Korabecny, Jan; Soukup, Ondrej; Sepsova, Vendula; Hrabinova, Martina; Kuca, Kamil; Bartolini, Manuela; Pena-Altamira, Luis Emiliano; Petralla, Sabrina; Monti, Barbara; Roberti, Marinella; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">250-262</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Multi-target drug discovery is one of the most followed approaches in the active central nervous system (CNS) therapeutic area, esp. in the search for new drugs against Alzheimer's disease (AD).  This is because innovative multi-target-directed ligands (MTDLs) could more adequately address the complexity of this pathol. condition.  In a continuation of our efforts aimed at a new series of anti-AD MTDLs, we combined the structural features of the cholinesterase inhibitor drug tacrine with that of resveratrol, which is known for its purported antioxidant and anti-neuroinflammatory activities.  The most interesting hybrid compds. (5, 8, 9 and 12) inhibited human acetylcholinesterase at micromolar concns. and effectively modulated Aβ self-aggregation in vitro.  In addn., 12 showed intriguing anti-inflammatory and immuno-modulatory properties in neuronal and glial AD cell models.  Importantly, the MTDL profile is accompanied by high-predicted blood-brain barrier permeability, and low cytotoxicity on primary neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHD8lQYiublbVg90H21EOLACvtfcHk0lj7Qj2EKuIzmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlChug%253D%253D&md5=6ebb19cb71b089213e7e0593c824faa1</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.12.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.12.048%26sid%3Dliteratum%253Aachs%26aulast%3DJe%25C5%2599%25C3%25A1bek%26aufirst%3DJ.%26aulast%3DUliassi%26aufirst%3DE.%26aulast%3DGuidotti%26aufirst%3DL.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DSoukup%26aufirst%3DO.%26aulast%3DSepsova%26aufirst%3DV.%26aulast%3DHrabinova%26aufirst%3DM.%26aulast%3DKuca%26aufirst%3DK.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DPena-Altamira%26aufirst%3DL.%2BE.%26aulast%3DPetralla%26aufirst%3DS.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DTacrine-Resveratrol%2520Fused%2520Hybrids%2520as%2520Multi-Target-Directed%2520Ligands%2520against%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D127%26spage%3D250%26epage%3D262%26doi%3D10.1016%2Fj.ejmech.2016.12.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span> <span> </span><span class="NLM_article-title">Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer’s Disease Drug Discovery</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2gtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=171-176&issue=3&author=X.+Y.+Jiangauthor=T.+K.+Chenauthor=J.+T.+Zhouauthor=S.+Y.+Heauthor=H.+Y.+Yangauthor=Y.+Chenauthor=W.+Quauthor=F.+Fengauthor=H.+P.+Sun&title=Dual+GSK-3%CE%B2%2FAChE+Inhibitors+as+a+New+Strategy+for+Multitargeting+Anti-Alzheimer%E2%80%99s+Disease+Drug+Discovery&doi=10.1021%2Facsmedchemlett.7b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery</span></div><div class="casAuthors">Jiang, Xue-Yang; Chen, Ting-Kai; Zhou, Jun-Ting; He, Si-Yu; Yang, Hong-Yu; Chen, Yao; Qu, Wei; Feng, Feng; Sun, Hao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-176</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget-directed ligands (MTDLs) is considered to be a promising approach to address complex and multifactorial maladies such as Alzheimer's disease (AD).  The concurrent inhibition of the two crucial AD targets, glycogen synthase kinase-3β (GSK-3β) and human acetylcholinesterase (hAChE), might represent a breakthrough in the quest for clin. efficacy.  Thus, a novel family of GSK-3β/AChE dual-target inhibitors was designed and synthesized.  Among these hybrids, I showed the most promising profile as a nanomolar inhibitor on both hAChE (IC50 = 6.5 nM) and hGSK-3β kinase activity (IC50 = 66 nM).  It also showed good inhibitory effect on β-amyloid self-aggregation (inhibitory rate = 46%) at 20 μM.  Western blot anal. revealed that compd. I inhibited hyperphosphorylation of tau protein in mouse neuroblastoma N2a-Tau cells.  In vivo studies confirmed that I significantly ameliorated the cognitive disorders in scopolamine-treated ICR mice and less hepatotoxicity than tacrine.  This study provides new leads for assessment of GSK-3β and AChE pathway dual inhibition as a promising strategy for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq103h9q_6uaLVg90H21EOLACvtfcHk0liN33Y3i2ouYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2gtrY%253D&md5=8858bb4cbc503c79896ccbc00fb23153</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00463%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DX.%2BY.%26aulast%3DChen%26aufirst%3DT.%2BK.%26aulast%3DZhou%26aufirst%3DJ.%2BT.%26aulast%3DHe%26aufirst%3DS.%2BY.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DH.%2BP.%26atitle%3DDual%2520GSK-3%25CE%25B2%252FAChE%2520Inhibitors%2520as%2520a%2520New%2520Strategy%2520for%2520Multitargeting%2520Anti-Alzheimer%25E2%2580%2599s%2520Disease%2520Drug%2520Discovery%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D3%26spage%3D171%26epage%3D176%26doi%3D10.1021%2Facsmedchemlett.7b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, R. J.</span></span> <span> </span><span class="NLM_article-title">Oxidative Damage in the Central Nervous System: Protection by Melatonin</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1016/S0301-0082(98)00052-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0301-0082%2898%2900052-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=9770244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFKhtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1998&pages=359-384&issue=3&author=R.+J.+Reiter&title=Oxidative+Damage+in+the+Central+Nervous+System%3A+Protection+by+Melatonin&doi=10.1016%2FS0301-0082%2898%2900052-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative damage in the central nervous system: protection by melatonin</span></div><div class="casAuthors">Reiter, Russel J.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">359-384</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with ∼275 refs.  Melatonin was recently reported to be an effective free radical scavenger and antioxidant.  Melatonin is believed to scavenge the highly toxic hydroxyl radical, the peroxynitrite anion, and possibly the peroxyl radical.  Also, secondarily, it reportedly scavenges the superoxide anion radical and it quenches singlet oxygen.  Addnl., it stimulates mRNA levels for superoxide dismutase and the activities of glutathione peroxidase, glutathione reductase and glucose-6-phosphate dehydrogenase (all of which are antioxidative enzymes), thereby increasing its antioxidative capacity.  Also, melatonin, at least at some sites, inhibits nitric oxide synthase, a pro-oxidative enzyme.  In both in vivo and in vitro expts. melatonin has been shown to reduce lipid peroxidn. and oxidative damage to nuclear DNA.  While these effects have been obsd. primarily using pharmacol. doses of melatonin, in a small no. of expts. melatonin has been found to be physiol. relevant as an antioxidant as well.  The efficacy of melatonin in inhibiting oxidative damage has been tested in a variety of neurol. disease models where free radicals have been implicated as being in part causative of the condition.  Thus, melatonin has been shown prophylactically to reduce amyloid β protein toxicity of Alzheimer's disease, to reduce oxidative damage in several models of Parkinson's disease (dopamine auto-oxidn., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine), to protect against glutamate excitotoxicity, to reduce ischemia-reperfusion injury, to lower neural damage due to δ-aminolevulinic acid (porphyria), hyperbaric hyperoxia and a variety of neural toxins.  Since endogenous melatonin levels fall markedly in advanced age, the implication of these findings is that the loss of this antioxidant may contribute to the incidence or severity of some age-assocd. neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbMBfTYQqFtLVg90H21EOLACvtfcHk0liN33Y3i2ouYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFKhtbc%253D&md5=2518032c1c106627bdef1151ab5d269f</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2FS0301-0082%2898%2900052-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0301-0082%252898%252900052-5%26sid%3Dliteratum%253Aachs%26aulast%3DReiter%26aufirst%3DR.%2BJ.%26atitle%3DOxidative%2520Damage%2520in%2520the%2520Central%2520Nervous%2520System%253A%2520Protection%2520by%2520Melatonin%26jtitle%3DProg.%2520Neurobiol.%26date%3D1998%26volume%3D56%26issue%3D3%26spage%3D359%26epage%3D384%26doi%3D10.1016%2FS0301-0082%2898%2900052-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. H.</span></span> <span> </span><span class="NLM_article-title">Melatonin Attenuates Amyloid Beta 25–35 -Induced Apoptosis in Mouse Microglial BV2 Cells</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2005.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.neulet.2005.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15854745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1Ght78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2005&pages=26-31&issue=1&author=M.+H.+Jangauthor=S.+B.+Jungauthor=M.+H.+Leeauthor=C.+J.+Kimauthor=Y.+T.+Ohauthor=I.+Kangauthor=J.+Kimauthor=E.+H.+Kim&title=Melatonin+Attenuates+Amyloid+Beta+25%E2%80%9335+-Induced+Apoptosis+in+Mouse+Microglial+BV2+Cells&doi=10.1016%2Fj.neulet.2005.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells</span></div><div class="casAuthors">Jang, Mi-Hyeon; Jung, Sae-Bin; Lee, Myoung-Hwa; Kim, Chang-Ju; Oh, Young-Taek; Kang, Insug; Kim, Jeongseon; Kim, Ee-Hwa</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">26-31</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Melatonin has been reported to possess strong antioxidant actions, and is able to directly scavenge a variety of reactive oxygen species (ROS).  The present study investigated whether melatonin possesses protective effects against Aβ-induced cytotoxicity in microglial cells.  Cells treated with Aβ exhibited several characteristic features of apoptosis, while cells pre-treated with melatonin prior to exposure to Aβ showed a decrease in the occurrence of such apoptotic features.  Several previous studies have demonstrated the involvement of ROS in Aβ-induced neurotoxicity, and ROS generated by Aβ have been reported to lead to the activation of nuclear factor-kappa B (NF-κB), a transcription factor; pretreatment with melatonin in the present study reduced the level of Aβ-induced intracellular ROS generation, inhibited NF-κB activation, and suppressed the Aβ-induced increase in caspase-3 enzyme activity.  In addn., it was found that pretreatment with melatonin inhibits Aβ-induced increase in the levels of bax mRNA and that it enhances the level of bcl-2 expression.  Based on these findings, the authors speculate that melatonin may provide an effective means of treatment for Alzheimer's disease through attenuation of Aβ-induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsKTq5KqS4qbVg90H21EOLACvtfcHk0lh1Vh4fj12law"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1Ght78%253D&md5=6a18f6b44c7544fa4e2dda66e6c1d607</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2005.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2005.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DM.%2BH.%26aulast%3DJung%26aufirst%3DS.%2BB.%26aulast%3DLee%26aufirst%3DM.%2BH.%26aulast%3DKim%26aufirst%3DC.%2BJ.%26aulast%3DOh%26aufirst%3DY.%2BT.%26aulast%3DKang%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DE.%2BH.%26atitle%3DMelatonin%2520Attenuates%2520Amyloid%2520Beta%252025%25E2%2580%259335%2520-Induced%2520Apoptosis%2520in%2520Mouse%2520Microglial%2520BV2%2520Cells%26jtitle%3DNeurosci.%2520Lett.%26date%3D2005%26volume%3D380%26issue%3D1%26spage%3D26%26epage%3D31%26doi%3D10.1016%2Fj.neulet.2005.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baydas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Özer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuzcu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koz, S. T.</span></span> <span> </span><span class="NLM_article-title">Melatonin Improves Learning and Memory Performances Impaired by Hyperhomocysteinemia in Rats</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1046</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2005.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.brainres.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15882843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVOltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1046&publication_year=2005&pages=187-194&issue=1&author=G.+Baydasauthor=M.+%C3%96zerauthor=A.+Yasarauthor=M.+Tuzcuauthor=S.+T.+Koz&title=Melatonin+Improves+Learning+and+Memory+Performances+Impaired+by+Hyperhomocysteinemia+in+Rats&doi=10.1016%2Fj.brainres.2005.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin improves learning and memory performances impaired by hyperhomocysteinemia in rats</span></div><div class="casAuthors">Baydas, Giyasettin; Oezer, Mehmet; Yasar, Abdullah; Tuzcu, Mehmet; Koz, Sema T.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1046</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">187-194</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Oxidative stress has been proposed as a possible mechanism underlying many neurodegenerative diseases assocd. with hyperhomocysteinemia.  In the present study, the authors investigated the possible link between oxidative stress, expression of neural cell adhesion mols. and spatial learning deficits induced by chronic hyperhomocysteinemia.  Furthermore, the effectiveness of antioxidant melatonin against homocysteine neurotoxicity was also examd.  Male Wistar rats were treated with either saline or methionine to induce hyperhomocysteinemia and half of methionine-treated rats administered daily melatonin in a dose of 10 mg/kg.  The authors obsd. that chronic administration of melatonin significantly reduced the lipid peroxidn. and restored the decreased glutathione levels induced by chronic hyperhomocysteinemia.  Chronic hyperhomocysteinemia significantly impaired learning and memory performance in the passive avoidance test and Morris water maze task.  The authors also found that these cognitive deficits were reversed by chronic treatment with antioxidant melatonin.  Furthermore, melatonin administration was able to modulate the expression pattern of neural cell adhesion mols. in hippocampus.  The results provide evidence that homocysteine induces long-lasting behavioral deficits, which are possibly caused by oxygen reactive species generation, and by changing in synaptic plasticity and also suggest that melatonin treatment has the ability to prevent nervous system against homocysteine toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSieXYnsI0G7Vg90H21EOLACvtfcHk0lh1Vh4fj12law"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVOltrk%253D&md5=ab68e7d4f9090f43495bd0ce32d653fd</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DBaydas%26aufirst%3DG.%26aulast%3D%25C3%2596zer%26aufirst%3DM.%26aulast%3DYasar%26aufirst%3DA.%26aulast%3DTuzcu%26aufirst%3DM.%26aulast%3DKoz%26aufirst%3DS.%2BT.%26atitle%3DMelatonin%2520Improves%2520Learning%2520and%2520Memory%2520Performances%2520Impaired%2520by%2520Hyperhomocysteinemia%2520in%2520Rats%26jtitle%3DBrain%2520Res.%26date%3D2005%26volume%3D1046%26issue%3D1%26spage%3D187%26epage%3D194%26doi%3D10.1016%2Fj.brainres.2005.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Franco, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Bachiller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Ledesma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolome, B.</span></span> <span> </span><span class="NLM_article-title">Novel Tacrine-Melatonin Hybrids as Dual-Acting Drugs for Alzheimer Disease, with Improved Acetylcholinesterase Inhibitory and Antioxidant Properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1021/jm050746d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050746d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlWmurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=459-462&issue=2&author=M.+I.+Rodriguez-Francoauthor=M.+Fernandez-Bachillerauthor=C.+Perezauthor=B.+Hernandez-Ledesmaauthor=B.+Bartolome&title=Novel+Tacrine-Melatonin+Hybrids+as+Dual-Acting+Drugs+for+Alzheimer+Disease%2C+with+Improved+Acetylcholinesterase+Inhibitory+and+Antioxidant+Properties&doi=10.1021%2Fjm050746d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Tacrine-Melatonin Hybrids as Dual-Acting Drugs for Alzheimer Disease, with Improved Acetylcholinesterase Inhibitory and Antioxidant Properties</span></div><div class="casAuthors">Rodriguez-Franco, Maria Isabel; Fernandez-Bachiller, Maria Isabel; Perez, Concepcion; Hernandez-Ledesma, Blanca; Bartolome, Begona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">459-462</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tacrine and melatonin are well-known drugs with activities as an acetylcholinesterase (AChE) inhibitor and free radical scavenger, resp.  In this work, the authors report new hybrids of both drugs that display higher in vitro properties than the sum of their parts.  As selective inhibitors of human AChE, their IC50 values range from sub-nanomolar to picomolar.  They exhibit a higher oxygen radical absorbance capacity than does melatonin and are predicted to be able to cross the blood-brain barrier to reach their targets in the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJx8cNT0dPfrVg90H21EOLACvtfcHk0lgWjlubSziu2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlWmurfM&md5=ee924cb63a2f3263853a6449e40cb69f</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Fjm050746d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050746d%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez-Franco%26aufirst%3DM.%2BI.%26aulast%3DFernandez-Bachiller%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DHernandez-Ledesma%26aufirst%3DB.%26aulast%3DBartolome%26aufirst%3DB.%26atitle%3DNovel%2520Tacrine-Melatonin%2520Hybrids%2520as%2520Dual-Acting%2520Drugs%2520for%2520Alzheimer%2520Disease%252C%2520with%2520Improved%2520Acetylcholinesterase%2520Inhibitory%2520and%2520Antioxidant%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D2%26spage%3D459%26epage%3D462%26doi%3D10.1021%2Fjm050746d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. J.</span></span> <span> </span><span class="NLM_article-title">Interactions of Nitrogen-Containing Xenobiotics with Monoamine Oxidase (MAO) Isozymes A and B: SAR Studies on MAO Substrates and Inhibitors</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1162</span>, <span class="refDoi"> DOI: 10.1021/tx010073b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx010073b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Orsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=1139-1162&issue=9&author=A.+S.+Kalgutkarauthor=D.+K.+Dalvieauthor=N.+Castagnoliauthor=T.+J.+Taylor&title=Interactions+of+Nitrogen-Containing+Xenobiotics+with+Monoamine+Oxidase+%28MAO%29+Isozymes+A+and+B%3A+SAR+Studies+on+MAO+Substrates+and+Inhibitors&doi=10.1021%2Ftx010073b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors</span></div><div class="casAuthors">Kalgutkar, Amit S.; Dalvie, Deepak K.; Castagnoli, Neal, Jr.; Taylor, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1139-1162</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 302 refs.  MAO inhibitors have been targets for therapeutic agents for many years.  However, inhibition and modulation of this enzyme system can result in undesirable elevations in plasma concns. of MAO substrates and, in some instances, cytochrome P 450 substrates.  The recent development of a new generation of highly selective, reversible MAO inhibitors has led to a renewed interest in the therapeutic potential of these compds.  The primary objective of this review is to summarize the interactions of amine-contg. xenobiotics with MAO, with particular emphasis on the structure-activity requirements for substrate and inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVbjk3FPJan7Vg90H21EOLACvtfcHk0lgWjlubSziu2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Orsb8%253D&md5=73fb2537f94f7dd8ac47be1953803264</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1021%2Ftx010073b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx010073b%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DT.%2BJ.%26atitle%3DInteractions%2520of%2520Nitrogen-Containing%2520Xenobiotics%2520with%2520Monoamine%2520Oxidase%2520%2528MAO%2529%2520Isozymes%2520A%2520and%2520B%253A%2520SAR%2520Studies%2520on%2520MAO%2520Substrates%2520and%2520Inhibitors%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2001%26volume%3D14%26issue%3D9%26spage%3D1139%26epage%3D1162%26doi%3D10.1021%2Ftx010073b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baram, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinreb, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandel, S.</span></span> <span> </span><span class="NLM_article-title">Propargylamine Containing Compounds as Modulators of Proteolytic Cleavage of Amyloid-β Protein Precursor: Involvement of MAPK and PKC Activation</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.3233/JAD-2010-100150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3233%2FJAD-2010-100150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20555137" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=361-371&issue=2&author=O.+Baramauthor=T.+Amitauthor=O.+Weinrebauthor=M.+B.+Youdimauthor=S.+Mandel&title=Propargylamine+Containing+Compounds+as+Modulators+of+Proteolytic+Cleavage+of+Amyloid-%CE%B2+Protein+Precursor%3A+Involvement+of+MAPK+and+PKC+Activation&doi=10.3233%2FJAD-2010-100150"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.3233%2FJAD-2010-100150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2010-100150%26sid%3Dliteratum%253Aachs%26aulast%3DBaram%26aufirst%3DO.%26aulast%3DAmit%26aufirst%3DT.%26aulast%3DWeinreb%26aufirst%3DO.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DMandel%26aufirst%3DS.%26atitle%3DPropargylamine%2520Containing%2520Compounds%2520as%2520Modulators%2520of%2520Proteolytic%2520Cleavage%2520of%2520Amyloid-%25CE%25B2%2520Protein%2520Precursor%253A%2520Involvement%2520of%2520MAPK%2520and%2520PKC%2520Activation%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2010%26volume%3D21%26issue%3D2%26spage%3D361%26epage%3D371%26doi%3D10.3233%2FJAD-2010-100150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">A Novel Series of Tacrine-Selegiline Hybrids with Cholinesterase and Monoamine Oxidase Inhibition Activities for the Treatment of Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2013.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23454517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslWgu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=745-753&author=C.+Luauthor=Q.+Zhouauthor=J.+Yanauthor=Z.+Duauthor=L.+Huangauthor=X.+Li&title=A+Novel+Series+of+Tacrine-Selegiline+Hybrids+with+Cholinesterase+and+Monoamine+Oxidase+Inhibition+Activities+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2013.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Lu, Chuanjun; Zhou, Qi; Yan, Jun; Du, Zhiyun; Huang, Ling; Li, Xingshu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">745-753</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of tacrine-selegiline hybrids was synthesized and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B).  The results demonstrate that most of the synthesized compds. exhibit high inhibitory activity.  Among these compds., compd. I provided a good balance of activity towards all targets (with IC50 values of 22.6 nM, 9.37 nM, 0.3724 μM, and 0.1810 μM for AChE, BuChE, MAO-A and MAO-B, resp.).  These results indicated that I has the potential to be a multi-functional candidate for Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB-OnHqpBtBrVg90H21EOLACvtfcHk0lgWjlubSziu2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslWgu7g%253D&md5=9e0cfdecbe4e8a2890482f8b32cbf4a4</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DA%2520Novel%2520Series%2520of%2520Tacrine-Selegiline%2520Hybrids%2520with%2520Cholinesterase%2520and%2520Monoamine%2520Oxidase%2520Inhibition%2520Activities%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D62%26spage%3D745%26epage%3D753%26doi%3D10.1016%2Fj.ejmech.2013.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendez, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehouse, P. J.</span></span> <span> </span><span class="NLM_article-title">Psychiatric Symptoms Associated with Alzheimer’s Disease</span>. <i>J. Neuropsychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1176/jnp.2.1.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1176%2Fjnp.2.1.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=2136060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADyaK38zjtVeksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1990&pages=28-33&issue=1&author=M.+F.+Mendezauthor=R.+J.+Martinauthor=K.+A.+Smythauthor=P.+J.+Whitehouse&title=Psychiatric+Symptoms+Associated+with+Alzheimer%E2%80%99s+Disease&doi=10.1176%2Fjnp.2.1.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Psychiatric symptoms associated with Alzheimer's disease</span></div><div class="casAuthors">Mendez M F; Martin R J; Smyth K A; Whitehouse P J</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of neuropsychiatry and clinical neurosciences</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-33</span>
        ISSN:<span class="NLM_cas:issn">0895-0172</span>.
    </div><div class="casAbstract">A retrospective chart review was undertaken to assess the prevalence of specifically defined psychiatric symptoms in 217 outpatients with clinically probable Alzheimer's disease.  A weak but significant correlation was found between Alzheimer's disease and suspiciousness and paranoia (reported by 35.5% of patients), delusions (30%), and formed visual hallucinations (18.4%).  Mild depressive symptoms, such as sad affect, hopelessness, and helplessness were reported by 40.6% of patients, anxiety and fearfulness by 30.9%, and aggressive acts by 24.9%.  Psychotropic medications used to manage these symptoms included antipsychotics, in 11.5% of patients, anxiolytics, in 9.2%, and antidepressants, in 7.4%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWaEl8pnXR99ts4TFFB11gfW6udTcc2eYz1zdmGMfh-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zjtVeksg%253D%253D&md5=dcd14997fd5783f347efdb10da95b534</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1176%2Fjnp.2.1.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fjnp.2.1.28%26sid%3Dliteratum%253Aachs%26aulast%3DMendez%26aufirst%3DM.%2BF.%26aulast%3DMartin%26aufirst%3DR.%2BJ.%26aulast%3DSmyth%26aufirst%3DK.%2BA.%26aulast%3DWhitehouse%26aufirst%3DP.%2BJ.%26atitle%3DPsychiatric%2520Symptoms%2520Associated%2520with%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Neuropsychiatry%2520Clin.%2520Neurosci.%26date%3D1990%26volume%3D2%26issue%3D1%26spage%3D28%26epage%3D33%26doi%3D10.1176%2Fjnp.2.1.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyketsos, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopunek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabins, P. V.</span></span> <span> </span><span class="NLM_article-title">Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Sertraline in the Treatment of Depression Complicating Alzheimer’s Disease: Initial Results from the Depression in Alzheimer’s Disease Study</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>157</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1686</span>– <span class="NLM_lpage">1689</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.157.10.1686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1176%2Fappi.ajp.157.10.1686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11007727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BD3M%252FgvVOguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2000&pages=1686-1689&issue=10&author=C.+G.+Lyketsosauthor=J.+M.+Sheppardauthor=C.+D.+Steeleauthor=S.+Kopunekauthor=M.+Steinbergauthor=A.+S.+Bakerauthor=J.+Brandtauthor=P.+V.+Rabins&title=Randomized%2C+Placebo-Controlled%2C+Double-Blind+Clinical+Trial+of+Sertraline+in+the+Treatment+of+Depression+Complicating+Alzheimer%E2%80%99s+Disease%3A+Initial+Results+from+the+Depression+in+Alzheimer%E2%80%99s+Disease+Study&doi=10.1176%2Fappi.ajp.157.10.1686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study</span></div><div class="casAuthors">Lyketsos C G; Sheppard J M; Steele C D; Kopunek S; Steinberg M; Baker A S; Brandt J; Rabins P V</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1686-9</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  This study evaluated the efficacy and safety of sertraline in the treatment of major depression in 22 outpatients with Alzheimer's disease.  METHOD:  Twelve of the 22 patients were given sertraline and 10 were given placebo by random group assignment for 12 weeks.  Response to treatment was measured by using the Cornell Scale for Depression in Dementia.  The patients were also assessed with the Hamilton Depression Rating Scale, the activities of daily living subscale of the Psychogeriatric Dependency Rating Scales, and the Mini-Mental State.  RESULTS:  After 12 weeks of double-blind, placebo-controlled treatment, nine of the patients given sertraline and two of those given placebo were at least partial responders.  Patients given sertraline had significantly greater mean declines from baseline in Cornell Scale for Depression in Dementia scores; the bulk of antidepressant response occurred by the third week of treatment.  CONCLUSIONS:  Sertraline is superior to placebo in reducing depression in patients with Alzheimer's disease who also suffer from major depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwuX3CVdo1_eIHSmpohpd0fW6udTcc2eYz1zdmGMfh-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M%252FgvVOguw%253D%253D&md5=90d4a4bf6bae01298fac85a9300f2d3b</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.157.10.1686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.157.10.1686%26sid%3Dliteratum%253Aachs%26aulast%3DLyketsos%26aufirst%3DC.%2BG.%26aulast%3DSheppard%26aufirst%3DJ.%2BM.%26aulast%3DSteele%26aufirst%3DC.%2BD.%26aulast%3DKopunek%26aufirst%3DS.%26aulast%3DSteinberg%26aufirst%3DM.%26aulast%3DBaker%26aufirst%3DA.%2BS.%26aulast%3DBrandt%26aufirst%3DJ.%26aulast%3DRabins%26aufirst%3DP.%2BV.%26atitle%3DRandomized%252C%2520Placebo-Controlled%252C%2520Double-Blind%2520Clinical%2520Trial%2520of%2520Sertraline%2520in%2520the%2520Treatment%2520of%2520Depression%2520Complicating%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Initial%2520Results%2520from%2520the%2520Depression%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Study%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2000%26volume%3D157%26issue%3D10%26spage%3D1686%26epage%3D1689%26doi%3D10.1176%2Fappi.ajp.157.10.1686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velkeniers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaelst, L.</span></span> <span> </span><span class="NLM_article-title">Effect of Fluoxetine, a Serotonin Reuptake Inhibitor, on the Pituitary-Thyroid Axis in Rat</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(83)90471-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2F0014-2999%2883%2990471-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=6413229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaL3sXltlemt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1983&pages=239-243&issue=2&author=J.+Golsteinauthor=S.+Schreiberauthor=B.+Velkeniersauthor=L.+Vanhaelst&title=Effect+of+Fluoxetine%2C+a+Serotonin+Reuptake+Inhibitor%2C+on+the+Pituitary-Thyroid+Axis+in+Rat&doi=10.1016%2F0014-2999%2883%2990471-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of fluoxetine, a serotonin reuptake inhibitor, on the pituitary-thyroid axis in rat</span></div><div class="casAuthors">Golstein, Jacqueline; Schreiber, Serge; Velkeniers, Brigitte; Vanhaelst, Luc</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">239-43</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">Fluoxetine (I)  [54910-89-3], a specific 5-HT  [50-67-9] reuptake inhibitor, was administered i.p. either acutely or chronically (2 and 10 mg doses) and intraventricularly to normal rats.  Basal TSH  [9002-71-5] levels were measured and the pituitary TSH reserve was estd. by direct detn. of pituitary TSH content and(or) by a TRH  [24305-27-9] test.  T4  [51-48-9] and T3  [6893-02-3] serum levels were also measured.  The acute administration elicited only a decrease in T4 levels, whereas the chronic administration resulted in a decrease in both T4 and T3 levels.  The 10-mg acute and chronic administrations induced an increase in basal TSH and in pituitary TSH reserve.  Intraventricular administration only prevented the initial stress-induced decline of serum TSH levels.  The major effect of the drug seems to be stimulation of TSH synthesis and release via the inhibition of T4-mediated thyroid-pituitary feedback.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEyFzgI-z-nrVg90H21EOLACvtfcHk0liHJTIWabQ94w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXltlemt7k%253D&md5=fd97905c5eb626ee2abd5da2126a53ec</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2883%2990471-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252883%252990471-5%26sid%3Dliteratum%253Aachs%26aulast%3DGolstein%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DVelkeniers%26aufirst%3DB.%26aulast%3DVanhaelst%26aufirst%3DL.%26atitle%3DEffect%2520of%2520Fluoxetine%252C%2520a%2520Serotonin%2520Reuptake%2520Inhibitor%252C%2520on%2520the%2520Pituitary-Thyroid%2520Axis%2520in%2520Rat%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1983%26volume%3D91%26issue%3D2%26spage%3D239%26epage%3D243%26doi%3D10.1016%2F0014-2999%2883%2990471-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dechant, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clissold, S. P.</span></span> <span> </span><span class="NLM_article-title">Paroxetine</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.2165/00003495-199141020-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2165%2F00003495-199141020-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1709852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK3MXktVSjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1991&pages=225-253&issue=2&author=K.+L.+Dechantauthor=S.+P.+Clissold&title=Paroxetine&doi=10.2165%2F00003495-199141020-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Paroxetine.  A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness</span></div><div class="casAuthors">Dechant, Kerry L.; Clissold, Stephen P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-53</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    </div><div class="casAbstract">A review with 96 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIfBGOQXnem7Vg90H21EOLACvtfcHk0lhJRwLcurUtrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXktVSjt7w%253D&md5=5b21e5123820f2d25b4d03147d6d0fe6</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.2165%2F00003495-199141020-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199141020-00007%26sid%3Dliteratum%253Aachs%26aulast%3DDechant%26aufirst%3DK.%2BL.%26aulast%3DClissold%26aufirst%3DS.%2BP.%26atitle%3DParoxetine%26jtitle%3DDrugs%26date%3D1991%26volume%3D41%26issue%3D2%26spage%3D225%26epage%3D253%26doi%3D10.2165%2F00003495-199141020-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogen, H.</span></span> <span> </span><span class="NLM_article-title">Development of an Efficient Therapeutic Agent for Alzheimer’s Disease: Design and Synthesis of Dual Inhibitors of Acetylcholinesterase and Serotonin Transporter</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1248/cpb.58.273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1248%2Fcpb.58.273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20190429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Oitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2010&pages=273-287&issue=3&author=N.+Todaauthor=T.+Kanekoauthor=H.+Kogen&title=Development+of+an+Efficient+Therapeutic+Agent+for+Alzheimer%E2%80%99s+Disease%3A+Design+and+Synthesis+of+Dual+Inhibitors+of+Acetylcholinesterase+and+Serotonin+Transporter&doi=10.1248%2Fcpb.58.273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Development of an efficient therapeutic agent for Alzheimer's disease: Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter</span></div><div class="casAuthors">Toda, Narihiro; Kaneko, Tsugio; Kogen, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A review.  To date, acetylcholinesterase (AChE) inhibitors have been clin. effective drugs for the palliative treatment of Alzheimer's disease, but their clin. efficacy is limited, mainly due to their adverse effects on peripheral organs.  Since patients of Alzheimer's disease often exhibit depression as well as memory impairment, dual inhibitors of AChE and serotonin transporter (SERT) would be a better therapeutic method.  Anti-depressive effects based on SERT inhibition would reduce the dose-related side effects of AChE inhibitors.  Such dual inhibitors were designed by the hybridization of rivastigmine and fluoxetine based on a hypothetical model of the AChE active site.  Various derivs. were synthesized and evaluated for their in vitro inhibition, and then (S)-5j (RS-1259), which possessed balanced inhibitory activities of AChE (IC50 = 101 nM) and SERT (IC50 = 42 nM), was successfully obtained.  An ex vivo expt. in mice indicated that (S)-5j (RS-1259) simultaneously inhibited AChE and SERT in the brain following an oral administration.  The simultaneous elevation of extracellular levels of acetylcholine and serotonin in the rat hippocampus was actually confirmed by microdialysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouvnUUscxWf7Vg90H21EOLACvtfcHk0lhJRwLcurUtrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Oitr4%253D&md5=d28037b205bb3052b6a5037da6d2be06</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1248%2Fcpb.58.273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.58.273%26sid%3Dliteratum%253Aachs%26aulast%3DToda%26aufirst%3DN.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DKogen%26aufirst%3DH.%26atitle%3DDevelopment%2520of%2520an%2520Efficient%2520Therapeutic%2520Agent%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Design%2520and%2520Synthesis%2520of%2520Dual%2520Inhibitors%2520of%2520Acetylcholinesterase%2520and%2520Serotonin%2520Transporter%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2010%26volume%3D58%26issue%3D3%26spage%3D273%26epage%3D287%26doi%3D10.1248%2Fcpb.58.273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giacobini, E.</span></span> <span> </span><span class="NLM_article-title">From Molecular Structure to Alzheimer Therapy</span>. <i>Jpn. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1254/jjp.74.225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1254%2Fjjp.74.225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=9268083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK2sXkslWqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1997&pages=225-241&issue=3&author=E.+Giacobini&title=From+Molecular+Structure+to+Alzheimer+Therapy&doi=10.1254%2Fjjp.74.225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">From molecular structure to Alzheimer therapy</span></div><div class="casAuthors">Giacobini, Ezio</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-241</span>CODEN:
                <span class="NLM_cas:coden">JJPAAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-5198</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">A review with 87 refs.  Clin. trials in the USA, Japan and Europe have confirmed the hypothesis that a steady state increase of acetylcholine resulting from cholinesterase inhibition in the brain results in an improvement of cognitive function in mild to moderate Alzheimer disease (AD) patients.  During the last decade, a systematic effort to develop a pharmacol. treatment for AD has resulted in two drugs being registered for the first time in the USA and Europe for this specific indication.  Both are cholinesterase inhibitors (ChEI).  Based on these first pos. results, several second generation ChEI are being developed.  An addnl. effect of certain ChEI is to maintain cognitive function at a const. level during a 6 mo to one year period of treatment as compared to placebo.  It is possible that the drug effect is one of slowing down cognitive deterioration.  Comparison of clin. effects of 5 ChEI demonstrates a rather similar magnitude of improvement.  For some drugs, this may represent a limit, while for others it may be possible to increase the benefit further.  To maximize and prolong pos. drug effects, it is important to start early and adjust the dosage during the treatment.  Other strategies may involve combinations with other cholinergic drugs such as muscarinic or nicotinic agonists.  A second important class of drugs which is being developed is that of muscarinic m1 agonists.  However, their clin. use is still limited by side effects.  The increased knowledge and recognition of the beta-amyloid mol. as a central focus of AD pathol. has strongly stimulated research with the hope of finding ways of influencing its processing and deposition.  At this point, no product in this line of development has reached clin. trial level.  Other pharmacol. approaches are related to preventive and neuroprotective interventions (estrogens, anti-oxidants and anti-inflammatories).  In conclusion, given the relatively short time of research in this field, results are encouraging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsL1ZPwM1EtbVg90H21EOLACvtfcHk0lhJRwLcurUtrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkslWqs7g%253D&md5=e6dabc8bd0d0862e55d7eda296faaf27</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1254%2Fjjp.74.225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjjp.74.225%26sid%3Dliteratum%253Aachs%26aulast%3DGiacobini%26aufirst%3DE.%26atitle%3DFrom%2520Molecular%2520Structure%2520to%2520Alzheimer%2520Therapy%26jtitle%3DJpn.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D74%26issue%3D3%26spage%3D225%26epage%3D241%26doi%3D10.1254%2Fjjp.74.225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamoorthy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savelieff, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brender, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derrick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span> <span> </span><span class="NLM_article-title">Rational Design of a Structural Framework with Potential Use to Develop Chemical Reagents That Target and Modulate Multiple Facets of Alzheimer’s Disease</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1021/ja409801p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja409801p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVWnsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=299-310&issue=1&author=S.+Leeauthor=X.+Y.+Zhengauthor=J.+Krishnamoorthyauthor=M.+G.+Savelieffauthor=H.+M.+Parkauthor=J.+R.+Brenderauthor=J.+H.+Kimauthor=J.+S.+Derrickauthor=A.+Kochiauthor=H.+J.+Leeauthor=C.+Kimauthor=A.+Ramamoorthyauthor=M.+T.+Bowersauthor=M.+H.+Lim&title=Rational+Design+of+a+Structural+Framework+with+Potential+Use+to+Develop+Chemical+Reagents+That+Target+and+Modulate+Multiple+Facets+of+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fja409801p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of a Structural Framework with Potential Use to Develop Chemical Reagents That Target and Modulate Multiple Facets of Alzheimer's Disease</span></div><div class="casAuthors">Lee, Sanghyun; Zheng, Xueyun; Krishnamoorthy, Janarthanan; Savelieff, Masha G.; Park, Hyun Min; Brender, Jeffrey R.; Kim, Jin Hoon; Derrick, Jeffrey S.; Kochi, Akiko; Lee, Hyuck Jin; Kim, Cheal; Ramamoorthy, Ayyalusamy; Bowers, Michael T.; Lim, Mi Hee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">299-310</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is characterized by multiple, intertwined pathol. features, including amyloid-β (Aβ) aggregation, metal ion dyshomeostasis, and oxidative stress.  The authors report a novel compd. (ML) prototype of a rationally designed mol. obtained by integrating structural elements for Aβ aggregation control, metal chelation, reactive oxygen species (ROS) regulation, and antioxidant activity within a single mol.  Chem., biochem., ion mobility mass spectrometric, and NMR studies indicate that the compd. ML targets metal-free and metal-bound Aβ (metal-Aβ) species, suppresses Aβ aggregation in vitro, and diminishes toxicity induced by Aβ and metal-treated Aβ in living cells.  Comparison of ML to its structural moieties (i.e., 4-(dimethylamino)-phenol (DAP) and (8-aminoquinolin-2-yl)-methanol ) for reactivity with Aβ and metal-Aβ suggests the synergy of incorporating structural components for both metal chelation and Aβ interaction.  Moreover, ML is water-sol. and potentially brain permeable, as well as regulates the formation and presence of free radicals.  Overall, the authors demonstrate that a rational structure-based design strategy can generate a small mol. that can target and modulate multiple factors, providing a new tool to uncover and address AD complexity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcx8TkzbV9U7Vg90H21EOLACvtfcHk0lhJRwLcurUtrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVWnsL3I&md5=808d231c5dca419453c176265d16bfe3</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1021%2Fja409801p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja409801p%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DX.%2BY.%26aulast%3DKrishnamoorthy%26aufirst%3DJ.%26aulast%3DSavelieff%26aufirst%3DM.%2BG.%26aulast%3DPark%26aufirst%3DH.%2BM.%26aulast%3DBrender%26aufirst%3DJ.%2BR.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DDerrick%26aufirst%3DJ.%2BS.%26aulast%3DKochi%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DRamamoorthy%26aufirst%3DA.%26aulast%3DBowers%26aufirst%3DM.%2BT.%26aulast%3DLim%26aufirst%3DM.%2BH.%26atitle%3DRational%2520Design%2520of%2520a%2520Structural%2520Framework%2520with%2520Potential%2520Use%2520to%2520Develop%2520Chemical%2520Reagents%2520That%2520Target%2520and%2520Modulate%2520Multiple%2520Facets%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26issue%3D1%26spage%3D299%26epage%3D310%26doi%3D10.1021%2Fja409801p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savelieff, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detoma, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derrick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span> <span> </span><span class="NLM_article-title">The Ongoing Search for Small Molecules to Study Metal-Associated Amyloid- Species in Alzheimer’s Disease</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2475</span>– <span class="NLM_lpage">2482</span>, <span class="refDoi"> DOI: 10.1021/ar500152x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar500152x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GlurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2014&pages=2475-2482&issue=8&author=M.+G.+Savelieffauthor=A.+S.+Detomaauthor=J.+S.+Derrickauthor=M.+H.+Lim&title=The+Ongoing+Search+for+Small+Molecules+to+Study+Metal-Associated+Amyloid-+Species+in+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Far500152x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">The Ongoing Search for Small Molecules to Study Metal-Associated Amyloid-β Species in Alzheimer's Disease</span></div><div class="casAuthors">Savelieff, Masha G.; DeToma, Alaina S.; Derrick, Jeffrey S.; Lim, Mi Hee</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2475-2482</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of a cure for Alzheimer's disease (AD) has been impeded by an inability to pinpoint the root cause of this disorder.  Although numerous potential pathol. factors have been indicated, acting either individually or mutually, the mol. mechanisms leading to disease onset and progression have not been clear.  Amyloid-β (Aβ), generated from proteolytic processing of the amyloid precursor protein (APP), and its aggregated forms, particularly oligomers, are suggested as key pathol. features in AD-affected brains.  Historically, highly concd. metals are found colocalized within Aβ plaques.  Metal binding to Aβ (metal-Aβ) generates/stabilizes potentially toxic Aβ oligomers, and produces reactive oxygen species (ROS) in vitro (redox active metal ions; plausible contribution to oxidative stress).  Consequently, clarification of the relationship between Aβ, metal ions, and toxicity, including oxidative stress via metal-Aβ, can lead to a deeper understanding of AD development.  To probe the involvement of metal-Aβ in AD pathogenesis, rationally designed and naturally occurring mols. have been examd. as chem. tools to target metal-Aβ species, modulate the interaction between the metal and Aβ, and subsequently redirect their aggregation into nontoxic, off-pathway unstructured aggregates.  These ligands are also capable of attenuating the generation of redox active metal-Aβ-induced ROS to mitigate oxidative stress.  One rational design concept, the incorporation approach, installs a metal binding site into a framework known to interact with Aβ.  This approach affords compds. with the simultaneous ability to chelate metal ions and interact with Aβ.  Natural products capable of Aβ interaction have been investigated for their influence on metal-induced Aβ aggregation and have inspired the construction of synthetic analogs.  Systematic studies of these synthetic or natural mols. could uncover relationships between chem. structures, metal/Aβ/metal-Aβ interactions, and inhibition of Aβ/metal-Aβ reactivity (i.e., aggregation modes of Aβ/metal-Aβ; assocd. ROS prodn.), suggesting mechanisms to refine the design strategy.  Interdisciplinary investigations have demonstrated that the designed mols. and natural products control the aggregation pathways of metal-Aβ species transforming their size/conformation distribution.  The aptitude of these mols. to impact metal-Aβ aggregation pathways, either via inhibition of Aβ aggregate formation, most importantly of oligomers, or disaggregation of preformed fibrils, could originate from their formation of complexes with metal-Aβ.  Potentially, these mols. could direct metal-Aβ size/conformational states into alternative nontoxic unstructured oligomers, and control the geometry at the Aβ-ligated metal center for limited ROS formation to lessen the overall toxicity induced by metal-Aβ.  Complexation between small mols. and Aβ/metal-Aβ has been obsd. by NMR spectroscopy (NMR) and ion mobility-mass spectrometry (IM-MS) pointing to mol. level interactions, validating the design strategy.  In addn., these mols. exhibit other attractive properties, such as antioxidant capacity, prevention of ROS prodn., potential blood-brain barrier (BBB) permeability, and redn. of Aβ-/metal-Aβ-induced cytotoxicity, making them desirable tools for unraveling AD complexity.  In this Account, we summarize the recent development of small mols., via both rational design and the selection and modification of natural products, as tools for investigating metal-Aβ complexes, to advance our understanding of their relation to AD pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonOeVndqFambVg90H21EOLACvtfcHk0lgCjlUWXZ1h4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GlurvF&md5=26cb7b5ff0499e657046f99776f48010</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Far500152x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far500152x%26sid%3Dliteratum%253Aachs%26aulast%3DSavelieff%26aufirst%3DM.%2BG.%26aulast%3DDetoma%26aufirst%3DA.%2BS.%26aulast%3DDerrick%26aufirst%3DJ.%2BS.%26aulast%3DLim%26aufirst%3DM.%2BH.%26atitle%3DThe%2520Ongoing%2520Search%2520for%2520Small%2520Molecules%2520to%2520Study%2520Metal-Associated%2520Amyloid-%2520Species%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2014%26volume%3D47%26issue%3D8%26spage%3D2475%26epage%3D2482%26doi%3D10.1021%2Far500152x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title"><sup>99m</sup>Tc(CO)<sub>3</sub>-Labeled Benzothiazole Derivatives Preferentially Bind Cerebrovascular Amyloid: Potential Use as Imaging Agents for Cerebral Amyloid Angiopathy</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2937</span>– <span class="NLM_lpage">2946</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00209</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00209" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSht7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=2937-2946&issue=8&author=J.+Jiaauthor=M.+Cuiauthor=J.+Daiauthor=B.+Liu&title=99mTc%28CO%293-Labeled+Benzothiazole+Derivatives+Preferentially+Bind+Cerebrovascular+Amyloid%3A+Potential+Use+as+Imaging+Agents+for+Cerebral+Amyloid+Angiopathy&doi=10.1021%2Facs.molpharmaceut.5b00209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">99mTc(CO)3-Labeled Benzothiazole Derivatives Preferentially Bind Cerebrovascular Amyloid: Potential Use as Imaging Agents for Cerebral Amyloid Angiopathy</span></div><div class="casAuthors">Jia, Jianhua; Cui, Mengchao; Dai, Jiapei; Liu, Boli</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2937-2946</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cerebral amyloid angiopathy (CAA) is a disorder affecting the elderly that is characterized by amyloid-β (Aβ) deposition in blood vessel walls of the brain.  A series of 99mTc(CO)3-labeled benzothiazole derivs. as potential SPECT imaging probes for cerebrovascular Aβ deposition is reported.  Rhenium surrogate displayed high affinities to Aβ aggregates with Ki values ranging from 106 to 42 nM, and they strongly stained Aβ deposits in transgenic mice (Tg) and Alzheimer's disease (AD) patients.  In vitro autoradiog. on brain sections of Tg and AD patients confirmed that [99mTc]24 possessed sufficient affinity for Aβ plaques, and [99mTc]24 could only label Aβ deposition in blood vessels but not Aβ plaques in the parenchyma of the brain of AD patients.  Moreover, [99mTc]24 possessed favorable initial uptake (1.21% ID/g) and fast blood washout (blood2 min/blood60 min = 23) in normal mice.  These preliminary results suggest that [99mTc]24 may be used as an Aβ imaging probe for the detection of CAA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozsbiTC_kIl7Vg90H21EOLACvtfcHk0lgCjlUWXZ1h4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSht7nO&md5=3900660dbc9f7fd8291662a882e8cc66</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00209%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3D99mTc%2528CO%25293-Labeled%2520Benzothiazole%2520Derivatives%2520Preferentially%2520Bind%2520Cerebrovascular%2520Amyloid%253A%2520Potential%2520Use%2520as%2520Imaging%2520Agents%2520for%2520Cerebral%2520Amyloid%2520Angiopathy%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26issue%3D8%26spage%3D2937%26epage%3D2946%26doi%3D10.1021%2Facs.molpharmaceut.5b00209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braymer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detoma, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampf, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span> <span> </span><span class="NLM_article-title">Development of Bifunctional Stilbene Derivatives for Targeting and Modulating Metal-Amyloid- Species</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">10724</span>– <span class="NLM_lpage">10734</span>, <span class="refDoi"> DOI: 10.1021/ic2012205</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic2012205" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Cht73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=10724-10734&issue=21&author=J.+J.+Braymerauthor=J.+S.+Choiauthor=A.+S.+Detomaauthor=C.+Wangauthor=K.+Namauthor=J.+W.+Kampfauthor=A.+Ramamoorthyauthor=M.+H.+Lim&title=Development+of+Bifunctional+Stilbene+Derivatives+for+Targeting+and+Modulating+Metal-Amyloid-+Species&doi=10.1021%2Fic2012205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Bifunctional Stilbene Derivatives for Targeting and Modulating Metal-Amyloid-β Species</span></div><div class="casAuthors">Braymer, Joseph J.; Choi, Jung-Suk; DeToma, Alaina S.; Wang, Chen; Nam, Kisoo; Kampf, Jeffrey W.; Ramamoorthy, Ayyalusamy; Lim, Mi Hee</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">10724-10734</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Amyloid-β (Aβ) peptides and their metal-assocd. aggregated states have been implicated in the pathogenesis of Alzheimer's disease (AD).  Although the etiol. of AD remains uncertain, understanding the role of metal-Aβ species could provide insights into the onset and development of the disease.  To unravel this, bifunctional small mols. that can specifically target and modulate metal-Aβ species have been developed, which could serve as suitable chem. tools for investigating metal-Aβ-assocd. events in AD.  Through a rational structure-based design principle involving the incorporation of a metal binding site into the structure of an Aβ interacting mol., we devised stilbene derivs. (L1-a and L1-b) and demonstrated their reactivity toward metal-Aβ species.  In particular, the dual functions of compds. with different structural features (e.g., with or without a dimethylamino group) were explored by UV-vis, X-ray crystallog., high-resoln. 2D NMR, and docking studies.  Enhanced bifunctionality of compds. provided greater effects on metal-induced Aβ aggregation and neurotoxicity in vitro and in living cells.  Mechanistic investigations of the reaction of L1-a and L1-b with Zn2+-Aβ species by UV-vis and 2D NMR suggest that metal chelation with ligand and/or metal-ligand interaction with the Aβ peptide may be driving factors for the obsd. modulation of metal-Aβ aggregation pathways.  Overall, the studies presented herein demonstrate the importance of a structure-interaction-reactivity relationship for designing small mols. to target metal-Aβ species allowing for the modulation of metal-induced Aβ reactivity and neurotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNUiFOBflT-rVg90H21EOLACvtfcHk0lgCjlUWXZ1h4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Cht73L&md5=6fa2692924456a5d1d281f451a307e3d</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Fic2012205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic2012205%26sid%3Dliteratum%253Aachs%26aulast%3DBraymer%26aufirst%3DJ.%2BJ.%26aulast%3DChoi%26aufirst%3DJ.%2BS.%26aulast%3DDetoma%26aufirst%3DA.%2BS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DNam%26aufirst%3DK.%26aulast%3DKampf%26aufirst%3DJ.%2BW.%26aulast%3DRamamoorthy%26aufirst%3DA.%26aulast%3DLim%26aufirst%3DM.%2BH.%26atitle%3DDevelopment%2520of%2520Bifunctional%2520Stilbene%2520Derivatives%2520for%2520Targeting%2520and%2520Modulating%2520Metal-Amyloid-%2520Species%26jtitle%3DInorg.%2520Chem.%26date%3D2011%26volume%3D50%26issue%3D21%26spage%3D10724%26epage%3D10734%26doi%3D10.1021%2Fic2012205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitcock, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokshagundam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Direct Nitric Oxide Detection in Aqueous Solution by Copper(II) Fluorescein Complexes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">14364</span>– <span class="NLM_lpage">14373</span>, <span class="refDoi"> DOI: 10.1021/ja064955e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja064955e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVKitbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=14364-14373&issue=44&author=M.+H.+Limauthor=B.+A.+Wongauthor=W.+H.+Pitcockauthor=D.+Mokshagundamauthor=M.-H.+Baikauthor=S.+J.+Lippard&title=Direct+Nitric+Oxide+Detection+in+Aqueous+Solution+by+Copper%28II%29+Fluorescein+Complexes&doi=10.1021%2Fja064955e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Direct Nitric Oxide Detection in Aqueous Solution by Copper(II) Fluorescein Complexes</span></div><div class="casAuthors">Lim, Mi Hee; Wong, Brian A.; Pitcock, William H., Jr.; Mokshagundam, Deepa; Baik, Mu-Hyun; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">14364-14373</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of FLn (n = 1-5) ligands, where FLn is a fluorescein modified with a functionalized 8-aminoquinoline group as a copper-binding moiety, were synthesized, and the chem. and photophys. properties of the free ligands and their copper complexes were investigated.  UV-visible spectroscopy revealed a 1:1 binding stoichiometry for the Cu(II) complexes of FL1, FL3, and FL5 in pH 7.0 buffered aq. solns.  The reactions of FL2 or FL4 with CuCl2, however, appear to produce a mixt. of 1:1 and 1:2 complexes, as suggested by Job's plots.  These binding modes were modeled by the synthesis and X-ray crystal structure detn. of Cu(II) complexes of 2-[(quinolin-8-ylamino)methyl]phenol (modL), employed as a surrogate of the FLn ligand family.  Two kinds of crystals, [Cu(modL)2](BF4)2 and [Cu2(modL')2(CH3OH)](BF4)2 (modL' = 2-[(quinolin-8-ylamino)methyl]phenolate), were obtained.  The structures suggest that one oxygen and two nitrogen atoms of the FLn ligands most likely bind to Cu(II).  Introduction of nitric oxide (NO) to pH 7.0 buffered aq. solns. of Cu(FLn) (1 μM CuCl2 and 1 μM FLn) at 37 °C induces an increase in fluorescence.  The fluorescence response of Cu(FLn) to NO is direct and specific, which is a significant improvement over com. available small mol.-based probes that are capable of detecting NO only indirectly.  The NO-triggered fluorescence increase of Cu(FL5) occurs by redn. of Cu(II) to Cu(I) with concomitant dissocn. of the N-nitrosated fluorophore ligand from copper.  Spectroscopic and product analyses of the reaction of the FL5 copper complex with NO indicated that the N-nitrosated fluorescein ligand (FL5-NO) is the species responsible for fluorescence turn-on.  D. functional theory (DFT) calcns. of FL5 vs. FL5-NO reveal how N-nitrosation of the fluorophore ligand brings about the fluorescence increase.  The copper-based probes described in the present work form the basis for real-time detection of nitric oxide prodn. in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHswkywkq-w7Vg90H21EOLACvtfcHk0ljG53brNXKykA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVKitbbN&md5=3c15b4e002de580f413b4729c148a39a</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Fja064955e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja064955e%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DM.%2BH.%26aulast%3DWong%26aufirst%3DB.%2BA.%26aulast%3DPitcock%26aufirst%3DW.%2BH.%26aulast%3DMokshagundam%26aufirst%3DD.%26aulast%3DBaik%26aufirst%3DM.-H.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DDirect%2520Nitric%2520Oxide%2520Detection%2520in%2520Aqueous%2520Solution%2520by%2520Copper%2528II%2529%2520Fluorescein%2520Complexes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26issue%3D44%26spage%3D14364%26epage%3D14373%26doi%3D10.1021%2Fja064955e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orhan Puskullu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tekiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzen, S.</span></span> <span> </span><span class="NLM_article-title">Recent Studies of Antioxidant Quinoline Derivatives</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.2174/138955713804999793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F138955713804999793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23190035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC3s7ntFGhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=365-372&issue=3&author=P.+M.+Orhan+Puskulluauthor=B.+Tekinerauthor=S.+Suzen&title=Recent+Studies+of+Antioxidant+Quinoline+Derivatives&doi=10.2174%2F138955713804999793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Recent studies of antioxidant quinoline derivatives</span></div><div class="casAuthors">Orhan Puskullu M; Tekiner Betul; Suzen Sibel</div><div class="citationInfo"><span class="NLM_cas:title">Mini reviews in medicinal chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Quinoline derivatives constitute an important class of compounds for new drug development.  As a large number of experimental and theoretical studies have shown that the quinoline ring system is an important structural unit widely existing in alkaloids, therapeutics and synthetic analogues with exciting biological activities.  The present review provides recent antioxidant activities covering in vivo and in vitro studies of natural and synthetic analogues, as well as the proposed mechanisms of action and structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRRBr5FFOk3FWTCLT8lX9SfW6udTcc2ebU0VVbrp_nYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7ntFGhtw%253D%253D&md5=d01bf474b64896b0250fd54c1e619d4f</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.2174%2F138955713804999793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955713804999793%26sid%3Dliteratum%253Aachs%26aulast%3DOrhan%2BPuskullu%26aufirst%3DP.%2BM.%26aulast%3DTekiner%26aufirst%3DB.%26aulast%3DSuzen%26aufirst%3DS.%26atitle%3DRecent%2520Studies%2520of%2520Antioxidant%2520Quinoline%2520Derivatives%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26issue%3D3%26spage%3D365%26epage%3D372%26doi%3D10.2174%2F138955713804999793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson’s Disease</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">E1010</span>, <span class="refDoi"> DOI: 10.3390/molecules22061010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3390%2Fmolecules22061010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28629145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGgtLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=E1010&issue=6&author=X.+Wangauthor=C.+Hanauthor=Y.+Xuauthor=K.+Wuauthor=S.+Chenauthor=M.+Huauthor=L.+Wangauthor=Y.+Yeauthor=F.+Ye&title=Synthesis+and+Evaluation+of+Phenylxanthine+Derivatives+as+Potential+Dual+A2AR+Antagonists%2FMAO-B+Inhibitors+for+Parkinson%E2%80%99s+Disease&doi=10.3390%2Fmolecules22061010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of phenylxanthine derivatives as potential dual A2AR antagonists/MAO-B inhibitors for Parkinson's disease</span></div><div class="casAuthors">Wang, Xuebao; Han, Chao; Xu, Yong; Wu, Kaiqi; Chen, Shuangya; Hu, Mangsha; Wang, Luyao; Ye, Yun; Ye, Faqing</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1010/1-1010/13</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The aim of this research was to prove the speculation that phenylxanthine (PX) derivs. possess adenosine A2A receptor (A2AR)-blocking properties and to screening and evaluate these PX derivs. as dual A2AR antagonists/MAO-B inhibitors for Parkinson0s disease.  To explore this hypothesis, two series of PX derivs. were prepd. and their antagonism against A2AR and inhibition against MAO-B were detd. in vitro.  In order to evaluate further the antiparkinsonian properties, pharmacokinetic and haloperidol-induced catalepsy expts. were carried out in vivo.  The PX-D and PX-E analogs acted as potent A2AR antagonists with Ki values ranging from 0.27 to 10 μM, and these analogs displayed relatively mild MAO-B inhibition potencies, with inhibitor dissocn. consts. (Ki values) ranging from 0.25 to 10 μM.  Further, the compds. PX-D-P6 and PX-E-P8 displayed efficacious antiparkinsonian properties in haloperidol-induced catalepsy expts., verifying that these two compds. were potent A2AR antagonists and MAO-B inhibitors.  We conclude that PX-D and PX-E analogs are a promising candidate class of dual-acting compds. for treating Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpkdoiOmu87rVg90H21EOLACvtfcHk0ljG53brNXKykA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGgtLbJ&md5=9804c51e9ea8302927601323590b65fb</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22061010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22061010%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DF.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520Phenylxanthine%2520Derivatives%2520as%2520Potential%2520Dual%2520A2AR%2520Antagonists%252FMAO-B%2520Inhibitors%2520for%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26issue%3D6%26spage%3DE1010%26doi%3D10.3390%2Fmolecules22061010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyce, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lera Ruiz, M. L.</span></span> <span> </span><span class="NLM_article-title">Histamine H<sub>3</sub> Receptor as a Drug Discovery Target</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1021/jm100064d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100064d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2lsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=26-53&issue=1&author=M.+Berlinauthor=C.+W.+Boyceauthor=M.+L.+de+Lera+Ruiz&title=Histamine+H3+Receptor+as+a+Drug+Discovery+Target&doi=10.1021%2Fjm100064d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H3 Receptor as a Drug Discovery Target</span></div><div class="casAuthors">Berlin, Michael; Boyce, Christopher W.; de Lera Ruiz, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-53</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ever since its pharmacol. discovery in 1983, the histamine H3 receptor has provided a tantalizing target for drug research,.  Connections between the biochem. signaling mechanisms and in vivo effects of the H3 agonists and antagonists, whether hypothetical or clearly supported by data, are contemplated throughout the review.  It seems likely, given the current activity level of research and development, that days of com. H3 drugs are approaching.  Whether a stand-alone treatment or a valuable add-on to an existing therapy, H3 antagonists seem well positioned to soon share in and expand the existing drug class designation of "antihistamines".  Led by the abundant preclin. data, drug companies finally seem to be in a position to probe the putative connections between the H3 mechanism and a no. of human therapeutic conditions.  The pressure is clearly on clin. research to generate convincing proof-of-concept data to support or reject those connections.  Further developments in H3 biol. are to be awaited with much interest and may serve to further substantiate the existing indications and suggest novel therapeutic uses.  Because of the wide spectrum of the potential indications, the need to reconcile and manage as a combination the various expected H3 therapeutic effects (most of which, adding to the level of complexity, are believed to be centrally mediated) may prove a significant challenge in itself.  Ever since its pharmacol. discovery in 1983, the histamine H receptor has provided a tantalizing target for drug research,.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEQYOWZmWyy7Vg90H21EOLACvtfcHk0lgrMQr_BmnjEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2lsb3F&md5=2a68aedccfd5f8887f048ead3c3a7517</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1021%2Fjm100064d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100064d%26sid%3Dliteratum%253Aachs%26aulast%3DBerlin%26aufirst%3DM.%26aulast%3DBoyce%26aufirst%3DC.%2BW.%26aulast%3Dde%2BLera%2BRuiz%26aufirst%3DM.%2BL.%26atitle%3DHistamine%2520H3%2520Receptor%2520as%2520a%2520Drug%2520Discovery%2520Target%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D1%26spage%3D26%26epage%3D53%26doi%3D10.1021%2Fjm100064d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sander, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kottke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Histamine H<sub>3</sub> Receptor Antagonists Go to Clinics</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2163</span>– <span class="NLM_lpage">2181</span>, <span class="refDoi"> DOI: 10.1248/bpb.31.2163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1248%2Fbpb.31.2163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19043195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1Kmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=2163-2181&issue=12&author=K.+Sanderauthor=T.+Kottkeauthor=H.+Stark&title=Histamine+H3+Receptor+Antagonists+Go+to+Clinics&doi=10.1248%2Fbpb.31.2163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H3 receptor antagonists go to clinics</span></div><div class="casAuthors">Sander, Kerstin; Kottke, Tim; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2163-2181</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A review.  Within the recent years novel lead optimizations for histamine H3 receptor antagonists made their way from bench to bedside.  Structure-activity relationships, cross-affinities and side effects as well as pharmacokinetic profiling will be discussed on selected promising compd. series.  Due to diversity in potential therapeutic applications and in some cases a controversial debate, different indications will be highlighted with the potential and the problems of the test compds., e.g. sleep-wake disorders, attention-deficient hyperactivity disorder, epilepsy, cognitive impairment, schizophrenia, obesity and neuropathic pain.  First data published on clin. trials phase II (IIb) are presented showing proof of concept of H3 receptor antagonists in narcolepsy and photoinduced epilepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJWogrOu3mmbVg90H21EOLACvtfcHk0lgrMQr_BmnjEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1Kmsbs%253D&md5=b816371be0c006bef83d279a426fee45</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1248%2Fbpb.31.2163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.31.2163%26sid%3Dliteratum%253Aachs%26aulast%3DSander%26aufirst%3DK.%26aulast%3DKottke%26aufirst%3DT.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DHistamine%2520H3%2520Receptor%2520Antagonists%2520Go%2520to%2520Clinics%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2008%26volume%3D31%26issue%3D12%26spage%3D2163%26epage%3D2181%26doi%3D10.1248%2Fbpb.31.2163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Affini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zivkovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Novel Indanone Derivatives as MAO B/H<sub>3</sub>R Dual-Targeting Ligands for Treatment of Parkinson’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2018.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29477889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsF2msbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=487-497&author=A.+Affiniauthor=S.+Hagenowauthor=A.+Zivkovicauthor=J.+Marco-Contellesauthor=H.+Stark&title=Novel+Indanone+Derivatives+as+MAO+B%2FH3R+Dual-Targeting+Ligands+for+Treatment+of+Parkinson%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2018.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease</span></div><div class="casAuthors">Affini, Anna; Hagenow, Stefanie; Zivkovic, Aleksandra; Marco-Contelles, Jose; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">487-497</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders.  As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, the authors synthesized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the treatment of PD.  Three series of compds. were developed by attaching the H3R pharmacophore to indanone-related MAO B motifs, leading to development of MAO B/H3R DTLs.  Among synthesized indanone DTLs, compds. bearing the 2-benzylidene-1-indanone core structure showed MAO B preferring inhibition capabilities along with nanomolar hH3R affinity.  Substitution of C5 and C6 position of the 2-benzylidene-1-indanones with lipophilic substituents revealed three promising candidates exhibiting inhibitory potencies for MAO B with IC50 values ranging from 1931 nM to 276 nM and high affinities at hH3R (Ki < 50 nM).  Compd. 3f ((E)-5-((4-bromobenzyl)oxy)-2-(4-(3-(piperidin-1-yl)propoxy)benzylidene)-2,3-dihydro-1H-inden-1-one, MAO B IC50 = 276 nM, hH3R Ki = 6.5 nM) showed highest preference for MAO B over MAO A (SI > 36).  Interestingly, IC50 detns. after preincubation of enzyme and DTLs revealed also nanomolar MAO B potency for 3e (MAO B IC50 = 232 nM), a structural isomer of 3f, and 3d ((E)-5-fluoro-2-[4-[3-(piperidin-1-yl)propoxy]benzylidene]-2,3-dihydro-1H-inden-1-one) (MAO B IC50 = 541 nM), suggesting time-dependent inhibition modes.  Reversibility of inhibition for all three compds. were confirmed by diln. studies in excess of substrate.  Thus, indanone-substituted derivs. are promising lead structures for the design of MAO B/hH3R DTLs as novel therapeutic approach of PD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozgPusP5M44bVg90H21EOLACvtfcHk0lgrMQr_BmnjEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsF2msbY%253D&md5=9b915ce055294d79bfa8e585a19e6466</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DAffini%26aufirst%3DA.%26aulast%3DHagenow%26aufirst%3DS.%26aulast%3DZivkovic%26aufirst%3DA.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DNovel%2520Indanone%2520Derivatives%2520as%2520MAO%2520B%252FH3R%2520Dual-Targeting%2520Ligands%2520for%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D148%26spage%3D487%26epage%3D497%26doi%3D10.1016%2Fj.ejmech.2018.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Monteagudo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordeiro, M. N. D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helguera, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejera, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-y-Mino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera-Sardina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Castillo, Y.</span></span> <span> </span><span class="NLM_article-title">Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.2174/1570159X15666170116145316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F1570159X15666170116145316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28093976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFens7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=1117-1135&issue=8&author=M.+Cruz-Monteagudoauthor=F.+Borgesauthor=M.+N.+D.+S.+Cordeiroauthor=A.+M.+Helgueraauthor=E.+Tejeraauthor=C.+Paz-y-Minoauthor=A.+Sanchez-Rodriguezauthor=Y.+Perera-Sardinaauthor=Y.+Perez-Castillo&title=Chemoinformatics+Profiling+of+the+Chromone+Nucleus+as+a+MAO-B%2FA2AAR+Dual+Binding+Scaffold&doi=10.2174%2F1570159X15666170116145316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold</span></div><div class="casAuthors">Cruz-Monteagudo, Maykel; Borges, Fernanda; S. Cordeiro, M. Natalia D.; Helguera, Aliuska Morales; Tejera, Eduardo; Paz-y-Mino, Cesar; Sanchez-Rodriguez, Aminael; Perera-Sardina, Yunier; Perez-Castillo, Yunierkis</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1117-1135</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: In the context of the current drug discovery efforts to find disease modifying therapies for Parkinson&#39;s disease (PD) the current single target strategy has proved inefficient.  Consequently, the search for multi-potent agents is attracting more and more attention due to the multiple pathogenetic factors implicated in PD.  Multiple evidences points to the dual inhibition of the monoamine oxidase B (MAO-B), as well as adenosine A2A receptor (A2AAR) blockade, as a promising approach to prevent the neurodegeneration involved in PD.  Currently, only two chem. scaffolds has been proposed as potential dual MAO-B inhibitors/A2AAR antagonists (caffeine derivs. and benzothiazinones).  Methods: In this study, we conduct a series of chemoinformatics anal. in order to evaluate and advance the potential of the chromone nucleus as a MAO-B/A2AAR dual binding scaffold.  Results: The information provided by SAR data mining anal. based on network similarity graphs and mol. docking studies support the suitability of the chromone nucleus as a potential MAOB/ A2AAR dual binding scaffold.  Addnl., a virtual screening tool based on a group fusion similarity search approach was developed for the prioritization of potential MAO-B/A2AAR dual binder candidates.  Among several data fusion schemes evaluated, the MEAN-SIM and MIN-RANK GFSS approaches demonstrated to be efficient virtual screening tools.  Then, a combinatorial library potentially enriched with MAO-B/A2AAR dual binding chromone derivs. was assembled and sorted by using the MIN-RANK and then the MEAN-SIM GFSS VS approaches.  Conclusion: The information and tools provided in this work represent valuable decision making elements in the search of novel chromone derivs. with a favorable dual binding profile as MAOB inhibitors and A2AAR antagonists with the potential to act as a disease-modifying therapeutic for Parkinson&#39;s disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoau4sw7FLhUrVg90H21EOLACvtfcHk0lgrMQr_BmnjEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFens7zI&md5=f90bd3d2805f7ef2af0410bb48f16877</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.2174%2F1570159X15666170116145316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X15666170116145316%26sid%3Dliteratum%253Aachs%26aulast%3DCruz-Monteagudo%26aufirst%3DM.%26aulast%3DBorges%26aufirst%3DF.%26aulast%3DCordeiro%26aufirst%3DM.%2BN.%2BD.%2BS.%26aulast%3DHelguera%26aufirst%3DA.%2BM.%26aulast%3DTejera%26aufirst%3DE.%26aulast%3DPaz-y-Mino%26aufirst%3DC.%26aulast%3DSanchez-Rodriguez%26aufirst%3DA.%26aulast%3DPerera-Sardina%26aufirst%3DY.%26aulast%3DPerez-Castillo%26aufirst%3DY.%26atitle%3DChemoinformatics%2520Profiling%2520of%2520the%2520Chromone%2520Nucleus%2520as%2520a%2520MAO-B%252FA2AAR%2520Dual%2520Binding%2520Scaffold%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2017%26volume%3D15%26issue%3D8%26spage%3D1117%26epage%3D1135%26doi%3D10.2174%2F1570159X15666170116145316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunschweiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Küppers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title">8-Benzyltetrahydropyrazino[2,1-f]Purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1704</span>– <span class="NLM_lpage">1724</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fcmdc.201402082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24817533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslWku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1704-1724&issue=8&author=A.+Brunschweigerauthor=P.+Kochauthor=M.+Schlenkauthor=F.+Pinedaauthor=P.+K%C3%BCppersauthor=S.+Hinzauthor=M.+K%C3%B6seauthor=S.+Ullrichauthor=J.+Hockemeyerauthor=M.+Wieseauthor=J.+Heerauthor=C.+E.+Muller&title=8-Benzyltetrahydropyrazino%5B2%2C1-f%5DPurinediones%3A+Water-Soluble+Tricyclic+Xanthine+Derivatives+as+Multitarget+Drugs+for+Neurodegenerative+Diseases&doi=10.1002%2Fcmdc.201402082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">8-Benzyltetrahydropyrazino[2,1-f]purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases</span></div><div class="casAuthors">Brunschweiger, Andreas; Koch, Pierre; Schlenk, Miriam; Pineda, Felipe; Kueppers, Petra; Hinz, Sonja; Koese, Meryem; Ullrich, Stefan; Hockemeyer, Joerg; Wiese, Michael; Heer, Jag; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1704-1724</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">8-Benzyl-substituted tetrahydropyrazino[2,1-f]purinediones were designed as tricyclic xanthine derivs. contg. a basic nitrogen atom in the tetrahydropyrazine ring to improve water soly.  A library of 69 derivs. was prepd. and evaluated in radioligand binding studies at adenosine receptor (AR) subtypes and for their ability to inhibit monoamine oxidases (MAO).  Potent dual-target-directed A1/A2A adenosine receptor antagonists were identified.  Several compds. showed triple-target inhibition; one of the best compds. was 8-(2,4-dichloro-5-fluorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4-(1H,3H)-dione (human AR: Ki A1 217 nm, A2A 233 nm; IC50 MAO-B: 508 nm).  Dichlorinated compd. [8-(3,4-dichlorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4-(1H,3H)-dione] was found to be the best triple-target drug in rat (Ki A1 351 nm, A2A 322 nm; IC50 MAO-B: 260 nm), and may serve as a useful tool for preclin. proof-of-principle studies.  Compds. that act at multiple targets relevant for symptomatic as well as disease-modifying treatment of neurodegenerative diseases are expected to show advantages over single-target therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq7_nlMNkyirVg90H21EOLACvtfcHk0lj1Yed7V3WeDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslWku7Y%253D&md5=d9965ddec52ab2304e9b14d4a52b0950</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402082%26sid%3Dliteratum%253Aachs%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DSchlenk%26aufirst%3DM.%26aulast%3DPineda%26aufirst%3DF.%26aulast%3DK%25C3%25BCppers%26aufirst%3DP.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DK%25C3%25B6se%26aufirst%3DM.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DWiese%26aufirst%3DM.%26aulast%3DHeer%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3D8-Benzyltetrahydropyrazino%255B2%252C1-f%255DPurinediones%253A%2520Water-Soluble%2520Tricyclic%2520Xanthine%2520Derivatives%2520as%2520Multitarget%2520Drugs%2520for%2520Neurodegenerative%2520Diseases%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26issue%3D8%26spage%3D1704%26epage%3D1724%26doi%3D10.1002%2Fcmdc.201402082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eskelinen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivipelto, M.</span></span> <span> </span><span class="NLM_article-title">Caffeine as a Protective Factor in Dementia and Alzheimer’s Disease</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">Suppl. 1</span>),  <span class="NLM_fpage">S167</span>– <span class="NLM_lpage">S174</span>, <span class="refDoi"> DOI: 10.3233/JAD-2010-1404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3233%2FJAD-2010-1404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20182054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXls12huro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=S167-S174&issue=Suppl.+1&author=M.+H.+Eskelinenauthor=M.+Kivipelto&title=Caffeine+as+a+Protective+Factor+in+Dementia+and+Alzheimer%E2%80%99s+Disease&doi=10.3233%2FJAD-2010-1404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Caffeine as a Protective Factor in Dementia and Alzheimer's Disease</span></div><div class="casAuthors">Eskelinen, Marjo H.; Kivipelto, Miia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S167-S174</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  Caffeine has well-known short-term stimulating effects on central nervous system, but the long-term impacts on cognition have been less clear.  Dementia and Alzheimer's disease (AD) are rapidly increasing public health problems in ageing populations and at the moment curative treatment is lacking.  Thus, the putative protective effects of caffeine against dementia/AD are of great interest.  Here, we discuss findings from the longitudinal epidemiol. studies about caffeine/coffee/tea and dementia/AD/cognitive functioning with a special emphasis on our recent results from the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) study.  The findings of the previous studies are somewhat inconsistent, but most studies (3 out of 5) support coffee's favorable effects against cognitive decline, dementia or AD.  In addn., two studies had combined coffee and tea drinking and indicated some pos. effects on cognitive functioning.  For tea drinking, protective effects against cognitive decline/dementia are still less evident.  In the CAIDE study, coffee drinking of 3-5 cups per day at midlife was assocd. with a decreased risk of dementia/AD by about 65% at late-life.  In conclusion, coffee drinking may be assocd. with a decreased risk of dementia/AD.  This may be mediated by caffeine and/or other mechanisms like antioxidant capacity and increased insulin sensitivity.  This finding might open possibilities for prevention or postponing the onset of dementia/AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomYnYizfcSebVg90H21EOLACvtfcHk0lj1Yed7V3WeDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXls12huro%253D&md5=52fd6e58bc3ceef5bbb8b86523e16f31</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.3233%2FJAD-2010-1404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2010-1404%26sid%3Dliteratum%253Aachs%26aulast%3DEskelinen%26aufirst%3DM.%2BH.%26aulast%3DKivipelto%26aufirst%3DM.%26atitle%3DCaffeine%2520as%2520a%2520Protective%2520Factor%2520in%2520Dementia%2520and%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2010%26volume%3D20%26issue%3DSuppl.%25201%26spage%3DS167%26epage%3DS174%26doi%3D10.3233%2FJAD-2010-1404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunschweiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Küppers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title">8-Benzyltetrahydropyrazino[2,1-F]Purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1704</span>– <span class="NLM_lpage">1724</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fcmdc.201402082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24817533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslWku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1704-1724&issue=8&author=A.+Brunschweigerauthor=P.+Kochauthor=M.+Schlenkauthor=F.+Pinedaauthor=P.+K%C3%BCppersauthor=S.+Hinzauthor=M.+K%C3%B6seauthor=S.+Ullrichauthor=J.+Hockemeyerauthor=M.+Wieseauthor=J.+Heerauthor=C.+E.+Muller&title=8-Benzyltetrahydropyrazino%5B2%2C1-F%5DPurinediones%3A+Water-Soluble+Tricyclic+Xanthine+Derivatives+as+Multitarget+Drugs+for+Neurodegenerative+Diseases&doi=10.1002%2Fcmdc.201402082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">8-Benzyltetrahydropyrazino[2,1-f]purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases</span></div><div class="casAuthors">Brunschweiger, Andreas; Koch, Pierre; Schlenk, Miriam; Pineda, Felipe; Kueppers, Petra; Hinz, Sonja; Koese, Meryem; Ullrich, Stefan; Hockemeyer, Joerg; Wiese, Michael; Heer, Jag; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1704-1724</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">8-Benzyl-substituted tetrahydropyrazino[2,1-f]purinediones were designed as tricyclic xanthine derivs. contg. a basic nitrogen atom in the tetrahydropyrazine ring to improve water soly.  A library of 69 derivs. was prepd. and evaluated in radioligand binding studies at adenosine receptor (AR) subtypes and for their ability to inhibit monoamine oxidases (MAO).  Potent dual-target-directed A1/A2A adenosine receptor antagonists were identified.  Several compds. showed triple-target inhibition; one of the best compds. was 8-(2,4-dichloro-5-fluorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4-(1H,3H)-dione (human AR: Ki A1 217 nm, A2A 233 nm; IC50 MAO-B: 508 nm).  Dichlorinated compd. [8-(3,4-dichlorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4-(1H,3H)-dione] was found to be the best triple-target drug in rat (Ki A1 351 nm, A2A 322 nm; IC50 MAO-B: 260 nm), and may serve as a useful tool for preclin. proof-of-principle studies.  Compds. that act at multiple targets relevant for symptomatic as well as disease-modifying treatment of neurodegenerative diseases are expected to show advantages over single-target therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq7_nlMNkyirVg90H21EOLACvtfcHk0lj1Yed7V3WeDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslWku7Y%253D&md5=d9965ddec52ab2304e9b14d4a52b0950</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402082%26sid%3Dliteratum%253Aachs%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DSchlenk%26aufirst%3DM.%26aulast%3DPineda%26aufirst%3DF.%26aulast%3DK%25C3%25BCppers%26aufirst%3DP.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DK%25C3%25B6se%26aufirst%3DM.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DWiese%26aufirst%3DM.%26aulast%3DHeer%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3D8-Benzyltetrahydropyrazino%255B2%252C1-F%255DPurinediones%253A%2520Water-Soluble%2520Tricyclic%2520Xanthine%2520Derivatives%2520as%2520Multitarget%2520Drugs%2520for%2520Neurodegenerative%2520Diseases%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26issue%3D8%26spage%3D1704%26epage%3D1724%26doi%3D10.1002%2Fcmdc.201402082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunschweiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafehi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radjainia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Küppers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denonne, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title">8-Substituted 1,3-Dimethyltetrahydropyrazino[2,1-f]Purinediones: Water-Soluble Adenosine Receptor Antagonists and Monoamine Oxidase B Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">5462</span>– <span class="NLM_lpage">5480</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2016.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27658798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFeqsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=5462-5480&issue=21&author=A.+Brunschweigerauthor=P.+Kochauthor=M.+Schlenkauthor=M.+Rafehiauthor=H.+Radjainiaauthor=P.+K%C3%BCppersauthor=S.+Hinzauthor=F.+Pinedaauthor=M.+Wieseauthor=J.+Hockemeyerauthor=J.+Heerauthor=F.+Denonneauthor=C.+E.+Muller&title=8-Substituted+1%2C3-Dimethyltetrahydropyrazino%5B2%2C1-f%5DPurinediones%3A+Water-Soluble+Adenosine+Receptor+Antagonists+and+Monoamine+Oxidase+B+Inhibitors&doi=10.1016%2Fj.bmc.2016.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors</span></div><div class="casAuthors">Brunschweiger, Andreas; Koch, Pierre; Schlenk, Miriam; Rafehi, Muhammad; Radjainia, Hamid; Kueppers, Petra; Hinz, Sonja; Pineda, Felipe; Wiese, Michael; Hockemeyer, Joerg; Heer, Jag; Denonne, Frederic; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5462-5480</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multitarget approaches, i.e., addressing two or more targets simultaneously with a therapeutic agent, are hypothesized to offer additive therapeutic benefit for the treatment of neurodegenerative diseases.  Validated targets for the treatment of Parkinson's disease are, among others, the A2A adenosine receptor (AR) and the enzyme monoamine oxidase B (MAO-B).  Addnl. blockade of brain A1 ARs may also be beneficial.  We recently described 8-benzyl-substituted tetrahydropyrazino[2,1-f]purinediones as a new lead structure for the development of such multi-target drugs.  We have now designed a new series of tetrahydropyrazino[2,1-f]purinediones to extensively explore their structure-activity-relationships.  Several compds. blocked human and rat A1 and A2AARs at similar concns. representing dual A1/A2A antagonists with high selectivity vs. the other AR subtypes.  Among the best dual A1/A2AAR antagonists were 8-(3-(4-chlorophenyl)propyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (41, Ki human A1: 65.5 nM, A2A: 230 nM; Ki rat A1: 352 nM, A2A: 316 nM) and 1,3-dimethyl-8-((2-(thiophen-2-yl)thiazol-4-yl)methyl)-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (57, Ki human A1: 642 nM, A2A: 203 nM; Ki rat A1: 166 nM, A2A: 121 nM).  Compd. 57 was found to be well water-sol. (0.7 mg/mL) at a physiol. pH value of 7.4.  One of the new compds. showed triple-target inhibition: (R)-1,3-dimethyl-8-(2,1,3,4-tetrahydronaphthalen-1-yl)-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (49) was about equipotent at A1 and A2AARs and at MAO-B (Ki human A1: 393 nM, human A2A: 595 nM, IC50 human MAO-B: 210 nM) thus allowing future in vivo explorations of the intended multi-target approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBB9CeveG_ObVg90H21EOLACvtfcHk0liNqGlBDWlc2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFeqsr%252FM&md5=1bbbe7bc2d2544f99c2dbcfb3d7d1fbd</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DSchlenk%26aufirst%3DM.%26aulast%3DRafehi%26aufirst%3DM.%26aulast%3DRadjainia%26aufirst%3DH.%26aulast%3DK%25C3%25BCppers%26aufirst%3DP.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DPineda%26aufirst%3DF.%26aulast%3DWiese%26aufirst%3DM.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DHeer%26aufirst%3DJ.%26aulast%3DDenonne%26aufirst%3DF.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3D8-Substituted%25201%252C3-Dimethyltetrahydropyrazino%255B2%252C1-f%255DPurinediones%253A%2520Water-Soluble%2520Adenosine%2520Receptor%2520Antagonists%2520and%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D21%26spage%3D5462%26epage%3D5480%26doi%3D10.1016%2Fj.bmc.2016.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whiteford, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhardt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erskine, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlson, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaxman, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, T.</span></span> <span> </span><span class="NLM_article-title">Global Burden of Disease Attributable to Mental and Substance Use Disorders: Findings from the Global Burden of Disease Study 2010</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>382</i></span> (<span class="NLM_issue">9904</span>),  <span class="NLM_fpage">1575</span>– <span class="NLM_lpage">1586</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(13)61611-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0140-6736%2813%2961611-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23993280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC3sbktFKktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2013&pages=1575-1586&issue=9904&author=H.+A.+Whitefordauthor=L.+Degenhardtauthor=J.+Rehmauthor=A.+J.+Baxterauthor=A.+J.+Ferrariauthor=H.+E.+Erskineauthor=F.+J.+Charlsonauthor=R.+E.+Normanauthor=A.+D.+Flaxmanauthor=N.+Johnsauthor=R.+Bursteinauthor=C.+J.+L.+Murrayauthor=T.+Vos&title=Global+Burden+of+Disease+Attributable+to+Mental+and+Substance+Use+Disorders%3A+Findings+from+the+Global+Burden+of+Disease+Study+2010&doi=10.1016%2FS0140-6736%2813%2961611-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010</span></div><div class="casAuthors">Whiteford Harvey A; Degenhardt Louisa; Rehm Jurgen; Baxter Amanda J; Ferrari Alize J; Erskine Holly E; Charlson Fiona J; Norman Rosana E; Flaxman Abraham D; Johns Nicole; Burstein Roy; Murray Christopher J L; Vos Theo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">9904</span>),
    <span class="NLM_cas:pages">1575-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We used data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) to estimate the burden of disease attributable to mental and substance use disorders in terms of disability-adjusted life years (DALYs), years of life lost to premature mortality (YLLs), and years lived with disability (YLDs).  METHODS:  For each of the 20 mental and substance use disorders included in GBD 2010, we systematically reviewed epidemiological data and used a Bayesian meta-regression tool, DisMod-MR, to model prevalence by age, sex, country, region, and year.  We obtained disability weights from representative community surveys and an internet-based survey to calculate YLDs.  We calculated premature mortality as YLLs from cause of death estimates for 1980-2010 for 20 age groups, both sexes, and 187 countries.  We derived DALYs from the sum of YLDs and YLLs.  We adjusted burden estimates for comorbidity and present them with 95% uncertainty intervals.  FINDINGS:  In 2010, mental and substance use disorders accounted for 183·9 million DALYs (95% UI 153·5 million-216·7 million), or 7·4% (6·2-8·6) of all DALYs worldwide.  Such disorders accounted for 8·6 million YLLs (6·5 million-12·1 million; 0·5% [0·4-0·7] of all YLLs) and 175·3 million YLDs (144·5 million-207·8 million; 22·9% [18·6-27·2] of all YLDs).  Mental and substance use disorders were the leading cause of YLDs worldwide.  Depressive disorders accounted for 40·5% (31·7-49·2) of DALYs caused by mental and substance use disorders, with anxiety disorders accounting for 14·6% (11·2-18·4), illicit drug use disorders for 10·9% (8·9-13·2), alcohol use disorders for 9·6% (7·7-11·8), schizophrenia for 7·4% (5·0-9·8), bipolar disorder for 7·0% (4·4-10·3), pervasive developmental disorders for 4·2% (3·2-5·3), childhood behavioural disorders for 3·4% (2·2-4·7), and eating disorders for 1·2% (0·9-1·5).  DALYs varied by age and sex, with the highest proportion of total DALYs occurring in people aged 10-29 years.  The burden of mental and substance use disorders increased by 37·6% between 1990 and 2010, which for most disorders was driven by population growth and ageing.  INTERPRETATION:  Despite the apparently small contribution of YLLs--with deaths in people with mental disorders coded to the physical cause of death and suicide coded to the category of injuries under self-harm--our findings show the striking and growing challenge that these disorders pose for health systems in developed and developing regions.  In view of the magnitude of their contribution, improvement in population health is only possible if countries make the prevention and treatment of mental and substance use disorders a public health priority.  FUNDING:  Queensland Department of Health, National Health and Medical Research Council of Australia, National Drug and Alcohol Research Centre-University of New South Wales, Bill & Melinda Gates Foundation, University of Toronto, Technische Universitat, Ontario Ministry of Health and Long Term Care, and the US National Institute of Alcohol Abuse and Alcoholism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiBNuRCD7D-CO2kE7krGOBfW6udTcc2eYMnssGTIIK57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbktFKktA%253D%253D&md5=b7b9b2c8428804bbec8c78dc8410454d</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2961611-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252961611-6%26sid%3Dliteratum%253Aachs%26aulast%3DWhiteford%26aufirst%3DH.%2BA.%26aulast%3DDegenhardt%26aufirst%3DL.%26aulast%3DRehm%26aufirst%3DJ.%26aulast%3DBaxter%26aufirst%3DA.%2BJ.%26aulast%3DFerrari%26aufirst%3DA.%2BJ.%26aulast%3DErskine%26aufirst%3DH.%2BE.%26aulast%3DCharlson%26aufirst%3DF.%2BJ.%26aulast%3DNorman%26aufirst%3DR.%2BE.%26aulast%3DFlaxman%26aufirst%3DA.%2BD.%26aulast%3DJohns%26aufirst%3DN.%26aulast%3DBurstein%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%2BJ.%2BL.%26aulast%3DVos%26aufirst%3DT.%26atitle%3DGlobal%2520Burden%2520of%2520Disease%2520Attributable%2520to%2520Mental%2520and%2520Substance%2520Use%2520Disorders%253A%2520Findings%2520from%2520the%2520Global%2520Burden%2520of%2520Disease%2520Study%25202010%26jtitle%3DLancet%26date%3D2013%26volume%3D382%26issue%3D9904%26spage%3D1575%26epage%3D1586%26doi%3D10.1016%2FS0140-6736%2813%2961611-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, G.</span></span> <span> </span><span class="NLM_article-title">Serotonin Reuptake Inhibition: An Update on Current Research Strategies</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.2174/0929867024606795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F0929867024606795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11966445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtlGruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=799-810&issue=8&author=D.+Spinksauthor=G.+Spinks&title=Serotonin+Reuptake+Inhibition%3A+An+Update+on+Current+Research+Strategies&doi=10.2174%2F0929867024606795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin reuptake inhibition: An update on current research strategies</span></div><div class="casAuthors">Spinks, D.; Spinks, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">799-810</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  Selective Serotonin reuptake inhibitors (SSRIs) have contributed to the major advances in the treatment of depression and other psychiatric diseases.  This review is on the current knowledge concerning the SSRI class of drugs and discusses the importance of secondary pharmacol. in the mechanism of action and effectiveness of these drugs.  Particular attention is given to the emerging importance of the SSRI "plus" approach: where the serotonin reuptake receptor inhibition of a drug is supplemented by one or more other receptor interactions either by the same drug or by a combination therapy.  This area of research has shed light on the pharmacol. mechanisms of SSRI therapy and has the therapeutic usefulness of serotonin reuptake inhibition, esp. in the area of depression.  There are many new emerging SSRI "plus" drugs, which address the pharmacol. and pharmacokinetic issues of current therapies and these, are discussed in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYTi-h24MOV7Vg90H21EOLACvtfcHk0liNqGlBDWlc2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtlGruro%253D&md5=36c0103adb1891d4bfed6f94787163fb</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.2174%2F0929867024606795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867024606795%26sid%3Dliteratum%253Aachs%26aulast%3DSpinks%26aufirst%3DD.%26aulast%3DSpinks%26aufirst%3DG.%26atitle%3DSerotonin%2520Reuptake%2520Inhibition%253A%2520An%2520Update%2520on%2520Current%2520Research%2520Strategies%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2002%26volume%3D9%26issue%3D8%26spage%3D799%26epage%3D810%26doi%3D10.2174%2F0929867024606795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derubeis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amsterdam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollon, S. D.</span></span> <span> </span><span class="NLM_article-title">Gains in Employment Status Following Antidepressant Medication or Cognitive Therapy for Depression</span>. <i>Br. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>206</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1192/bjp.bp.113.133694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1192%2Fbjp.bp.113.133694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24925985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC2cfhvVertw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=2015&pages=332-338&issue=4&author=J.+C.+Fournierauthor=R.+J.+Derubeisauthor=J.+Amsterdamauthor=R.+C.+Sheltonauthor=S.+D.+Hollon&title=Gains+in+Employment+Status+Following+Antidepressant+Medication+or+Cognitive+Therapy+for+Depression&doi=10.1192%2Fbjp.bp.113.133694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Gains in employment status following antidepressant medication or cognitive therapy for depression</span></div><div class="casAuthors">Fournier Jay C; DeRubeis Robert J; Amsterdam Jay; Shelton Richard C; Hollon Steven D</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of psychiatry : the journal of mental science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Depression can adversely affect employment status.  AIMS:  To examine whether there is a relative advantage of cognitive therapy or antidepressant medication in improving employment status following treatment, using data from a previously reported trial.  METHOD:  Random assignment to cognitive therapy (n = 48) or the selective serotonin reuptake inhibitor paroxetine (n = 93) for 4 months; treatment responders were followed for up to 24 months.  Differential effects of treatment on employment status were examined.  RESULTS:  At the end of 28 months, cognitive therapy led to higher rates of full-time employment (88.9%) than did antidepressant medication among treatment responders (70.8%), χ(2) 1 = 5.78, P = 0.02, odds ratio (OR) = 5.66, 95% CI 1.16-27.69.  In the shorter-term, the main effect of treatment on employment status was not significant following acute treatment (χ(2) 1 = 1.74, P = 0.19, OR = 1.77, 95% CI 0.75-4.17); however, we observed a site×treatment interaction (χ(2) 1 = 6.87, P = 0.009) whereby cognitive therapy led to a higher rate of full-time employment at one site but not at the other.  CONCLUSIONS:  Cognitive therapy may produce greater improvements in employment v. medication, particularly over the longer term.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQ7eaU3K4jhuvW160gIxP_fW6udTcc2ebcQGx5-7KVsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfhvVertw%253D%253D&md5=90cd4f0ebeaa01caf4395db444d34ae0</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1192%2Fbjp.bp.113.133694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fbjp.bp.113.133694%26sid%3Dliteratum%253Aachs%26aulast%3DFournier%26aufirst%3DJ.%2BC.%26aulast%3DDerubeis%26aufirst%3DR.%2BJ.%26aulast%3DAmsterdam%26aufirst%3DJ.%26aulast%3DShelton%26aufirst%3DR.%2BC.%26aulast%3DHollon%26aufirst%3DS.%2BD.%26atitle%3DGains%2520in%2520Employment%2520Status%2520Following%2520Antidepressant%2520Medication%2520or%2520Cognitive%2520Therapy%2520for%2520Depression%26jtitle%3DBr.%2520J.%2520Psychiatry%26date%3D2015%26volume%3D206%26issue%3D4%26spage%3D332%26epage%3D338%26doi%3D10.1192%2Fbjp.bp.113.133694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millan, M. J.</span></span> <span> </span><span class="NLM_article-title">Dual- and Triple-Acting Agents for Treating Core and Co-Morbid Symptoms of Major Depression: Novel Concepts, New Drugs</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.nurt.2008.10.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.nurt.2008.10.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19110199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsF2ntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=53-77&issue=1&author=M.+J.+Millan&title=Dual-+and+Triple-Acting+Agents+for+Treating+Core+and+Co-Morbid+Symptoms+of+Major+Depression%3A+Novel+Concepts%2C+New+Drugs&doi=10.1016%2Fj.nurt.2008.10.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs</span></div><div class="casAuthors">Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-77</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1933-7213</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The past decade of efforts to find improved treatment for major depression has been dominated by genome-driven programs of rational drug discovery directed toward highly selective ligands for nonmonoaminergic agents.  Selective drugs may prove beneficial for specific symptoms, for certain patient subpopulations, or both.  However, network analyses of the brain and its dysfunction suggest that agents with multiple and complementary modes of action are more likely to show broad-based efficacy against core and comorbid symptoms of depression.  Strategies for improved multitarget exploitation of monoaminergic mechanisms include triple inhibitors of dopamine, serotonin (5-HT) and noradrenaline reuptake, and drugs interfering with feedback actions of monoamines at inhibitory 5-HT1A, 5-HT1B and possibly 5-HT5A and 5-HT7 receptors.  Specific subsets of postsynaptic 5-HT receptors mediating antidepressant actions are under study (e.g., 5-HT4 and 5-HT6).  Assocn. of a clin. characterized antidepressant mechanism with a nonmonoaminergic component of activity is an attractive strategy.  For example, agomelatine (a melatonin agonist/5-HT2C antagonist) has clin. proven activity in major depression.  Dual neurokinin1 antagonists/5-HT reuptake inhibitors (SRIs) and melanocortin4 antagonists/SRIs should display advantages over their selective counterparts, and histamine H3 antagonists/SRIs, GABAB antagonists/SRIs, glutamatergic/SRIs, and cholinergic agents/SRIs may counter the compromised cognitive function of depression.  Finally, drugs that suppress 5-HT reuptake and blunt hypothalamo-pituitary-adrenocorticotrophic axis overdrive, or that act at intracellular proteins such as GSK-3β, may abrogate the neg. effects of chronic stress on mood and neuronal integrity.  This review discusses the discovery and development of dual- and triple-acting antidepressants, focusing on novel concepts and new drugs disclosed over the last 2 to 3 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHNCBcMgEfc7Vg90H21EOLACvtfcHk0lifm_ZKD4Onpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsF2ntb8%253D&md5=547817a97dca367c68416bd852572c0e</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2008.10.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2008.10.039%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DDual-%2520and%2520Triple-Acting%2520Agents%2520for%2520Treating%2520Core%2520and%2520Co-Morbid%2520Symptoms%2520of%2520Major%2520Depression%253A%2520Novel%2520Concepts%252C%2520New%2520Drugs%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26issue%3D1%26spage%3D53%26epage%3D77%26doi%3D10.1016%2Fj.nurt.2008.10.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Artigas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celada, P.</span></span> <span> </span><span class="NLM_article-title">Pindolol Augmentation of Antidepressant Response</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.2174/138945006775515446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F138945006775515446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16475955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Ghsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=139-147&issue=2&author=F.+Artigasauthor=A.+Adellauthor=P.+Celada&title=Pindolol+Augmentation+of+Antidepressant+Response&doi=10.2174%2F138945006775515446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Pindolol augmentation of antidepressant response</span></div><div class="casAuthors">Artigas, Francesc; Adell, Albert; Celada, Pau</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-147</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Pindolol, a partial β-adrenoceptor/5-HT1A receptor antagonist was first used to accelerate the onset of action of antidepressant drugs in 1994.  Since then, it has been used in more than a dozen controlled trials to examine whether it can reduce the lag to clin. improvement, and/or improve the clin. response in treatment-resistant patients.  A recent metaanal. concluded that pindolol accelerates the antidepressant response but does not increase the effectiveness of SSRIs in unresponsive patients.  Several studies have examd. the pharmacol. of pindolol to clarify the neurobiol. basis of its clin. action.  Pindolol was initially used due to its ability to block 5-HT1A receptor-mediated responses and to enhance the neurochem. effects of SSRIs.  In transfected cells, however, pindolol is a weak (20-25%) partial agonist at 5-HT1A receptors and, as such, its actions greatly depend on the system used.  In line with this, other reports have also shown that pindolol can reduce serotonergic cell firing when given alone.  Positron emission tomog. (PET) scan studies have shown that pindolol displays a preferential occupancy of pre- vs. postsynaptic 5-HT1A receptors, although the overall occupancy is lower than desirable, which suggests that higher doses (e.g., 15 mg/day) may be more effective than the currently used 7.5 mg daily dosage.  However, given the complex pharmacol. of pindolol, it is hoped that new developments in this field can proceed through the use of (a) selective and silent 5-HT1A receptor antagonists in combination with SSRIs, or (b) dual action agents (SSRI + 5-HT1A receptor blockers).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnn4ribHJkybVg90H21EOLACvtfcHk0lifm_ZKD4Onpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Ghsrw%253D&md5=abcdcbeb45be139d18db5b08342e0848</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.2174%2F138945006775515446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945006775515446%26sid%3Dliteratum%253Aachs%26aulast%3DArtigas%26aufirst%3DF.%26aulast%3DAdell%26aufirst%3DA.%26aulast%3DCelada%26aufirst%3DP.%26atitle%3DPindolol%2520Augmentation%2520of%2520Antidepressant%2520Response%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2006%26volume%3D7%26issue%3D2%26spage%3D139%26epage%3D147%26doi%3D10.2174%2F138945006775515446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vermeulen, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprouse, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrom, H. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grol, C. J.</span></span> <span> </span><span class="NLM_article-title">Characterization of the 5-HT<sub>7</sub> Receptor. Determination of the Pharmacophore for 5-HT<sub>7</sub> Receptor Agonism and CoMFA-Based Modeling of the Agonist Binding Site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">5365</span>– <span class="NLM_lpage">5374</span>, <span class="refDoi"> DOI: 10.1021/jm030826m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030826m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5365-5374&issue=25&author=E.+S.+Vermeulenauthor=A.+W.+Schmidtauthor=J.+S.+Sprouseauthor=H.+K.+V.+Wikstromauthor=C.+J.+Grol&title=Characterization+of+the+5-HT7+Receptor.+Determination+of+the+Pharmacophore+for+5-HT7+Receptor+Agonism+and+CoMFA-Based+Modeling+of+the+Agonist+Binding+Site&doi=10.1021%2Fjm030826m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the 5-HT7 Receptor. Determination of the Pharmacophore for 5-HT7 Receptor Agonism and CoMFA-Based Modeling of the Agonist Binding Site</span></div><div class="casAuthors">Vermeulen, Erik S.; Schmidt, Anne W.; Sprouse, Jeffrey S.; Wikstroem, Haakan V.; Grol, Cor J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">5365-5374</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of a set of 20 diverse 5-HT7 receptor agonists, the pharmacophore for 5-HT7 receptor agonism was detd.  Addnl. two CoMFA models were developed, based on different alignments of the agonists.  Both models show good correlations between exptl. and predictive pKi values and show a high degree of similarity.  The CoMFA fields were subsequently used to map the agonist binding site of the model of the 5-HT7 receptor.  Important roles in ligand binding are attributed to Asp162 of TM3 (interaction with a protonated nitrogen), and Thr244 of TM5 (interaction with a substituent at an arom. moiety).  Amino acid residues of the arom. cluster of TM6 are hypothesized to play an important role in ligand binding as π-π stacking moieties.  Agonists missing a hydrogen-bond-accepting moiety, but possessing an arom. substituent instead, seem to bind the receptor with high affinity as well by occupying a lipophilic pocket hosted by residues of TM5 and TM6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8qchiC4OGerVg90H21EOLACvtfcHk0lhSXcj0zeV1Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cit74%253D&md5=22551bbc09658d0b4fa804e9708f297a</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1021%2Fjm030826m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030826m%26sid%3Dliteratum%253Aachs%26aulast%3DVermeulen%26aufirst%3DE.%2BS.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DSprouse%26aufirst%3DJ.%2BS.%26aulast%3DWikstrom%26aufirst%3DH.%2BK.%2BV.%26aulast%3DGrol%26aufirst%3DC.%2BJ.%26atitle%3DCharacterization%2520of%2520the%25205-HT7%2520Receptor.%2520Determination%2520of%2520the%2520Pharmacophore%2520for%25205-HT7%2520Receptor%2520Agonism%2520and%2520CoMFA-Based%2520Modeling%2520of%2520the%2520Agonist%2520Binding%2520Site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D25%26spage%3D5365%26epage%3D5374%26doi%3D10.1021%2Fjm030826m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationship Study on N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-Aryl-1-Piperazinehexanamides, a Class of 5-HT<sub>7</sub> Receptor Agents. 2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4214</span>– <span class="NLM_lpage">4221</span>, <span class="refDoi"> DOI: 10.1021/jm070487n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070487n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotVKht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=4214-4221&issue=17&author=M.+Leopoldoauthor=E.+Lacivitaauthor=M.+Continoauthor=N.+A.+Colabufoauthor=F.+Berardiauthor=R.+Perrone&title=Structure-Activity+Relationship+Study+on+N-%281%2C2%2C3%2C4-Tetrahydronaphthalen-1-yl%29-4-Aryl-1-Piperazinehexanamides%2C+a+Class+of+5-HT7+Receptor+Agents.+2&doi=10.1021%2Fjm070487n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Study on N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a Class of 5-HT7 Receptor Agents. 2</span></div><div class="casAuthors">Leopoldo, Marcello; Lacivita, Enza; Contino, Marialessandra; Colabufo, Nicola A.; Berardi, Francesco; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4214-4221</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here the authors report the synthesis of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides 16-29 that were designed to elucidate both structure-affinity and -activity relations for the 5-HT7 receptor, by targeting the substituent in 2-position of the aryl linked to the piperazine ring.  The affinities of 16-29 for 5-HT7, 5-HT1A, 5-HT2A, and D2 receptors were assessed by radioligand binding assays.  The intrinsic activities at the 5-HT7 receptor of the most potent compds. were detd.  Substituents covering a wide range of electronic, steric, and polar properties were evaluated, revealing a key role on 5-HT7 receptor affinity and intrinsic activity.  Certain lipophilic substituents (SCH3, CHMe2, NMe2, CH3, Ph) led to high-affinity agonists, whereas OH and NHCH3 substituents switched intrinsic activity toward antagonism.  4-[2-(1-Methylethyl)phenyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (19), 4-(2-diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (21), and 4-(2-dimethylaminophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (22) were identified as potent 5-HT7 receptor agonists (Ki = 0.13-1.1 nM, EC50 = 0.90-1.77 μM), showing selectivity over 5-HT1A, 5-HT2A, and D2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1C_BPfXRj5bVg90H21EOLACvtfcHk0lhSXcj0zeV1Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotVKht7o%253D&md5=0243631a73c3aea226d83da9b2799329</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1021%2Fjm070487n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070487n%26sid%3Dliteratum%253Aachs%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DStructure-Activity%2520Relationship%2520Study%2520on%2520N-%25281%252C2%252C3%252C4-Tetrahydronaphthalen-1-yl%2529-4-Aryl-1-Piperazinehexanamides%252C%2520a%2520Class%2520of%25205-HT7%2520Receptor%2520Agents.%25202%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D17%26spage%3D4214%26epage%3D4221%26doi%3D10.1021%2Fjm070487n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Giorgio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fracasso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzzetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Structural Modifications of N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: Influence on Lipophilicity and 5-HT<sub>7</sub> Receptor Activity. Part III</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5813</span>– <span class="NLM_lpage">5822</span>, <span class="refDoi"> DOI: 10.1021/jm800615e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800615e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVChs7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5813-5822&issue=18&author=M.+Leopoldoauthor=E.+Lacivitaauthor=P.+De+Giorgioauthor=C.+Fracassoauthor=S.+Guzzettiauthor=S.+Cacciaauthor=M.+Continoauthor=N.+A.+Colabufoauthor=F.+Berardiauthor=R.+Perrone&title=Structural+Modifications+of+N-%281%2C2%2C3%2C4-Tetrahydronaphthalen-1-yl%29-4-aryl-1-piperazinehexanamides%3A+Influence+on+Lipophilicity+and+5-HT7+Receptor+Activity.+Part+III&doi=10.1021%2Fjm800615e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Modifications of N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-Aryl-1-piperazinehexanamides: Influence on Lipophilicity and 5-HT7 Receptor Activity. Part III</span></div><div class="casAuthors">Leopoldo, Marcello; Lacivita, Enza; De Giorgio, Paola; Fracasso, Claudia; Guzzetti, Sara; Caccia, Silvio; Contino, Marialessandra; Colabufo, Nicola A.; Berardi, Francesco; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5813-5822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from the previously reported 5-HT7 receptor agents 4-7 with N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamide structure, the 1-(2-methylthiophenyl)-, 1-(2-diphenyl)-, 1-(2-isopropylphenyl)-, and 1-(2-methoxyphenyl)piperazine derivs. 8-31 were designed with the primary aim to obtain new compds. endowed with suitable physicochem. properties for rapid and extensive penetration into the brain.  The affinities for 5-HT7, 5-HT1A, and D2 receptors of compds. 8-31 were assessed, and several compds. displayed 5-HT7 receptor affinities in the nanomolar range.  Among these, N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide (25) showed high 5-HT7 receptor affinity (Ki = 0.58 nM), high selectivity over 5-HT1A and D2 receptors (324- and 245-fold, resp.), and agonist properties (maximal effect = 82%, EC50 = 0.60 μM).  After i.p. injection in mice, 25 rapidly reached the systemic circulation and entered the brain.  Its brain concn.-time profile paralleled that in plasma, indicating that 25 rapidly and freely distributes across the blood-brain barrier.  Compd. 25 underwent N-dealkylation to the corresponding 1-arylpiperazine metabolite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobpnnFHb4H1bVg90H21EOLACvtfcHk0lhSXcj0zeV1Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVChs7rJ&md5=035e122d1b4fec52b1ce8258f520b0a9</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1021%2Fjm800615e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800615e%26sid%3Dliteratum%253Aachs%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DDe%2BGiorgio%26aufirst%3DP.%26aulast%3DFracasso%26aufirst%3DC.%26aulast%3DGuzzetti%26aufirst%3DS.%26aulast%3DCaccia%26aufirst%3DS.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DStructural%2520Modifications%2520of%2520N-%25281%252C2%252C3%252C4-Tetrahydronaphthalen-1-yl%2529-4-aryl-1-piperazinehexanamides%253A%2520Influence%2520on%2520Lipophilicity%2520and%25205-HT7%2520Receptor%2520Activity.%2520Part%2520III%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D18%26spage%3D5813%26epage%3D5822%26doi%3D10.1021%2Fjm800615e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patarnello, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caroli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Giorgio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pilato, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svenningsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedlund, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 1-(2-Biphenyl)Piperazine Motif: Identification of New Potent and Selective Ligands for the Serotonin 7 (5-HT<sub>7</sub>) Receptor with Agonist or Antagonist Action in Vitro or ex Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6375</span>– <span class="NLM_lpage">6380</span>, <span class="refDoi"> DOI: 10.1021/jm3003679</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003679" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1Cgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6375-6380&issue=14&author=E.+Lacivitaauthor=D.+Patarnelloauthor=N.+Strothauthor=A.+Caroliauthor=M.+Nisoauthor=M.+Continoauthor=P.+De+Giorgioauthor=P.+Di+Pilatoauthor=N.+A.+Colabufoauthor=F.+Berardiauthor=R.+Perroneauthor=P.+Svenningssonauthor=P.+B.+Hedlundauthor=M.+Leopoldo&title=Investigations+on+the+1-%282-Biphenyl%29Piperazine+Motif%3A+Identification+of+New+Potent+and+Selective+Ligands+for+the+Serotonin+7+%285-HT7%29+Receptor+with+Agonist+or+Antagonist+Action+in+Vitro+or+ex+Vivo&doi=10.1021%2Fjm3003679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 1-(2-Biphenyl)piperazine Motif: Identification of New Potent and Selective Ligands for the Serotonin7 (5-HT7) Receptor with Agonist or Antagonist Action in Vitro or ex Vivo</span></div><div class="casAuthors">Lacivita, Enza; Patarnello, Daniela; Stroth, Nikolas; Caroli, Antonia; Niso, Mauro; Contino, Marialessandra; De Giorgio, Paola; Di Pilato, Pantaleo; Colabufo, Nicola A.; Berardi, Francesco; Perrone, Roberto; Svenningsson, Per; Hedlund, Peter B.; Leopoldo, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6375-6380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the design, synthesis, and 5-HT7 receptor affinity of a set of 1-(3-biphenyl)- and 1-(2-biphenyl)piperazines are reported.  The effect on 5-HT7 affinity of various substituents on the second (distal) Ph ring was analyzed.  Several compds. showed 5-HT7 affinities in the nanomolar range and >100-fold selectivity over 5-HT1A and adrenergic α1 receptors.  1-[2-(4-Methoxyphenyl)phenyl]piperazine showed 5-HT7 agonist properties in a guinea pig ileum assay but blocked 5-HT-mediated cAMP accumulation in 5-HT7-expressing HeLa cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_7UpY3EFLzbVg90H21EOLACvtfcHk0liONFAgUC41ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1Cgt78%253D&md5=2a1fce8eef267844ee7ac08748b001a2</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1021%2Fjm3003679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003679%26sid%3Dliteratum%253Aachs%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DPatarnello%26aufirst%3DD.%26aulast%3DStroth%26aufirst%3DN.%26aulast%3DCaroli%26aufirst%3DA.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DDe%2BGiorgio%26aufirst%3DP.%26aulast%3DDi%2BPilato%26aufirst%3DP.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DSvenningsson%26aufirst%3DP.%26aulast%3DHedlund%26aufirst%3DP.%2BB.%26aulast%3DLeopoldo%26aufirst%3DM.%26atitle%3DInvestigations%2520on%2520the%25201-%25282-Biphenyl%2529Piperazine%2520Motif%253A%2520Identification%2520of%2520New%2520Potent%2520and%2520Selective%2520Ligands%2520for%2520the%2520Serotonin%25207%2520%25285-HT7%2529%2520Receptor%2520with%2520Agonist%2520or%2520Antagonist%2520Action%2520in%2520Vitro%2520or%2520ex%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D14%26spage%3D6375%26epage%3D6380%26doi%3D10.1021%2Fjm3003679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antidepressant-Like Activity of Novel Aralkyl Piperazine Derivatives Targeting SSRI/5-HT<sub>1a</sub> /5-HT<sub>7</sub></span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">701</span>– <span class="NLM_lpage">715</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2017.12.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29291438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=701-715&author=Z.+S.+Guauthor=A.+N.+Zhouauthor=Y.+Xiaoauthor=Q.+W.+Zhangauthor=J.+Q.+Li&title=Synthesis+and+Antidepressant-Like+Activity+of+Novel+Aralkyl+Piperazine+Derivatives+Targeting+SSRI%2F5-HT1a+%2F5-HT7&doi=10.1016%2Fj.ejmech.2017.12.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antidepressant-like activity of novel aralkyl piperazine derivatives targeting SSRI/5-HT1A/5-HT7</span></div><div class="casAuthors">Gu, Zheng-Song; Zhou, Ai-nan; Xiao, Ying; Zhang, Qing-Wei; Li, Jian-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">701-715</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel aralkyl piperazine derivs. I (Ar = benzofuran-3-yl, 5-F-indol-3-yl; R1 = H, OMe, SMe, etc.; R2 = H, 3-F, 4-F, 5-F, 3-Ph; m = 0, 1, or 2) were synthesized, and evaluated for their serotonin reuptake inhibitory and 5-HT1A/5-HT7 receptors affinities activity.  Antidepressant activities in vivo of the compds. were screened using the forced swimming test (FST) and tail suspension test (TST).  The results indicated that compds. I (Ar = 5-F-indol-3-yl; R1 = 3-FC6H4; R2 = 4-F) (RUI, IC50 = 31nM; 5-HT1A, 5-HT7, ki = 62, 12nM) and I (Ar = 5-F-indol-3-yl; R1 = Ph; R2 = 4-F) (RUI, IC50 = 25nM; 5-HT1A, 5-HT7, ki = 28, 3.3nM) exhibited high affinities for the 5-HT1A/5-HT7 receptors coupled with potent serotonin reuptake inhibition.  Specifically, the most promising compd. I (Ar = 5-F-indol-3-yl; R1 = Ph; R2 = 4-F) possessed a good oral pharmacokinetic properties and an acceptable hERG profile, and showed potent antidepressant-like effect in the FST and TST models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSMf00wCn8lLVg90H21EOLACvtfcHk0liONFAgUC41ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWntg%253D%253D&md5=7eca8795937fca66aabce7ec1704bc54</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.063%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DZ.%2BS.%26aulast%3DZhou%26aufirst%3DA.%2BN.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.%2BW.%26aulast%3DLi%26aufirst%3DJ.%2BQ.%26atitle%3DSynthesis%2520and%2520Antidepressant-Like%2520Activity%2520of%2520Novel%2520Aralkyl%2520Piperazine%2520Derivatives%2520Targeting%2520SSRI%252F5-HT1a%2520%252F5-HT7%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D701%26epage%3D715%26doi%3D10.1016%2Fj.ejmech.2017.12.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skene, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakken, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giusti-Rodriguez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz-Manchado, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donovan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardiñas, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, J. T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linnarsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lein, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjerling-Leffler, J.</span></span> <span> </span><span class="NLM_article-title">Genetic Identification of Brain Cell Types Underlying Schizophrenia</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">825</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.1038/s41588-018-0129-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fs41588-018-0129-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29785013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVShu73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=825-833&issue=6&author=N.+G.+Skeneauthor=J.+Bryoisauthor=T.+E.+Bakkenauthor=G.+Breenauthor=J.+J.+Crowleyauthor=H.+A.+Gasparauthor=P.+Giusti-Rodriguezauthor=R.+D.+Hodgeauthor=J.+A.+Millerauthor=A.+B.+Mu%C3%B1oz-Manchadoauthor=M.+C.+O%E2%80%99Donovanauthor=M.+J.+Owenauthor=A.+F.+Pardi%C3%B1asauthor=J.+Rygeauthor=J.+T.+R.+Waltersauthor=S.+Linnarssonauthor=E.+S.+Leinauthor=P.+F.+Sullivanauthor=J.+Hjerling-Leffler&title=Genetic+Identification+of+Brain+Cell+Types+Underlying+Schizophrenia&doi=10.1038%2Fs41588-018-0129-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic identification of brain cell types underlying schizophrenia</span></div><div class="casAuthors">Skene, Nathan G.; Bryois, Julien; Bakken, Trygve E.; Breen, Gerome; Crowley, James J.; Gaspar, Helena A.; Giusti-Rodriguez, Paola; Hodge, Rebecca D.; Miller, Jeremy A.; Munoz-Manchado, Ana B.; O'Donovan, Michael C.; Owen, Michael J.; Pardinas, Antonio F.; Ryge, Jesper; Walters, James T. R.; Linnarsson, Sten; Lein, Ed S.; Sullivan, Patrick F.; Hjerling-Leffler, Jens</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">825-833</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">With few exceptions, the marked advances in knowledge about the genetic basis of schizophrenia have not converged on findings that can be confidently used for precise exptl. modeling.  By applying knowledge of the cellular taxonomy of the brain from single-cell RNA sequencing, we evaluated whether the genomic loci implicated in schizophrenia map onto specific brain cell types.  We found that the common-variant genomic results consistently mapped to pyramidal cells, medium spiny neurons (MSNs) and certain interneurons, but far less consistently to embryonic, progenitor or glial cells.  These enrichments were due to sets of genes that were specifically expressed in each of these cell types.  We also found that many of the diverse gene sets previously assocd. with schizophrenia (genes involved in synaptic function, those encoding mRNAs that interact with FMRP, antipsychotic targets, etc.) generally implicated the same brain cell types.  Our results suggest a parsimonious explanation: the common-variant genetic results for schizophrenia point at a limited set of neurons, and the gene sets point to the same cells.  The genetic risk assocd. with MSNs did not overlap with that of glutamatergic pyramidal cells and interneurons, suggesting that different cell types have biol. distinct roles in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkacm1fdPmwbVg90H21EOLACvtfcHk0liONFAgUC41ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVShu73K&md5=b6493f76b9fa3fa0311c1decf251271f</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1038%2Fs41588-018-0129-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41588-018-0129-5%26sid%3Dliteratum%253Aachs%26aulast%3DSkene%26aufirst%3DN.%2BG.%26aulast%3DBryois%26aufirst%3DJ.%26aulast%3DBakken%26aufirst%3DT.%2BE.%26aulast%3DBreen%26aufirst%3DG.%26aulast%3DCrowley%26aufirst%3DJ.%2BJ.%26aulast%3DGaspar%26aufirst%3DH.%2BA.%26aulast%3DGiusti-Rodriguez%26aufirst%3DP.%26aulast%3DHodge%26aufirst%3DR.%2BD.%26aulast%3DMiller%26aufirst%3DJ.%2BA.%26aulast%3DMu%25C3%25B1oz-Manchado%26aufirst%3DA.%2BB.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%2BC.%26aulast%3DOwen%26aufirst%3DM.%2BJ.%26aulast%3DPardi%25C3%25B1as%26aufirst%3DA.%2BF.%26aulast%3DRyge%26aufirst%3DJ.%26aulast%3DWalters%26aufirst%3DJ.%2BT.%2BR.%26aulast%3DLinnarsson%26aufirst%3DS.%26aulast%3DLein%26aufirst%3DE.%2BS.%26aulast%3DSullivan%26aufirst%3DP.%2BF.%26aulast%3DHjerling-Leffler%26aufirst%3DJ.%26atitle%3DGenetic%2520Identification%2520of%2520Brain%2520Cell%2520Types%2520Underlying%2520Schizophrenia%26jtitle%3DNat.%2520Genet.%26date%3D2018%26volume%3D50%26issue%3D6%26spage%3D825%26epage%3D833%26doi%3D10.1038%2Fs41588-018-0129-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure of the D<sub>2</sub>Dopamine Receptor Bound to the Atypical Antipsychotic Drug Risperidone</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span> (<span class="NLM_issue">7695</span>),  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1038/nature25758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnature25758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29466326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=269-273&issue=7695&author=S.+Wangauthor=T.+Cheauthor=A.+Levitauthor=B.+K.+Shoichetauthor=D.+Wackerauthor=B.+L.+Roth&title=Structure+of+the+D2Dopamine+Receptor+Bound+to+the+Atypical+Antipsychotic+Drug+Risperidone&doi=10.1038%2Fnature25758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span></div><div class="casAuthors">Wang, Sheng; Che, Tao; Levit, Anat; Shoichet, Brian K.; Wacker, Daniel; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">7695</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metab. and hormonal secretion.  Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such as schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, and nausea and vomiting.  The actions of dopamine are mediated by a family of five G-protein-coupled receptors.  The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.  Unfortunately, many drugs that target DRD2 cause serious and potentially life-threatening side effects due to promiscuous activities against related receptors.  Accordingly, a mol. understanding of the structure and function of DRD2 could provide a template for the design of safer and more effective medications.  Here we report the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone.  The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at DRD2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeo4Ov49kft7Vg90H21EOLACvtfcHk0lh74-shE5ZOyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D&md5=2842adc1893293ea8dbf98ae3270a1b2</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1038%2Fnature25758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25758%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520of%2520the%2520D2Dopamine%2520Receptor%2520Bound%2520to%2520the%2520Atypical%2520Antipsychotic%2520Drug%2520Risperidone%26jtitle%3DNature%26date%3D2018%26volume%3D555%26issue%3D7695%26spage%3D269%26epage%3D273%26doi%3D10.1038%2Fnature25758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span> <span> </span><span class="NLM_article-title">Association of DRD2 Polymorphisms and Chlorpromazine-Induced Extrapyramidal Syndrome in Chinese Schizophrenic Patients</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">966</span>– <span class="NLM_lpage">970</span>, <span class="refDoi"> DOI: 10.1111/j.1745-7254.2006.00355.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1111%2Fj.1745-7254.2006.00355.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16867246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVKhtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=966-970&issue=8&author=S.+N.+Wuauthor=R.+Gaoauthor=Q.+H.+Xingauthor=H.+F.+Liauthor=Y.+F.+Shenauthor=N.+F.+Guauthor=G.+Y.+Fengauthor=L.+He&title=Association+of+DRD2+Polymorphisms+and+Chlorpromazine-Induced+Extrapyramidal+Syndrome+in+Chinese+Schizophrenic+Patients&doi=10.1111%2Fj.1745-7254.2006.00355.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients</span></div><div class="casAuthors">Wu, Sheng-nan; Gao, Rui; Xing, Qing-he; Li, Hua-fang; Shen, Yi-feng; Gu, Niu-fan; Feng, Guo-yin; He, Lin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">966-970</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">Aim: Extrapyramidal syndrome (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor.  Recently, many research groups have reported on the pos. relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression.  In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.  Methods: We identified seven SNP(single nucleotide polymorphism) (-141 Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 wk.  The alleles of all loci were detd. by PCR (polymerase chain reaction).  Results: Polymorphisms TaqID, Ser311Cys and rs6277 were not polymorphic in the population recruited in the present study.  No statistical significance was found in the allele distribution of -141 Cins>del, TaqIB, rs6275 and TaqIA or in the estd. haplotypes (constituted by TaqIB, rs6275 and TaqIA) in linkage disequil. between the two groups.  Conclusion: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia.  Our results confirmed a previous study on the relationship between DRD2 and EPS in Caucasians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkbk0GB1iaMbVg90H21EOLACvtfcHk0lh74-shE5ZOyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVKhtLc%253D&md5=05808a4c3cf12e2a537884e4c34d123e</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1111%2Fj.1745-7254.2006.00355.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1745-7254.2006.00355.x%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DS.%2BN.%26aulast%3DGao%26aufirst%3DR.%26aulast%3DXing%26aufirst%3DQ.%2BH.%26aulast%3DLi%26aufirst%3DH.%2BF.%26aulast%3DShen%26aufirst%3DY.%2BF.%26aulast%3DGu%26aufirst%3DN.%2BF.%26aulast%3DFeng%26aufirst%3DG.%2BY.%26aulast%3DHe%26aufirst%3DL.%26atitle%3DAssociation%2520of%2520DRD2%2520Polymorphisms%2520and%2520Chlorpromazine-Induced%2520Extrapyramidal%2520Syndrome%2520in%2520Chinese%2520Schizophrenic%2520Patients%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2006%26volume%3D27%26issue%3D8%26spage%3D966%26epage%3D970%26doi%3D10.1111%2Fj.1745-7254.2006.00355.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breier, A.</span></span> <span> </span><span class="NLM_article-title">Fluoxetine Augmentation of Clozapine Treatment in Patients with Schizophrenia</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>153</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1627</span>, <span class="refDoi"> DOI: 10.1176/ajp.153.12.1625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1176%2Fajp.153.12.1625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=8942462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADyaK2s%252Fpsl2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=1996&pages=1625-1627&issue=12&author=R.+W.+Buchananauthor=B.+Kirkpatrickauthor=N.+Bryantauthor=P.+Ballauthor=A.+Breier&title=Fluoxetine+Augmentation+of+Clozapine+Treatment+in+Patients+with+Schizophrenia&doi=10.1176%2Fajp.153.12.1625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Fluoxetine augmentation of clozapine treatment in patients with schizophrenia</span></div><div class="casAuthors">Buchanan R W; Kirkpatrick B; Bryant N; Ball P; Breier A</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1625-7</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The authors examined the efficacy of fluoxetine augmentation of clozapine treatment response in schizophrenic outpatients who, despite adequate treatment with clozapine, continued to exhibit persistent positive or negative symptoms.  METHOD:  Thirty-three patients completed on 8-week, double-blind, parallel-groups comparison of adjunctive fluoxetine and placebo.  RESULTS:  There were no significant differences in positive, negative, depressive, or obsessive-compulsive symptoms between patients given adjunctive fluoxetine or placebo.  CONCLUSIONS:  These results suggest that fluoxetine is not effective in augmenting clozapine treatment response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZRh8mt7jW-ZdYoSR9eyvsfW6udTcc2ebcReIubX-QYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s%252Fpsl2hsw%253D%253D&md5=dd02b14d5073762bbcb2e94e9f7968e4</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1176%2Fajp.153.12.1625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fajp.153.12.1625%26sid%3Dliteratum%253Aachs%26aulast%3DBuchanan%26aufirst%3DR.%2BW.%26aulast%3DKirkpatrick%26aufirst%3DB.%26aulast%3DBryant%26aufirst%3DN.%26aulast%3DBall%26aufirst%3DP.%26aulast%3DBreier%26aufirst%3DA.%26atitle%3DFluoxetine%2520Augmentation%2520of%2520Clozapine%2520Treatment%2520in%2520Patients%2520with%2520Schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1996%26volume%3D153%26issue%3D12%26spage%3D1625%26epage%3D1627%26doi%3D10.1176%2Fajp.153.12.1625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coolen, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keizer, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Moes, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Hartog, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stork, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plekkenpol, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroomer, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulp, M. Th. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Stuivenberg, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCreary, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesselink, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herremans, A. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, C. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Structure-Activity Relationships, and Biological Properties of 1-Heteroaryl-4-[Omega-(1H-Indol-3-yl)Alkyl]Piperazines, Novel Potential Antipsychotics Combining Potent Dopamine D<sub>2</sub> Receptor Antagonism with Potent Serotonin Reuptake Inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6855</span>– <span class="NLM_lpage">6869</span>, <span class="refDoi"> DOI: 10.1021/jm050148z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050148z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGqsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6855-6869&issue=22&author=P.+Smidauthor=H.+K.+Coolenauthor=H.+G.+Keizerauthor=R.+van+Hesauthor=J.+P.+de+Moesauthor=A.+P.+den+Hartogauthor=B.+Storkauthor=R.+H.+Plekkenpolauthor=L.+C.+Niemannauthor=C.+N.+Stroomerauthor=M.+Th.+M.+Tulpauthor=H.+H.+van%0AStuivenbergauthor=A.+C.+McCrearyauthor=M.+B.+Hesselinkauthor=A.+H.+J.+Herremansauthor=C.+G.+Kruse&title=Synthesis%2C+Structure-Activity+Relationships%2C+and+Biological+Properties+of+1-Heteroaryl-4-%5BOmega-%281H-Indol-3-yl%29Alkyl%5DPiperazines%2C+Novel+Potential+Antipsychotics+Combining+Potent+Dopamine+D2+Receptor+Antagonism+with+Potent+Serotonin+Reuptake+Inhibition&doi=10.1021%2Fjm050148z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and Biological Properties of 1-Heteroaryl-4-[ω-(1H-indol-3-yl)alkyl]piperazines, Novel Potential Antipsychotics Combining Potent Dopamine D2 Receptor Antagonism with Potent Serotonin Reuptake Inhibition</span></div><div class="casAuthors">Smid, Pieter; Coolen, Hein K. A. C.; Keizer, Hiskias G.; Van Hes, Rolf; De Moes, Jan-Peter; Den Hartog, Arnold P.; Stork, Bob; Plekkenpol, Rob H.; Niemann, Leonarda C.; Stroomer, Cees N. J.; Tulp, Martin Th. M.; Van Stuivenberg, Herman H.; McCreary, Andrew C.; Hesselink, Mayke B.; Herremans, Arnoud H. J.; Kruse, Chris G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6855-6869</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel bicyclic 1-heteroaryl-4-[ω-(1H-indol-3-yl)alkyl]piperazines was synthesized and evaluated on binding to dopamine D2 receptors and serotonin reuptake sites.  This class of compds. proved to be potent in vitro dopamine D2 receptor antagonists and in addn. were highly active as serotonin reuptake inhibitors.  Some key representatives showed potent pharmacol. in vivo activities after oral dosing in both the antagonism of apomorphine-induced climbing and the potentiation of 5-HTP-induced behavior in mice.  On the basis of the preclin. data, 8-{4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazin-1-yl}-4H-benzo[1,4]oxazin-(R)-2-methyl-3-one (I, SLV314) was selected for clin. development.  In vitro and in vivo studies revealed that I has favorable pharmacokinetic properties and a high CNS-plasma ratio.  Mol. modeling studies showed that the bifunctional activity of I can be explained by its ability to adopt two different conformations fitting either the dopamine D2 receptor pharmacophore or the serotonin transporter pharmacophore.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNC21__bpXaLVg90H21EOLACvtfcHk0li68xoNxcCnvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGqsr3E&md5=226ab1990d08e2635b716f2f3a01b764</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1021%2Fjm050148z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050148z%26sid%3Dliteratum%253Aachs%26aulast%3DSmid%26aufirst%3DP.%26aulast%3DCoolen%26aufirst%3DH.%2BK.%26aulast%3DKeizer%26aufirst%3DH.%2BG.%26aulast%3Dvan%2BHes%26aufirst%3DR.%26aulast%3Dde%2BMoes%26aufirst%3DJ.%2BP.%26aulast%3Dden%2BHartog%26aufirst%3DA.%2BP.%26aulast%3DStork%26aufirst%3DB.%26aulast%3DPlekkenpol%26aufirst%3DR.%2BH.%26aulast%3DNiemann%26aufirst%3DL.%2BC.%26aulast%3DStroomer%26aufirst%3DC.%2BN.%26aulast%3DTulp%26aufirst%3DM.%2BTh.%2BM.%26aulast%3Dvan%2BStuivenberg%26aufirst%3DH.%2BH.%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26aulast%3DHesselink%26aufirst%3DM.%2BB.%26aulast%3DHerremans%26aufirst%3DA.%2BH.%2BJ.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DSynthesis%252C%2520Structure-Activity%2520Relationships%252C%2520and%2520Biological%2520Properties%2520of%25201-Heteroaryl-4-%255BOmega-%25281H-Indol-3-yl%2529Alkyl%255DPiperazines%252C%2520Novel%2520Potential%2520Antipsychotics%2520Combining%2520Potent%2520Dopamine%2520D2%2520Receptor%2520Antagonism%2520with%2520Potent%2520Serotonin%2520Reuptake%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D22%26spage%3D6855%26epage%3D6869%26doi%3D10.1021%2Fjm050148z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feenstra, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Moes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofma, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuipers, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulp, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Heyden, J. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, C. G.</span></span> <span> </span><span class="NLM_article-title">New 1-Aryl-4-(biarylmethylene)piperazines as Potential Atypical Antipsychotics Sharing Dopamine D<sub>2</sub>-Receptor and Serotonin 5-HT<sub>1a</sub>-Receptor Affinities</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2345</span>– <span class="NLM_lpage">2349</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00425-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0960-894X%2801%2900425-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11527728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmt12jsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=2345-2349&issue=17&author=R.+W.+Feenstraauthor=J.+de+Moesauthor=J.+J.+Hofmaauthor=H.+Klingauthor=W.+Kuipersauthor=S.+K.+Longauthor=M.+T.+Tulpauthor=J.+A.+M.+van+der%0AHeydenauthor=C.+G.+Kruse&title=New+1-Aryl-4-%28biarylmethylene%29piperazines+as+Potential+Atypical+Antipsychotics+Sharing+Dopamine+D2-Receptor+and+Serotonin+5-HT1a-Receptor+Affinities&doi=10.1016%2FS0960-894X%2801%2900425-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1A-receptor affinities</span></div><div class="casAuthors">Feenstra, R. W.; de Moes, J.; Hofma, J. J.; Kling, H.; Kuipers, W.; Long, S. K.; Tulp, M. T. M.; van der Heyden, J. A. M.; Kruse, C. G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2345-2349</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">1-Aryl-4-(biarylmethylene)piperazines were prepd. and their affinity for D2 and 5-HT1A receptors was detd..  A selection of these compds. was evaluated in vivo, resulting in the identification of a drug candidate which is being clin. evaluated as a potential atypical antipsychotic with reduced extrapyrimidal side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIUePqOrsrlbVg90H21EOLACvtfcHk0li68xoNxcCnvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmt12jsr4%253D&md5=9c8ecd3674e9361a038ecced7a481e5e</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900425-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900425-5%26sid%3Dliteratum%253Aachs%26aulast%3DFeenstra%26aufirst%3DR.%2BW.%26aulast%3Dde%2BMoes%26aufirst%3DJ.%26aulast%3DHofma%26aufirst%3DJ.%2BJ.%26aulast%3DKling%26aufirst%3DH.%26aulast%3DKuipers%26aufirst%3DW.%26aulast%3DLong%26aufirst%3DS.%2BK.%26aulast%3DTulp%26aufirst%3DM.%2BT.%26aulast%3Dvan%2Bder%2BHeyden%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DNew%25201-Aryl-4-%2528biarylmethylene%2529piperazines%2520as%2520Potential%2520Atypical%2520Antipsychotics%2520Sharing%2520Dopamine%2520D2-Receptor%2520and%2520Serotonin%25205-HT1a-Receptor%2520Affinities%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26issue%3D17%26spage%3D2345%26epage%3D2349%26doi%3D10.1016%2FS0960-894X%2801%2900425-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runyon, S. P.</span></span> <span> </span><span class="NLM_article-title">Regulation of the Apelinergic System and Its Potential in Cardiovascular Disease: Peptides and Small Molecules as Tools for Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">7913</span>– <span class="NLM_lpage">7927</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00527</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKit7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7913-7927&issue=20&author=S.+Narayananauthor=D.+L.+Harrisauthor=R.+Maitraauthor=S.+P.+Runyon&title=Regulation+of+the+Apelinergic+System+and+Its+Potential+in+Cardiovascular+Disease%3A+Peptides+and+Small+Molecules+as+Tools+for+Discovery&doi=10.1021%2Facs.jmedchem.5b00527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the Apelinergic System and Its Potential in Cardiovascular Disease: Peptides and Small Molecules as Tools for Discovery</span></div><div class="casAuthors">Narayanan, Sanju; Harris, Danni L.; Maitra, Rangan; Runyon, Scott P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7913-7927</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Apelin peptides and the apelin receptor represent a relatively new therapeutic axis for the potential treatment of cardiovascular disease.  Several reports suggest apelin receptor activation with apelin peptides results in cardioprotection as noted through pos. ionotropy, angiogenesis, redn. of mean arterial blood pressure, and apoptosis.  Considering the potential therapeutic benefit attainable through modulation of the apelinergic system, research is expanding to develop novel therapies that limit the inherent rapid degrdn. of endogenous apelin peptides and produce metabolically stable small mol. agonists and antagonists to more rigorously interrogate the apelin receptor system.  This review details the structure-activity relationships for chem. modified apelin peptides and recent disclosures of small mol. agonists and antagonists and summarizes the peer reviewed and patented literature.  Development of metabolically stable ligands of apelin receptor and their effects in various models over the coming years will hopefully lead to establishment of this receptor as a validated target for cardiovascular indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTIngNdWxX87Vg90H21EOLACvtfcHk0li68xoNxcCnvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKit7rN&md5=6c116a42d7b523905e811c33c46e256f</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00527%26sid%3Dliteratum%253Aachs%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DD.%2BL.%26aulast%3DMaitra%26aufirst%3DR.%26aulast%3DRunyon%26aufirst%3DS.%2BP.%26atitle%3DRegulation%2520of%2520the%2520Apelinergic%2520System%2520and%2520Its%2520Potential%2520in%2520Cardiovascular%2520Disease%253A%2520Peptides%2520and%2520Small%2520Molecules%2520as%2520Tools%2520for%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D20%26spage%3D7913%26epage%3D7927%26doi%3D10.1021%2Facs.jmedchem.5b00527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katselou, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matralis, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kourounakis, A. P.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Drug Design Approaches for Multifactorial Diseases: From Neurodegenerative to Cardiovascular Applications</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">2743</span>– <span class="NLM_lpage">2787</span>, <span class="refDoi"> DOI: 10.2174/0929867321666140303144625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F0929867321666140303144625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24606519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOjsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=2743-2787&issue=24&author=M.+G.+Katselouauthor=A.+N.+Matralisauthor=A.+P.+Kourounakis&title=Multi-Target+Drug+Design+Approaches+for+Multifactorial+Diseases%3A+From+Neurodegenerative+to+Cardiovascular+Applications&doi=10.2174%2F0929867321666140303144625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Target Drug Design Approaches for Multifactorial Diseases: From Neurodegenerative to Cardiovascular Applications</span></div><div class="casAuthors">Katselou, M. G.; Matralis, A. N.; Kourounakis, A. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2743-2787</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In multi-target drug design (MTD) medicinal chem. aims to integrate multiple pharmacophores into a single drug mol. in order to make it active on several mol. biol. mechanisms simultaneously.  Given the fact that most diseases are multifactorial in nature, MTD is being pursued with increasing intensity, which has resulted in improved outcomes in disease models and several compds. have entered clin. trials.  In a wide range of examples we illustrate how various functionalities have been combined within single structures and how this has affected their (pre)clin. outcome.  This review describes the successful application of MTD for disorders such as neurodegenerative, cardiovascular, diabetes, metabolic and inflammatory diseases, esp. focusing on the field of atherosclerosis where multi-target strategies are a promising alternative to the classical "one target-one drug" design approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbQu-xgU1fC7Vg90H21EOLACvtfcHk0lhLzhjjJgiRQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOjsrjP&md5=6a13bd9362f7caa1362983ac84e526b0</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.2174%2F0929867321666140303144625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666140303144625%26sid%3Dliteratum%253Aachs%26aulast%3DKatselou%26aufirst%3DM.%2BG.%26aulast%3DMatralis%26aufirst%3DA.%2BN.%26aulast%3DKourounakis%26aufirst%3DA.%2BP.%26atitle%3DMulti-Target%2520Drug%2520Design%2520Approaches%2520for%2520Multifactorial%2520Diseases%253A%2520From%2520Neurodegenerative%2520to%2520Cardiovascular%2520Applications%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26issue%3D24%26spage%3D2743%26epage%3D2787%26doi%3D10.2174%2F0929867321666140303144625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dimitropoulos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papakyriakou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalkas, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyroulias, G. A.</span></span> <span> </span><span class="NLM_article-title">A Computational Approach to the Study of the Binding Mode of Dual ACE/NEP Inhibitors</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1021/ci9005047</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci9005047" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFyhsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=388-396&issue=3&author=N.+Dimitropoulosauthor=A.+Papakyriakouauthor=G.+A.+Dalkasauthor=E.+D.+Sturrockauthor=G.+A.+Spyroulias&title=A+Computational+Approach+to+the+Study+of+the+Binding+Mode+of+Dual+ACE%2FNEP+Inhibitors&doi=10.1021%2Fci9005047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">A Computational Approach to the Study of the Binding Mode of Dual ACE/NEP Inhibitors</span></div><div class="casAuthors">Dimitropoulos, Nikolaos; Papakyriakou, Athanasios; Dalkas, Georgios A.; Sturrock, Edward D.; Spyroulias, Georgios A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">388-396</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combined blockade of the renin-angiotensin-aldosterone system (RAAS) is an attractive therapeutic strategy for the treatment of cardiovascular diseases.  Vasopeptidase inhibitors are a group of compds. capable of inhibiting more than one enzyme, which leads to potentiation of natriuretic peptide actions and suppression of the RAAS.  In this study, mol. modeling has been used to elucidate key structural features that govern the binding and/or selectivity of a single compd. toward the zinc catalytic sites of the N- and C-domains of the angiotensin-converting enzyme (ACE) and the neutral endopeptidase (NEP).  Eleven dual inhibitors were categorized in three classes, according to their zinc binding groups.  Anal. of their docked conformers revealed the mol. environment of the catalytic sites and the specific interactions between the inhibitors and amino acid residues that are important for selectivity and cooperativity.  In addn., inhibitors were predicted to bind to the C-domain of the ACE with greater affinity than the N-domain, with an av. difference in the free energy of binding ∼2-3 kcal mol-1.  Residues that were identified to actively participate in the binding and stabilizing of the enzyme-inhibitor complexes were analyzed in a consensus way for both the ACE and the NEP.  These at.-level insights into enzyme-ligand binding can be used to drive new structure-based drug design processes in the quest for more selective and effective vasopeptidase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlmtVNKnY-CbVg90H21EOLACvtfcHk0lhLzhjjJgiRQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFyhsLg%253D&md5=b88dadb9dc6da855a31264c038e51212</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1021%2Fci9005047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci9005047%26sid%3Dliteratum%253Aachs%26aulast%3DDimitropoulos%26aufirst%3DN.%26aulast%3DPapakyriakou%26aufirst%3DA.%26aulast%3DDalkas%26aufirst%3DG.%2BA.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DSpyroulias%26aufirst%3DG.%2BA.%26atitle%3DA%2520Computational%2520Approach%2520to%2520the%2520Study%2520of%2520the%2520Binding%2520Mode%2520of%2520Dual%2520ACE%252FNEP%2520Inhibitors%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26issue%3D3%26spage%3D388%26epage%3D396%26doi%3D10.1021%2Fci9005047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milani, F.</span></span> <span> </span><span class="NLM_article-title">Three Key Proteases - angiotensin-I-Converting Enzyme (ACE), ACE2 and Renin - within and Beyond the Renin-Angiotensin System</span>. <i>Arch. Cardiovasc. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1016/j.acvd.2012.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.acvd.2012.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22800722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC38fgtlCquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2012&pages=373-385&issue=6&author=C.+Guangauthor=R.+D.+Phillipsauthor=B.+Jiangauthor=F.+Milani&title=Three+Key+Proteases+-+angiotensin-I-Converting+Enzyme+%28ACE%29%2C+ACE2+and+Renin+-+within+and+Beyond+the+Renin-Angiotensin+System&doi=10.1016%2Fj.acvd.2012.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system</span></div><div class="casAuthors">Guang Cuie; Phillips Robert D; Jiang Bo; Milani Franco</div><div class="citationInfo"><span class="NLM_cas:title">Archives of cardiovascular diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">373-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The discovery of angiotensin-I-converting enzyme 2 (ACE2) and a (pro)renin receptor has renewed interest in the physiology of the renin-angiotensin system (RAS).  Through the ACE2/angiotensin-(1-7)/Mas counter-regulatory axis, ACE2 balances the vasoconstrictive, proliferative, fibrotic and proinflammatory effects of the ACE/angiotensin II/AT1 axis.  The (pro)renin receptor system shows an angiotensin-dependent function related to increased generation of angiotensin I, and an angiotensin-independent aspect related to intracellular signalling.  Activation of ACE2 and inhibition of ACE and renin have been at the core of the RAS regulation.  The aim of this review is to discuss the biochemistry and biological functions of ACE, ACE2 and renin within and beyond the RAS, and thus provide a perspective for future bioactives from natural plant and/or food resources related to the three proteases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnsgXqrVfI05SWdIdmEou5fW6udTcc2ebsB1IAD61Db7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fgtlCquw%253D%253D&md5=a2d1df6c0259ce6e51e6607cb92a0058</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1016%2Fj.acvd.2012.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.acvd.2012.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DGuang%26aufirst%3DC.%26aulast%3DPhillips%26aufirst%3DR.%2BD.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DMilani%26aufirst%3DF.%26atitle%3DThree%2520Key%2520Proteases%2520-%2520angiotensin-I-Converting%2520Enzyme%2520%2528ACE%2529%252C%2520ACE2%2520and%2520Renin%2520-%2520within%2520and%2520Beyond%2520the%2520Renin-Angiotensin%2520System%26jtitle%3DArch.%2520Cardiovasc.%2520Dis.%26date%3D2012%26volume%3D105%26issue%3D6%26spage%3D373%26epage%3D385%26doi%3D10.1016%2Fj.acvd.2012.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodfriend, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catt, K. J.</span></span> <span> </span><span class="NLM_article-title">Angiotensin Receptors and Their Antagonists</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>334</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">1649</span>– <span class="NLM_lpage">1655</span>, <span class="refDoi"> DOI: 10.1056/NEJM199606203342507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1056%2FNEJM199606203342507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=8628362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1emur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=1996&pages=1649-1655&issue=25&author=T.+L.+Goodfriendauthor=M.+E.+Elliottauthor=K.+J.+Catt&title=Angiotensin+Receptors+and+Their+Antagonists&doi=10.1056%2FNEJM199606203342507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin receptors and their antagonists</span></div><div class="casAuthors">Goodfriend, Theodore L.; Elliott, Mary E.; Catt, Kevin J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1649-1654</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review, with 81 refs., of the major actions of angiotensins, the properties of angiotensin receptors, and some aspects of the action and therapeutic applications of the new angiotensin receptor antagonists.  Specific topics discussed were: nomenclature; actions of angiotensins; angiotensin receptors; signal transduction; regulation of angiotensin receptors and their actions; angiotensin receptors in growth and development; mechanism of action of angiotensin-receptor antagonists; clin. trials of angiotensin-receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAVgAOZHXd2LVg90H21EOLACvtfcHk0lhLzhjjJgiRQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1emur0%253D&md5=40ab7efdeabd677d0729f11f3fd0728c</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1056%2FNEJM199606203342507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199606203342507%26sid%3Dliteratum%253Aachs%26aulast%3DGoodfriend%26aufirst%3DT.%2BL.%26aulast%3DElliott%26aufirst%3DM.%2BE.%26aulast%3DCatt%26aufirst%3DK.%2BJ.%26atitle%3DAngiotensin%2520Receptors%2520and%2520Their%2520Antagonists%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1996%26volume%3D334%26issue%3D25%26spage%3D1649%26epage%3D1655%26doi%3D10.1056%2FNEJM199606203342507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prins, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thenappan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritzker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, S. L.</span></span> <span> </span><span class="NLM_article-title">Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What’s Old Is New Again</span>. <i>J. Am. Heart Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e011343</span>, <span class="refDoi"> DOI: 10.1161/JAHA.118.011343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1161%2FJAHA.118.011343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=30590974" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=e011343&issue=1&author=K.+W.+Prinsauthor=T.+Thenappanauthor=E.+K.+Weirauthor=R.+Kalraauthor=M.+Pritzkerauthor=S.+L.+Archer&title=Repurposing+Medications+for+Treatment+of+Pulmonary+Arterial+Hypertension%3A+What%E2%80%99s+Old+Is+New+Again&doi=10.1161%2FJAHA.118.011343"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1161%2FJAHA.118.011343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FJAHA.118.011343%26sid%3Dliteratum%253Aachs%26aulast%3DPrins%26aufirst%3DK.%2BW.%26aulast%3DThenappan%26aufirst%3DT.%26aulast%3DWeir%26aufirst%3DE.%2BK.%26aulast%3DKalra%26aufirst%3DR.%26aulast%3DPritzker%26aufirst%3DM.%26aulast%3DArcher%26aufirst%3DS.%2BL.%26atitle%3DRepurposing%2520Medications%2520for%2520Treatment%2520of%2520Pulmonary%2520Arterial%2520Hypertension%253A%2520What%25E2%2580%2599s%2520Old%2520Is%2520New%2520Again%26jtitle%3DJ.%2520Am.%2520Heart%2520Assoc.%26date%3D2019%26volume%3D8%26issue%3D1%26spage%3De011343%26doi%3D10.1161%2FJAHA.118.011343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, N.</span></span> <span> </span><span class="NLM_article-title">Tale of 2 Endothelin Receptor Antagonists in Eisenmenger Syndrome</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>139</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.118.037171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1161%2FCIRCULATIONAHA.118.037171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=30592659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BB3cnmtlOkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2019&pages=64-66&issue=1&author=D.+Ivyauthor=N.+Wilson&title=Tale+of+2+Endothelin+Receptor+Antagonists+in+Eisenmenger+Syndrome&doi=10.1161%2FCIRCULATIONAHA.118.037171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Tale of 2 Endothelin Receptor Antagonists in Eisenmenger Syndrome</span></div><div class="casAuthors">Ivy Dunbar; Wilson Neil; Ivy Dunbar; Wilson Neil</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-66</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLKk-rFuWa2JPq5LRczm8ffW6udTcc2eaVOkTlTvn9lLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnmtlOkuw%253D%253D&md5=507f4e130abefafa928df0435b830230</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.118.037171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.118.037171%26sid%3Dliteratum%253Aachs%26aulast%3DIvy%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DN.%26atitle%3DTale%2520of%25202%2520Endothelin%2520Receptor%2520Antagonists%2520in%2520Eisenmenger%2520Syndrome%26jtitle%3DCirculation%26date%3D2019%26volume%3D139%26issue%3D1%26spage%3D64%26epage%3D66%26doi%3D10.1161%2FCIRCULATIONAHA.118.037171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blixt, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanes, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstrup
Christiansen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warfvinge, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edvinsson, L.</span></span> <span> </span><span class="NLM_article-title">Increased Endothelin-1-Mediated Vasoconstriction after Organ Culture in Rat and Pig Ocular Arteries Can Be Suppressed with MEK/ERK1/2 Inhibitors</span>. <i>Acta Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">5</span>), <span class="NLM_elocation-id">e619</span> <span class="refDoi"> DOI: 10.1111/aos.13651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1111%2Faos.13651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29369532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1KltbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2018&issue=5&author=F.+W.+Blixtauthor=K.+A.+Haanesauthor=L.+Ohlssonauthor=A.+Tolstrup%0AChristiansenauthor=K.+Warfvingeauthor=L.+Edvinsson&title=Increased+Endothelin-1-Mediated+Vasoconstriction+after+Organ+Culture+in+Rat+and+Pig+Ocular+Arteries+Can+Be+Suppressed+with+MEK%2FERK1%2F2+Inhibitors&doi=10.1111%2Faos.13651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Increased endothelin-1-mediated vasoconstriction after organ culture in rat and pig ocular arteries can be suppressed with MEK/ERK1/2 inhibitors</span></div><div class="casAuthors">Blixt, Frank W.; Haanes, Kristian Agmund; Ohlsson, Lena; Tolstrup Christiansen, Anders; Warfvinge, Karin; Edvinsson, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Acta Ophthalmologica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e619-e625</span>CODEN:
                <span class="NLM_cas:coden">AOOUAQ</span>;
        ISSN:<span class="NLM_cas:issn">1755-375X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Purpose : Even though retinal vascular changes following ischemia have been poorly understood, the upregulation of vasoconstrictive endothelin-1 (ET-1) receptors (ETA/ETB) following global cerebral ischemia has been described.  The aim of this study was to investigate whether or not the MEK/ERK1/2 pathway is involved in the obsd. upregulation and whether specific MEK/ERK1/2 inhibitors U0126 and trametinib can prevent it.  Methods : The aim was also to localize ETA and ETB receptors using immunohistochem. in both fresh rat ophthalmic arteries and after 24-h organ culture and study the receptors functionally using myog.  Pig retinal arteries also underwent 24-h organ culture to validate similar responses across species and the retinal vasculature.  Results : Results showed that following organ culture there is a significant increase in ET-1-mediated vasoconstriction, in particular via the ETB receptor.  Furthermore, immunohistochem. revealed a clear increase in pERK in the smooth muscle cells of rat ophthalmic artery.  U0126 and trametinib were successful in attenuating the functional vasoconstriction in both rat and pig, as well as restoring immunofluorescence of pERK to fresh levels and counteracting ETB expression in the smooth muscle cells of the rat ophthalmic artery.  Conclusion : This is the first study to show that the MEK/ERK1/2 pathway in responsible for the increase in functional vasoconstriction via ET-1 receptor in rat ophthalmic and pig retinal arteries.  Furthermore, this study is the first to suggest a way of inhibiting and preventing such an increase.  With these results, we suggest a novel approach in retinal ischemia therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiCekzbMo8JLVg90H21EOLACvtfcHk0lj6vm_wqPqOWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1KltbrP&md5=7e179f617f69c9a24831844771f44120</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1111%2Faos.13651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Faos.13651%26sid%3Dliteratum%253Aachs%26aulast%3DBlixt%26aufirst%3DF.%2BW.%26aulast%3DHaanes%26aufirst%3DK.%2BA.%26aulast%3DOhlsson%26aufirst%3DL.%26aulast%3DTolstrup%2BChristiansen%26aufirst%3DA.%26aulast%3DWarfvinge%26aufirst%3DK.%26aulast%3DEdvinsson%26aufirst%3DL.%26atitle%3DIncreased%2520Endothelin-1-Mediated%2520Vasoconstriction%2520after%2520Organ%2520Culture%2520in%2520Rat%2520and%2520Pig%2520Ocular%2520Arteries%2520Can%2520Be%2520Suppressed%2520with%2520MEK%252FERK1%252F2%2520Inhibitors%26jtitle%3DActa%2520Ophthalmol.%26date%3D2018%26volume%3D96%26issue%3D5%26doi%3D10.1111%2Faos.13651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Pascual, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busnadiego, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagares, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamas, S.</span></span> <span> </span><span class="NLM_article-title">Role of Endothelin in the Cardiovascular System</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2011.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.phrs.2011.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21296157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1Krsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=463-472&issue=6&author=F.+Rodr%C3%ADguez-Pascualauthor=O.+Busnadiegoauthor=D.+Lagaresauthor=S.+Lamas&title=Role+of+Endothelin+in+the+Cardiovascular+System&doi=10.1016%2Fj.phrs.2011.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Role of endothelin in the cardiovascular system</span></div><div class="casAuthors">Rodriguez-Pascual, Fernando; Busnadiego, Oscar; Lagares, David; Lamas, Santiago</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">463-472</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The endothelin (ET) system consists of three peptide ligands (ET-1, ET-2 and ET-3) and two G-protein-coupled receptors, ETA and ETB.  In the cardiovascular system, ETs, particularly ET-1, are expressed in smooth muscle cells, cardiomyocytes, fibroblasts, and notably in vascular endothelial cells.  Intense research over the last 10 years has changed the original view of ET-1 as mainly a vasoconstrictor regulating blood pressure, into a biol. factor regulating processes such as vascular remodeling, angiogenesis or extracellular matrix synthesis.  The advent of specific (and type-selective) ET receptor antagonists has greatly fostered our knowledge of the biol. function of ET-1, and has offered a potential therapeutic approach for numerous diseases including hypertension, atherosclerosis or fibrosis.  In this article, we review the regulation of the expression of vascular ET-1, as well as the contribution of ET-1 to endothelial, smooth muscle and fibroblast cell function, with particular interest in the role of ET-1 in the development of cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqq8yOLna2rbVg90H21EOLACvtfcHk0lj6vm_wqPqOWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1Krsr8%253D&md5=7d2bb6049eab438cd3db0ca460915e91</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2011.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2011.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DRodr%25C3%25ADguez-Pascual%26aufirst%3DF.%26aulast%3DBusnadiego%26aufirst%3DO.%26aulast%3DLagares%26aufirst%3DD.%26aulast%3DLamas%26aufirst%3DS.%26atitle%3DRole%2520of%2520Endothelin%2520in%2520the%2520Cardiovascular%2520System%26jtitle%3DPharmacol.%2520Res.%26date%3D2011%26volume%3D63%26issue%3D6%26spage%3D463%26epage%3D472%26doi%3D10.1016%2Fj.phrs.2011.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benson, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pershadsingh, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittiboyina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pravenec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, T. W.</span></span> <span> </span><span class="NLM_article-title">Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist with Selective Ppargamma-Modulating Activity</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.0000123072.34629.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1161%2F01.HYP.0000123072.34629.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15007034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1GmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=993-1002&issue=5&author=S.+C.+Bensonauthor=H.+A.+Pershadsinghauthor=C.+I.+Hoauthor=A.+Chittiboyinaauthor=P.+Desaiauthor=M.+Pravenecauthor=N.+Qiauthor=J.+Wangauthor=M.+A.+Averyauthor=T.+W.+Kurtz&title=Identification+of+Telmisartan+as+a+Unique+Angiotensin+II+Receptor+Antagonist+with+Selective+Ppargamma-Modulating+Activity&doi=10.1161%2F01.HYP.0000123072.34629.57"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ-Modulating Activity</span></div><div class="casAuthors">Benson, Stephen C.; Pershadsingh, Harrihar A.; Ho, Christopher I.; Chittiboyina, Amar; Desai, Prashant; Pravenec, Michal; Qi, Nianning; Wang, Jiaming; Avery, Mitchell A.; Kurtz, Theodore W.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">993-1002</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes that is characterized by the clustering of insulin resistance, dyslipidemia, and increased blood pressure.  In humans, mutations in the peroxisome proliferator-activated receptor-γ (PPARγ) have been reported to cause the full-blown metabolic syndrome, and drugs that activate PPARγ have proven to be effective agents for the prevention and treatment of insulin resistance and type 2 diabetes.  Here the authors report that telmisartan, a structurally unique angiotensin II receptor antagonist used for the treatment of hypertension, can function as a partial agonist of PPARγ; influence the expression of PPARγ target genes involved in carbohydrate and lipid metab.; and reduce glucose, insulin, and triglyceride levels in rats fed a high-fat, high-carbohydrate diet.  None of the other com. available angiotensin II receptor antagonists appeared to activate PPARγ when tested at concns. typically achieved in plasma with conventional oral dosing.  In contrast to ordinary antihypertensive and antidiabetic agents, mols. that can simultaneously block the angiotensin II receptor and activate PPARγ have the potential to treat both hemodynamic and biochem. features of the metabolic syndrome and could provide unique opportunities for the prevention and treatment of diabetes and cardiovascular disease in high-risk populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVMnSBXhf_gLVg90H21EOLACvtfcHk0lje1XEtZ5EJGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1GmtrY%253D&md5=9f3075e771df41d59ac75d2e78ac304b</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000123072.34629.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000123072.34629.57%26sid%3Dliteratum%253Aachs%26aulast%3DBenson%26aufirst%3DS.%2BC.%26aulast%3DPershadsingh%26aufirst%3DH.%2BA.%26aulast%3DHo%26aufirst%3DC.%2BI.%26aulast%3DChittiboyina%26aufirst%3DA.%26aulast%3DDesai%26aufirst%3DP.%26aulast%3DPravenec%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAvery%26aufirst%3DM.%2BA.%26aulast%3DKurtz%26aufirst%3DT.%2BW.%26atitle%3DIdentification%2520of%2520Telmisartan%2520as%2520a%2520Unique%2520Angiotensin%2520II%2520Receptor%2520Antagonist%2520with%2520Selective%2520Ppargamma-Modulating%2520Activity%26jtitle%3DHypertension%26date%3D2004%26volume%3D43%26issue%3D5%26spage%3D993%26epage%3D1002%26doi%3D10.1161%2F01.HYP.0000123072.34629.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chait, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckel, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. C.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowers, J. R.</span></span> <span> </span><span class="NLM_article-title">Diabetes and Cardiovascular Disease</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1134</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.100.10.1134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1161%2F01.CIR.100.10.1134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10477542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADyaK1Mvgs1KjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1999&pages=1134-1146&issue=10&author=S.+M.+Grundyauthor=I.+J.+Benjaminauthor=G.+L.+Burkeauthor=A.+Chaitauthor=R.+H.+Eckelauthor=B.+V.+Howardauthor=W.+Mitchauthor=S.+C.+Smithauthor=J.+R.+Sowers&title=Diabetes+and+Cardiovascular+Disease&doi=10.1161%2F01.CIR.100.10.1134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association</span></div><div class="casAuthors">Grundy S M; Benjamin I J; Burke G L; Chait A; Eckel R H; Howard B V; Mitch W; Smith S C Jr; Sowers J R</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1134-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAXnkBr0-67a-9TkgmBqTqfW6udTcc2eaqOHxlLMrQebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1Mvgs1KjsA%253D%253D&md5=7aaa4b0cddedfc2b7fcae3fb91802b46</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.100.10.1134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.100.10.1134%26sid%3Dliteratum%253Aachs%26aulast%3DGrundy%26aufirst%3DS.%2BM.%26aulast%3DBenjamin%26aufirst%3DI.%2BJ.%26aulast%3DBurke%26aufirst%3DG.%2BL.%26aulast%3DChait%26aufirst%3DA.%26aulast%3DEckel%26aufirst%3DR.%2BH.%26aulast%3DHoward%26aufirst%3DB.%2BV.%26aulast%3DMitch%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DSowers%26aufirst%3DJ.%2BR.%26atitle%3DDiabetes%2520and%2520Cardiovascular%2520Disease%26jtitle%3DCirculation%26date%3D1999%26volume%3D100%26issue%3D10%26spage%3D1134%26epage%3D1146%26doi%3D10.1161%2F01.CIR.100.10.1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filzen, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigge, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmaeil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemstra, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohren, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostroski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaum, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Series of Imidazo[4,5-B]Pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4219</span>– <span class="NLM_lpage">4233</span>, <span class="refDoi"> DOI: 10.1021/jm200409s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200409s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4219-4233&issue=12&author=A.+Casimiro-Garciaauthor=G.+F.+Filzenauthor=D.+Flynnauthor=C.+F.+Biggeauthor=J.+Chenauthor=J.+A.+Davisauthor=D.+A.+Dudleyauthor=J.+J.+Edmundsauthor=N.+Esmaeilauthor=A.+Geyerauthor=R.+J.+Heemstraauthor=M.+Jalaieauthor=J.+F.+Ohrenauthor=R.+Ostroskiauthor=T.+Ellisauthor=R.+P.+Schaumauthor=C.+Stoner&title=Discovery+of+a+Series+of+Imidazo%5B4%2C5-B%5DPyridines+with+Dual+Activity+at+Angiotensin+II+Type+1+Receptor+and+Peroxisome+Proliferator-Activated+Receptor-%CE%B3&doi=10.1021%2Fjm200409s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Series of Imidazo[4,5-b]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ</span></div><div class="casAuthors">Casimiro-Garcia, Agustin; Filzen, Gary F.; Flynn, Declan; Bigge, Christopher F.; Chen, Jing; Davis, Jo Ann; Dudley, Danette A.; Edmunds, Jeremy J.; Esmaeil, Nadia; Geyer, Andrew; Heemstra, Ronald J.; Jalaie, Mehran; Ohren, Jeffrey F.; Ostroski, Robert; Ellis, Teresa; Schaum, Robert P.; Stoner, Chad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4219-4233</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mining of an inhouse collection of angiotensin II type 1 receptor antagonists to identify compds. with activity at the peroxisome proliferator-activated receptor-γ (PPARγ) revealed a new series of imidazo[4,5-b]pyridines 2 possessing activity at these two receptors.  Early availability of the crystal structure of the lead compd. bound to the ligand binding domain of human PPARγ confirmed the mode of interaction of this scaffold to the nuclear receptor and assisted in the optimization of PPARγ activity.  Among the new compds., (S)-3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-5-isobutyl-7-methyl-3H-imidazo[4,5-b]pyridine (I) was identified as a potent angiotensin II type I receptor blocker (IC50 = 1.6 nM) with partial PPARγ agonism (EC50 = 212 nM, 31% max) and oral bioavailability in rat.  The dual pharmacol. of I was demonstrated in animal models of hypertension (SHR) and insulin resistance (ZDF rat).  In the SHR, I was highly efficacious in lowering blood pressure, while robust lowering of glucose and triglycerides was obsd. in the male ZDF rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMdOow5t9CALVg90H21EOLACvtfcHk0lje1XEtZ5EJGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGls78%253D&md5=cd55be8d481fccc319ca10c7a2ca2d8b</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1021%2Fjm200409s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200409s%26sid%3Dliteratum%253Aachs%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DFilzen%26aufirst%3DG.%2BF.%26aulast%3DFlynn%26aufirst%3DD.%26aulast%3DBigge%26aufirst%3DC.%2BF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DEdmunds%26aufirst%3DJ.%2BJ.%26aulast%3DEsmaeil%26aufirst%3DN.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DHeemstra%26aufirst%3DR.%2BJ.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DOstroski%26aufirst%3DR.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DSchaum%26aufirst%3DR.%2BP.%26aulast%3DStoner%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520a%2520Series%2520of%2520Imidazo%255B4%252C5-B%255DPyridines%2520with%2520Dual%2520Activity%2520at%2520Angiotensin%2520II%2520Type%25201%2520Receptor%2520and%2520Peroxisome%2520Proliferator-Activated%2520Receptor-%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D12%26spage%3D4219%26epage%3D4233%26doi%3D10.1021%2Fjm200409s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sowers, J.
R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frohlich, E. D.</span></span> <span> </span><span class="NLM_article-title">Diabetes, Hypertension, and Cardiovascular Disease: An Update</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1053</span>– <span class="NLM_lpage">1–59</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.37.4.1053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1161%2F01.HYP.37.4.1053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11304502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFejt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=1053-1%E2%80%9359&issue=4&author=J.%0AR.+Sowersauthor=M.+Epsteinauthor=E.+D.+Frohlich&title=Diabetes%2C+Hypertension%2C+and+Cardiovascular+Disease%3A+An+Update&doi=10.1161%2F01.HYP.37.4.1053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetes, hypertension, and cardiovascular disease. An update</span></div><div class="casAuthors">Sowers, James R.; Epstein, Murray; Frohlich, Edward D.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1053-1059</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 60 refs.  Cardiovascular diseases (CVDs) are the major causes of mortality in persons with diabetes, and many factors, including hypertension, contribute to this high prevalence of CVD.  Hypertension is approx. twice as frequent in patients with diabetes compared with patients without the disease.  Conversely, recent data suggest that hypertensive persons are more predisposed to the development of diabetes than are normotensive persons.  Furthermore, up to 75% of CVD in diabetes may be attributable to hypertension, leading to recommendations for more aggressive treatment (ie. reducing blood pressure to < 130/85 mm Hg) in persons with coexistent diabetes and hypertension.  Other important risk factors for CVD in these patients include the following: obesity, atherosclerosis. dyslipidemia, microalbuminuria, endothelial dysfunction, platelet hyperaggregability, coagulation abnormalities, and "diabetic cardiomyopathy." The cardiomyopathy assocd. with diabetes is a unique myopathic state that appears to be independent of macrovascular/ microvascular disease and contributes significantly to CVD morbidity and mortality in diabetic patients, esp. those with coexistent hypertension.  This update reviews the current knowledge regarding these risk factors and their treatment, with special emphasis on the cardiometabolic syndrome, hypertension. microalbuminuria, and diabetic cardiomyopathy.  This update also examines the role of the renin-angiotensin system in the increased risk for CVD in diabetic patients and the impact of interrupting this system on the development of clin. diabetes as well as CVD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSwE2PsyOpSbVg90H21EOLACvtfcHk0lhmMIpCl20Cfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFejt7g%253D&md5=4450a490263d9a54aea57b9377dd297a</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.37.4.1053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.37.4.1053%26sid%3Dliteratum%253Aachs%26aulast%3DSowers%26aufirst%3DJ.%2BR.%26aulast%3DEpstein%26aufirst%3DM.%26aulast%3DFrohlich%26aufirst%3DE.%2BD.%26atitle%3DDiabetes%252C%2520Hypertension%252C%2520and%2520Cardiovascular%2520Disease%253A%2520An%2520Update%26jtitle%3DHypertension%26date%3D2001%26volume%3D37%26issue%3D4%26spage%3D1053%26epage%3D1%25E2%2580%259359%26doi%3D10.1161%2F01.HYP.37.4.1053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gress, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wofford, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancati, F. L.</span></span> <span> </span><span class="NLM_article-title">Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus. Atherosclerosis Risk in Communities Study</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1056/NEJM200003303421301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1056%2FNEJM200003303421301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10738048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFWmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2000&pages=905-912&author=T.+W.+Gressauthor=F.+J.+Nietoauthor=E.+Shaharauthor=M.+R.+Woffordauthor=F.+L.+Brancati&title=Hypertension+and+Antihypertensive+Therapy+as+Risk+Factors+for+Type+2+Diabetes+Mellitus.+Atherosclerosis+Risk+in+Communities+Study&doi=10.1056%2FNEJM200003303421301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus</span></div><div class="casAuthors">Gress, Todd W.; Nieto, F. Javier; Shahar, Eyal; Wofford, Marion R.; Brancati, Frederick L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">905-912</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Previous research has suggested that thiazide diuretics and beta-blockers may promote the development of type 2 diabetes mellitus.  However, the results of these studies have been inconsistent, and many studies have been limited by inadequate data on outcomes and by potential confounding.  Methods: We conducted a prospective study of 12,550 adults 45 to 64 yr old who did not have diabetes.  An extensive health evaluation conducted at base line included assessment of medication use and measurement of blood pressure with a random-zero sphygmomanometer.  The incidence of new cases of diabetes was assessed after three years and after six years by measurement of serum glucose concns. while the subjects were fasting.  Results: After simultaneous adjustment for age, sex, race, education, adiposity, family history with respect to diabetes, phys.-activity level, other health-related behavior, and coexisting illnesses, subjects with hypertension who were taking thiazide diuretics were not at greater risk for the subsequent development of diabetes than were subjects with hypertension who were not receiving any antihypertensive therapy (relative hazard, 0.91; 95 % confidence interval, 0.73 to 1.13).  Likewise, subjects who were taking angiotensin-converting-enzyme inhibitors and calcium-channel antagonists were not at greater risk than those not taking any medication.  In contrast, subjects with hypertension who were taking beta-blockers had a 28 % higher risk of subsequent diabetes (relative hazard, 1.28; 95 % confidence interval, 1.04 to 1.57).  Conclusions: Concern about the risk of diabetes should not discourage physicians from prescribing thiazide diuretics to nondiabetic adults who have hypertension.  The use of beta-blockers appears to increase the risk of diabetes, but this adverse effect must be weighed against the proven benefits of beta-blockers in reducing the risk of cardiovascular events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYtqVQbLAwl7Vg90H21EOLACvtfcHk0lhmMIpCl20Cfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFWmt7o%253D&md5=11ed15ef60744770a18f6e4acd3f13dc</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1056%2FNEJM200003303421301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200003303421301%26sid%3Dliteratum%253Aachs%26aulast%3DGress%26aufirst%3DT.%2BW.%26aulast%3DNieto%26aufirst%3DF.%2BJ.%26aulast%3DShahar%26aufirst%3DE.%26aulast%3DWofford%26aufirst%3DM.%2BR.%26aulast%3DBrancati%26aufirst%3DF.%2BL.%26atitle%3DHypertension%2520and%2520Antihypertensive%2520Therapy%2520as%2520Risk%2520Factors%2520for%2520Type%25202%2520Diabetes%2520Mellitus.%2520Atherosclerosis%2520Risk%2520in%2520Communities%2520Study%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2000%26volume%3D342%26spage%3D905%26epage%3D912%26doi%3D10.1056%2FNEJM200003303421301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sattigeri, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayasam, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilla, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadhave, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulasi, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voleti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udupa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cliffe, I. A.</span></span> <span> </span><span class="NLM_article-title">Approaches Towards the Development of Chimeric DPP4/ACE Inhibitors for Treating Metabolic Syndrome</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2313</span>– <span class="NLM_lpage">2318</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmcl.2017.04.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28442252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsFelu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2313-2318&issue=11&author=J.+A.+Sattigeriauthor=S.+Sethiauthor=J.+A.+Davisauthor=S.+Ahmedauthor=G.+V.+Rayasamauthor=B.+G.+Jadhavauthor=S.+M.+Chillaauthor=D.+Dattaauthor=A.+Gadhaveauthor=V.+K.+Tulasiauthor=T.+Jainauthor=S.+Voletiauthor=B.+Benjaminauthor=S.+Udupaauthor=G.+Jainauthor=Y.+Singhauthor=K.+Srinivasauthor=V.+S.+Bansalauthor=A.+Rayauthor=P.+K.+Bhatnagarauthor=I.+A.+Cliffe&title=Approaches+Towards+the+Development+of+Chimeric+DPP4%2FACE+Inhibitors+for+Treating+Metabolic+Syndrome&doi=10.1016%2Fj.bmcl.2017.04.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome</span></div><div class="casAuthors">Sattigeri, Jitendra A.; Sethi, Sachin; Davis, Joseph A.; Ahmed, Shahadat; Rayasam, Geeta V.; Jadhav, Balasaheb G.; Chilla, Satya M.; Datta, Dhrubajyoti; Gadhave, A.; Tulasi, Vamshi K.; Jain, Tarun; Voleti, Sreedhara; Benjamin, Biju; Udupa, Sunitha; Jain, Garima; Singh, Yogender; Srinivas, Kona; Bansal, Vinay S.; Ray, Abhijit; Bhatnagar, Pradip K.; Cliffe, Ian A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2313-2318</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Designing drug candidates exhibiting polypharmacol. is one of the strategies adopted by medicinal chemists to address multifactorial diseases.  Metabolic disease is one such multifactorial disorder characterized by hyperglycemia, hypertension and dyslipidemia among others.  In this paper we report a new class of mol. framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvhiGzVmag5rVg90H21EOLACvtfcHk0lhmMIpCl20Cfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsFelu7s%253D&md5=e163a870ca5ca3fd3d3ea46fbcc3ec3f</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.036%26sid%3Dliteratum%253Aachs%26aulast%3DSattigeri%26aufirst%3DJ.%2BA.%26aulast%3DSethi%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DRayasam%26aufirst%3DG.%2BV.%26aulast%3DJadhav%26aufirst%3DB.%2BG.%26aulast%3DChilla%26aufirst%3DS.%2BM.%26aulast%3DDatta%26aufirst%3DD.%26aulast%3DGadhave%26aufirst%3DA.%26aulast%3DTulasi%26aufirst%3DV.%2BK.%26aulast%3DJain%26aufirst%3DT.%26aulast%3DVoleti%26aufirst%3DS.%26aulast%3DBenjamin%26aufirst%3DB.%26aulast%3DUdupa%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DY.%26aulast%3DSrinivas%26aufirst%3DK.%26aulast%3DBansal%26aufirst%3DV.%2BS.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DBhatnagar%26aufirst%3DP.%2BK.%26aulast%3DCliffe%26aufirst%3DI.%2BA.%26atitle%3DApproaches%2520Towards%2520the%2520Development%2520of%2520Chimeric%2520DPP4%252FACE%2520Inhibitors%2520for%2520Treating%2520Metabolic%2520Syndrome%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2313%26epage%3D2318%26doi%3D10.1016%2Fj.bmcl.2017.04.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Natesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwager, S. L. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Human Angiotensin-Converting Enzyme-Lisinopril Complex</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>421</i></span> (<span class="NLM_issue">6922</span>),  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">554</span>, <span class="refDoi"> DOI: 10.1038/nature01370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnature01370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=12540854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFSqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=421&publication_year=2003&pages=551-554&issue=6922&author=R.+Nateshauthor=S.+L.+U.+Schwagerauthor=E.+D.+Sturrockauthor=K.+R.+Acharya&title=Crystal+Structure+of+the+Human+Angiotensin-Converting+Enzyme-Lisinopril+Complex&doi=10.1038%2Fnature01370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human angiotensin-converting enzyme-lisinopril complex</span></div><div class="casAuthors">Natesh, Ramanathan; Schwager, Sylva L. U.; Sturrock, Edward D.; Acharya, K. Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">421</span>
        (<span class="NLM_cas:issue">6922</span>),
    <span class="NLM_cas:pages">551-554</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Angiotensin-converting enzyme (ACE) has a crit. role in cardiovascular function by cleaving the carboxy terminal His-Leu dipeptide from angiotensin I to produce a potent vasopressor octapeptide, angiotensin II.  Inhibitors of ACE are a first line of therapy for hypertension, heart failure, myocardial infarction and diabetic nephropathy.  Notably, these inhibitors were developed without knowledge of the structure of human ACE, but were instead designed on the basis of an assumed mechanistic homol. with carboxypeptidase A.  Here we present the x-ray structure of human testicular ACE and its complex with one of the most widely used inhibitors, lisinopril (N2-[(S)-1-carboxy-3-phenylpropyl]-l-lysyl-l-proline; also known as Prinivil or Zestril), at 2.0 Å resoln.  Anal. of the three-dimensional structure of ACE shows that it bears little similarity to that of carboxypeptidase A, but instead resembles neurolysin and Pyrococcus furiosus carboxypeptidase-zinc metallopeptidases with no detectable sequence similarity to ACE.  The structure provides an opportunity to design domain-selective ACE inhibitors that may exhibit new pharmacol. profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxHYbWU8PmP7Vg90H21EOLACvtfcHk0lhcm__yMIVdCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFSqtg%253D%253D&md5=84f2f474ac20541b0352691128782b1d</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1038%2Fnature01370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01370%26sid%3Dliteratum%253Aachs%26aulast%3DNatesh%26aufirst%3DR.%26aulast%3DSchwager%26aufirst%3DS.%2BL.%2BU.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Human%2520Angiotensin-Converting%2520Enzyme-Lisinopril%2520Complex%26jtitle%3DNature%26date%3D2003%26volume%3D421%26issue%3D6922%26spage%3D551%26epage%3D554%26doi%3D10.1038%2Fnature01370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Natesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwager, S. L. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span> <span> </span><span class="NLM_article-title">Structural Details on the Binding of Antihypertensive Drugs Captopril and Enalaprilat to Human Testicular Angiotensin I-Converting Enzyme</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">27</span>),  <span class="NLM_fpage">8718</span>– <span class="NLM_lpage">8724</span>, <span class="refDoi"> DOI: 10.1021/bi049480n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi049480n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFSqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=8718-8724&issue=27&author=R.+Nateshauthor=S.+L.+U.+Schwagerauthor=H.+R.+Evansauthor=E.+D.+Sturrockauthor=K.+R.+Acharya&title=Structural+Details+on+the+Binding+of+Antihypertensive+Drugs+Captopril+and+Enalaprilat+to+Human+Testicular+Angiotensin+I-Converting+Enzyme&doi=10.1021%2Fbi049480n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Details on the Binding of Antihypertensive Drugs Captopril and Enalaprilat to Human Testicular Angiotensin I-Converting Enzyme</span></div><div class="casAuthors">Natesh, Ramanathan; Schwager, Sylva L. U.; Evans, Hazel R.; Sturrock, Edward D.; Acharya, K. Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">8718-8724</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Angiotensin converting enzyme (ACE) plays a crit. role in the circulating or endocrine renin-angiotensin system (RAS) as well as the local regulation that exists in tissues such as the myocardium and skeletal muscle.  Here the authors report the high-resoln. crystal structures of testis ACE (tACE) in complex with the first successfully designed ACE inhibitor captopril and enalaprilat, the Phe-Ala-Pro analog.  The authors have compared these structures with the recently reported structure of a tACE-lisinopril complex [Natesh et al. (2003) Nature 421, 551-554].  The analyses reveal that all three inhibitors make direct interactions with the catalytic Zn2+ ion at the active site of the enzyme: the thiol group of captopril and the carboxylate group of enalaprilat and lisinopril.  Subtle differences are also obsd. at other regions of the binding pocket.  These are compared with N-domain models and discussed with ref. to published biochem. data.  The chloride coordination geometries of the three structures are discussed and compared with other ACE analogs.  It is anticipated that the mol. details provided by these structures will be used to improve the binding and/or the design of new, more potent domain-specific inhibitors of ACE that could serve as new generation antihypertensive drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpbHflOxjd7Vg90H21EOLACvtfcHk0lhcm__yMIVdCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFSqsLs%253D&md5=3c60917f638eaec862889c14576b9624</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1021%2Fbi049480n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi049480n%26sid%3Dliteratum%253Aachs%26aulast%3DNatesh%26aufirst%3DR.%26aulast%3DSchwager%26aufirst%3DS.%2BL.%2BU.%26aulast%3DEvans%26aufirst%3DH.%2BR.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26atitle%3DStructural%2520Details%2520on%2520the%2520Binding%2520of%2520Antihypertensive%2520Drugs%2520Captopril%2520and%2520Enalaprilat%2520to%2520Human%2520Testicular%2520Angiotensin%2520I-Converting%2520Enzyme%26jtitle%3DBiochemistry%26date%3D2004%26volume%3D43%26issue%3D27%26spage%3D8718%26epage%3D8724%26doi%3D10.1021%2Fbi049480n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longenecker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Geldern, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiedeman, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubben, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballaron, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mika, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, D. W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempf-Grote, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madar, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagavatula, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fickes, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pireh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lake, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edalji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevillyan, J. M.</span></span> <span> </span><span class="NLM_article-title">Discovery, Structure-Activity Relationship, and Pharmacological Evaluation of (5-Substituted-Pyrrolidinyl-2-Carbonyl)-2-Cyanopyrrolidines as Potent Dipeptidyl Peptidase IV Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3520</span>– <span class="NLM_lpage">3535</span>, <span class="refDoi"> DOI: 10.1021/jm051283e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051283e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFKks78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3520-3535&issue=12&author=Z.+Peiauthor=X.+Liauthor=K.+Longeneckerauthor=T.+W.+von+Geldernauthor=P.+E.+Wiedemanauthor=T.+H.+Lubbenauthor=B.+A.+Zinkerauthor=K.+Stewartauthor=S.+J.+Ballaronauthor=M.+A.+Stashkoauthor=A.+K.+Mikaauthor=D.+W.+A.+Benoauthor=M.+Longauthor=H.+Wellsauthor=A.+J.+Kempf-Groteauthor=D.+J.+Madarauthor=T.+S.+McDermottauthor=L.+Bhagavatulaauthor=M.+G.+Fickesauthor=D.+Pirehauthor=L.+R.+Solomonauthor=M.+R.+Lakeauthor=R.+Edaljiauthor=E.+H.+Fryauthor=H.+L.+Shamauthor=J.+M.+Trevillyan&title=Discovery%2C+Structure-Activity+Relationship%2C+and+Pharmacological+Evaluation+of+%285-Substituted-Pyrrolidinyl-2-Carbonyl%29-2-Cyanopyrrolidines+as+Potent+Dipeptidyl+Peptidase+IV+Inhibitors&doi=10.1021%2Fjm051283e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, Structure-Activity Relationship, and Pharmacological Evaluation of (5-Substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as Potent Dipeptidyl Peptidase IV Inhibitors</span></div><div class="casAuthors">Pei, Zhonghua; Li, Xiaofeng; Longenecker, Kenton; Von Geldern, Thomas W.; Wiedeman, Paul E.; Lubben, Thomas H.; Zinker, Bradley A.; Stewart, Kent; Ballaron, Stephen J.; Stashko, Michael A.; Mika, Amanda K.; Beno, David W. A.; Long, Michelle; Wells, Heidi; Kempf-Grote, Anita J.; Madar, David J.; McDermott, Todd S.; Bhagavatula, Lakshmi; Fickes, Michael G.; Pireh, Daisy; Solomon, Larry R.; Lake, Marc R.; Edalji, Rohinton; Fry, Elizabeth H.; Sham, Hing L.; Trevillyan, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3520-3535</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of (5-substituted pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidine (C5-Pro-Pro) analogs was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potential treatment of diabetes and obesity.  X-ray crystallog. data show that these inhibitors bind to the catalytic site of DPPIV with the cyano group forming a covalent bond with the serine residue of DPPIV.  The C5-substituents make various interactions with the enzyme and affect potency, chem. stability, selectivity, and PK properties of the inhibitors.  Optimized analogs are extremely potent with subnanomolar Ki's, are chem. stable, show very little potency decrease in the presence of plasma, and exhibit more than 1,000-fold selectivity against related peptidases.  The best compds. also possess good PK and are efficacious in lowering blood glucose in an oral glucose tolerance test in ZDF rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyvx-xfp8nZ7Vg90H21EOLACvtfcHk0lhcm__yMIVdCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFKks78%253D&md5=05ed6daf508ea3cb7c3294c4662f61fb</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1021%2Fjm051283e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051283e%26sid%3Dliteratum%253Aachs%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLongenecker%26aufirst%3DK.%26aulast%3Dvon%2BGeldern%26aufirst%3DT.%2BW.%26aulast%3DWiedeman%26aufirst%3DP.%2BE.%26aulast%3DLubben%26aufirst%3DT.%2BH.%26aulast%3DZinker%26aufirst%3DB.%2BA.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DBallaron%26aufirst%3DS.%2BJ.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DMika%26aufirst%3DA.%2BK.%26aulast%3DBeno%26aufirst%3DD.%2BW.%2BA.%26aulast%3DLong%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DH.%26aulast%3DKempf-Grote%26aufirst%3DA.%2BJ.%26aulast%3DMadar%26aufirst%3DD.%2BJ.%26aulast%3DMcDermott%26aufirst%3DT.%2BS.%26aulast%3DBhagavatula%26aufirst%3DL.%26aulast%3DFickes%26aufirst%3DM.%2BG.%26aulast%3DPireh%26aufirst%3DD.%26aulast%3DSolomon%26aufirst%3DL.%2BR.%26aulast%3DLake%26aufirst%3DM.%2BR.%26aulast%3DEdalji%26aufirst%3DR.%26aulast%3DFry%26aufirst%3DE.%2BH.%26aulast%3DSham%26aufirst%3DH.%2BL.%26aulast%3DTrevillyan%26aufirst%3DJ.%2BM.%26atitle%3DDiscovery%252C%2520Structure-Activity%2520Relationship%252C%2520and%2520Pharmacological%2520Evaluation%2520of%2520%25285-Substituted-Pyrrolidinyl-2-Carbonyl%2529-2-Cyanopyrrolidines%2520as%2520Potent%2520Dipeptidyl%2520Peptidase%2520IV%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D12%26spage%3D3520%26epage%3D3535%26doi%3D10.1021%2Fjm051283e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beconi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalchick, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiting, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scapin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyvratt, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornberry, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A. E.</span></span> <span> </span><span class="NLM_article-title">(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1021/jm0493156</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0493156" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOjtrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=141-151&issue=1&author=D.+Kimauthor=L.+Wangauthor=M.+Beconiauthor=G.+J.+Eiermannauthor=M.+H.+Fisherauthor=H.+Heauthor=G.+J.+Hickeyauthor=J.+E.+Kowalchickauthor=B.+Leitingauthor=K.+Lyonsauthor=F.+Marsilioauthor=M.+E.+McCannauthor=R.+A.+Patelauthor=A.+Petrovauthor=G.+Scapinauthor=S.+B.+Patelauthor=R.+S.+Royauthor=J.+K.+Wuauthor=M.+J.+Wyvrattauthor=B.+B.+Zhangauthor=L.+Zhuauthor=N.+A.+Thornberryauthor=A.+E.+Weber&title=%282R%29-4-Oxo-4-%5B3-%28trifluoromethyl%29-5%2C6-dihydro%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyrazin-7%288H%29-yl%5D-1-%282%2C4%2C5-trifluorophenyl%29butan-2-amine%3A+A+Potent%2C+Orally+Active+Dipeptidyl+Peptidase+IV+Inhibitor+for+the+Treatment+of+Type+2+Diabetes&doi=10.1021%2Fjm0493156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">(2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Kim, Dooseop; Wang, Liping; Beconi, Maria; Eiermann, George J.; Fisher, Michael H.; He, Huaibing; Hickey, Gerard J.; Kowalchick, Jennifer E.; Leiting, Barbara; Lyons, Kathryn; Marsilio, Frank; McCann, Margaret E.; Patel, Reshma A.; Petrov, Aleksandr; Scapin, Giovanna; Patel, Sangita B.; Roy, Ranabir Sinha; Wu, Joseph K.; Wyvratt, Matthew J.; Zhang, Bei B.; Zhu, Lan; Thornberry, Nancy A.; Weber, Ann E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-151</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of β-amino amides incorporating fused heterocycles, i.e., triazolopiperazines, were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes.  (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (I) is a potent, orally active DPP-IV inhibitor (IC50 = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclin. species, and in vivo efficacy in animal models.  MK-0431, the phosphate salt of I, was selected for development as a potential new treatment for type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0auDWQGbykLVg90H21EOLACvtfcHk0lgFi-HYqtAs2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOjtrbE&md5=85b8a8f3813d7d3d3949945574a684d4</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1021%2Fjm0493156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0493156%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBeconi%26aufirst%3DM.%26aulast%3DEiermann%26aufirst%3DG.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DHickey%26aufirst%3DG.%2BJ.%26aulast%3DKowalchick%26aufirst%3DJ.%2BE.%26aulast%3DLeiting%26aufirst%3DB.%26aulast%3DLyons%26aufirst%3DK.%26aulast%3DMarsilio%26aufirst%3DF.%26aulast%3DMcCann%26aufirst%3DM.%2BE.%26aulast%3DPatel%26aufirst%3DR.%2BA.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DScapin%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DRoy%26aufirst%3DR.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BK.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DB.%2BB.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3D%25282R%2529-4-Oxo-4-%255B3-%2528trifluoromethyl%2529-5%252C6-dihydro%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyrazin-7%25288H%2529-yl%255D-1-%25282%252C4%252C5-trifluorophenyl%2529butan-2-amine%253A%2520A%2520Potent%252C%2520Orally%2520Active%2520Dipeptidyl%2520Peptidase%2520IV%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D1%26spage%3D141%26epage%3D151%26doi%3D10.1021%2Fjm0493156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Dual Inhibitors of HIV Reverse Transcriptase and Integrase: Introducing a Diketoacid Functionality into Delavirdine</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3587</span>– <span class="NLM_lpage">3595</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2008.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18314335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=3587-3595&issue=7&author=Z.+Wangauthor=R.+Vince&title=Design+and+Synthesis+of+Dual+Inhibitors+of+HIV+Reverse+Transcriptase+and+Integrase%3A+Introducing+a+Diketoacid+Functionality+into+Delavirdine&doi=10.1016%2Fj.bmc.2008.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing a diketoacid functionality into delavirdine</span></div><div class="casAuthors">Wang, Zhengqiang; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3587-3595</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cost and toxicity problems assocd. with highly active antiretroviral therapy (HAART) in HIV/AIDS treatment could be alleviated by using designed multiple ligands (DMLs).  Dual inhibitors of HIV reverse transcriptase (RT) and integrase (IN) were rationally designed by introducing a diketoacid (DKA) functionality into the tolerant C-5 site of RT inhibitor delavirdine.  The resulting compds. all demonstrate good activity against both RT and IN in enzymic assays and HIV in cell-based assay, whereas their C-7 regioisomers are all inactive in these assays.  Balanced activities were obsd. with C-3 halogenated inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8iOAhge6i37Vg90H21EOLACvtfcHk0lgFi-HYqtAs2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gqsrg%253D&md5=3f90483b8bac1ee028a201690e34412c</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Dual%2520Inhibitors%2520of%2520HIV%2520Reverse%2520Transcriptase%2520and%2520Integrase%253A%2520Introducing%2520a%2520Diketoacid%2520Functionality%2520into%2520Delavirdine%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26issue%3D7%26spage%3D3587%26epage%3D3595%26doi%3D10.1016%2Fj.bmc.2008.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Advances in Rationally Designed Dual Inhibitors of HIV-1 Reverse Transcriptase and Integrase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">5007</span>– <span class="NLM_lpage">5016</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2016.09.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27658796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFems77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=5007-5016&issue=21&author=S.+X.+Guauthor=P.+Xueauthor=X.+L.+Juauthor=Y.+Y.+Zhu&title=Advances+in+Rationally+Designed+Dual+Inhibitors+of+HIV-1+Reverse+Transcriptase+and+Integrase&doi=10.1016%2Fj.bmc.2016.09.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase</span></div><div class="casAuthors">Gu, Shuang-Xi; Xue, Ping; Ju, Xiu-Lian; Zhu, Yuan-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5007-5016</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Reverse transcriptase (RT) and integrase (IN) are two indispensable enzymes in human immunodeficiency virus type 1 (HIV-1) replication.  RT is responsible for the transformation of the single-stranded RNA viral genome into double-stranded DNA, and IN catalyzes the integration of viral DNA into the host DNA.  Although highly active antiretroviral therapy (HAART) combining nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) with nonnucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) could suppress successfully HIV viral load and reduce evidently the mortality of HIV infected people, it involves the difficulty of perfect adherence, and other drawbacks such as viral rebound, toxicities and multi-drug resistances.  Recently, rational drug design has become a dominant technique for the development of multi-target drugs.  And the rationally designed dual inhibitors of HIV-1 RT and IN have become a hot topic of anti-HIV research.  In this review, the advances in rationally designed dual inhibitors of HIV-1 RT and IN were summarized, including structurally diverse inhibitors, their structure-activity relationship (SAR) studies as well as binding mode anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfniMsd0mbnrVg90H21EOLACvtfcHk0lgFi-HYqtAs2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFems77L&md5=8bf3cf2c5b9873f60397846288e0fb16</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DS.%2BX.%26aulast%3DXue%26aufirst%3DP.%26aulast%3DJu%26aufirst%3DX.%2BL.%26aulast%3DZhu%26aufirst%3DY.%2BY.%26atitle%3DAdvances%2520in%2520Rationally%2520Designed%2520Dual%2520Inhibitors%2520of%2520HIV-1%2520Reverse%2520Transcriptase%2520and%2520Integrase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D21%26spage%3D5007%26epage%3D5016%26doi%3D10.1016%2Fj.bmc.2016.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Pyrimidine and Quinolone Conjugates as a Scaffold for Dual Inhibitors of HIV Reverse Transcriptase and Integrase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1293</span>– <span class="NLM_lpage">1296</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.01.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmcl.2008.01.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18226894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlajt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1293-1296&issue=4&author=Z.+Wangauthor=R.+Vince&title=Synthesis+of+Pyrimidine+and+Quinolone+Conjugates+as+a+Scaffold+for+Dual+Inhibitors+of+HIV+Reverse+Transcriptase+and+Integrase&doi=10.1016%2Fj.bmcl.2008.01.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase</span></div><div class="casAuthors">Wang, Zhengqiang; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1293-1296</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Title conjugates I [R = H, Me, Et, CH2CH2OH] were designed and synthesized.  The assay results show that these compds. inhibit both reverse transcriptase and integrase and therefore provide a useful scaffold for identifying inhibitors with balanced dual activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuLdCTF2kgJLVg90H21EOLACvtfcHk0lgjKoqtjZ76rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlajt7c%253D&md5=0a8143d7ee7ca3aa4511c027d1262f1e</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.01.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.01.025%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520Pyrimidine%2520and%2520Quinolone%2520Conjugates%2520as%2520a%2520Scaffold%2520for%2520Dual%2520Inhibitors%2520of%2520HIV%2520Reverse%2520Transcriptase%2520and%2520Integrase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D4%26spage%3D1293%26epage%3D1296%26doi%3D10.1016%2Fj.bmcl.2008.01.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esnouf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willcox, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. I.</span></span> <span> </span><span class="NLM_article-title">Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1589</span>– <span class="NLM_lpage">1600</span>, <span class="refDoi"> DOI: 10.1021/jm960056x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960056x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK28XhslGqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=1589-1600&issue=8&author=A.+L.+Hopkinsauthor=J.+Renauthor=R.+M.+Esnoufauthor=B.+E.+Willcoxauthor=E.+Y.+Jonesauthor=C.+Rossauthor=T.+Miyasakaauthor=R.+T.+Walkerauthor=H.+Tanakaauthor=D.+K.+Stammersauthor=D.+I.+Stuart&title=Complexes+of+HIV-1+Reverse+Transcriptase+with+Inhibitors+of+the+HEPT+Series+Reveal+Conformational+Changes+Relevant+to+the+Design+of+Potent+Non-Nucleoside+Inhibitors&doi=10.1021%2Fjm960056x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors</span></div><div class="casAuthors">Hopkins, Andrew L.; Ren, Jingshan; Esnouf, Robert M.; Willcox, Benjamin E.; Jones, E. Yvonne; Ross, Carl; Miyasaka, Tadashi; Walker, Richard T.; Tanaka, Hiromichi; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1589-600</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crystal structures of HIV-1 reverse transcriptase (RT) complexed with a range of chem. diverse non-nucleoside inhibitors (NNIs) have shown a single pocket in which the inhibitors bind and details of the inhibitor-protein interactions.  To delineate the structural requirements for an effective inhibitor, the authors have detd. the structures of three closely related NNIs which vary widely in their potencies.  Crystal structures of HIV-1 RT complexed with two very potent inhibitors, MKC-442 and TNK-651, at 2.55 Å resoln. complement the authors previous anal. of the complex with the less effective inhibitor, HEPT.  These structures reveal conformational changes which correlate with changes in potency.  The authors suggest that a major determinant of increased potency in the analogs of HEPT is an improved interaction between residue Tyr181 in the protein and the 6-benzyl ring of the inhibitors which stabilizes the structure of the complex.  This arises through a conformational switching of the protein structure triggered by the steric bulk of the 5-substituent of the inhibitor pyrimidine ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1BU3pXNwf67Vg90H21EOLACvtfcHk0lgjKoqtjZ76rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhslGqsrc%253D&md5=a279a5fe9e82e231f0e898c3dff5bb66</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1021%2Fjm960056x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960056x%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DEsnouf%26aufirst%3DR.%2BM.%26aulast%3DWillcox%26aufirst%3DB.%2BE.%26aulast%3DJones%26aufirst%3DE.%2BY.%26aulast%3DRoss%26aufirst%3DC.%26aulast%3DMiyasaka%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26atitle%3DComplexes%2520of%2520HIV-1%2520Reverse%2520Transcriptase%2520with%2520Inhibitors%2520of%2520the%2520HEPT%2520Series%2520Reveal%2520Conformational%2520Changes%2520Relevant%2520to%2520the%2520Design%2520of%2520Potent%2520Non-Nucleoside%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26issue%3D8%26spage%3D1589%26epage%3D1600%26doi%3D10.1021%2Fjm960056x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3416</span>– <span class="NLM_lpage">3419</span>, <span class="refDoi"> DOI: 10.1021/jm070512p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070512p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVehtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3416-3419&issue=15&author=Z.+Wangauthor=E.+M.+Bennettauthor=D.+J.+Wilsonauthor=C.+Salomonauthor=R.+Vince&title=Rationally+Designed+Dual+Inhibitors+of+HIV+Reverse+Transcriptase+and+Integrase&doi=10.1021%2Fjm070512p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase</span></div><div class="casAuthors">Wang, Zhengqiang; Bennett, Eric M.; Wilson, Daniel J.; Salomon, Christine; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3416-3419</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bifunctional inhibitors were designed and synthesized based on 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) non-nucleoside reverse transcriptase (RT) inhibitors and diketoacid (DKA) integrase (IN) inhibitors.  Biochem. studies revealed activity against RT and IN at low nanomolar and low micromolar concns., resp.  Exceptionally low IC50 values from a cell-based assay were achieved along with remarkably high therapeutic indexes.  Compd. I was identified as the best compd. of the series (IC50: 24 nM against RT, 4.4 μM against IN, and 10 nM against HIV-1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvKQ5ZDoIQqLVg90H21EOLACvtfcHk0lgjKoqtjZ76rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVehtbo%253D&md5=021d763f7f62919cc1fe9d010ab56e60</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1021%2Fjm070512p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070512p%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DWilson%26aufirst%3DD.%2BJ.%26aulast%3DSalomon%26aufirst%3DC.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DRationally%2520Designed%2520Dual%2520Inhibitors%2520of%2520HIV%2520Reverse%2520Transcriptase%2520and%2520Integrase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D15%26spage%3D3416%26epage%3D3419%26doi%3D10.1021%2Fjm070512p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motomura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aramaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamataka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinkai, H.</span></span> <span> </span><span class="NLM_article-title">Quinolone Carboxylic Acids as a Novel Monoketo Acid Class of Human Immunodeficiency Virus Type 1 Integrase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4869</span>– <span class="NLM_lpage">4882</span>, <span class="refDoi"> DOI: 10.1021/jm900460z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900460z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4869-4882&issue=15&author=M.+Satoauthor=H.+Kawakamiauthor=T.+Motomuraauthor=H.+Aramakiauthor=T.+Matsudaauthor=M.+Yamashitaauthor=Y.+Itoauthor=Y.+Matsuzakiauthor=K.+Yamatakaauthor=S.+Ikedaauthor=H.+Shinkai&title=Quinolone+Carboxylic+Acids+as+a+Novel+Monoketo+Acid+Class+of+Human+Immunodeficiency+Virus+Type+1+Integrase+Inhibitors&doi=10.1021%2Fjm900460z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Quinolone Carboxylic Acids as a Novel Monoketo Acid Class of Human Immunodeficiency Virus Type 1 Integrase Inhibitors</span></div><div class="casAuthors">Sato, Motohide; Kawakami, Hiroshi; Motomura, Takahisa; Aramaki, Hisateru; Matsuda, Takashi; Yamashita, Masaki; Ito, Yoshiharu; Matsuzaki, Yuji; Yamataka, Kazunobu; Ikeda, Satoru; Shinkai, Hisashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4869-4882</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and detailed structure-activity relationship of quinolonecarboxylic acids as a novel monoketo acid class of HIV-1 integrase inhibitors was presented.  Compds. I (R = t-Bu), which showed an IC50 of 5.8 nM in the strand transfer assay and an ED50 of 0.6 nM in the antiviral assay, and I (R = i-Pr), which had an IC50 of 7.2 nM and an ED50 of 0.9 nM, were the most potent compds. in this class.  The monoketo acid I (R = i-Pr) was much more potent at inhibiting integrase-catalyzed strand transfer processes than 3'-processing reactions, as is the case with the keto-enol acids.  Elvitegravir I (R = i-Pr) was chosen as a candidate for further studies and was reported as being in phase 3 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozJb9SzajWHbVg90H21EOLACvtfcHk0lgfQ7uXXAWbQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGjsr0%253D&md5=2eb5292b5c6e9efa8471f293cc9f6bb0</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1021%2Fjm900460z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900460z%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DM.%26aulast%3DKawakami%26aufirst%3DH.%26aulast%3DMotomura%26aufirst%3DT.%26aulast%3DAramaki%26aufirst%3DH.%26aulast%3DMatsuda%26aufirst%3DT.%26aulast%3DYamashita%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DMatsuzaki%26aufirst%3DY.%26aulast%3DYamataka%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DS.%26aulast%3DShinkai%26aufirst%3DH.%26atitle%3DQuinolone%2520Carboxylic%2520Acids%2520as%2520a%2520Novel%2520Monoketo%2520Acid%2520Class%2520of%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Integrase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D15%26spage%3D4869%26epage%3D4882%26doi%3D10.1021%2Fjm900460z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esnouf, R.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. I.</span></span> <span> </span><span class="NLM_article-title">Unique Features in the Structure of the Complex between HIV-1 Reverse Transcriptase and the Bis(Heteroaryl)Piperazine (BHAP) U-90152 Explain Resistance Mutations for This Nonnucleoside Inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3984</span>– <span class="NLM_lpage">3989</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.8.3984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1073%2Fpnas.94.8.3984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=9108091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK2sXis1ehuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=3984-3989&issue=8&author=R.%0AM.+Esnoufauthor=J.+Renauthor=A.+L.+Hopkinsauthor=C.+K.+Rossauthor=E.+Y.+Jonesauthor=D.+K.+Stammersauthor=D.+I.+Stuart&title=Unique+Features+in+the+Structure+of+the+Complex+between+HIV-1+Reverse+Transcriptase+and+the+Bis%28Heteroaryl%29Piperazine+%28BHAP%29+U-90152+Explain+Resistance+Mutations+for+This+Nonnucleoside+Inhibitor&doi=10.1073%2Fpnas.94.8.3984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor</span></div><div class="casAuthors">Esnouf, Robert M.; Ren, Jingshan; Hopkins, Andrew L.; Ross, Carl K.; Jones, E. Yvonne; Stammers, David K.; Stuart, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3984-3989</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The viral reverse transcriptase (RT) provides an attractive target in the search for anti-HIV therapies.  The nonnucleoside inhibitors (NNIs) are a diverse set of compds. (usually HIV-1 specific) that function by distorting the polymerase active site upon binding in a nearby pocket.  Despite being potent and of generally low toxicity, their clin. use has been limited by rapid selection for resistant viral populations.  The 2.65-Å resoln. structure of the complex between HIV-1 RT and the bis(heteroaryl)piperazine (BHAP) NNI, 1-(5-methanesulfonamido-1H-indol-2-yl-carbonyl)-4-[3-(1-methyl-ethylamino)pyridinyl] piperazine (U-90152), reveals the inhibitor conformation and bound water mols.  The bulky U-90152 mol. occupies the same pocket as other NNIs, but the complex is stabilized quite differently, in particular by hydrogen bonding to the main chain of Lys-103 and extensive hydrophobic contacts with Pro-236.  These interactions rationalize obsd. resistance mutations, notably Pro-236-Leu, which occurs characteristically for BHAPs.  When bound, part of U-90152 protrudes into the solvent creating a channel between Pro-236 and the polypeptide segments 225-226 and 105-106, giving the first clear evidence of the entry mode for NNIs.  The structure allows prediction of binding modes for related inhibitors [(altrylamino)piperidine-BHAPs] and suggests changes to U-90152, such as the addn. of a 6 amino group to the pyridine ring, which may make binding more resilient to mutations in the RT.  The observation of novel hydrogen bonding to the protein main chain may provide lessons for the improvement of quite different inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzQuIdPkm-oLVg90H21EOLACvtfcHk0lgfQ7uXXAWbQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1ehuro%253D&md5=d9027e0d3dc8ad612fb84d9e98b7f30e</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.8.3984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.8.3984%26sid%3Dliteratum%253Aachs%26aulast%3DEsnouf%26aufirst%3DR.%2BM.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DRoss%26aufirst%3DC.%2BK.%26aulast%3DJones%26aufirst%3DE.%2BY.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26atitle%3DUnique%2520Features%2520in%2520the%2520Structure%2520of%2520the%2520Complex%2520between%2520HIV-1%2520Reverse%2520Transcriptase%2520and%2520the%2520Bis%2528Heteroaryl%2529Piperazine%2520%2528BHAP%2529%2520U-90152%2520Explain%2520Resistance%2520Mutations%2520for%2520This%2520Nonnucleoside%2520Inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26issue%3D8%26spage%3D3984%26epage%3D3989%26doi%3D10.1073%2Fpnas.94.8.3984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daily, J. P.</span></span> <span> </span><span class="NLM_article-title">Antimalarial Drug Therapy: The Role of Parasite Biology and Drug Resistance</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1487</span>– <span class="NLM_lpage">1497</span>, <span class="refDoi"> DOI: 10.1177/0091270006294276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1177%2F0091270006294276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17101748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlajsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=1487-1497&issue=12&author=J.+P.+Daily&title=Antimalarial+Drug+Therapy%3A+The+Role+of+Parasite+Biology+and+Drug+Resistance&doi=10.1177%2F0091270006294276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial drug therapy: the role of parasite biology and drug resistance</span></div><div class="casAuthors">Daily, Johanna P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1487-1497</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Malaria continues to affect public health and economic growth in many regions of the world.  The no. of infections continues to rise and is assocd. with increased mortality, despite basic science and public health efforts.  Drug therapy remains the mainstay of treatment and prevention of this disease.  Plasmodium has a complex life cycle involving an arthropod vector and distinct stages within the human host.  Each parasite stage plays a unique role in transmission, disease, and latency.  These different stages may vary in their response to the various anti-malarial compds.  This article will review antimalarial therapies and drug resistance in the context of the parasites' biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCZpemYeNAXbVg90H21EOLACvtfcHk0lgfQ7uXXAWbQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlajsbjP&md5=3b019832c10d60a35955edf6549cd256</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1177%2F0091270006294276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270006294276%26sid%3Dliteratum%253Aachs%26aulast%3DDaily%26aufirst%3DJ.%2BP.%26atitle%3DAntimalarial%2520Drug%2520Therapy%253A%2520The%2520Role%2520of%2520Parasite%2520Biology%2520and%2520Drug%2520Resistance%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D46%26issue%3D12%26spage%3D1487%26epage%3D1497%26doi%3D10.1177%2F0091270006294276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bich, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thien, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kager, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisterkamp, S. H.</span></span> <span> </span><span class="NLM_article-title">Combinations of Artemisinin and Quinine for Uncomplicated Falciparum Malaria: Efficacy and Pharmacodynamics</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1302</span>– <span class="NLM_lpage">1308</span>, <span class="refDoi"> DOI: 10.1128/AAC.44.5.1302-1308.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1128%2FAAC.44.5.1302-1308.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10770766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3cXislKitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=1302-1308&issue=5&author=P.+J.+de+Vriesauthor=N.+N.+Bichauthor=H.+V.+Thienauthor=L.+N.+Hungauthor=T.+K.+Anhauthor=P.+A.+Kagerauthor=S.+H.+Heisterkamp&title=Combinations+of+Artemisinin+and+Quinine+for+Uncomplicated+Falciparum+Malaria%3A+Efficacy+and+Pharmacodynamics&doi=10.1128%2FAAC.44.5.1302-1308.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics</span></div><div class="casAuthors">De Vries, Peter J.; Bich, Nguyen Ngoc; Thien, Huynh Van; Hung, Le Ngoc; Anh, Trinh Kim; Kager, Piet A.; Heisterkamp, Siem H.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1302-1308</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Combinations of artemisinin and quinine for uncomplicated falciparum malaria were studied.  A total of 268 patients were randomized to 7 days of quinine at 10 mg/kg of body wt. three times a day (Q) or to artemisinin at 20 mg/kg of body wt. followed by 3 (AQ3) or 5 (AQ5) days of quinine.  Recrudescence rates were 16, 38, and 15% for the Q, AQ3, and AQ5 groups, resp. (P < 0.001).  Recrudescence was assocd. with shorter parasite clearance time (PCT) and longer treatment after the blood smear had become neg. (eradication time).  However, classification of patients to outcome-recrudescence or radical cure-was correct in only 77% of patients.  The population kinetics of the parasitemia was estd. with nonlinear mixed-effect models.  Several models were tested, but the best model was a monoexponential decline of the parasitemia in which the mean parasite elimination half-life was shorter after artemisinin (5.1 h; 95% confidence interval [CI], 4.9 to 5.2 h) than after quinine (8.0 h [95% CI, 7.5 to 8.3 h]).  Attempts to simulate the initial increase of the parasitemia did not result in better models with a biol. plausible interpretation.  Recrudescence was assocd. with slower parasite clearance and a higher simulated terminal parasitemia (Pterm).  The classification of patients to outcome groups based on Pterm was correct in 78% of patients.  The data suggest that parasite strains with reduced sensitivity to quinine are prevalent in Vietnam, with slower parasite clearance and consequent recrudescence.  A single dose of artemisinin induces rapid parasite redn. and lowers the value of Pterm, but to prevent recrudescence, this should be followed by quinine for at least 3 days after parasite clearance, or 5 days in total.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp2PYp44yE8bVg90H21EOLACvtfcHk0lgfQ7uXXAWbQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXislKitro%253D&md5=86c7cdfc671038ca0fafb18d1a9c9cf5</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1128%2FAAC.44.5.1302-1308.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.44.5.1302-1308.2000%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BVries%26aufirst%3DP.%2BJ.%26aulast%3DBich%26aufirst%3DN.%2BN.%26aulast%3DThien%26aufirst%3DH.%2BV.%26aulast%3DHung%26aufirst%3DL.%2BN.%26aulast%3DAnh%26aufirst%3DT.%2BK.%26aulast%3DKager%26aufirst%3DP.%2BA.%26aulast%3DHeisterkamp%26aufirst%3DS.%2BH.%26atitle%3DCombinations%2520of%2520Artemisinin%2520and%2520Quinine%2520for%2520Uncomplicated%2520Falciparum%2520Malaria%253A%2520Efficacy%2520and%2520Pharmacodynamics%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2000%26volume%3D44%26issue%3D5%26spage%3D1302%26epage%3D1308%26doi%3D10.1128%2FAAC.44.5.1302-1308.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heneghan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaynor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, A.</span></span> <span> </span><span class="NLM_article-title">A Novel Artemisinin-Quinine Hybrid with Potent Antimalarial Activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3599</span>– <span class="NLM_lpage">3602</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.04.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmcl.2007.04.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17482816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFait7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3599-3602&issue=13&author=J.+J.+Walshauthor=D.+Coughlanauthor=N.+Heneghanauthor=C.+Gaynorauthor=A.+Bell&title=A+Novel+Artemisinin-Quinine+Hybrid+with+Potent+Antimalarial+Activity&doi=10.1016%2Fj.bmcl.2007.04.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">A novel artemisinin-quinine hybrid with potent antimalarial activity</span></div><div class="casAuthors">Walsh, John J.; Coughlan, David; Heneghan, Nicola; Gaynor, Caroline; Bell, Angus</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3599-3602</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Artemisinin (I) was reduced to dihydroartemisinin and coupled to a carboxylic acid deriv. of quinine (II) via an ester linkage.  This novel hybrid mol. III had potent activity against the 3D7 and (drug-resistant) FcB1 strains of Plasmodium falciparum in culture.  The activity was superior to that of artemisinin alone, quinine alone, or a 1:1 mixt. of artemisinin and quinine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrjW7iX9xRWbVg90H21EOLACvtfcHk0liN8sreNh268g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFait7Y%253D&md5=4f74e16f4e19e101476a7b623720a2a4</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.04.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.04.054%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DJ.%2BJ.%26aulast%3DCoughlan%26aufirst%3DD.%26aulast%3DHeneghan%26aufirst%3DN.%26aulast%3DGaynor%26aufirst%3DC.%26aulast%3DBell%26aufirst%3DA.%26atitle%3DA%2520Novel%2520Artemisinin-Quinine%2520Hybrid%2520with%2520Potent%2520Antimalarial%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D13%26spage%3D3599%26epage%3D3602%26doi%3D10.1016%2Fj.bmcl.2007.04.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bray, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span> <span> </span><span class="NLM_article-title">Quinolines and Artemisinin: Chemistry, Biology and History</span>. <i>Curr. Top. Microbiol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>295</i></span> (<span class="NLM_issue">295</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1007/3-540-29088-5_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1007%2F3-540-29088-5_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16265885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtF2jsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2005&pages=3-38&issue=295&author=P.+G.+Brayauthor=S.+A.+Wardauthor=P.+M.+O%E2%80%99Neill&title=Quinolines+and+Artemisinin%3A+Chemistry%2C+Biology+and+History&doi=10.1007%2F3-540-29088-5_1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Quinolines and artemisinin: chemistry, biology and history</span></div><div class="casAuthors">Bray, P. G.; Ward, S. A.; O'Neill, P. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Microbiology and Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">Malaria</span>),
    <span class="NLM_cas:pages">3-38</span>CODEN:
                <span class="NLM_cas:coden">CTMIA3</span>;
        ISSN:<span class="NLM_cas:issn">0070-217X</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Plasmodium falciparum is the most important parasitic pathogen in humans, causing hundreds of millions of malaria infections and millions of deaths each year.  At present there is no effective malaria vaccine and malaria therapy is totally reliant on the use of drugs.  New drugs are urgently needed because of the rapid evolution and spread of parasite resistance to the current therapies.  Drug resistance is one of the major factors contributing to the resurgence of malaria, esp. resistance to the most affordable drugs such as chloroquine.  We need to fully understand the antimalarial mode of action of the existing drugs and the way that the parasite becomes resistant to them in order to design and develop the new therapies that are so urgently needed.  In respect of the quinolines and artemisinins, great progress has been made recently in studying the mechanisms of drug action and drug resistance in malaria parasites.  Here we summarize from a historical, biol. and chem., perspective the exciting new advances that have been made in the study of these important antimalarial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnLgjzw5hRErVg90H21EOLACvtfcHk0liN8sreNh268g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtF2jsrrP&md5=99d7e17c3a40dc321d6ddc515037a55d</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1007%2F3-540-29088-5_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F3-540-29088-5_1%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DP.%2BG.%26aulast%3DWard%26aufirst%3DS.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26atitle%3DQuinolines%2520and%2520Artemisinin%253A%2520Chemistry%252C%2520Biology%2520and%2520History%26jtitle%3DCurr.%2520Top.%2520Microbiol.%2520Immunol.%26date%3D2005%26volume%3D295%26issue%3D295%26spage%3D3%26epage%3D38%26doi%3D10.1007%2F3-540-29088-5_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref258"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref258'); return false;" data-citation="" class="refNumLink">258</a></strong><div class="NLM_citation" id="cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werz, O.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Approach for Natural Products in Inflammation</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1871</span>– <span class="NLM_lpage">1882</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2014.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25172801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyhtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1871-1882&issue=12&author=A.+Koeberleauthor=O.+Werz&title=Multi-Target+Approach+for+Natural+Products+in+Inflammation&doi=10.1016%2Fj.drudis.2014.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target approach for natural products in inflammation</span></div><div class="casAuthors">Koeberle, Andreas; Werz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1871-1882</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Although an increasing no. of studies show the (pre)clin. efficiency and safety of multi-target natural products, they are still underrepresented as starting points for multi-target drug discovery.  This article provides an overview about the multi-target drug concept and discusses strategies to use the enormous pharmacol. knowledge of natural products with privileged structures (i.e. curcumin, epigallocatechin-3-gallate, resveratrol, salicylate and quercetin) for developing anti-inflammatory multi-target drugs.  Focus is placed on selecting mol. targets, judging their relevance and estg. safety concerns.  An attractive aim might be to modulate natural product affinity to concrete but multiple mol. targets (based on the current knowledge of inflammation-relevant pathways) while maintaining their apparently beneficial broad target profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSJ77tkJ2UerVg90H21EOLACvtfcHk0liN8sreNh268g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyhtrnL&md5=69bf3f871fc69612a71125834e98ab43</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DKoeberle%26aufirst%3DA.%26aulast%3DWerz%26aufirst%3DO.%26atitle%3DMulti-Target%2520Approach%2520for%2520Natural%2520Products%2520in%2520Inflammation%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26issue%3D12%26spage%3D1871%26epage%3D1882%26doi%3D10.1016%2Fj.drudis.2014.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref259"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref259'); return false;" data-citation="" class="refNumLink">259</a></strong><div class="NLM_citation" id="cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacob P, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manju, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethiraj, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, G.</span></span> <span> </span><span class="NLM_article-title">Safer Anti-Inflammatory Therapy through Dual COX-2/5-LOX Inhibitors: A Structure-Based Approach</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">356</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2018.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejps.2018.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29883727" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2018&pages=356-381&author=J.+Jacob+Pauthor=S.+L.+Manjuauthor=K.+R.+Ethirajauthor=G.+Elias&title=Safer+Anti-Inflammatory+Therapy+through+Dual+COX-2%2F5-LOX+Inhibitors%3A+A+Structure-Based+Approach&doi=10.1016%2Fj.ejps.2018.06.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2018.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2018.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DJacob%2BP%26aufirst%3DJ.%26aulast%3DManju%26aufirst%3DS.%2BL.%26aulast%3DEthiraj%26aufirst%3DK.%2BR.%26aulast%3DElias%26aufirst%3DG.%26atitle%3DSafer%2520Anti-Inflammatory%2520Therapy%2520through%2520Dual%2520COX-2%252F5-LOX%2520Inhibitors%253A%2520A%2520Structure-Based%2520Approach%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2018%26volume%3D121%26spage%3D356%26epage%3D381%26doi%3D10.1016%2Fj.ejps.2018.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref260"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref260'); return false;" data-citation="" class="refNumLink">260</a></strong><div class="NLM_citation" id="cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eleftheriadis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poelman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leus, N. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honrath, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neochoritis, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, F. J.</span></span> <span> </span><span class="NLM_article-title">Design of a Novel Thiophene Inhibitor of 15-Lipoxygenase-1 with Both Anti-Inflammatory and Neuroprotective Properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">801</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2016.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27477687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1OnsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2016&pages=786-801&author=N.+Eleftheriadisauthor=H.+Poelmanauthor=N.+G.+J.+Leusauthor=B.+Honrathauthor=C.+G.+Neochoritisauthor=A.+Dolgaauthor=A.+D%C3%B6mlingauthor=F.+J.+Dekker&title=Design+of+a+Novel+Thiophene+Inhibitor+of+15-Lipoxygenase-1+with+Both+Anti-Inflammatory+and+Neuroprotective+Properties&doi=10.1016%2Fj.ejmech.2016.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Design of a novel thiophene inhibitor of 15-lipoxygenase-1 with both anti-inflammatory and neuroprotective properties</span></div><div class="casAuthors">Eleftheriadis, Nikolaos; Poelman, Hessel; Leus, Niek G. J.; Honrath, Birgit; Neochoritis, Constantinos G.; Dolga, Amalia; Doemling, Alexander; Dekker, Frank J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">786-801</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The enzyme 15-lipoxygenase-1 (15-LOX-1) plays a dual role in diseases with an inflammatory component.  On one hand 15-LOX-1 plays a role in pro-inflammatory gene expression and on the other hand it has been shown to be involved in central nervous system (CNS) disorders by its ability to mediate oxidative stress and damage of mitochondrial membranes under hypoxic conditions.  In order to further explore applications in the CNS, novel 15-LOX-1 inhibitors with favorable physicochem. properties need to be developed.  Here, we present Substitution Oriented Screening (SOS) in combination with Multi Component Chem. (MCR) as an effective strategy to identify a diversely substituted small heterocyclic inhibitors for 15-LOX-1, denoted ThioLox, with physicochem. properties superior to previously identified inhibitors.  Ex vivo biol. evaluation in precision-cut lung slices (PCLS) showed inhibition of pro-inflammatory gene expression and in vitro studies on neuronal HT-22 cells showed a strong protection against glutamate toxicity for this 15-LOX-1 inhibitor.  This provides a novel approach to identify novel small with favorable physicochem. properties for exploring 15-LOX-1 as a drug target in inflammatory diseases and neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJgitwoMsVk7Vg90H21EOLACvtfcHk0liiyQn0CycbZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1OnsLbM&md5=931aea61ddecf51462afa126deedc302</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DEleftheriadis%26aufirst%3DN.%26aulast%3DPoelman%26aufirst%3DH.%26aulast%3DLeus%26aufirst%3DN.%2BG.%2BJ.%26aulast%3DHonrath%26aufirst%3DB.%26aulast%3DNeochoritis%26aufirst%3DC.%2BG.%26aulast%3DDolga%26aufirst%3DA.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26aulast%3DDekker%26aufirst%3DF.%2BJ.%26atitle%3DDesign%2520of%2520a%2520Novel%2520Thiophene%2520Inhibitor%2520of%252015-Lipoxygenase-1%2520with%2520Both%2520Anti-Inflammatory%2520and%2520Neuroprotective%2520Properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D122%26spage%3D786%26epage%3D801%26doi%3D10.1016%2Fj.ejmech.2016.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref261"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref261'); return false;" data-citation="" class="refNumLink">261</a></strong><div class="NLM_citation" id="cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vane, J. R.</span></span> <span> </span><span class="NLM_article-title">The Mechanism of Action of Anti-Inflammatory Drugs</span>. <i>Acta Rheumatol. Scand.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">Suppl. 102</span>),  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">21</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1997&pages=9-21&issue=Suppl.+102&author=J.+R.+Vane&title=The+Mechanism+of+Action+of+Anti-Inflammatory+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520Mechanism%2520of%2520Action%2520of%2520Anti-Inflammatory%2520Drugs%26jtitle%3DActa%2520Rheumatol.%2520Scand.%26date%3D1997%26volume%3D25%26issue%3DSuppl.%2520102%26spage%3D9%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref262"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref262'); return false;" data-citation="" class="refNumLink">262</a></strong><div class="NLM_citation" id="cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martel-Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lajeunesse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reboul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J. P.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Role of Dual Inhibitors of 5-LOX and COX, Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1136/ard.62.6.501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1136%2Fard.62.6.501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=12759283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkslKqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2003&pages=501-509&issue=6&author=J.+Martel-Pelletierauthor=D.+Lajeunesseauthor=P.+Reboulauthor=J.+P.+Pelletier&title=Therapeutic+Role+of+Dual+Inhibitors+of+5-LOX+and+COX%2C+Selective+and+Non-Selective+Non-Steroidal+Anti-Inflammatory+Drugs&doi=10.1136%2Fard.62.6.501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs</span></div><div class="casAuthors">Martel-Pelletier, J.; Lajeunesse, D.; Reboul, P.; Pelletier, J.-P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">501-509</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dual 5-LOX/COX inhibitors are potential new drugs to treat inflammation.  They act by blocking the formation of both prostaglandins and leucotrienes but do not affect lipoxin formation.  Such combined inhibition avoids some of the disadvantages of selective COX-2 inhibitors and spares the gastrointestinal mucosa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHAzAjNtkY5LVg90H21EOLACvtfcHk0liiyQn0CycbZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkslKqu78%253D&md5=abb97e7397cdcfa7e7921d4cbc3771c3</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.1136%2Fard.62.6.501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.62.6.501%26sid%3Dliteratum%253Aachs%26aulast%3DMartel-Pelletier%26aufirst%3DJ.%26aulast%3DLajeunesse%26aufirst%3DD.%26aulast%3DReboul%26aufirst%3DP.%26aulast%3DPelletier%26aufirst%3DJ.%2BP.%26atitle%3DTherapeutic%2520Role%2520of%2520Dual%2520Inhibitors%2520of%25205-LOX%2520and%2520COX%252C%2520Selective%2520and%2520Non-Selective%2520Non-Steroidal%2520Anti-Inflammatory%2520Drugs%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2003%26volume%3D62%26issue%3D6%26spage%3D501%26epage%3D509%26doi%3D10.1136%2Fard.62.6.501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref263"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref263'); return false;" data-citation="" class="refNumLink">263</a></strong><div class="NLM_citation" id="cit263"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blobaum, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marnett, L. J.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Basis of Cyclooxygenase Inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1441</span>, <span class="refDoi"> DOI: 10.1021/jm0613166</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0613166" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFeisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1425-1441&issue=7&author=A.+L.+Blobaumauthor=L.+J.+Marnett&title=Structural+and+Functional+Basis+of+Cyclooxygenase+Inhibition&doi=10.1021%2Fjm0613166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Basis of Cyclooxygenase Inhibition</span></div><div class="casAuthors">Blobaum, Anna L.; Marnett, Lawrence J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1425-1441</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will focus on the structural and functional basis of the inhibition of cyclooxygenase (COX) enzymes by nonselective and COX-2 selective inhibitors.  It will integrate kinetic, mechanistic, and structural information to illustrate not only the range of mols. with COX inhibitory activity but also the diversity of mechanisms by which they act.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8SMg_SRasDLVg90H21EOLACvtfcHk0liiyQn0CycbZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFeisL8%253D&md5=b9de2eafa7d2b510c866245b09fba546</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1021%2Fjm0613166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0613166%26sid%3Dliteratum%253Aachs%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26atitle%3DStructural%2520and%2520Functional%2520Basis%2520of%2520Cyclooxygenase%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D7%26spage%3D1425%26epage%3D1441%26doi%3D10.1021%2Fjm0613166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref264"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref264'); return false;" data-citation="" class="refNumLink">264</a></strong><div class="NLM_citation" id="cit264"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geerts, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiros, A.</span></span> <span> </span><span class="NLM_article-title">Assessing the Synergy between Cholinomimetics and Memantine as Augmentation Therapy in Cognitive Impairment in Schizophrenia. A Virtual Human Patient Trial Using Quantitative Systems Pharmacology</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1208</span>– <span class="NLM_lpage">1217</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3389%2Ffphar.2015.00198" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1208-1217&issue=4&author=H.+Geertsauthor=P.+Robertsauthor=A.+Spiros&title=Assessing+the+Synergy+between+Cholinomimetics+and+Memantine+as+Augmentation+Therapy+in+Cognitive+Impairment+in+Schizophrenia.+A+Virtual+Human+Patient+Trial+Using+Quantitative+Systems+Pharmacology&doi=10.3389%2Ffphar.2015.00198"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00198%26sid%3Dliteratum%253Aachs%26aulast%3DGeerts%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%26aulast%3DSpiros%26aufirst%3DA.%26atitle%3DAssessing%2520the%2520Synergy%2520between%2520Cholinomimetics%2520and%2520Memantine%2520as%2520Augmentation%2520Therapy%2520in%2520Cognitive%2520Impairment%2520in%2520Schizophrenia.%2520A%2520Virtual%2520Human%2520Patient%2520Trial%2520Using%2520Quantitative%2520Systems%2520Pharmacology%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26issue%3D4%26spage%3D1208%26epage%3D1217%26doi%3D10.3389%2Ffphar.2015.00198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref265"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref265'); return false;" data-citation="" class="refNumLink">265</a></strong><div class="NLM_citation" id="cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speck-Planche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleandrova, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordeiro, M. N. D. S.</span></span> <span> </span><span class="NLM_article-title">Rational Drug Design for Anti-Cancer Chemotherapy: Multi-Target QSAR Models for the in Silico Discovery of Anti-Colorectal Cancer Agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4848</span>– <span class="NLM_lpage">4855</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.05.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2012.05.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22750007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVyjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=4848-4855&issue=15&author=A.+Speck-Plancheauthor=V.+V.+Kleandrovaauthor=F.+Luanauthor=M.+N.+D.+S.+Cordeiro&title=Rational+Drug+Design+for+Anti-Cancer+Chemotherapy%3A+Multi-Target+QSAR+Models+for+the+in+Silico+Discovery+of+Anti-Colorectal+Cancer+Agents&doi=10.1016%2Fj.bmc.2012.05.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">Rational drug design for anti-cancer chemotherapy: Multi-target QSAR models for the in silico discovery of anti-colorectal cancer agents</span></div><div class="casAuthors">Speck-Planche, Alejandro; Kleandrova, Valeria V.; Luan, Feng; Cordeiro, M. Natalia D. S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4848-4855</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery of new and more potent anti-cancer agents constitutes one of the most active fields of research in chemotherapy.  Colorectal cancer (CRC) is one of the most studied cancers because of its high prevalence and no. of deaths.  In the current pharmaceutical design of more efficient anti-CRC drugs, the use of methodologies based on Chemoinformatics has played a decisive role, including Quant.-Structure-Activity Relationship (QSAR) techniques.  However, until now, there is no methodol. able to predict anti-CRC activity of compds. against more than one CRC cell line, which should constitute the principal goal.  In an attempt to overcome this problem we develop here the first multi-target (mt) approach for the virtual screening and rational in silico discovery of anti-CRC agents against ten cell lines.  Here, two mt-QSAR classification models were constructed using a large and heterogeneous database of compds.  The first model was based on linear discriminant anal. (mt-QSAR-LDA) employing fragment-based descriptors while the second model was obtained using artificial neural networks (mt-QSAR-ANN) with global 2D descriptors.  Both models correctly classified more than 90% of active and inactive compds. in training and prediction sets.  Some fragments were extd. from the mols. and their contributions to anti-CRC activity were calcd. using mt-QSAR-LDA model.  Several fragments were identified as potential substructural features responsible for the anti-CRC activity and new mols. designed from those fragments with pos. contributions were suggested and correctly predicted by the two models as possible potent and versatile anti-CRC agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzYPKmeEc7SrVg90H21EOLACvtfcHk0lglldvRtHyItg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVyjurg%253D&md5=ad1fcf5e992a4a4f43caf1a5b470529b</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.05.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.05.071%26sid%3Dliteratum%253Aachs%26aulast%3DSpeck-Planche%26aufirst%3DA.%26aulast%3DKleandrova%26aufirst%3DV.%2BV.%26aulast%3DLuan%26aufirst%3DF.%26aulast%3DCordeiro%26aufirst%3DM.%2BN.%2BD.%2BS.%26atitle%3DRational%2520Drug%2520Design%2520for%2520Anti-Cancer%2520Chemotherapy%253A%2520Multi-Target%2520QSAR%2520Models%2520for%2520the%2520in%2520Silico%2520Discovery%2520of%2520Anti-Colorectal%2520Cancer%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26issue%3D15%26spage%3D4848%26epage%3D4855%26doi%3D10.1016%2Fj.bmc.2012.05.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref266"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref266'); return false;" data-citation="" class="refNumLink">266</a></strong><div class="NLM_citation" id="cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speck-Planche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleandrova, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordeiro, M. N. D. S.</span></span> <span> </span><span class="NLM_article-title">In Silico Discovery and Virtual Screening of Multi-Target Inhibitors for Proteins in Mycobacterium Tuberculosis</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.2174/138620712802650487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F138620712802650487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22452349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFGru7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=666-673&issue=8&author=A.+Speck-Plancheauthor=V.+V.+Kleandrovaauthor=F.+Luanauthor=M.+N.+D.+S.+Cordeiro&title=In+Silico+Discovery+and+Virtual+Screening+of+Multi-Target+Inhibitors+for+Proteins+in+Mycobacterium+Tuberculosis&doi=10.2174%2F138620712802650487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis</span></div><div class="casAuthors">Speck-Planche, Alejandro; Kleandrova, Valeria V.; Luan, Feng; Cordeiro, M. Natalia D. S.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">666-673</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis (MTB) is the principal pathogen which causes tuberculosis (TB), a disease that remains as one of the most alarming health problems worldwide.  An active area for the search of new anti-TB therapies is concerned with the use of computational approaches based on Chemoinformatics and/or Bioinformatics toward the discovery of new and potent anti-TB agents.  These approaches consider only small series of structurally related compds. and the studies are generally realized for only one target like a protein.  This fact constitutes an important limitation.  The present work is an effort to overcome this problem.  We introduce here the first chemo-bioinformatic approach by developing a multi-target (mt) QSAR discriminant model, for the in silico design and virtual screening of anti-TB agents against six proteins in MTB.  The mt-QSAR model was developed by employing a large and heterogeneous database of compds. and substructural descriptors.  The model correctly classified more than 90% of active and inactive compds. in both, training and prediction series.  Some fragments were extd. from the mols. and their contributions to anti-TB activity through inhibition of the six proteins, were calcd.  Several fragments were identified as responsible for anti-TB activity and new mol. entities were designed from those fragments with pos. contributions, being suggested as possible anti-TB agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ivBLhLx_DLVg90H21EOLACvtfcHk0lglldvRtHyItg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFGru7bO&md5=299fc21b83a8afaa190d943c163f4086</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.2174%2F138620712802650487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620712802650487%26sid%3Dliteratum%253Aachs%26aulast%3DSpeck-Planche%26aufirst%3DA.%26aulast%3DKleandrova%26aufirst%3DV.%2BV.%26aulast%3DLuan%26aufirst%3DF.%26aulast%3DCordeiro%26aufirst%3DM.%2BN.%2BD.%2BS.%26atitle%3DIn%2520Silico%2520Discovery%2520and%2520Virtual%2520Screening%2520of%2520Multi-Target%2520Inhibitors%2520for%2520Proteins%2520in%2520Mycobacterium%2520Tuberculosis%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2012%26volume%3D15%26issue%3D8%26spage%3D666%26epage%3D673%26doi%3D10.2174%2F138620712802650487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref267"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref267'); return false;" data-citation="" class="refNumLink">267</a></strong><div class="NLM_citation" id="cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thangapandian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakkiah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. W.</span></span> <span> </span><span class="NLM_article-title">Molecular Docking and Pharmacophore Filtering in the Discovery of Dual-Inhibitors for Human Leukotriene A4 Hydrolase and Leukotriene C4 Synthase</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1021/ci1002813</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci1002813" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWgtrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=33-44&issue=1&author=S.+Thangapandianauthor=S.+Johnauthor=S.+Sakkiahauthor=K.+W.+Lee&title=Molecular+Docking+and+Pharmacophore+Filtering+in+the+Discovery+of+Dual-Inhibitors+for+Human+Leukotriene+A4+Hydrolase+and+Leukotriene+C4+Synthase&doi=10.1021%2Fci1002813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit267R"><div class="casContent"><span class="casTitleNuber">267</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Docking and Pharmacophore Filtering in the Discovery of Dual-Inhibitors for Human Leukotriene A4 Hydrolase and Leukotriene C4 Synthase</span></div><div class="casAuthors">Thangapandian, Sundarapandian; John, Shalini; Sakkiah, Sugunadevi; Lee, Keun Woo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-44</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combination of drugs for multiple targets has been a std. treatment in treating various diseases.  A single chem. entity that acts upon multiple targets is emerging nowadays because of their predictable pharmacokinetic and pharmacodynamic properties.  We have employed a computer-aided methodol. combining mol. docking and pharmacophore filtering to identify chem. compds. that can simultaneously inhibit the human leukotriene hydrolase (hLTA4H) and the human leukotriene C4 synthase (hLTC4S) enzymes.  These enzymes are the members of arachidonic acid pathway and act upon the same substrate, LTA4, producing different inflammatory products.  A huge set of 4966 druglike compds. from the Maybridge database were docked into the active site of hLTA4H using the GOLD program.  Common feature pharmacophore models were developed from the known inhibitors of both the targets using Accelrys Discovery Studio 2.5.  The hits from the hLTA4H docking were filtered to match the chem. features of both the pharmacophore models.  The compds. that resulted from the pharmacophore filtering were docked into the active site of hLTC4S and the hits those bind well at both the active sites and matched the pharmacophore models were identified as possible dual inhibitors for hLTA4H and hLTC4S enzymes.  Reverse validation was performed to ensure the results of the study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA6jX1D7KbArVg90H21EOLACvtfcHk0lglldvRtHyItg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWgtrbN&md5=815b2e9b582ddb109d141114ea32a2fa</span></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1021%2Fci1002813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci1002813%26sid%3Dliteratum%253Aachs%26aulast%3DThangapandian%26aufirst%3DS.%26aulast%3DJohn%26aufirst%3DS.%26aulast%3DSakkiah%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DK.%2BW.%26atitle%3DMolecular%2520Docking%2520and%2520Pharmacophore%2520Filtering%2520in%2520the%2520Discovery%2520of%2520Dual-Inhibitors%2520for%2520Human%2520Leukotriene%2520A4%2520Hydrolase%2520and%2520Leukotriene%2520C4%2520Synthase%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26issue%3D1%26spage%3D33%26epage%3D44%26doi%3D10.1021%2Fci1002813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref268"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref268'); return false;" data-citation="" class="refNumLink">268</a></strong><div class="NLM_citation" id="cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Antibody-Drug Conjugates in Cancer Therapy</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-050311-201823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1146%2Fannurev-med-050311-201823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23043493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFKls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=15-29&issue=3&author=E.+L.+Sieversauthor=P.+D.+Senter&title=Antibody-Drug+Conjugates+in+Cancer+Therapy&doi=10.1146%2Fannurev-med-050311-201823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit268R"><div class="casContent"><span class="casTitleNuber">268</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug copnjugates in cancer therapy</span></div><div class="casAuthors">Sievers, Eric L.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-29</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  An antibody-drug conjugate (ADC) provides the possibility of selectively ablating cancer cells by combining the specificity of a monoclonal antibody (mAb) for a target antigen with the delivery of a highly potent cytotoxic agent.  ADC target antigens are typically highly expressed on the surface of cancer cells compared to normal cells.  The tumor target, the cytotoxic agent, and the manner in which the agent is attached to the antibody are key determinants of clin. activity and tolerability.  Recently, several clin. trials have demonstrated that ADCs achieve higher clin. response rates than unconjugated mAbs targeting the same cell surface antigen.  Brentuximab vedotin represents one such ADC that has recently been approved for the treatment of relapsed Hodgkin and systemic anaplastic large cell lymphomas-both characterized by high expression of the target antigen, CD30, on the surface of malignant cells.  This review summarizes key characteristics of current, clin. active ADCs and highlights recent clin. data illustrating the benefit of antibody-targeted delivery of cytotoxic agents to cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYUxUWLJwNgbVg90H21EOLACvtfcHk0lhfQDJOE7X6Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFKls7w%253D&md5=17779a142df44c67601d7e9555511ab7</span></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-050311-201823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-050311-201823%26sid%3Dliteratum%253Aachs%26aulast%3DSievers%26aufirst%3DE.%2BL.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DAntibody-Drug%2520Conjugates%2520in%2520Cancer%2520Therapy%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2013%26volume%3D64%26issue%3D3%26spage%3D15%26epage%3D29%26doi%3D10.1146%2Fannurev-med-050311-201823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref269"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref269'); return false;" data-citation="" class="refNumLink">269</a></strong><div class="NLM_citation" id="cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ducry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, B.</span></span> <span> </span><span class="NLM_article-title">Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1021/bc9002019</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc9002019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGiu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=5-13&issue=1&author=L.+Ducryauthor=B.+Stump&title=Antibody-Drug+Conjugates%3A+Linking+Cytotoxic+Payloads+to+Monoclonal+Antibodies&doi=10.1021%2Fbc9002019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies</span></div><div class="casAuthors">Ducry, Laurent; Stump, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-13</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic mols., thereby taking advantage of the best characteristics of both components.  Along with the development of the mAbs and cytotoxins, the design of chem. linkers to covalently bind these building blocks is making rapid progress but remains challenging.  Recent advances have resulted in linkers having increased stability in the bloodstream while allowing efficient payload release within the tumor cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlMw1v5iWdG7Vg90H21EOLACvtfcHk0lhfQDJOE7X6Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGiu77I&md5=bf79ac611e08674604d6b8cc29636abb</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1021%2Fbc9002019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc9002019%26sid%3Dliteratum%253Aachs%26aulast%3DDucry%26aufirst%3DL.%26aulast%3DStump%26aufirst%3DB.%26atitle%3DAntibody-Drug%2520Conjugates%253A%2520Linking%2520Cytotoxic%2520Payloads%2520to%2520Monoclonal%2520Antibodies%26jtitle%3DBioconjugate%2520Chem.%26date%3D2010%26volume%3D21%26issue%3D1%26spage%3D5%26epage%3D13%26doi%3D10.1021%2Fbc9002019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref270"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref270'); return false;" data-citation="" class="refNumLink">270</a></strong><div class="NLM_citation" id="cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis
Phillips, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blattler, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwall, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenkare-Mitra, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9280</span>– <span class="NLM_lpage">9290</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19010901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&issue=22&author=G.+D.+Lewis%0APhillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=R.+V.+J.+Chariauthor=R.+J.+Lutzauthor=W.+L.+T.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-Positive+Breast+Cancer+with+Trastuzumab-DM1%2C+an+Antibody-Cytotoxic+Drug+Conjugate&doi=10.1158%2F0008-5472.CAN-08-1776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit270R"><div class="casContent"><span class="casTitleNuber">270</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span></div><div class="casAuthors">Lewis Phillips, Gail D.; Li, Guangmin; Dugger, Debra L.; Crocker, Lisa M.; Parsons, Kathryn L.; Mai, Elaine; Blaettler, Walter A.; Lambert, John M.; Chari, Ravi V. J.; Lutz, Robert J.; Wong, Wai Lee T.; Jacobson, Frederic S.; Koeppen, Hartmut; Schwall, Ralph H.; Kenkare-Mitra, Sara R.; Spencer, Susan D.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9280-9290</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER2 is a validated target in breast cancer therapy.  Two drugs are currently approved for HER2-pos. breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (Tykerb), in 2007.  Despite these advances, some patients progress through therapy and succumb to their disease.  A variation on antibody-targeted therapy is utilization of antibodies to deliver cytotoxic agents specifically to antigen-expressing tumors.  We detd. in vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymg. agents) conjugates using disulfide and thioether linkers.  Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured normal and tumor cells.  In vivo activity was detd. in mouse breast cancer models, and toxicity was assessed in rats as measured by body wt. loss.  Surprisingly, trastuzumab linked to DM1 through a nonreducible thioether linkage (SMCC), displayed superior activity compared with unconjugated trastuzumab or trastuzumab linked to other maytansinoids through disulfide linkers.  Serum concns. of trastuzumab-MCC-DM1 remained elevated compared with other conjugates, and toxicity in rats was negligible compared with free DM1 or trastuzumab linked to DM1 through a reducible linker.  Potent activity was obsd. on all HER2-overexpressing tumor cells, whereas nontransformed cells and tumor cell lines with normal HER2 expression were unaffected.  In addn., trastuzumab-DM1 was active on HER2-overexpressing, trastuzumab-refractory tumors.  In summary, trastuzumab-DM1 shows greater activity compared with nonconjugated trastuzumab while maintaining selectivity for HER2-overexpressing tumor cells.  Because trastuzumab linked to DM1 through a nonreducible linker offers improved efficacy and pharmacokinetics and reduced toxicity over the reducible disulfide linkers evaluated, trastuzumab-MCC-DM1 was selected for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpP5fkJnRorrVg90H21EOLACvtfcHk0lhfQDJOE7X6Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK&md5=e86e8687d5f8884f8e28514299dcbbf1</span></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%2BT.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-Positive%2520Breast%2520Cancer%2520with%2520Trastuzumab-DM1%252C%2520an%2520Antibody-Cytotoxic%2520Drug%2520Conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D22%26spage%3D9280%26epage%3D9290%26doi%3D10.1158%2F0008-5472.CAN-08-1776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref271"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref271'); return false;" data-citation="" class="refNumLink">271</a></strong><div class="NLM_citation" id="cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, E. L.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Development of Brentuximab Vedotin for Use in Relapsed Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1038/nbt.2289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnbt.2289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22781692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFCqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=631-637&issue=7&author=P.+D.+Senterauthor=E.+L.+Sievers&title=The+Discovery+and+Development+of+Brentuximab+Vedotin+for+Use+in+Relapsed+Hodgkin+Lymphoma+and+Systemic+Anaplastic+Large+Cell+Lymphoma&doi=10.1038%2Fnbt.2289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma</span></div><div class="casAuthors">Senter, Peter D.; Sievers, Eric L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-637</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Progress was made recently in developing antibody-drug conjugates (ADCs) that can selectively deliver cancer drugs to tumor cells.  In principle, the idea is simple: by attaching drugs to tumor-seeking antibodies, target cells will be killed and nontarget cells will be spared.  In practice, many parameters needed to be addressed to develop safe and effective ADCs, including the expression profiles of tumor vs. normal tissues, the potency of the drug, the linker attaching the drug and placement of the drug on the antibody, and the pharmacokinetic and stability profiles of the resulting ADC.  All these issues had been taken into account in developing brentuximab vedotin (Adcetris), an ADC that recently received accelerated approval by the US Food and Drug Administration for the treatment of relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).  Research is under way to extend the applications of brentuximab vedotin and to advance the field by developing other ADCs with new linker and conjugation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyPib6JxGsSrVg90H21EOLACvtfcHk0liGVNcAqN2_Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFCqtbw%253D&md5=6940eb8178e8c8c150a7b21361e23234</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2289%26sid%3Dliteratum%253Aachs%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DSievers%26aufirst%3DE.%2BL.%26atitle%3DThe%2520Discovery%2520and%2520Development%2520of%2520Brentuximab%2520Vedotin%2520for%2520Use%2520in%2520Relapsed%2520Hodgkin%2520Lymphoma%2520and%2520Systemic%2520Anaplastic%2520Large%2520Cell%2520Lymphoma%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26issue%3D7%26spage%3D631%26epage%3D637%26doi%3D10.1038%2Fnbt.2289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref272"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref272'); return false;" data-citation="" class="refNumLink">272</a></strong><div class="NLM_citation" id="cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T.
K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneekloth, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stulberg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundberg, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holley, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Hydrophobic Tagging-Induced Degradation of Halotag Fusion Proteins</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1038/nchembio.597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnchembio.597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21725302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlCmtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=538-548&author=T.%0AK.+Neklesaauthor=H.+S.+Taeauthor=A.+R.+Schneeklothauthor=M.+J.+Stulbergauthor=T.+W.+Corsonauthor=T.+B.+Sundbergauthor=K.+Rainaauthor=S.+A.+Holleyauthor=C.+M.+Crews&title=Small-Molecule+Hydrophobic+Tagging-Induced+Degradation+of+Halotag+Fusion+Proteins&doi=10.1038%2Fnchembio.597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit272R"><div class="casContent"><span class="casTitleNuber">272</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins</span></div><div class="casAuthors">Neklesa, Taavi K.; Tae, Hyun Seop; Schneekloth, Ashley R.; Stulberg, Michael J.; Corson, Timothy W.; Sundberg, Thomas B.; Raina, Kanak; Holley, Scott A.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">538-543</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ability to regulate any protein of interest in living systems with small mols. remains a challenge.  The authors hypothesized that appending a hydrophobic moiety to the surface of a protein would mimic the partially denatured state of the protein, thus engaging the cellular quality control machinery to induce its proteasomal degrdn.  The authors designed and synthesized bifunctional small mols. to bind a bacterial dehalogenase (the HaloTag protein) and present a hydrophobic group on its surface.  Hydrophobic tagging of the HaloTag protein with an adamantyl moiety induced the degrdn. of cytosolic, isoprenylated and transmembrane HaloTag fusion proteins in cell culture.  The authors demonstrated the in vivo utility of hydrophobic tagging by degrading proteins expressed in zebrafish embryos and by inhibiting Hras1G12V-driven tumor progression in mice.  Therefore, hydrophobic tagging of HaloTag fusion proteins affords small-mol. control over any protein of interest, making it an ideal system for validating potential drug targets in disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYZYbwqzwXZ7Vg90H21EOLACvtfcHk0liGVNcAqN2_Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlCmtL0%253D&md5=1f358f7900884f91a1ac6f1a51664952</span></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.597%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DTae%26aufirst%3DH.%2BS.%26aulast%3DSchneekloth%26aufirst%3DA.%2BR.%26aulast%3DStulberg%26aufirst%3DM.%2BJ.%26aulast%3DCorson%26aufirst%3DT.%2BW.%26aulast%3DSundberg%26aufirst%3DT.%2BB.%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DHolley%26aufirst%3DS.%2BA.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DSmall-Molecule%2520Hydrophobic%2520Tagging-Induced%2520Degradation%2520of%2520Halotag%2520Fusion%2520Proteins%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D538%26epage%3D548%26doi%3D10.1038%2Fnchembio.597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref273"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref273'); return false;" data-citation="" class="refNumLink">273</a></strong><div class="NLM_citation" id="cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcdonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for an Unexpected Mode of Serm-Mediated Er Antagonism</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.molcel.2005.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15893725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=413-424&issue=4&author=Y.+L.+Wuauthor=X.+Yangauthor=Z.+Renauthor=D.+P.+Mcdonnellauthor=J.+D.+Norrisauthor=T.+M.+Willsonauthor=G.+L.+Greene&title=Structural+Basis+for+an+Unexpected+Mode+of+Serm-Mediated+Er+Antagonism&doi=10.1016%2Fj.molcel.2005.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span></div><div class="casAuthors">Wu, Ya-Ling; Yang, Xiaojing; Ren, Zhong; McDonnell, Donald P.; Norris, John D.; Willson, Timothy M.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-424</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tamoxifen is effective for the prevention and treatment of estrogen-dependent breast cancers, but is assocd. with an increased incidence of endometrial tumors.  The authors report the crystal structure of the estrogen receptor α (ERα) ligand binding domain (LBD) bound to the structurally similar compd. GW5638, which has therapeutic potential and does not stimulate the uterus.  Like tamoxifen, GW5638 relocates the carboxy-terminal helix (H12) to the known coactivator-docking site in the ERα LBD.  However, GW5638 repositions residues in H12 through specific contacts with the N terminus of this helix.  In contrast to tamoxifen, the resulting increase in exposed hydrophobic surface of ERα LBD correlates with a significant destabilization of ERα in MCF-7 cells.  Thus, the GW5638-ERα LBD structure reveals an unexpected mode of SERM-mediated ER antagonism, in which the stability of ERα is decreased through an altered position of H12.  This dual mechanism of antagonism may explain why GW5638 can inhibit tamoxifen-resistant breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBuyhLNSdbQbVg90H21EOLACvtfcHk0liGVNcAqN2_Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D&md5=c60e01b31b57c07b934da01a34efb255</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DMcdonnell%26aufirst%3DD.%2BP.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DStructural%2520Basis%2520for%2520an%2520Unexpected%2520Mode%2520of%2520Serm-Mediated%2520Er%2520Antagonism%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26issue%3D4%26spage%3D413%26epage%3D424%26doi%3D10.1016%2Fj.molcel.2005.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref274"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref274'); return false;" data-citation="" class="refNumLink">274</a></strong><div class="NLM_citation" id="cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cyrus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">Two-Headed Protac: An Effective New Tool for Targeted Protein Degradation</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1531</span>– <span class="NLM_lpage">1534</span>, <span class="refDoi"> DOI: 10.1002/cbic.201000222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fcbic.201000222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20572252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Cksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1531-1534&issue=11&author=K.+Cyrusauthor=M.+Wehenkelauthor=E.+Y.+Choiauthor=H.+Swansonauthor=K.+B.+Kim&title=Two-Headed+Protac%3A+An+Effective+New+Tool+for+Targeted+Protein+Degradation&doi=10.1002%2Fcbic.201000222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">Two-Headed PROTAC: an Effective New Tool for Targeted Protein Degradation</span></div><div class="casAuthors">Cyrus, Kedra; Wehenkel, Marie; Choi, Eun-Young; Swanson, Hollie; Kim, Kyung-Bo</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1531-1534</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system (UPS) is the principle conduit for protein turnover in all eukaryotic cells.  Exploiting the UPS, the authors and others have developed a novel class of small mols., the PROTACs (proteolysis targeting chimeric) mols., designed to induce ubiquitination and degrdn. of targeted proteins.  A new class of PROTACs reported herein use a chimeric mol. that consists of two estradiol ligands linked to a von Hippel-Lindau (pVHL) E3 ubiquitin ligase-recognition motif-targeting pentapeptide.  Because the PROTAC functions as a bridging mol. that promotes the recruitment of a target protein to an E3 ligase complex, the authors envisioned that the introduction of two ligands might recruit the binding protein to an E3 ubiquitin ligase more effectively than the one-ligand PROTAC system.  The authors' proof-of-concept study clearly showed that the two-headed PROTAC gives superior estrogen receptor (ER) degrdn. to one-headed PROTACs.  The two-headed PROTAC also provides improved binding affinity between the PROTAC and the ER.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqznfcen3kCYbVg90H21EOLACvtfcHk0liGVNcAqN2_Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Cksr8%253D&md5=ecbb816d417627eacdfdf1fe6a79f4e6</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201000222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201000222%26sid%3Dliteratum%253Aachs%26aulast%3DCyrus%26aufirst%3DK.%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DE.%2BY.%26aulast%3DSwanson%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DTwo-Headed%2520Protac%253A%2520An%2520Effective%2520New%2520Tool%2520for%2520Targeted%2520Protein%2520Degradation%26jtitle%3DChemBioChem%26date%3D2010%26volume%3D11%26issue%3D11%26spage%3D1531%26epage%3D1534%26doi%3D10.1002%2Fcbic.201000222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref275"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref275'); return false;" data-citation="" class="refNumLink">275</a></strong><div class="NLM_citation" id="cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced Protein Degradation: An Emerging Drug Discovery Paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&issue=2&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+Protein+Degradation%3A+An+Emerging+Drug+Discovery+Paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0lhSF0B2COHTlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520Protein%2520Degradation%253A%2520An%2520Emerging%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D2%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257'],'ref258':['cit258'],'ref259':['cit259'],'ref260':['cit260'],'ref261':['cit261'],'ref262':['cit262'],'ref263':['cit263'],'ref264':['cit264'],'ref265':['cit265'],'ref266':['cit266'],'ref267':['cit267'],'ref268':['cit268'],'ref269':['cit269'],'ref270':['cit270'],'ref271':['cit271'],'ref272':['cit272'],'ref273':['cit273'],'ref274':['cit274'],'ref275':['cit275']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 59 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Antonino N. Fallica, Valeria Pittalà, Maria N. Modica, Loredana Salerno, Giuseppe Romeo, Agostino Marrazzo, Mohamed A. Helal, <span class="NLM_string-name hlFld-ContribAuthor">Sebastiano Intagliata</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7926-7962. <a href="https://doi.org/10.1021/acs.jmedchem.0c02265" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02265%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Bof%252BSigma%252BReceptor%252BLigands%252Bas%252BCytotoxic%252BAgents%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DFallica%26aufirst%3DAntonino%2BN.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D31122020%26date%3D02062021%26volume%3D64%26issue%3D12%26spage%3D7926%26epage%3D7962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lukas Gorecki, Elisa Uliassi, Manuela Bartolini, Jana Janockova, Martina Hrabinova, Vendula Hepnarova, Lukas Prchal, Lubica Muckova, Jaroslav Pejchal, Jana Z. Karasova, Eva Mezeiova, Marketa Benkova, Tereza Kobrlova, Ondrej Soukup, Sabrina Petralla, Barbara Monti, Jan Korabecny, <span class="NLM_string-name hlFld-ContribAuthor">Maria Laura Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2021,</strong> <em>12 </em>
                                    (9)
                                     , 1698-1715. <a href="https://doi.org/10.1021/acschemneuro.1c00184" title="DOI URL">https://doi.org/10.1021/acschemneuro.1c00184</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.1c00184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.1c00184%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DPhenothiazine-Tacrine%252BHeterodimers%25253A%252BPursuing%252BMultitarget%252BDirected%252BApproach%252Bin%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DGorecki%26aufirst%3DLukas%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D26032021%26date%3D07042021%26date%3D14042021%26volume%3D12%26issue%3D9%26spage%3D1698%26epage%3D1715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michele Rossi, Michela Freschi, Luciana de Camargo Nascente, Alessandra Salerno, Sarah de Melo Viana Teixeira, Florian Nachon, Fabien Chantegreil, Ondrej Soukup, Lukáš Prchal, Marco Malaguti, Christian Bergamini, Manuela Bartolini, Cristina Angeloni, Silvana Hrelia, Luiz Antonio Soares Romeiro, <span class="NLM_string-name hlFld-ContribAuthor">Maria Laura Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4972-4990. <a href="https://doi.org/10.1021/acs.jmedchem.1c00048" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00048%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSustainable%252BDrug%252BDiscovery%252Bof%252BMulti-Target-Directed%252BLigands%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DRossi%26aufirst%3DMichele%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D11012021%26date%3D08042021%26volume%3D64%26issue%3D8%26spage%3D4972%26epage%3D4990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Feng He, C. James Chou, Matthias Scheiner, Eleonora Poeta, Natalia Yuan Chen, Sandra Gunesch, Matthias Hoffmann, Christoph Sotriffer, Barbara Monti, Tangui Maurice, <span class="NLM_string-name hlFld-ContribAuthor">Michael Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer’s Disease Mouse Model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3794-3812. <a href="https://doi.org/10.1021/acs.jmedchem.0c01940" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01940</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01940%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMelatonin-%252Band%252BFerulic%252BAcid-Based%252BHDAC6%252BSelective%252BInhibitors%252BExhibit%252BPronounced%252BImmunomodulatory%252BEffects%252BIn%252BVitro%252Band%252BNeuroprotective%252BEffects%252Bin%252Ba%252BPharmacological%252BAlzheimer%2525E2%252580%252599s%252BDisease%252BMouse%252BModel%26aulast%3DHe%26aufirst%3DFeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D09112020%26date%3D26032021%26volume%3D64%26issue%3D7%26spage%3D3794%26epage%3D3812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mónica García, Marina Virgili, Mònica Alonso, Carles Alegret, Joan Farran, Begoña Fernández, Magda Bordas, Rosalia Pascual, Javier Burgueño, Alba Vidal-Torres, Antonio R. Fernández de Henestrosa, Eva Ayet, Manuel Merlos, Jose Miguel Vela, Carlos R. Plata-Salamán, <span class="NLM_string-name hlFld-ContribAuthor">Carmen Almansa</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ1 Receptor Antagonist Clinical Candidate for the Treatment of Pain. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15508-15526. <a href="https://doi.org/10.1021/acs.jmedchem.0c01127" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01127%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BEST73502%25252C%252Ba%252BDual%252B%2525CE%2525BC-Opioid%252BReceptor%252BAgonist%252Band%252B%2525CF%2525831%252BReceptor%252BAntagonist%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BPain%26aulast%3DGarc%25C3%25ADa%26aufirst%3DM%25C3%25B3nica%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01072020%26date%3D16102020%26volume%3D63%26issue%3D24%26spage%3D15508%26epage%3D15526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christian Feldmann, Dimitar Yonchev, Dagmar Stumpfe, <span class="NLM_string-name hlFld-ContribAuthor">Jürgen Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Data Analysis and Diagnostic Machine Learning Reveal Differences between Compounds with Single- and Multitarget Activity. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2020,</strong> <em>17 </em>
                                    (12)
                                     , 4652-4666. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00901" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00901</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00901%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DSystematic%252BData%252BAnalysis%252Band%252BDiagnostic%252BMachine%252BLearning%252BReveal%252BDifferences%252Bbetween%252BCompounds%252Bwith%252BSingle-%252Band%252BMultitarget%252BActivity%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04092020%26date%3D23102020%26date%3D02102020%26date%3D05112020%26volume%3D17%26issue%3D12%26spage%3D4652%26epage%3D4666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Moustafa T. Gabr, <span class="NLM_string-name hlFld-ContribAuthor">Francesca Peccati</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Targeting of Monomeric Tau and α-Synuclein Aggregation: A New Multitarget Therapeutic Strategy for Neurodegeneration. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (14)
                                     , 2051-2057. <a href="https://doi.org/10.1021/acschemneuro.0c00281" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00281%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DDual%252BTargeting%252Bof%252BMonomeric%252BTau%252Band%252B%2525CE%2525B1-Synuclein%252BAggregation%25253A%252BA%252BNew%252BMultitarget%252BTherapeutic%252BStrategy%252Bfor%252BNeurodegeneration%26aulast%3DGabr%26aufirst%3DMoustafa%2BT.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11052020%26date%3D24062020%26date%3D29062020%26date%3D24062020%26volume%3D11%26issue%3D14%26spage%3D2051%26epage%3D2057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Loganathan Rangasamy, Irene Ortín, José María Zapico, Claire Coderch, Ana Ramos, <span class="NLM_string-name hlFld-ContribAuthor">Beatriz de Pascual-Teresa</span>. </span><span class="cited-content_cbyCitation_article-title">New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (5)
                                     , 713-719. <a href="https://doi.org/10.1021/acsmedchemlett.9b00561" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00561</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00561%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNew%252BDual%252BCK2%25252FHDAC1%252BInhibitors%252Bwith%252BNanomolar%252BInhibitory%252BActivity%252Bagainst%252BBoth%252BEnzymes%26aulast%3DRangasamy%26aufirst%3DLoganathan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D30112019%26date%3D07042020%26date%3D10042020%26date%3D07042020%26volume%3D11%26issue%3D5%26spage%3D713%26epage%3D719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Santosh Kumar  Behera</span>, <span class="hlFld-ContribAuthor ">Nazmina  Vhora</span>, <span class="hlFld-ContribAuthor ">Darshan  Contractor</span>, <span class="hlFld-ContribAuthor ">Amit  Shard</span>, <span class="hlFld-ContribAuthor ">Dinesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Kiran  Kalia</span>, <span class="hlFld-ContribAuthor ">Alok  Jain</span>. </span><span class="cited-content_cbyCitation_article-title">Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-86712-2" title="DOI URL">https://doi.org/10.1038/s41598-021-86712-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-86712-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-86712-2%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DComputational%252Bdrug%252Brepurposing%252Bstudy%252Belucidating%252Bsimultaneous%252Binhibition%252Bof%252Bentry%252Band%252Breplication%252Bof%252Bnovel%252Bcorona%252Bvirus%252Bby%252BGrazoprevir%26aulast%3DBehera%26aufirst%3DSantosh%2BKumar%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Feldmann</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Machine learning reveals that structural features distinguishing promiscuous and non-promiscuous compounds depend on target combinations. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-87042-z" title="DOI URL">https://doi.org/10.1038/s41598-021-87042-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-87042-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-87042-z%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DMachine%252Blearning%252Breveals%252Bthat%252Bstructural%252Bfeatures%252Bdistinguishing%252Bpromiscuous%252Band%252Bnon-promiscuous%252Bcompounds%252Bdepend%252Bon%252Btarget%252Bcombinations%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Zhuang</span>, <span class="hlFld-ContribAuthor ">Jiaying  Xiong</span>, <span class="hlFld-ContribAuthor ">Shuaishuai  Hao</span>, <span class="hlFld-ContribAuthor ">Wei  Du</span>, <span class="hlFld-ContribAuthor ">Zhenming  Liu</span>, <span class="hlFld-ContribAuthor ">Bifeng  Liu</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhang</span>, <span class="hlFld-ContribAuthor ">Yin  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional μ opioid and σ1 receptor ligands as novel analgesics with reduced side effects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113658. <a href="https://doi.org/10.1016/j.ejmech.2021.113658" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113658%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBifunctional%252B%2525CE%2525BC%252Bopioid%252Band%252B%2525CF%2525831%252Breceptor%252Bligands%252Bas%252Bnovel%252Banalgesics%252Bwith%252Breduced%252Bside%252Beffects%26aulast%3DZhuang%26aufirst%3DTao%26date%3D2021%26volume%3D223%26spage%3D113658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Chao  Duan</span>, <span class="hlFld-ContribAuthor ">Shao-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Jing  Shi</span>, <span class="hlFld-ContribAuthor ">Lin-Feng  Jin</span>, <span class="hlFld-ContribAuthor ">Tong  Yu</span>, <span class="hlFld-ContribAuthor ">Yu  Song</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Guan</span>. </span><span class="cited-content_cbyCitation_article-title">Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113588. <a href="https://doi.org/10.1016/j.ejmech.2021.113588" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113588</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113588%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DResearch%252Bprogress%252Bof%252Bdual%252Binhibitors%252Btargeting%252Bcrosstalk%252Bbetween%252Bhistone%252Bepigenetic%252Bmodulators%252Bfor%252Bcancer%252Btherapy%26aulast%3DDuan%26aufirst%3DYing-Chao%26date%3D2021%26volume%3D222%26spage%3D113588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianan  Guo</span>, <span class="hlFld-ContribAuthor ">Yujia  Zhang</span>, <span class="hlFld-ContribAuthor ">Changjun  Zhang</span>, <span class="hlFld-ContribAuthor ">Chuansheng  Yao</span>, <span class="hlFld-ContribAuthor ">Jingqi  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoying  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhichao  Zhong</span>, <span class="hlFld-ContribAuthor ">Jiamin  Ge</span>, <span class="hlFld-ContribAuthor ">Tao  Zhou</span>, <span class="hlFld-ContribAuthor ">Renren  Bai</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">N-Propargylamine-hydroxypyridinone hybrids as multitarget agents for the treatment of Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>113 </em>, 105013. <a href="https://doi.org/10.1016/j.bioorg.2021.105013" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105013%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DN-Propargylamine-hydroxypyridinone%252Bhybrids%252Bas%252Bmultitarget%252Bagents%252Bfor%252Bthe%252Btreatment%252Bof%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DGuo%26aufirst%3DJianan%26date%3D2021%26volume%3D113%26spage%3D105013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatima Y.  Adeowo</span>, <span class="hlFld-ContribAuthor ">Murtala A.  Ejalonibu</span>, <span class="hlFld-ContribAuthor ">Ahmed A.  Elrashedy</span>, <span class="hlFld-ContribAuthor ">Monsurat M.  Lawal</span>, <span class="hlFld-ContribAuthor ">Hezekiel M.  Kumalo</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-target approach for Alzheimer’s disease treatment: computational biomolecular modeling of cholinesterase enzymes with a novel 4-
              N
              -phenylaminoquinoline derivative reveal promising potentials. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>39 </em>
                                    (11)
                                     , 3825-3841. <a href="https://doi.org/10.1080/07391102.2020.1826129" title="DOI URL">https://doi.org/10.1080/07391102.2020.1826129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1826129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1826129%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DMulti-target%252Bapproach%252Bfor%252BAlzheimer%2525E2%252580%252599s%252Bdisease%252Btreatment%25253A%252Bcomputational%252Bbiomolecular%252Bmodeling%252Bof%252Bcholinesterase%252Benzymes%252Bwith%252Ba%252Bnovel%252B4-%252BN%252B-phenylaminoquinoline%252Bderivative%252Breveal%252Bpromising%252Bpotentials%26aulast%3DAdeowo%26aufirst%3DFatima%2BY.%26date%3D2021%26date%3D2020%26volume%3D39%26issue%3D11%26spage%3D3825%26epage%3D3841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Romeo</span>, <span class="hlFld-ContribAuthor ">Valeria  Ciaffaglione</span>, <span class="hlFld-ContribAuthor ">Emanuele  Amata</span>, <span class="hlFld-ContribAuthor ">Maria  Dichiara</span>, <span class="hlFld-ContribAuthor ">Loredana  Calabrese</span>, <span class="hlFld-ContribAuthor ">Luca  Vanella</span>, <span class="hlFld-ContribAuthor ">Valeria  Sorrenti</span>, <span class="hlFld-ContribAuthor ">Salvo  Grosso</span>, <span class="hlFld-ContribAuthor ">Agata Grazia  D’Amico</span>, <span class="hlFld-ContribAuthor ">Velia  D’Agata</span>, <span class="hlFld-ContribAuthor ">Sebastiano  Intagliata</span>, <span class="hlFld-ContribAuthor ">Loredana  Salerno</span>. </span><span class="cited-content_cbyCitation_article-title">Combination of Heme Oxygenase-1 Inhibition and Sigma Receptor Modulation for Anticancer Activity. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (13)
                                     , 3860. <a href="https://doi.org/10.3390/molecules26133860" title="DOI URL">https://doi.org/10.3390/molecules26133860</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26133860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26133860%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DCombination%252Bof%252BHeme%252BOxygenase-1%252BInhibition%252Band%252BSigma%252BReceptor%252BModulation%252Bfor%252BAnticancer%252BActivity%26aulast%3DRomeo%26aufirst%3DGiuseppe%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D13%26spage%3D3860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heng  Zhang</span>, <span class="hlFld-ContribAuthor ">Qing  Song</span>, <span class="hlFld-ContribAuthor ">Guangjun  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongcheng  Cao</span>, <span class="hlFld-ContribAuthor ">Xiaoming  Qiang</span>, <span class="hlFld-ContribAuthor ">Xiuxiu  Liu</span>, <span class="hlFld-ContribAuthor ">Yong  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Phthalimide‐(
              N
              ‐alkylbenzylamine) cysteamide hybrids as multifunctional agents against Alzheimer’s disease: Design, synthesis, and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.1111/cbdd.13905" title="DOI URL">https://doi.org/10.1111/cbdd.13905</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13905%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DPhthalimide%2525E2%252580%252590%252528%252BN%252B%2525E2%252580%252590alkylbenzylamine%252529%252Bcysteamide%252Bhybrids%252Bas%252Bmultifunctional%252Bagents%252Bagainst%252BAlzheimer%2525E2%252580%252599s%252Bdisease%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%26aulast%3DZhang%26aufirst%3DHeng%26date%3D2021%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei‐Jung  Chiu</span>, <span class="hlFld-ContribAuthor ">Jin‐Yu  Chen</span>, <span class="hlFld-ContribAuthor ">Shih‐I  Liu</span>, <span class="hlFld-ContribAuthor ">Indrajeet J.  Barve</span>, <span class="hlFld-ContribAuthor ">Wan‐Wen  Huang</span>, <span class="hlFld-ContribAuthor ">Chung‐Ming  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">One‐pot Synthesis of Isoquinoline‐Fused Isoquinolines via Intramolecular Hydroamination/Aza‐Claisen Type Rearrangement Cascade. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (11)
                                     , 2834-2842. <a href="https://doi.org/10.1002/adsc.202001576" title="DOI URL">https://doi.org/10.1002/adsc.202001576</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202001576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202001576%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DOne%2525E2%252580%252590pot%252BSynthesis%252Bof%252BIsoquinoline%2525E2%252580%252590Fused%252BIsoquinolines%252Bvia%252BIntramolecular%252BHydroamination%25252FAza%2525E2%252580%252590Claisen%252BType%252BRearrangement%252BCascade%26aulast%3DChiu%26aufirst%3DWei%25E2%2580%2590Jung%26date%3D2021%26date%3D2021%26volume%3D363%26issue%3D11%26spage%3D2834%26epage%3D2842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Pasieka</span>, <span class="hlFld-ContribAuthor ">Dawid  Panek</span>, <span class="hlFld-ContribAuthor ">Jakub  Jończyk</span>, <span class="hlFld-ContribAuthor ">Justyna  Godyń</span>, <span class="hlFld-ContribAuthor ">Natalia  Szałaj</span>, <span class="hlFld-ContribAuthor ">Gniewomir  Latacz</span>, <span class="hlFld-ContribAuthor ">Julia  Tabor</span>, <span class="hlFld-ContribAuthor ">Eva  Mezeiova</span>, <span class="hlFld-ContribAuthor ">Fabien  Chantegreil</span>, <span class="hlFld-ContribAuthor ">José  Dias</span>, <span class="hlFld-ContribAuthor ">Damijan  Knez</span>, <span class="hlFld-ContribAuthor ">Junfeng  Lu</span>, <span class="hlFld-ContribAuthor ">Rongbiao  Pi</span>, <span class="hlFld-ContribAuthor ">Jan  Korabecny</span>, <span class="hlFld-ContribAuthor ">Xavier  Brazzolotto</span>, <span class="hlFld-ContribAuthor ">Stanislav  Gobec</span>, <span class="hlFld-ContribAuthor ">Georg  Höfner</span>, <span class="hlFld-ContribAuthor ">Klaus  Wanner</span>, <span class="hlFld-ContribAuthor ">Anna  Więckowska</span>, <span class="hlFld-ContribAuthor ">Barbara  Malawska</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of multifunctional anti-Alzheimer’s agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and γ-aminobutyric acid transporters. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113397. <a href="https://doi.org/10.1016/j.ejmech.2021.113397" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113397</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113397%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bmultifunctional%252Banti-Alzheimer%2525E2%252580%252599s%252Bagents%252Bwith%252Ba%252Bunique%252Bmechanism%252Bof%252Baction%252Bincluding%252Binhibition%252Bof%252Bthe%252Benzyme%252Bbutyrylcholinesterase%252Band%252B%2525CE%2525B3-aminobutyric%252Bacid%252Btransporters%26aulast%3DPasieka%26aufirst%3DAnna%26date%3D2021%26volume%3D218%26spage%3D113397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tanay  Dalvi</span>, <span class="hlFld-ContribAuthor ">Bhaskar  Dewangan</span>, <span class="hlFld-ContribAuthor ">Gopal  Agarwal</span>, <span class="hlFld-ContribAuthor ">Dattatray  Shinde Suchita</span>, <span class="hlFld-ContribAuthor ">Alok  Jain</span>, <span class="hlFld-ContribAuthor ">Akshay  Srivastava</span>, <span class="hlFld-ContribAuthor ">Bichismita  Sahu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and in-vitro evaluation of fluorinated triazoles as multi-target directed ligands for Alzheimer disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>42 </em>, 127999. <a href="https://doi.org/10.1016/j.bmcl.2021.127999" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127999</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127999%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bin-vitro%252Bevaluation%252Bof%252Bfluorinated%252Btriazoles%252Bas%252Bmulti-target%252Bdirected%252Bligands%252Bfor%252BAlzheimer%252Bdisease%26aulast%3DDalvi%26aufirst%3DTanay%26date%3D2021%26volume%3D42%26spage%3D127999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Justyna  Godyń</span>, <span class="hlFld-ContribAuthor ">Paula  Zaręba</span>, <span class="hlFld-ContribAuthor ">Dorota  Łażewska</span>, <span class="hlFld-ContribAuthor ">Dorota  Stary</span>, <span class="hlFld-ContribAuthor ">David  Reiner-Link</span>, <span class="hlFld-ContribAuthor ">Annika  Frank</span>, <span class="hlFld-ContribAuthor ">Gniewomir  Latacz</span>, <span class="hlFld-ContribAuthor ">Szczepan  Mogilski</span>, <span class="hlFld-ContribAuthor ">Maria  Kaleta</span>, <span class="hlFld-ContribAuthor ">Agata  Doroz-Płonka</span>, <span class="hlFld-ContribAuthor ">Annamaria  Lubelska</span>, <span class="hlFld-ContribAuthor ">Ewelina  Honkisz-Orzechowska</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Olejarz-Maciej</span>, <span class="hlFld-ContribAuthor ">Jadwiga  Handzlik</span>, <span class="hlFld-ContribAuthor ">Holger  Stark</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Kieć-Kononowicz</span>, <span class="hlFld-ContribAuthor ">Barbara  Malawska</span>, <span class="hlFld-ContribAuthor ">Marek  Bajda</span>. </span><span class="cited-content_cbyCitation_article-title">Cyanobiphenyls: novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>7 </em>, 105129. <a href="https://doi.org/10.1016/j.bioorg.2021.105129" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105129%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DCyanobiphenyls%25253A%252Bnovel%252BH3%252Breceptor%252Bligands%252Bwith%252Bcholinesterase%252Band%252BMAO%252BB%252Binhibitory%252Bactivity%252Bas%252Bmultitarget%252Bcompounds%252Bfor%252Bpotential%252Btreatment%252Bof%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DGody%25C5%2584%26aufirst%3DJustyna%26date%3D2021%26volume%3D7%26spage%3D105129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manuela  Jörg</span>, <span class="hlFld-ContribAuthor ">Katrina S.  Madden</span>. </span><span class="cited-content_cbyCitation_article-title">The right tools for the job: the central role for next generation chemical probes and chemistry-based target deconvolution methods in phenotypic drug discovery. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 646-665. <a href="https://doi.org/10.1039/D1MD00022E" title="DOI URL">https://doi.org/10.1039/D1MD00022E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00022E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00022E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bright%252Btools%252Bfor%252Bthe%252Bjob%25253A%252Bthe%252Bcentral%252Brole%252Bfor%252Bnext%252Bgeneration%252Bchemical%252Bprobes%252Band%252Bchemistry-based%252Btarget%252Bdeconvolution%252Bmethods%252Bin%252Bphenotypic%252Bdrug%252Bdiscovery%26aulast%3DJ%25C3%25B6rg%26aufirst%3DManuela%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D5%26spage%3D646%26epage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adrianne  Wallace-Povirk</span>, <span class="hlFld-ContribAuthor ">Nian  Tong</span>, <span class="hlFld-ContribAuthor ">Jennifer  Wong-Roushar</span>, <span class="hlFld-ContribAuthor ">Carrie  O'Connor</span>, <span class="hlFld-ContribAuthor ">Xilin  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhanjun  Hou</span>, <span class="hlFld-ContribAuthor ">Xun  Bao</span>, <span class="hlFld-ContribAuthor ">Gloria E.  Garcia</span>, <span class="hlFld-ContribAuthor ">Jing  Li</span>, <span class="hlFld-ContribAuthor ">Seongho  Kim</span>, <span class="hlFld-ContribAuthor ">Charles E.  Dann</span>, <span class="hlFld-ContribAuthor ">Larry H.  Matherly</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>37 </em>, 116093. <a href="https://doi.org/10.1016/j.bmc.2021.116093" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116093%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B6-substituted%252Bthieno%25255B2%25252C3-d%25255Dpyrimidine%252Banalogs%252Bas%252Bdual%252Binhibitors%252Bof%252Bglycinamide%252Bribonucleotide%252Bformyltransferase%252Band%252B5-aminoimidazole-4-carboxamide%252Bribonucleotide%252Bformyltransferase%252Bin%252Bde%252Bnovo%252Bpurine%252Bnucleotide%252Bbiosynthesis%252Bin%252Bfolate%252Breceptor%252Bexpressing%252Bhuman%252Btumors%26aulast%3DWallace-Povirk%26aufirst%3DAdrianne%26date%3D2021%26volume%3D37%26spage%3D116093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dagmar  Stumpfe</span>, <span class="hlFld-ContribAuthor ">Alexander  Hoch</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Introducing the metacore concept for multi-target ligand design. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 628-635. <a href="https://doi.org/10.1039/D1MD00056J" title="DOI URL">https://doi.org/10.1039/D1MD00056J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00056J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00056J%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DIntroducing%252Bthe%252Bmetacore%252Bconcept%252Bfor%252Bmulti-target%252Bligand%252Bdesign%26aulast%3DStumpfe%26aufirst%3DDagmar%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D628%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shruti  Choudhary</span>, <span class="hlFld-ContribAuthor ">Arpit  Doshi</span>, <span class="hlFld-ContribAuthor ">Lerin  Luckett-Chastain</span>, <span class="hlFld-ContribAuthor ">Michael  Ihnat</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Susan L.  Mooberry</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>35 </em>, 116061. <a href="https://doi.org/10.1016/j.bmc.2021.116061" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116061%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DPotential%252Bof%252Bsubstituted%252Bquinazolines%252Bto%252Binteract%252Bwith%252Bmultiple%252Btargets%252Bin%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DChoudhary%26aufirst%3DShruti%26date%3D2021%26volume%3D35%26spage%3D116061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhongcheng  Cao</span>, <span class="hlFld-ContribAuthor ">Qing  Song</span>, <span class="hlFld-ContribAuthor ">Guangjun  Yu</span>, <span class="hlFld-ContribAuthor ">Zhuoling  Liu</span>, <span class="hlFld-ContribAuthor ">Shiqing  Cong</span>, <span class="hlFld-ContribAuthor ">Zhenghuai  Tan</span>, <span class="hlFld-ContribAuthor ">Yong  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>35 </em>, 116074. <a href="https://doi.org/10.1016/j.bmc.2021.116074" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116074%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B3-benzylidene%25252Fbenzylphthalide%252BMannich%252Bbase%252Bderivatives%252Bas%252Bpotential%252Bmultifunctional%252Bagents%252Bfor%252Bthe%252Btreatment%252Bof%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DCao%26aufirst%3DZhongcheng%26date%3D2021%26volume%3D35%26spage%3D116074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniela  Malafaia</span>, <span class="hlFld-ContribAuthor ">Ana  Oliveira</span>, <span class="hlFld-ContribAuthor ">Pedro A.  Fernandes</span>, <span class="hlFld-ContribAuthor ">Maria J.  Ramos</span>, <span class="hlFld-ContribAuthor ">Hélio M. T.  Albuquerque</span>, <span class="hlFld-ContribAuthor ">Artur M. S.  Silva</span>. </span><span class="cited-content_cbyCitation_article-title">Chromeno[3,4-b]xanthones as First-in-Class AChE and Aβ Aggregation Dual-Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (8)
                                     , 4145. <a href="https://doi.org/10.3390/ijms22084145" title="DOI URL">https://doi.org/10.3390/ijms22084145</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22084145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22084145%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DChromeno%25255B3%25252C4-b%25255Dxanthones%252Bas%252BFirst-in-Class%252BAChE%252Band%252BA%2525CE%2525B2%252BAggregation%252BDual-Inhibitors%26aulast%3DMalafaia%26aufirst%3DDaniela%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D8%26spage%3D4145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu. A.  Kovygin</span>, <span class="hlFld-ContribAuthor ">D. Yu.  Vandyshev</span>, <span class="hlFld-ContribAuthor ">I. V.  Ledenyova</span>, <span class="hlFld-ContribAuthor ">E. A.  Kosheleva</span>, <span class="hlFld-ContribAuthor ">V. A.  Polikarchuk</span>, <span class="hlFld-ContribAuthor ">O. A.  Kozaderov</span>, <span class="hlFld-ContribAuthor ">Kh. S.  Shikhaliev</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient synthesis of (5-oxo-6,7-dihydro-4H-[1,2,4]triazolo-[1,5-a]pyrimidin-6-yl)acetanilides based on the recyclization of N-arylitaconimides with 3-amino[1,2,4]triazoles. </span><span class="cited-content_cbyCitation_journal-name">Russian Chemical Bulletin</span><span> <strong>2021,</strong> <em>70 </em>
                                    (3)
                                     , 520-526. <a href="https://doi.org/10.1007/s11172-021-3118-2" title="DOI URL">https://doi.org/10.1007/s11172-021-3118-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11172-021-3118-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11172-021-3118-2%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Chemical%2520Bulletin%26atitle%3DEfficient%252Bsynthesis%252Bof%252B%2525285-oxo-6%25252C7-dihydro-4H-%25255B1%25252C2%25252C4%25255Dtriazolo-%25255B1%25252C5-a%25255Dpyrimidin-6-yl%252529acetanilides%252Bbased%252Bon%252Bthe%252Brecyclization%252Bof%252BN-arylitaconimides%252Bwith%252B3-amino%25255B1%25252C2%25252C4%25255Dtriazoles%26aulast%3DKovygin%26aufirst%3DYu.%2BA.%26date%3D2021%26date%3D2021%26volume%3D70%26issue%3D3%26spage%3D520%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianbo  Sun</span>, <span class="hlFld-ContribAuthor ">Hui  Zhong</span>, <span class="hlFld-ContribAuthor ">Kun  Wang</span>, <span class="hlFld-ContribAuthor ">Na  Li</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Gains from no real PAINS: Where ‘Fair Trial Strategy’ stands in the development of multi-target ligands. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>13 </em><a href="https://doi.org/10.1016/j.apsb.2021.02.023" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.02.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.02.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.02.023%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DGains%252Bfrom%252Bno%252Breal%252BPAINS%25253A%252BWhere%252B%2525E2%252580%252598Fair%252BTrial%252BStrategy%2525E2%252580%252599%252Bstands%252Bin%252Bthe%252Bdevelopment%252Bof%252Bmulti-target%252Bligands%26aulast%3DSun%26aufirst%3DJianbo%26date%3D2021%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniela  Malafaia</span>, <span class="hlFld-ContribAuthor ">Hélio M.T.  Albuquerque</span>, <span class="hlFld-ContribAuthor ">Artur M.S.  Silva</span>. </span><span class="cited-content_cbyCitation_article-title">Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113209. <a href="https://doi.org/10.1016/j.ejmech.2021.113209" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113209%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAmyloid-%2525CE%2525B2%252Band%252Btau%252Baggregation%252Bdual-inhibitors%25253A%252BA%252Bsynthetic%252Band%252Bstructure-activity%252Brelationship%252Bfocused%252Breview%26aulast%3DMalafaia%26aufirst%3DDaniela%26date%3D2021%26volume%3D214%26spage%3D113209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikita M.  Sotnikov</span>, <span class="hlFld-ContribAuthor ">Yurii А.  Kovygin</span>, <span class="hlFld-ContribAuthor ">Dmitrii Yu.  Vandyshev</span>, <span class="hlFld-ContribAuthor ">Irina V.  Ledenyova</span>, <span class="hlFld-ContribAuthor ">Yevgeniya А.  Kosheleva</span>, <span class="hlFld-ContribAuthor ">Oleg А.  Kozadyorov</span>, <span class="hlFld-ContribAuthor ">Khidmet S.  Shikhaliev</span>. </span><span class="cited-content_cbyCitation_article-title">Recyclization of N-arylitaconimides with carboximidamides – a novel efficient method for the synthesis of 2-(2-amino-6-oxo- 1,4,5,6-tetrahydropyrimidin-5-yl)acetanilides. </span><span class="cited-content_cbyCitation_journal-name">Chemistry of Heterocyclic Compounds</span><span> <strong>2021,</strong> <em>57 </em>
                                    (2)
                                     , 154-158. <a href="https://doi.org/10.1007/s10593-021-02887-6" title="DOI URL">https://doi.org/10.1007/s10593-021-02887-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10593-021-02887-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10593-021-02887-6%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520of%2520Heterocyclic%2520Compounds%26atitle%3DRecyclization%252Bof%252BN-arylitaconimides%252Bwith%252Bcarboximidamides%252B%2525E2%252580%252593%252Ba%252Bnovel%252Befficient%252Bmethod%252Bfor%252Bthe%252Bsynthesis%252Bof%252B2-%2525282-amino-6-oxo-%252B1%25252C4%25252C5%25252C6-tetrahydropyrimidin-5-yl%252529acetanilides%26aulast%3DSotnikov%26aufirst%3DNikita%2BM.%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D2%26spage%3D154%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">You  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin  Lu</span>, <span class="hlFld-ContribAuthor ">Chenxi  Du</span>, <span class="hlFld-ContribAuthor ">Yijun  Liu</span>, <span class="hlFld-ContribAuthor ">Yifan  Wang</span>, <span class="hlFld-ContribAuthor ">Kwon Ho  Hong</span>, <span class="hlFld-ContribAuthor ">Yao  Chen</span>, <span class="hlFld-ContribAuthor ">Haopeng  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>34 </em>, 127756. <a href="https://doi.org/10.1016/j.bmcl.2020.127756" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127756</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127756%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252BBuChE-IDO1%252Binhibitors%252Bfrom%252Bsertaconazole%25253A%252BVirtual%252Bscreening%25252C%252Bchemical%252Boptimization%252Band%252Bmolecular%252Bmodeling%252Bstudies%26aulast%3DZhou%26aufirst%3DYou%26date%3D2021%26volume%3D34%26spage%3D127756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Piotr  Stępnicki</span>, <span class="hlFld-ContribAuthor ">Magda  Kondej</span>, <span class="hlFld-ContribAuthor ">Oliwia  Koszła</span>, <span class="hlFld-ContribAuthor ">Justyna  Żuk</span>, <span class="hlFld-ContribAuthor ">Agnieszka A.  Kaczor</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-targeted drug design strategies for the treatment of schizophrenia. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (1)
                                     , 101-114. <a href="https://doi.org/10.1080/17460441.2020.1816962" title="DOI URL">https://doi.org/10.1080/17460441.2020.1816962</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2020.1816962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2020.1816962%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DMulti-targeted%252Bdrug%252Bdesign%252Bstrategies%252Bfor%252Bthe%252Btreatment%252Bof%252Bschizophrenia%26aulast%3DSt%25C4%2599pnicki%26aufirst%3DPiotr%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D1%26spage%3D101%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyu  Qing</span>, <span class="hlFld-ContribAuthor ">Shiwei  Wang</span>, <span class="hlFld-ContribAuthor ">Yaxia  Yuan</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Pei</span>, <span class="hlFld-ContribAuthor ">Luhua  Lai</span>. </span><span class="cited-content_cbyCitation_article-title">Multiple Target Drug Design Using LigBuilder 3. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 279-298. <a href="https://doi.org/10.1007/978-1-0716-1209-5_16" title="DOI URL">https://doi.org/10.1007/978-1-0716-1209-5_16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-0716-1209-5_16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-0716-1209-5_16%26sid%3Dliteratum%253Aachs%26atitle%3DMultiple%252BTarget%252BDrug%252BDesign%252BUsing%252BLigBuilder%252B3%26aulast%3DQing%26aufirst%3DXiaoyu%26date%3D2021%26date%3D2021%26spage%3D279%26epage%3D298%26pub%3DSpringer%2520US%26atitle%3DProtein-Ligand%252BInteractions%252Band%252BDrug%252BDesign%26aulast%3DBallante%26aufirst%3DFlavio%26date%3D2021%26volume%3D2266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xueyang  Jiang</span>, <span class="hlFld-ContribAuthor ">Yang  Wang</span>, <span class="hlFld-ContribAuthor ">Chang  Liu</span>, <span class="hlFld-ContribAuthor ">Caiyi  Xing</span>, <span class="hlFld-ContribAuthor ">Yingming  Wang</span>, <span class="hlFld-ContribAuthor ">Weiping  Lyu</span>, <span class="hlFld-ContribAuthor ">Saisai  Wang</span>, <span class="hlFld-ContribAuthor ">Qihang  Li</span>, <span class="hlFld-ContribAuthor ">Tingkai  Chen</span>, <span class="hlFld-ContribAuthor ">Yao  Chen</span>, <span class="hlFld-ContribAuthor ">Feng  Feng</span>, <span class="hlFld-ContribAuthor ">Wenyuan  Liu</span>, <span class="hlFld-ContribAuthor ">Haopeng  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>30 </em>, 115940. <a href="https://doi.org/10.1016/j.bmc.2020.115940" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115940</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115940%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Bglycogen%252Bsynthase%252Bkinase%252B3%25252Fcholinesterase%252Binhibitors%252Bwith%252Bneuroprotection%252Bas%252Bpotential%252Btherapeutic%252Bagent%252Bfor%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DJiang%26aufirst%3DXueyang%26date%3D2021%26volume%3D30%26spage%3D115940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kármen  Szabó</span>, <span class="hlFld-ContribAuthor ">Rosanna  Maccari</span>, <span class="hlFld-ContribAuthor ">Rosaria  Ottanà</span>, <span class="hlFld-ContribAuthor ">Gyöngyi  Gyémánt</span>. </span><span class="cited-content_cbyCitation_article-title">Extending the investigation of 4-thiazolidinone derivatives as potential multi-target ligands of enzymes involved in diabetes mellitus and its long-term complications: A study with pancreatic α-amylase. </span><span class="cited-content_cbyCitation_journal-name">Carbohydrate Research</span><span> <strong>2021,</strong> <em>499 </em>, 108220. <a href="https://doi.org/10.1016/j.carres.2020.108220" title="DOI URL">https://doi.org/10.1016/j.carres.2020.108220</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.carres.2020.108220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.carres.2020.108220%26sid%3Dliteratum%253Aachs%26jtitle%3DCarbohydrate%2520Research%26atitle%3DExtending%252Bthe%252Binvestigation%252Bof%252B4-thiazolidinone%252Bderivatives%252Bas%252Bpotential%252Bmulti-target%252Bligands%252Bof%252Benzymes%252Binvolved%252Bin%252Bdiabetes%252Bmellitus%252Band%252Bits%252Blong-term%252Bcomplications%25253A%252BA%252Bstudy%252Bwith%252Bpancreatic%252B%2525CE%2525B1-amylase%26aulast%3DSzab%25C3%25B3%26aufirst%3DK%25C3%25A1rmen%26date%3D2021%26volume%3D499%26spage%3D108220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tim  Storr</span>. </span><span class="cited-content_cbyCitation_article-title">Multifunctional compounds for the treatment of Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Canadian Journal of Chemistry</span><span> <strong>2021,</strong> <em>99 </em>
                                    (1)
                                     , 1-9. <a href="https://doi.org/10.1139/cjc-2020-0279" title="DOI URL">https://doi.org/10.1139/cjc-2020-0279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1139/cjc-2020-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1139%2Fcjc-2020-0279%26sid%3Dliteratum%253Aachs%26jtitle%3DCanadian%2520Journal%2520of%2520Chemistry%26atitle%3DMultifunctional%252Bcompounds%252Bfor%252Bthe%252Btreatment%252Bof%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DStorr%26aufirst%3DTim%26date%3D2021%26volume%3D99%26issue%3D1%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John  Bremner</span>. </span><span class="cited-content_cbyCitation_article-title">Antibacterials. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-20. <a href="https://doi.org/10.1007/978-981-16-0999-2_1" title="DOI URL">https://doi.org/10.1007/978-981-16-0999-2_1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-16-0999-2_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-16-0999-2_1%26sid%3Dliteratum%253Aachs%26atitle%3DAntibacterials%26aulast%3DBremner%26aufirst%3DJohn%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D20%26pub%3DSpringer%2520Singapore%26atitle%3DMultiple%252BAction-Based%252BDesign%252BApproaches%252Bto%252BAntibacterials%26aulast%3DBremner%26aufirst%3DJohn%26date%3D2021%26volume%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Loredana  Salerno</span>, <span class="hlFld-ContribAuthor ">Luca  Vanella</span>, <span class="hlFld-ContribAuthor ">Valeria  Sorrenti</span>, <span class="hlFld-ContribAuthor ">Valeria  Consoli</span>, <span class="hlFld-ContribAuthor ">Valeria  Ciaffaglione</span>, <span class="hlFld-ContribAuthor ">Antonino N.  Fallica</span>, <span class="hlFld-ContribAuthor ">Vittorio  Canale</span>, <span class="hlFld-ContribAuthor ">Paweł  Zajdel</span>, <span class="hlFld-ContribAuthor ">Rosario  Pignatello</span>, <span class="hlFld-ContribAuthor ">Sebastiano  Intagliata</span>. </span><span class="cited-content_cbyCitation_article-title">Novel mutual prodrug of 5-fluorouracil and heme oxygenase-1 inhibitor (5-FU/HO-1 hybrid): design and preliminary
              in vitro
              evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (1)
                                     , 1378-1386. <a href="https://doi.org/10.1080/14756366.2021.1928111" title="DOI URL">https://doi.org/10.1080/14756366.2021.1928111</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2021.1928111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2021.1928111%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bmutual%252Bprodrug%252Bof%252B5-fluorouracil%252Band%252Bheme%252Boxygenase-1%252Binhibitor%252B%2525285-FU%25252FHO-1%252Bhybrid%252529%25253A%252Bdesign%252Band%252Bpreliminary%252Bin%252Bvitro%252Bevaluation%26aulast%3DSalerno%26aufirst%3DLoredana%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D1%26spage%3D1378%26epage%3D1386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniela  Tomaselli</span>, <span class="hlFld-ContribAuthor ">Nicola  Mautone</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>, <span class="hlFld-ContribAuthor ">Dante  Rotili</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112750. <a href="https://doi.org/10.1016/j.ejmech.2020.112750" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112750</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112750%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bepigenetic%252Bproteolysis%252Btargeting%252Bchimeras%252B%252528Epi-PROTACs%252529%26aulast%3DTomaselli%26aufirst%3DDaniela%26date%3D2020%26volume%3D207%26spage%3D112750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xueyang  Jiang</span>, <span class="hlFld-ContribAuthor ">Junting  Zhou</span>, <span class="hlFld-ContribAuthor ">Yang  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Yan  Duan</span>, <span class="hlFld-ContribAuthor ">Jianping  Huang</span>, <span class="hlFld-ContribAuthor ">Chang  Liu</span>, <span class="hlFld-ContribAuthor ">Yao  Chen</span>, <span class="hlFld-ContribAuthor ">Wenyuan  Liu</span>, <span class="hlFld-ContribAuthor ">Haopeng  Sun</span>, <span class="hlFld-ContribAuthor ">Feng  Feng</span>, <span class="hlFld-ContribAuthor ">Wei  Qu</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112751. <a href="https://doi.org/10.1016/j.ejmech.2020.112751" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112751</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112751%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252Bdesign%252Band%252Bbiological%252Bevaluation%252Bof%252Ba%252Bnew%252Bclass%252Bof%252Bthiazolopyridyl%252Btetrahydroacridines%252Bas%252Bcholinesterase%252Band%252BGSK-3%252Bdual%252Binhibitors%252Bfor%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DJiang%26aufirst%3DXueyang%26date%3D2020%26volume%3D207%26spage%3D112751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Feldmann</span>, <span class="hlFld-ContribAuthor ">Dimitar  Yonchev</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>. </span><span class="cited-content_cbyCitation_article-title">Analysis of Biological Screening Compounds with Single- or Multi-Target Activity via Diagnostic Machine Learning. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2020,</strong> <em>10 </em>
                                    (12)
                                     , 1605. <a href="https://doi.org/10.3390/biom10121605" title="DOI URL">https://doi.org/10.3390/biom10121605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom10121605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom10121605%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DAnalysis%252Bof%252BBiological%252BScreening%252BCompounds%252Bwith%252BSingle-%252Bor%252BMulti-Target%252BActivity%252Bvia%252BDiagnostic%252BMachine%252BLearning%26aulast%3DFeldmann%26aufirst%3DChristian%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D12%26spage%3D1605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatima Y.  Adeowo</span>, <span class="hlFld-ContribAuthor ">Monsurat M.  Lawal</span>, <span class="hlFld-ContribAuthor ">Hezekiel M.  Kumalo</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Development of Cholinesterase Dual Inhibitors towards Alzheimer's Disease Treatment: A Focus on Recent Contributions from Computational and Theoretical Perspective. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2020,</strong> <em>5 </em>
                                    (44)
                                     , 14136-14152. <a href="https://doi.org/10.1002/slct.202003573" title="DOI URL">https://doi.org/10.1002/slct.202003573</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202003573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202003573%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DDesign%252Band%252BDevelopment%252Bof%252BCholinesterase%252BDual%252BInhibitors%252Btowards%252BAlzheimer%252527s%252BDisease%252BTreatment%25253A%252BA%252BFocus%252Bon%252BRecent%252BContributions%252Bfrom%252BComputational%252Band%252BTheoretical%252BPerspective%26aulast%3DAdeowo%26aufirst%3DFatima%2BY.%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D44%26spage%3D14136%26epage%3D14152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ankita  Srivastava</span>, <span class="hlFld-ContribAuthor ">Kaneez  Fatima</span>, <span class="hlFld-ContribAuthor ">Eram  Fatima</span>, <span class="hlFld-ContribAuthor ">Arjun  Singh</span>, <span class="hlFld-ContribAuthor ">Aastha  Singh</span>, <span class="hlFld-ContribAuthor ">Aparna  Shukla</span>, <span class="hlFld-ContribAuthor ">Suaib  Luqman</span>, <span class="hlFld-ContribAuthor ">Karuna  Shanker</span>, <span class="hlFld-ContribAuthor ">Debabrata  Chanda</span>, <span class="hlFld-ContribAuthor ">Feroz  Khan</span>, <span class="hlFld-ContribAuthor ">Arvind S.  Negi</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorinated benzylidene indanone exhibits antiproliferative activity through modulation of microtubule dynamics and antiangiogenic activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>154 </em>, 105513. <a href="https://doi.org/10.1016/j.ejps.2020.105513" title="DOI URL">https://doi.org/10.1016/j.ejps.2020.105513</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2020.105513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2020.105513%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DFluorinated%252Bbenzylidene%252Bindanone%252Bexhibits%252Bantiproliferative%252Bactivity%252Bthrough%252Bmodulation%252Bof%252Bmicrotubule%252Bdynamics%252Band%252Bantiangiogenic%252Bactivity%26aulast%3DSrivastava%26aufirst%3DAnkita%26date%3D2020%26volume%3D154%26spage%3D105513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuedong  He</span>, <span class="hlFld-ContribAuthor ">Lu  Zhao</span>, <span class="hlFld-ContribAuthor ">Weihe  Zhong</span>, <span class="hlFld-ContribAuthor ">Hsin-Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoting  Shan</span>, <span class="hlFld-ContribAuthor ">Ning  Tang</span>, <span class="hlFld-ContribAuthor ">Calvin Yu-Chian  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Insight into potent leads for alzheimer's disease by using several artificial intelligence algorithms. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2020,</strong> <em>129 </em>, 110360. <a href="https://doi.org/10.1016/j.biopha.2020.110360" title="DOI URL">https://doi.org/10.1016/j.biopha.2020.110360</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2020.110360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2020.110360%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DInsight%252Binto%252Bpotent%252Bleads%252Bfor%252Balzheimer%252527s%252Bdisease%252Bby%252Busing%252Bseveral%252Bartificial%252Bintelligence%252Balgorithms%26aulast%3DHe%26aufirst%3DXuedong%26date%3D2020%26volume%3D129%26spage%3D110360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongguang  Ma</span>, <span class="hlFld-ContribAuthor ">Boshi  Huang</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (9)
                                     , 1682-1692. <a href="https://doi.org/10.1016/j.drudis.2020.07.004" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.07.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.07.004%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DRecent%252Badvances%252Bin%252Bmultitarget-directed%252Bligands%252Btargeting%252BG-protein-coupled%252Breceptors%26aulast%3DMa%26aufirst%3DHongguang%26date%3D2020%26volume%3D25%26issue%3D9%26spage%3D1682%26epage%3D1692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sai-Sai  Xie</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Chunli  Tang</span>, <span class="hlFld-ContribAuthor ">Chengyun  Pang</span>, <span class="hlFld-ContribAuthor ">Qing  Li</span>, <span class="hlFld-ContribAuthor ">Yuelian  Qin</span>, <span class="hlFld-ContribAuthor ">Xiaojie  Nong</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Jie  Guo</span>, <span class="hlFld-ContribAuthor ">Maojun  Cheng</span>, <span class="hlFld-ContribAuthor ">Weizhong  Tang</span>, <span class="hlFld-ContribAuthor ">Ningsheng  Liang</span>, <span class="hlFld-ContribAuthor ">Neng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>202 </em>, 112475. <a href="https://doi.org/10.1016/j.ejmech.2020.112475" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112475</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112475%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Brasagiline-clorgyline%252Bhybrids%252Bas%252Bnovel%252Bdual%252Binhibitors%252Bof%252Bmonoamine%252Boxidase-B%252Band%252Bamyloid-%2525CE%2525B2%252Baggregation%252Bagainst%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DXie%26aufirst%3DSai-Sai%26date%3D2020%26volume%3D202%26spage%3D112475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masako  Yumura</span>, <span class="hlFld-ContribAuthor ">Tatsuya  Nagano</span>, <span class="hlFld-ContribAuthor ">Yoshihiro  Nishimura</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (17)
                                     , 3987. <a href="https://doi.org/10.3390/molecules25173987" title="DOI URL">https://doi.org/10.3390/molecules25173987</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25173987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25173987%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DNovel%252BMultitarget%252BTherapies%252Bfor%252BLung%252BCancer%252Band%252BRespiratory%252BDisease%26aulast%3DYumura%26aufirst%3DMasako%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D17%26spage%3D3987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kun  Xing</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Han</span>, <span class="hlFld-ContribAuthor ">Tong  Tong</span>, <span class="hlFld-ContribAuthor ">Dan  Liu</span>, <span class="hlFld-ContribAuthor ">Linxiang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Bioactivity Evaluation of 4,6-Disubstituted Pyrido[3,2-d]pyrimidine Derivatives as Mnk and HDAC Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (18)
                                     , 4318. <a href="https://doi.org/10.3390/molecules25184318" title="DOI URL">https://doi.org/10.3390/molecules25184318</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25184318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25184318%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBioactivity%252BEvaluation%252Bof%252B4%25252C6-Disubstituted%252BPyrido%25255B3%25252C2-d%25255Dpyrimidine%252BDerivatives%252Bas%252BMnk%252Band%252BHDAC%252BInhibitors%26aulast%3DXing%26aufirst%3DKun%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D18%26spage%3D4318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Márcia  Martins</span>, <span class="hlFld-ContribAuthor ">Renata  Silva</span>, <span class="hlFld-ContribAuthor ">Madalena  M. M. Pinto</span>, <span class="hlFld-ContribAuthor ">Emília  Sousa</span>. </span><span class="cited-content_cbyCitation_article-title">Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (9)
                                     , 242. <a href="https://doi.org/10.3390/ph13090242" title="DOI URL">https://doi.org/10.3390/ph13090242</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13090242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13090242%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DMarine%252BNatural%252BProducts%25252C%252BMultitarget%252BTherapy%252Band%252BRepurposed%252BAgents%252Bin%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DMartins%26aufirst%3DM%25C3%25A1rcia%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D9%26spage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajan  Chaudhari</span>, <span class="hlFld-ContribAuthor ">Long Wolf  Fong</span>, <span class="hlFld-ContribAuthor ">Zhi  Tan</span>, <span class="hlFld-ContribAuthor ">Beibei  Huang</span>, <span class="hlFld-ContribAuthor ">Shuxing  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">An up-to-date overview of computational polypharmacology in modern drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2020,</strong> <em>15 </em>
                                    (9)
                                     , 1025-1044. <a href="https://doi.org/10.1080/17460441.2020.1767063" title="DOI URL">https://doi.org/10.1080/17460441.2020.1767063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2020.1767063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2020.1767063%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAn%252Bup-to-date%252Boverview%252Bof%252Bcomputational%252Bpolypharmacology%252Bin%252Bmodern%252Bdrug%252Bdiscovery%26aulast%3DChaudhari%26aufirst%3DRajan%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D9%26spage%3D1025%26epage%3D1044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel R.  de Lera</span>, <span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Two-hit wonders: The expanding universe of multitargeting epigenetic agents. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>57 </em>, 135-154. <a href="https://doi.org/10.1016/j.cbpa.2020.05.009" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTwo-hit%252Bwonders%25253A%252BThe%252Bexpanding%252Buniverse%252Bof%252Bmultitargeting%252Bepigenetic%252Bagents%26aulast%3Dde%2BLera%26aufirst%3DAngel%2BR.%26date%3D2020%26volume%3D57%26spage%3D135%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Damijan  Knez</span>, <span class="hlFld-ContribAuthor ">Izidor  Sosič</span>, <span class="hlFld-ContribAuthor ">Ana  Mitrović</span>, <span class="hlFld-ContribAuthor ">Anja  Pišlar</span>, <span class="hlFld-ContribAuthor ">Janko  Kos</span>, <span class="hlFld-ContribAuthor ">Stanislav  Gobec</span>. </span><span class="cited-content_cbyCitation_article-title">8-Hydroxyquinoline-based anti-Alzheimer multimodal agents. </span><span class="cited-content_cbyCitation_journal-name">Monatshefte für Chemie - Chemical Monthly</span><span> <strong>2020,</strong> <em>151 </em>
                                    (7)
                                     , 1111-1120. <a href="https://doi.org/10.1007/s00706-020-02651-0" title="DOI URL">https://doi.org/10.1007/s00706-020-02651-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00706-020-02651-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00706-020-02651-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMonatshefte%2520f%25C3%25BCr%2520Chemie%2520-%2520Chemical%2520Monthly%26atitle%3D8-Hydroxyquinoline-based%252Banti-Alzheimer%252Bmultimodal%252Bagents%26aulast%3DKnez%26aufirst%3DDamijan%26date%3D2020%26date%3D2020%26volume%3D151%26issue%3D7%26spage%3D1111%26epage%3D1120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Albertini</span>, <span class="hlFld-ContribAuthor ">Alessandra  Salerno</span>, <span class="hlFld-ContribAuthor ">Pedro  Sena Murteira Pinheiro</span>, <span class="hlFld-ContribAuthor ">Maria L.  Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.1002/med.21699" title="DOI URL">https://doi.org/10.1002/med.21699</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21699%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DFrom%252Bcombinations%252Bto%252Bmultitarget%2525E2%252580%252590directed%252Bligands%25253A%252BA%252Bcontinuum%252Bin%252BAlzheimer%252527s%252Bdisease%252Bpolypharmacology%26aulast%3DAlbertini%26aufirst%3DClaudia%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">István  Gyertyán</span>. </span><span class="cited-content_cbyCitation_article-title">How can preclinical cognitive research further neuropsychiatric drug discovery? Chances and challenges. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2020,</strong> <em>15 </em>
                                    (6)
                                     , 659-670. <a href="https://doi.org/10.1080/17460441.2020.1739645" title="DOI URL">https://doi.org/10.1080/17460441.2020.1739645</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2020.1739645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2020.1739645%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DHow%252Bcan%252Bpreclinical%252Bcognitive%252Bresearch%252Bfurther%252Bneuropsychiatric%252Bdrug%252Bdiscovery%25253F%252BChances%252Band%252Bchallenges%26aulast%3DGyerty%25C3%25A1n%26aufirst%3DIstv%25C3%25A1n%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D6%26spage%3D659%26epage%3D670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinghong  Liao</span>, <span class="hlFld-ContribAuthor ">Qi  Li</span>, <span class="hlFld-ContribAuthor ">Yifan  Zhao</span>, <span class="hlFld-ContribAuthor ">Pan  Jiang</span>, <span class="hlFld-ContribAuthor ">Yuhui  Yan</span>, <span class="hlFld-ContribAuthor ">Haopeng  Sun</span>, <span class="hlFld-ContribAuthor ">Wenyuan  Liu</span>, <span class="hlFld-ContribAuthor ">Feng  Feng</span>, <span class="hlFld-ContribAuthor ">Wei  Qu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel carboline-cinnamic acid hybrids as multifunctional agents for treatment of Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103844. <a href="https://doi.org/10.1016/j.bioorg.2020.103844" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103844%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bcarboline-cinnamic%252Bacid%252Bhybrids%252Bas%252Bmultifunctional%252Bagents%252Bfor%252Btreatment%252Bof%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DLiao%26aufirst%3DQinghong%26date%3D2020%26volume%3D99%26spage%3D103844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  He</span>, <span class="hlFld-ContribAuthor ">Wentao  Ning</span>, <span class="hlFld-ContribAuthor ">Zhiye  Hu</span>, <span class="hlFld-ContribAuthor ">Jian  Huang</span>, <span class="hlFld-ContribAuthor ">Chune  Dong</span>, <span class="hlFld-ContribAuthor ">Hai-Bing  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>195 </em>, 112281. <a href="https://doi.org/10.1016/j.ejmech.2020.112281" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112281%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bdual-acting%252Bmodulators%252Btargeting%252Bboth%252Bestrogen%252Breceptor%252B%2525CE%2525B1%252B%252528ER%2525CE%2525B1%252529%252Band%252Blysine-specific%252Bdemethylase%252B1%252B%252528LSD1%252529%252Bfor%252Btreatment%252Bof%252Bbreast%252Bcancer%26aulast%3DHe%26aufirst%3DMing%26date%3D2020%26volume%3D195%26spage%3D112281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dorota  Łażewska</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Olejarz-Maciej</span>, <span class="hlFld-ContribAuthor ">David  Reiner</span>, <span class="hlFld-ContribAuthor ">Maria  Kaleta</span>, <span class="hlFld-ContribAuthor ">Gniewomir  Latacz</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Zygmunt</span>, <span class="hlFld-ContribAuthor ">Agata  Doroz-Płonka</span>, <span class="hlFld-ContribAuthor ">Tadeusz  Karcz</span>, <span class="hlFld-ContribAuthor ">Annika  Frank</span>, <span class="hlFld-ContribAuthor ">Holger  Stark</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Kieć-Kononowicz</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Target Ligands with 4-tert-Butylphenoxy Scaffold as Histamine H3 Receptor Antagonists and Monoamine Oxidase B Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (10)
                                     , 3411. <a href="https://doi.org/10.3390/ijms21103411" title="DOI URL">https://doi.org/10.3390/ijms21103411</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21103411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21103411%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDual%252BTarget%252BLigands%252Bwith%252B4-tert-Butylphenoxy%252BScaffold%252Bas%252BHistamine%252BH3%252BReceptor%252BAntagonists%252Band%252BMonoamine%252BOxidase%252BB%252BInhibitors%26aulast%3D%25C5%2581a%25C5%25BCewska%26aufirst%3DDorota%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D10%26spage%3D3411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yasser M.  Omar</span>, <span class="hlFld-ContribAuthor ">Samia G.  Abdel-Moty</span>, <span class="hlFld-ContribAuthor ">Hajjaj H.M.  Abdu-Allah</span>. </span><span class="cited-content_cbyCitation_article-title">Further insight into the dual COX-2 and 15-LOX anti-inflammatory activity of 1,3,4-thiadiazole-thiazolidinone hybrids: The contribution of the substituents at 5th positions is size dependent. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>97 </em>, 103657. <a href="https://doi.org/10.1016/j.bioorg.2020.103657" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103657</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103657%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DFurther%252Binsight%252Binto%252Bthe%252Bdual%252BCOX-2%252Band%252B15-LOX%252Banti-inflammatory%252Bactivity%252Bof%252B1%25252C3%25252C4-thiadiazole-thiazolidinone%252Bhybrids%25253A%252BThe%252Bcontribution%252Bof%252Bthe%252Bsubstituents%252Bat%252B5th%252Bpositions%252Bis%252Bsize%252Bdependent%26aulast%3DOmar%26aufirst%3DYasser%2BM.%26date%3D2020%26volume%3D97%26spage%3D103657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gopichand  Gutti</span>, <span class="hlFld-ContribAuthor ">Ramakrishna  Kakarla</span>, <span class="hlFld-ContribAuthor ">Devendra  Kumar</span>, <span class="hlFld-ContribAuthor ">Mahima  Beohar</span>, <span class="hlFld-ContribAuthor ">Ankit  Ganeshpurkar</span>, <span class="hlFld-ContribAuthor ">Ashok  Kumar</span>, <span class="hlFld-ContribAuthor ">Sairam  Krishnamurthy</span>, <span class="hlFld-ContribAuthor ">Sushil Kumar  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel series of 2-substituted benzo[d]oxazol-5-amine derivatives as multi-target directed ligands for the treatment of Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111613. <a href="https://doi.org/10.1016/j.ejmech.2019.111613" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111613</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111613%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bseries%252Bof%252B2-substituted%252Bbenzo%25255Bd%25255Doxazol-5-amine%252Bderivatives%252Bas%252Bmulti-target%252Bdirected%252Bligands%252Bfor%252Bthe%252Btreatment%252Bof%252BAlzheimer%252527s%252Bdisease%26aulast%3DGutti%26aufirst%3DGopichand%26date%3D2019%26volume%3D182%26spage%3D111613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0033.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0031.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Multitarget drug design strategy based on pharmacophore.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In linked MTDLs, the pharmacophores are connected by stable or biodegradable linkers. In fused MTDLs, the pharmacophores are attached directly. In merged MTDLs, the pharmacophores are merged together.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Two Categories of Linked MTDLs: Cleavable MTDLs and Noncleavable MTDLs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Compound <b>3</b> is a cleavable MTDL, with an ester linker that can be hydrolyzed in vivo.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> (B) Compound <b>6</b> is a noncleavable MTDL, the linker of which is stable in vivo.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Structures of Fused Pharmacophores<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>The two pharmacophores are in blue and red; purple illustrates the fused/merged pharmacophore from two selective ligands. (A) Dual cholinesterase/MAO-B inhibitor (<b>9</b>).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> (B) Neuroprotection/antioxidative bisfunctional agent (<b>12</b>).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Both compounds <b>9</b> and <b>12</b> are the products of fused pharmacophores approach.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Representative Structures of Merged Pharmacophores<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Multifunctional agent (<b>16</b>) is designed by merging the pharmacophores of the aminopropoxyphenyl scaffolds from compounds <b>13</b>, <b>14</b>, and <b>15</b>.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> (B) Bisfunctional compound <b>19</b> is designed via merging the pharmacophores from chelator HLA20 (<b>17</b>), rivastigmine (<b>7</b>), and donepezil (<b>18</b>).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0032.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. The screening of compounds libraries may generate a lead compound that obtains all activities toward both targets of interest (A and B). (a) But a single compound may be unlikely to have balanced affinity to all targets; therefore its activities should be optimized. (b) In another case, the lead compound also has activity toward undesired targets, which must be “designed out” during optimization.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Representative Example of Design-In Strategy<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Based on design-in approach, the pharmacophore of <b>20</b> is designed into that of <b>21</b>, according to molecular docking and cocrystals information.<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75,76)</a></p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Representative Example of Design-Out Approach<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>In the design-out approach, compound <b>25</b> is obtained by reducing the affinity to the undesired target NK<sub>3</sub>, meanwhile retaining the affinities on NK<sub>1</sub> and NK<sub>2</sub>.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. General Scheme and Representative Example of CuAAC Reaction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) 1,3-Dipolar cycloaddition between alkynes and azides; (B) representative example of CuAAC reaction.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. General Schemes and Representative Example of DA and Thiol–Ene/Yne Click Reaction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Diels–Alder (DA) reaction; (B) TEC reaction (top) and the TYC reaction (bottom); (C) representative example of DA reaction.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></p></p></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. General Scheme and Representative Example of Suzuki Reaction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Aryl Suzuki reaction: C(sp<sup>2</sup>–sp<sup>2</sup>) cross-coupling. (B) Acyl Suzuki reaction: C(acyl-sp<sup>2</sup>) cross-coupling. (C) Representative example of Suzuki reaction.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></p></p></figure><figure data-id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. General Scheme and Representative Example of Stille Reaction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Stille reaction; (B) representative example of Stille reaction.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></p></p></figure><figure data-id="sch10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. General Scheme and Representative Example of Sonogashira Reaction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Sonogashira reaction; (B) representative example of Sonogashira reaction.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></p></p></figure><figure data-id="sch11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0011.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. General Scheme and Representative Example of Heck Reaction<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Heck reaction; (B) representative example of Heck reaction.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></p></p></figure><figure data-id="sch12" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0012.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. MTDLs Targeting HDAC and Other Targets<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Most HDACi consist of three parts: a ZBG, a hydrophobic linker, and a surface cognition cap.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The HDACi pharmacophores can tolerate diverse cap groups, enabling MTDLs strategies.</p></p></figure><figure data-id="sch13" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0013.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. MTDLs Targeting Src and MEK Kinases<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch14" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0014.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. MTDLs Targeting ERα and VEGFR-2<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch15" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0015.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. MTDLs Targeting Tyrosine Kinase and Microtubule<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch16" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0016.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. MTDLs Targeting GSK-3β and Tau-Aggregation for AD<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch17" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0017.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. MTDLs Targeting ChE and Other Targets for AD<a onclick="showRef(event, 'ref183 ref187 ref190'); return false;" href="javascript:void(0);" class="ref ref183 ref187 ref190">(183,187,190)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch18" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0018.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. MTDLs Targeting AChE and SERT for AD<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch19" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0019.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. MTDLs Targeting Metal Chelation, Aβ, Metal-Aβ, and ROS for AD<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch20" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0020.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. MTDLs Targeting MAO-B and H<sub>3</sub>R for PD<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch21" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0021.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. MTDLs Targeting MAO-B and A<sub>1</sub>/A<sub>2A</sub> AR for PD<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch22" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0022.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. MTDLs Targeting SERT/5-HT<sub>1A</sub>/5-HT<sub>7</sub> for Depression<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch23" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0023.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. MTDLs Targeting Dopamine D<sub>2</sub> Receptor and Serotonin Reuptake for Schizophrenia<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch24" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0024.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. MTDLs Targeting AT<sub>1</sub> and ET<sub>A</sub> for Hypertension<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch25" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0025.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Design of Multitargeted Agents Targeting PPARγ and AT<sub>1</sub> for Hypertension<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch26" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0026.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. MTDLs Targeting ACE and DPP4 for Hypertension and Diabetes<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) Representative scaffold of ACE and DPP4 inhibitors.<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a> (B) ACE/DPP4 dual inhibitors merged by enalaprilat <b>82</b> and sitagliptin <b>85</b>.</p></p></figure><figure data-id="sch27" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0027.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. MTDLs Targeting IN and RT for AIDS<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch28" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0028.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. MTDLs Targeting IN and RT for AIDS<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch29" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0029.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. MTDLs Targeting PfATP6 and Host Hemoglobin Digestion for Malaria</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch30" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/medium/jm-2019-000178_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0030.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 30. MTDLs Targeting 15-LOX and COX-2 for Inflammation<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00017/20191018/images/large/jm-2019-000178_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00017&amp;id=sch30"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i109">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30822" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30822" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 275 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giulianotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welmaker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghten, R. A.</span></span> <span> </span><span class="NLM_article-title">Shifting from the Single to the Multitarget Paradigm in Drug Discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">9–10</span>),  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2013.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23340113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC3szhsV2rsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=495-501&issue=9%E2%80%9310&author=J.+L.+Medina-Francoauthor=M.+A.+Giulianottiauthor=G.+S.+Welmakerauthor=R.+A.+Houghten&title=Shifting+from+the+Single+to+the+Multitarget+Paradigm+in+Drug+Discovery&doi=10.1016%2Fj.drudis.2013.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Shifting from the single to the multitarget paradigm in drug discovery</span></div><div class="casAuthors">Medina-Franco Jose L; Giulianotti Marc A; Welmaker Gregory S; Houghten Richard A</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">495-501</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increasing evidence that several drug compounds exert their effects through interactions with multiple targets is boosting the development of research fields that challenge the data reductionism approach.  In this article, we review and discuss the concepts of drug repurposing, polypharmacology, chemogenomics, phenotypic screening and high-throughput in vivo testing of mixture-based libraries in an integrated manner.  These research fields offer alternatives to the current paradigm of drug discovery, from a one target-one drug model to a multiple-target approach.  Furthermore, the goals of lead identification are being expanded accordingly to identify not only 'key' compounds that fit with a single-target 'lock', but also 'master key' compounds that favorably interact with multiple targets (i.e. operate a set of desired locks to gain access to the expected clinical effects).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOFtVP-kWcL7qxQ2mb9Pu8fW6udTcc2ebDMSi51HbVeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szhsV2rsQ%253D%253D&md5=b4f8c7d1ebbbf32ed4c6c87500baf66f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26aulast%3DGiulianotti%26aufirst%3DM.%2BA.%26aulast%3DWelmaker%26aufirst%3DG.%2BS.%26aulast%3DHoughten%26aufirst%3DR.%2BA.%26atitle%3DShifting%2520from%2520the%2520Single%2520to%2520the%2520Multitarget%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26issue%3D9%25E2%2580%259310%26spage%3D495%26epage%3D501%26doi%3D10.1016%2Fj.drudis.2013.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A.</span></span> <span> </span><span class="NLM_article-title">Network Pharmacology: The Next Paradigm in Drug Discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&issue=11&author=A.+Hopkins&title=Network+Pharmacology%3A+The+Next+Paradigm+in+Drug+Discovery&doi=10.1038%2Fnchembio.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0lhrlMRiMaqqFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%26atitle%3DNetwork%2520Pharmacology%253A%2520The%2520Next%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26issue%3D11%26spage%3D682%26epage%3D690%26doi%3D10.1038%2Fnchembio.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D. F.</span></span> <span> </span><span class="NLM_article-title">Designing Multi-Targeted Agents: An Emerging Anticancer Drug Discovery Paradigm</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2017.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28494256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=195-211&author=R.+G.+Fuauthor=Y.+Sunauthor=W.+B.+Shengauthor=D.+F.+Liao&title=Designing+Multi-Targeted+Agents%3A+An+Emerging+Anticancer+Drug+Discovery+Paradigm&doi=10.1016%2Fj.ejmech.2017.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm</span></div><div class="casAuthors">Fu, Rong-geng; Sun, Yuan; Sheng, Wen-bing; Liao, Duan-fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195-211</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is to design ligands with max. selectivity to act on individual drug targets.  With the target-based approach, many new chem. entities have been discovered, developed, and further approved as drugs.  However, there are a large no. of complex diseases such as cancer that cannot be effectively treated or cured only with one medicine to modulate the biol. function of a single target.  As simultaneous intervention of two (or multiple) cancer progression relevant targets has shown improved therapeutic efficacy, the innovation of multi-targeted drugs has become a promising and prevailing research topic and numerous multi-targeted anticancer agents are currently at various developmental stages.  However, most multi-pharmacophore scaffolds are usually discovered by serendipity or screening, while rational design by combining existing pharmacophore scaffolds remains an enormous challenge.  In this review, four types of multi-pharmacophore modes are discussed, and the examples from literature will be used to introduce attractive lead compds. with the capability of simultaneously interfering with different enzyme or signaling pathway of cancer progression, which will reveal the trends and insights to help the design of the next generation multi-targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGjXR-zscrArVg90H21EOLACvtfcHk0lhrlMRiMaqqFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D&md5=511561bd2cd186d5dafa905b7257bf32</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DR.%2BG.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DW.%2BB.%26aulast%3DLiao%26aufirst%3DD.%2BF.%26atitle%3DDesigning%2520Multi-Targeted%2520Agents%253A%2520An%2520Emerging%2520Anticancer%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D136%26spage%3D195%26epage%3D211%26doi%3D10.1016%2Fj.ejmech.2017.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valabrega, G.</span></span> <span> </span><span class="NLM_article-title">Multitarget Drugs: The Present and the Future of Cancer Therapy</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1517/14656560902781907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1517%2F14656560902781907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19284362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtF2mu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=589-600&issue=4&author=A.+Petrelliauthor=G.+Valabrega&title=Multitarget+Drugs%3A+The+Present+and+the+Future+of+Cancer+Therapy&doi=10.1517%2F14656560902781907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget drugs: the present and the future of cancer therapy</span></div><div class="casAuthors">Petrelli, Annalisa; Valabrega, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-600</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Target therapies for the treatment of human cancers have revolutionized the concept of oncol. medicine.  This type of therapeutic approach is directed to the inhibition of mol. targets that play a pivotal role in tumor progression - such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival - mainly by means of compds. able to block their activity.  In the beginning, the aim of target therapies was specifically to hit a single mol. expressed in neoplastic cells.  Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease.  Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different mols.  This review summarizes the mol. basis of multitarget therapies and the most relevant results obtained in different cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSM1xsRJGBX7Vg90H21EOLACvtfcHk0lhrNy_vx3_4OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtF2mu70%253D&md5=c84e048407e6d9354a1f4a595fb4a468</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F14656560902781907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560902781907%26sid%3Dliteratum%253Aachs%26aulast%3DPetrelli%26aufirst%3DA.%26aulast%3DValabrega%26aufirst%3DG.%26atitle%3DMultitarget%2520Drugs%253A%2520The%2520Present%2520and%2520the%2520Future%2520of%2520Cancer%2520Therapy%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26issue%3D4%26spage%3D589%26epage%3D600%26doi%3D10.1517%2F14656560902781907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghavendra, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pingili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadasi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S. V. U. M.</span></span> <span> </span><span class="NLM_article-title">Dual or Multi-Targeting Inhibitors: The Next Generation Anticancer Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1277</span>– <span class="NLM_lpage">1300</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2017.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29126724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslyrt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1277-1300&author=N.+M.+Raghavendraauthor=D.+Pingiliauthor=S.+Kadasiauthor=A.+Mettuauthor=S.+V.+U.+M.+Prasad&title=Dual+or+Multi-Targeting+Inhibitors%3A+The+Next+Generation+Anticancer+Agents&doi=10.1016%2Fj.ejmech.2017.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dual or multi-targeting inhibitors: The next generation anticancer agents</span></div><div class="casAuthors">Raghavendra, Nulgumnalli Manjunathaiah; Pingili, Divya; Kadasi, Sundeep; Mettu, Akhila; Prasad, S. V. U. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1277-1300</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Dual-targeting/Multi-targeting of oncoproteins by a single drug mol. represents an efficient, logical and alternative approach to drug combinations.  An increasing interest in this approach is indicated by a steady upsurge in the no. of articles on targeting dual/multi proteins published in the last 5 years.  Combining different inhibitors that destiny specific single target is the std. treatment for cancer.  A new generation of dual or multi-targeting drugs is emerging, where a single chem. entity can act on multiple mol. targets.  Dual/Multi-targeting agents are beneficial for solving limited efficiencies, poor safety and resistant profiles of an individual target.  Designing dual/multi-target inhibitors with predefined biol. profiles present a challenge.  The latest advances in bioinformatic tools and the availability of detailed structural information of target proteins have shown a way of discovering multi-targeting mols.  This neoteric artifice that amalgamates the mol. docking of small mols. with protein-based common pharmacophore to design multi-targeting inhibitors is gaining great importance in anticancer drug discovery.  Current review focus on the discoveries of dual targeting agents in cancer therapy using rational, computational, proteomic, bioinformatics and polypharmacol. approach that enables the discovery and rational design of effective and safe multi-target anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVpBUpxW1okLVg90H21EOLACvtfcHk0lhrNy_vx3_4OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslyrt7jO&md5=a14783194c23f7dc5f200cf6eabf9269</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DRaghavendra%26aufirst%3DN.%2BM.%26aulast%3DPingili%26aufirst%3DD.%26aulast%3DKadasi%26aufirst%3DS.%26aulast%3DMettu%26aufirst%3DA.%26aulast%3DPrasad%26aufirst%3DS.%2BV.%2BU.%2BM.%26atitle%3DDual%2520or%2520Multi-Targeting%2520Inhibitors%253A%2520The%2520Next%2520Generation%2520Anticancer%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1277%26epage%3D1300%26doi%3D10.1016%2Fj.ejmech.2017.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Co-Targeting Cancer Drug Escape Pathways Confers Clinical Advantage for Multi-Target Anticancer Drugs</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2015.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.phrs.2015.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=26438971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ShtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=123-131&author=L.+Taoauthor=F.+Zhuauthor=F.+Xuauthor=Z.+Chenauthor=Y.+Y.+Jiangauthor=Y.+Z.+Chen&title=Co-Targeting+Cancer+Drug+Escape+Pathways+Confers+Clinical+Advantage+for+Multi-Target+Anticancer+Drugs&doi=10.1016%2Fj.phrs.2015.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs</span></div><div class="casAuthors">Tao, Lin; Zhu, Feng; Xu, Feng; Chen, Zhe; Jiang, Yu Yang; Chen, Yu Zong</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123-131</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent investigations have suggested that anticancer therapeutics may be enhanced by co-targeting the primary anticancer target and the corresponding drug escape pathways.  Whether this strategy confers statistically significant clin. advantage has not been systematically investigated.  This question was probed by the evaluation of the clin. status and the multiple targets of 23 approved and 136 clin. trial multi-target anticancer drugs with particular focus on those co-targeting EGFR, HER2, Abl, VEGFR2, mTOR, PI3K, Alk, MEK, KIT, and DNA topoisomerase, and some of the 14, 7, 13, 20, 6, 5, 7, 2, 4 and 10 cancer drug escape pathways resp.  Most of the approved (73.9%) and phase III (75.0%), the majority of the Phase II (62.8%) and I (53.6%), and the minority of the discontinued (35.3%) multi-target drugs were found to co-target cancer drug escape pathways.  This suggests that co-targeting anticancer targets and drug escape pathways confer significant clin. advantage and such strategy can be more extensively explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZKuYkoBNEebVg90H21EOLACvtfcHk0lg6KuPxU8NSUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ShtbnM&md5=8596b0d20f94e8e4ec7d74f6cb5c618a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26atitle%3DCo-Targeting%2520Cancer%2520Drug%2520Escape%2520Pathways%2520Confers%2520Clinical%2520Advantage%2520for%2520Multi-Target%2520Anticancer%2520Drugs%26jtitle%3DPharmacol.%2520Res.%26date%3D2015%26volume%3D102%26spage%3D123%26epage%3D131%26doi%3D10.1016%2Fj.phrs.2015.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Multi-Target-Directed Ligands To Combat Neurodegenerative Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1021/jm7009364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&issue=3&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-Target-Directed+Ligands+To+Combat+Neurodegenerative+Diseases&doi=10.1021%2Fjm7009364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0lg6KuPxU8NSUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-Target-Directed%2520Ligands%2520To%2520Combat%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D3%26spage%3D347%26epage%3D372%26doi%3D10.1021%2Fjm7009364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
der Schyf, C. J.</span></span> <span> </span><span class="NLM_article-title">The Use of Multi-Target Drugs in the Treatment of Neurodegenerative Diseases</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1586/ecp.11.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1586%2Fecp.11.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22114774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFGgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=293-298&issue=3&author=C.+J.+Van%0Ader+Schyf&title=The+Use+of+Multi-Target+Drugs+in+the+Treatment+of+Neurodegenerative+Diseases&doi=10.1586%2Fecp.11.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The use of multi-target drugs in the treatment of neurodegenerative diseases</span></div><div class="casAuthors">Van der Schyf, Cornelis J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">293-298</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative disorders lead to increased mortality and morbidity in older patients, and are a great burden on society, where there is currently no approved treatment to prevent the progression of these diseases.  Many clinicians and basic scientists have become persuaded that a strategy aimed at the simultaneous targeting of multiple proteins (and therefore etiologies) involved in the development of a disease should be more beneficial than the currently accepted 'silver bullet' approach.  Select examples of multi-target drug candidates currently under investigation for neurodegenerative diseases are shown.  Importantly, such transition from a 'magic bullet' to a 'magic shotgun' approach may be key in designing future treatment regimens for neurodegenerative diseases and assocd. cognitive decline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAwTj0XbQk3LVg90H21EOLACvtfcHk0lh9w1ijR3a9IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFGgsrk%253D&md5=7aa001180af3e144548f7f617aa12c2d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1586%2Fecp.11.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.11.13%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520Use%2520of%2520Multi-Target%2520Drugs%2520in%2520the%2520Treatment%2520of%2520Neurodegenerative%2520Diseases%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D4%26issue%3D3%26spage%3D293%26epage%3D298%26doi%3D10.1586%2Fecp.11.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belluti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampa, A.</span></span> <span> </span><span class="NLM_article-title">Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1759</span>– <span class="NLM_lpage">1782</span>, <span class="refDoi"> DOI: 10.2174/0929867311320130012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F0929867311320130012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23410171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2juro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1759-1782&issue=13&author=A.+Bisiauthor=S.+Gobbiauthor=F.+Bellutiauthor=A.+Rampa&title=Design+of+Multifunctional+Compounds+for+Cardiovascular+Disease%3A+From+Natural+Scaffolds+to+%E2%80%9CClassical%E2%80%9D+Multitarget+Approach&doi=10.2174%2F0929867311320130012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Design of multifunctional compounds for cardiovascular disease: from natural scaffolds to "classical" multitarget approach</span></div><div class="casAuthors">Bisi, A.; Gobbi, S.; Belluti, F.; Rampa, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1759-1782</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cardiovascular disease represents the main cause of death worldwide.  Novel therapies to reduce elevated blood pressure and treat resistant hypertension, to consequently reduce the assocd. cardiovascular risk factors, are still required.  Among the different strategies commonly used in medicinal chem. to develop new mols., the synthesis of multitarget/hybrid compds. combining two or more pharmacophore groups targeting simultaneously selected factors involved in cardiovascular diseases, has gained increasing interest.  This review will focus on the most recent literature on multifunctional cardiovascular drugs, paying particular attention on hybrid compds. bearing natural scaffolds, considering that compds. derived from medicinal exts. are generally appealing for the medicinal chemist as they often bear the so-called "privileged structures".  Moreover, taking into account many excellent reviews dealing with multitarget cardiovascular drugs published in the last few years, mainly devoted to RAAS inhibition and/or NO donors hybrid drugs, herein the most significant results obtained and the benefits and limitations of these approaches will be highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBZAxoIKJrM7Vg90H21EOLACvtfcHk0lh9w1ijR3a9IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2juro%253D&md5=0d6cdd19a2850a461b8b4c576caabd2f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130012%26sid%3Dliteratum%253Aachs%26aulast%3DBisi%26aufirst%3DA.%26aulast%3DGobbi%26aufirst%3DS.%26aulast%3DBelluti%26aufirst%3DF.%26aulast%3DRampa%26aufirst%3DA.%26atitle%3DDesign%2520of%2520Multifunctional%2520Compounds%2520for%2520Cardiovascular%2520Disease%253A%2520From%2520Natural%2520Scaffolds%2520to%2520%25E2%2580%259CClassical%25E2%2580%259D%2520Multitarget%2520Approach%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D13%26spage%3D1759%26epage%3D1782%26doi%3D10.2174%2F0929867311320130012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gattrell, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, M.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands in Metabolic Disease Research: From Concept to Platform</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">15–16</span>),  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2013.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23454344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVertL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=692-696&issue=15%E2%80%9316&author=W.+Gattrellauthor=C.+Johnstoneauthor=S.+Patelauthor=C.+S.+Smithauthor=A.+Scheelauthor=M.+Schindler&title=Designed+Multiple+Ligands+in+Metabolic+Disease+Research%3A+From+Concept+to+Platform&doi=10.1016%2Fj.drudis.2013.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Designed multiple ligands in metabolic disease research: from concept to platform</span></div><div class="casAuthors">Gattrell, W.; Johnstone, C.; Patel, S.; Smith, C. Sambrook; Scheel, A.; Schindler, M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15-16</span>),
    <span class="NLM_cas:pages">692-696</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Type 2 diabetes mellitus (T2DM) is a multifactorial disease, and drug monotherapy typically results in unsatisfactory treatment outcomes for patients.  Even when used in combination, existing therapies lack efficacy in the long term.  Designed multiple ligands (DMLs) are compds. developed to modulate multiple targets relevant to a disease.  DMLs offer the potential to yield greater efficacy over monotherapies, either by modulating different biol. pathways, or by boosting a single one.  However, examples of DMLs progressing into clin. trials, or onto the market are rare; DML drug discovery is challenging, and perceived by some to be almost impossible.  Nevertheless, with the judicious selection of biol. targets, both from a biol. and chem. perspective, it is possible to develop drug-like DMLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqsRea2XH7-7Vg90H21EOLACvtfcHk0lh9w1ijR3a9IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVertL8%253D&md5=56204a6c37b64ee11d3f6bd617cad00b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DGattrell%26aufirst%3DW.%26aulast%3DJohnstone%26aufirst%3DC.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DC.%2BS.%26aulast%3DScheel%26aufirst%3DA.%26aulast%3DSchindler%26aufirst%3DM.%26atitle%3DDesigned%2520Multiple%2520Ligands%2520in%2520Metabolic%2520Disease%2520Research%253A%2520From%2520Concept%2520to%2520Platform%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26issue%3D15%25E2%2580%259316%26spage%3D692%26epage%3D696%26doi%3D10.1016%2Fj.drudis.2013.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grivennikov, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greten, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span> <span> </span><span class="NLM_article-title">Immunity, Inflammation, and Cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.01.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.cell.2010.01.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20303878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVSgu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=883-899&issue=6&author=S.+I.+Grivennikovauthor=F.+R.+Gretenauthor=M.+Karin&title=Immunity%2C+Inflammation%2C+and+Cancer&doi=10.1016%2Fj.cell.2010.01.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Immunity, inflammation, and cancer</span></div><div class="casAuthors">Grivennikov, Sergei I.; Greten, Florian R.; Karin, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">883-899</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Inflammatory responses play decisive roles at different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis.  Inflammation also affects immune surveillance and responses to therapy.  Immune cells that infiltrate tumors engage in an extensive and dynamic crosstalk with cancer cells, and some of the mol. events that mediate this dialog have been revealed.  This review outlines the principal mechanisms that govern the effects of inflammation and immunity on tumor development and discusses attractive new targets for cancer therapy and prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSKC7HKir8HLVg90H21EOLACvtfcHk0liZal8Zod49lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVSgu7g%253D&md5=5d554f70b26c479b72d934a462ac2086</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.01.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.01.025%26sid%3Dliteratum%253Aachs%26aulast%3DGrivennikov%26aufirst%3DS.%2BI.%26aulast%3DGreten%26aufirst%3DF.%2BR.%26aulast%3DKarin%26aufirst%3DM.%26atitle%3DImmunity%252C%2520Inflammation%252C%2520and%2520Cancer%26jtitle%3DCell%26date%3D2010%26volume%3D140%26issue%3D6%26spage%3D883%26epage%3D899%26doi%3D10.1016%2Fj.cell.2010.01.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlocco, D.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands: Basic Research vs Clinical Outcomes</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3387</span>, <span class="refDoi"> DOI: 10.2174/092986712801215883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F092986712801215883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22680630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOhtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=3353-3387&issue=20&author=L.+Costantinoauthor=D.+Barlocco&title=Designed+Multiple+Ligands%3A+Basic+Research+vs+Clinical+Outcomes&doi=10.2174%2F092986712801215883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Designed multiple ligands: basic research vs clinical outcomes</span></div><div class="casAuthors">Costantino, L.; Barlocco, D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3353-3387</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The clin. treatment of multifactorial pathologies (e.g. cancer, Alzheimer's disease, psychiatric disorders), is still a major challenge.  Many researches have been published dealing with the design of multiple ligands, able to act at the same time towards several targets relevant for a given pathol.  In the present review, the clin. results about these compds. have been reported, together with the design strategy adopted, in order to allow a crit. evaluation of the outcomes of these efforts.  What is emerging is that several effective design strategies of multitarget compds. are available, and the choice among these appears to be dependent on the therapeutic area considered.  However, at present, besides multitarget drugs discovered during optimization efforts by means of phenotypic assays, drug coadministrations or fixed dose formulations appear to be more useful therapeutic options than designed multiple ligands; this scenario will change when systems biol. will be able to select crit. targets, i.e. nodal proteins that should be inhibited in order to obtain a therapeutic action; at this point, the design of multiple ligands will allow a renaissance of medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobv_P2UM6L_7Vg90H21EOLACvtfcHk0liZal8Zod49lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOhtrrN&md5=82123bbafc10a19c65a0bc0c5be72546</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F092986712801215883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712801215883%26sid%3Dliteratum%253Aachs%26aulast%3DCostantino%26aufirst%3DL.%26aulast%3DBarlocco%26aufirst%3DD.%26atitle%3DDesigned%2520Multiple%2520Ligands%253A%2520Basic%2520Research%2520vs%2520Clinical%2520Outcomes%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26issue%3D20%26spage%3D3353%26epage%3D3387%26doi%3D10.2174%2F092986712801215883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology in a Single Drug: Multitarget Drugs</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.2174/0929867311320130004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F0929867311320130004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23410164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1639-1645&issue=13&author=M.+L.+Bolognesi&title=Polypharmacology+in+a+Single+Drug%3A+Multitarget+Drugs&doi=10.2174%2F0929867311320130004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology in a single drug: multitarget drugs</span></div><div class="casAuthors">Bolognesi, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1639-1645</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases.  It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these.  Polypharmacol. can involve combinations and/or multitarget drugs (MTD).  Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations.  This review article focuses on MTDs from a medicinal chem. perspective.  I will explore their use in current clin. practice, their likely application in the future, and the challenges to be overcome to achieve this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeSnmeFeRpMrVg90H21EOLACvtfcHk0liMJ7nV4pgZ6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D&md5=0e69395566711e018db8a61b1ae0f56e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130004%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DPolypharmacology%2520in%2520a%2520Single%2520Drug%253A%2520Multitarget%2520Drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D13%26spage%3D1639%26epage%3D1645%26doi%3D10.2174%2F0929867311320130004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehár, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Therapeutics: When the Whole Is Greater Than the Sum of the Parts</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&issue=1&author=G.+R.+Zimmermannauthor=J.+Leh%C3%A1rauthor=C.+T.+Keith&title=Multi-Target+Therapeutics%3A+When+the+Whole+Is+Greater+Than+the+Sum+of+the+Parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2eYMBrf2Kq8zKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-Target%2520Therapeutics%253A%2520When%2520the%2520Whole%2520Is%2520Greater%2520Than%2520the%2520Sum%2520of%2520the%2520Parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D1%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitznagel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybeck, T. R.</span></span> <span> </span><span class="NLM_article-title">The Effect of Prescribed Daily Dose Frequency on Patient Medication Compliance</span>. <i>Arch. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>150</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1881</span>– <span class="NLM_lpage">1884</span>, <span class="refDoi"> DOI: 10.1001/archinte.1990.00390200073014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1001%2Farchinte.1990.00390200073014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=2102668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADyaK3czmsFGltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=1990&pages=1881-1884&issue=9&author=S.+A.+Eisenauthor=D.+K.+Millerauthor=R.+S.+Woodwardauthor=E.+Spitznagelauthor=T.+R.+Przybeck&title=The+Effect+of+Prescribed+Daily+Dose+Frequency+on+Patient+Medication+Compliance&doi=10.1001%2Farchinte.1990.00390200073014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of prescribed daily dose frequency on patient medication compliance</span></div><div class="casAuthors">Eisen S A; Miller D K; Woodward R S; Spitznagel E; Przybeck T R</div><div class="citationInfo"><span class="NLM_cas:title">Archives of internal medicine</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1881-4</span>
        ISSN:<span class="NLM_cas:issn">0003-9926</span>.
    </div><div class="casAbstract">The objective of this study was to determine the relationship between prescribed daily dose frequency and patient medication compliance.  The medication compliance of 105 patients receiving antihypertensive medications was monitored by analyzing data obtained from special pill containers that electronically record the date and time of medication removal.  Inaccurate compliance estimates derived using the simple pill count method were thereby avoided.  Compliance was defined as the percent of days during which the prescribed number of doses were removed.  Compliance improved from 59.0% on a three-time daily regimen to 83.6% on a once-daily regimen.  Thus, compliance improves dramatically as prescribed dose frequency decreases.  Probably the single most important action that health care providers can take to improve compliance is to select medications that permit the lowest daily prescribed dose frequency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ77B5mAT4PZMRAV4D_Ins_fW6udTcc2ebTdThE8V8Y0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3czmsFGltg%253D%253D&md5=83afa34a4f1dafc6e0ab4bc87c33026c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1001%2Farchinte.1990.00390200073014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchinte.1990.00390200073014%26sid%3Dliteratum%253Aachs%26aulast%3DEisen%26aufirst%3DS.%2BA.%26aulast%3DMiller%26aufirst%3DD.%2BK.%26aulast%3DWoodward%26aufirst%3DR.%2BS.%26aulast%3DSpitznagel%26aufirst%3DE.%26aulast%3DPrzybeck%26aufirst%3DT.%2BR.%26atitle%3DThe%2520Effect%2520of%2520Prescribed%2520Daily%2520Dose%2520Frequency%2520on%2520Patient%2520Medication%2520Compliance%26jtitle%3DArch.%2520Intern.%2520Med.%26date%3D1990%26volume%3D150%26issue%3D9%26spage%3D1881%26epage%3D1884%26doi%3D10.1001%2Farchinte.1990.00390200073014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benazzi, F.</span></span> <span> </span><span class="NLM_article-title">Severe Anticholinergic Side Effects with Venlafaxine-Fluoxetine Combination</span>. <i>Can. J. Psychiat.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">980</span>– <span class="NLM_lpage">981</span>, <span class="refDoi"> DOI: 10.1177/070674379704200916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1177%2F070674379704200916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=9429070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADyaK1c%252FptVOlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1997&pages=980-981&issue=9&author=F.+Benazzi&title=Severe+Anticholinergic+Side+Effects+with+Venlafaxine-Fluoxetine+Combination&doi=10.1177%2F070674379704200916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Severe anticholinergic side effects with venlafaxine-fluoxetine combination</span></div><div class="casAuthors">Benazzi F</div><div class="citationInfo"><span class="NLM_cas:title">Canadian journal of psychiatry. Revue canadienne de psychiatrie</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">980-1</span>
        ISSN:<span class="NLM_cas:issn">0706-7437</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOuldGgM09iwHqQV89nF-2fW6udTcc2ebTdThE8V8Y0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252FptVOlug%253D%253D&md5=851586ec8f23a093b7ed9a172f855ad8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1177%2F070674379704200916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F070674379704200916%26sid%3Dliteratum%253Aachs%26aulast%3DBenazzi%26aufirst%3DF.%26atitle%3DSevere%2520Anticholinergic%2520Side%2520Effects%2520with%2520Venlafaxine-Fluoxetine%2520Combination%26jtitle%3DCan.%2520J.%2520Psychiat.%26date%3D1997%26volume%3D42%26issue%3D9%26spage%3D980%26epage%3D981%26doi%3D10.1177%2F070674379704200916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&issue=2&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+Design%3A+A+Medicinal+Chemist%E2%80%99s+Perspective+on+Multitargeting+Compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0lggWKvLEP1mFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520Design%253A%2520A%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Perspective%2520on%2520Multitargeting%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D2%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry Approaches for Multitarget Drugs</span>. <i>Burger’s Med. Chem. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1002/0471266949.bmc124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2F0471266949.bmc124" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=249-274&author=R.+Morphyauthor=Z.+Rankovic&title=Medicinal+Chemistry+Approaches+for+Multitarget+Drugs&doi=10.1002%2F0471266949.bmc124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2F0471266949.bmc124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471266949.bmc124%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DMedicinal%2520Chemistry%2520Approaches%2520for%2520Multitarget%2520Drugs%26jtitle%3DBurger%25E2%2580%2599s%2520Med.%2520Chem.%2520Drug%2520Discovery%26date%3D2010%26spage%3D249%26epage%3D274%26doi%3D10.1002%2F0471266949.bmc124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">From Magic Bullets to Designed Multiple Ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&issue=15&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+Magic+Bullets+to+Designed+Multiple+Ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lggWKvLEP1mFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520Magic%2520Bullets%2520to%2520Designed%2520Multiple%2520Ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D15%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designing Multiple Ligands - Medicinal Chemistry Strategies and Challenges</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.2174/138161209787315594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F138161209787315594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19199984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=587-600&issue=6&author=R.+Morphyauthor=Z.+Rankovic&title=Designing+Multiple+Ligands+-+Medicinal+Chemistry+Strategies+and+Challenges&doi=10.2174%2F138161209787315594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multiple ligands - medicinal chemistry strategies and challenges</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been widely recognized over the recent years that parallel modulation of multiple biol. targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease.  In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a no. of illustrative example are given.  Designing multiple ligands is frequently a challenging endeavor for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets while obtaining physicochem. and pharmacokinetic properties that are consistent with the administration of an oral drug.  Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUo6NjoK5D-LVg90H21EOLACvtfcHk0ljfFBbdOE9UEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D&md5=fa34039be6e9c3b489f530fc74fd0346</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F138161209787315594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315594%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigning%2520Multiple%2520Ligands%2520-%2520Medicinal%2520Chemistry%2520Strategies%2520and%2520Challenges%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26issue%3D6%26spage%3D587%26epage%3D600%26doi%3D10.2174%2F138161209787315594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Fragments, Network Biology and Designing Multiple Ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2006.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17275736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=156-160&issue=3&author=R.+Morphyauthor=Z.+Rankovic&title=Fragments%2C+Network+Biology+and+Designing+Multiple+Ligands&doi=10.1016%2Fj.drudis.2006.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Fragments, network biology and designing multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3&4</span>),
    <span class="NLM_cas:pages">156-160</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Modulating multiple protein targets simultaneously can be beneficial for treating complex diseases.  The redundancy that exists within biol. networks means that modulating single proteins might not be sufficient to produce the desired efficacy while, at the same time, minimizing adverse effects.  Designing multi-target drugs can be challenging for medicinal chemists, with current lead-discovery strategies often producing large, complex mols. with low ligand efficiency and poor oral bioavailability.  Paradoxically, analyses of the relationship between the selectivity of biol. active compds. and their mol. size suggest that promiscuous compds. should typically be smaller than target-selective compds.  A fragment-based approach to multi-target drug discovery could lead to a new generation of compds. with improved physicochem. and pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXRYwI33BCNLVg90H21EOLACvtfcHk0ljfFBbdOE9UEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtleisbs%253D&md5=64a3c7e8c3280db166dda799a77d689a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFragments%252C%2520Network%2520Biology%2520and%2520Designing%2520Multiple%2520Ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26issue%3D3%26spage%3D156%26epage%3D160%26doi%3D10.1016%2Fj.drudis.2006.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed Multiple Ligands. An Emerging Drug Discovery Paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&issue=21&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+Multiple+Ligands.+An+Emerging+Drug+Discovery+Paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ljcntIXWYh1Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520Multiple%2520Ligands.%2520An%2520Emerging%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D21%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valgimigli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Multi-Target-Directed Drug Design Strategy: From a Dual Binding Site Acetylcholinesterase Inhibitor to a Trifunctional Compound against Alzheimer’s Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">6446</span>– <span class="NLM_lpage">6449</span>, <span class="refDoi"> DOI: 10.1021/jm701225u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701225u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOgsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6446-6449&issue=26&author=M.+L.+Bolognesiauthor=A.+Cavalliauthor=L.+Valgimigliauthor=M.+Bartoliniauthor=M.+Rosiniauthor=V.+Andrisanoauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-Target-Directed+Drug+Design+Strategy%3A+From+a+Dual+Binding+Site+Acetylcholinesterase+Inhibitor+to+a+Trifunctional+Compound+against+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fjm701225u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-directed drug design strategy: From a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease</span></div><div class="casAuthors">Bolognesi, Maria Laura; Cavalli, Andrea; Valgimigli, Luca; Bartolini, Manuela; Rosini, Michela; Andrisano, Vincenza; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">6446-6449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A design strategy to convert a dual-binding site AChE inhibitor into triple functional compds. with promising in vitro profile against multifactorial syndromes, such as Alzheimer's disease, is proposed.  The lead compd. bis(7)-tacrine was properly modified to confer to the new mols. the ability of chelating metals, involved in the neurodegenerative process.  The multifunctional compds. show activity against human AChE, are able to inhibit the AChE-induced amyloid-β aggregation, and chelate metals, such as iron and copper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEt8652LxJMbVg90H21EOLACvtfcHk0ljcntIXWYh1Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOgsr7O&md5=07a8b5a6495b9759256a36d2bfebbd29</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm701225u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701225u%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DValgimigli%26aufirst%3DL.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-Target-Directed%2520Drug%2520Design%2520Strategy%253A%2520From%2520a%2520Dual%2520Binding%2520Site%2520Acetylcholinesterase%2520Inhibitor%2520to%2520a%2520Trifunctional%2520Compound%2520against%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D26%26spage%3D6446%26epage%3D6449%26doi%3D10.1021%2Fjm701225u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lötsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span> <span> </span><span class="NLM_article-title">Low-Dose Drug Combinations Along Molecular Pathways Could Maximize Therapeutic Effectiveness While Minimizing Collateral Adverse Effects</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2011.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22016087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FjtVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=1001-1006&issue=23&author=J.+L%C3%B6tschauthor=G.+Geisslinger&title=Low-Dose+Drug+Combinations+Along+Molecular+Pathways+Could+Maximize+Therapeutic+Effectiveness+While+Minimizing+Collateral+Adverse+Effects&doi=10.1016%2Fj.drudis.2011.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects</span></div><div class="casAuthors">Lotsch Jorn; Geisslinger Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">1001-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increasing knowledge of molecular signaling processes has enabled the identification of drug targets that synergistically address multifactorial symptoms along several contributing pathways.  The idea behind 'polypills' is that minor doses of pharmacodynamically interacting drugs would selectively achieve intended clinical effects.  Analogously, monofactorial symptoms could be addressed vertically along their main pathway.  Clinical selectivity follows from successive incomplete inhibitions of the pathological pathway at several steps.  Here, we discuss and exemplify of how successive inhibitions in the prostaglandin E2 (PGE(2)) signaling pathway could achieve anti-inflammatory and analgesic effects while preserving physiological PGE(2) signaling in organs of major toxicity.  Intentionally using intelligent low-dose drug combinations might provide an innovative therapeutic concept that directs combined small-drug effects towards a large, selective clinical effect with minor collateral damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRu7M3C_0-j-dfST00W0BcfW6udTcc2eb9R1d6_OI3hbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FjtVygtg%253D%253D&md5=f88337f88016a3736e13e493dc064089</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6tsch%26aufirst%3DJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26atitle%3DLow-Dose%2520Drug%2520Combinations%2520Along%2520Molecular%2520Pathways%2520Could%2520Maximize%2520Therapeutic%2520Effectiveness%2520While%2520Minimizing%2520Collateral%2520Adverse%2520Effects%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26issue%3D23%26spage%3D1001%26epage%3D1006%26doi%3D10.1016%2Fj.drudis.2011.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&issue=19&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+Opportunities+in+Drug+Discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lhaG2rln53iLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520Opportunities%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D19%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Strategies for Modern Biomarker and Drug Development in Oncology</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1186/s13045-014-0070-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1186%2Fs13045-014-0070-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25277503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=70-85&issue=1&author=A.+D.+Smithauthor=D.+Rodaauthor=T.+A.+Yap&title=Strategies+for+Modern+Biomarker+and+Drug+Development+in+Oncology&doi=10.1186%2Fs13045-014-0070-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for modern biomarker and drug development in oncology</span></div><div class="casAuthors">Smith, Alan D.; Roda, Desam; Yap, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">70/1-70/16</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Technol. advancements in the mol. characterization of cancers have enabled researchers to identify an increasing no. of key mol. drivers of cancer progression.  These discoveries have led to multiple novel anticancer therapeutics, and clin. benefit in selected patient populations.  Despite this, the identification of clin. relevant predictive biomarkers of response continues to lag behind.  In this review, we discuss strategies for the mol. characterization of cancers and the importance of biomarkers for the development of novel antitumor therapeutics.  We also review crit. successes and failures in oncol., and detail the lessons learnt, which may aid in the acceleration of anticancer drug development and biomarker discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWNEkFi4M0pLVg90H21EOLACvtfcHk0lhaG2rln53iLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVOrsQ%253D%253D&md5=735ba9bd2f866b407057dd5cb89e839f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1186%2Fs13045-014-0070-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-014-0070-8%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BD.%26aulast%3DRoda%26aufirst%3DD.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DStrategies%2520for%2520Modern%2520Biomarker%2520and%2520Drug%2520Development%2520in%2520Oncology%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2014%26volume%3D7%26issue%3D1%26spage%3D70%26epage%3D85%26doi%3D10.1186%2Fs13045-014-0070-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, A.</span></span> <span> </span><span class="NLM_article-title">Glivec (STI571, Imatinib), a Rationally Developed, Targeted Anticancer Drug</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1038/nrd839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&issue=7&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+Imatinib%29%2C+a+Rationally+Developed%2C+Targeted+Anticancer+Drug&doi=10.1038%2Fnrd839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0liDbVKN2c9Cgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520Imatinib%2529%252C%2520a%2520Rationally%2520Developed%252C%2520Targeted%2520Anticancer%2520Drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D7%26spage%3D493%26epage%3D502%26doi%3D10.1038%2Fnrd839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
los Ríos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iriepa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gálvez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarroya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Inhibitory Activity of Cholinesterases, and Neuroprotective Profile of Novel 1,8-Naphthyridine Derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5129</span>– <span class="NLM_lpage">5143</span>, <span class="refDoi"> DOI: 10.1021/jm901902w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901902w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVKqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5129-5143&issue=14&author=C.+De%0Alos+R%C3%ADosauthor=J.+Egeaauthor=J.+Marco-Contellesauthor=R.+Le%C3%B3nauthor=A.+Samadiauthor=I.+Iriepaauthor=I.+Moraledaauthor=E.+G%C3%A1lvezauthor=A.+G.+Garc%C3%ADaauthor=M.+G.+L%C3%B3pezauthor=M.+Villarroyaauthor=A.+Romero&title=Synthesis%2C+Inhibitory+Activity+of+Cholinesterases%2C+and+Neuroprotective+Profile+of+Novel+1%2C8-Naphthyridine+Derivatives&doi=10.1021%2Fjm901902w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Inhibitory Activity of Cholinesterases, and Neuroprotective Profile of Novel 1,8-Naphthyridine Derivatives</span></div><div class="casAuthors">de los Rios, Cristobal; Egea, Javier; Marco-Contelles, Jose; Leon, Rafael; Samadi, Abdelouahid; Iriepa, Isabel; Moraleda, Ignacio; Galvez, Enrique; Garcia, Antonio G.; Lopez, Manuela G.; Villarroya, Mercedes; Romero, Alejandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5129-5143</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1,8-Naphthyridine derivs. related to neuroprotective compd. I (ITH4012) have been synthesized.  In general, they have shown better inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) than most related tacrine derivs.  The compds. presented an interesting neuroprotective profile in SH-SY5Y neuroblastoma cells stressed with rotenone/oligomycin A.  Moreover, compd. II also caused protection in cells stressed with okadaic acid (OA) or amyloid β 1-42 peptide (Aβ1-42).  Interestingly, compd. II prevented the OA-induced PP2A inhibition, one of the enzymes implicated in τ dephosphorylation.  This compd. also exhibited neuroprotection against neurotoxicity elicited by oxygen and glucose deprivation in hippocampal slices.  Because these stressors caused neuronal damage related to physiopathol. hallmarks found in the brain of Alzheimer's disease (AD) patients, we conclude that compd. II deserves further in vivo studies in AD models to test its therapeutic potential in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn990-FK7y87Vg90H21EOLACvtfcHk0liDbVKN2c9Cgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVKqsbg%253D&md5=92d0cf582eb9816f03c72a2f8344883f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm901902w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901902w%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2Blos%2BR%25C3%25ADos%26aufirst%3DC.%26aulast%3DEgea%26aufirst%3DJ.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DLe%25C3%25B3n%26aufirst%3DR.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DG%25C3%25A1lvez%26aufirst%3DE.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25B3pez%26aufirst%3DM.%2BG.%26aulast%3DVillarroya%26aufirst%3DM.%26aulast%3DRomero%26aufirst%3DA.%26atitle%3DSynthesis%252C%2520Inhibitory%2520Activity%2520of%2520Cholinesterases%252C%2520and%2520Neuroprotective%2520Profile%2520of%2520Novel%25201%252C8-Naphthyridine%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D14%26spage%3D5129%26epage%3D5143%26doi%3D10.1021%2Fjm901902w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de los Ríos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huertas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Franco, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">do Carmo Carreiras, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarroya, M.</span></span> <span> </span><span class="NLM_article-title">Tacripyrines, the First Tacrine-Dihydropyridine Hybrids, as Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2724</span>– <span class="NLM_lpage">2732</span>, <span class="refDoi"> DOI: 10.1021/jm801292b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801292b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkslCqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2724-2732&issue=9&author=J.+Marco-Contellesauthor=R.+Le%C3%B3nauthor=C.+de+los+R%C3%ADosauthor=A.+Samadiauthor=M.+Bartoliniauthor=V.+Andrisanoauthor=O.+Huertasauthor=X.+Barrilauthor=F.+J.+Luqueauthor=M.+I.+Rodr%C3%ADguez-Francoauthor=B.+L%C3%B3pezauthor=M.+G.+L%C3%B3pezauthor=A.+G.+Garc%C3%ADaauthor=M.+do+Carmo+Carreirasauthor=M.+Villarroya&title=Tacripyrines%2C+the+First+Tacrine-Dihydropyridine+Hybrids%2C+as+Multitarget-Directed+Ligands+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fjm801292b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Tacripyrines, the First Tacrine-Dihydropyridine Hybrids, as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Marco-Contelles, Jose; Leon, Rafael; de los Rios, Cristobal; Samadi, Abdelouahid; Bartolini, Manuela; Andrisano, Vincenza; Huertas, Oscar; Barril, Xavier; Luque, F. Javier; Rodriguez-Franco, Maria I.; Lopez, Beatriz; Lopez, Manuela G.; Garcia, Antonio G.; Carreiras, Maria do Carmo; Villarroya, Mercedes</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2724-2732</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tacripyrines (1-14) have been designed by combining an AChE inhibitor (tacrine) with a calcium antagonist such as nimodipine and are targeted to develop a multitarget therapeutic strategy to confront AD.  Tacripyrines are selective and potent AChE inhibitors in the nanomolar range.  The mixed type inhibition of hAChE activity of compd. 11 (IC50 105 ± 15 nM) is assocd. to a 30.7 ± 8.6% inhibition of the proaggregating action of AChE on the Aβ and a moderate inhibition of Aβ self-aggregation (34.9 ± 5.4%).  Mol. modeling indicates that binding of compd. 11 to the AChE PAS mainly involves the (R)-11 enantiomer, which also agrees with the noncompetitive inhibition mechanism exhibited by p-methoxytacripyrine 11.  Tacripyrines are neuroprotective agents, show moderate Ca2+ channel blocking effect, and cross the blood-brain barrier, emerging as lead candidates for treating AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrz5BaASigkrVg90H21EOLACvtfcHk0lhv9V7M0oFvZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkslCqtL4%253D&md5=ca6ad88e3ac305a398654c26e936cf5e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm801292b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801292b%26sid%3Dliteratum%253Aachs%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DLe%25C3%25B3n%26aufirst%3DR.%26aulast%3Dde%2Blos%2BR%25C3%25ADos%26aufirst%3DC.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DHuertas%26aufirst%3DO.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DRodr%25C3%25ADguez-Franco%26aufirst%3DM.%2BI.%26aulast%3DL%25C3%25B3pez%26aufirst%3DB.%26aulast%3DL%25C3%25B3pez%26aufirst%3DM.%2BG.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DA.%2BG.%26aulast%3Ddo%2BCarmo%2BCarreiras%26aufirst%3DM.%26aulast%3DVillarroya%26aufirst%3DM.%26atitle%3DTacripyrines%252C%2520the%2520First%2520Tacrine-Dihydropyridine%2520Hybrids%252C%2520as%2520Multitarget-Directed%2520Ligands%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D9%26spage%3D2724%26epage%3D2732%26doi%3D10.1021%2Fjm801292b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Priest, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdemli, G.</span></span> <span> </span><span class="NLM_article-title">Phenotypic Screening in the 21st Century</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.3389/fphar.2014.00264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3389%2Ffphar.2014.00264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25520660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC2MvgvVKqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=264-265&author=B.+T.+Priestauthor=G.+Erdemli&title=Phenotypic+Screening+in+the+21st+Century&doi=10.3389%2Ffphar.2014.00264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening in the 21st century</span></div><div class="casAuthors">Priest Birgit T; Erdemli Gul</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">264</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOCl0Oo1R-_MSzjBFCN0BJfW6udTcc2ebQx1E3moJ-7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvgvVKqtw%253D%253D&md5=d9f314f46f7272d0cb6c43d50eccce87</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00264%26sid%3Dliteratum%253Aachs%26aulast%3DPriest%26aufirst%3DB.%2BT.%26aulast%3DErdemli%26aufirst%3DG.%26atitle%3DPhenotypic%2520Screening%2520in%2520the%252021st%2520Century%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D264%26epage%3D265%26doi%3D10.3389%2Ffphar.2014.00264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seshacharyulu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponnusamy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haridas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganti, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, S. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the EGFR Signaling Pathway in Cancer Therapy</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1517/14728222.2011.648617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1517%2F14728222.2011.648617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22239438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Wksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=15-31&issue=1&author=P.+Seshacharyuluauthor=M.+P.+Ponnusamyauthor=D.+Haridasauthor=M.+Jainauthor=A.+K.+Gantiauthor=S.+K.+Batra&title=Targeting+the+EGFR+Signaling+Pathway+in+Cancer+Therapy&doi=10.1517%2F14728222.2011.648617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the EGFR signaling pathway in cancer therapy</span></div><div class="casAuthors">Seshacharyulu, Parthasarathy; Ponnusamy, Moorthy P.; Haridas, Dhanya; Jain, Maneesh; Ganti, Apar K.; Batra, Surinder K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-31</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Cancer is a devastating disease; however, several therapeutic advances have recently been made, wherein EGFR and its family members have emerged as useful biomarkers and therapeutic targets.  EGFR, a transmembrane glycoprotein is a member of the ERBB receptor tyrosine kinase superfamily.  EGFR binds to its cognate ligand EGF, which further induces tyrosine phosphorylation and receptor dimerization with other family members leading to enhanced uncontrolled proliferation.  Several anti-EGFR therapies such as monoclonal antibodies and tyrosine kinase inhibitors have been developed, which has enabled clinicians to identify and treat specific patient cohorts.Areas covered: This review covers the basic mechanism of EGFR activation and the role of EGFR signaling in cancer progression.  Furthermore, current developments made toward targeting the EGFR signaling pathway for the treatment of epithelial cancers and a summary of the various anti-EGFR therapeutic agents that are currently in use are also presented in this review.Expert opinion: EGFR signaling is a part of a complex network that has been the target of effective cancer therapies.  However, a further understanding of the system is required to develop an effective anticancer regimen.  A combination therapy that comprises an anti-EGFR and a chemotherapeutic/chemopreventive agent will exhibit a multi-pronged approach that can be developed into a highly attractive and specific mol. oriented remedy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDi_-cVSomx7Vg90H21EOLACvtfcHk0lgACz0Y0JD2cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Wksw%253D%253D&md5=91357f1fb76bd06c03d4269f90ad907a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.648617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.648617%26sid%3Dliteratum%253Aachs%26aulast%3DSeshacharyulu%26aufirst%3DP.%26aulast%3DPonnusamy%26aufirst%3DM.%2BP.%26aulast%3DHaridas%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DM.%26aulast%3DGanti%26aufirst%3DA.%2BK.%26aulast%3DBatra%26aufirst%3DS.%2BK.%26atitle%3DTargeting%2520the%2520EGFR%2520Signaling%2520Pathway%2520in%2520Cancer%2520Therapy%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2012%26volume%3D16%26issue%3D1%26spage%3D15%26epage%3D31%26doi%3D10.1517%2F14728222.2011.648617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Läubli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amico, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashyap, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zippelius, A.</span></span> <span> </span><span class="NLM_article-title">The Multi-Receptor Inhibitor Axitinib Reverses Tumor-Induced Immunosuppression and Potentiates Treatment with Immune-Modulatory Antibodies in Preclinical Murine Models</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">824</span>, <span class="refDoi"> DOI: 10.1007/s00262-018-2136-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1007%2Fs00262-018-2136-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29487979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktVyru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2018&pages=815-824&issue=5&author=H.+L%C3%A4ubliauthor=P.+M%C3%BCllerauthor=L.+D%E2%80%99Amicoauthor=M.+Buchiauthor=A.+S.+Kashyapauthor=A.+Zippelius&title=The+Multi-Receptor+Inhibitor+Axitinib+Reverses+Tumor-Induced+Immunosuppression+and+Potentiates+Treatment+with+Immune-Modulatory+Antibodies+in+Preclinical+Murine+Models&doi=10.1007%2Fs00262-018-2136-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models</span></div><div class="casAuthors">Laubli, Heinz; Muller, Philipp; D'Amico, Lucia; Buchi, Melanie; Kashyap, Abhishek S.; Zippelius, Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">815-824</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cancer immunotherapies have significantly improved the prognosis of cancer patients.  Despite the clin. success of targeting inhibitory checkpoint receptors, including PD-1 and/or CTLA-4 on T cells, only a minority of patients derive benefit from these therapies.  New strategies to improve cancer immunotherapy are therefore needed.  Combination therapy of checkpoint inhibitors with targeted agents has promisingly shown to increase the efficacy of immunotherapy.  Here, we analyzed the immunomodulatory effects of the multi-receptor tyrosine kinase inhibitor axitinib and its efficacy in combination with immunotherapies.  In different syngeneic murine tumor models, axitinib showed therapeutic efficacy that was not only mediated by VEGF-VEGFR inhibition, but also through the induction of anti-cancer immunity.  Mechanistically, a significant redn. of immune-suppressive cells, including a decrease of tumor-promoting mast cells and tumor-assocd. macrophages was obsd. upon axitinib treatment.  Inhibition of mast cells by axitinib as well as their exptl. depletion led to reduced tumor growth.  Of note, treatment with axitinib led to an improved T cell response, while the latter was pivotal for the therapeutic efficacy.  Combination with immune checkpoint inhibitors anti-PD-1 and anti-TIM-3 and/or agonistic engagement of the activating receptor CD137 resulted in a synergistic therapeutic efficacy.  This demonstrates non-redundant immune activation induced by axitinib via modulation of myeloid and mast cells.  These findings provide important mechanistic insights into axitinib-mediated anti-cancer immunity and provide rationale for clin. combinations of axitinib with different immunotherapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCLQVx7zMMu7Vg90H21EOLACvtfcHk0lgACz0Y0JD2cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktVyru74%253D&md5=0cc2cfdc9c7caf2da9f9854705ca9e94</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs00262-018-2136-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-018-2136-x%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25A4ubli%26aufirst%3DH.%26aulast%3DM%25C3%25BCller%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Amico%26aufirst%3DL.%26aulast%3DBuchi%26aufirst%3DM.%26aulast%3DKashyap%26aufirst%3DA.%2BS.%26aulast%3DZippelius%26aufirst%3DA.%26atitle%3DThe%2520Multi-Receptor%2520Inhibitor%2520Axitinib%2520Reverses%2520Tumor-Induced%2520Immunosuppression%2520and%2520Potentiates%2520Treatment%2520with%2520Immune-Modulatory%2520Antibodies%2520in%2520Preclinical%2520Murine%2520Models%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2018%26volume%3D67%26issue%3D5%26spage%3D815%26epage%3D824%26doi%3D10.1007%2Fs00262-018-2136-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balancon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berton, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genicot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberty, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallemand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirlot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quere, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talaga, P.</span></span> <span> </span><span class="NLM_article-title">First Dual NK<sub>1</sub> Antagonists-Serotonin Reuptake Inhibitors: Synthesis and SAR of a New Class of Potential Antidepressants</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00727-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0960-894X%2801%2900727-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11755367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsV2i" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=261-261&issue=2&author=T.+Ryckmansauthor=L.+Balanconauthor=O.+Bertonauthor=C.+Genicotauthor=Y.+Lambertyauthor=B.+Lallemandauthor=P.+Pasauauthor=N.+Pirlotauthor=L.+Quereauthor=P.+Talaga&title=First+Dual+NK1+Antagonists-Serotonin+Reuptake+Inhibitors%3A+Synthesis+and+SAR+of+a+New+Class+of+Potential+Antidepressants&doi=10.1016%2FS0960-894X%2801%2900727-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">First dual NK1 antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants</span></div><div class="casAuthors">Ryckmans, Thomas; Balancon, Laurent; Berton, Olivier; Genicot, Christophe; Lamberty, Yves; Lallemand, Benedicte; Pasau, Patrick; Pirlot, Nathalie; Quere, Luc; Talaga, Patrice</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">261-264</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Compds. combining NK1 antagonism and serotonin reuptake inhibition are described, and potentially represent a new generation of antidepressants.  Compd. I displays good affinities for both the NK1 receptor and the serotonin reuptake site (32 and 25 nM, resp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgto-S8efa1rVg90H21EOLACvtfcHk0lhVOKoSH8wO0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsV2i&md5=c0b66a90c6d86e650fd1782409ea4976</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900727-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900727-2%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DBalancon%26aufirst%3DL.%26aulast%3DBerton%26aufirst%3DO.%26aulast%3DGenicot%26aufirst%3DC.%26aulast%3DLamberty%26aufirst%3DY.%26aulast%3DLallemand%26aufirst%3DB.%26aulast%3DPasau%26aufirst%3DP.%26aulast%3DPirlot%26aufirst%3DN.%26aulast%3DQuere%26aufirst%3DL.%26aulast%3DTalaga%26aufirst%3DP.%26atitle%3DFirst%2520Dual%2520NK1%2520Antagonists-Serotonin%2520Reuptake%2520Inhibitors%253A%2520Synthesis%2520and%2520SAR%2520of%2520a%2520New%2520Class%2520of%2520Potential%2520Antidepressants%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26issue%3D2%26spage%3D261%26epage%3D261%26doi%3D10.1016%2FS0960-894X%2801%2900727-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, T.</span></span> <span> </span><span class="NLM_article-title">Approach to Dual-Acting Platelet Activating Factor (PAF) Receptor Antagonist/Thromboxane Synthase Inhibitor (TxSI) Based on the Link of Paf Antagonists and TxSIs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00731-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0960-894X%2801%2900731-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11814792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslKlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=341-344&issue=3&author=M.+Fujitaauthor=T.+Sekiauthor=H.+Inadaauthor=K.+Shimizuauthor=A.+Takahamaauthor=T.+Sano&title=Approach+to+Dual-Acting+Platelet+Activating+Factor+%28PAF%29+Receptor+Antagonist%2FThromboxane+Synthase+Inhibitor+%28TxSI%29+Based+on+the+Link+of+Paf+Antagonists+and+TxSIs&doi=10.1016%2FS0960-894X%2801%2900731-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs</span></div><div class="casAuthors">Fujita, Masakazu; Seki, Taketsugu; Inada, Haruaki; Shimizu, Kazuhiro; Takahama, Akane; Sano, Tetsuro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-344</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of compds. which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxSIs, such as ridogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5EjkkdRo9orVg90H21EOLACvtfcHk0lhVOKoSH8wO0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslKlug%253D%253D&md5=7fb11467ba0f5afff9ff1c7ed37a0263</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900731-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900731-4%26sid%3Dliteratum%253Aachs%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DInada%26aufirst%3DH.%26aulast%3DShimizu%26aufirst%3DK.%26aulast%3DTakahama%26aufirst%3DA.%26aulast%3DSano%26aufirst%3DT.%26atitle%3DApproach%2520to%2520Dual-Acting%2520Platelet%2520Activating%2520Factor%2520%2528PAF%2529%2520Receptor%2520Antagonist%252FThromboxane%2520Synthase%2520Inhibitor%2520%2528TxSI%2529%2520Based%2520on%2520the%2520Link%2520of%2520Paf%2520Antagonists%2520and%2520TxSIs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26issue%3D3%26spage%3D341%26epage%3D344%26doi%3D10.1016%2FS0960-894X%2801%2900731-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarcsay, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span> <span> </span><span class="NLM_article-title">Contributions of Molecular Properties to Drug Promiscuity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1795</span>, <span class="refDoi"> DOI: 10.1021/jm301514n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301514n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXns1ehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1789-1795&issue=5&author=%C3%81.+Tarcsayauthor=G.+M.+Keseru&title=Contributions+of+Molecular+Properties+to+Drug+Promiscuity&doi=10.1021%2Fjm301514n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Contributions of Molecular Properties to Drug Promiscuity</span></div><div class="casAuthors">Tarcsay, Akos; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1789-1795</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In contrast to designed polypharmacol. that can result in efficient drugs for complex disorders, unintended drug promiscuity has detrimental contribution to side effects and toxicol.  Characterization of promiscuous compds. enhances the understanding of complex interaction patterns and aids the design of compds. with broader selectivity against off-targets that has a major impact on medicinal chem. outcome.  In this Miniperspective we provide insights to the effect of physicochem. parameters on promiscuity.  Information collected from recent, large-scale in vitro studies enabled us to discuss the relationships between physicochem. properties and promiscuity in detail.  In light of these data, lipophilicity and basic character have the highest influence.  On the basis of the accumulated knowledge, we propose the extensive use of pre- and postsynthesis metrics, as well as strict control of physicochem. properties during medicinal chem. optimizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf1J_jqkK3DrVg90H21EOLACvtfcHk0lhVOKoSH8wO0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXns1ehug%253D%253D&md5=c5763ee1aed897ff19e5a2344b95b9c1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm301514n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301514n%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3D%25C3%2581.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DContributions%2520of%2520Molecular%2520Properties%2520to%2520Drug%2520Promiscuity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D5%26spage%3D1789%26epage%3D1795%26doi%3D10.1021%2Fjm301514n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Omar, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdu-Allah, A. A.H. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Moty, S. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Biological Evaluation and Docking Study of 1,3,4-Thiadiazole-Thiazolidinone Hybrids as Anti-Inflammatory Agents with Dual Inhibition of COX-2 and 15-LOX</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bioorg.2018.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29986191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yrs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2018&pages=461-471&author=Y.+M.+Omarauthor=A.+A.H.+H.+M.+Abdu-Allahauthor=S.+G.+Abdel-Moty&title=Synthesis%2C+Biological+Evaluation+and+Docking+Study+of+1%2C3%2C4-Thiadiazole-Thiazolidinone+Hybrids+as+Anti-Inflammatory+Agents+with+Dual+Inhibition+of+COX-2+and+15-LOX&doi=10.1016%2Fj.bioorg.2018.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation and docking study of 1,3,4-thiadiazole-thiazolidinone hybrids as anti-inflammatory agents with dual inhibition of COX-2 and 15-LOX</span></div><div class="casAuthors">Omar, Yasser M.; Abdu-Allah, Hajjaj H. M.; Abdel-Moty, Samia G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">461-471</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present study describes the synthesis, full characterization and biol. evaluation of a series of thiadiazole-thiazolidinone hybrids bearing 5-alk/arylidene as dual inhibitors of these enzymes.  The design was based on merging pharmacophores that exhibit potent anti-inflammatory activities in one mol. frame.  5-(4-Hydroxyphenyl)-1,3,4-thiadiazol-2-amine was efficiently synthesized, chloroacetylated and cyclized to give the key 4-thiazolidinone.  Knoevenagel condensation of the above compd. with different aldehydes afforded 1,3,4-thiadiazole-thiazolidinone hybrids I (R = Ph, pyridin-3-yl, styryl, etc.).  These compds. were subjected to in vitro COX-1/COX-2, 15-LOX inhibition assays.  Few compds. with promising potency (IC50 = 70-100 nM) and selectivity index (SI = 220-55) were further tested for in vivo anti-inflammatory activity and effect on gastric mucosa.  The most promising compd. I (R = 3,4-(Cl)2C6H3) inhibits COX-2 enzyme at a nanomolar concn. (IC50 = 70 nM, SI = 220) with simultaneous inhibition of 15-LOX (IC50 = 11 μM).  These results are comparable to the potency and selectivity of the std. drugs of both enzymes; celecoxib (COX-2 IC50 = 49 nM, SI = 308) and zileuton (15-LOX IC50 = 15 μM) in one construct.  Interestingly three compds. exhibited equiv. to or even higher activity than that of celecoxib in vivo anti-inflammatory activity at 3 h interval with good GIT safety profile.  Mol. docking study conferred binding sites of these compds. on COX-2 and 15-LOX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxsqbJIO0ZSbVg90H21EOLACvtfcHk0liZOXllck0dZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yrs7bF&md5=063987e9bc07741542e788826add193c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DOmar%26aufirst%3DY.%2BM.%26aulast%3DAbdu-Allah%26aufirst%3DA.%2BA.H.%2BH.%2BM.%26aulast%3DAbdel-Moty%26aufirst%3DS.%2BG.%26atitle%3DSynthesis%252C%2520Biological%2520Evaluation%2520and%2520Docking%2520Study%2520of%25201%252C3%252C4-Thiadiazole-Thiazolidinone%2520Hybrids%2520as%2520Anti-Inflammatory%2520Agents%2520with%2520Dual%2520Inhibition%2520of%2520COX-2%2520and%252015-LOX%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D80%26spage%3D461%26epage%3D471%26doi%3D10.1016%2Fj.bioorg.2018.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadnis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baska, R. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monshizadegan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowala, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">Dual Angiotensin II and Endothelin a Receptor Antagonists: Synthesis of 2’-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1021/jm049548x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049548x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyltrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=171-179&issue=1&author=N.+Murugesanauthor=Z.+Guauthor=L.+Fadnisauthor=J.+E.+Tellewauthor=R.+A.+F.+Baskaauthor=Y.+Yangauthor=S.+M.+Beyerauthor=H.+Monshizadeganauthor=K.+E.+Dickinsonauthor=M.+T.+Valentineauthor=W.+G.+Humphreysauthor=S.-J.+Lanauthor=W.+R.+Ewingauthor=K.+E.+Carlsonauthor=M.+C.+Kowalaauthor=R.+Zahlerauthor=J.+E.+Macor&title=Dual+Angiotensin+II+and+Endothelin+a+Receptor+Antagonists%3A+Synthesis+of+2%E2%80%99-Substituted+N-3-Isoxazolyl+Biphenylsulfonamides+with+Improved+Potency+and+Pharmacokinetics&doi=10.1021%2Fjm049548x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2'-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics</span></div><div class="casAuthors">Murugesan, Natesan; Gu, Zhengxiang; Fadnis, Leena; Tellew, John E.; Baska, Rose Ann F.; Yang, Yifan; Beyer, Sophie M.; Monshizadegan, Hossain; Dickinson, Kenneth E.; Valentine, Maria T.; Humphreys, W. Griffith; Lan, Shih-Jung; Ewing, William R.; Carlson, Kenneth E.; Kowala, Mark C.; Zahler, Robert; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a previous report its was demonstrated that merging together key structural elements present in an AT1 receptor antagonist (irbesartan) with key structural elements in a biphenylsulfonamide ETA receptor antagonist followed by addnl. optimization provided a product which is a dual-action receptor antagonist (DARA), which potently blocked both AT1 and ETA receptors.  Described herein are our efforts directed toward improving both the pharmacokinetic profile as well as the AT1 and ETA receptor potency of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-2-sulfonamide (I).  Efforts centered on modifying the 2'-side chain of I and examg. the (isoxazolyl)sulfonamide moiety in I.  This effort resulted in the discovery of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)[1,1'-biphenyl]-2-sulfonamide (II) as a highly potent second-generation DARA.  This compd. also showed substantially improved pharmacokinetic properties compared to I.  In rats, DARA II reduced blood pressure elevations caused by i.v. infusion of Ang II or big ET-1 to a greater extent and with longer duration than DARA I or AT1 or ETA receptor antagonists alone.  II clearly demonstrated superiority over irbesartan (an AT1 receptor antagonist) in the normal SHR model of hypertension in a dose-dependent manner, demonstrating the synergy of AT1 and ETA receptor blockade in a single mol.  The crystal and mol. structures of II were reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2G8_AfjEVOrVg90H21EOLACvtfcHk0liZOXllck0dZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyltrzO&md5=d4e66dc82cd65970cde8ca8f3094c8c6</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm049548x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049548x%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DFadnis%26aufirst%3DL.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DBaska%26aufirst%3DR.%2BA.%2BF.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DBeyer%26aufirst%3DS.%2BM.%26aulast%3DMonshizadegan%26aufirst%3DH.%26aulast%3DDickinson%26aufirst%3DK.%2BE.%26aulast%3DValentine%26aufirst%3DM.%2BT.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DLan%26aufirst%3DS.-J.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DKowala%26aufirst%3DM.%2BC.%26aulast%3DZahler%26aufirst%3DR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DDual%2520Angiotensin%2520II%2520and%2520Endothelin%2520a%2520Receptor%2520Antagonists%253A%2520Synthesis%2520of%25202%25E2%2580%2599-Substituted%2520N-3-Isoxazolyl%2520Biphenylsulfonamides%2520with%2520Improved%2520Potency%2520and%2520Pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D1%26spage%3D171%26epage%3D179%26doi%3D10.1021%2Fjm049548x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poornima, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blunder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efferth, T.</span></span> <span> </span><span class="NLM_article-title">Network Pharmacology of Cancer: From Understanding of Complex Interactomes to the Design of Multi-Target Specific Therapeutics from Nature</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.phrs.2016.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27329331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFShsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=290-302&author=P.+Poornimaauthor=J.+D.+Kumarauthor=Q.+Zhaoauthor=M.+Blunderauthor=T.+Efferth&title=Network+Pharmacology+of+Cancer%3A+From+Understanding+of+Complex+Interactomes+to+the+Design+of+Multi-Target+Specific+Therapeutics+from+Nature&doi=10.1016%2Fj.phrs.2016.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature</span></div><div class="casAuthors">Poornima, Paramasivan; Kumar, Jothi Dinesh; Zhao, Qiaoli; Blunder, Martina; Efferth, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">290-302</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite massive investments in drug research and development, the significant decline in the no. of new drugs approved or translated to clin. use raises the question, whether single targeted drug discovery is the right approach.  To combat complex systemic diseases that harbor robust biol. networks such as cancer, single target intervention is proved to be ineffective.  In such cases, network pharmacol. approaches are highly useful, because they differ from conventional drug discovery by addressing the ability of drugs to target numerous proteins or networks involved in a disease.  Pleiotropic natural products are one of the promising strategies due to their multi-targeting and due to lower side effects.  In this review, we discuss the application of network pharmacol. for cancer drug discovery.  We provide an overview of the current state of knowledge on network pharmacol., focus on different tech. approaches and implications for cancer therapy (e.g. polypharmacol. and synthetic lethality), and illustrate the therapeutic potential with selected examples green tea polyphenolics, Eleutherococcus senticosus, Rhodiola rosea, and Schisandra chinensis.  Finally, we present future perspectives on their plausible applications for diagnosis and therapy of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwqqjqEH_wtrVg90H21EOLACvtfcHk0liZOXllck0dZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFShsr%252FM&md5=be3757ac287f3b90ebbcb69016a9410c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DPoornima%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DJ.%2BD.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DBlunder%26aufirst%3DM.%26aulast%3DEfferth%26aufirst%3DT.%26atitle%3DNetwork%2520Pharmacology%2520of%2520Cancer%253A%2520From%2520Understanding%2520of%2520Complex%2520Interactomes%2520to%2520the%2520Design%2520of%2520Multi-Target%2520Specific%2520Therapeutics%2520from%2520Nature%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D290%26epage%3D302%26doi%3D10.1016%2Fj.phrs.2016.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jørgensen, J. T.</span></span> <span> </span><span class="NLM_article-title">The Importance of Predictive Biomarkers in Oncology Drug Development</span>. <i>Expert Rev. Mol. Diagn.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">807</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1080/14737159.2016.1199962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1080%2F14737159.2016.1199962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27282189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FosVChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=807-809&issue=8&author=J.+T.+J%C3%B8rgensen&title=The+Importance+of+Predictive+Biomarkers+in+Oncology+Drug+Development&doi=10.1080%2F14737159.2016.1199962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The importance of predictive biomarkers in oncology drug development</span></div><div class="casAuthors">Jorgensen Jan Trost</div><div class="citationInfo"><span class="NLM_cas:title">Expert review of molecular diagnostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">807-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpjsop5xOrXENoizSOkG_FfW6udTcc2eZiEKvJMjzCiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FosVChug%253D%253D&md5=a98aabac63825ef0d86e882456e73061</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1080%2F14737159.2016.1199962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737159.2016.1199962%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520Importance%2520of%2520Predictive%2520Biomarkers%2520in%2520Oncology%2520Drug%2520Development%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Diagn.%26date%3D2016%26volume%3D16%26issue%3D8%26spage%3D807%26epage%3D809%26doi%3D10.1080%2F14737159.2016.1199962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeep, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choonara, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillay, V.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Therapeutics for Neuropsychiatric and Neurodegenerative Disorders</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1886</span>– <span class="NLM_lpage">1914</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27506871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaiu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1886-1914&issue=12&author=P.+Bawaauthor=P.+Pradeepauthor=P.+Kumarauthor=Y.+E.+Choonaraauthor=G.+Modiauthor=V.+Pillay&title=Multi-Target+Therapeutics+for+Neuropsychiatric+and+Neurodegenerative+Disorders&doi=10.1016%2Fj.drudis.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders</span></div><div class="casAuthors">Bawa, Priya; Pradeep, Priyamvada; Kumar, Pradeep; Choonara, Yahya E.; Modi, Girish; Pillay, Viness</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1886-1914</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Historically, neuropsychiatric and neurodegenerative disease treatments focused on the 'magic bullet' concept; however multi-targeted strategies are increasingly attractive gauging from the escalating research in this area.  Because these diseases are typically co-morbid, multi-targeted drugs capable of interacting with multiple targets will expand treatment to the co-morbid disease condition.  Despite their theor. efficacy, there are significant impediments to clin. success (e.g., difficulty titrating individual aspects of the drug and inconclusive pathophysiol. mechanisms).  The new and revised diagnostic frameworks along with studies detailing the endophenotypic characteristics of the diseases promise to provide the foundation for the circumvention of these impediments.  This review serves to evaluate the various marketed and nonmarketed multi-targeted drugs with particular emphasis on their design strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaUcziq8vK_bVg90H21EOLACvtfcHk0ljH4Bp3iXO_kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaiu7rL&md5=47734b25b4b55be4f04f3ef936dfa313</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DBawa%26aufirst%3DP.%26aulast%3DPradeep%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DChoonara%26aufirst%3DY.%2BE.%26aulast%3DModi%26aufirst%3DG.%26aulast%3DPillay%26aufirst%3DV.%26atitle%3DMulti-Target%2520Therapeutics%2520for%2520Neuropsychiatric%2520and%2520Neurodegenerative%2520Disorders%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26issue%3D12%26spage%3D1886%26epage%3D1914%26doi%3D10.1016%2Fj.drudis.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E. H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarazi, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahid, M.</span></span> <span> </span><span class="NLM_article-title">The Effectiveness of Multi-Target Agents in Schizophrenia and Mood Disorders: Relevance of Receptor Signature to Clinical Action</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>126</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2010.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.pharmthera.2010.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20171983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksF2qur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=173-185&issue=2&author=E.+H.+F.+Wongauthor=F.+I.+Taraziauthor=M.+Shahid&title=The+Effectiveness+of+Multi-Target+Agents+in+Schizophrenia+and+Mood+Disorders%3A+Relevance+of+Receptor+Signature+to+Clinical+Action&doi=10.1016%2Fj.pharmthera.2010.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action</span></div><div class="casAuthors">Wong, Erik H. F.; Tarazi, Frank I.; Shahid, Mohammed</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-185</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Schizophrenia, bipolar disorder and unipolar depression are multi-dimensional and severely disabling psychiatric diseases with a strong need for improved pharmacotherapies with better adherence, long-term outcome and patient functionality.  Progress has been achieved with the emergence of tailored multi-target agents (MTAs), such as second-generation antipsychotics for schizophrenia, with expanding clin. utility in bipolar disorder and depression.  Better understanding of how these MTAs exert their beneficial and undesirable clin. effects in terms of receptor interaction remains an area for further elucidation, which may provide insight towards a new generation of individualized, and optimized therapies.  This review explores to what extent the receptor signature of MTAs informs about their clin. action and therapeutic utility.  Compelling clin. validation exists only for a limited no. of mol. targets (e.g. D2 receptor blockade, serotonin transport inhibition), indicating overall high attrition and poor translation of predictive preclin. pharmacol.  Nevertheless, recent advances have identified promising novel approaches for schizophrenia, bipolar disorder and depression that require further clin. validation.  It is hoped that the expanding clin. and mechanistic knowledge garnered from the use of existing MTAs will provide addnl. opportunities for "reverse translation" and towards target validation.  There is considerable scope for further developing and applying the knowledge linking receptor signature to clin. activity to drive stronger target validation, and ultimately support rational development of the next generation of MTAs for the improved treatment of schizophrenia and mood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprA36orGSrq7Vg90H21EOLACvtfcHk0ljH4Bp3iXO_kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksF2qur8%253D&md5=3ecf4d69c5847b205e004f5379bf3b1a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DE.%2BH.%2BF.%26aulast%3DTarazi%26aufirst%3DF.%2BI.%26aulast%3DShahid%26aufirst%3DM.%26atitle%3DThe%2520Effectiveness%2520of%2520Multi-Target%2520Agents%2520in%2520Schizophrenia%2520and%2520Mood%2520Disorders%253A%2520Relevance%2520of%2520Receptor%2520Signature%2520to%2520Clinical%2520Action%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D126%26issue%3D2%26spage%3D173%26epage%3D185%26doi%3D10.1016%2Fj.pharmthera.2010.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroeze, W. K.</span></span> <span> </span><span class="NLM_article-title">Magic Shotguns Versus Magic Bullets: Selectively Non-Selective Drugs for Mood Disorders and Schizophrenia</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1038/nrd1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&issue=4&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+Shotguns+Versus+Magic+Bullets%3A+Selectively+Non-Selective+Drugs+for+Mood+Disorders+and+Schizophrenia&doi=10.1038%2Fnrd1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0ljH4Bp3iXO_kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520Shotguns%2520Versus%2520Magic%2520Bullets%253A%2520Selectively%2520Non-Selective%2520Drugs%2520for%2520Mood%2520Disorders%2520and%2520Schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D4%26spage%3D353%26epage%3D359%26doi%3D10.1038%2Fnrd1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeshima, M.</span></span> <span> </span><span class="NLM_article-title">Treating Mixed Mania/Hypomania: A Review and Synthesis of the Evidence</span>. <i>CNS Spectrums.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1017/S1092852916000845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1017%2FS1092852916000845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28004626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FnsVKksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=177-185&issue=2&author=M.+Takeshima&title=Treating+Mixed+Mania%2FHypomania%3A+A+Review+and+Synthesis+of+the+Evidence&doi=10.1017%2FS1092852916000845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Treating mixed mania/hypomania: a review and synthesis of the evidence</span></div><div class="casAuthors">Takeshima Minoru</div><div class="citationInfo"><span class="NLM_cas:title">CNS spectrums</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">177-185</span>
        ISSN:<span class="NLM_cas:issn">1092-8529</span>.
    </div><div class="casAbstract">The DSM-5 incorporates a broad concept of mixed states and captured ≥3 nonoverlapping symptoms of the opposite polarity using a "with mixed features" specifier to be applied to manic/hypomanic and major depressive episodes.  Pharmacotherapy of mixed states is challenging because of the necessity to treat both manic/hypomanic and depressive symptoms concurrently.  High-potency antipsychotics used to treat manic symptoms and antidepressants can potentially deteriorate symptoms of the opposite polarity.  This review aimed to provide a synthesis of the current evidence for pharmacotherapy of mixed states with an emphasis on mixed mania/hypomania.  A PubMed search was conducted for randomized controlled trials (RCTs) that were at least moderately sized, included a placebo arm, and contained information on acute-phase and maintenance treatments of adult patients with mixed episodes or mania/hypomania with significant depressive symptoms.  Most studies were post-hoc subgroup and pooled analyses of the data from RCTs for acute manic and mixed episodes of bipolar I disorder; only two prospectively examined efficacy for mixed mania/hypomania specifically.  Aripiprazole, asenapine, carbamazepine, olanzapine, and ziprasidone showed the strongest evidence of efficacy in acute-phase treatment.  Quetiapine and divalproex/valproate were also efficacious.  Combination therapies with these atypical antipsychotics and mood stabilizers can be considered in severe cases.  Olanzapine and quetiapine (alone or in combination with lithium/divalproex) showed the strongest evidence of efficacy in maintenance treatment.  Lithium and lamotrigine may be beneficial given their preventive effects on suicide and depressive relapse.  Further prospective studies primarily focusing on mixed states are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5cBz8zkyS2Nj_Vg2vObihfW6udTcc2eZUFnWy3jbrPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FnsVKksQ%253D%253D&md5=87a4b1fe530051dc37c3aa50eb1b8e00</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1017%2FS1092852916000845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1092852916000845%26sid%3Dliteratum%253Aachs%26aulast%3DTakeshima%26aufirst%3DM.%26atitle%3DTreating%2520Mixed%2520Mania%252FHypomania%253A%2520A%2520Review%2520and%2520Synthesis%2520of%2520the%2520Evidence%26jtitle%3DCNS%2520Spectrums.%26date%3D2017%26volume%3D22%26issue%3D2%26spage%3D177%26epage%3D185%26doi%3D10.1017%2FS1092852916000845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuplin, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holahan, M. R.</span></span> <span> </span><span class="NLM_article-title">Aripiprazole, a Drug That Displays Partial Agonism and Functional Selectivity</span>. <i>Curr. Neuropharnacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1192</span>– <span class="NLM_lpage">1207</span>, <span class="refDoi"> DOI: 10.2174/1570159X15666170413115754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F1570159X15666170413115754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28412910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFens7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=1192-1207&issue=8&author=E.+W.+Tuplinauthor=M.+R.+Holahan&title=Aripiprazole%2C+a+Drug+That+Displays+Partial+Agonism+and+Functional+Selectivity&doi=10.2174%2F1570159X15666170413115754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity</span></div><div class="casAuthors">Tuplin, Erin W.; Holahan, Matthew R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1192-1207</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: The treatment of schizophrenia is challenging due to the wide range of symptoms (pos., neg., cognitive) assocd. with the disease.  Typical antipsychotics that antagonize D2 receptors are effective in treating pos. symptoms, but extrapyramidal side-effects (EPS) are a common occurrence.  Atypical antipsychotics targeting 5-HT2A and D2 receptors are more effective at treating cognitive and neg. symptoms compared to typical antipsychotics, but these drugs also result in side-effects such as metabolic syndromes.  Objective: To identify evidence in the literature that elucidates the pharmacol. profile of aripiprazole.s.  Methods: We searched PubMed for peer reviewed articles on aripiprazole and its clin. efficacy, side-effects, pharmacol., and effects in animal models of schizophrenia symptoms.  Results: Aripiprazole is a newer atypical antipsychotic that displays a unique pharmacol. profile, including partial D2 agonism and functionally selective properties.  Aripiprazole is effective at treating the pos. symptoms of schizophrenia and has the potential to treat neg. and cognitive symptoms at least as well as other atypical antipsychotics.  The drug has a favorable side-effect profile and has a low propensity to result in EPS or metabolic syndromes.  Animal models of schizophrenia have been used to det. the efficacy of aripiprazole in symptom management.  In these instances, aripiprazole resulted in the reversal of deficits in extinction, pre-pulse inhibition, and social withdrawal.  Because aripiprazole requires a greater than 90% occupancy rate at D2 receptors to be clin. active and does not produce EPS, this suggests a functionally selective effect on intracellular signaling pathways.  Conclusion: A combination of factors such as dopamine system stabilization via partial agonism, functional selectivity at D2 receptors, and serotonin-dopamine system interaction may contribute to the ability of aripiprazole to successfully manage schizophrenia symptoms.  This review examines these mechanisms of action to further clarify the pharmacol. actions of aripiprazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiNaT3zwOCzLVg90H21EOLACvtfcHk0lj7yF0s9zjb3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFens7vM&md5=a3e01bec5ee707325ac14bcee420a4d2</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.2174%2F1570159X15666170413115754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X15666170413115754%26sid%3Dliteratum%253Aachs%26aulast%3DTuplin%26aufirst%3DE.%2BW.%26aulast%3DHolahan%26aufirst%3DM.%2BR.%26atitle%3DAripiprazole%252C%2520a%2520Drug%2520That%2520Displays%2520Partial%2520Agonism%2520and%2520Functional%2520Selectivity%26jtitle%3DCurr.%2520Neuropharnacol.%26date%3D2017%26volume%3D15%26issue%3D8%26spage%3D1192%26epage%3D1207%26doi%3D10.2174%2F1570159X15666170413115754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caraci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggio, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drago, F.</span></span> <span> </span><span class="NLM_article-title">New Drugs in Psychiatry: Focus on New Pharmacological Targets</span>. <i>F1000Research</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.12688/f1000research.10233.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.12688%2Ff1000research.10233.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28408985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnslOhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=397-405&author=F.+Caraciauthor=G.+M.+Leggioauthor=S.+Salomoneauthor=F.+Drago&title=New+Drugs+in+Psychiatry%3A+Focus+on+New+Pharmacological+Targets&doi=10.12688%2Ff1000research.10233.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">New drugs in psychiatry: focus on new pharmacological targets</span></div><div class="casAuthors">Caraci Filippo; Caraci Filippo; Leggio Gian Marco; Salomone Salvatore; Drago Filippo</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">397</span>
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    </div><div class="casAbstract">The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years.  To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications.  In this report, we detail drug candidates being examined as treatments for psychiatric disorders.  Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer's disease.  All of the compounds considered were recently approved for human use or are in advanced clinical trials.  Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression.  New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine.  As for Alzheimer's disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQm8I_QiD3OJNhSDZx9hyjKfW6udTcc2eZUFnWy3jbrPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnslOhsw%253D%253D&md5=a49356e1ef4094435d21d838138a120f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.10233.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.10233.1%26sid%3Dliteratum%253Aachs%26aulast%3DCaraci%26aufirst%3DF.%26aulast%3DLeggio%26aufirst%3DG.%2BM.%26aulast%3DSalomone%26aufirst%3DS.%26aulast%3DDrago%26aufirst%3DF.%26atitle%3DNew%2520Drugs%2520in%2520Psychiatry%253A%2520Focus%2520on%2520New%2520Pharmacological%2520Targets%26jtitle%3DF1000Research%26date%3D2017%26volume%3D6%26spage%3D397%26epage%3D405%26doi%3D10.12688%2Ff1000research.10233.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huhn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider-Thoma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bighelli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolakopoulou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leucht, S.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic Drugs for Patients with Schizophrenia and Predominant or Prominent Negative Symptoms: A Systematic Review and Meta-Analysis</span>. <i>Eur. Arch. Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>268</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1007/s00406-018-0869-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1007%2Fs00406-018-0869-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29368205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC1MvktFensg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=2018&pages=625-639&issue=7&author=M.+Krauseauthor=Y.+Zhuauthor=M.+Huhnauthor=J.+Schneider-Thomaauthor=I.+Bighelliauthor=A.+Nikolakopoulouauthor=S.+Leucht&title=Antipsychotic+Drugs+for+Patients+with+Schizophrenia+and+Predominant+or+Prominent+Negative+Symptoms%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1007%2Fs00406-018-0869-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis</span></div><div class="casAuthors">Krause Marc; Zhu Yikang; Huhn Maximilian; Schneider-Thoma Johannes; Bighelli Irene; Leucht Stefan; Krause Marc; Zhu Yikang; Nikolakopoulou Adriani</div><div class="citationInfo"><span class="NLM_cas:title">European archives of psychiatry and clinical neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">625-639</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Negative symptoms are the core of schizophrenia, but whether antipsychotics are efficacious for their treatment is unclear.  Moreover, there is debate whether patients in relevant trials should have predominant negative symptoms or whether prominent negative symptoms are also acceptable.  METHODS:  We systematically reviewed randomised, blinded antipsychotic drug trials in patients with schizophrenia and either predominant or prominent negative symptoms (last search Dec 12, 2017).  Separate pairwise meta-analyses were conducted in these two populations.  The primary outcome was negative symptoms.  Depressive, symptoms, positive symptoms, and extrapyramidal side-effects were analysed as causes of secondary negative symptoms.  FINDINGS:  We included 21 randomized-controlled trials with 3451 participants which revealed the following significant differences in the primary outcome: in patients with predominant negative symptoms amisulpride was superior to placebo (N = 4; n = 590, SMD 0.47, CI 0.23, 0.71), olanzapine was superior to haloperidol in a small trial (n = 35) and cariprazine outperformed risperidone (N = 1, n = 456, SMD - 0.29, CI - 0.48, - 0.11).  In patients with prominent negative symptoms, olanzapine and quetiapine were superior to risperidone in single trials.  Overall, studies in prominent negative symptoms were potentially more confounded by improvements of secondary negative symptoms.  INTERPRETATION:  Amisulpride is the only antipsychotic that outperformed placebo in the treatment of predominant negative symptoms, but there was a parallel reduction of depression.  Cariprazine was better than risperidone in a large trial that was well-controlled for secondary negative symptoms, but the trial was sponsored by its manufacturer.  Future trials should apply scientifically developed definitions such as the deficit syndrome and the persistent negative symptoms concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwQM34mV101rBItaL1WaVAfW6udTcc2eZUFnWy3jbrPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvktFensg%253D%253D&md5=240bd56132a816c7282544f143ba983a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs00406-018-0869-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-018-0869-3%26sid%3Dliteratum%253Aachs%26aulast%3DKrause%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DHuhn%26aufirst%3DM.%26aulast%3DSchneider-Thoma%26aufirst%3DJ.%26aulast%3DBighelli%26aufirst%3DI.%26aulast%3DNikolakopoulou%26aufirst%3DA.%26aulast%3DLeucht%26aufirst%3DS.%26atitle%3DAntipsychotic%2520Drugs%2520for%2520Patients%2520with%2520Schizophrenia%2520and%2520Predominant%2520or%2520Prominent%2520Negative%2520Symptoms%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DEur.%2520Arch.%2520Psychiatry%2520Clin.%2520Neurosci.%26date%3D2018%26volume%3D268%26issue%3D7%26spage%3D625%26epage%3D639%26doi%3D10.1007%2Fs00406-018-0869-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koutsoukas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchmair, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitmore, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span> <span> </span><span class="NLM_article-title">From in Silico Target Prediction to Multi-Target Drug Design: Current Databases, Methods and Applications</span>. <i>J. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2554</span>– <span class="NLM_lpage">2574</span>, <span class="refDoi"> DOI: 10.1016/j.jprot.2011.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.jprot.2011.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21621023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2011&pages=2554-2574&issue=12&author=A.+Koutsoukasauthor=B.+Simmsauthor=J.+Kirchmairauthor=P.+J.+Bondauthor=A.+V.+Whitmoreauthor=S.+Zimmerauthor=M.+P.+Youngauthor=J.+L.+Jenkinsauthor=M.+Glickauthor=R.+C.+Glenauthor=A.+Bender&title=From+in+Silico+Target+Prediction+to+Multi-Target+Drug+Design%3A+Current+Databases%2C+Methods+and+Applications&doi=10.1016%2Fj.jprot.2011.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">From in silico target prediction to multi-target drug design: Current databases, methods and applications</span></div><div class="casAuthors">Koutsoukas, Alexios; Simms, Benjamin; Kirchmair, Johannes; Bond, Peter J.; Whitmore, Alan V.; Zimmer, Steven; Young, Malcolm P.; Jenkins, Jeremy L.; Glick, Meir; Glen, Robert C.; Bender, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2554-2574</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Given the tremendous growth of bioactivity databases, the use of computational tools to predict protein targets of small mols. has been gaining importance in recent years.  Applications span a wide range, from the designed polypharmacol.' of compds. to mode-of-action anal.  In this review, we firstly survey databases that can be used for ligand-based target prediction and which have grown tremendously in size in the past.  We furthermore outline methods for target prediction that exist, both based on the knowledge of bioactivities from the ligand side and methods that can be applied in situations when a protein structure is known.  Applications of successful in silico target identification attempts are discussed in detail, which were based partly or in whole on computational target predictions in the first instance.  This includes the authors' own experience using target prediction tools, in this case considering phenotypic antibacterial screens and the anal. of high-throughput screening data.  Finally, we will conclude with the prospective application of databases to not only predict, retrospectively, the protein targets of a small mol., but also how to design ligands with desired polypharmacol. in a prospective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQAhthzL8wiLVg90H21EOLACvtfcHk0liYer_v3s2_Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE&md5=3fd699639ef3faf347537ef400030dd9</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2011.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2011.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DKoutsoukas%26aufirst%3DA.%26aulast%3DSimms%26aufirst%3DB.%26aulast%3DKirchmair%26aufirst%3DJ.%26aulast%3DBond%26aufirst%3DP.%2BJ.%26aulast%3DWhitmore%26aufirst%3DA.%2BV.%26aulast%3DZimmer%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DM.%2BP.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DBender%26aufirst%3DA.%26atitle%3DFrom%2520in%2520Silico%2520Target%2520Prediction%2520to%2520Multi-Target%2520Drug%2520Design%253A%2520Current%2520Databases%252C%2520Methods%2520and%2520Applications%26jtitle%3DJ.%2520Proteomics%26date%3D2011%26volume%3D74%26issue%3D12%26spage%3D2554%26epage%3D2574%26doi%3D10.1016%2Fj.jprot.2011.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, D.</span></span> <span> </span><span class="NLM_article-title">Phenotypic Screening in Cancer Drug Discovery—Past, Present and Future</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1038/nrd4366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd4366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25033736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=588-602&issue=8&author=J.+G.+Moffatauthor=J.+Rudolphauthor=D.+Bailey&title=Phenotypic+Screening+in+Cancer+Drug+Discovery%E2%80%94Past%2C+Present+and+Future&doi=10.1038%2Fnrd4366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening in cancer drug discovery - past, present and future</span></div><div class="casAuthors">Moffat, John G.; Rudolph, Joachim; Bailey, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">588-602</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches.  Given that oncol. is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncol. drug discovery by analyzing the origins of all new small-mol. cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clin. development.  Although the majority of these drugs originated from target-based discovery, we identified a significant no. whose discovery depended on phenotypic screening approaches.  We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes.  However, tech. and biol. advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTWtoTIgWqvbVg90H21EOLACvtfcHk0li0T5NeKN_AZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L&md5=0e8efed90e5bc4b47f959b83a6ab5b96</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrd4366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4366%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DD.%26atitle%3DPhenotypic%2520Screening%2520in%2520Cancer%2520Drug%2520Discovery%25E2%2580%2594Past%252C%2520Present%2520and%2520Future%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D8%26spage%3D588%26epage%3D602%26doi%3D10.1038%2Fnrd4366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H. J.</span></span> <span> </span><span class="NLM_article-title">Identification and Validation of Bioactive Small Molecule Target through Phenotypic Screening</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1922</span>– <span class="NLM_lpage">1928</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.11.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2011.11.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22153994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlOmsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1922-1928&issue=6&author=Y.+S.+Choauthor=H.+J.+Kwon&title=Identification+and+Validation+of+Bioactive+Small+Molecule+Target+through+Phenotypic+Screening&doi=10.1016%2Fj.bmc.2011.11.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and validation of bioactive small molecule target through phenotypic screening</span></div><div class="casAuthors">Cho, Yoon Sun; Kwon, Ho Jeong</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1922-1928</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">For effective bioactive small mol. discovery and development into new therapeutic drug, a systematic screening and target protein identification is required.  Different from the conventional screening system, herein phenotypic screening in combination with multi-omics-based target identification and validation (MOTIV) is introduced.  First, phenotypic screening provides visual effect of bioactive small mols. in the cell or organism level.  It is important to know the effect on the cell or organism level since small mols. affect not only a single target but the entire cellular mechanism within a cell or organism.  Secondly, MOTIV provides systemic approach to discover the target protein of bioactive small mol.  With the chem. genomics and proteomics approach of target identification methods, various target protein candidates are identified.  Then network anal. and validations of these candidates result in identifying the biol. relevant target protein and cellular mechanism.  Overall, the combination of phenotypic screening and MOTIV will provide an effective approach to discover new bioactive small mols. and their target protein and mechanism identification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRmAssvm8bYbVg90H21EOLACvtfcHk0li0T5NeKN_AZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlOmsr8%253D&md5=29ba512d59e1dab3832572d39713dd4b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.11.021%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DY.%2BS.%26aulast%3DKwon%26aufirst%3DH.%2BJ.%26atitle%3DIdentification%2520and%2520Validation%2520of%2520Bioactive%2520Small%2520Molecule%2520Target%2520through%2520Phenotypic%2520Screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26issue%3D6%26spage%3D1922%26epage%3D1928%26doi%3D10.1016%2Fj.bmc.2011.11.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mett, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydon, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, P.</span></span> <span> </span><span class="NLM_article-title">Phenylamino-Pyrimidine (PAP) - Derivatives: A New Class of Potent and Highly Selective PDGF -Receptor Autophosphorylation Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1226</span>, <span class="refDoi"> DOI: 10.1016/0960-894X(96)00197-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2F0960-894X%2896%2900197-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK28Xjs1ykt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=1221-1226&issue=11&author=J.+Zimmermannauthor=E.+Buchdungerauthor=H.+Mettauthor=T.+Meyerauthor=N.+B.+Lydonauthor=P.+Traxler&title=Phenylamino-Pyrimidine+%28PAP%29+-+Derivatives%3A+A+New+Class+of+Potent+and+Highly+Selective+PDGF+-Receptor+Autophosphorylation+Inhibitors&doi=10.1016%2F0960-894X%2896%2900197-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">(Phenylamino)pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors</span></div><div class="casAuthors">Zimmermann, Juerg; Buchdunger, Elisabeth; Mett, Helmut; Meyer, Thomas; Lydon, Nicholas B.; Traxler, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1221-1226</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">(Phenylamino)pyrimidines represent a novel class of inhibitors of the PDGF-receptor autophosphorylation with a high degree of selectivity vs. other tyrosine and serine/threonine kinases.  Optimum activity of ca 10 nM (IC50) was obsd. when the phenylamino-group which is attached to the pyrimidine carries a benzamide-moiety with a lipophilic substituent in 4-position.  The target compds. were derivs. of 4-methyl-N3-[4-(3-pyridinyl)-2-pyrimidinyl]-1,3-benzenediamine I (R2 = H, Me; R3 = H, benzoyl, Me, etc.; R4 = H, benzoyl, etc.).  A 2-thienyl analog of I was also prepd. and tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU5f-7b9Q_77Vg90H21EOLACvtfcHk0lhjeFL3I350iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjs1ykt70%253D&md5=0c35d8248e2e396caaf518b2abb62835</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2896%2900197-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252896%252900197-7%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26aulast%3DTraxler%26aufirst%3DP.%26atitle%3DPhenylamino-Pyrimidine%2520%2528PAP%2529%2520-%2520Derivatives%253A%2520A%2520New%2520Class%2520of%2520Potent%2520and%2520Highly%2520Selective%2520PDGF%2520-Receptor%2520Autophosphorylation%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26issue%3D11%26spage%3D1221%26epage%3D1226%26doi%3D10.1016%2F0960-894X%2896%2900197-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlik, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moxham, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomandl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sall, D. J.</span></span> <span> </span><span class="NLM_article-title">Modern Phenotypic Drug Discovery is a Viable, Neoclassic Pharma Strategy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4527</span>– <span class="NLM_lpage">4538</span>, <span class="refDoi"> DOI: 10.1021/jm201649s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201649s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1OitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4527-4538&issue=10&author=J.+A.+Leeauthor=M.+T.+Uhlikauthor=C.+M.+Moxhamauthor=D.+Tomandlauthor=D.+J.+Sall&title=Modern+Phenotypic+Drug+Discovery+is+a+Viable%2C+Neoclassic+Pharma+Strategy&doi=10.1021%2Fjm201649s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy</span></div><div class="casAuthors">Lee, Jonathan A.; Uhlik, Mark T.; Moxham, Christopher M.; Tomandl, Dirk; Sall, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4527-4538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmaceutical industry (Pharma) is currently facing unprecedented challenges.  In addn. to strategic patent expirations, the rate of drug launches has been essentially const. for 60 years with overall productivity falling since the 1970s.  Similarly, the appearance of novel targets to FDA approved drugs, a measure of industry innovation, has not dramatically improved since the 1980s.  Although Pharma productivity is a multifaceted problem, detailed analyses of comprehensive, industry-wide data indicate that late stage clin. failures are a major contributor that has been attributed to poor target validation (TV) and the lack of predictive biomarkers that translate to the clinic.  In the spirit of "reinventing innovation" Pharma needs to introspectively identify areas for improvement.  This communication considers how choices in drug screening strategies may relate to target validation issues and influence the probability of identifying novel medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8CcODiYYNgLVg90H21EOLACvtfcHk0lhjeFL3I350iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1OitLs%253D&md5=1937641b632e348d7566c016ca4cf51d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm201649s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201649s%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BA.%26aulast%3DUhlik%26aufirst%3DM.%2BT.%26aulast%3DMoxham%26aufirst%3DC.%2BM.%26aulast%3DTomandl%26aufirst%3DD.%26aulast%3DSall%26aufirst%3DD.%2BJ.%26atitle%3DModern%2520Phenotypic%2520Drug%2520Discovery%2520is%2520a%2520Viable%252C%2520Neoclassic%2520Pharma%2520Strategy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D10%26spage%3D4527%26epage%3D4538%26doi%3D10.1021%2Fjm201649s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mccarroll, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendelev, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokel, D.</span></span> <span> </span><span class="NLM_article-title">Leveraging Large-Scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00800</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00800" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=842-849&issue=4&author=M.+N.+Mccarrollauthor=L.+Gendelevauthor=M.+J.+Keiserauthor=D.+Kokel&title=Leveraging+Large-Scale+Behavioral+Profiling+in+Zebrafish+to+Explore+Neuroactive+Polypharmacology&doi=10.1021%2Facschembio.5b00800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology</span></div><div class="casAuthors">McCarroll, Matthew N.; Gendelev, Leo; Keiser, Michael J.; Kokel, David</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">842-849</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Many psychiatric drugs modulate the nervous system through multitarget mechanisms.  However, systematic identification of multitarget compds. has been difficult using traditional in vitro screening assays.  New approaches to phenotypic profiling in zebrafish can help researchers identify novel compds. with complex polypharmacol.  For example, large-scale behavior-based chem. screens can rapidly identify large nos. of structurally diverse and phenotype-related compds.  Once these compds. have been identified, a systems-level anal. of their structures may help to identify statistically enriched target pathways.  Together, systematic behavioral profiling and multitarget predictions may help researchers identify new behavior-modifying pathways and CNS therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3QN11t7PEEbVg90H21EOLACvtfcHk0lhjeFL3I350iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSlsL8%253D&md5=6d69351d9c3e6c711881947aac517e75</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00800%26sid%3Dliteratum%253Aachs%26aulast%3DMccarroll%26aufirst%3DM.%2BN.%26aulast%3DGendelev%26aufirst%3DL.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DKokel%26aufirst%3DD.%26atitle%3DLeveraging%2520Large-Scale%2520Behavioral%2520Profiling%2520in%2520Zebrafish%2520to%2520Explore%2520Neuroactive%2520Polypharmacology%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3D842%26epage%3D849%26doi%3D10.1021%2Facschembio.5b00800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonoshita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scopton, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, P. M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Real, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagan, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A. C.</span></span> <span> </span><span class="NLM_article-title">A Whole-Animal Platform to Advance a Clinical Kinase Inhibitor into New Disease Space</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnchembio.2556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29355849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=291-298&issue=3&author=M.+Sonoshitaauthor=A.+P.+Scoptonauthor=P.+M.+U.+Ungauthor=M.+A.+Murrayauthor=L.+Silberauthor=A.+Y.+Maldonadoauthor=A.+Realauthor=A.+Schlessingerauthor=R.+L.+Caganauthor=A.+C.+Dar&title=A+Whole-Animal+Platform+to+Advance+a+Clinical+Kinase+Inhibitor+into+New+Disease+Space&doi=10.1038%2Fnchembio.2556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A whole-animal platform to advance a clinical kinase inhibitor into new disease space</span></div><div class="casAuthors">Sonoshita, Masahiro; Scopton, Alex P.; Ung, Peter M. U.; Murray, Matthew A.; Silber, Lisa; Maldonado, Andres Y.; Real, Alexander; Schlessinger, Avner; Cagan, Ross L.; Dar, Arvin C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-298</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Synthetic tailoring of approved drugs for new indications is often difficult, as the most appropriate targets may not be readily apparent, and therefore few roadmaps exist to guide chem.  Here, we report a multidisciplinary approach for accessing novel target and chem. space starting from an FDA-approved kinase inhibitor.  By combining chem. and genetic modifier screening with computational modeling, we identify distinct kinases that strongly enhance ('pro-targets') or limit ('anti-targets') whole-animal activity of the clin. kinase inhibitor sorafenib in a Drosophila medullary thyroid carcinoma (MTC) model.  We demonstrate that RAF-the original intended sorafenib target-and MKNK kinases function as pharmacol. liabilities because of inhibitor-induced transactivation and neg. feedback, resp.  Through progressive synthetic refinement, we report a new class of 'tumor calibrated inhibitors' with unique polypharmacol. and strongly improved therapeutic index in fly and human MTC xenograft models.  This platform provides a rational approach to creating new high-efficacy and low-toxicity drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokPGDBCxqaILVg90H21EOLACvtfcHk0lhimjV64Y0__Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2msrk%253D&md5=54fd159e29ffa581e7c53983d92dd134</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2556%26sid%3Dliteratum%253Aachs%26aulast%3DSonoshita%26aufirst%3DM.%26aulast%3DScopton%26aufirst%3DA.%2BP.%26aulast%3DUng%26aufirst%3DP.%2BM.%2BU.%26aulast%3DMurray%26aufirst%3DM.%2BA.%26aulast%3DSilber%26aufirst%3DL.%26aulast%3DMaldonado%26aufirst%3DA.%2BY.%26aulast%3DReal%26aufirst%3DA.%26aulast%3DSchlessinger%26aufirst%3DA.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26aulast%3DDar%26aufirst%3DA.%2BC.%26atitle%3DA%2520Whole-Animal%2520Platform%2520to%2520Advance%2520a%2520Clinical%2520Kinase%2520Inhibitor%2520into%2520New%2520Disease%2520Space%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26issue%3D3%26spage%3D291%26epage%3D298%26doi%3D10.1038%2Fnchembio.2556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span> <span> </span><span class="NLM_article-title">In-Silico Approaches to Multi-Target Drug Discovery</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1007/s11095-010-0065-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1007%2Fs11095-010-0065-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20221898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVWrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2010&pages=739-749&issue=5&author=X.+H.+Maauthor=Z.+Shiauthor=C.+Tanauthor=Y.+Jiangauthor=M.+L.+Goauthor=B.+C.+Lowauthor=Y.+Z.+Chen&title=In-Silico+Approaches+to+Multi-Target+Drug+Discovery&doi=10.1007%2Fs11095-010-0065-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">In-Silico Approaches to Multi-target Drug Discovery - Computer Aided Multi-target Drug Design, Multi-target Virtual Screening</span></div><div class="casAuthors">Ma, Xiao Hua; Shi, Zhe; Tan, Chunyan; Jiang, Yuyang; Go, Mei Lin; Low, Boon Chuan; Chen, Yu Zong</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">739-749</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Multi-target drugs against selective multiple targets improve therapeutic efficacy, safety and resistance profiles by collective regulations of a primary therapeutic target together with compensatory elements and resistance activities.  Efforts have been made to employ in-silico methods for facilitating the search and design of selective multi-target agents.  These methods have shown promising potential in facilitating drug discovery directed at selective multiple targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob4gKJy9MUFLVg90H21EOLACvtfcHk0lhimjV64Y0__Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVWrsbc%253D&md5=c530372ddbcce5e35f52984d5f6e32e2</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs11095-010-0065-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-010-0065-2%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%2BH.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DGo%26aufirst%3DM.%2BL.%26aulast%3DLow%26aufirst%3DB.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26atitle%3DIn-Silico%2520Approaches%2520to%2520Multi-Target%2520Drug%2520Discovery%26jtitle%3DPharm.%2520Res.%26date%3D2010%26volume%3D27%26issue%3D5%26spage%3D739%26epage%3D749%26doi%3D10.1007%2Fs11095-010-0065-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span> <span> </span><span class="NLM_article-title">Advances in Computational Approaches in Identifying Synergistic Drug Combinations</span>. <i>Briefings Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1172</span>– <span class="NLM_lpage">1182</span>, <span class="refDoi"> DOI: 10.1093/bib/bbx047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1093%2Fbib%2Fbbx047" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=1172-1182&issue=6&author=Z.+Shengauthor=Y.+Sunauthor=Z.+Yinauthor=K.+Tangauthor=Z.+Cao&title=Advances+in+Computational+Approaches+in+Identifying+Synergistic+Drug+Combinations&doi=10.1093%2Fbib%2Fbbx047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1093%2Fbib%2Fbbx047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbib%252Fbbx047%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DZ.%26atitle%3DAdvances%2520in%2520Computational%2520Approaches%2520in%2520Identifying%2520Synergistic%2520Drug%2520Combinations%26jtitle%3DBriefings%2520Bioinf.%26date%3D2017%26volume%3D19%26issue%3D6%26spage%3D1172%26epage%3D1182%26doi%3D10.1093%2Fbib%2Fbbx047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chua, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker-Kellogg, L.</span></span> <span> </span><span class="NLM_article-title">Synergistic Target Combination Prediction from Curated Signaling Networks: Machine Learning Meets Systems Biology and Pharmacology</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.ymeth.2017.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ymeth.2017.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28552265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsVKjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=60-80&author=H.+E.+Chuaauthor=S.+S.+Bhowmickauthor=L.+Tucker-Kellogg&title=Synergistic+Target+Combination+Prediction+from+Curated+Signaling+Networks%3A+Machine+Learning+Meets+Systems+Biology+and+Pharmacology&doi=10.1016%2Fj.ymeth.2017.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic target combination prediction from curated signaling networks: Machine learning meets systems biology and pharmacology</span></div><div class="casAuthors">Chua, Huey Eng; Bhowmick, Sourav S.; Tucker-Kellogg, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Methods (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-80</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Given a signaling network, the target combination prediction problem aims to predict efficacious and safe target combinations for combination therapy.  State-of-the-art in silico methods use Monte Carlo simulated annealing (MCSA) to modify a candidate soln. stochastically, and use the Metropolis criterion to accept or reject the proposed modifications.  However, such stochastic modifications ignore the impact of the choice of targets and their activities on the combination's therapeutic effect and off-target effects, which directly affect the soln. quality.  In this paper, we present MASCOT, a method that addresses this limitation by leveraging two addnl. heuristic criteria to minimize off-target effects and achieve synergy for candidate modification.  Specifically, off-target effects measure the unintended response of a signaling network to the target combination and is often assocd. with toxicity.  Synergy occurs when a pair of targets exerts effects that are greater than the sum of their individual effects, and is generally a beneficial strategy for maximizing effect while minimizing toxicity. MASCOT leverages on a machine learning-based target prioritization method which prioritizes potential targets in a given disease-assocd. network to select more effective targets (better therapeutic effect and/or lower off-target effects); and on Loewe additivity theory from pharmacol. which assesses the non-additive effects in a combination drug treatment to select synergistic target activities.  Our exptl. study on two disease-related signaling networks demonstrates the superiority of MASCOT in comparison to existing approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0NdKdd4aa5rVg90H21EOLACvtfcHk0lhimjV64Y0__Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsVKjur0%253D&md5=aeb07b7c7c6a58e6c4e7e70418e6fdec</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2017.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2017.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DChua%26aufirst%3DH.%2BE.%26aulast%3DBhowmick%26aufirst%3DS.%2BS.%26aulast%3DTucker-Kellogg%26aufirst%3DL.%26atitle%3DSynergistic%2520Target%2520Combination%2520Prediction%2520from%2520Curated%2520Signaling%2520Networks%253A%2520Machine%2520Learning%2520Meets%2520Systems%2520Biology%2520and%2520Pharmacology%26jtitle%3DMethods%26date%3D2017%26volume%3D129%26spage%3D60%26epage%3D80%26doi%3D10.1016%2Fj.ymeth.2017.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Network Pharmacology: The Next Paradigm in Drug Discovery</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnchembio.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18936753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=682-690&issue=11&author=A.+L.+Hopkins&title=Network+Pharmacology%3A+The+Next+Paradigm+in+Drug+Discovery&doi=10.1038%2Fnchembio.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology: the next paradigm in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">682-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets.  However, many effective drugs act via modulation of multiple proteins rather than single targets.  Advances in systems biol. are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compds., compared with multi-target drugs, may exhibit lower than desired clin. efficacy.  This new appreciation of the role of polypharmacol. has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity.  Integrating network biol. and polypharmacol. holds the promise of expanding the current opportunity space for druggable targets.  However, the rational design of polypharmacol. faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties.  Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHy4FqkK-h7Vg90H21EOLACvtfcHk0ljWe_6NBK19Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Kgs7fK&md5=03b8be3ddbcab7dc65afd17df7ee8395</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.118%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DNetwork%2520Pharmacology%253A%2520The%2520Next%2520Paradigm%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D4%26issue%3D11%26spage%3D682%26epage%3D690%26doi%3D10.1038%2Fnchembio.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinelli, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korkut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crago, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span> <span> </span><span class="NLM_article-title">Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">294</span>), <span class="NLM_elocation-id">ra85</span> <span class="refDoi"> DOI: 10.1126/scisignal.2004014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1126%2Fscisignal.2004014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24065146" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&issue=294&author=M.+L.+Millerauthor=E.+J.+Molinelliauthor=J.+S.+Nairauthor=T.+Sheikhauthor=R.+Samyauthor=X.+Jingauthor=Q.+Heauthor=A.+Korkutauthor=A.+M.+Cragoauthor=S.+Singerauthor=G.+K.+Schwartzauthor=C.+Sander&title=Drug+Synergy+Screen+and+Network+Modeling+in+Dedifferentiated+Liposarcoma+Identifies+CDK4+and+IGF1R+as+Synergistic+Drug+Targets&doi=10.1126%2Fscisignal.2004014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004014%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DMolinelli%26aufirst%3DE.%2BJ.%26aulast%3DNair%26aufirst%3DJ.%2BS.%26aulast%3DSheikh%26aufirst%3DT.%26aulast%3DSamy%26aufirst%3DR.%26aulast%3DJing%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DKorkut%26aufirst%3DA.%26aulast%3DCrago%26aufirst%3DA.%2BM.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DSander%26aufirst%3DC.%26atitle%3DDrug%2520Synergy%2520Screen%2520and%2520Network%2520Modeling%2520in%2520Dedifferentiated%2520Liposarcoma%2520Identifies%2520CDK4%2520and%2520IGF1R%2520as%2520Synergistic%2520Drug%2520Targets%26jtitle%3DSci.%2520Signaling%26date%3D2013%26volume%3D6%26issue%3D294%26doi%3D10.1126%2Fscisignal.2004014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">Can We Rationally Design Promiscuous Drugs?</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2006.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&issue=1&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can+We+Rationally+Design+Promiscuous+Drugs%3F&doi=10.1016%2Fj.sbi.2006.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0ljWe_6NBK19Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan%2520We%2520Rationally%2520Design%2520Promiscuous%2520Drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26issue%3D1%26spage%3D127%26epage%3D136%26doi%3D10.1016%2Fj.sbi.2006.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savelieff, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span> <span> </span><span class="NLM_article-title">Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1322</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00138</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00138" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOis7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=1221-1322&author=M.+G.+Savelieffauthor=G.+Namauthor=J.+Kangauthor=H.+J.+Leeauthor=M.+Leeauthor=M.+H.+Lim&title=Development+of+Multifunctional+Molecules+as+Potential+Therapeutic+Candidates+for+Alzheimer%E2%80%99s+Disease%2C+Parkinson%E2%80%99s+Disease%2C+and+Amyotrophic+Lateral+Sclerosis+in+the+Last+Decade&doi=10.1021%2Facs.chemrev.8b00138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade</span></div><div class="casAuthors">Savelieff, Masha G.; Nam, Geewoo; Kang, Juhye; Lee, Hyuck Jin; Lee, Misun; Lim, Mi Hee</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1221-1322</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative diseases pose a substantial socioeconomic burden on society.  Unfortunately, the aging world population and lack of effective cures foreshadow a neg. outlook.  Although a large amt. of research has been dedicated to elucidating the pathologies of neurodegenerative diseases, their principal causes remain elusive.  Metal ion dyshomeostasis, proteopathy, oxidative stress, and neurotransmitter deficiencies are pathol. features shared across multiple neurodegenerative disorders.  In addn., these factors are proposed to be interrelated upon disease progression.  Thus, the development of multifunctional compds. capable of simultaneously interacting with several pathol. components has been suggested as a soln. to undertake the complex pathologies of neurodegenerative diseases.  In this review, the authors outline and discuss possible therapeutic targets in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis and mols., previously designed or discovered as potential drug candidates for these disorders with emphasis on multifunctionality.  In addn., underrepresented areas of research are discussed to indicate new directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeYBpXrefkZbVg90H21EOLACvtfcHk0ljWe_6NBK19Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOis7jL&md5=ee3763784767afe96c57e10439183f82</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00138%26sid%3Dliteratum%253Aachs%26aulast%3DSavelieff%26aufirst%3DM.%2BG.%26aulast%3DNam%26aufirst%3DG.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DM.%2BH.%26atitle%3DDevelopment%2520of%2520Multifunctional%2520Molecules%2520as%2520Potential%2520Therapeutic%2520Candidates%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%252C%2520Parkinson%25E2%2580%2599s%2520Disease%252C%2520and%2520Amyotrophic%2520Lateral%2520Sclerosis%2520in%2520the%2520Last%2520Decade%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D1221%26epage%3D1322%26doi%3D10.1021%2Facs.chemrev.8b00138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetsch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvaïa, N.</span></span> <span> </span><span class="NLM_article-title">Strategies and Challenges for the Next Generation of Antibody-Drug Conjugates</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd.2016.268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28303026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=315-337&issue=5&author=A.+Beckauthor=L.+Goetschauthor=C.+Dumontetauthor=N.+Corva%C3%AFa&title=Strategies+and+Challenges+for+the+Next+Generation+of+Antibody-Drug+Conjugates&doi=10.1038%2Fnrd.2016.268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies and challenges for the next generation of antibody-drug conjugates</span></div><div class="casAuthors">Beck, Alain; Goetsch, Liliane; Dumontet, Charles; Corvaia, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-337</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncol. therapeutics.  After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clin. trials that are evaluating more than 60 further ADC candidates.  The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody.  Furthermore, lessons learned during the past decade are now being used in the development of third-generation ADCs.  In this Review, we discuss strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues.  The selection and engineering of antibodies for site-specific drug conjugation, which will result in higher homogeneity and increased stability, as well as the quest for new conjugation chemistries and mechanisms of action, are priorities in ADC research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP7lV63Ws8rbVg90H21EOLACvtfcHk0liokJGMuKxfuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D&md5=7358b6080dd1aed1d21e98c078cd9ef1</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.268%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DGoetsch%26aufirst%3DL.%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DCorva%25C3%25AFa%26aufirst%3DN.%26atitle%3DStrategies%2520and%2520Challenges%2520for%2520the%2520Next%2520Generation%2520of%2520Antibody-Drug%2520Conjugates%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D5%26spage%3D315%26epage%3D337%26doi%3D10.1038%2Fnrd.2016.268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peperidou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoukranidou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontogiorgis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadjipavlou-Litina, D.</span></span> <span> </span><span class="NLM_article-title">Multitarget Molecular Hybrids of Cinnamic Acids</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">20197</span>– <span class="NLM_lpage">20226</span>, <span class="refDoi"> DOI: 10.3390/molecules191220197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3390%2Fmolecules191220197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25474291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOksL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=20197-20226&issue=12&author=A.+Peperidouauthor=D.+Kapoukranidouauthor=C.+Kontogiorgisauthor=D.+Hadjipavlou-Litina&title=Multitarget+Molecular+Hybrids+of+Cinnamic+Acids&doi=10.3390%2Fmolecules191220197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target molecular hybrids of cinnamic acids</span></div><div class="casAuthors">Peperidou, Aikaterini; Kapoukranidou, Dorothea; Kontogiorgis, Christos; Hadjipavlou-Litina, Dimitra</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">20197-20226, 30 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The synthesis of 11 potential multi-target hybrids incorporating cinnamic acids and paracetamol/4-hydroxycoumarin/7-hydroxycoumarin/benzocaine/p-aminophenol/m-aminophenol, e.g., I (R = 4-AcNHC6H4, coumarin-4-yl, coumarin-7-yl, etc.), II (R = 4-AcNHC6H4, 4-methylcoumarin-7-yl) and III was reported.  Four hybrids I [R = 4-AcNHC6H4 (IV), 3-AcNHC6H4 (V)], II [R = 4-methylcoumarin-7-yl (VI)] and III were found to be multifunctional biol. agents.  Hybrid V showed the highest lipoxygenase (LOX) inhibition (IC50 = 0.34 μM) and analgesic activity (98.1%), whereas hybrid VI exhibited good LOX inhibitory activity (IC50 = 50 μM) and the highest anti-proteolytic activity (IC50 = 5 μM).  Hybrid IV showed high analgesic activity (91%) and appeared to be a promising agent for treating peripheral nerve injuries.  Hybrid III presented an interesting combination of anti-LOX and anti-proteolytic activity.  The 2D-structure-activity relationship studies showed that both steric and electronic parameters played major roles in the activity of these compds. while mol. docking studies pointed to the fact that allosteric interactions may govern the LOX-inhibitor binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvjS082qO0-rVg90H21EOLACvtfcHk0liokJGMuKxfuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOksL%252FP&md5=d4983b67b6842066139bc56e2ef8a490</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.3390%2Fmolecules191220197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules191220197%26sid%3Dliteratum%253Aachs%26aulast%3DPeperidou%26aufirst%3DA.%26aulast%3DKapoukranidou%26aufirst%3DD.%26aulast%3DKontogiorgis%26aufirst%3DC.%26aulast%3DHadjipavlou-Litina%26aufirst%3DD.%26atitle%3DMultitarget%2520Molecular%2520Hybrids%2520of%2520Cinnamic%2520Acids%26jtitle%3DMolecules%26date%3D2014%26volume%3D19%26issue%3D12%26spage%3D20197%26epage%3D20226%26doi%3D10.3390%2Fmolecules191220197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertolini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerzoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tacchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, S.</span></span> <span> </span><span class="NLM_article-title">Paracetamol: New Vistas of an Old Drug</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3–4</span>),  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2006.00250.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1111%2Fj.1527-3458.2006.00250.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17227290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=250-275&issue=3%E2%80%934&author=A.+Bertoliniauthor=A.+Ferrariauthor=A.+Ottaniauthor=S.+Guerzoniauthor=R.+Tacchiauthor=S.+Leone&title=Paracetamol%3A+New+Vistas+of+an+Old+Drug&doi=10.1111%2Fj.1527-3458.2006.00250.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Paracetamol: new vistas of an old drug</span></div><div class="casAuthors">Bertolini, Alfio; Ferrari, Anna; Ottani, Alessandra; Guerzoni, Simona; Tacchi, Raffaella; Leone, Sheila</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">250-275</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  Paracetamol (acetaminophen) is one of the most popular and widely used drugs for the treatment of pain and fever.  It occupies a unique position among analgesic drugs.  Unlike NSAIDs it is almost unanimously considered to have no antiinflammatory activity and does not produce gastrointestinal damage or untoward cardiorenal effects.  Unlike opiates it is almost ineffective in intense pain and has no depressant effect on respiration.  Although paracetamol has been used clin. for more than a century, its mode of action has been a mystery until about one year ago, when two independent groups (Zygmunt and colleagues and Bertolini and colleagues) produced exptl. data unequivocally demonstrating that the analgesic effect of paracetamol is due to the indirect activation of cannabinoid CB1 receptors.  In brain and spinal cord, paracetamol, following deacetylation to its primary amine (p-aminophenol), is conjugated with arachidonic acid to form N-arachidonoylphenolamine, a compd. already known (AM404) as an endogenous cannabinoid.  The involved enzyme is fatty acid amide hydrolase.  N-arachidonoylphenolamine is an agonist at TRPV1 receptors and an inhibitor of cellular anandamide uptake, which leads to increased levels of endogenous cannabinoids; moreover, it inhibits cyclooxygenases in the brain, albeit at concns. that are probably not attainable with analgesic doses of paracetamol.  CB1 receptor antagonist, at a dose level that completely prevents the analgesic activity of a selective CB1 receptor agonist, completely prevents the analgesic activity of paracetamol.  Thus, paracetamol acts as a pro-drug, the active one being a cannabinoid.  These findings finally explain the mechanism of action of paracetamol and the peculiarity of its effects, including the behavioral ones.  Curiously, just when the first CB1 agonists are being introduced for pain treatment, it comes out that an indirect cannabinomimetic had been extensively used (and sometimes overused) for more than a century.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoYiJbYPLTT7Vg90H21EOLACvtfcHk0liokJGMuKxfuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSmtbk%253D&md5=41135b8ce21cff099651a01af348b98b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2006.00250.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2006.00250.x%26sid%3Dliteratum%253Aachs%26aulast%3DBertolini%26aufirst%3DA.%26aulast%3DFerrari%26aufirst%3DA.%26aulast%3DOttani%26aufirst%3DA.%26aulast%3DGuerzoni%26aufirst%3DS.%26aulast%3DTacchi%26aufirst%3DR.%26aulast%3DLeone%26aufirst%3DS.%26atitle%3DParacetamol%253A%2520New%2520Vistas%2520of%2520an%2520Old%2520Drug%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2006%26volume%3D12%26issue%3D3%25E2%2580%25934%26spage%3D250%26epage%3D275%26doi%3D10.1111%2Fj.1527-3458.2006.00250.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alisch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elz, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Dual Histamine H<sub>1</sub> and H<sub>2</sub> Receptor Antagonist Activity of Cyanoguanidine Derivatives</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">14186</span>– <span class="NLM_lpage">14202</span>, <span class="refDoi"> DOI: 10.3390/molecules181114186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3390%2Fmolecules181114186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24248146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFamu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=14186-14202&issue=11&author=B.+Sadekauthor=R.+Alischauthor=A.+Buschauerauthor=S.+Elz&title=Synthesis+and+Dual+Histamine+H1+and+H2+Receptor+Antagonist+Activity+of+Cyanoguanidine+Derivatives&doi=10.3390%2Fmolecules181114186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and dual histamine H1 and H2 receptor antagonist activity of cyanoguanidine derivatives</span></div><div class="casAuthors">Sadek, Bassem; Alisch, Rudi; Buschauer, Armin; Elz, Sigurd</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">14186-14202, 17 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Aiming at pharmacol. hybrids combining H1R and H2R antagonistic activity a series of cyanoguanidines I (R1 = OCH3, F; n = 2, 3, 4, etc.) was synthesized by linking mepyramine-type H1R antagonist substructures with roxatidine- tiotidine- or ranitidine-type H2R antagonist moieties.  N-desmethylmepyramine was connected via a poly-methylene spacer to a cyanoguanidine group as the "urea equiv." of the H2R antagonist moiety.  The title compds. were screened for histamine antagonistic activity at the isolated ileum (H1R) and the isolated spontaneously beating right atrium (H2R) of the guinea pig.  The results indicate that depending on the nature of the H2R antagonist partial structure the highest H1R antagonist potency resided in roxatidine-type compds. with spacers of six methylene groups in length (compd. I (R1 = OCH3 n = 6)) and tiotidine-type compds. irresp. of the alkyl chain length (compds. I (R1 = F; n = 3), I (R1 = OCH3; n = 6), I (R1 = F; n = 6)) N-cyano-N'-[2-[[(2-guanidino-4-thiazolyl)methyl]thio]ethyl]-N&quot;-[2-[N-[2-[N-(4-methoxybenzyl)-N-(pyridyl)-amino] ethyl]-N-methylamino]ethyl] guanidine I (R1 = OCH3; n = 2) pKB values: 8.05 (H1R, ileum) and 7.73 (H2R, atrium) and the homolog with the mepyramine moiety connected by a six-membered chain to the tiotidine-like partial structure (compd. I (R1 = OCH3; n = 6)) pKB values: 8.61 (H1R) and 6.61 (H2R) were among the most potent hybrid compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCNbcDkpmgQbVg90H21EOLACvtfcHk0lgr-hK9HmZMdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFamu70%253D&md5=3844b36899c180423eb4281c6900c923</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3390%2Fmolecules181114186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules181114186%26sid%3Dliteratum%253Aachs%26aulast%3DSadek%26aufirst%3DB.%26aulast%3DAlisch%26aufirst%3DR.%26aulast%3DBuschauer%26aufirst%3DA.%26aulast%3DElz%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520Dual%2520Histamine%2520H1%2520and%2520H2%2520Receptor%2520Antagonist%2520Activity%2520of%2520Cyanoguanidine%2520Derivatives%26jtitle%3DMolecules%26date%3D2013%26volume%3D18%26issue%3D11%26spage%3D14186%26epage%3D14202%26doi%3D10.3390%2Fmolecules181114186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sterling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzig, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkelstein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miskolczi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molnar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rantal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagyva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zekany, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krais, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, M.</span></span> <span> </span><span class="NLM_article-title">Novel Dual Inhibitors of Ache and Mao Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer’s Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">5260</span>– <span class="NLM_lpage">5279</span>, <span class="refDoi"> DOI: 10.1021/jm020120c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020120c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVymsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=5260-5279&issue=24&author=J.+Sterlingauthor=Y.+Herzigauthor=T.+Gorenauthor=N.+Finkelsteinauthor=D.+Lernerauthor=W.+Goldenbergauthor=I.+Miskolcziauthor=S.+Molnarauthor=F.+Rantalauthor=T.+Tamasauthor=G.+Tothauthor=A.+Zagyvaauthor=A.+Zekanyauthor=G.+Lavianauthor=A.+Grossauthor=R.+Friedmanauthor=M.+Razinauthor=W.+Huangauthor=B.+Kraisauthor=M.+Chorevauthor=M.+B.+Youdimauthor=M.+Weinstock&title=Novel+Dual+Inhibitors+of+Ache+and+Mao+Derived+from+Hydroxy+Aminoindan+and+Phenethylamine+as+Potential+Treatment+for+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fjm020120c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer's Disease</span></div><div class="casAuthors">Sterling, Jeffrey; Herzig, Yaacov; Goren, Tamar; Finkelstein, Nina; Lerner, David; Goldenberg, Willy; Miskolczi, Istvan; Molnar, Sandor; Rantal, Ferenc; Tamas, Tivadar; Toth, Gyorgy; Zagyva, Adela; Zekany, Andras; Lavian, Gila; Gross, Aviva; Friedman, Rachel; Razin, Michal; Huang, Wei; Krais, Boris; Chorev, Michael; Youdim, Moussa B.; Weinstock, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5260-5279</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Carbamate derivs. of N-propargylaminoindanes (Series I) and N-propargylphenethylamines (Series II) were synthesized via multistep procedures from the corresponding hydroxy precursors.  The resp. rasagiline- and selegiline-related series were designed to combine inhibitory activities of both acetylcholine esterase (AChE) and monoamine oxidase (MAO) by virtue of their carbamoyl and propargylamine pharmacophores.  Each compd. was tested for these activities in vitro in order to find mols. with similar potencies against each enzyme.  Compds. with such dual AChE and MAO inhibitory activities are expected to have potential for the treatment of Alzheimer's disease.  The obsd. SAR also offers insight into the requirements of the active sites on these enzymes.  A carbamate moiety was found to be essential for AChE inhibition, which was absent in the corresponding hydroxy precursors.  The propargyl group caused 2-70-fold decrease in AChE inhibitory activity (depending on the position of the carbamoyl group) of Series I, but had little or no effect in Series II.  Thus, the 6- and 7-carbamyloxyphenyls in Series I were either equipotent to, or slightly (2- to 5-fold) less active as AChE inhibitors than, the corresponding compds. in Series II, while the 4-carbamyloxyphenyls were more potent.  The presence of the carbamate moiety in 6- and 7-carbamyloxyphenyls of Series I, considerably decreased MAO-A and -B inhibitory activity, compared to that of the parent hydroxy analogs, while the opposite was true for Series II.  Thus, the 6- and 7-carbamyloxyphenyls in Series I were 2-3 orders of magnitude weaker MAO inhibitors while the 4- carbamyloxyphenyls were equipotent with the corresponding compds. in Series II.  In both series, N-methylation of the propargylamine enhanced the MAO (A and B equally) inhibitory activities and decreased the AChE inhibitory activity.  Two candidates belonging to the indan and tetralin ring systems (HCl salts of I and II) and one phenethylamine (mesylate salt of III) were identified as possible leads for further development based on the following criteria: (a) comparable AChE and MAO-B inhibitory activities, (b) good to moderate AChE inhibitory activity, and (c) lack of strong MAO-A selectivity.  However, it is likely that these compds. will be metabolized to the corresponding phenols, with inhibitory activities against AChE and/or MAO-A or -B, different from those of the parent carbamates.  Thus, the apparent enzyme inhibition will be a result of the combined inhibition of all of these individual metabolites.  The results of our ongoing in vivo screening programs will be published elsewhere.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0RScteajUEbVg90H21EOLACvtfcHk0lgr-hK9HmZMdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVymsLg%253D&md5=62136a48889ce0fe28a76aa70e577eb9</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm020120c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020120c%26sid%3Dliteratum%253Aachs%26aulast%3DSterling%26aufirst%3DJ.%26aulast%3DHerzig%26aufirst%3DY.%26aulast%3DGoren%26aufirst%3DT.%26aulast%3DFinkelstein%26aufirst%3DN.%26aulast%3DLerner%26aufirst%3DD.%26aulast%3DGoldenberg%26aufirst%3DW.%26aulast%3DMiskolczi%26aufirst%3DI.%26aulast%3DMolnar%26aufirst%3DS.%26aulast%3DRantal%26aufirst%3DF.%26aulast%3DTamas%26aufirst%3DT.%26aulast%3DToth%26aufirst%3DG.%26aulast%3DZagyva%26aufirst%3DA.%26aulast%3DZekany%26aufirst%3DA.%26aulast%3DLavian%26aufirst%3DG.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DR.%26aulast%3DRazin%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DKrais%26aufirst%3DB.%26aulast%3DChorev%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DWeinstock%26aufirst%3DM.%26atitle%3DNovel%2520Dual%2520Inhibitors%2520of%2520Ache%2520and%2520Mao%2520Derived%2520from%2520Hydroxy%2520Aminoindan%2520and%2520Phenethylamine%2520as%2520Potential%2520Treatment%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26issue%3D24%26spage%3D5260%26epage%3D5279%26doi%3D10.1021%2Fjm020120c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chojnacki, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toldo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Franco, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halquist, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-(4-Hydroxy-Phenyl)-3-oxo-Pentanoic Acid [2-(5-Methoxy-1H-indol-3-yl)-ethyl]-amide as a Potential Neuroprotectant for Alzheimer’s Disease by Hybridization of Curcumin and Melatonin</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1021/cn500081s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn500081s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=690-699&issue=8&author=J.+E.+Chojnackiauthor=K.+Liuauthor=X.+Yanauthor=S.+Toldoauthor=T.+Seldenauthor=M.+Estradaauthor=M.+I.+Rodr%C3%ADguez-Francoauthor=M.+S.+Halquistauthor=D.+Yeauthor=S.+Zhang&title=Discovery+of+5-%284-Hydroxy-Phenyl%29-3-oxo-Pentanoic+Acid+%5B2-%285-Methoxy-1H-indol-3-yl%29-ethyl%5D-amide+as+a+Potential+Neuroprotectant+for+Alzheimer%E2%80%99s+Disease+by+Hybridization+of+Curcumin+and+Melatonin&doi=10.1021%2Fcn500081s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-(4-Hydroxyphenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1H-indol-3-yl)-ethyl]-amide as a Neuroprotectant for Alzheimer's Disease by Hybridization of Curcumin and Melatonin</span></div><div class="casAuthors">Chojnacki, Jeremy E.; Liu, Kai; Yan, Xing; Toldo, Stefano; Selden, Tyler; Estrada, Martin; Rodriguez-Franco, Maria Isabel; Halquist, Matthew S.; Ye, Dexian; Zhang, Shijun</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">690-699</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our effort to develop effective neuroprotectants as potential treatments for Alzheimer's disease (AD), hybrid compds. of curcumin and melatonin, two natural products that have been extensively studied in various AD models, were designed, synthesized, and biol. characterized.  A lead hybrid compd. (7) was discovered to show significant neuroprotection with nanomolar potency (EC50 = 27.60 ± 9.4 nM) in MC65 cells, a cellular AD model.  Multiple in vitro assay results established that 7 exhibited moderate inhibitory effects on the prodn. of amyloid-β oligomers (AβOs) in MC65 cells, but not on the aggregation of Aβ species.  It also exhibited significant antioxidative properties.  Further mechanistic studies demonstrated that 7's antioxidant effects correlate well with its neuroprotective potency for MC65 cells, and these effects might be due to its interference with the interactions of AβOs within the mitochondria of MC65 cells.  Furthermore, 7 was confirmed to cross the blood-brain barrier (BBB) and deliver a sufficient amt. to brain tissue after oral administration.  Collectively, these results strongly support the hybridization approach as an efficient strategy to help identify novel scaffolds with a desired pharmacol., and strongly encourage further optimization of 7 to develop more potent neuroprotectants for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJVho5ZWpCabVg90H21EOLACvtfcHk0lgr-hK9HmZMdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSntb0%253D&md5=0d01ae996fd26e64c03457fc74a271b3</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fcn500081s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn500081s%26sid%3Dliteratum%253Aachs%26aulast%3DChojnacki%26aufirst%3DJ.%2BE.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DToldo%26aufirst%3DS.%26aulast%3DSelden%26aufirst%3DT.%26aulast%3DEstrada%26aufirst%3DM.%26aulast%3DRodr%25C3%25ADguez-Franco%26aufirst%3DM.%2BI.%26aulast%3DHalquist%26aufirst%3DM.%2BS.%26aulast%3DYe%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%25205-%25284-Hydroxy-Phenyl%2529-3-oxo-Pentanoic%2520Acid%2520%255B2-%25285-Methoxy-1H-indol-3-yl%2529-ethyl%255D-amide%2520as%2520a%2520Potential%2520Neuroprotectant%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%2520by%2520Hybridization%2520of%2520Curcumin%2520and%2520Melatonin%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26issue%3D8%26spage%3D690%26epage%3D699%26doi%3D10.1021%2Fcn500081s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Novel 1-Phenyl-3-Hydroxy-4-Pyridinone Derivatives as Multifunctional Agents for the Therapy of Alzheimer’s Disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00224</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00224" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OhurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=69-81&issue=1&author=R.+Shengauthor=L.+Tangauthor=L.+Jiangauthor=L.+Hongauthor=Y.+Shiauthor=N.+Zhouauthor=Y.+Hu&title=Novel+1-Phenyl-3-Hydroxy-4-Pyridinone+Derivatives+as+Multifunctional+Agents+for+the+Therapy+of+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Facschemneuro.5b00224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 1-Phenyl-3-hydroxy-4-pyridinone Derivatives as Multifunctional Agents for the Therapy of Alzheimer's Disease</span></div><div class="casAuthors">Sheng, Rong; Tang, Li; Jiang, Liu; Hong, Lingjuan; Shi, Ying; Zhou, Naiming; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-81</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 1-phenyl-3-hydroxy-4-pyridinone derivs. were designed and synthesized as multifunctional agents for Alzheimer's disease (AD) therapy through incorporation of 3-hydroxy-4-pyridinone moiety from deferiprone into the scaffold of H3 receptor antagonists.  Most of these new compds. displayed designed quadruple functions, H3 receptor antagonism, Aβ aggregation inhibition, metal ion chelation, and radical scavenging.  Esp., the most promising compd. I displayed nanomolar IC50 values in H3 receptor antagonism with high selectivity, efficient capability to interrupt the formation of Aβ1-42 fibrils, good copper and iron chelating properties, and more potent 2,2'-azino-bis(3-ethyl-benzothiazoline-6-sulfonic acid) radical cation (ABTS•+) scavenging activity than Trolox.  Further biol. evaluation revealed that it did not show obvious cytotoxicity and hERG potassium channel inhibition at micromolar concn.  In addn., compd. I demonstrated suitable pharmacokinetic properties and acceptable blood-brain barrier permeability in vivo.  All these results indicate that compd. I is a potential multifunctional candidate for AD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOIWDXJyxn1bVg90H21EOLACvtfcHk0lhD7br0EHIHhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OhurnJ&md5=66c8440d6a02d18c7cbbd948f5b97540</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00224%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DHong%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DNovel%25201-Phenyl-3-Hydroxy-4-Pyridinone%2520Derivatives%2520as%2520Multifunctional%2520Agents%2520for%2520the%2520Therapy%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26issue%3D1%26spage%3D69%26epage%3D81%26doi%3D10.1021%2Facschemneuro.5b00224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridkin, M.</span></span> <span> </span><span class="NLM_article-title">Site-Activated Multifunctional Chelator with Acetylcholinesterase and Neuroprotective-Neurorestorative Moieties for Alzheimer’s Therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">4095</span>– <span class="NLM_lpage">4098</span>, <span class="refDoi"> DOI: 10.1021/jm900504c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900504c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1entLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4095-4098&issue=14&author=H.+Zhengauthor=M.+B.+H.+Youdimauthor=M.+Fridkin&title=Site-Activated+Multifunctional+Chelator+with+Acetylcholinesterase+and+Neuroprotective-Neurorestorative+Moieties+for+Alzheimer%E2%80%99s+Therapy&doi=10.1021%2Fjm900504c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Site-Activated Multifunctional Chelator with Acetylcholinesterase and Neuroprotective-Neurorestorative Moieties for Alzheimer's Therapy</span></div><div class="casAuthors">Zheng, Hailin; Youdim, Moussa B. H.; Fridkin, Mati</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4095-4098</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel strategy to develop site-activated multifunctional chelators for targeting multiple etiologies of Alzheimer's disease is reported.  The novel prochelator HLA20A with improved cytotoxicity shows little affinity for metal ions until it is activated by binding and inhibiting acetylcholinesterase (AChE), releasing an active chelator HLA20 that modulates amyloid precursor protein (APP) regulation and β-amyloid (Aβ) redn., suppresses oxidative stress, and passivates excess metal ions (Fe, Cu, and Zn) in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAebTKcHHU_LVg90H21EOLACvtfcHk0lhD7br0EHIHhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1entLg%253D&md5=aa0826ea6d65e7cffb171e5aaf27a141</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm900504c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900504c%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26aulast%3DFridkin%26aufirst%3DM.%26atitle%3DSite-Activated%2520Multifunctional%2520Chelator%2520with%2520Acetylcholinesterase%2520and%2520Neuroprotective-Neurorestorative%2520Moieties%2520for%2520Alzheimer%25E2%2580%2599s%2520Therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D14%26spage%3D4095%26epage%3D4098%26doi%3D10.1021%2Fjm900504c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jenwitheesuk, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horst, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhis, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samudrala, R.</span></span> <span> </span><span class="NLM_article-title">Novel Paradigms for Drug Discovery: Computational Multitarget Screening</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2007.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.tips.2007.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18190973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslOjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=62-71&issue=2&author=E.+Jenwitheesukauthor=J.+A.+Horstauthor=K.+L.+Rivasauthor=W.+C.+Van+Voorhisauthor=R.+Samudrala&title=Novel+Paradigms+for+Drug+Discovery%3A+Computational+Multitarget+Screening&doi=10.1016%2Fj.tips.2007.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Novel paradigms for drug discovery: computational multitarget screening</span></div><div class="casAuthors">Jenwitheesuk, Ekachai; Horst, Jeremy A.; Rivas, Kasey L.; Van Voorhis, Wesley C.; Samudrala, Ram</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">62-71</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  An established paradigm in current drug development is (i) to identify a single protein target whose inhibition is likely to result in the successful treatment of a disease of interest; (ii) to assay exptl. large libraries of small-mol. compds. in vitro and in vivo to identify promising inhibitors in model systems; and (iii) to det. whether the findings are extensible to humans.  This complex process, which is largely based on trial and error, is risk-, time- and cost-intensive.  Computational (virtual) screening of drug-like compds. simultaneously against the at. structures of multiple protein targets, taking into account protein-inhibitor dynamics, might help to identify lead inhibitors more efficiently, particularly for complex drug-resistant diseases.  Here we discuss the potential benefits of this approach, using HIV-1 and Plasmodium falciparum infections as examples.  We propose a virtual drug discovery pipeline' that will not only identify lead inhibitors efficiently, but also help minimize side-effects and toxicity, thereby increasing the likelihood of successful therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcA1qFl-hV8bVg90H21EOLACvtfcHk0lhD7br0EHIHhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslOjsLo%253D&md5=0dd3e34e8bf4a9799194d7add9ff7343</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DJenwitheesuk%26aufirst%3DE.%26aulast%3DHorst%26aufirst%3DJ.%2BA.%26aulast%3DRivas%26aufirst%3DK.%2BL.%26aulast%3DVan%2BVoorhis%26aufirst%3DW.%2BC.%26aulast%3DSamudrala%26aufirst%3DR.%26atitle%3DNovel%2520Paradigms%2520for%2520Drug%2520Discovery%253A%2520Computational%2520Multitarget%2520Screening%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26issue%3D2%26spage%3D62%26epage%3D71%26doi%3D10.1016%2Fj.tips.2007.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Virtual Screening of Selective Multitarget Kinase Inhibitors by Combinatorial Support Vector Machines</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.1021/mp100179t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp100179t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVKrtrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=1545-1560&issue=5&author=X.+H.+Maauthor=R.+Wangauthor=C.+Y.+Tanauthor=Y.+Y.+Jiangauthor=T.+Luauthor=H.+B.+Raoauthor=X.+Y.+Liauthor=M.+L.+Goauthor=B.+C.+Lowauthor=Y.+Z.+Chen&title=Virtual+Screening+of+Selective+Multitarget+Kinase+Inhibitors+by+Combinatorial+Support+Vector+Machines&doi=10.1021%2Fmp100179t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening of Selective Multitarget Kinase Inhibitors by Combinatorial Support Vector Machines</span></div><div class="casAuthors">Ma, X. H.; Wang, R.; Tan, C. Y.; Jiang, Y. Y.; Lu, T.; Rao, H. B.; Li, X. Y.; Go, M. L.; Low, B. C.; Chen, Y. Z.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1545-1560</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitarget agents have been increasingly explored for enhancing efficacy and reducing counter-target activities and toxicities.  Efficient virtual screening (VS) tools for searching selective multitarget agents are desired.  Combinatorial support vector machines (C-SVM) were tested as VS tools for searching dual-inhibitors of 11 combinations of 9 anticancer kinase targets (EGFR, VEGFR, PDGFR, Src, FGFR, Lck, CDK1, CDK2, GSK3).  C-SVM trained on 233-1,316 non-dual-inhibitors correctly identified 26.8%-57.3% (majority >36%) of the 56-230 intra-kinase-group dual-inhibitors (equiv. to the 50-70% yields of two independent individual target VS tools), and 12.2% of the 41 inter-kinase-group dual-inhibitors.  C-SVM were fairly selective in misidentifying as dual-inhibitors 3.7%-48.1% (majority <20%) of the 233-1,316 non-dual-inhibitors of the same kinase pairs and 0.98%-4.77% of the 3,971-5,180 inhibitors of other kinases.  C-SVM produced low false-hit rates in misidentifying as dual-inhibitors 1,746-4,817 (0.013%-0.036%) of the 13.56 M PubChem compds., 12-175 (0.007%-0.104%) of the 168 K MDDR compds., and 0-84 (0.0%-2.9%) of the 19,495-38,483 MDDR compds. similar to the known dual-inhibitors.  C-SVM was compared to other VS methods Surflex-Dock, DOCK Blaster, kNN and PNN against the same sets of kinase inhibitors and the full set or subset of the 1.02 M Zinc clean-leads data set.  C-SVM produced comparable dual-inhibitor yields, slightly better false-hit rates for kinase inhibitors, and significantly lower false-hit rates for the Zinc clean-leads data set.  Combinatorial SVM showed promising potential for searching selective multitarget agents against intra-kinase-group kinases without explicit knowledge of multitarget agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKJ6MMCBxMtrVg90H21EOLACvtfcHk0lhD7br0EHIHhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVKrtrjE&md5=83803384463f5a03a9f3d7a0e2c9b594</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fmp100179t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp100179t%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%2BH.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DC.%2BY.%26aulast%3DJiang%26aufirst%3DY.%2BY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DRao%26aufirst%3DH.%2BB.%26aulast%3DLi%26aufirst%3DX.%2BY.%26aulast%3DGo%26aufirst%3DM.%2BL.%26aulast%3DLow%26aufirst%3DB.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26atitle%3DVirtual%2520Screening%2520of%2520Selective%2520Multitarget%2520Kinase%2520Inhibitors%2520by%2520Combinatorial%2520Support%2520Vector%2520Machines%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2010%26volume%3D7%26issue%3D5%26spage%3D1545%26epage%3D1560%26doi%3D10.1021%2Fmp100179t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favia, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">The Role of Fragment-Based and Computational Methods in Polypharmacology</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2011.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21864710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns12gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=23-34&issue=1&author=G.+Bottegoniauthor=A.+D.+Faviaauthor=M.+Recanatiniauthor=A.+Cavalli&title=The+Role+of+Fragment-Based+and+Computational+Methods+in+Polypharmacology&doi=10.1016%2Fj.drudis.2011.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The role of fragment-based and computational methods in polypharmacology</span></div><div class="casAuthors">Bottegoni, Giovanni; Favia, Angelo D.; Recanatini, Maurizio; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">23-34</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol.-based strategies are gaining increased attention as a novel approach to obtaining potentially innovative medicines for multifactorial diseases.  However, some within the pharmaceutical community have resisted these strategies because they can be resource-hungry in the early stages of the drug discovery process.  Here, we report on fragment-based and computational methods that might accelerate and optimize the discovery of multitarget drugs.  In particular, we illustrate that fragment-based approaches can be particularly suited for polypharmacol., owing to the inherent promiscuous nature of fragments.  In parallel, we explain how computer-assisted protocols can provide invaluable insights into how to unveil compds. theor. able to bind to more than one protein.  Furthermore, several pragmatic aspects related to the use of these approaches are covered, thus offering the reader practical insights on multitarget-oriented drug discovery projects.  We report on fragment-based and computational approaches as possible ways to accelerate and optimize the discovery of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqX_beZ_hY17Vg90H21EOLACvtfcHk0ljVIzQ-GkrcOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns12gtw%253D%253D&md5=c774326a467a2b8fef62c6e1224c2a78</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DFavia%26aufirst%3DA.%2BD.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DThe%2520Role%2520of%2520Fragment-Based%2520and%2520Computational%2520Methods%2520in%2520Polypharmacology%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D1%26spage%3D23%26epage%3D34%26doi%3D10.1016%2Fj.drudis.2011.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahon, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V.</span></span> <span> </span><span class="NLM_article-title">Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1423</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fcmdc.201100145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21608133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptFKrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1423-1438&issue=8&author=P.+M.+Woodauthor=L.+W.+Wooauthor=M.+P.+Thomasauthor=M.+F.+Mahonauthor=A.+Purohitauthor=B.+V.+Potter&title=Aromatase+and+Dual+Aromatase-Steroid+Sulfatase+Inhibitors+from+the+Letrozole+and+Vorozole+Templates&doi=10.1002%2Fcmdc.201100145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates</span></div><div class="casAuthors">Wood, Paul M.; Woo, L. W. Lawrence; Thomas, Mark P.; Mahon, Mary F.; Purohit, Atul; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1423-1438</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Concurrent inhibition of aromatase and steroid sulfatase (STS) may provide a more effective treatment for hormone-dependent breast cancer than monotherapy against individual enzymes, and several dual aromatase-sulfatase inhibitors (DASIs) have been reported.  Three aromatase inhibitors with sub-nanomolar potency, better than the benchmark agent letrozole, were designed.  To further explore the DASI concept, a new series of letrozole-derived sulfamates and a vorozole-based sulfamate were designed and biol. evaluated in JEG-3 cells to reveal structure-activity relationships.  Amongst achiral and racemic compds., 2-bromo-4-(2-(4-cyanophenyl)-2-(1H-1,2,4-triazol-1-yl)ethyl)phenyl sulfamate is the most potent DASI (aromatase: IC50=0.87 nM; STS: IC50=593 nM).  The enantiomers of the phenolic precursor to this compd. were sepd. by chiral HPLC and their abs. configuration detd. by X-ray crystallog.  Following conversion to their corresponding sulfamates, the S-(+)-enantiomer was found to inhibit aromatase and sulfatase most potently (aromatase: IC50=0.52 nM; STS: IC50=280 nM).  The docking of each enantiomer and other ligands into the aromatase and sulfatase active sites was also investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq91XsDqvKlHrVg90H21EOLACvtfcHk0ljVIzQ-GkrcOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptFKrtrw%253D&md5=94dae7013fdf874ffe1540b8d31122c5</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100145%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DP.%2BM.%26aulast%3DWoo%26aufirst%3DL.%2BW.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DB.%2BV.%26atitle%3DAromatase%2520and%2520Dual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%2520from%2520the%2520Letrozole%2520and%2520Vorozole%2520Templates%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26issue%3D8%26spage%3D1423%26epage%3D1438%26doi%3D10.1002%2Fcmdc.201100145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1021/ml100273k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100273k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ags7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=243-247&issue=3&author=L.+W.+L.+Wooauthor=C.+Bubertauthor=A.+Purohitauthor=B.+V.+L.+Potter&title=Hybrid+Dual+Aromatase-Steroid+Sulfatase+Inhibitors+with+Exquisite+Picomolar+Inhibitory+Activity&doi=10.1021%2Fml100273k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity</span></div><div class="casAuthors">Woo, L. W. Lawrence; Bubert, Christian; Purohit, Atul; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-247</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Single agents against multiple drug targets are highly topical.  Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS), and several dual aromatase-sulfatase inhibitors (DASIs) have been recently reported.  The best compds. from two leading classes of DASI, 3 and 9, are low nanomolar inhibitors.  In search of a novel class of DASI, core motifs of two leading classes were combined to give a series of hybrid structures, with several compds. showing markedly improved dual inhibitory activities in the picomolar range in JEG-3 cells.  Thus, DASIs 14 (I, IC50: aromatase, 15 pM; STS, 830 pM) and 15 (IC50: aromatase, 18 pM; STS, 130 pM) are the first examples of an exceptional new class of highly potent dual inhibitor that should encourage further development toward multitargeted therapeutic intervention in HDBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_WoO0V3JbF7Vg90H21EOLACvtfcHk0ljVIzQ-GkrcOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ags7zK&md5=2805cabcf0c8210afec7bf65825b24c7</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fml100273k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100273k%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DHybrid%2520Dual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%2520with%2520Exquisite%2520Picomolar%2520Inhibitory%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26issue%3D3%26spage%3D243%26epage%3D247%26doi%3D10.1021%2Fml100273k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-Triazol-4-YL)amino]methyl}phenyl sulfamate</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fcmdc.201300015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23495205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVentLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=779-799&issue=5&author=L.+W.+L.+Wooauthor=P.+M.+Woodauthor=C.+Bubertauthor=M.+P.+Thomasauthor=A.+Purohitauthor=B.+V.+L.+Potter&title=Synthesis+and+Structure-Activity+Relationship+Studies+of+Derivatives+of+the+Dual+Aromatase-Sulfatase+Inhibitor+4-%7B%5B%284-Cyanophenyl%29%284H-1%2C2%2C4-Triazol-4-YL%29amino%5Dmethyl%7Dphenyl+sulfamate&doi=10.1002%2Fcmdc.201300015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship studies of derivatives of the dual aromatase-sulfatase inhibitor 4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate</span></div><div class="casAuthors">Woo, L. W. Lawrence; Wood, Paul M.; Bubert, Christian; Thomas, Mark P.; Purohit, Atul; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">779-799</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivs. are first-generation dual aromatase and sulfatase inhibitors (DASIs).  Structure-activity relationship studies were performed on these compds., and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para-cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group.  The most potent in vitro DASI discovered is an imidazole deriv. with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell prepn. of 0.2 and 2.5 nM, resp.  The parent phenol of this compd. inhibits aromatase with an IC50 value of 0.028 nM in the same assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDg_Fo94VkELVg90H21EOLACvtfcHk0lgcLOb9zUQ3Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVentLo%253D&md5=2d34b5f5c7e29c46c959dabd15c441e5</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300015%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DWood%26aufirst%3DP.%2BM.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Relationship%2520Studies%2520of%2520Derivatives%2520of%2520the%2520Dual%2520Aromatase-Sulfatase%2520Inhibitor%25204-%257B%255B%25284-Cyanophenyl%2529%25284H-1%252C2%252C4-Triazol-4-YL%2529amino%255Dmethyl%257Dphenyl%2520sulfamate%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26issue%3D5%26spage%3D779%26epage%3D799%26doi%3D10.1002%2Fcmdc.201300015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahon, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">Dual Aromatase-Steroid Sulfatase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3540</span>– <span class="NLM_lpage">3560</span>, <span class="refDoi"> DOI: 10.1021/jm061462b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061462b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1CjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3540-3560&issue=15&author=L.+W.+L.+Wooauthor=C.+Bubertauthor=O.+B.+Sutcliffeauthor=A.+Smithauthor=S.+K.+Chanderauthor=M.+F.+Mahonauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+L.+Potter&title=Dual+Aromatase-Steroid+Sulfatase+Inhibitors&doi=10.1021%2Fjm061462b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Aromatase-Steroid Sulfatase Inhibitors</span></div><div class="casAuthors">Woo, L. W. Lawrence; Bubert, Christian; Sutcliffe, Oliver B.; Smith, Andrew; Chander, Surinder K.; Mahon, Mary F.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3540-3560</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By introducing the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated.  Two best DASIs (I and II) in vitro (JEG-3 cells) had IC50(aromatase) = 0.82 nM; IC50(sulfatase) = 39 nM, and IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM, resp.  X-ray crystallog. of I, and docking studies of selected compds. into an aromatase homol. model and the steroid sulfatase crystal structure are presented.  Both I and II inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose.  Almost complete dual inhibition is obsd. for I but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h.  DASI I did not inhibit aldosterone synthesis.  The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPvCTamzS0qbVg90H21EOLACvtfcHk0lgcLOb9zUQ3Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1CjtLs%253D&md5=69641aaecd430daad1c2f8074be4b436</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm061462b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061462b%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DSutcliffe%26aufirst%3DO.%2BB.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DDual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D15%26spage%3D3540%26epage%3D3560%26doi%3D10.1021%2Fjm061462b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V.</span></span> <span> </span><span class="NLM_article-title">Highly Potent First Examples of Dual Aromatase-Steroid Sulfatase Inhibitors Based on a Biphenyl Template</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2155</span>– <span class="NLM_lpage">2170</span>, <span class="refDoi"> DOI: 10.1021/jm901705h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901705h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFKit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2155-2170&issue=5&author=L.+W.+L.+Wooauthor=T.+Jacksonauthor=A.+Puteyauthor=G.+Cozierauthor=P.+Leonardauthor=K.+R.+Acharyaauthor=S.+K.+Chanderauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+Potter&title=Highly+Potent+First+Examples+of+Dual+Aromatase-Steroid+Sulfatase+Inhibitors+Based+on+a+Biphenyl+Template&doi=10.1021%2Fjm901705h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Potent First Examples of Dual Aromatase-Steroid Sulfatase Inhibitors based on a Biphenyl Template</span></div><div class="casAuthors">Woo, L. W. Lawrence; Jackson, Toby; Putey, Aurelien; Cozier, Gyles; Leonard, Philip; Acharya, K. Ravi; Chander, Surinder K.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2155-2170</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hormone-dependent breast cancer may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS).  Therefore, an aromatase inhibitory pharmacophore was introduced into a known biphenyl STS inhibitor to give a series of novel dual aromatase-sulfatase inhibitors (DASIs).  Several compds. were good aromatase or STS inhibitors and DASI I (R = H) (IC50: aromatase, 2.0 nM; STS, 35 nM) and its chlorinated congener I (R = Cl) (IC50: aromatase, 0.5 nM; STS, 5.5 nM) were examples that showed exceptional dual potency in JEG-3 cells.  At 1 mg/kg po, I (R = H, Cl) strongly reduced plasma estradiol levels and inhibited liver STS activity potently in vivo.  DASI I (R = Cl) was non-estrogenic and potently inhibited carbonic anhydrase II (hCAII) (IC50 86 nM).  A complex of I (R = Cl) and hCAII was crystd. and its structure solved by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMz59lyRAt-rVg90H21EOLACvtfcHk0lgcLOb9zUQ3Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFKit70%253D&md5=3cdf0a54b96c189fd18cae4361f3338e</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm901705h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901705h%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DJackson%26aufirst%3DT.%26aulast%3DPutey%26aufirst%3DA.%26aulast%3DCozier%26aufirst%3DG.%26aulast%3DLeonard%26aufirst%3DP.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%26atitle%3DHighly%2520Potent%2520First%2520Examples%2520of%2520Dual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%2520Based%2520on%2520a%2520Biphenyl%2520Template%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D5%26spage%3D2155%26epage%3D2170%26doi%3D10.1021%2Fjm901705h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span> <span> </span><span class="NLM_article-title">First Dual Aromatase-Steroid Sulfatase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3193</span>– <span class="NLM_lpage">3196</span>, <span class="refDoi"> DOI: 10.1021/jm034033b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034033b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksFWjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3193-3196&issue=15&author=L.+W.+L.+Wooauthor=O.+B.+Sutcliffeauthor=C.+Bubertauthor=A.+Grassoauthor=S.+K.+Chanderauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+L.+Potter&title=First+Dual+Aromatase-Steroid+Sulfatase+Inhibitors&doi=10.1021%2Fjm034033b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">First Dual Aromatase-Steroid Sulfatase Inhibitors</span></div><div class="casAuthors">Woo, L. W. Lawrence; Sutcliffe, Oliver B.; Bubert, Christian; Grasso, Anna; Chander, Surinder K.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3193-3196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aromatase inhibitors in clin. use block the biosynthesis of estrogens.  Hydrolysis of estrone 3-sulfate by steroid sulfatase is an important addnl. source of tumor estrogen, and blockade of both enzymes should provide a more effective endocrine therapy.  Sulfamoylated derivs. of the aromatase inhibitor YM511 inhibited sulfatase and aromatase in JEG-3 cells with resp. IC50 values of 20-227 and 0.82-100 nM (cf. letrozole, 0.89 nM).  One dual inhibitor was potent against both enzymes in vivo, validating the concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOq7z9wm030LVg90H21EOLACvtfcHk0lgmIL1fyYy99A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksFWjsrk%253D&md5=b487f4b92cab559a36f69b7aaebeb9d1</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fjm034033b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034033b%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%2BL.%26aulast%3DSutcliffe%26aufirst%3DO.%2BB.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DGrasso%26aufirst%3DA.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26atitle%3DFirst%2520Dual%2520Aromatase-Steroid%2520Sulfatase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D15%26spage%3D3193%26epage%3D3196%26doi%3D10.1021%2Fjm034033b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, J.
R.</span></span> <span> </span><span class="NLM_article-title">Chapter 10:The Challenges of Multi-Target Lead Optimization</span>. <i>Designing Multi-Target Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1039/9781849734912-00141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1039%2F9781849734912-00141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=141-154&author=J.%0AR.+Morphy&title=Chapter+10%3AThe+Challenges+of+Multi-Target+Lead+Optimization&doi=10.1039%2F9781849734912-00141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1039%2F9781849734912-00141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252F9781849734912-00141%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26atitle%3DChapter%252010%253AThe%2520Challenges%2520of%2520Multi-Target%2520Lead%2520Optimization%26jtitle%3DDesigning%2520Multi-Target%2520Drugs%26date%3D2012%26spage%3D141%26epage%3D154%26doi%3D10.1039%2F9781849734912-00141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reichard, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grice, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majmundar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthes, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Oxime Dual NK<sub>1</sub>/NK<sub>2</sub> Antagonists with Reduced NK Affinity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2355</span>– <span class="NLM_lpage">2358</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)00462-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0960-894X%2802%2900462-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=12161132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvVGju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=2355-2358&issue=17&author=G.+A.+Reichardauthor=C.+A.+Griceauthor=N.+Y.+Shihauthor=J.+Spitlerauthor=S.+Majmundarauthor=S.+D.+Wangauthor=S.+Paliwalauthor=J.+C.+Anthesauthor=J.+J.+Piwinski&title=Preparation+of+Oxime+Dual+NK1%2FNK2+Antagonists+with+Reduced+NK+Affinity&doi=10.1016%2FS0960-894X%2802%2900462-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of oxime dual NK1/NK2 antagonists with reduced NK3 affinity</span></div><div class="casAuthors">Reichard, Gregory A.; Grice, Cheryl A.; Shih, Neng-Yang; Spitler, James; Majmundar, Sapna; Wang, Steven D.; Paliwal, Sunil; Anthes, John C.; Piwinski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2355-2358</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">By employing a stereosimplification approach, a thorough SAR exploration of the piperidine region of Sch 206272 was possible through a practical and efficient synthesis of substituted cyclic ureas.  This SAR study led to the identification of a benzimidazolinone series of compds. which display single digit nanomolar NK1/NK2 affinity and near micromolar binding for the NK3 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpoegeWv2YvbVg90H21EOLACvtfcHk0lgmIL1fyYy99A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvVGju7g%253D&md5=3271156060eeb818bd5b7823196b5ec3</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900462-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900462-6%26sid%3Dliteratum%253Aachs%26aulast%3DReichard%26aufirst%3DG.%2BA.%26aulast%3DGrice%26aufirst%3DC.%2BA.%26aulast%3DShih%26aufirst%3DN.%2BY.%26aulast%3DSpitler%26aufirst%3DJ.%26aulast%3DMajmundar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%2BD.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DAnthes%26aufirst%3DJ.%2BC.%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26atitle%3DPreparation%2520of%2520Oxime%2520Dual%2520NK1%252FNK2%2520Antagonists%2520with%2520Reduced%2520NK%2520Affinity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26issue%3D17%26spage%3D2355%26epage%3D2358%26doi%3D10.1016%2FS0960-894X%2802%2900462-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entsuah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, R. L.</span></span> <span> </span><span class="NLM_article-title">Comparative Efficacy between Venlafaxine and SSRIs: A Pooled Analysis of Patients with Depression</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1166</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/S0006-3223(02)01425-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0006-3223%2802%2901425-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=12488062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsFSqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2002&pages=1166-1174&issue=12&author=S.+M.+Stahlauthor=R.+Entsuahauthor=R.+L.+Rudolph&title=Comparative+Efficacy+between+Venlafaxine+and+SSRIs%3A+A+Pooled+Analysis+of+Patients+with+Depression&doi=10.1016%2FS0006-3223%2802%2901425-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression</span></div><div class="casAuthors">Stahl, Stephen M.; Entsuah, Richard; Rudolph, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1166-1174</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Serotonergic and adrenergic enhancement may be synergistic and more effective than serotonergic enhancement alone in treating depression.  The dual serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine is a dual reuptake inhibitor that may therefore offer greater efficacy than selective serotonin reuptake inhibitors (SSRIs).  Data from eight randomized, double-blind, controlled studies were pooled to compare efficacy in depressed patients receiving venlafaxine/venlafaxine extended release (XR), SSRIs, or placebo for ≤8 wk.  The mean changes from baseline in the 21-item Hamilton Rating Scale for Depression (HAM-D21), Montgomery-Asberg Depression Rating Scale (MADRS), and Clin. Global Impressions-Global Improvement (CGI-I) and CGI-Severity of Illness (CGI-S) item scores were compared, as were response rates derived from these scales.  Statistically significant differences in mean HAM-D21 score decrease between venlafaxine (14.5) and SSRIs (12.6) and between the active treatments and placebo (11.3) were obsd.  Venlafaxine significantly decreased the mean MADRS scores more than SSRIs (17.8 vs. 15.9), and both treatments were significantly better than placebo (12.9).  The same pattern of significance for CGI-I, HAM-D21, and MADRS response rates between venlafaxine (71%, 64%, and 67%, resp.), SSRIs (64%, 57%, and 59%, resp.), and placebo (50%, 42%, and 41%, resp.) was obsd.  Thus, venlafaxine was significantly more effective than SSRIs in improving depression, perhaps due to enhancing both serotonin and norepinephrine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRCMEi9kcN7bVg90H21EOLACvtfcHk0lgmIL1fyYy99A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsFSqur4%253D&md5=0fb286dab5f16acb4e0074c547ae2e6c</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2802%2901425-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252802%252901425-7%26sid%3Dliteratum%253Aachs%26aulast%3DStahl%26aufirst%3DS.%2BM.%26aulast%3DEntsuah%26aufirst%3DR.%26aulast%3DRudolph%26aufirst%3DR.%2BL.%26atitle%3DComparative%2520Efficacy%2520between%2520Venlafaxine%2520and%2520SSRIs%253A%2520A%2520Pooled%2520Analysis%2520of%2520Patients%2520with%2520Depression%26jtitle%3DBiol.%2520Psychiatry%26date%3D2002%26volume%3D52%26issue%3D12%26spage%3D1166%26epage%3D1174%26doi%3D10.1016%2FS0006-3223%2802%2901425-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic-Nikolic, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uliassi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">A Perspective on Multi-Target Drug Discovery and Design for Complex Diseases</span>. <i>Clini. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1186/s40169-017-0181-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1186%2Fs40169-017-0181-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29318404" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=1-14&issue=3&author=R.+R.+Ramsayauthor=M.+R.+Popovic-Nikolicauthor=K.+Nikolicauthor=E.+Uliassiauthor=M.+L.+Bolognesi&title=A+Perspective+on+Multi-Target+Drug+Discovery+and+Design+for+Complex+Diseases&doi=10.1186%2Fs40169-017-0181-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1186%2Fs40169-017-0181-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40169-017-0181-2%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DPopovic-Nikolic%26aufirst%3DM.%2BR.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DUliassi%26aufirst%3DE.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DA%2520Perspective%2520on%2520Multi-Target%2520Drug%2520Discovery%2520and%2520Design%2520for%2520Complex%2520Diseases%26jtitle%3DClini.%2520Transl.%2520Med.%26date%3D2018%26volume%3D7%26issue%3D3%26spage%3D1%26epage%3D14%26doi%3D10.1186%2Fs40169-017-0181-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurkauf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieltyka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodbeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Primus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasley, J.</span></span> <span> </span><span class="NLM_article-title">Indoline and Piperazine Containing Derivatives as a Novel Class of Mixed D<sub>2</sub>/D<sub>4</sub> Receptor Antagonists. Part 2: Asymmetric Synthesis and Biological Evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">3111</span>– <span class="NLM_lpage">3115</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)00656-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0960-894X%2802%2900656-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=12372513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38Xns1Ogs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=3111-3115&issue=21&author=H.+Zhaoauthor=X.+A.+Heauthor=A.+Thurkaufauthor=D.+Hoffmanauthor=A.+Kieltykaauthor=R.+Brodbeckauthor=R.+Primusauthor=J.+Wasley&title=Indoline+and+Piperazine+Containing+Derivatives+as+a+Novel+Class+of+Mixed+D2%2FD4+Receptor+Antagonists.+Part+2%3A+Asymmetric+Synthesis+and+Biological+Evaluation&doi=10.1016%2FS0960-894X%2802%2900656-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 2: Asymmetric synthesis and biological evaluation</span></div><div class="casAuthors">Zhao, He; He, Xiaoshu; Thurkauf, Andrew; Hoffman, Diane; Kieltyka, Andrzej; Brodbeck, Robbin; Primus, Renee; Wasley, Jan W. F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3111-3115</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of chiral benzylpiperazinyl-1-(2,3-dihydroindol-1-yl)ethanone derivs. were prepd. and examd. for their affinity at dopamine D2 and D4 receptors.  Three compds. having D2/D4 affinity ratios approximating that found for the atypical neuroleptic clozapine were further evaluated in behavioral tests of antipsychotic efficacy and motor side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEiDLTvWdcp7Vg90H21EOLACvtfcHk0ljETKh8TIBLnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xns1Ogs7s%253D&md5=7f84a80314abed56ceb2ff61b9dd8477</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900656-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900656-X%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DX.%2BA.%26aulast%3DThurkauf%26aufirst%3DA.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DKieltyka%26aufirst%3DA.%26aulast%3DBrodbeck%26aufirst%3DR.%26aulast%3DPrimus%26aufirst%3DR.%26aulast%3DWasley%26aufirst%3DJ.%26atitle%3DIndoline%2520and%2520Piperazine%2520Containing%2520Derivatives%2520as%2520a%2520Novel%2520Class%2520of%2520Mixed%2520D2%252FD4%2520Receptor%2520Antagonists.%2520Part%25202%253A%2520Asymmetric%2520Synthesis%2520and%2520Biological%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26issue%3D21%26spage%3D3111%26epage%3D3115%26doi%3D10.1016%2FS0960-894X%2802%2900656-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agalave, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maujan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pore, V. S.</span></span> <span> </span><span class="NLM_article-title">Click Chemistry: 1,2,3-Triazoles as Pharmacophores</span>. <i>Chem. - Asian J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2696</span>– <span class="NLM_lpage">2718</span>, <span class="refDoi"> DOI: 10.1002/asia.201100432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fasia.201100432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21954075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSjur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=2696-2718&issue=10&author=S.+G.+Agalaveauthor=S.+R.+Maujanauthor=V.+S.+Pore&title=Click+Chemistry%3A+1%2C2%2C3-Triazoles+as+Pharmacophores&doi=10.1002%2Fasia.201100432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Click Chemistry: 1,2,3-Triazoles as Pharmacophores</span></div><div class="casAuthors">Agalave, Sandip G.; Maujan, Suleman R.; Pore, Vandana S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - An Asian Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2696-2718</span>CODEN:
                <span class="NLM_cas:coden">CAAJBI</span>;
        ISSN:<span class="NLM_cas:issn">1861-4728</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The copper(I)-catalyzed 1,2,3-triazole-forming reaction between azides and terminal alkynes has become the gold std. of click chem.' due to its reliability, specificity, and biocompatibility.  Applications of click chem. are increasingly found in all aspects of drug discovery; they range from lead finding through combinatorial chem. and target-templated in vitro chem., to proteomics and DNA research by using bioconjugation reactions.  The triazole products are more than just passive linkers; they readily assoc. with biol. targets, through hydrogen-bonding and dipole interactions.  The present review will focus mainly on the recent literature for applications of this reaction in the field of medicinal chem., in particular on use of the 1,2,3-triazole moiety as pharmacophore.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUyLcfL241V7Vg90H21EOLACvtfcHk0ljETKh8TIBLnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSjur7P&md5=73631df03b9b2e58c7870e7239bb2548</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fasia.201100432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fasia.201100432%26sid%3Dliteratum%253Aachs%26aulast%3DAgalave%26aufirst%3DS.%2BG.%26aulast%3DMaujan%26aufirst%3DS.%2BR.%26aulast%3DPore%26aufirst%3DV.%2BS.%26atitle%3DClick%2520Chemistry%253A%25201%252C2%252C3-Triazoles%2520as%2520Pharmacophores%26jtitle%3DChem.%2520-%2520Asian%2520J.%26date%3D2011%26volume%3D6%26issue%3D10%26spage%3D2696%26epage%3D2718%26doi%3D10.1002%2Fasia.201100432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span> <span> </span><span class="NLM_article-title">Click Chemistry: Diverse Chemical Function from a Few Good Reactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2004</span>– <span class="NLM_lpage">2021</span>, <span class="refDoi"> DOI: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksVOis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=2004-2021&issue=11&author=H.+C.+Kolbauthor=M.+G.+Finnauthor=K.+B.+Sharpless&title=Click+Chemistry%3A+Diverse+Chemical+Function+from+a+Few+Good+Reactions&doi=10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Click chemistry: diverse chemical function from a few good reactions</span></div><div class="casAuthors">Kolb, Hartmuth C.; Finn, M. G.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2004-2021</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">Review with > 88 refs.  Examn. of nature's favorite mols. reveals a striking preference for making carbon-heteroatom bonds over carbon-carbon bonds - surely no surprise given that carbon dioxide is nature's starting material and that most reactions are performed in water.  Nucleic acids, proteins, and polysaccharides are condensation polymers of small subunits stitched together by carbon-heteroatom bonds.  Even the 35 or so building blocks from which these crucial mols. are made each contain, at most, six contiguous C-C bonds, except for the three arom. amino acids.  Taking a cue from nature's approach, the development of a set of powerful, highly reliable, and selective reactions for the rapid synthesis of useful new compds. and combinatorial libraries through heteroatom links (C-X-C), an approach called "click chem." is addressed.  Click chem. is at once defined, enabled, and constrained by a handful of nearly perfect "spring-loaded" reactions.  The stringent criteria for a process to earn click chem. status are described along with examples of the mol. frameworks that are easily made using this spartan, but powerful, synthetic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptrjo9nxXNRrVg90H21EOLACvtfcHk0ljETKh8TIBLnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksVOis78%253D&md5=61c28b416c42c87821bc8a5bc2fdec36</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3773%252820010601%252940%253A11%253C2004%253A%253AAID-ANIE2004%253E3.0.CO%253B2-5%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DClick%2520Chemistry%253A%2520Diverse%2520Chemical%2520Function%2520from%2520a%2520Few%2520Good%2520Reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2001%26volume%3D40%26issue%3D11%26spage%3D2004%26epage%3D2021%26doi%3D10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellamaggiore, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mccarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipford, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span> <span> </span><span class="NLM_article-title">A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01781</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01781" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=453-461&issue=2&author=R.+P.+Wurzauthor=K.+Dellamaggioreauthor=H.+Douauthor=N.+Javierauthor=M.+C.+Loauthor=J.+D.+Mccarterauthor=D.+Mohlauthor=C.+Sastriauthor=J.+R.+Lipfordauthor=V.+J.+Cee&title=A+%E2%80%9CClick+Chemistry+Platform%E2%80%9D+for+the+Rapid+Synthesis+of+Bispecific+Molecules+for+Inducing+Protein+Degradation&doi=10.1021%2Facs.jmedchem.6b01781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation</span></div><div class="casAuthors">Wurz, Ryan P.; Dellamaggiore, Ken; Dou, Hannah; Javier, Noelle; Lo, Mei-Chu; McCarter, John D.; Mohl, Dane; Sastri, Christine; Lipford, J. Russell; Cee, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">453-461</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Proteolysis targeting chimeras (PROTACs) are bispecific mols. contg. a target protein binder and an ubiquitin ligase binder connected by a linker.  By recruiting an ubiquitin ligase to a target protein, PROTACs promote ubiquitination and proteasomal degrdn. of the target protein.  The generation of effective PROTACs depends on the nature of the protein/ligase ligand pair, linkage site, linker length, and linker compn., all of which have been difficult to address in a systematic way.  Herein, the authors describe a "click chem." approach for the synthesis of PROTACs.  The authors demonstrate the utility of this approach with the bromodomain and extra terminal domain-4 (BRD4) ligand JQ-1 (3) and ligase binders targeting cereblon (CRBN) and Von Hippel-Lindau (VHL) proteins.  An AlphaScreen proximity assay was used to det. the ability of PROTACs to form the ternary ligase-PROTAC-target protein complex and a MSD assay to measure cellular degrdn. of the target protein promoted by PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpooapLJ2Zln7Vg90H21EOLACvtfcHk0liBrgryrmdk0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7w%253D&md5=090c569ae1f079ab6504348aabec8909</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01781%26sid%3Dliteratum%253Aachs%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DDellamaggiore%26aufirst%3DK.%26aulast%3DDou%26aufirst%3DH.%26aulast%3DJavier%26aufirst%3DN.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DMccarter%26aufirst%3DJ.%2BD.%26aulast%3DMohl%26aufirst%3DD.%26aulast%3DSastri%26aufirst%3DC.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26atitle%3DA%2520%25E2%2580%259CClick%2520Chemistry%2520Platform%25E2%2580%259D%2520for%2520the%2520Rapid%2520Synthesis%2520of%2520Bispecific%2520Molecules%2520for%2520Inducing%2520Protein%2520Degradation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D2%26spage%3D453%26epage%3D461%26doi%3D10.1021%2Facs.jmedchem.6b01781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laplante, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fader, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandrick, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandrick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hucke, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. J.</span></span> <span> </span><span class="NLM_article-title">Assessing Atropisomer Axial Chirality in Drug Discovery and Development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">7005</span>– <span class="NLM_lpage">7022</span>, <span class="refDoi"> DOI: 10.1021/jm200584g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200584g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7005-7022&issue=20&author=S.+R.+Laplanteauthor=L.+D.+Faderauthor=K.+R.+Fandrickauthor=D.+R.+Fandrickauthor=O.+Huckeauthor=R.+Kemperauthor=S.+P.+Millerauthor=P.+J.+Edwards&title=Assessing+Atropisomer+Axial+Chirality+in+Drug+Discovery+and+Development&doi=10.1021%2Fjm200584g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing Atropisomer Axial Chirality in Drug Discovery and Development</span></div><div class="casAuthors">LaPlante, Steven R.; Fader, Lee D.; Fandrick, Keith R.; Fandrick, Daniel R.; Hucke, Oliver; Kemper, Ray; Miller, Stephen P. F.; Edwards, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7005-7022</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ8uS-SDx68bVg90H21EOLACvtfcHk0liBrgryrmdk0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFygu7zN&md5=6b44135b3871d2460fba4b3246b899e3</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjm200584g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200584g%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DS.%2BR.%26aulast%3DFader%26aufirst%3DL.%2BD.%26aulast%3DFandrick%26aufirst%3DK.%2BR.%26aulast%3DFandrick%26aufirst%3DD.%2BR.%26aulast%3DHucke%26aufirst%3DO.%26aulast%3DKemper%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DS.%2BP.%26aulast%3DEdwards%26aufirst%3DP.%2BJ.%26atitle%3DAssessing%2520Atropisomer%2520Axial%2520Chirality%2520in%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D20%26spage%3D7005%26epage%3D7022%26doi%3D10.1021%2Fjm200584g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elder, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokin, V. V.</span></span> <span> </span><span class="NLM_article-title">Rapid Discovery and Structure-Activity Profiling of Novel Inhibitors of Human Immunodeficiency Virus Type 1 Protease Enabled by the Copper(I)-Catalyzed Synthesis of 1,2,3-Triazoles and Their Further Functionalization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">7697</span>– <span class="NLM_lpage">7710</span>, <span class="refDoi"> DOI: 10.1021/jm060754+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060754%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GjsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7697-7710&issue=26&author=M.+Whitingauthor=J.+C.+Trippauthor=Y.+C.+Linauthor=W.+Lindstromauthor=A.+J.+Olsonauthor=J.+H.+Elderauthor=K.+B.+Sharplessauthor=V.+V.+Fokin&title=Rapid+Discovery+and+Structure-Activity+Profiling+of+Novel+Inhibitors+of+Human+Immunodeficiency+Virus+Type+1+Protease+Enabled+by+the+Copper%28I%29-Catalyzed+Synthesis+of+1%2C2%2C3-Triazoles+and+Their+Further+Functionalization&doi=10.1021%2Fjm060754%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Discovery and Structure-Activity Profiling of Novel Inhibitors of Human Immunodeficiency Virus Type 1 Protease Enabled by the Copper(I)-Catalyzed Synthesis of 1,2,3-Triazoles and Their Further Functionalization</span></div><div class="casAuthors">Whiting, Matthew; Tripp, Jonathan C.; Lin, Ying-Chuan; Lindstrom, William; Olson, Arthur J.; Elder, John H.; Sharpless, K. Barry; Fokin, Valery V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7697-7710</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Building from the results of a computational screen of a range of triazole-contg. compds. for binding efficiency to human immunodeficiency virus type 1 protease (HIV-1-Pr), a novel series of potent inhibitors has been developed.  The copper(I)-catalyzed azide-alkyne cycloaddn. (CuAAC), which provides ready access to 1,4-disubstituted-1,2,3-triazoles, was used to unite a focused library of azide-contg. fragments with a diverse array of functionalized alkyne-contg. building blocks.  In combination with direct screening of the crude reaction products, this method led to the rapid identification of a lead structure and readily enabled optimization of both azide and alkyne fragments.  Replacement of the triazole with a range of alternative linkers led to greatly reduced protease inhibition; however, further functionalization of the triazoles at the 5-position gave a series of compds. with increased activity, exhibiting Ki values as low as 8 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxP4sXbJdAZbVg90H21EOLACvtfcHk0liBrgryrmdk0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GjsbjL&md5=252fb639055fb8e55a1e1a0eb0842853</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm060754%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060754%252B%26sid%3Dliteratum%253Aachs%26aulast%3DWhiting%26aufirst%3DM.%26aulast%3DTripp%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DY.%2BC.%26aulast%3DLindstrom%26aufirst%3DW.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26aulast%3DElder%26aufirst%3DJ.%2BH.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26aulast%3DFokin%26aufirst%3DV.%2BV.%26atitle%3DRapid%2520Discovery%2520and%2520Structure-Activity%2520Profiling%2520of%2520Novel%2520Inhibitors%2520of%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Protease%2520Enabled%2520by%2520the%2520Copper%2528I%2529-Catalyzed%2520Synthesis%2520of%25201%252C2%252C3-Triazoles%2520and%2520Their%2520Further%2520Functionalization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D26%26spage%3D7697%26epage%3D7710%26doi%3D10.1021%2Fjm060754%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somu, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, C. C.</span></span> <span> </span><span class="NLM_article-title">Rationally Designed Nucleoside Antibiotics That Inhibit Siderophore Biosynthesis of Mycobacterium Tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1021/jm051060o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051060o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht12rtbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=31-34&issue=1&author=R.+V.+Somuauthor=H.+Boshoffauthor=C.+Qiaoauthor=E.+M.+Bennettauthor=C.+E.+Barryauthor=C.+C.+Aldrich&title=Rationally+Designed+Nucleoside+Antibiotics+That+Inhibit+Siderophore+Biosynthesis+of+Mycobacterium+Tuberculosis&doi=10.1021%2Fjm051060o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed Nucleoside Antibiotics That Inhibit Siderophore Biosynthesis of Mycobacterium tuberculosis</span></div><div class="casAuthors">Somu, Ravindranadh V.; Boshoff, Helena; Qiao, Chunhua; Bennett, Eric M.; Barry, Clifton E., III; Aldrich, Courtney C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-34</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A rationally designed nucleoside inhibitor of Mycobacterium tuberculosis growth (MIC99 = 0.19 μM) that disrupts siderophore biosynthesis was identified.  The activity is due to inhibition of the adenylate-forming enzyme MbtA which is involved in biosynthesis of the mycobactins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGothJgh0PSwprVg90H21EOLACvtfcHk0lh23GtEuTGNeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht12rtbjO&md5=48a498dce7210655779519d534dff088</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm051060o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051060o%26sid%3Dliteratum%253Aachs%26aulast%3DSomu%26aufirst%3DR.%2BV.%26aulast%3DBoshoff%26aufirst%3DH.%26aulast%3DQiao%26aufirst%3DC.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DAldrich%26aufirst%3DC.%2BC.%26atitle%3DRationally%2520Designed%2520Nucleoside%2520Antibiotics%2520That%2520Inhibit%2520Siderophore%2520Biosynthesis%2520of%2520Mycobacterium%2520Tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D1%26spage%3D31%26epage%3D34%26doi%3D10.1021%2Fjm051060o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aher, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pore, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, M. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antifungal Activity of 1,2,3-Triazole Containing Fluconazole Analogues</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmcl.2008.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19110424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2isLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=759-763&issue=3&author=N.+G.+Aherauthor=V.+S.+Poreauthor=N.+N.+Mishraauthor=A.+Kumarauthor=P.+K.+Shuklaauthor=A.+Sharmaauthor=M.+K.+Bhat&title=Synthesis+and+Antifungal+Activity+of+1%2C2%2C3-Triazole+Containing+Fluconazole+Analogues&doi=10.1016%2Fj.bmcl.2008.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antifungal activity of 1,2,3-triazole containing fluconazole analogues</span></div><div class="casAuthors">Aher, Nilkanth G.; Pore, Vandana S.; Mishra, Nripendra N.; Kumar, Awanit; Shukla, Praveen K.; Sharma, Aanchal; Bhat, Manoj K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">759-763</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fluconazole based mimics contg. 1,2,3-triazole were designed and synthesized as antifungal agents.  Their antifungal activities were evaluated in vitro by measuring the minimal inhibitory concns. (MICs).  Three compds. were found to be more potent against Candida fungal pathogens than control drugs fluconazole and amphotericin B.  The studies presented here provide structural modification of fluconazole to give 1,2,3-triazole contg. mols.  Furthermore, these mols. were evaluated in vivo against Candida albicans i.v. challenge in Swiss mice and antiproliferative activities were tested against human hepatocellular carcinoma Hep3B and human epithelial carcinoma A431.  It was found that compd. I resulted in 97.4% redn. in fungal load in mice and did not show any profound proliferative effect at lower dose (0.001 mg/mL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSEDdN0gVgG7Vg90H21EOLACvtfcHk0lh23GtEuTGNeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2isLs%253D&md5=2f36e9db134f3f849482a359de94b525</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DAher%26aufirst%3DN.%2BG.%26aulast%3DPore%26aufirst%3DV.%2BS.%26aulast%3DMishra%26aufirst%3DN.%2BN.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DShukla%26aufirst%3DP.%2BK.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DBhat%26aufirst%3DM.%2BK.%26atitle%3DSynthesis%2520and%2520Antifungal%2520Activity%2520of%25201%252C2%252C3-Triazole%2520Containing%2520Fluconazole%2520Analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D3%26spage%3D759%26epage%3D763%26doi%3D10.1016%2Fj.bmcl.2008.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pore, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, P. K.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Fluconazole/Bile Acid Conjugate Using Click Reaction</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">11178</span>– <span class="NLM_lpage">11186</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2006.09.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.tet.2006.09.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWjtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=11178-11186&issue=48&author=V.+S.+Poreauthor=N.+G.+Aherauthor=M.+Kumarauthor=P.+K.+Shukla&title=Design+and+Synthesis+of+Fluconazole%2FBile+Acid+Conjugate+Using+Click+Reaction&doi=10.1016%2Fj.tet.2006.09.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of fluconazole/bile acid conjugate using click reaction</span></div><div class="casAuthors">Pore, Vandana S.; Aher, Nilkanth G.; Kumar, Manish; Shukla, Praveen K.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">11178-11186</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Novel fluconazole/bile acid conjugates I (R1 = H, OH) and II (R2 = H, OH) were designed and their regioselective synthesis was achieved in very high yield via Cu(I) catalyzed intermol. 1,3-dipolar cycloaddn.  These new mols. showed good antifungal activity against Candida species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKpCIH_kQb1bVg90H21EOLACvtfcHk0lh23GtEuTGNeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWjtLfO&md5=404c12ebd37361363d759143d0138ba8</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2006.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2006.09.021%26sid%3Dliteratum%253Aachs%26aulast%3DPore%26aufirst%3DV.%2BS.%26aulast%3DAher%26aufirst%3DN.%2BG.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DShukla%26aufirst%3DP.%2BK.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Fluconazole%252FBile%2520Acid%2520Conjugate%2520Using%2520Click%2520Reaction%26jtitle%3DTetrahedron%26date%3D2006%26volume%3D62%26issue%3D48%26spage%3D11178%26epage%3D11186%26doi%3D10.1016%2Fj.tet.2006.09.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, C. M.</span></span> <span> </span><span class="NLM_article-title">What Makes a Neutral Imino Dieneophile Undergo a Thermal, Non-Catalysed, Diels-Alder Reaction?</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6035</span>– <span class="NLM_lpage">6050</span>, <span class="refDoi"> DOI: 10.1016/S0040-4020(98)00284-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0040-4020%2898%2900284-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK1cXjsFSjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=6035-6050&issue=22&author=A.+Whitingauthor=C.+M.+Windsor&title=What+Makes+a+Neutral+Imino+Dieneophile+Undergo+a+Thermal%2C+Non-Catalysed%2C+Diels-Alder+Reaction%3F&doi=10.1016%2FS0040-4020%2898%2900284-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">What makes a neutral imino dieneophile undergo a thermal, non-catalyzed, Diels-Alder reaction?</span></div><div class="casAuthors">Whiting, Andrew; Windsor, Carl M.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6035-6050</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Ab initio calcns. have been carried out at the MP2/6-31G* level of theory on the aza-Diels-Alder reaction of a range electron deficient imines (with sulfonyl and/or carbonyl substituents) with buta-1,3-diene.  In all cases but one, an early cyclic transition-state could be located in which most often, the forming N-C bond was more fully formed than the forming C-C bond.  However, examples were found in which this order of bond formation was reversed.  Examn. of HOMO-LUMO energy levels show that aza-Diels-Alder reactions are HOMO (diene)-LUMO (dienophile) controlled and that the most electron deficient imines should be more reactive than simple alkyl or aryl imines and imines possessing less electron withdrawing groups.  Evidence is also found for exo-lone pair effects, but these effects become obscured by other stereoelectronic effects as electron withdrawing substituents are added to the imine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO3WeQiHMFM7Vg90H21EOLACvtfcHk0lh23GtEuTGNeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjsFSjsrw%253D&md5=36f7cead30efcaf6f537fc098a8634a9</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2898%2900284-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252898%252900284-1%26sid%3Dliteratum%253Aachs%26aulast%3DWhiting%26aufirst%3DA.%26aulast%3DWindsor%26aufirst%3DC.%2BM.%26atitle%3DWhat%2520Makes%2520a%2520Neutral%2520Imino%2520Dieneophile%2520Undergo%2520a%2520Thermal%252C%2520Non-Catalysed%252C%2520Diels-Alder%2520Reaction%253F%26jtitle%3DTetrahedron%26date%3D1998%26volume%3D54%26issue%3D22%26spage%3D6035%26epage%3D6050%26doi%3D10.1016%2FS0040-4020%2898%2900284-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arepalli, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of 1,3-Diphenylbenzo[F][1,7]Naphthyrdines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5586</span>– <span class="NLM_lpage">5597</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.08.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2017.08.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28870801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVertL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=5586-5597&issue=20&author=S.+K.+Arepalliauthor=B.+Parkauthor=K.+Leeauthor=H.+Joauthor=K.+Y.+Junauthor=Y.+Kwonauthor=J.+S.+Kangauthor=J.+K.+Jungauthor=H.+Lee&title=Design%2C+Synthesis+and+Biological+Evaluation+of+1%2C3-Diphenylbenzo%5BF%5D%5B1%2C7%5DNaphthyrdines&doi=10.1016%2Fj.bmc.2017.08.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 1,3-diphenylbenzo[f][1,7]naphthyrdines</span></div><div class="casAuthors">Arepalli, Sateesh Kumar; Park, Byeongwoo; Lee, Kiho; Jo, Hyunji; Jun, Kyu-Yeon; Kwon, Youngjoo; Kang, Jong-Soon; Jung, Jae-Kyung; Lee, Heesoon</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5586-5597</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel twenty 1,3-diphenylbenzo[f][1,7]benzonaphthyrdine derivs. I [R = H, Me; R1 = 2-thienyl, 4-BrC6H4, 1-naphthyl, etc.] were designed and synthesized through intermol. imino Diels-Alder reaction.  Their in vitro cytotoxic activities were evaluated against six human cancer cell lines (NCIH23, HCT15, NUGC-3, ACHN, PC-3, and MDA-MB-231).  Majority of synthesized compds. exhibited significant cytotoxic activities against all tested human cancer cell lines.  Among them I [R = H; R1 = 4-Me2NC6H4, 4-ClC6H4, 3-CNC6H4] derivs. exhibited most promising cytotoxic activities.  Furthermore these compds. were evaluated against human topoisomerase IIα inhibition, out of which the compd. I [R = H; R1 = 4-Me2NC6H4] exhibited 1.3 and 1.2 times more potent human topoisomerase IIα inhibition than the ref. drug etoposide in both 100 μM and 20 μM concns. resp.  Mol. docking studies for the compd. I [R = H; R1 = 4-Me2NC6H4] have also been executed by sybyl X-2.1 in which it revealed that it's binding site with topo IIα DNA cleavage site where etoposide was situated.  The benzo[f][1,7]naphthyridine ring was stacked between the DNA bases of the cleavage site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUsjR1RS3bd7Vg90H21EOLACvtfcHk0lgX3WCtUu-jXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVertL3E&md5=aa64050fe197fda2887e901ef0b25ae8</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.08.030%26sid%3Dliteratum%253Aachs%26aulast%3DArepalli%26aufirst%3DS.%2BK.%26aulast%3DPark%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DJo%26aufirst%3DH.%26aulast%3DJun%26aufirst%3DK.%2BY.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DJung%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25201%252C3-Diphenylbenzo%255BF%255D%255B1%252C7%255DNaphthyrdines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D20%26spage%3D5586%26epage%3D5597%26doi%3D10.1016%2Fj.bmc.2017.08.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span> <span> </span><span class="NLM_article-title">Transition Metal-Catalyzed Decarboxylative Cross-Coupling Reactions</span>. <i>Sci. China: Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1670</span>– <span class="NLM_lpage">1687</span>, <span class="refDoi"> DOI: 10.1007/s11426-011-4381-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1007%2Fs11426-011-4381-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVamtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1670-1687&issue=11&author=R.+Shangauthor=L.+Liu&title=Transition+Metal-Catalyzed+Decarboxylative+Cross-Coupling+Reactions&doi=10.1007%2Fs11426-011-4381-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Transition metal-catalyzed decarboxylative cross-coupling reactions</span></div><div class="casAuthors">Shang, Rui; Liu, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Science China: Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1670-1687</span>CODEN:
                <span class="NLM_cas:coden">SCCCCS</span>;
        ISSN:<span class="NLM_cas:issn">1869-1870</span>.
    
            (<span class="NLM_cas:orgname">Science China Press</span>)
        </div><div class="casAbstract">A review.  Transition metal-catalyzed decarboxylative cross-coupling reactions recently emerged as a new and important category of org. transformations that find versatile applications in the construction of carbon-carbon and carbon-heteroatom bonds.  The use of relatively cheap and stable carboxylic acids to replace organometallic reagents enables the decarboxylative cross-coupling reactions to proceed with good selectivities and functional group tolerance.  The present review summarized the various types of decarboxylative cross-coupling reactions catalyzed by different transition metal complexes.  The scope and applications of these reactions were described.  The challenges and opportunities in the field were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2w4ggGiGk17Vg90H21EOLACvtfcHk0lgX3WCtUu-jXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVamtb3J&md5=8724384faf443545d40c0e78e4ad844c</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1007%2Fs11426-011-4381-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11426-011-4381-0%26sid%3Dliteratum%253Aachs%26aulast%3DShang%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DL.%26atitle%3DTransition%2520Metal-Catalyzed%2520Decarboxylative%2520Cross-Coupling%2520Reactions%26jtitle%3DSci.%2520China%253A%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D11%26spage%3D1670%26epage%3D1687%26doi%3D10.1007%2Fs11426-011-4381-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stüer, R.</span></span> <span> </span><span class="NLM_article-title">Metal-Catalyzed Cross-Coupling Reactions</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>347</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1002/adsc.200404362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fadsc.200404362" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2005&pages=197-197&issue=1&author=R.+St%C3%BCer&title=Metal-Catalyzed+Cross-Coupling+Reactions&doi=10.1002%2Fadsc.200404362"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2Fadsc.200404362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.200404362%26sid%3Dliteratum%253Aachs%26aulast%3DSt%25C3%25BCer%26aufirst%3DR.%26atitle%3DMetal-Catalyzed%2520Cross-Coupling%2520Reactions%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2005%26volume%3D347%26issue%3D1%26spage%3D197%26epage%3D197%26doi%3D10.1002%2Fadsc.200404362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span> <span> </span><span class="NLM_article-title">Cross-Coupling Reactions of Organoboranes: An Easy Method for C-C Bonding</span>. <i>Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">894</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.1246/cl.2011.894</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1246%2Fcl.2011.894" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1CjurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=894-901&issue=9&author=A.+Suzukiauthor=Y.+Yamamoto&title=Cross-Coupling+Reactions+of+Organoboranes%3A+An+Easy+Method+for+C-C+Bonding&doi=10.1246%2Fcl.2011.894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-coupling reactions of organoboranes: an easy method for C-C bonding</span></div><div class="casAuthors">Suzuki, Akira; Yamamoto, Yasunori</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">894-901</span>CODEN:
                <span class="NLM_cas:coden">CMLTAG</span>;
        ISSN:<span class="NLM_cas:issn">0366-7022</span>.
    
            (<span class="NLM_cas:orgname">Chemical Society of Japan</span>)
        </div><div class="casAbstract">A review was given on cross-coupling reactions of organoboranes.  The Pd-catalyzed cross-coupling reaction between different types of organoboron compds. and various org. halides or triflates in the presence of base provides a powerful and general methodol. for the formation of C-C bonds.  C(sp2)-B compds. (such as aryl- and 1-alkenylborons) and C(sp3)-B compds. (alkylborons) readily cross-couple with org. electrophiles to give coupled products selectively in high yields.  Recently, C(sp)-B compds. (1-alkynylborons) were also obsd. to react with org. electrophiles to produce expected cross-coupled products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBPWtZI9vbx7Vg90H21EOLACvtfcHk0lgX3WCtUu-jXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1CjurfP&md5=608c14749c275d669f66bddd1fae4f3b</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1246%2Fcl.2011.894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.2011.894%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DY.%26atitle%3DCross-Coupling%2520Reactions%2520of%2520Organoboranes%253A%2520An%2520Easy%2520Method%2520for%2520C-C%2520Bonding%26jtitle%3DChem.%2520Lett.%26date%3D2011%26volume%3D40%26issue%3D9%26spage%3D894%26epage%3D901%26doi%3D10.1246%2Fcl.2011.894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyaura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2457</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.1021/cr00039a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&issue=7&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-Catalyzed+Cross-Coupling+Reactions+of+Organoboron+Compounds&doi=10.1021%2Fcr00039a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0lgJXqmxTunTgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-Catalyzed%2520Cross-Coupling%2520Reactions%2520of%2520Organoboron%2520Compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26issue%3D7%26spage%3D2457%26epage%3D2483%26doi%3D10.1021%2Fcr00039a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a Multiple Target Receptor Tyrosine Kinase Inhibitors ABT-869</span>. <i>Youji Huaxue</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1196</span>– <span class="NLM_lpage">1200</span>, <span class="refDoi"> DOI: 10.6023/cjoc201402025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.6023%2Fcjoc201402025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVent7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=1196-1200&issue=6&author=X.+Houauthor=J.+Zhangauthor=H.+Liu&title=Synthesis+of+a+Multiple+Target+Receptor+Tyrosine+Kinase+Inhibitors+ABT-869&doi=10.6023%2Fcjoc201402025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a multiple target receptor tyrosine kinase inhibitors ABT-869</span></div><div class="casAuthors">Hou, Xuehui; Zhang, Jingyu; Liu, Hongmin</div><div class="citationInfo"><span class="NLM_cas:title">Youji Huaxue</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1196-1200</span>CODEN:
                <span class="NLM_cas:coden">YCHHDX</span>;
        ISSN:<span class="NLM_cas:issn">0253-2786</span>.
    
            (<span class="NLM_cas:orgname">Youji Huaxue Bianjibu</span>)
        </div><div class="casAbstract">An efficient and convenient protocol for the synthesis of ABT-869, which is a multiple target receptor tyrosine kinase inhibitors with novel structure and high inhibitory activity, was developed in seven steps from cheap and com. available of 3-fluoroaniline.  The target mol. was obtained in 42.3% overall yield without any traditional purifn. (column chromatog. or crystn.).  Ultrasonic reaction technol. was introduced in the Suzuki coupling reaction which is the key step of the prepn. of ABT-869.  The synthetic process was more suitable for industrialized prodn. due to the advantages of available starting material, simplicity and cheapness, well yield and purity (HPLC > 99.0%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6tge5jRoMfLVg90H21EOLACvtfcHk0lgJXqmxTunTgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVent7zK&md5=0f6ffc16b507eb01bd320a4b41e197f9</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.6023%2Fcjoc201402025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6023%252Fcjoc201402025%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520a%2520Multiple%2520Target%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%2520ABT-869%26jtitle%3DYouji%2520Huaxue%26date%3D2014%26volume%3D34%26issue%3D6%26spage%3D1196%26epage%3D1200%26doi%3D10.6023%2Fcjoc201402025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cordovilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolomé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Ilarduya, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinet, P.</span></span> <span> </span><span class="NLM_article-title">The Stille Reaction, 38 Years Later</span>. <i>ACS Catal.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">3040</span>– <span class="NLM_lpage">3053</span>, <span class="refDoi"> DOI: 10.1021/acscatal.5b00448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscatal.5b00448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslWjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=3040-3053&issue=5&author=C.+Cordovillaauthor=C.+Bartolom%C3%A9author=J.+M.+Mart%C3%ADnez-Ilarduyaauthor=P.+Espinet&title=The+Stille+Reaction%2C+38+Years+Later&doi=10.1021%2Facscatal.5b00448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">The Stille Reaction, 38 Years Later</span></div><div class="casAuthors">Cordovilla, Carlos; Bartolome, Camino; Martinez-Ilarduya, Jesus Ma; Espinet, Pablo</div><div class="citationInfo"><span class="NLM_cas:title">ACS Catalysis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3040-3053</span>CODEN:
                <span class="NLM_cas:coden">ACCACS</span>;
        ISSN:<span class="NLM_cas:issn">2155-5435</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This review concs. on the mechanistic new knowledge and on important aspects such as the revolution with the use of bulky phosphines, the bimetallic alternative of the Stille reaction, the enantioselectivity in Stille and palladium-free Stille processes, the meaning of copper effect, or the possible approaches to make Stille coupling a greener process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Ha3gQr1-3LVg90H21EOLACvtfcHk0lgJXqmxTunTgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslWjtLw%253D&md5=290571217e0fad67940a22ec95ede583</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facscatal.5b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscatal.5b00448%26sid%3Dliteratum%253Aachs%26aulast%3DCordovilla%26aufirst%3DC.%26aulast%3DBartolom%25C3%25A9%26aufirst%3DC.%26aulast%3DMart%25C3%25ADnez-Ilarduya%26aufirst%3DJ.%2BM.%26aulast%3DEspinet%26aufirst%3DP.%26atitle%3DThe%2520Stille%2520Reaction%252C%252038%2520Years%2520Later%26jtitle%3DACS%2520Catal.%26date%3D2015%26volume%3D5%26issue%3D5%26spage%3D3040%26epage%3D3053%26doi%3D10.1021%2Facscatal.5b00448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echavarren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R.</span></span> <span> </span><span class="NLM_article-title">Discussion Addendum For: 4-Methoxy-4′-Nitrophenyl. Recent Advances in the Stille Biaryl Coupling Reaction and Applications in Complex Natural Products Synthesis</span>. <i>Org. Synth.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>88</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1002/0471264229.os088.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2F0471264229.os088.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21960729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1ertr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2011&pages=197-201&issue=3&author=R.+M.+Williamsauthor=J.+Stilleauthor=A.+Echavarrenauthor=J.+Hendrixauthor=B.+Albrechtauthor=R.+Williams&title=Discussion+Addendum+For%3A+4-Methoxy-4%E2%80%B2-Nitrophenyl.+Recent+Advances+in+the+Stille+Biaryl+Coupling+Reaction+and+Applications+in+Complex+Natural+Products+Synthesis&doi=10.1002%2F0471264229.os088.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Discussion addendum for: 4-methoxy-4'-nitrophenyl. Recent advances in the Stille biaryl coupling reaction and applications in complex natural products synthesis</span></div><div class="casAuthors">Williams, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Syntheses</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">197-201</span>CODEN:
                <span class="NLM_cas:coden">ORSYAT</span>;
        ISSN:<span class="NLM_cas:issn">0078-6209</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Addendum to an original article published by Stille, J., Echavarren, A., Hendrix, J., Albrecht, B., Williams, R., Org. Synth. 1993, 71, 97.  Recent advances in the application of the Stille coupling reaction were discussed.  This cross-coupling reaction was applied to the synthesis of TMC-95A, TMC-95B, chloropeptin, himastatin [i.e., (2S,2'S,3aR,3'aR,8aS,8'aS)-1,1',2,2',3,3',3a,3'a,8,8',8a,8'a-dodecahydro-3a,3'a-dihydroxy[5,5'-bipyrrolo[2,3-b]indole]-2,2'-dicarbonylbis[D-valyl-(2S)-2-hydroxy-3-methylbutanoyl-(3R,5R)-hexahydro-5-hydroxy-3-pyridazinecarbonyl-L-leucyl-D-threonine] (6→11),(6'→11')-dilactam].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF9mqwrGRaDLVg90H21EOLACvtfcHk0lgJXqmxTunTgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1ertr8%253D&md5=33eb5ec5bfbe1cea4d470477a7fd5e90</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1002%2F0471264229.os088.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471264229.os088.18%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DR.%2BM.%26aulast%3DStille%26aufirst%3DJ.%26aulast%3DEchavarren%26aufirst%3DA.%26aulast%3DHendrix%26aufirst%3DJ.%26aulast%3DAlbrecht%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DR.%26atitle%3DDiscussion%2520Addendum%2520For%253A%25204-Methoxy-4%25E2%2580%25B2-Nitrophenyl.%2520Recent%2520Advances%2520in%2520the%2520Stille%2520Biaryl%2520Coupling%2520Reaction%2520and%2520Applications%2520in%2520Complex%2520Natural%2520Products%2520Synthesis%26jtitle%3DOrg.%2520Synth.%26date%3D2011%26volume%3D88%26issue%3D3%26spage%3D197%26epage%3D201%26doi%3D10.1002%2F0471264229.os088.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasolofonjatovo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provot, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brion, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alami, M.</span></span> <span> </span><span class="NLM_article-title">Regioselective Hydrostannation of Diarylalkynes Directed by a Labile Ortho Bromine Atom: An Easy Access to Stereodefined Triarylolefins, Hybrids of Combretastatin A-4 and Isocombretastatin A-4</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3617</span>– <span class="NLM_lpage">3626</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2010.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2010.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20627378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=3617-3626&issue=9&author=E.+Rasolofonjatovoauthor=O.+Provotauthor=A.+Hamzeauthor=J.+Bignonauthor=S.+Thoretauthor=J.+D.+Brionauthor=M.+Alami&title=Regioselective+Hydrostannation+of+Diarylalkynes+Directed+by+a+Labile+Ortho+Bromine+Atom%3A+An+Easy+Access+to+Stereodefined+Triarylolefins%2C+Hybrids+of+Combretastatin+A-4+and+Isocombretastatin+A-4&doi=10.1016%2Fj.ejmech.2010.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective hydrostannation of diarylalkynes directed by a labile ortho bromine atom: An easy access to stereodefined triarylolefins, hybrids of combretastatin A-4 and isocombretastatin A-4</span></div><div class="casAuthors">Rasolofonjatovo, Evelia; Provot, Olivier; Hamze, Abdallah; Bignon, Jerome; Thoret, Sylviane; Brion, Jean-Daniel; Alami, Mouad</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3617-3626</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of triarylolefins bearing the combretastatin A-4 and the isocombretastatin A-4 cores, e.g. I, were synthesized and evaluated.  The cooperative ortho-effect of a labile bromine atom in the regioselective hydrostannation of unsym. diarylalkynes leading to stereodefined triarylolefins is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_b9lfH7fywbVg90H21EOLACvtfcHk0lhIhykdUyGeoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKiurs%253D&md5=0d9cbc3112ce1bc9946b28341294cf37</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DRasolofonjatovo%26aufirst%3DE.%26aulast%3DProvot%26aufirst%3DO.%26aulast%3DHamze%26aufirst%3DA.%26aulast%3DBignon%26aufirst%3DJ.%26aulast%3DThoret%26aufirst%3DS.%26aulast%3DBrion%26aufirst%3DJ.%2BD.%26aulast%3DAlami%26aufirst%3DM.%26atitle%3DRegioselective%2520Hydrostannation%2520of%2520Diarylalkynes%2520Directed%2520by%2520a%2520Labile%2520Ortho%2520Bromine%2520Atom%253A%2520An%2520Easy%2520Access%2520to%2520Stereodefined%2520Triarylolefins%252C%2520Hybrids%2520of%2520Combretastatin%2520A-4%2520and%2520Isocombretastatin%2520A-4%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26issue%3D9%26spage%3D3617%26epage%3D3626%26doi%3D10.1016%2Fj.ejmech.2010.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chinchilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najera, C.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in Sonogashira Reactions</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">5084</span>– <span class="NLM_lpage">5121</span>, <span class="refDoi"> DOI: 10.1039/c1cs15071e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1039%2Fc1cs15071e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21655588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=5084-5121&issue=10&author=R.+Chinchillaauthor=C.+Najera&title=Recent+Advances+in+Sonogashira+Reactions&doi=10.1039%2Fc1cs15071e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in Sonogashira reactions</span></div><div class="casAuthors">Chinchilla, Rafael; Najera, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5084-5121</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review with 352 refs. discusses the Sonogashira reaction of alkynes and aryl halides to yield aryl alkynes and, in particular, the development of catalysts for Sonogashira reactions.  The mechanism of the Sonogashira reaction, the use of supported and unsupported palladium complexes with phosphines, nitrogen-contg. (imine and pyridine) ligands, ligands contg. phosphorus, nitrogen, and oxygen, and N-heterocyclic carbenes as catalysts, the use of palladacycles, ligand-free palladium species, and palladium nanoparticles as catalysts, and the use of other metals as catalysts or cocatalysts for Sonogashira coupling reactions are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRRxM3DrQgRrVg90H21EOLACvtfcHk0lhIhykdUyGeoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2jtbvE&md5=daa28257436731bf1fc800f0d1ce46f3</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1039%2Fc1cs15071e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cs15071e%26sid%3Dliteratum%253Aachs%26aulast%3DChinchilla%26aufirst%3DR.%26aulast%3DNajera%26aufirst%3DC.%26atitle%3DRecent%2520Advances%2520in%2520Sonogashira%2520Reactions%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2011%26volume%3D40%26issue%3D10%26spage%3D5084%26epage%3D5121%26doi%3D10.1039%2Fc1cs15071e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khatyr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziessel, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Quasi-Linear and Segmented Bis- to Penta-2, 2′-Bipyridine Polytopic Ligands Built Via a Convergent Approach</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7814</span>– <span class="NLM_lpage">7824</span>, <span class="refDoi"> DOI: 10.1021/jo000836k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo000836k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1OisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2000&pages=7814-7824&issue=23&author=A.+Khatyrauthor=R.+Ziessel&title=Synthesis+of+Quasi-Linear+and+Segmented+Bis-+to+Penta-2%2C+2%E2%80%B2-Bipyridine+Polytopic+Ligands+Built+Via+a+Convergent+Approach&doi=10.1021%2Fjo000836k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Quasi-Linear and Segmented Bis- to Penta-2,2'-bipyridine Polytopic Ligands Built via a Convergent Approach</span></div><div class="casAuthors">Khatyr, Abderrahim; Ziessel, Raymond</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7814-7824</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reliable and practical routes for the prepn. of segmented oligomeric 2,2'-bipyridine-based ligands possessing rigid and conjugated spacers are presented.  The first series of ligands bears a single alkyne function as a bridge and has been built by Pd(0)-catalyzed cross-coupling reactions between ethynylated and bromo-substituted derivs. of 2,2'-bipyridine (bipy).  These new ligands provide access to numerous hexameric, octameric, and decameric pyridine-based materials.  Optimum conditions were found with [Pd(PPh3)4] (6 mol %) in benzene contg. diisopropylamine at 80 °C.  The second series of sol. ligands was synthesized around a 1,4-diethynyl-2,5-didodecyloxybenzene bridging unit.  The synthesis required a protection/deprotection methodol., as well as a chemoselective palladium-catalyzed Sonogashira-Hagihara cross-coupling protocol to obtain the target multitopic ligands.  Within this strategy, the pivotal intermediates bearing one or two bipy and Ph units are required and such entities were isolated in excellent yield.  The products are highly sol. and photostable.  In each case, the final step involves a double cross-coupling reaction between the appropriate constituents, with the best preparative conditions involving [Pd(PPh3)4] (6 mol %) in propylamine at 70 °C.  The main advantage of this methodol. lies in its synthetic versatility and adaptability for creating multitopic metal-binding scaffolds with a potentially large variety of bridging units and Ph substituents.  Spectroscopic data for the new oligomers show a steady decrease in optical energy with an increasing degree of oligomerization.  The different results obtained with these ligands highlight the importance of the rigid 1,4-diethynylphenyl linker in directing the outcome of the nanosized mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZX0Q5T4wJF7Vg90H21EOLACvtfcHk0lhIhykdUyGeoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1OisLg%253D&md5=945e70b53725a438b67d828c26567983</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fjo000836k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo000836k%26sid%3Dliteratum%253Aachs%26aulast%3DKhatyr%26aufirst%3DA.%26aulast%3DZiessel%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520Quasi-Linear%2520and%2520Segmented%2520Bis-%2520to%2520Penta-2%252C%25202%25E2%2580%25B2-Bipyridine%2520Polytopic%2520Ligands%2520Built%2520Via%2520a%2520Convergent%2520Approach%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2000%26volume%3D65%26issue%3D23%26spage%3D7814%26epage%3D7824%26doi%3D10.1021%2Fjo000836k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cabri, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candiani, I.</span></span> <span> </span><span class="NLM_article-title">Recent Developments and New Perspectives in the Heck Reaction</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1021/ar00049a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar00049a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK2MXjtF2rs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1995&pages=2-7&issue=1&author=W.+Cabriauthor=I.+Candiani&title=Recent+Developments+and+New+Perspectives+in+the+Heck+Reaction&doi=10.1021%2Far00049a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Developments and New Perspectives in the Heck Reaction</span></div><div class="casAuthors">Cabri, Walter; Candiani, Ilaria</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-7</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with ∼34 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCqeZaru8_x7Vg90H21EOLACvtfcHk0ljzSkkJYiekOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtF2rs78%253D&md5=5cb0bb6cf962e1573c70cfb1a895bba1</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Far00049a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far00049a001%26sid%3Dliteratum%253Aachs%26aulast%3DCabri%26aufirst%3DW.%26aulast%3DCandiani%26aufirst%3DI.%26atitle%3DRecent%2520Developments%2520and%2520New%2520Perspectives%2520in%2520the%2520Heck%2520Reaction%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1995%26volume%3D28%26issue%3D1%26spage%3D2%26epage%3D7%26doi%3D10.1021%2Far00049a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morazzoni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrangolini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bombardelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabri, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riva, A.</span></span> <span> </span><span class="NLM_article-title">Samital®: A New Botanical Drug for the Treatment of Mucositis Induced by Oncological Therapies</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1717</span>– <span class="NLM_lpage">1725</span>, <span class="refDoi"> DOI: 10.2217/fon.13.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2217%2Ffon.13.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24156331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KktbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=1717-1725&issue=11&author=P.+Morazzoniauthor=G.+Petrangoliniauthor=E.+Bombardelliauthor=M.+Ronchiauthor=W.+Cabriauthor=A.+Riva&title=Samital%C2%AE%3A+A+New+Botanical+Drug+for+the+Treatment+of+Mucositis+Induced+by+Oncological+Therapies&doi=10.2217%2Ffon.13.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">SAMITAL: a new botanical drug for the treatment of mucositis induced by oncological therapies</span></div><div class="casAuthors">Morazzoni, Paolo; Petrangolini, Giovanna; Bombardelli, Ezio; Ronchi, Massimo; Cabri, Walter; Riva, Antonella</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1717-1725</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  SAMITAL (Indena SpA, Milan, Italy) is a new multicomponent and multiacting botanical formulation rationally designed for the relief of oral mucositis induced by chemotherapy and/or radiotherapy in oncol. patients.  Each of the individual botanical constituents of SAMITAL-standardized exts. of Vaccinium myrtillus, Macleaya cordata and Echinacea angustifolia have a long history of clin. use that corroborates their safety and activity in SAMITAL.  A no. of pilot trials in oncol. patients demonstrated that SAMITAL has good clin. efficacy and tolerability as evidenced by its significant effects in terms of redn. of mucositis, pain and a general improvement in patient quality of life.  Importantly, the use of this botanical formulation had the added benefit that patients were able to complete their chemotherapy/radiotherapy regimen.  Phase II trials with SAMITAL as part of an overall clin. development program are currently ongoing in Italy and are planned in the USA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRBNaXYekUgbVg90H21EOLACvtfcHk0ljzSkkJYiekOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KktbbN&md5=0a0398f115ba24462c6c041f33f40d56</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.2217%2Ffon.13.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.13.165%26sid%3Dliteratum%253Aachs%26aulast%3DMorazzoni%26aufirst%3DP.%26aulast%3DPetrangolini%26aufirst%3DG.%26aulast%3DBombardelli%26aufirst%3DE.%26aulast%3DRonchi%26aufirst%3DM.%26aulast%3DCabri%26aufirst%3DW.%26aulast%3DRiva%26aufirst%3DA.%26atitle%3DSamital%25C2%25AE%253A%2520A%2520New%2520Botanical%2520Drug%2520for%2520the%2520Treatment%2520of%2520Mucositis%2520Induced%2520by%2520Oncological%2520Therapies%26jtitle%3DFuture%2520Oncol.%26date%3D2013%26volume%3D9%26issue%3D11%26spage%3D1717%26epage%3D1725%26doi%3D10.2217%2Ffon.13.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palem, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alugubelli, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarapu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polepalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manga, V.</span></span> <span> </span><span class="NLM_article-title">Quinazolinones-Phenylquinoxaline Hybrids with Unsaturation/Saturation Linkers as Novel Anti-Proliferative Agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3014</span>– <span class="NLM_lpage">3018</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmcl.2016.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27209232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28Xotleju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3014-3018&issue=13&author=J.+D.+Palemauthor=G.+R.+Alugubelliauthor=R.+Bantuauthor=L.+Nagarapuauthor=S.+Polepalliauthor=S.+N.+Jainauthor=R.+Bathiniauthor=V.+Manga&title=Quinazolinones-Phenylquinoxaline+Hybrids+with+Unsaturation%2FSaturation+Linkers+as+Novel+Anti-Proliferative+Agents&doi=10.1016%2Fj.bmcl.2016.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Quinazolinones-Phenylquinoxaline hybrids with unsaturation/saturation linkers as novel anti-proliferative agents</span></div><div class="casAuthors">Palem, Jyothsna Devi; Alugubelli, Gopi Reddy; Bantu, Rajashaker; Nagarapu, Lingaiah; Polepalli, Sowjanya; Jain, S. Nishanth; Bathini, Raju; Manga, Vijjulatha</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3014-3018</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of novel quinazolinones with allylphenyl quinoxaline hybrids were efficiently synthesized in good yields by the reaction of 3-allyl-2-methylquinazolin-4(3H)-one with bromophenyl quinoxaline utilizing Pd catalyzed Heck-cross coupling and evaluated for anti-proliferative activity against four cancer cell lines such as HeLa (cervical), MIAPACA (pancreatic), MDA-MB-231 (breast) and IMR32 (neuroblastoma).  Compds. I (R = Ph, 4-OMeC6H4, 4-MeC6H4, 2,4-OMeC6H3) exhibited promising anti-proliferative activity with GI50 values ranging from 0.06 to 0.2 μM against four cell lines, while compds. I (R = 4-OMeC6H4, 4-CF3C6H4) showed significant activity against HeLa and MIAPACA cell lines and compds. I (R = 4-ClC6H4, 2,4-MeC6H3, 2,3,4-OMeC6H2,2-F-4-OMeC6H3) showed selective potency against IMR32 and MDA-MB-231 cell lines.  This is the first report on the synthesis and in vitro anti-proliferative evaluation of E-2-(4-substituted)-3-(3-(4-(quinoxalin-2-yl)phenyl)allyl)quinazolin-4(3H)-ones.  Docking results indicate a sign of good correlation between exptl. activity and calcd. binding affinity (dock score), suggesting that these compds. could act as promising DNA intercalates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZP6Vaf976VbVg90H21EOLACvtfcHk0ljzSkkJYiekOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xotleju74%253D&md5=652d3865f9dadec257c7f894e90e39ba</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DPalem%26aufirst%3DJ.%2BD.%26aulast%3DAlugubelli%26aufirst%3DG.%2BR.%26aulast%3DBantu%26aufirst%3DR.%26aulast%3DNagarapu%26aufirst%3DL.%26aulast%3DPolepalli%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DS.%2BN.%26aulast%3DBathini%26aufirst%3DR.%26aulast%3DManga%26aufirst%3DV.%26atitle%3DQuinazolinones-Phenylquinoxaline%2520Hybrids%2520with%2520Unsaturation%252FSaturation%2520Linkers%2520as%2520Novel%2520Anti-Proliferative%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D13%26spage%3D3014%26epage%3D3018%26doi%3D10.1016%2Fj.bmcl.2016.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, z.</span></span> <span> </span><span class="NLM_article-title">The Physicochemical Challenges of Designing Multiple Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&issue=16&author=R.+Morphyauthor=z.+Rankovic&title=The+Physicochemical+Challenges+of+Designing+Multiple+Ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0ljzSkkJYiekOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3Dz.%26atitle%3DThe%2520Physicochemical%2520Challenges%2520of%2520Designing%2520Multiple%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D16%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostrom, J.</span></span> <span> </span><span class="NLM_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9442</span>– <span class="NLM_lpage">9468</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00675</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00675" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9442-9468&issue=21&author=D.%0AG.+Brownauthor=J.+Bostrom&title=Where+Do+Recent+Small+Molecule+Clinical+Development+Candidates+Come+From%3F&doi=10.1021%2Facs.jmedchem.8b00675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9442-9468</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An anal. of 66 published clin. candidates from Journal of Medicinal Chem. has been conducted to shed light on which lead generation strategies are most frequently employed in identifying drug candidates.  The most frequent lead generation strategy (producing a drug candidate) was based on starting points derived from previously known compds. (43%) followed by random high throughput screening (29%).  The remainder of approaches included focused screening, structure-based drug design (SBDD), fragment-based lead generation (FBLG), and DNA-encoded library screening (DEL).  An anal. of physicochem. properties on the hit-to-clin. pairs shows an av. increase in mol. wt. (ΔMW = +85) but no change in lipophilicity (ΔclogP = -0.2), although exceptions are noted.  The majority (>50%) of clin. candidates were found to be structurally very different from their starting point and were more complex.  Finally, several reports of noncovalent scaffolds modified by a covalent warhead using SBDD approaches are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKVZOYYj87bLVg90H21EOLACvtfcHk0lgL0YRQkQKu9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F&md5=211341fa12156e9512650d3352893a5e</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostrom%26aufirst%3DJ.%26atitle%3DWhere%2520Do%2520Recent%2520Small%2520Molecule%2520Clinical%2520Development%2520Candidates%2520Come%2520From%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468%26doi%3D10.1021%2Facs.jmedchem.8b00675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sameem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeedi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahdavi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafiee, A.</span></span> <span> </span><span class="NLM_article-title">A Review on Tacrine-Based Scaffolds as Multi-Target Drugs (MTDLs) for Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.10.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2016.10.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27876467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFait77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2017&pages=332-345&author=B.+Sameemauthor=M.+Saeediauthor=M.+Mahdaviauthor=A.+Shafiee&title=A+Review+on+Tacrine-Based+Scaffolds+as+Multi-Target+Drugs+%28MTDLs%29+for+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2016.10.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease</span></div><div class="casAuthors">Sameem, Bilqees; Saeedi, Mina; Mahdavi, Mohammad; Shafiee, Abbas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">332-345</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a multifactorial neurol. disorder among elderly people and combinatorial factors such as genetic, lifestyle, and environmental are involved in onset and disease progression.  It has been demonstrated that loss of cholinergic transmission is one of the most significant causes of AD.  One strategy currently being investigated for the development of new therapeutics relates to the enhancement of cholinergic system through several ways.  At this juncture, anticholinesterase inhibitors have absorbed lots of attention and different marketed drugs such as donepezil, rivastigmine, tacrine, and galantamine have been developed. 9-Amino-1,2,3,4-tetrahydroacridine known as tacrine was introduced in 1945 as an efficient anticholinesterase agent.  The mechanism of action of tacrine was proved to inhibit the metab. of acetylcholine and therefore extending its activity and raising levels in the cerebral cortex.  However, extensive use of tacrine was limited since it showed various side effects and toxicity.  Thus, lots of efforts were carried out to prep. tacrine analogs to overcome the related adverse effects.  This review describes differently synthesized tacrine-based scaffolds as cholinesterase inhibitors to manage Alzheimer's disease (AD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrURdMfJvk17bVg90H21EOLACvtfcHk0lgL0YRQkQKu9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFait77F&md5=2462b18c5601b6491dfe553452268f40</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.10.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.10.060%26sid%3Dliteratum%253Aachs%26aulast%3DSameem%26aufirst%3DB.%26aulast%3DSaeedi%26aufirst%3DM.%26aulast%3DMahdavi%26aufirst%3DM.%26aulast%3DShafiee%26aufirst%3DA.%26atitle%3DA%2520Review%2520on%2520Tacrine-Based%2520Scaffolds%2520as%2520Multi-Target%2520Drugs%2520%2528MTDLs%2529%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D128%26spage%3D332%26epage%3D345%26doi%3D10.1016%2Fj.ejmech.2016.10.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stacchiotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Vullo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morosi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barisella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaffaroni, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagrada, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, P. G.</span></span> <span> </span><span class="NLM_article-title">Activity of Axitinib in Progressive Advanced Solitary Fibrous Tumour: Results from an Exploratory, Investigator-Driven Phase 2 Clinical Study</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2018.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejca.2018.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=30528807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlKmur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2019&pages=225-233&author=S.+Stacchiottiauthor=N.+Simeoneauthor=S.+Lo+Vulloauthor=C.+Morosiauthor=F.+G.+Grecoauthor=A.+Gronchiauthor=M.+Barisellaauthor=P.+Colliniauthor=N.+Zaffaroniauthor=G.+P.+Dagradaauthor=A.+M.+Frezzaauthor=L.+Marianiauthor=P.+G.+Casali&title=Activity+of+Axitinib+in+Progressive+Advanced+Solitary+Fibrous+Tumour%3A+Results+from+an+Exploratory%2C+Investigator-Driven+Phase+2+Clinical+Study&doi=10.1016%2Fj.ejca.2018.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study</span></div><div class="casAuthors">Stacchiotti, S.; Simeone, N.; Lo Vullo, S.; Morosi, C.; Greco, F. G.; Gronchi, A.; Barisella, M.; Collini, P.; Zaffaroni, N.; Dagrada, G. P.; Frezza, A. M.; Mariani, L.; Casali, P. G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">225-233</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To explore the activity of axitinib in advanced solitary fibrous tumor (SFT).In this investigator-driven phase II study on axitinib in advanced and progressive SFT, patients received axitinib, 5 mg bis in day (BID), until progression or limiting toxicity.  Pathol. diagnosis was centrally reviewed, distinguishing malignant SFT (M-SFT) and high-grade/dedifferentiated SFT (HG/D-SFT) subtypes.  The primary end-point was the overall response rate (ORR) by Choi criteria (Choi).  Secondary end-points were response by Response Evaluation Criteria in Solid Tumors (RECIST), progression-free survival (PFS) and overall survival (OS).From Apr. 2015 and Oct. 2017, 17 eligible patients entered the study (metastatic: 17; SFT subtype: 13 M-SFT, 4 HG/D-SFT; prior treatment: 9 antiangiogenics, 5 cytotoxics).  All patients were evaluable for response.  The best Choi response was seven partial response (PR) (ORR, 41.2%), six stable disease (SD) and four progressions.  Choi-ORR was 54% (7/13) when only M-SFTs were considered.  Four of seven responsive patients were pretreated with pazopanib.  No responses were detected in HG/D-SFT.  Best RECIST response was one PR (5.9%), 14 SD and two progressions.  Toxicity was as expected.  Median Choi-PFS was 5.1 (interquartile range [IQR]: 2.5-14.8) months.  Median Choi-PFS was 14.8 (IQR: 5.1-18.0) and 2.8 (IQR: 2.0-5.9) months for patients responsive and non-responsive by Choi, resp. (p = 0.0416).  At a 14.4-mo median follow-up, median OS was 25.3 mo.This study showed that axitinib is active in progressive advanced SFT.  One-half of patients carrying the malignant variant of the disease responded, with a >12-mo median progression arrest.  Responses were better detected with Choi and seen even in patients resistant to other antiangiogenics.  Tolerability was good.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp513UQk09o87Vg90H21EOLACvtfcHk0ljnfLUNJcAscA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlKmur%252FI&md5=98003e74d221bf4eea3fca05e06672fe</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2018.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2018.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DStacchiotti%26aufirst%3DS.%26aulast%3DSimeone%26aufirst%3DN.%26aulast%3DLo%2BVullo%26aufirst%3DS.%26aulast%3DMorosi%26aufirst%3DC.%26aulast%3DGreco%26aufirst%3DF.%2BG.%26aulast%3DGronchi%26aufirst%3DA.%26aulast%3DBarisella%26aufirst%3DM.%26aulast%3DCollini%26aufirst%3DP.%26aulast%3DZaffaroni%26aufirst%3DN.%26aulast%3DDagrada%26aufirst%3DG.%2BP.%26aulast%3DFrezza%26aufirst%3DA.%2BM.%26aulast%3DMariani%26aufirst%3DL.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DActivity%2520of%2520Axitinib%2520in%2520Progressive%2520Advanced%2520Solitary%2520Fibrous%2520Tumour%253A%2520Results%2520from%2520an%2520Exploratory%252C%2520Investigator-Driven%2520Phase%25202%2520Clinical%2520Study%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2019%26volume%3D106%26spage%3D225%26epage%3D233%26doi%3D10.1016%2Fj.ejca.2018.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konecny, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegram, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Untch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spehar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podratz, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D. J.</span></span> <span> </span><span class="NLM_article-title">Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1630</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-1182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1158%2F0008-5472.CAN-05-1182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16452222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVemsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1630-1639&issue=3&author=G.+E.+Konecnyauthor=M.+D.+Pegramauthor=N.+Venkatesanauthor=R.+Finnauthor=G.+Yangauthor=M.+Rahmehauthor=M.+Untchauthor=D.+W.+Rusnakauthor=G.+Speharauthor=R.+J.+Mullinauthor=B.+R.+Keithauthor=T.+M.+Gilmerauthor=M.+Bergerauthor=K.+C.+Podratzauthor=D.+J.+Slamon&title=Activity+of+the+Dual+Kinase+Inhibitor+Lapatinib+%28GW572016%29+against+HER-2-Overexpressing+and+Trastuzumab-Treated+Breast+Cancer+Cells&doi=10.1158%2F0008-5472.CAN-05-1182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells</span></div><div class="casAuthors">Konecny, Gottfried E.; Pegram, Mark D.; Venkatesan, Natarajan; Finn, Richard; Yang, Guorong; Rahmeh, Martina; Untch, Michael; Rusnak, David W.; Spehar, Glenn; Mullin, Robert J.; Keith, Barry R.; Gilmer, Tona M.; Berger, Mark; Podratz, Karl C.; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1630-1639</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases.  Here, we explore the therapeutic potential of lapatinib by testing its effect on tumor cell growth in a panel of 31 characterized human breast cancer cell lines, including trastuzumab-conditioned HER-2-pos. cell lines.  We further characterize its activity in combination with trastuzumab and analyze whether EGFR and HER-2 expression or changes induced in the activation of EGFR, HER-2, Raf, AKT, or extracellular signal-regulated kinase (ERK) are markers of drug activity.  We report that concn.-dependent antiproliferative effects of lapatinib were seen in all breast cancer cell lines tested but varied significantly between individual cell lines with up to 1,000-fold difference in the IC50s (range, 0.010-18.6 μmol/L).  Response to lapatinib was significantly correlated with HER-2 expression and its ability to inhibit HER-2, Raf, AKT, and ERK phosphorylation.  Long-term in vivo lapatinib studies were conducted with human breast cancer xenografts in athymic mice.  Treatment over 77 days resulted in a sustained and significant redn. in xenograft vol. compared with untreated controls.  For the combination of lapatinib plus trastuzumab, synergistic drug interactions were obsd. in four different HER-2-overexpressing cell lines.  Moreover, lapatinib retained significant in vitro activity against cell lines selected for long-term outgrowth (>9 mo) in trastuzumab-contg. (100 μg/mL) culture medium.  These observations provide a clear biol. rationale to test lapatinib as a single agent or in combination with trastuzumab in HER-2-overexpressing breast cancer and in patients with clin. resistance to trastuzumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1QJyAqugZmLVg90H21EOLACvtfcHk0ljnfLUNJcAscA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVemsg%253D%253D&md5=f81c4f6671403021fce2df854c07e8c9</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-1182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-1182%26sid%3Dliteratum%253Aachs%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26aulast%3DPegram%26aufirst%3DM.%2BD.%26aulast%3DVenkatesan%26aufirst%3DN.%26aulast%3DFinn%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DRahmeh%26aufirst%3DM.%26aulast%3DUntch%26aufirst%3DM.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DSpehar%26aufirst%3DG.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DPodratz%26aufirst%3DK.%2BC.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DActivity%2520of%2520the%2520Dual%2520Kinase%2520Inhibitor%2520Lapatinib%2520%2528GW572016%2529%2520against%2520HER-2-Overexpressing%2520and%2520Trastuzumab-Treated%2520Breast%2520Cancer%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D3%26spage%3D1630%26epage%3D1639%26doi%3D10.1158%2F0008-5472.CAN-05-1182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doak, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobritzsch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span> <span> </span><span class="NLM_article-title">How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2312</span>– <span class="NLM_lpage">2327</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Cgu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2312-2327&issue=6&author=B.+C.+Doakauthor=J.+Zhengauthor=D.+Dobritzschauthor=J.+Kihlberg&title=How+Beyond+Rule+of+5+Drugs+and+Clinical+Candidates+Bind+to+Their+Targets&doi=10.1021%2Facs.jmedchem.5b01286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets</span></div><div class="casAuthors">Doak, Bradley C.; Zheng, Jie; Dobritzsch, Doreen; Kihlberg, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2312-2327</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve discovery of drugs for difficult targets, the opportunities of chem. space beyond the rule of 5 (bRo5) were examd. by retrospective anal. of a comprehensive set of structures for complexes between drugs and clin. candidates and their targets.  The anal. illustrates the potential of compds. far beyond rule of 5 space to modulate novel and difficult target classes that have large, flat, and groove-shaped binding sites.  However, ligand efficiencies are significantly reduced for flat- and groove-shape binding sites, suggesting that adjustments of how to use such metrics are required.  Ligands bRo5 appear to benefit from an appropriate balance between rigidity and flexibility to bind with sufficient affinity to their targets, with macrocycles and nonmacrocycles being found to have similar flexibility.  However, macrocycles were more disk- and spherelike, which may contribute to their superior binding to flat sites, while rigidification of nonmacrocycles lead to rodlike ligands that bind well to groove-shaped binding sites.  These insights should contribute to altering perceptions of what targets are considered "druggable" and provide support for drug design in beyond rule of 5 space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZD-h9VodiPLVg90H21EOLACvtfcHk0lh8R1HxdPHTSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Cgu77F&md5=a417b605d1a3ffbc7ee84706401f01f4</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01286%26sid%3Dliteratum%253Aachs%26aulast%3DDoak%26aufirst%3DB.%2BC.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DDobritzsch%26aufirst%3DD.%26aulast%3DKihlberg%26aufirst%3DJ.%26atitle%3DHow%2520Beyond%2520Rule%2520of%25205%2520Drugs%2520and%2520Clinical%2520Candidates%2520Bind%2520to%2520Their%2520Targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D6%26spage%3D2312%26epage%3D2327%26doi%3D10.1021%2Facs.jmedchem.5b01286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basten, J. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dinther, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boeckel, C. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boom, J. H.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of a Novel Synthetic Napap-Penta-Saccharide Conjugate Displaying a Dual Antithrombotic Action</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2013</span>– <span class="NLM_lpage">2018</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(99)00320-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0960-894X%2899%2900320-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10450972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK1MXltVChtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=2013-2018&issue=14&author=R.+C.+Buijsmanauthor=J.+E.+M.+Bastenauthor=T.+G.+van+Dintherauthor=G.+A.+van+der+Marelauthor=C.+A.+A.+van+Boeckelauthor=J.+H.+van+Boom&title=Design+and+Synthesis+of+a+Novel+Synthetic+Napap-Penta-Saccharide+Conjugate+Displaying+a+Dual+Antithrombotic+Action&doi=10.1016%2FS0960-894X%2899%2900320-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of a novel synthetic NAPAP-pentasaccharide conjugate displaying a dual antithrombotic action</span></div><div class="casAuthors">Buijsman, Rogier C.; Basten, Jan E. M.; Van Dinther, Theo G.; Van der Marel, Gijsbert A.; Van Boeckel, Constant A. A.; Van Boom, Jacques H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2013-2018</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The synthesis of a novel antithrombotic consisting of a heparin pentasaccharide conjugated to the active site inhibitor N-(2-naphtalenesulfonyl)-glycyl-(D)-4-aminophenyl-alanyl-piperidine (NAPAP) (I) is reported.  This conjugate shows a unique pharmacol. profile both in vitro and in vivo having direct anti-thrombin and ATIII-mediated anti-Xa activity.  Furthermore, conjugate I has a prolonged in vivo half-life compared to NAPAP (1.5 h vs 9 min.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp03SwXZa8FfrVg90H21EOLACvtfcHk0lh8R1HxdPHTSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVChtb0%253D&md5=617ef74eba7661c4dc883c76dac2b91d</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900320-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900320-0%26sid%3Dliteratum%253Aachs%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DBasten%26aufirst%3DJ.%2BE.%2BM.%26aulast%3Dvan%2BDinther%26aufirst%3DT.%2BG.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3Dvan%2BBoeckel%26aufirst%3DC.%2BA.%2BA.%26aulast%3Dvan%2BBoom%26aufirst%3DJ.%2BH.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520a%2520Novel%2520Synthetic%2520Napap-Penta-Saccharide%2520Conjugate%2520Displaying%2520a%2520Dual%2520Antithrombotic%2520Action%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26issue%3D14%26spage%3D2013%26epage%3D2018%26doi%3D10.1016%2FS0960-894X%2899%2900320-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, A.</span></span> <span> </span><span class="NLM_article-title">From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.2174/092986708783503212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F092986708783503212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18288997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVyisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=422-432&issue=5&author=S.+Giordanoauthor=A.+Petrelli&title=From+Single-+to+Multi-Target+Drugs+in+Cancer+Therapy%3A+When+Aspecificity+Becomes+an+Advantage&doi=10.2174%2F092986708783503212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">From single- to multi-target drugs in cancer therapy: when a specificity becomes an advantage</span></div><div class="casAuthors">Petrelli, A.; Giordano, S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">422-432</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeted therapies by means of compds. that inhibit a specific target mol. represent a new perspective in the treatment of cancer.  In contrast to conventional chemotherapy which acts on all dividing cells generating toxic effects and damage of normal tissues, targeted drugs allow to hit, in a more specific manner, subpopulations of cells directly involved in tumor progression.  Mols. controlling cell proliferation and death, such as Tyrosine Kinase Receptors (RTKs) for growth factors, are among the best targets for this type of therapeutic approach.  Two classes of compds. targeting RTKs are currently used in clin. practice: monoclonal antibodies and tyrosine kinase inhibitors.  The era of targeted therapy began with the approval of Trastuzumab, a monoclonal antibody against HER2, for treatment of metastatic breast cancer, and Imatinib, a small tyrosine kinase inhibitor targeting BCR-Abl, in Chronic Myeloid Leukemia.  Despite the initial enthusiasm for the efficacy of these treatments, clinicians had to face soon the problem of relapse, as almost invariably cancer patients developed drug resistance, often due to the activation of alternative RTKs pathways.  In this view, the rationale at the basis of targeting drugs is radically shifting.  In the past, the main effort was aimed at developing highly specific inhibitors acting on single RTKs.  Now, there is a general agreement that mols. interfering simultaneously with multiple RTKs might be more effective than single target agents.  With the recent approval by FDA of Sorafenib and Sunitinib - targeting VEGFR, PDGFR, FLT-3 and c-Kit - a different scenario has been emerging, where a new generation of anti-cancer drugs, able to inhibit more than one pathway, would probably play a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8AXb2ROTStLVg90H21EOLACvtfcHk0ljDscEmAv7Ebw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVyisL0%253D&md5=d90df6a670921b6fad58caa46db01fa5</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.2174%2F092986708783503212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708783503212%26sid%3Dliteratum%253Aachs%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DPetrelli%26aufirst%3DA.%26atitle%3DFrom%2520Single-%2520to%2520Multi-Target%2520Drugs%2520in%2520Cancer%2520Therapy%253A%2520When%2520Aspecificity%2520Becomes%2520an%2520Advantage%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26issue%3D5%26spage%3D422%26epage%3D432%26doi%3D10.2174%2F092986708783503212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Issa, J. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S.</span></span> <span> </span><span class="NLM_article-title">Targeting the Cancer Epigenome for Therapy</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">630</span>– <span class="NLM_lpage">641</span>, <span class="refDoi"> DOI: 10.1038/nrg.2016.93</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrg.2016.93" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27629931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWiu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=630-641&author=P.+A.+Jonesauthor=J.+P.+J.+Issaauthor=S.+Baylin&title=Targeting+the+Cancer+Epigenome+for+Therapy&doi=10.1038%2Fnrg.2016.93"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer epigenome for therapy</span></div><div class="casAuthors">Jones, Peter A.; Issa, Jean-Pierre J.; Baylin, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">630-641</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Next-generation sequencing has revealed that more than 50% of human cancers harbor mutations in enzymes that are involved in chromatin organization.  Tumor cells not only are activated by genetic and epigenetic alterations, but also routinely use epigenetic processes to ensure their escape from chemotherapy and host immune surveillance.  Hence, a growing emphasis of recent drug discovery efforts has been on targeting the epigenome, including DNA methylation and histone modifications, with several new drugs being tested and some already approved by the US Food and Drug Administration (FDA).  The future will see the increasing success of combining epigenetic drugs with other therapies.  As epigenetic drugs target the epigenome as a whole, these true 'genomic medicines' lessen the need for precision approaches to individualized therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5pfbPOnZMtbVg90H21EOLACvtfcHk0ljDscEmAv7Ebw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWiu77O&md5=22d98e58a4637d61af34a382e92adace</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1038%2Fnrg.2016.93&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg.2016.93%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%2BA.%26aulast%3DIssa%26aufirst%3DJ.%2BP.%2BJ.%26aulast%3DBaylin%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520Cancer%2520Epigenome%2520for%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2016%26volume%3D17%26spage%3D630%26epage%3D641%26doi%3D10.1038%2Fnrg.2016.93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+Deacetylases+and+Their+Inhibitors+in+Cancer%2C+Neurological+Diseases+and+Immune+Disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0ljDscEmAv7Ebw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520Deacetylases%2520and%2520Their%2520Inhibitors%2520in%2520Cancer%252C%2520Neurological%2520Diseases%2520and%2520Immune%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezzeldin, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diasio, R. B.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1934</span>, <span class="refDoi"> DOI: 10.2165/11315680-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2165%2F11315680-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19747008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOrsLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1911-1934&issue=14&author=X.+Maauthor=H.+H.+Ezzeldinauthor=R.+B.+Diasio&title=Histone+Deacetylase+Inhibitors&doi=10.2165%2F11315680-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: current status and overview of recent clinical trials</span></div><div class="casAuthors">Ma, Xujun; Ezzeldin, Hany H.; Diasio, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1934</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are a new group of anticancer agents that have a potential role in the regulation of gene expression, induction of cell death, apoptosis and cell cycle arrest of cancer cells by altering the acetylation status of chromatin and other non-histone proteins.  In clin. trials, HDAC inhibitors have demonstrated promising antitumor activity as monotherapy in cutaneous T-cell lymphoma and other haematol. malignancies.  In solid tumors, several HDAC inhibitors have been shown to be efficacious as single agents; however, results of most clin. trials were in favor of using HDAC inhibitors either prior to the initiation of chemotherapy or in combination with other treatments.  Currently, the mol. basis of response to HDAC inhibitors in patients is not fully understood.  In this review, we summarize the current status of HDAC inhibitors, as single agents or in combination with other agents in different phases of clin. trials.  In most of the clin. trials, HDAC inhibitors were tolerable and exerted biol. or antitumor activity.  HDAC inhibitors have been studied in phase I, II and III clin. trials with variable efficacy.  The combination of HDAC inhibitors with other anticancer agents including epigenetic or chemotherapeutic agents demonstrated favorable clin. outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdv-nIzRilyLVg90H21EOLACvtfcHk0ljDscEmAv7Ebw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOrsLbI&md5=7bffcf6f0627d58907d0e98085f4bdf5</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.2165%2F11315680-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11315680-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%26aulast%3DEzzeldin%26aufirst%3DH.%2BH.%26aulast%3DDiasio%26aufirst%3DR.%2BB.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%26jtitle%3DDrugs%26date%3D2009%26volume%3D69%26issue%3D14%26spage%3D1911%26epage%3D1934%26doi%3D10.2165%2F11315680-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Vorinostat</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/nrd2227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd2227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17269160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=21-22&author=S.+Grantauthor=C.+Easleyauthor=P.+Kirkpatrick&title=Vorinostat&doi=10.1038%2Fnrd2227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat</span></div><div class="casAuthors">Grant, Steven; Easley, Chris; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-22</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYtFgooxRrcbVg90H21EOLACvtfcHk0ljFpyeMuay1Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfK&md5=4017dcf775971088e24fca37e8a369af</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fnrd2227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2227%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DEasley%26aufirst%3DC.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DVorinostat%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D21%26epage%3D22%26doi%3D10.1038%2Fnrd2227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poole, R. M.</span></span> <span> </span><span class="NLM_article-title">Belinostat: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0275-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1007%2Fs40265-014-0275-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25134672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtl2nsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1543-1554&issue=13&author=R.+M.+Poole&title=Belinostat%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0275-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Belinostat: First Global Approval</span></div><div class="casAuthors">Poole, Raewyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1543-1554</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Belinostat [Beleodaq (US)], a small-mol. hydroxamate-type inhibitor of class I, II and IV histone deacetylase (HDAC) enzymes, has been developed by TopoTarget and Spectrum Pharmaceuticals for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).  Belinostat has received its first global approval as monotherapy for this indication in the US, under the Food and Drug Administration's accelerated approval program.  This article summarizes the milestones in the development of belinostat leading to this first approval for the treatment of PTCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm9C6yBRy7Q7Vg90H21EOLACvtfcHk0ljFpyeMuay1Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtl2nsrzL&md5=b8bc6efe62e7fd78d6a9d022a8d96559</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0275-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0275-8%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%2BM.%26atitle%3DBelinostat%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26issue%3D13%26spage%3D1543%26epage%3D1554%26doi%3D10.1007%2Fs40265-014-0275-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vandermolen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberlies, N. H.</span></span> <span> </span><span class="NLM_article-title">Romidepsin (Istodax, NSC 630176, FR901228, FK228, Depsipeptide): A Natural Product Recently Approved for Cutaneous T-Cell Lymphoma</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1038/ja.2011.35</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fja.2011.35" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21587264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC3MjptFWqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2011&pages=525-531&author=K.+M.+Vandermolenauthor=W.+McCullochauthor=C.+J.+Pearceauthor=N.+H.+Oberlies&title=Romidepsin+%28Istodax%2C+NSC+630176%2C+FR901228%2C+FK228%2C+Depsipeptide%29%3A+A+Natural+Product+Recently+Approved+for+Cutaneous+T-Cell+Lymphoma&doi=10.1038%2Fja.2011.35"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma</span></div><div class="casAuthors">VanderMolen Karen M; McCulloch William; Pearce Cedric J; Oberlies Nicholas H</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of antibiotics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">525-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Romidepsin (Istodax), a selective inhibitor of histone deacetylases (HDACs), was approved for the treatment of cutaneous T-cell lymphoma in November 2009 by the US Food and Drug Administration.  This unique natural product was discovered from cultures of Chromobacterium violaceum, a Gram-negative bacterium isolated from a Japanese soil sample.  This bicyclic compound acts as a prodrug, its disulfide bridge being reduced by glutathione on uptake into the cell, allowing the free thiol groups to interact with Zn ions in the active site of class I and II HDAC enzymes.  Due to the synthetic complexity of the compound, as well as the low yield from the producing organism, analogs are sought to create synthetically accessible alternatives.  As a T-cell lymphoma drug, romidepsin offers a valuable new treatment for diseases with few effective therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6-aG7G4t02v69nzq6467DfW6udTcc2eYqqR4QhgcU3rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjptFWqtg%253D%253D&md5=7d9d400857a6cf11cfe1f58acf5c1558</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fja.2011.35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2011.35%26sid%3Dliteratum%253Aachs%26aulast%3DVandermolen%26aufirst%3DK.%2BM.%26aulast%3DMcCulloch%26aufirst%3DW.%26aulast%3DPearce%26aufirst%3DC.%2BJ.%26aulast%3DOberlies%26aufirst%3DN.%2BH.%26atitle%3DRomidepsin%2520%2528Istodax%252C%2520NSC%2520630176%252C%2520FR901228%252C%2520FK228%252C%2520Depsipeptide%2529%253A%2520A%2520Natural%2520Product%2520Recently%2520Approved%2520for%2520Cutaneous%2520T-Cell%2520Lymphoma%26jtitle%3DJ.%2520Antibiot.%26date%3D2011%26volume%3D64%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fja.2011.35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floresta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monciino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span> <span> </span><span class="NLM_article-title">The Search for Potent, Small-Molecule Hdacis in Cancer Treatment: A Decade after Vorinostat</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1373</span>– <span class="NLM_lpage">1428</span>, <span class="refDoi"> DOI: 10.1002/med.21437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fmed.21437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28181261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1373-1428&issue=6&author=C.+Zagniauthor=G.+Florestaauthor=G.+Monciinoauthor=A.+Rescifina&title=The+Search+for+Potent%2C+Small-Molecule+Hdacis+in+Cancer+Treatment%3A+A+Decade+after+Vorinostat&doi=10.1002%2Fmed.21437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat</span></div><div class="casAuthors">Zagni Chiara; Floresta Giuseppe; Monciino Giulia; Rescifina Antonio; Floresta Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1373-1428</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression.  In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases.  Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T-cell lymphoma.  This review provides an overview of current knowledge, progress, and molecular mechanisms of HDACIs, covering a period from 2011 until 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPT4s_HXWveWmbXvSEQle5fW6udTcc2eYqqR4QhgcU3rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D&md5=79f4fe123e5ee6ba072e9147536fab67</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1002%2Fmed.21437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21437%26sid%3Dliteratum%253Aachs%26aulast%3DZagni%26aufirst%3DC.%26aulast%3DFloresta%26aufirst%3DG.%26aulast%3DMonciino%26aufirst%3DG.%26aulast%3DRescifina%26aufirst%3DA.%26atitle%3DThe%2520Search%2520for%2520Potent%252C%2520Small-Molecule%2520Hdacis%2520in%2520Cancer%2520Treatment%253A%2520A%2520Decade%2520after%2520Vorinostat%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26issue%3D6%26spage%3D1373%26epage%3D1428%26doi%3D10.1002%2Fmed.21437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaempf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rofelty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolosky, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span> <span> </span><span class="NLM_article-title">Molecularly Targeted Drug Combinations Demonstrate Selective Effectiveness for Myeloid- and Lymphoid-Derived Hematologic Malignancies</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">E7554</span>– <span class="NLM_lpage">E7563</span>, <span class="refDoi"> DOI: 10.1073/pnas.1703094114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1073%2Fpnas.1703094114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28784769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yku7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=E7554-E7563&issue=36&author=S.+E.+Kurtzauthor=C.+A.+Eideauthor=A.+Kaempfauthor=V.+Khannaauthor=S.+L.+Savageauthor=A.+Rofeltyauthor=I.+Englishauthor=H.+Hoauthor=R.+Pandyaauthor=W.+J.+Boloskyauthor=H.+Poonauthor=M.+W.+Deiningerauthor=R.+Collinsauthor=R.+T.+Swordsauthor=J.+Wattsauthor=D.+A.+Pollyeaauthor=B.+C.+Medeirosauthor=E.+Traerauthor=C.+E.+Tognonauthor=M.+Moriauthor=B.+J.+Drukerauthor=J.+W.+Tyner&title=Molecularly+Targeted+Drug+Combinations+Demonstrate+Selective+Effectiveness+for+Myeloid-+and+Lymphoid-Derived+Hematologic+Malignancies&doi=10.1073%2Fpnas.1703094114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies</span></div><div class="casAuthors">Kurtz, Stephen E.; Eide, Christopher A.; Kaempf, Andy; Khanna, Vishesh; Savage, Samantha L.; Rofelty, Angela; English, Isabel; Ho, Hibery; Pandya, Ravi; Bolosky, William J.; Poon, Hoifung; Deininger, Michael W.; Collins, Robert; Swords, Ronan T.; Watts, Justin; Pollyea, Daniel A.; Medeiros, Bruno C.; Traer, Elie; Tognon, Cristina E.; Mori, Motomi; Druker, Brian J.; Tyner, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">E7554-E7563</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Translating the genetic and epigenetic heterogeneity underlying human cancers into therapeutic strategies is an ongoing challenge.  Large-scale sequencing efforts have uncovered a spectrum of mutations in many hematol. malignancies, including acute myeloid leukemia (AML), suggesting that combinations of agents will be required to treat these diseases effectively.  Combinatorial approaches will also be crit. for combating the emergence of genetically heterogeneous subclones, rescue signals in the microenvironment, and tumor-intrinsic feedback pathways that all contribute to disease relapse.  To identify novel and effective drug combinations, the authors performed ex vivo sensitivity profiling of 122 primary patient samples from a variety of hematol. malignancies against a panel of 48 drug combinations.  The combinations were designed as drug pairs that target nonoverlapping biol. pathways and comprise drugs from different classes, preferably with Food and Drug Administration approval.  A combination ratio (CR) was derived for each drug pair, and CRs were evaluated with respect to diagnostic categories as well as against genetic, cytogenetic, and cellular phenotypes of specimens from the two largest disease categories: AML and chronic lymphocytic leukemia (CLL).  Nearly all tested combinations involving a BCL2 inhibitor showed addnl. benefit in patients with myeloid malignancies, whereas select combinations involving PI3K, CSF1R, or bromodomain inhibitors showed preferential benefit in lymphoid malignancies.  Expanded analyses of patients with AML and CLL revealed specific patterns of ex vivo drug combination efficacy that were assocd. with select genetic, cytogenetic, and phenotypic disease subsets, warranting further evaluation.  These findings highlight the heuristic value of an integrated functional genomic approach to the identification of novel treatment strategies for hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS5BseZMmHHrVg90H21EOLACvtfcHk0ljbipCfdexnrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yku7jI&md5=1a8ece4125f7a943cffe2066b4d9b0ed</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1703094114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1703094114%26sid%3Dliteratum%253Aachs%26aulast%3DKurtz%26aufirst%3DS.%2BE.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DKaempf%26aufirst%3DA.%26aulast%3DKhanna%26aufirst%3DV.%26aulast%3DSavage%26aufirst%3DS.%2BL.%26aulast%3DRofelty%26aufirst%3DA.%26aulast%3DEnglish%26aufirst%3DI.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DPandya%26aufirst%3DR.%26aulast%3DBolosky%26aufirst%3DW.%2BJ.%26aulast%3DPoon%26aufirst%3DH.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DWatts%26aufirst%3DJ.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26aulast%3DTraer%26aufirst%3DE.%26aulast%3DTognon%26aufirst%3DC.%2BE.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26atitle%3DMolecularly%2520Targeted%2520Drug%2520Combinations%2520Demonstrate%2520Selective%2520Effectiveness%2520for%2520Myeloid-%2520and%2520Lymphoid-Derived%2520Hematologic%2520Malignancies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26issue%3D36%26spage%3DE7554%26epage%3DE7563%26doi%3D10.1073%2Fpnas.1703094114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamand, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butrynski, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornicek, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Phase 1 Study of Oral Abexinostat, a Histone Deacetylase Inhibitor, in Combination with Doxorubicin in Patients with Metastatic Sarcoma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1223</span>– <span class="NLM_lpage">1230</span>, <span class="refDoi"> DOI: 10.1002/cncr.29175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fcncr.29175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25536954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlCmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=1223-1230&issue=8&author=E.+Choyauthor=Y.+Flamandauthor=S.+Balasubramanianauthor=J.+E.+Butrynskiauthor=D.+C.+Harmonauthor=S.+Georgeauthor=G.+M.+Coteauthor=A.+J.+Wagnerauthor=J.+A.+Morganauthor=M.+Sirisawadauthor=C.+Maniauthor=F.+J.+Hornicekauthor=Z.+Duanauthor=G.+D.+demetri&title=Phase+1+Study+of+Oral+Abexinostat%2C+a+Histone+Deacetylase+Inhibitor%2C+in+Combination+with+Doxorubicin+in+Patients+with+Metastatic+Sarcoma&doi=10.1002%2Fcncr.29175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma</span></div><div class="casAuthors">Choy, Edwin; Flamand, Yael; Balasubramanian, Sriram; Butrynski, James E.; Harmon, David C.; George, Suzanne; Cote, Gregory M.; Wagner, Andrew J.; Morgan, Jeffrey A.; Sirisawad, Mint; Mani, Chitra; Hornicek, Francis J.; Duan, Zhenfeng; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1223-1230</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : It has been demonstrated that several inhibitors of histone deacetylase (HDAC) can enhance chemotherapy-induced apoptosis and reduce sarcoma tumor vol. in preclin. models.  The authors sought to det. the max. tolerated dose, pharmacokinetics/pharmacodynamics, safety, and toxicity of the HDAC inhibitor abexinostat (PCI-24781) when administered with doxorubicin to patients with metastatic sarcomas.  METHODS : Participants were enrolled in a std., phase 1, 3 + 3, dose-escalation study design.  Abexinostat was administered on days 1 through 5 with 75 mg/m2 of doxorubicin administered on day 4 of every 21-day cycle until patients developed disease progression or drug intolerance or reached a cumulative lifetime doxorubicin dose of 450 mg/m2.  Granulocyte-colony-stimulating factor (G-CSF) support was provided at physician discretion on arm A and was provided to all participants in arm B. From 3 to 6 participants initially received abexinostat 30 mg/m2 twice daily, and subsequent cohorts were administered doses of 15 mg/m2, 45 mg/m2, or 60 mg/m2 twice daily.  All patients without progressive disease after receiving a cumulative lifetime doxorubicin dose of 450 mg/m2 were given the option to continue with abexinostat as a single agent until they developed disease progression.  RESULTS : In total, 22 participants (10 who had previously experienced tumor growth after doxorubicin therapy) were enrolled (6 in arm A, 14 in arm B), 20 were evaluable for dose-limiting toxicity (DLT), and 17 were evaluable for radiol. response.  In arm A, participants received abexinostat 15 mg/m2 or 30 mg/m2 twice daily.  DLTs of grade 3 and 4 neutropenia were obsd. in 2 of 3 participants who received abexinostat 30 mg/m2 twice daily.  Neither of those patients received G-CSF prophylaxis.  In arm B, participants received abexinostat at doses of 30 mg/m2, 45 mg/m2, or 60 mg/m2 twice daily, all with mandated G-CSF support.  Two DLTs were obsd. at the 60 mg/m2 twice-daily dose (grade 3 infection, grade 4 thrombocytopenia).  The pharmacokinetics of abexinostat were not affected by doxorubicin.  HDAC activity, as measured by histone acetylation in peripheral blood mononuclear cells, was maximally inhibited at the abexinostat 30 mg/m2 twice-daily dose.  Of the 17 participants who were evaluable for radiol. response, 1 patient had a partial response, 9 patients had stable disease, and 7 patients had progressive disease as their best response; and 8 patients completed ≥5 cycles.  Three of those participants had stable disease as their most recent disease status when the current report was written.  Four participants who continued on monotherapy remained in stable disease for a median of 9.8 wk after completing doxorubicin.  The most common toxicities were fatigue, thrombocytopenia, and anemia.  No study-related deaths were obsd.  CONCLUSIONS : The max. tolerated dose for abexinostat was 45 mg/m2 twice daily administered on days 1 through 5 when patients received doxorubicin 75 mg/m2 on day 4 of a 3-wk cycle and G-CSF support was mandated.  Toxicities were manageable, and tumor responses were obsd.  Addnl. studies are needed to further define the specific contributions of HDAC inhibition in patients who receive doxorubicin for the treatment of metastatic sarcoma.  Cancer 2015;121:1223-1230. cpr 2014 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXHVb_DjNZbVg90H21EOLACvtfcHk0ljbipCfdexnrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlCmt7w%253D&md5=f07b212088bc2e919656a3737feee3ef</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29175%26sid%3Dliteratum%253Aachs%26aulast%3DChoy%26aufirst%3DE.%26aulast%3DFlamand%26aufirst%3DY.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DButrynski%26aufirst%3DJ.%2BE.%26aulast%3DHarmon%26aufirst%3DD.%2BC.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DCote%26aufirst%3DG.%2BM.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DMani%26aufirst%3DC.%26aulast%3DHornicek%26aufirst%3DF.%2BJ.%26aulast%3DDuan%26aufirst%3DZ.%26aulast%3Ddemetri%26aufirst%3DG.%2BD.%26atitle%3DPhase%25201%2520Study%2520of%2520Oral%2520Abexinostat%252C%2520a%2520Histone%2520Deacetylase%2520Inhibitor%252C%2520in%2520Combination%2520with%2520Doxorubicin%2520in%2520Patients%2520with%2520Metastatic%2520Sarcoma%26jtitle%3DCancer%26date%3D2015%26volume%3D121%26issue%3D8%26spage%3D1223%26epage%3D1230%26doi%3D10.1002%2Fcncr.29175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2034</span>– <span class="NLM_lpage">2042</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1158%2F1535-7163.MCT-11-0433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22072815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2034-2042&issue=11&author=T.+Hideshimaauthor=P.+G.+Richardsonauthor=K.+C.+Anderson&title=Mechanism+of+Action+of+Proteasome+Inhibitors+and+Deacetylase+Inhibitors+and+the+Biological+Basis+of+Synergy+in+Multiple+Myeloma&doi=10.1158%2F1535-7163.MCT-11-0433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma</span></div><div class="casAuthors">Hideshima, Teru; Richardson, Paul G.; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2034-2042</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Novel agents, including the proteasome inhibitor bortezomib, have significantly improved the response and survival of patients with multiple myeloma over the last decade.  Despite these advances, many patients relapse or do not benefit from the currently available therapies; thus, multiple myeloma remains an incurable disease.  Deacetylase inhibitors (DACi), including panobinostat and vorinostat, have recently emerged as novel agents being evaluated in the treatment of multiple myeloma.  Deacetylases are a group of enzymes with effects on various intracellular proteins, including histones, transcription factors, and mol. chaperones.  Although DACi inhibit cell growth and induce apoptosis in multiple myeloma cells as a single agent, synergistic activity has been obsd. when they were used in combination with bortezomib.  The mechanistic basis of synergy is multifactorial and includes disruption of protein degrdn. and inhibition of the interaction of multiple myeloma cells with the tumor microenvironment.  This review summarizes recent advancements in the understanding of the mechanism of action of proteasome inhibitors and DACi in multiple myeloma and examines the biol. basis of their synergistic effects.  Data from the studies summarized here have been used as the rationale for the implementation of phase II and III clin. trials of DACi, alone and combined with bortezomib, in relapsed and refractory multiple myeloma.  Mol Cancer Ther; 10(11); 2034-42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWTic1RyTJsbVg90H21EOLACvtfcHk0lgMiRJtBlZkIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVeltLbJ&md5=741285acef164545c3388037dc42f73f</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0433%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DMechanism%2520of%2520Action%2520of%2520Proteasome%2520Inhibitors%2520and%2520Deacetylase%2520Inhibitors%2520and%2520the%2520Biological%2520Basis%2520of%2520Synergy%2520in%2520Multiple%2520Myeloma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26issue%3D11%26spage%3D2034%26epage%3D2042%26doi%3D10.1158%2F1535-7163.MCT-11-0433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Booth, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poklepovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, P.</span></span> <span> </span><span class="NLM_article-title">The HDAC Inhibitor Ar42 Interacts with Pazopanib to Kill Trametinib/Dabrafenib-Resistant Melanoma Cells in Vitro and in Vivo</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">16367</span>– <span class="NLM_lpage">16386</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.18632%2Foncotarget.14829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28146421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC1c3hs1ensg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=16367-16386&issue=10&author=L.+Boothauthor=J.+L.+Robertsauthor=C.+Sanderauthor=J.+Leeauthor=J.+M.+Kirkwoodauthor=A.+Poklepovicauthor=P.+Dent&title=The+HDAC+Inhibitor+Ar42+Interacts+with+Pazopanib+to+Kill+Trametinib%2FDabrafenib-Resistant+Melanoma+Cells+in+Vitro+and+in+Vivo&doi=10.18632%2Foncotarget.14829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo</span></div><div class="casAuthors">Booth Laurence; Roberts Jane L; Dent Paul; Sander Cindy; Kirkwood John M; Lee John; Poklepovic Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">16367-16386</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Studies focused on the killing of activated B-RAF melanoma cells by the histone deacetylase (HDAC) inhibitor AR42.  Compared to other tumor cell lines, PDX melanoma isolates were significantly more sensitive to AR42-induced killing.  AR42 and the multi-kinase inhibitor pazopanib interacted to activate: an eIF2α-Beclin1 pathway causing autophagosome formation; an eIF2α-DR4/DR5/CD95 pathway; and an eIF2α-dependent reduction in the expression of c-FLIP-s, MCL-1 and BCL-XL.  AR42 did not alter basal chaperone activity but increased the ability of pazopanib to inhibit HSP90, HSP70 and GRP78.  AR42 and pazopanib caused HSP90/HSP70 dissociation from RAF-1 and B-RAF that resulted in reduced 'RAF' expression.  The drug combination activated a DNA-damage-ATM-AMPK pathway that was associated with: NFκB activation; reduced mTOR S2448 and ULK-1 S757 phosphorylation; and increased ULK-1 S317 and ATG13 S318 phosphorylation.  Knock down of PERK, eIF2α, Beclin1, ATG5 or AMPKα, or expression of IκB S32A S36A, ca-mTOR or TRX, reduced cell killing.  AR42, via lysosomal degradation, reduced the protein expression of HDACs 2/5/6/10/11.  In vivo, a 3-day exposure of dabrafenib/trametinib resistant melanoma cells to the AR42 pazopanib combination reduced tumor growth and enhanced survival from ~25 to ~40 days.  Tumor cells that had adapted through therapy exhibited elevated HGF expression and the c-MET inhibitor crizotinib enhanced AR42 pazopanib lethality in this evolved drug-resistant population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnL7dhQ2F3lw8IxFYvehhofW6udTcc2eaiu77Hi6AZlbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3hs1ensg%253D%253D&md5=c3f08fc94db5e44b13b903fb366ec656</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14829%26sid%3Dliteratum%253Aachs%26aulast%3DBooth%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DJ.%2BL.%26aulast%3DSander%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DPoklepovic%26aufirst%3DA.%26aulast%3DDent%26aufirst%3DP.%26atitle%3DThe%2520HDAC%2520Inhibitor%2520Ar42%2520Interacts%2520with%2520Pazopanib%2520to%2520Kill%2520Trametinib%252FDabrafenib-Resistant%2520Melanoma%2520Cells%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26issue%3D10%26spage%3D16367%26epage%3D16386%26doi%3D10.18632%2Foncotarget.14829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavallai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamed, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poklepovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, P.</span></span> <span> </span><span class="NLM_article-title">Pazopanib and HDAC Inhibitors Interact to Kill Sarcoma Cells</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.4161/cbt.28163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.4161%2Fcbt.28163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24556916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC2cvmvVWkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=578-585&issue=5&author=S.+Tavallaiauthor=H.+A.+Hamedauthor=S.+Grantauthor=A.+Poklepovicauthor=P.+Dent&title=Pazopanib+and+HDAC+Inhibitors+Interact+to+Kill+Sarcoma+Cells&doi=10.4161%2Fcbt.28163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Pazopanib and HDAC inhibitors interact to kill sarcoma cells</span></div><div class="casAuthors">Tavallai Seyedmehrad; Hamed Hossein A; Dent Paul; Grant Steven; Poklepovic Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer biology & therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">578-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The present studies were to determine whether the multi-kinase inhibitor pazopanib interacted with histone deacetylase inhibitors (HDACI: valproate, vorinostat) to kill sarcoma cells.  In multiple sarcoma cell lines, at clinically achievable doses, pazopanib and HDACI interacted in an additive to greater than additive fashion to cause tumor cell death.  The drug combination increased the numbers of LC3-GFP and LC3-RFP vesicles.  Knockdown of Beclin1 or ATG5 significantly suppressed drug combination lethality.  Expression of c-FLIP-s, and to a lesser extent BCL-XL or dominant negative caspase 9 reduced drug combination toxicity; knock down of FADD or CD95 was protective.  Expression of both activated AKT and activated MEK1 was required to strongly suppress drug combination lethality.  The drug combination inactivated mTOR and expression of activated mTOR strongly suppressed drug combination lethality.  Treatment of animals carrying sarcoma tumors with pazopanib and valproate resulted in a greater than additive reduction in tumor volume compared with either drug individually.  As both pazopanib and HDACIs are FDA-approved agents, our data argue for further determination as to whether this drug combination is a useful sarcoma therapy in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKYvhlH_G7rdXdcedVHT5tfW6udTcc2eaiu77Hi6AZlbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvmvVWkug%253D%253D&md5=b9875edef70fd1197911c61095330466</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.4161%2Fcbt.28163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.28163%26sid%3Dliteratum%253Aachs%26aulast%3DTavallai%26aufirst%3DS.%26aulast%3DHamed%26aufirst%3DH.%2BA.%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DPoklepovic%26aufirst%3DA.%26aulast%3DDent%26aufirst%3DP.%26atitle%3DPazopanib%2520and%2520HDAC%2520Inhibitors%2520Interact%2520to%2520Kill%2520Sarcoma%2520Cells%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2014%26volume%3D15%26issue%3D5%26spage%3D578%26epage%3D585%26doi%3D10.4161%2Fcbt.28163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span> <span> </span><span class="NLM_article-title">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2051</span>– <span class="NLM_lpage">2059</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1158%2F1078-0432.CCR-13-0279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24583800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2051-2059&issue=8&author=S.+C.+Meyerauthor=R.+L.+Levine&title=Molecular+Pathways%3A+Molecular+Basis+for+Sensitivity+and+Resistance+to+JAK+Kinase+Inhibitors&doi=10.1158%2F1078-0432.CCR-13-0279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span></div><div class="casAuthors">Meyer, Sara C.; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2059</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.  Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is assocd. with hematol. malignancies, autoimmune disorders, and immune-deficient conditions.  Genetic alterations of JAK2 occur in the majority of patients with myeloproliferative neoplasms and occur in a subset of patients with acute leukemias.  JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes.  Hyperactive JAK at the apex of these potent oncogenic signaling pathways therefore represents an important target for small-mol. kinase inhibitors in different disease states.  The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, resp., and addnl. ATP-competitive JAK inhibitors are in clin. development.  Although these agents show clin. activity, the ability of these JAK inhibitors to induce clin./mol. remissions in hematol. malignancies seems limited and resistance upon chronic drug exposure is seen.  Alternative modes of targeting JAK2 such as allosteric kinase inhibition or HSP90 inhibition are under evaluation, as is the use of histone deacetylase inhibitors.  Combination therapy approaches integrating inhibition of STAT, PI3K/Akt, and MAPK pathways with JAK kinase inhibitors might be crit. to overcome malignancies characterized by dysregulated JAK signaling.  Clin Cancer Res; 20(8); 2051-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgmYqhJDI07Vg90H21EOLACvtfcHk0lgMiRJtBlZkIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D&md5=7c7ad00b5c8020fd660d86c057827eb2</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0279%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMolecular%2520Pathways%253A%2520Molecular%2520Basis%2520for%2520Sensitivity%2520and%2520Resistance%2520to%2520JAK%2520Kinase%2520Inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D8%26spage%3D2051%26epage%3D2059%26doi%3D10.1158%2F1078-0432.CCR-13-0279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ressing, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkhardt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span> <span> </span><span class="NLM_article-title">Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10299</span>– <span class="NLM_lpage">10309</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWrur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10299-10309&issue=22&author=S.+Bhatiaauthor=V.+Kriegerauthor=M.+Grollauthor=J.+D.+Oskoauthor=N.+Ressingauthor=H.+Ahlertauthor=A.+Borkhardtauthor=T.+Kurzauthor=D.+W.+Christiansonauthor=J.+Hauerauthor=F.+K.+Hansen&title=Discovery+of+the+First-in-Class+Dual+Histone+Deacetylase-Proteasome+Inhibitor&doi=10.1021%2Facs.jmedchem.8b01487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor</span></div><div class="casAuthors">Bhatia, Sanil; Krieger, Viktoria; Groll, Michael; Osko, Jeremy D.; Ressing, Nina; Ahlert, Heinz; Borkhardt, Arndt; Kurz, Thomas; Christianson, David W.; Hauer, Julia; Hansen, Finn K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10299-10309</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual- or multitarget drugs have emerged as a promising alternative to combination therapies.  Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase (HDAC) inhibitors due to the simultaneous blockage of the ubiquitin degrdn. and aggresome pathways.  Here, the authors present the design, synthesis, binding modes, and anticancer properties of RTS-V5 as the first-in-class dual HDAC-proteasome ligand.  The inhibition of both targets was confirmed by biochem. and cellular assays as well as x-ray crystal structures of the 20S proteasome and HDAC6 complexed with RTS-V5.  Cytotoxicity assays with leukemia and multiple myeloma cell lines as well as therapy refractory primary patient-derived leukemia cells demonstrated that RTS-V5 possesses potent and selective anticancer activity.  The results will thus guide the structure-based optimization of dual HDAC-proteasome inhibitors for the treatment of hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwJMqcDlzXA7Vg90H21EOLACvtfcHk0liNTHHyQtmC0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWrur7K&md5=7d47e664bd77ac1bc5ebd39ea6eed02a</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01487%26sid%3Dliteratum%253Aachs%26aulast%3DBhatia%26aufirst%3DS.%26aulast%3DKrieger%26aufirst%3DV.%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DRessing%26aufirst%3DN.%26aulast%3DAhlert%26aufirst%3DH.%26aulast%3DBorkhardt%26aufirst%3DA.%26aulast%3DKurz%26aufirst%3DT.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DHauer%26aufirst%3DJ.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26atitle%3DDiscovery%2520of%2520the%2520First-in-Class%2520Dual%2520Histone%2520Deacetylase-Proteasome%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D22%26spage%3D10299%26epage%3D10309%26doi%3D10.1021%2Facs.jmedchem.8b01487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallastegui, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arciniega, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillebrand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">Hydroxyureas as Noncovalent Proteasome Inhibitors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1002/anie.201106010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fanie.201106010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2rurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=247-249&issue=1&author=N.+Gallasteguiauthor=P.+Beckauthor=M.+Arciniegaauthor=R.+Huberauthor=S.+Hillebrandauthor=M.+Groll&title=Hydroxyureas+as+Noncovalent+Proteasome+Inhibitors&doi=10.1002%2Fanie.201106010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxyureas as Noncovalent Proteasome Inhibitors</span></div><div class="casAuthors">Gallastegui, Nerea; Beck, Philipp; Arciniega, Marcelino; Huber, Robert; Hillebrand, Stefan; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">247-249</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Inhibitors with a new mechanism of action are needed for 20S proteasome (CP) inhibition owing to the ineffectiveness of current market drugs against some types of solid tumors.  A novel class of nonpeptidic CP inhibitors has been developed, which display reversible and noncovalent binding.  The structure-based design of these highly active and site-specific inhibitors revealed unexplored binding subpockets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV0vwa018n0rVg90H21EOLACvtfcHk0liNTHHyQtmC0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2rurfI&md5=22dcc1101f70a3d4920f467240add238</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1002%2Fanie.201106010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201106010%26sid%3Dliteratum%253Aachs%26aulast%3DGallastegui%26aufirst%3DN.%26aulast%3DBeck%26aufirst%3DP.%26aulast%3DArciniega%26aufirst%3DM.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DHillebrand%26aufirst%3DS.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3DHydroxyureas%2520as%2520Noncovalent%2520Proteasome%2520Inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26issue%3D1%26spage%3D247%26epage%3D249%26doi%3D10.1002%2Fanie.201106010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigstad, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sappal, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J. L.</span></span> <span> </span><span class="NLM_article-title">Characterization of a New Series of Non-Covalent Proteasome Inhibitors with Exquisite Potency and Selectivity for the 20Sβ5-Subunit</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>430</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1042/BJ20100383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1042%2FBJ20100383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20632995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=461-476&issue=3&author=C.+Blackburnauthor=K.+M.+Gigstadauthor=P.+Halesauthor=K.+Garciaauthor=M.+Jonesauthor=F.+J.+Bruzzeseauthor=C.+Barrettauthor=J.+X.+Liuauthor=T.+A.+Soucyauthor=D.+S.+Sappalauthor=N.+Bumpauthor=E.+J.+Olhavaauthor=P.+Flemingauthor=L.+R.+Dickauthor=C.+Tsuauthor=M.+D.+Sintchakauthor=J.+L.+Blank&title=Characterization+of+a+New+Series+of+Non-Covalent+Proteasome+Inhibitors+with+Exquisite+Potency+and+Selectivity+for+the+20S%CE%B25-Subunit&doi=10.1042%2FBJ20100383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit</span></div><div class="casAuthors">Blackburn, Christopher; Gigstad, Kenneth M.; Hales, Paul; Garcia, Khristofer; Jones, Matthew; Bruzzese, Frank J.; Barrett, Cynthia; Liu, Jane X.; Soucy, Teresa A.; Sappal, Darshan S.; Bump, Nancy; Olhava, Edward J.; Fleming, Paul; Dick, Lawrence R.; Tsu, Christopher; Sintchak, Michael D.; Blank, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-476</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The mammalian 26S proteasome is a 2500 kDa multi-catalytic complex involved in intracellular protein degrdn.  The authors describe the synthesis and properties of a novel series of non-covalent di-peptide inhibitors of the proteasome based on a capped tripeptide that was first identified by high-throughput screening of a library of approx. 350000 compds. for inhibitors of the ubiquitin-proteasome system in cells.  It is shown that these compds. are entirely selective for the β5 (chymotrypsin-like) site over the β1 (caspase-like) and β2 (trypsin-like) sites of the 20S core particle of the proteasome, and over a panel of less closely related proteases.  Compd. optimization, guided by x-ray crystallog. of the liganded 20S core particle, confirmed their non-covalent binding mode and provided a structural basis for their enhanced in vitro and cellular potencies.  The authors demonstrate that such compds. show low nanomolar IC50 values for the human 20S β5 site in vitro, and that pharmacol. inhibition of this site in cells is sufficient to potently inhibit the degrdn. of a tetra-ubiquitin-luciferase reporter, activation of NFκB (nuclear factor κB) in response to TNF-α (tumor necrosis factor-α) and the proliferation of cancer cells.  Finally, the authors identified capped dipeptides that show differential selectivity for the β5 site of the constitutively expressed proteasome and immunoproteasome in vitro and in B-cell lymphomas.  Collectively, these studies describe the synthesis, activity and binding mode of a new series of non-covalent proteasome inhibitors with unprecedented potency and selectivity for the β5 site, and which can discriminate between the constitutive proteasome and immunoproteasome in vitro and in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodAundpO9R0LVg90H21EOLACvtfcHk0liNTHHyQtmC0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtb3O&md5=de750c60263f0ec83961326ae2b94445</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1042%2FBJ20100383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100383%26sid%3Dliteratum%253Aachs%26aulast%3DBlackburn%26aufirst%3DC.%26aulast%3DGigstad%26aufirst%3DK.%2BM.%26aulast%3DHales%26aufirst%3DP.%26aulast%3DGarcia%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DBarrett%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%2BX.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DSappal%26aufirst%3DD.%2BS.%26aulast%3DBump%26aufirst%3DN.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DTsu%26aufirst%3DC.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DBlank%26aufirst%3DJ.%2BL.%26atitle%3DCharacterization%2520of%2520a%2520New%2520Series%2520of%2520Non-Covalent%2520Proteasome%2520Inhibitors%2520with%2520Exquisite%2520Potency%2520and%2520Selectivity%2520for%2520the%252020S%25CE%25B25-Subunit%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26issue%3D3%26spage%3D461%26epage%3D476%26doi%3D10.1042%2FBJ20100383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small Molecules Simultaneously Inhibiting P53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7245</span>– <span class="NLM_lpage">7260</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00664</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00664" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlykur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7245-7260&issue=16&author=S.+Heauthor=G.+Dongauthor=S.+Wuauthor=K.+Fangauthor=Z.+Miaoauthor=W.+Wangauthor=C.+Sheng&title=Small+Molecules+Simultaneously+Inhibiting+P53-Murine+Double+Minute+2+%28MDM2%29+Interaction+and+Histone+Deacetylases+%28HDACs%29%3A+Discovery+of+Novel+Multitargeting+Antitumor+Agents&doi=10.1021%2Facs.jmedchem.8b00664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Wu, Shanchao; Fang, Kun; Miao, Zhenyuan; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7245-7260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P53-Murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important targets in antitumor drug development.  Inspired by the synergistic effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors were identified, which showed excellent activities against both targets.  In particular, compd. 14d was proven to be a potent and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms were validated in cancer cells.  Compd. 14d showed excellent in vivo antitumor potency in the A549 xenograft model, providing a promising lead compd. for the development of novel antitumor agents.  Also, this proof-of-concept study offers a novel and efficient strategy for multitargeting antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx94Uvm3pP8bVg90H21EOLACvtfcHk0lguekUpmeDzBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlykur3L&md5=68871e41ecb786e135b01742e59eec85</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00664%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520Molecules%2520Simultaneously%2520Inhibiting%2520P53-Murine%2520Double%2520Minute%25202%2520%2528MDM2%2529%2520Interaction%2520and%2520Histone%2520Deacetylases%2520%2528HDACs%2529%253A%2520Discovery%2520of%2520Novel%2520Multitargeting%2520Antitumor%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D16%26spage%3D7245%26epage%3D7260%26doi%3D10.1021%2Facs.jmedchem.8b00664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vousden, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D. P.</span></span> <span> </span><span class="NLM_article-title">P53 in Health and Disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1038/nrm2147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrm2147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17380161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtlygsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=275-283&issue=4&author=K.+H.+Vousdenauthor=D.+P.+Lane&title=P53+in+Health+and+Disease&doi=10.1038%2Fnrm2147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">p53 in health and disease</span></div><div class="casAuthors">Vousden, Karen H.; Lane, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">275-283</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  As a component of the response to acute stress, p53 has a well established role in protecting against cancer development.  However, it is now becoming clear that p53 can have a much broader role and can contribute to the development, life expectancy and overall fitness of an organism.  Although the function of p53 as a tumor suppressor ensures that we can't live without it, an integrated view of p53 suggests that not all of its functions are conducive to a long and healthy life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoND8MaF-_GGbVg90H21EOLACvtfcHk0lguekUpmeDzBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtlygsr0%253D&md5=c39c719e12d6cb436786acb162101b28</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1038%2Fnrm2147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2147%26sid%3Dliteratum%253Aachs%26aulast%3DVousden%26aufirst%3DK.%2BH.%26aulast%3DLane%26aufirst%3DD.%2BP.%26atitle%3DP53%2520in%2520Health%2520and%2520Disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26issue%3D4%26spage%3D275%26epage%3D283%26doi%3D10.1038%2Fnrm2147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5304</span>– <span class="NLM_lpage">5322</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00384</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00384" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5304-5322&issue=12&author=J.+Zangauthor=X.+Liangauthor=Y.+Huangauthor=Y.+Jiaauthor=X.+Liauthor=W.+Xuauthor=C.+J.+Chouauthor=Y.+Zhang&title=Discovery+of+Novel+Pazopanib-Based+HDAC+and+VEGFR+Dual+Inhibitors+Targeting+Cancer+Epigenetics+and+Angiogenesis+Simultaneously&doi=10.1021%2Facs.jmedchem.8b00384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously</span></div><div class="casAuthors">Zang, Jie; Liang, Xuewu; Huang, Yongxue; Jia, Yuping; Li, Xiaoyang; Xu, Wenfang; Chou, C. James; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5304-5322</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein a novel series of pazopanib hybrids as polypharmacol. antitumor agents were developed based on the crosstalk between histone deacetylases (HDACs) and vascular endothelial growth factor (VEGF) pathway.  Among them, one ortho-aminoanilide 6d and one hydroxamic acid 13f exhibited considerable total HDACs and VEGFR-2 inhibitory activities.  The HDAC inhibitory activities endowed 6d and 13f with potent antiproliferative activities, which was not obsd. in the approved VEGFR inhibitor pazopanib.  Compds. 6d and 13f possessed comparable HDAC isoform selectivity profiles to the clin. class I HDAC inhibitor MS-275 and the approved pan-HDAC inhibitor SAHA, resp. 6d and 13f also exhibited uncompromised multiple tyrosine kinases inhibitory activities relative to pazopanib.  The intracellular dual inhibition to HDAC and VEGFR of 6d and 13f was validated by Western blot anal.  In both HUVECs tube formation assay and rat thoracic aorta rings assay, 6d and 13f showed comparable antiangiogenic potencies to pazopanib.  What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpmz6rwKiKSbVg90H21EOLACvtfcHk0lguekUpmeDzBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVGrsL8%253D&md5=437da0a6cca1ec211219aef87a6ddbc5</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Novel%2520Pazopanib-Based%2520HDAC%2520and%2520VEGFR%2520Dual%2520Inhibitors%2520Targeting%2520Cancer%2520Epigenetics%2520and%2520Angiogenesis%2520Simultaneously%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D12%26spage%3D5304%26epage%3D5322%26doi%3D10.1021%2Facs.jmedchem.8b00384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vyse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broncel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhamra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P. H.</span></span> <span> </span><span class="NLM_article-title">Quantitative Phosphoproteomic Analysis of Acquired Cancer Drug Resistance to Pazopanib and Dasatinib</span>. <i>J. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1016/j.jprot.2017.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.jprot.2017.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28842319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKgu7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2018&pages=130-140&author=S.+Vyseauthor=F.+McCarthyauthor=M.+Broncelauthor=A.+Paulauthor=J.+P.+Wongauthor=A.+Bhamraauthor=P.+H.+Huang&title=Quantitative+Phosphoproteomic+Analysis+of+Acquired+Cancer+Drug+Resistance+to+Pazopanib+and+Dasatinib&doi=10.1016%2Fj.jprot.2017.08.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib</span></div><div class="casAuthors">Vyse, Simon; McCarthy, Frank; Broncel, Malgorzata; Paul, Angela; Wong, Jocelyn P.; Bhamra, Amandeep; Huang, Paul H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">130-140</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acquired drug resistance impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy.  The lack of clin. effective therapies to overcome resistance represents an unmet need.  Understanding the signalling that drives drug resistance will facilitate the development of new salvage therapies to treat patients with secondary TKI resistance.  In this study, we utilize mass spectrometry to characterize the global phosphoproteomic alterations that accompany the acquisition of resistance to two FDA-approved TKIs, pazopanib and dasatinib, in the A204 rhabdoid tumor cell line.  Our anal. finds that only 6% and 9.7% of the quantified phosphoproteome is altered upon the acquisition of pazopanib and dasatinib resistance, resp.  Pazopanib resistant cells display elevated phosphorylation in cytoskeletal regulatory pathways while dasatinib resistant cells show an upregulation of the insulin receptor/IGF-1R signalling pathway.  Drug response profiling rediscovers several previously reported vulnerabilities assocd. with pazopanib and dasatinib resistance and identifies a new dependency to the second generation HSP90 inhibitor NVP-AUY-922.  This study provides a useful resource detailing the candidate signalling determinants of acquired TKI resistance; and reveals a therapeutic approach of inhibiting HSP90 function as a means of salvage therapy to overcome pazopanib and dasatinib resistance.  Pazopanib and dasatinib are tyrosine kinase inhibitors (TKIs) approved for the treatment of multiple cancer types.  Patients who are treated with these drugs are prone to the development of drug resistance and consequently tumor relapse.  Here we use quant. phosphoproteomics to characterize the signalling pathways which are enriched in cells that have acquired resistance to these two drugs.  Furthermore, targeted drug screens were used to identify salvage therapies capable of overcoming pazopanib and dasatinib resistance.  This data advances our understanding of the mechanisms of TKI resistance and highlights candidate targets for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYFjUX3bTf-bVg90H21EOLACvtfcHk0liLMhsNm-iJTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKgu7rK&md5=b659908784eff089023d81c1a1c98436</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2017.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2017.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DVyse%26aufirst%3DS.%26aulast%3DMcCarthy%26aufirst%3DF.%26aulast%3DBroncel%26aufirst%3DM.%26aulast%3DPaul%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DJ.%2BP.%26aulast%3DBhamra%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DP.%2BH.%26atitle%3DQuantitative%2520Phosphoproteomic%2520Analysis%2520of%2520Acquired%2520Cancer%2520Drug%2520Resistance%2520to%2520Pazopanib%2520and%2520Dasatinib%26jtitle%3DJ.%2520Proteomics%26date%3D2018%26volume%3D170%26spage%3D130%26epage%3D140%26doi%3D10.1016%2Fj.jprot.2017.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezeli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelemen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vegvari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tisza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laszlo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helbich, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegedus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klikovits, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoda, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klepetko, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paku, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marko-Varga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dome, B.</span></span> <span> </span><span class="NLM_article-title">Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.7150/thno.16767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.7150%2Fthno.16767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28042343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtVGktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=400-412&issue=2&author=S.+Torokauthor=M.+Rezeliauthor=O.+Kelemenauthor=A.+Vegvariauthor=K.+Watanabeauthor=Y.+Sugiharaauthor=A.+Tiszaauthor=T.+Martonauthor=I.+Kovacsauthor=J.+Tovariauthor=V.+Laszloauthor=T.+H.+Helbichauthor=B.+Hegedusauthor=T.+Klikovitsauthor=M.+A.+Hodaauthor=W.+Klepetkoauthor=S.+Pakuauthor=G.+Marko-Vargaauthor=B.+Dome&title=Limited+Tumor+Tissue+Drug+Penetration+Contributes+to+Primary+Resistance+against+Angiogenesis+Inhibitors&doi=10.7150%2Fthno.16767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Limited tumor tissue drug penetration contributes to primary resistance against angiogenesis inhibitors</span></div><div class="casAuthors">Torok, Szilvia; Rezeli, Melinda; Kelemen, Olga; Vegvari, Akos; Watanabe, Kenichi; Sugihara, Yutaka; Tisza, Anna; Marton, Timea; Kovacs, Ildiko; Tovari, Jozsef; Laszlo, Viktoria; Helbich, Thomas H.; Hegedus, Balazs; Klikovits, Thomas; Hoda, Mir Alireza; Klepetko, Walter; Paku, Sandor; Marko-Varga, Gyorgy; Dome, Balazs</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">400-412</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Resistance mechanisms against antiangiogenic drugs are unclear.  Here, we correlated the antitumor and antivascular properties of five different antiangiogenic receptor tyrosine kinase inhibitors (RTKIs) (motesanib, pazopanib, sorafenib, sunitinib, vatalanib) with their intratumoral distribution data obtained by matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI).  In the first mouse model, only sunitinib exhibited broad-spectrum antivascular and antitumor activities by simultaneously suppressing vascular endothelial growth factor receptor-2 (VEGFR2) and desmin expression, and by increasing intratumoral hypoxia and inhibiting both tumor growth and vascularisation significantly.  Importantly, the highest and most homogeneous intratumoral drug concns. have been found in sunitinib-treated animals.  In another animal model, where in contrast to the first model vatalanib was detectable at homogeneously high intratumoral concns., the drug significantly reduced tumor growth and angiogenesis.  In conclusion, the tumor tissue penetration and thus the antiangiogenic and antitumor potential of antiangiogenic RTKIs vary among the tumor models and our study demonstrates the potential of MALDI-MSI to predict the efficacy of unlabeled small mol. antiangiogenic drugs in malignant tissue.  Our approach is thus a major tech. and preclin. advance demonstrating that primary resistance to angiogenesis inhibitors involves limited tumor tissue drug penetration.  We also conclude that MALDI-MSI may significantly contribute to the improvement of antivascular cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjaQn-h68CBbVg90H21EOLACvtfcHk0liLMhsNm-iJTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtVGktr0%253D&md5=39e01c9ae14fc2251309c23d39027e90</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.7150%2Fthno.16767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.16767%26sid%3Dliteratum%253Aachs%26aulast%3DTorok%26aufirst%3DS.%26aulast%3DRezeli%26aufirst%3DM.%26aulast%3DKelemen%26aufirst%3DO.%26aulast%3DVegvari%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DSugihara%26aufirst%3DY.%26aulast%3DTisza%26aufirst%3DA.%26aulast%3DMarton%26aufirst%3DT.%26aulast%3DKovacs%26aufirst%3DI.%26aulast%3DTovari%26aufirst%3DJ.%26aulast%3DLaszlo%26aufirst%3DV.%26aulast%3DHelbich%26aufirst%3DT.%2BH.%26aulast%3DHegedus%26aufirst%3DB.%26aulast%3DKlikovits%26aufirst%3DT.%26aulast%3DHoda%26aufirst%3DM.%2BA.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DPaku%26aufirst%3DS.%26aulast%3DMarko-Varga%26aufirst%3DG.%26aulast%3DDome%26aufirst%3DB.%26atitle%3DLimited%2520Tumor%2520Tissue%2520Drug%2520Penetration%2520Contributes%2520to%2520Primary%2520Resistance%2520against%2520Angiogenesis%2520Inhibitors%26jtitle%3DTheranostics%26date%3D2017%26volume%3D7%26issue%3D2%26spage%3D400%26epage%3D412%26doi%3D10.7150%2Fthno.16767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musumeci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span> <span> </span><span class="NLM_article-title">Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">10797</span>– <span class="NLM_lpage">10822</span>, <span class="refDoi"> DOI: 10.1021/jm301085w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301085w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10797-10822&issue=24&author=F.+Musumeciauthor=M.+Radiauthor=C.+Brulloauthor=S.+Schenone&title=Vascular+Endothelial+Growth+Factor+%28VEGF%29+Receptors%3A+Drugs+and+New+Inhibitors&doi=10.1021%2Fjm301085w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors</span></div><div class="casAuthors">Musumeci, Francesca; Radi, Marco; Brullo, Chiara; Schenone, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10797-10822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these agents and the importance of the research in the field of angiogenesis inhibitors for future oncol. therapy.  In this Perspective we briefly report the inhibitors that are in clin. use, while we dedicate two wider sections to the compds. that are in clin. trials and to the new derivs. appearing in the literature.  We esp. consider the medicinal chem. aspect of the topic and report the structure-activity relationship studies and the binding mode of some inhibitors as well as the biol. data of the compds. discovered in the past 5 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP5ioBH5ZGAbVg90H21EOLACvtfcHk0liLMhsNm-iJTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbvL&md5=d995df9120c8f56c1ab142b1aea8dfbc</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Fjm301085w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301085w%26sid%3Dliteratum%253Aachs%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DRadi%26aufirst%3DM.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DVascular%2520Endothelial%2520Growth%2520Factor%2520%2528VEGF%2529%2520Receptors%253A%2520Drugs%2520and%2520New%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D24%26spage%3D10797%26epage%3D10822%26doi%3D10.1021%2Fjm301085w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6074</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6056-6074&issue=14&author=Y.+Huangauthor=G.+Dongauthor=H.+Liauthor=N.+Liuauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+Janus+Kinase+2+%28JAK2%29+and+Histone+Deacetylase+%28HDAC%29+Dual+Inhibitors+as+a+Novel+Strategy+for+the+Combinational+Treatment+of+Leukemia+and+Invasive+Fungal+Infections&doi=10.1021%2Facs.jmedchem.8b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span></div><div class="casAuthors">Huang, Yahui; Dong, Guoqiang; Li, Huanqiu; Liu, Na; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6056-6074</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin., leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens.  Herein, a novel therapeutic strategy was developed in which a small mol. can simultaneously treat leukemia and invasive fungal infections (IFIs).  Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematol. cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections.  In particular, compd. I, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections.  This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_ii7EQG1qLVg90H21EOLACvtfcHk0lgLxqDeZbb0yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN&md5=ba7cf74761120f0526ab520196e3dded</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Janus%2520Kinase%25202%2520%2528JAK2%2529%2520and%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Dual%2520Inhibitors%2520as%2520a%2520Novel%2520Strategy%2520for%2520the%2520Combinational%2520Treatment%2520of%2520Leukemia%2520and%2520Invasive%2520Fungal%2520Infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D14%26spage%3D6056%26epage%3D6074%26doi%3D10.1021%2Facs.jmedchem.8b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, M.</span></span> <span> </span><span class="NLM_article-title">Targeting JAK Kinase in Solid Tumors: Emerging Opportunities and Challenges</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1038/onc.2015.150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fonc.2015.150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25982279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVOns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=939-951&issue=8&author=M.+Buchertauthor=C.+J.+Burnsauthor=M.+Ernst&title=Targeting+JAK+Kinase+in+Solid+Tumors%3A+Emerging+Opportunities+and+Challenges&doi=10.1038%2Fonc.2015.150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting JAK kinase in solid tumors: emerging opportunities and challenges</span></div><div class="casAuthors">Buchert, M.; Burns, C. J.; Ernst, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">939-951</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Various human malignancies are characterized by excessive activation of the Janus family of cytoplasmic tyrosine kinases (JAK) and their assocd. transcription factors STAT3 and STAT5.  In the majority of solid tumors, this occurs in response to increased abundance of inflammatory cytokines in the tumor microenvironment prominently produced by infiltrating innate immune cells.  Many of these cytokines share common receptor subunits and belong to the interleukin (IL)-6/IL-11, IL-10/IL-22 and IL-12/IL-23 families.  Therapeutic inhibition of the JAK/STAT3 pathway potentially offers considerable benefit owing to the capacity of JAK/STAT3 signaling to promote cancer hallmarks in the tumor and its environment, including proliferation, survival, angiogenesis, tumor metab. while suppressing antitumor immunity.  This is further emphasized by the current successful clin. applications of JAK-specific small mol. inhibitors for the treatment of inflammatory disorders and hematopoietic malignancies.  Here we review current preclin. applications for JAK inhibitors for the treatment of solid cancers in mice, with a focus on the most common malignancies emanating from oncogenic transformation of the epithelial mucosa in the stomach and colon.  Emerging data with small mol. JAK-specific ATP-binding analogs corroborate genetic findings and suggest that interference with the JAK/STAT3 pathway may suppress the growth of the most common forms of sporadic colon cancers that arise from mutations of the APC tumor suppressor gene.  Likewise inhibition of cytokine-dependent activation of the JAK/STAT3 pathway may also afford orthogonal treatment opportunities for other oncogene-addicted cancer cells that have gained drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ogRfeEyKErVg90H21EOLACvtfcHk0lgLxqDeZbb0yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVOns7s%253D&md5=fd63866700ca096c476f1942157deccc</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1038%2Fonc.2015.150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2015.150%26sid%3Dliteratum%253Aachs%26aulast%3DBuchert%26aufirst%3DM.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DErnst%26aufirst%3DM.%26atitle%3DTargeting%2520JAK%2520Kinase%2520in%2520Solid%2520Tumors%253A%2520Emerging%2520Opportunities%2520and%2520Challenges%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26issue%3D8%26spage%3D939%26epage%3D951%26doi%3D10.1038%2Fonc.2015.150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offidani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fianchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picardi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chierichini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramatti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Invernizzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lint, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcucci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentini, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girmenia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosari, A.</span></span> <span> </span><span class="NLM_article-title">The Epidemiology of Fungal Infections in Patients with Hematologic Malignancies: The SEIFEM-2004 Study</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1068</span>– <span class="NLM_lpage">1075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16885047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BD28vmtFyiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2006&pages=1068-1075&issue=8&author=L.+Paganoauthor=M.+Cairaauthor=A.+Candoniauthor=M.+Offidaniauthor=L.+Fianchiauthor=B.+Martinoauthor=D.+Pastoreauthor=M.+Picardiauthor=A.+Boniniauthor=A.+Chierichiniauthor=R.+Fanciauthor=C.+Caramattiauthor=R.+Invernizziauthor=D.+Matteiauthor=M.+E.+Mitraauthor=L.+Melilloauthor=F.+Aversaauthor=M.+T.+Van+Lintauthor=P.+Falcucciauthor=C.+G.+Valentiniauthor=C.+Girmeniaauthor=A.+Nosari&title=The+Epidemiology+of+Fungal+Infections+in+Patients+with+Hematologic+Malignancies%3A+The+SEIFEM-2004+Study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study</span></div><div class="casAuthors">Pagano Livio; Caira Morena; Candoni Anna; Offidani Massimo; Fianchi Luana; Martino Bruno; Pastore Domenico; Picardi Marco; Bonini Alessandro; Chierichini Anna; Fanci Rosa; Caramatti Cecilia; Invernizzi Rosangela; Mattei Daniele; Mitra Maria Enza; Melillo Lorella; Aversa Franco; Van Lint Maria Teresa; Falcucci Paolo; Valentini Caterina Giovanna; Girmenia Corrado; Nosari Annamaria</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1068-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND OBJECTIVES:  The aim of this study was to evaluate the incidence and outcome of invasive fungal infections (IFI) in patients with hematologic malignancies.  DESIGN AND METHODS:  This was a retrospective cohort study of patients admitted between 1999 and 2003 to 18 hematology wards in Italy.  Each participating center provided information on all patients with newly diagnosed hematologic malignancies admitted during the survery period and on all episodes of IFI experienced by these patients.  RESULTS:  The cohort was formed of 11,802 patients with hematologic malignacies: acute leukemia (myeloid 3012, lymphoid 1173), chronic leukemia (myeloid 596, lymphoid 1104), lymphoma (Hodgkin's 844, non-Hodgkin's 3457), or multiple myeloma (1616).  There were 538 proven or probable IFI (4.6%); 373 (69%) occurred in patients with acute myeloid leukemia.  Over half (346/538) were caused by molds (2.9%), in most cases Aspergillus spp. (310/346).  The 192 yeast infections (1.6%) included 175 cases of candidemia.  Overall and IFI-attributable mortality rates were 2% (209/11802) and 39% (209/538), respectively.  The highest IFI-attributable mortality rates were associated with zygomycosis (64%) followed by fusariosis (53%), aspergillosis (42%), and candidemia (33%).  INTERPRETATION AND CONCLUSIONS:  Patients with hematologic malignancies are currently at higher risk of IFI caused by molds than by yeasts, and the incidence of IFI is highest among patients with acute myeloid leukemia.  Aspergillus spp are still the most common pathogens, followed by Candida spp.  Other agents are rare.  The attributable mortality rate for aspergillosis has dropped from 60-70% to approximately 40%.  Candidemia-related mortality remains within the 30-40% range reported in literature although the incidence has decreased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjYIQsWCoicbZpSb_XWfMrfW6udTcc2eZzSkA9KxWIM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vmtFyiug%253D%253D&md5=a892c750b021aed0db557d66852aaabc</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPagano%26aufirst%3DL.%26aulast%3DCaira%26aufirst%3DM.%26aulast%3DCandoni%26aufirst%3DA.%26aulast%3DOffidani%26aufirst%3DM.%26aulast%3DFianchi%26aufirst%3DL.%26aulast%3DMartino%26aufirst%3DB.%26aulast%3DPastore%26aufirst%3DD.%26aulast%3DPicardi%26aufirst%3DM.%26aulast%3DBonini%26aufirst%3DA.%26aulast%3DChierichini%26aufirst%3DA.%26aulast%3DFanci%26aufirst%3DR.%26aulast%3DCaramatti%26aufirst%3DC.%26aulast%3DInvernizzi%26aufirst%3DR.%26aulast%3DMattei%26aufirst%3DD.%26aulast%3DMitra%26aufirst%3DM.%2BE.%26aulast%3DMelillo%26aufirst%3DL.%26aulast%3DAversa%26aufirst%3DF.%26aulast%3DVan%2BLint%26aufirst%3DM.%2BT.%26aulast%3DFalcucci%26aufirst%3DP.%26aulast%3DValentini%26aufirst%3DC.%2BG.%26aulast%3DGirmenia%26aufirst%3DC.%26aulast%3DNosari%26aufirst%3DA.%26atitle%3DThe%2520Epidemiology%2520of%2520Fungal%2520Infections%2520in%2520Patients%2520with%2520Hematologic%2520Malignancies%253A%2520The%2520SEIFEM-2004%2520Study%26jtitle%3DHaematologica%26date%3D2006%26volume%3D91%26issue%3D8%26spage%3D1068%26epage%3D1075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aleshin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span> <span> </span><span class="NLM_article-title">Src: A Century of Science Brought to the Clinic</span>. <i>Neoplasia.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1593/neo.10328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1593%2Fneo.10328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20689754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVClsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=599-607&issue=8&author=A.+Aleshinauthor=R.+S.+Finn&title=Src%3A+A+Century+of+Science+Brought+to+the+Clinic&doi=10.1593%2Fneo.10328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">SRC: a century of science brought to the clinic</span></div><div class="casAuthors">Aleshin, Alexey; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">599-607</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">A review.  The SRC family kinases are the largest family of nonreceptor tyrosine kinases and one of the best-studied targets for cancer therapy.  SRC, arguably the oldest oncogene, has been implicated in pathways regulating proliferation, angiogenesis, invasion and metastasis, and bone metab.  More recently, researchers have proposed that the transforming ability of SRC is linked to its ability to activate key signaling mols. in these pathways, rather than through direct activity.  It has been hypothesized that blocking SRC activation may inhibit these pathways, resulting in antitumor activity.  However, successfully targeting SRC in a clin. setting remains a challenge, and SRC inhibitors have only recently begun to move through clin. development.  Preclin. studies have identified specific mol. "subgroups" and histologies that may be more sensitive to SRC inhibition.  In addn., other studies have demonstrated synergistic interactions between SRC inhibitors and other targeted therapies and cytotoxics.  In this review, we summarize SRC biol. and how it has been applied to the clin. development of SRC inhibitors.  The status of SRC inhibitors, including dasatinib, saracatinib, and bosutinib, which are in phase 1, 2, and 3 trials, is highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_g3wyg6sIcLVg90H21EOLACvtfcHk0lgOXAZ1CsM0RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVClsrs%253D&md5=4eaa783194fb3abb0a8234f4e16d5af4</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1593%2Fneo.10328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.10328%26sid%3Dliteratum%253Aachs%26aulast%3DAleshin%26aufirst%3DA.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DSrc%253A%2520A%2520Century%2520of%2520Science%2520Brought%2520to%2520the%2520Clinic%26jtitle%3DNeoplasia.%26date%3D2010%26volume%3D12%26issue%3D8%26spage%3D599%26epage%3D607%26doi%3D10.1593%2Fneo.10328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westhoff, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fincham, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N. O.</span></span> <span> </span><span class="NLM_article-title">Src-Mediated Phosphorylation of Focal Adhesion Kinase Couples Actin and Adhesion Dynamics to Survival Signaling</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8113</span>, <span class="refDoi"> DOI: 10.1128/MCB.24.18.8113-8133.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1128%2FMCB.24.18.8113-8133.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15340073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnslCrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=8113&issue=18&author=M.+A.+Westhoffauthor=B.+Serrelsauthor=V.+J.+Finchamauthor=M.+C.+Frameauthor=N.+O.+Carragher&title=Src-Mediated+Phosphorylation+of+Focal+Adhesion+Kinase+Couples+Actin+and+Adhesion+Dynamics+to+Survival+Signaling&doi=10.1128%2FMCB.24.18.8113-8133.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Src-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling</span></div><div class="casAuthors">Westhoff, M. A.; Serrels, B.; Fincham, V. J.; Frame, M. C.; Carragher, N. O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8113-8133</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Integrin-assocd. focal adhesions not only provide adhesive links between cellular actin and extracellular matrix but also are sites of signal transmission into the cell interior.  Many cell responses signal through focal adhesion kinase (FAK), often by integrin-induced autophosphorylation of FAK or phosphorylation by Src family kinases.  Here, we used an interfering FAK mutant (4-9F-FAK) to show that Src-dependent FAK phosphorylation is required for focal adhesion turnover and cell migration, by controlling assembly of a calpain 2/FAK/Src/p42ERK complex, calpain activation, and proteolysis of FAK.  Expression of 4-9F-FAK in FAK-deficient fibroblasts also disrupts F-actin assembly assocd. with normal adhesion and spreading.  In addn., we found that FAK's ability to regulate both assembly and disassembly of the actin and adhesion networks may be linked to regulation of the protease calpain.  Surprisingly, we also found that the same interfering 4-9F-FAK mutant protein causes apoptosis of serum-deprived, transformed cells and suppresses anchorage-independent growth.  These data show that Src-mediated phosphorylation of FAK acts as a pivotal regulator of both actin and adhesion dynamics and survival signaling, which, in turn, control apparently distinct processes such as cell migration and anchorage-independent growth.  This also highlights that dynamic regulation of actin and adhesions (which include the integrin matrix receptors) is crit. to signaling output and biol. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2pNhJXdyh1bVg90H21EOLACvtfcHk0lgOXAZ1CsM0RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnslCrsbw%253D&md5=d5cc89848c8147fcb46299ce04c5c72c</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1128%2FMCB.24.18.8113-8133.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.24.18.8113-8133.2004%26sid%3Dliteratum%253Aachs%26aulast%3DWesthoff%26aufirst%3DM.%2BA.%26aulast%3DSerrels%26aufirst%3DB.%26aulast%3DFincham%26aufirst%3DV.%2BJ.%26aulast%3DFrame%26aufirst%3DM.%2BC.%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26atitle%3DSrc-Mediated%2520Phosphorylation%2520of%2520Focal%2520Adhesion%2520Kinase%2520Couples%2520Actin%2520and%2520Adhesion%2520Dynamics%2520to%2520Survival%2520Signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2004%26volume%3D24%26issue%3D18%26spage%3D8113%26doi%3D10.1128%2FMCB.24.18.8113-8133.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagemann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, J. L.</span></span> <span> </span><span class="NLM_article-title">The UPS and Downs of MEK Kinase Interactions</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">875</span>, <span class="refDoi"> DOI: 10.1016/S0898-6568(01)00220-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0898-6568%2801%2900220-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11728826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXos1Cmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2001&pages=863-875&issue=12&author=C.+Hagemannauthor=J.+L.+Blank&title=The+UPS+and+Downs+of+MEK+Kinase+Interactions&doi=10.1016%2FS0898-6568%2801%2900220-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">The ups and downs of MEK kinase interactions</span></div><div class="casAuthors">Hagemann, Carsten; Blank, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">863-875</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 107 refs.  MEK kinases (MEKKs) comprise a family of related serine-threonine protein kinases that regulate MAP kinase (MAPK) signaling pathways leading to c-Jun N-terminal kinase (JNK) and p38 activation, induced by cellular stress (e.g., UV and γ-irradn., osmotic stress, heat shock, protein synthesis inhibitors), inflammatory cytokines [e.g., tumor necrosis factor-α (TNFα) and interleukin-1 (IL1), and G protein-coupled receptor agonists (e.g., thrombin)].  These stress-activated kinases have been implicated in apoptosis, oncogenic transformation, and inflammatory responses in various cell types.  At present, the signaling events involving MEKKs are not well understood.  This review summarizes the current knowledge concerning the regulation and function of MEKK family members, with particular emphasis on those factors capable of directly interacting with distinct MEKK isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBlpNKGd09WrVg90H21EOLACvtfcHk0li5OnxvQiXH4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXos1Cmsr0%253D&md5=9e469d562cc1610a71cb200404032931</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2FS0898-6568%2801%2900220-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0898-6568%252801%252900220-0%26sid%3Dliteratum%253Aachs%26aulast%3DHagemann%26aufirst%3DC.%26aulast%3DBlank%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520UPS%2520and%2520Downs%2520of%2520MEK%2520Kinase%2520Interactions%26jtitle%3DCell.%2520Signalling%26date%3D2001%26volume%3D13%26issue%3D12%26spage%3D863%26epage%3D875%26doi%3D10.1016%2FS0898-6568%2801%2900220-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciombor, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekaii-Saab, T.</span></span> <span> </span><span class="NLM_article-title">Selumetinib for the Treatment of Cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.982275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1517%2F13543784.2015.982275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25385055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=111-123&issue=1&author=K.+K.+Ciomborauthor=T.+Bekaii-Saab&title=Selumetinib+for+the+Treatment+of+Cancer&doi=10.1517%2F13543784.2015.982275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">selumetinib for the treatment of cancer</span></div><div class="casAuthors">Ciombor, Kristen Keon; Bekaii-Saab, Tanios</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-123</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: The MAPK pathway is essential for regulation of cellular proliferation, differentiation and survival.  Multiple human cancers have demonstrated activation of Raf-mitogen-activated kinase kinase (MEK)-extracellular signal-related kinase signaling, a hallmark of these tumors.  Efforts to inhibit various protein kinases in this pathway have led to the development of MEK inhibitors. is one such drug, functioning as an oral, selective non-ATP-competitive MEK1/2 inhibitor.  Areas covered: In this article, the authors discuss the underlying biol. of MEK inhibition and its rationale in cancer treatment.  Furthermore, the authors summarize the clin. development of selumetinib in various tumor types, from initial Phase I studies to randomized Phase II studies, both as monotherapy or in combination with other chemotherapeutics.  Expert opinion: Given the frequency of activated MAPK signaling in multiple tumor types, the potent MEK inhibitor selumetinib had strong preclin. and early clin. rationale, particularly in those tumors harboring KRAS or BRAF mutations.  While efficacy signals have been seen in various tumor types treated with selumetinib, better biomarkers are needed to select patients most likely to respond favorably to this agent.  Furthermore, combinatorial therapy with selumetinib and other targeted agents can likely be optimized to maximize the antitumor effect of inhibiting RAS/MAPK signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzukRIrAMzm7Vg90H21EOLACvtfcHk0li5OnxvQiXH4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCls7rL&md5=7f1a1a192f5c0f22cddda91dc21c753b</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.982275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.982275%26sid%3Dliteratum%253Aachs%26aulast%3DCiombor%26aufirst%3DK.%2BK.%26aulast%3DBekaii-Saab%26aufirst%3DT.%26atitle%3DSelumetinib%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26issue%3D1%26spage%3D111%26epage%3D123%26doi%3D10.1517%2F13543784.2015.982275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sill, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaker, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcguire, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotmensch, J.</span></span> <span> </span><span class="NLM_article-title">A Phase II Evaluation of Selumetinib (AZD6244, ARRY-142886), a Selective MEK-1/2 Inhibitor in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ygyno.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25887099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslGitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2015&pages=30-35&issue=1&author=R.+L.+Colemanauthor=M.+W.+Sillauthor=P.+H.+Thakerauthor=D.+P.+Benderauthor=D.+Streetauthor=W.+Mcguireauthor=C.+M.+Johnstonauthor=J.+Rotmensch&title=A+Phase+II+Evaluation+of+Selumetinib+%28AZD6244%2C+ARRY-142886%29%2C+a+Selective+MEK-1%2F2+Inhibitor+in+the+Treatment+of+Recurrent+or+Persistent+Endometrial+Cancer%3A+An+NRG+Oncology%2FGynecologic+Oncology+Group+Study&doi=10.1016%2Fj.ygyno.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study</span></div><div class="casAuthors">Coleman, Robert L.; Sill, Michael W.; Thaker, Premal H.; Bender, David P.; Street, Daron; McGuire, William P.; Johnston, Carolyn M.; Rotmensch, Jacob</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-35</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Activation of the mitogen activated protein kinase pathway plays a pivotal role in cell proliferation and is frequently activated in endometrial cancer.  We sought to evaluate the efficacy/safety of selumetinib, a selective MEK-1/2 inhibitor in women with recurrent endometrial cancer.This was a phase II, single-arm, open-label study evaluating response and 6-mo event-free survival (EFS) as primary endpoints.  Eligible patients had measurable disease, 1-2 prior cytotoxic regimens, and performance status 0-2.  Selumetinib 75 mg PO BID was administered daily until progression or intolerance.  One cycle was 28 days.Fifty-four patients were enrolled; 2 were excluded due to improper pre-study treatment (1) and never treated (1), leaving 52 evaluable for efficacy/safety.  Median age was 62; histol. included endometrioid (58%), serous (17%) and mixed (23%).  Seventeen patients (33%) had 2 prior cytotoxic regimens.  The median no. of cycles administered was 2 (1-34).  Three (6%) patients had objective response (1 CR, 2 PR); 13 had SD as best response.  The proportion of patients with 6-mo EFS was 12%.  Median EFS, progression-free and overall survival was 2.1, 2.3, and 8.5 mo, resp.  Drug-attributed grade 3/4 adverse events were obsd. (≥ 5%) were fatigue (15%), anemia (10%), pain (10%), extremity edema (8%), and dyspnea (6%).  There was 1 grade 4 infection (renal), 1 grade 4 anemia, and 1 death due to hemorrhage (rectum).Selumetinib was tolerable in this population but did not meet pre-trial specifications for clin. efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvnX9fLy0Bw7Vg90H21EOLACvtfcHk0lhElIUBXrvn0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslGitbs%253D&md5=2736b28e137c79ec23cffb3ff05d4782</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DSill%26aufirst%3DM.%2BW.%26aulast%3DThaker%26aufirst%3DP.%2BH.%26aulast%3DBender%26aufirst%3DD.%2BP.%26aulast%3DStreet%26aufirst%3DD.%26aulast%3DMcguire%26aufirst%3DW.%26aulast%3DJohnston%26aufirst%3DC.%2BM.%26aulast%3DRotmensch%26aufirst%3DJ.%26atitle%3DA%2520Phase%2520II%2520Evaluation%2520of%2520Selumetinib%2520%2528AZD6244%252C%2520ARRY-142886%2529%252C%2520a%2520Selective%2520MEK-1%252F2%2520Inhibitor%2520in%2520the%2520Treatment%2520of%2520Recurrent%2520or%2520Persistent%2520Endometrial%2520Cancer%253A%2520An%2520NRG%2520Oncology%252FGynecologic%2520Oncology%2520Group%2520Study%26jtitle%3DGynecol.%2520Oncol.%26date%3D2015%26volume%3D138%26issue%3D1%26spage%3D30%26epage%3D35%26doi%3D10.1016%2Fj.ygyno.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arozarena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellbrock, C.</span></span> <span> </span><span class="NLM_article-title">Combination of MEK and Src Inhibition Suppresses Melanoma Cell Growth and Invasion</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1038/onc.2012.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fonc.2012.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22310287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFCq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=86-96&issue=1&author=J.+Fergusonauthor=I.+Arozarenaauthor=M.+Ehrhardtauthor=C.+Wellbrock&title=Combination+of+MEK+and+Src+Inhibition+Suppresses+Melanoma+Cell+Growth+and+Invasion&doi=10.1038%2Fonc.2012.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion</span></div><div class="casAuthors">Ferguson, J.; Arozarena, I.; Ehrhardt, M.; Wellbrock, C.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-96</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The RAS-RAF-MEK-ERK pathway is deregulated in over 90% of malignant melanomas, and targeting MEK as a central kinase of this pathway is currently tested in clin. trials.  However, dose-limiting side effects are obsd., and MEK inhibitors that sufficiently reduce ERK activation in patients show a low clin. response.  Apart from dose limitations, a reason for the low response to MEK targeting drugs is thought to be the upregulation of counteracting signalling cascades as a direct response to MEK inhibition.  Therefore, understanding the biol. of melanoma cells and the effects of MEK inhibition on these cells will help to identify new combinatorial approaches that are more potent and allow for lower concns. of the drug being used.  We have discovered that in melanoma cells MEK inhibition by selumetinib (AZD6244, ARRY-142886) or PD184352, while efficiently suppressing proliferation, stimulates increased invasiveness.  Inhibition of MEK suppresses actin-cortex contraction and increases integrin-mediated adhesion.  Most importantly, and surprisingly, MEK inhibition results in a significant increase in matrix metalloproteases (MMP)-2 and membrane-type 1-MMP expression.  All together, MEK inhibition in melanoma cells induces a mesenchymal' phenotype that is characterised by protease-driven invasion.  This mode of invasion is dependent on integrin-mediated adhesion, and because SRC kinases are the main regulators of this process, the SRC kinase inhibitor, saracatinib (AZD0530), completely abolished the MEK inhibitor-induced invasion.  Moreover, the combination of saracatinib and selumetinib effectively suppressed the growth and invasion of melanoma cells in a 3D environment, suggesting that combined inhibition of MEK and SRC is a promising approach to improve the efficacy of targeting the ERK/MAP kinase pathway in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4HItW1RDTErVg90H21EOLACvtfcHk0lhElIUBXrvn0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFCq&md5=d95e45d305f634cd19ea354fb8546871</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.25%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DJ.%26aulast%3DArozarena%26aufirst%3DI.%26aulast%3DEhrhardt%26aufirst%3DM.%26aulast%3DWellbrock%26aufirst%3DC.%26atitle%3DCombination%2520of%2520MEK%2520and%2520Src%2520Inhibition%2520Suppresses%2520Melanoma%2520Cell%2520Growth%2520and%2520Invasion%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26issue%3D1%26spage%3D86%26epage%3D96%26doi%3D10.1038%2Fonc.2012.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Evaluation of Acridine Derivatives as Multi-Target Src and Mek Kinase Inhibitors for Anti-Tumor Treatment</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2015.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=26707846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKju7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=261-269&issue=2&author=Z.+Cuiauthor=X.+Liauthor=L.+Liauthor=B.+Zhangauthor=C.+Gaoauthor=Y.+Chenauthor=C.+Tanauthor=H.+Liuauthor=W.+Xieauthor=T.+Yangauthor=Y.+Jiang&title=Design%2C+Synthesis+and+Evaluation+of+Acridine+Derivatives+as+Multi-Target+Src+and+Mek+Kinase+Inhibitors+for+Anti-Tumor+Treatment&doi=10.1016%2Fj.bmc.2015.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment</span></div><div class="casAuthors">Cui, Zhishan; Li, Xi; Li, Lulu; Zhang, Bin; Gao, Chunmei; Chen, Yuzong; Tan, Chunyan; Liu, Hongxia; Xie, Weiyi; Yang, Ti; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">261-269</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Clin. studies have shown enhanced anticancer effects of combined inhibition of Src and MEK kinases.  Development of multi-target drugs against Src and MEK is of potential therapeutic advantage against cancers.  As a follow-up of our previous studies, and by using mol. docking method, we designed and synthesized a new series of 9-anilinoacridines contg. phenyl-urea moieties as potential novel dual Src and MEK inhibitors.  The anti-proliferative assays against K562 and HepG-2 tumor cells showed that most of the derivs. displayed good cytotoxicity in vitro.  In particular, kinase inhibition assays showed that compd. 8m inhibited Src (59.67%) and MEK (43.23%) at 10 μM, and displayed moderate inhibitory activity against ERK and AKT, the downstream effectors of both Src and MEK.  Moreover, compd. 8m was found to induce K562 cells apoptosis.  Structure-activity relationships of these derivs. were analyzed.  Our study suggested that acridine scaffold, particularly compd. 8m, is of potential interest for developing novel multi-target Src and MEK kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL1R3KFWycz7Vg90H21EOLACvtfcHk0lj4Ujiqyiz4Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKju7%252FJ&md5=27d5f1427be1e73781816f5e6a046da9</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Evaluation%2520of%2520Acridine%2520Derivatives%2520as%2520Multi-Target%2520Src%2520and%2520Mek%2520Kinase%2520Inhibitors%2520for%2520Anti-Tumor%2520Treatment%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D2%26spage%3D261%26epage%3D269%26doi%3D10.1016%2Fj.bmc.2015.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Recognition of C-Src Via the Imatinib-Binding Conformation</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1022</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2008.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.chembiol.2008.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18940662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KmsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1015-1022&issue=10&author=A.+C.+Darauthor=M.+S.+Lopezauthor=K.+M.+Shokat&title=Small+Molecule+Recognition+of+C-Src+Via+the+Imatinib-Binding+Conformation&doi=10.1016%2Fj.chembiol.2008.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation</span></div><div class="casAuthors">Dar, Arvin C.; Lopez, Michael S.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The cancer drug, Imatinib, is a selective Abl kinase inhibitor that does not inhibit the closely related kinase c-Src.  This one drug and its ability to selectively inhibit Abl over c-Src has been a guiding principle in virtually all kinase drug discovery efforts in the last 15 years.  A prominent hypothesis explaining the selectivity of Imatinib is that Abl has an intrinsic ability to adopt an inactive conformation (termed DFG-out), whereas c-Src appears to pay a high intrinsic energetic penalty for adopting this conformation, effectively excluding Imatinib from its ATP pocket.  This explanation of the difference in binding affinity of Imatinib for Abl vs. c-Src makes the striking prediction that it would not be possible to design an inhibitor that binds to the DFG-out conformation of c-Src with high affinity.  The authors report the discovery of a series of such inhibitors.  The authors use structure-activity relationships and x-ray crystallog. to confirm the authors' findings.  These studies suggest that small mols. are capable of inducing the generally unfavorable DFG-out conformation in c-Src.  Structural comparison between c-Src in complex with these inhibitors allows the authors to speculate on the differential selectivity of Imatinib for c-Src and Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgbxnfmxtR-LVg90H21EOLACvtfcHk0lj4Ujiqyiz4Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KmsrfP&md5=f1047f4a56359511939164a3c2604cb6</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2008.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2008.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DLopez%26aufirst%3DM.%2BS.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DSmall%2520Molecule%2520Recognition%2520of%2520C-Src%2520Via%2520the%2520Imatinib-Binding%2520Conformation%26jtitle%3DChem.%2520Biol.%26date%3D2008%26volume%3D15%26issue%3D10%26spage%3D1015%26epage%3D1022%26doi%3D10.1016%2Fj.chembiol.2008.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J. J.</span></span> <span> </span><span class="NLM_article-title">Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1021/jm0608107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0608107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=409-424&issue=3&author=J.+J.+Liao&title=Molecular+Recognition+of+Protein+Kinase+Binding+Pockets+for+Design+of+Potent+and+Selective+Kinase+Inhibitors&doi=10.1021%2Fjm0608107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many kinase inhibitors have failed in preclin. or clin. development because of the lack of such selectivity that induces intolerable side effects, mostly because the catalytic cleft is highly conserved in sequence and conformation.  Systematic anal. of the crystal structures of protein kinases can offer insight into the design of highly selective kinase inhibitors to overcome these effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroDTl2SBUfbbVg90H21EOLACvtfcHk0lj4Ujiqyiz4Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D&md5=77542d3ba589bd834a0d2b97a24eea05</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fjm0608107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608107%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.%26atitle%3DMolecular%2520Recognition%2520of%2520Protein%2520Kinase%2520Binding%2520Pockets%2520for%2520Design%2520of%2520Potent%2520and%2520Selective%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D3%26spage%3D409%26epage%3D424%26doi%3D10.1021%2Fjm0608107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hare, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriaux, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramoorthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snodgrass, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commodore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span> <span> </span><span class="NLM_article-title">AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ccr.2009.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19878872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&issue=5&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.+S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+Pan-BCR-ABL+Inhibitor+for+Chronic+Myeloid+Leukemia%2C+Potently+Inhibits+the+T315I+Mutant+and+Overcomes+Mutation-Based+Resistance&doi=10.1016%2Fj.ccr.2009.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span></div><div class="casAuthors">O'Hare, Thomas; Shakespeare, William C.; Zhu, Xiaotian; Eide, Christopher A.; Rivera, Victor M.; Wang, Frank; Adrian, Lauren T.; Zhou, Tianjun; Huang, Wei-Sheng; Xu, Qihong; Metcalf, Chester A., III; Tyner, Jeffrey W.; Loriaux, Marc M.; Corbin, Amie S.; Wardwell, Scott; Ning, Yaoyu; Keats, Jeffrey A.; Wang, Yihan; Sundaramoorthi, Raji; Thomas, Mathew; Zhou, Dong; Snodgrass, Joseph; Commodore, Lois; Sawyer, Tomi K.; Dalgarno, David C.; Deininger, Michael W. N.; Druker, Brian J.; Clackson, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">401-412</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib.  Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compd. mutants selected on sequential inhibitor therapy remain major clin. challenges.  We report design and preclin. evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants.  AP24534 inhibited all tested BCR-ABL mutants in cellular and biochem. assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.  Our work supports clin. evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3g7ZYNXwLbVg90H21EOLACvtfcHk0lgrDTZUfAN53Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFKltb3N&md5=62a383734fc345b97647ba71aa7aee04</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520Pan-BCR-ABL%2520Inhibitor%2520for%2520Chronic%2520Myeloid%2520Leukemia%252C%2520Potently%2520Inhibits%2520the%2520T315I%2520Mutant%2520and%2520Overcomes%2520Mutation-Based%2520Resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26issue%3D5%26spage%3D401%26epage%3D412%26doi%3D10.1016%2Fj.ccr.2009.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staab, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmanová, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hawari, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisiela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wsol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maser, E.</span></span> <span> </span><span class="NLM_article-title">Studies on Reduction of S-Nitrosoglutathione by Human Carbonyl Reductases 1 and 3</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2011.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.cbi.2011.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21256830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFaisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2011&pages=95-103&issue=1&author=C.+A.+Staabauthor=T.+Hartmanov%C3%A1author=Y.+El-Hawariauthor=B.+Ebertauthor=M.+Kisielaauthor=V.+Wsolauthor=H.+J.+Martinauthor=E.+Maser&title=Studies+on+Reduction+of+S-Nitrosoglutathione+by+Human+Carbonyl+Reductases+1+and+3&doi=10.1016%2Fj.cbi.2011.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3</span></div><div class="casAuthors">Staab, Claudia A.; Hartmanova, Tereza; El-Hawari, Yasser; Ebert, Bettina; Kisiela, Michael; Wsol, Vladimir; Martin, Hans-Joerg; Maser, Edmund</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">95-103</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Human carbonyl reductases 1 and 3 (CBR1 and CBR3) are monomeric NADPH-dependent enzymes of the short-chain dehydrogenase/reductase superfamily.  Despite 72% identity in primary structure they exhibit substantial differences in substrate specificity.  Recently, the endogenous low mol. wt. S-nitrosothiol S-nitrosoglutathione (GSNO) has been added to the broad substrate spectrum of CBR1.  The current study initially addressed whether CBR3 could equally reduce GSNO which was not the case.  Neither the introduction of residues which contribute to glutathione binding in CBR1, i.e. K106Q and S97V/D98A, nor the exchange C143S, which prevents a theor. disulfide bond with C227 in CBR3, could engender activity towards GSNO.  However, exchanging amino acids 236-244 in CBR3 to correspond to CBR1 was sufficient to engender catalytic activity towards GSNO.  Catalytic efficiency was further improved by the exchanges Q142M, C143S, P230W and H270S.  Hence, the same residues previously reported as important for redn. of carbonyl compds. appear to be key to CBR1-mediated redn. of GSNO.  Furthermore, for CBR1-mediated redn. of GSNO, considerable substrate inhibition at concns. >5 K m was obsd.  Treatment of CBR1 with GSNO followed by removal of low mol. wt. compds. decreased the GSNO reducing activity, suggesting a covalent modification.  Treatment with dithiothreitol, but not with ascorbic acid, could rescue the activity, indicating S-glutathionylation rather than S-nitrosation as the underlying mechanism.  As C227 has previously been identified as the reactive cysteine in CBR1, the variant CBR1 C227S was generated, which, in comparison to the wild-type protein, displayed a similar k cat, but a 30-fold higher K m, and did not show substrate inhibition.  Collectively, the results clearly argue for a physiol. role of CBR1, but not for CBR3, in GSNO redn. and thus ultimately in regulation of NO signaling.  Furthermore, at higher concns., GSNO appears to work as a suicide inhibitor for CBR1, probably through glutathionylation of C227.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Vd97BSeEd7Vg90H21EOLACvtfcHk0lgrDTZUfAN53Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFaisLw%253D&md5=697b17c7e676aa0b081d6a2afc29d87e</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2011.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2011.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DStaab%26aufirst%3DC.%2BA.%26aulast%3DHartmanov%25C3%25A1%26aufirst%3DT.%26aulast%3DEl-Hawari%26aufirst%3DY.%26aulast%3DEbert%26aufirst%3DB.%26aulast%3DKisiela%26aufirst%3DM.%26aulast%3DWsol%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DH.%2BJ.%26aulast%3DMaser%26aufirst%3DE.%26atitle%3DStudies%2520on%2520Reduction%2520of%2520S-Nitrosoglutathione%2520by%2520Human%2520Carbonyl%2520Reductases%25201%2520and%25203%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2011%26volume%3D191%26issue%3D1%26spage%3D95%26epage%3D103%26doi%3D10.1016%2Fj.cbi.2011.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranjitkar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maly, D. J.</span></span> <span> </span><span class="NLM_article-title">Affinity Reagents That Target a Specific Inactive Form of Protein Kinases</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.chembiol.2010.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20189109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1WksLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=195-206&issue=2&author=P.+Ranjitkarauthor=A.+M.+Brockauthor=D.+J.+Maly&title=Affinity+Reagents+That+Target+a+Specific+Inactive+Form+of+Protein+Kinases&doi=10.1016%2Fj.chembiol.2010.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Affinity reagents that target a specific inactive form of protein kinases</span></div><div class="casAuthors">Ranjitkar, Pratistha; Brock, Amanda M.; Maly, Dustin J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A no. of small-mol. inhibitors have been developed that target the catalytic domains of protein kinases that are not in an active conformation.  An inactive form that has been obsd. in several kinases is the DFG-out conformation.  This conformation is characterized by an almost 180° rotation of the conserved Asp-Phe-Gly (DFG) motif in the ATP-binding cleft relative to the active form.  However, the sequence and structural determinants that allow a kinase to stably adopt the DFG-out conformation are not known.  Here, we characterize a series of inhibitors based on a general pharmacophore for this inactive form.  We demonstrate that modified versions of these inhibitors can be used to study the thermodn. and kinetics of ligand binding to DFG-out-adopting kinases and for enriching these kinases from complex protein mixts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5wAdraHMJRLVg90H21EOLACvtfcHk0lj3n-pOYxCGXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1WksLo%253D&md5=63d0140c2cb16eb8cf8b4e4052b57013</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DRanjitkar%26aufirst%3DP.%26aulast%3DBrock%26aufirst%3DA.%2BM.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26atitle%3DAffinity%2520Reagents%2520That%2520Target%2520a%2520Specific%2520Inactive%2520Form%2520of%2520Protein%2520Kinases%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26issue%3D2%26spage%3D195%26epage%3D206%26doi%3D10.1016%2Fj.chembiol.2010.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S. A.</span></span> <span> </span><span class="NLM_article-title">Estrogen Receptor and Breast Cancer</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1006/scbi.2001.0389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1006%2Fscbi.2001.0389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11562176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmvVGgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=339-352&issue=5&author=S.+Sommerauthor=S.+A.+Fuqua&title=Estrogen+Receptor+and+Breast+Cancer&doi=10.1006%2Fscbi.2001.0389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor and breast cancer</span></div><div class="casAuthors">Sommer, Stephanie; Fuqua, Suzanne A. W.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">339-352</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review.  Breast cancer, the most common malignancy in women, was already known to be assocd. with the steroid hormone estrogen more than a century ago.  The discovery of the estrogen receptor (ER) provided not only a powerful predictive and prognostic marker, but also an efficient target for the treatment of hormone-dependent breast cancer with antiestrogens.  In this paper the authors will sketch the important role of ER in the development, progression, and treatment of the disease, which is complicated by the receptor's interaction with co-regulatory proteins, its cross-talk with other signal transduction pathways, and its involvement in the development of antiestrogen resistance.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosLN8VQ1UX_bVg90H21EOLACvtfcHk0lj3n-pOYxCGXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmvVGgtro%253D&md5=6681648d7604b4c3c3404e6782888818</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1006%2Fscbi.2001.0389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fscbi.2001.0389%26sid%3Dliteratum%253Aachs%26aulast%3DSommer%26aufirst%3DS.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%26atitle%3DEstrogen%2520Receptor%2520and%2520Breast%2520Cancer%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2001%26volume%3D11%26issue%3D5%26spage%3D339%26epage%3D352%26doi%3D10.1006%2Fscbi.2001.0389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D. J.</span></span> <span> </span><span class="NLM_article-title">Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7471</span>– <span class="NLM_lpage">7478</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-1070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1158%2F1078-0432.CCR-09-1070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20008847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGgur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=7471-7478&issue=24&author=L.+M.+Ellisauthor=D.+J.+Hicklin&title=Resistance+to+Targeted+Therapies%3A+Refining+Anticancer+Therapy+in+the+Era+of+Molecular+Oncology&doi=10.1158%2F1078-0432.CCR-09-1070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology</span></div><div class="casAuthors">Ellis, Lee M.; Hicklin, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7471-7478</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The advent of targeted therapy for treatment of human cancers has added significantly to our armamentarium as we strive to prolong patient survival while minimizing toxicity.  In cancers driven by a dominant oncogene, targeted therapies have led to remarkable improvements in response and survival, whereas in others the outcome has been more modest.  One key aspect toward realizing the potential of targeted therapies is a better understanding of the intrinsic or acquired resistance mechanisms that limit their efficacy.  The articles in this CCR Focus provide insights into mol. mechanisms of resistance to targeted therapy.  Recent discoveries of the mol. pathways that mediate intrinsic resistance to targeted therapy have led to the identification of predictive biomarkers that allow for better patient selection for front line treatment.  Equally important, the identification of mechanisms of acquired resistance following front line therapy has led to the discovery of novel agents that overcome these resistance mechanisms.  Improving the efficacy of targeted therapies in the future will require expanding our understanding of resistance mechanisms, the development of new generations of rationally designed targeted agents, and translating this information to the clinic to select patients for appropriate therapy. (Clin Cancer Res 2009;15(24):7471-8).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriS0Jdxl1tIrVg90H21EOLACvtfcHk0lj3n-pOYxCGXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGgur3E&md5=e439319776b37225d3b6b6d7062753c1</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1070%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DL.%2BM.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26atitle%3DResistance%2520to%2520Targeted%2520Therapies%253A%2520Refining%2520Anticancer%2520Therapy%2520in%2520the%2520Era%2520of%2520Molecular%2520Oncology%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26issue%3D24%26spage%3D7471%26epage%3D7478%26doi%3D10.1158%2F1078-0432.CCR-09-1070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fratto, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imperatori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincenzi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, G.</span></span> <span> </span><span class="NLM_article-title">New Perspectives: Role of Sunitinib in Breast Cancer</span>. <i>Clin. Ter.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21717054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC3MnksFGhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2011&pages=251-257&issue=3&author=M.+E.+Frattoauthor=M.+Imperatoriauthor=B.+Vincenziauthor=F.+Tomaoauthor=D.+Santiniauthor=G.+Tonini&title=New+Perspectives%3A+Role+of+Sunitinib+in+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">New perspectives: role of Sunitinib in breast cancer</span></div><div class="casAuthors">Fratto M E; Imperatori M; Vincenzi B; Tomao F; Santini D; Tonini G</div><div class="citationInfo"><span class="NLM_cas:title">La Clinica terapeutica</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">251-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sunitinib malate (SU11248) is a multitarget oral tyrosine kinase receptor (RTKs) inhibitor which was approved by FDA in renal cells carcinoma (RCC) and imatinib-resistant or imatinib-intollerant gastro-intestinal stromal tumour (GIST).  Sunitinib is able to inhibit RTKs such as receptors for platelet-derived growth factor (PDGF-Rα and β) and for vascular endothelial growth factor (VEGFRs).  It is able to inhibit KIT receptor, colony stimulating factor type 1 receptor (CSF-1R), glial cell line neutrophic factor receptor (RET), fms-like tyrosine kinase receptor-3 (FLT-3 or CD135), signal transducer and activator of transcription 3 (STAT3) and AKT (protein kinase B) in tumour cells.  Many Sunitinib targets play important roles in growth and survival of human breast cancer (BC).  The "rationale" of Sunitinib in BC (with or without others antiagiogenetic therapy) is its ability to block simultaneously intracellular portion of RTKs inhibiting many downstream signals.  We overviewed the most relevant studies concerning Sunitinib in metastatic BC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtkJeUsPHMgOvW160gIxP_fW6udTcc2eZ9jUVvT6WPnLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnksFGhsw%253D%253D&md5=eef9a27b4e853f725fad134dfd9ec055</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFratto%26aufirst%3DM.%2BE.%26aulast%3DImperatori%26aufirst%3DM.%26aulast%3DVincenzi%26aufirst%3DB.%26aulast%3DTomao%26aufirst%3DF.%26aulast%3DSantini%26aufirst%3DD.%26aulast%3DTonini%26aufirst%3DG.%26atitle%3DNew%2520Perspectives%253A%2520Role%2520of%2520Sunitinib%2520in%2520Breast%2520Cancer%26jtitle%3DClin.%2520Ter.%26date%3D2011%26volume%3D162%26issue%3D3%26spage%3D251%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinszanto, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyle, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oseni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargnoli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">Experimental Treatment of Estrogen Receptor (ER) Positive Breast Cancer with Tamoxifen and Brivanib Alaninate, a VEGFR-2/FGFR-1 Kinase Inhibitor: A Potential Clinical Application of Angiogenesis Inhibitors</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1537</span>– <span class="NLM_lpage">1553</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2010.02.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejca.2010.02.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20303261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslersrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=1537-1553&issue=9&author=R.+R.+Patelauthor=S.+Senguptaauthor=H.+R.+Kimauthor=A.+J.+Kleinszantoauthor=J.+R.+Pyleauthor=F.+Zhuauthor=T.+Liauthor=E.+A.+Rossauthor=S.+Oseniauthor=J.+Fargnoliauthor=V.+C.+Jordan&title=Experimental+Treatment+of+Estrogen+Receptor+%28ER%29+Positive+Breast+Cancer+with+Tamoxifen+and+Brivanib+Alaninate%2C+a+VEGFR-2%2FFGFR-1+Kinase+Inhibitor%3A+A+Potential+Clinical+Application+of+Angiogenesis+Inhibitors&doi=10.1016%2Fj.ejca.2010.02.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors</span></div><div class="casAuthors">Patel, Roshani R.; Sengupta, Surojeet; Kim, Helen R.; Klein-Szanto, Andres J.; Pyle, Jennifer R.; Zhu, Fang; Li, Tianyu; Ross, Eric A.; Oseni, Salewa; Fargnoli, Joseph; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1537-1553</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Purpose: Tamoxifen, a selective estrogen receptor modulator (SERM), and brivanib alaninate, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, are two target specific agents that result in a substantial decrease in tumor growth when given alone.  Tamoxifen activates SERM stimulated breast and endometrial tumor growth.  Tamoxifen and brivanib alaninate have side-effects that can affect therapeutic outcomes.  The primary goal of the current study was to evaluate the therapeutic effects of lower doses of both agents when given in combination to mice with SERM sensitive, estrogen stimulated tumor xenografts (MCF-7 E2 tumors).  Expts. were conducted to evaluate the response of SERM stimulated breast (MCF-7 Tam, MCF-7 Ral) and endometrial tumors (EnCa 101) to demonstrate the activity of brivanib alaninate in SERM resistant models.  Exptl. design: In the current study, tumor xenografts were minced and bi-transplanted into the mammary fat pads of athymic, ovariectomized mice.  Preliminary expts. were conducted to det. an effective oral dose of tamoxifen and brivanib alaninate that had minimal effect on tumor growth.  Doses of 125 μg of tamoxifen and 0.05 mg/g of brivanib alaninate were evaluated.  An expt. was designed to evaluate the effect of the two agents together when started at the time of tumor implantation.  An addnl. expt. was done in which tumors were already established and then treated, to obtain enough tumor tissue for mol. anal.  Results: Brivanib alaninate was effective at inhibiting tumor growth in SERM sensitive (MCF-7 E2) and SERM stimulated (EnCa 101, MCF-7 Ral, MCF-7 Tam) models.  The effect of the low dose drug combination as an anti-tumor strategy for SERM sensitive (MCF-7 E2) in early treatment was as effective as higher doses of either drug used alone.  In established tumors, the combination is successful at decreasing tumor growth, while neither agent alone is effective.  Mol. anal. revealed a decreased phosphorylation of VEGFR-2 in tumors that were treated with brivanib alaninate and an increase in VEGFA transcription to compensate for the blockade of VEGFR-2 by increasing the transcription of VEGFA.  Tamoxifen increases the phosphorylation of VEGFR-2 and this effect is abrogated by brivanib alaninate.  There was also increased necrosis in tumors treated with brivanib alaninate.  Conclusion: Historically, tamoxifen has a role in blocking angiogenesis as well as the blockade of the ER.  Tamoxifen and a low dose of an angiogenesis inhibitor, brivanib alaninate, can potentially be combined not only to maximise therapeutic efficacy but also to retard SERM resistant tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofVr791Q6E_7Vg90H21EOLACvtfcHk0liF3bLjR6ZZGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslersrc%253D&md5=7e9196684220a65879aefa14b1ca5e67</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2010.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2010.02.018%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DR.%2BR.%26aulast%3DSengupta%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DKleinszanto%26aufirst%3DA.%2BJ.%26aulast%3DPyle%26aufirst%3DJ.%2BR.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DRoss%26aufirst%3DE.%2BA.%26aulast%3DOseni%26aufirst%3DS.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DExperimental%2520Treatment%2520of%2520Estrogen%2520Receptor%2520%2528ER%2529%2520Positive%2520Breast%2520Cancer%2520with%2520Tamoxifen%2520and%2520Brivanib%2520Alaninate%252C%2520a%2520VEGFR-2%252FFGFR-1%2520Kinase%2520Inhibitor%253A%2520A%2520Potential%2520Clinical%2520Application%2520of%2520Angiogenesis%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26issue%3D9%26spage%3D1537%26epage%3D1553%26doi%3D10.1016%2Fj.ejca.2010.02.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of 2,3-Diaryl Isoquinolinone Derivatives as Anti-Breast Cancer Agents Targeting ERα and VEGFR-2</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2133</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.03.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmcl.2014.03.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24721727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvVSnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2129-2133&issue=9&author=Z.+Tangauthor=S.+Niuauthor=F.+Liuauthor=K.+Laoauthor=J.+Miaoauthor=J.+Jiauthor=X.+Wangauthor=M.+Yanauthor=L.+Zhangauthor=Q.+Youauthor=H.+Xiaoauthor=H.+Xiang&title=Synthesis+and+Biological+Evaluation+of+2%2C3-Diaryl+Isoquinolinone+Derivatives+as+Anti-Breast+Cancer+Agents+Targeting+ER%CE%B1+and+VEGFR-2&doi=10.1016%2Fj.bmcl.2014.03.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2</span></div><div class="casAuthors">Tang, Zhichao; Niu, Shaoxiong; Liu, Fei; Lao, Kejing; Miao, Jingshan; Ji, Jinzi; Wang, Xiang; Yan, Ming; Zhang, Luyong; You, Qidong; Xiao, Hong; Xiang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2129-2133</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The estrogen receptor α is recognized as important pharmaceutical target for breast cancer therapy, and vascular endothelial growth factor receptors (VEGFRs) play important roles in tumor angiogenesis including breast cancer.  A series of 2,3-diaryl isoquinolinone derivs. were designed and synthesized targeting both estrogen receptor α (ERα) and VEGFR-2.  Bioactivity evaluation showed that compds. I, II and III exhibited significant anti-proliferative and anti-angiogenesis activities via ERα and VEGFR-2 dependent mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrej5jO0H8Cg7Vg90H21EOLACvtfcHk0liF3bLjR6ZZGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvVSnu7w%253D&md5=7317c65c33d0b516403d0b0f6ea0eaf0</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.03.042%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DNiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DLao%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYou%26aufirst%3DQ.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DXiang%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%25202%252C3-Diaryl%2520Isoquinolinone%2520Derivatives%2520as%2520Anti-Breast%2520Cancer%2520Agents%2520Targeting%2520ER%25CE%25B1%2520and%2520VEGFR-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D9%26spage%3D2129%26epage%3D2133%26doi%3D10.1016%2Fj.bmcl.2014.03.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muyaba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Evaluation of 6-Aryl-Indenoisoquinolone Derivatives Dual Targeting ERα and VEGFR-2 as Anti-Breast Cancer Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.04.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2016.04.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27176944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnslarsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2016&pages=328-339&author=Z.+Tangauthor=C.+Wuauthor=T.+Wangauthor=K.+Laoauthor=Y.+Wangauthor=L.+Liuauthor=M.+Muyabaauthor=P.+Xuauthor=C.+Heauthor=G.+Luoauthor=Z.+Qianauthor=S.+Niuauthor=L.+Wangauthor=Y.+Wangauthor=H.+Xiaoauthor=Q.+Youauthor=H.+Xiang&title=Design%2C+Synthesis+and+Evaluation+of+6-Aryl-Indenoisoquinolone+Derivatives+Dual+Targeting+ER%CE%B1+and+VEGFR-2+as+Anti-Breast+Cancer+Agents&doi=10.1016%2Fj.ejmech.2016.04.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents</span></div><div class="casAuthors">Tang, Zhichao; Wu, Chengzhe; Wang, Tianlin; Lao, Kejing; Wang, Yejun; Liu, Linyi; Muyaba, Moses; Xu, Pei; He, Conghui; Luo, Guoshun; Qian, Zhouyang; Niu, Shaoxiong; Wang, Lijun; Wang, Ying; Xiao, Hong; You, Qidong; Xiang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">328-339</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The estrogen receptors have played important roles in breast cancer development and progression.  Selective estrogen receptor modulators, such as Tamoxifen, have showed great benefits in the treatment and prevention of breast cancer.  But the disadvantages of induction of endometrial cancer and drug resistance have limited their use.  Multiple ligand which act at multiple biomol. targets may exert favorable advantages of improved efficacy with lower incidence of side effects.  In this work, we described the synthesis and evaluation of a series of 6-aryl-indenoisoquinolone derivs. as dual ERα and VEGFR-2 inhibitors.  These compds. presented good ERα binding affinity and ERα antagonistic activity, as well as potent VEGFR-2 inhibitory potency.  They also possessed excellent anti-proliferative activities against MCF-7, MDA-MB-231, Ishikawa and HUVEC cell lines.  Further investigation of selective compd. I showed that it was able to inhibit the activation of VEGFR-2 and the signaling transduction of Raf-1/MAPK/ERK pathway in MCF-7 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8cPcZlnhWCrVg90H21EOLACvtfcHk0ljY2yfsOS167A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnslarsbk%253D&md5=00cc7ead9649299f9692143a91ac01fa</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.04.029%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLao%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMuyaba%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DNiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DYou%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Evaluation%2520of%25206-Aryl-Indenoisoquinolone%2520Derivatives%2520Dual%2520Targeting%2520ER%25CE%25B1%2520and%2520VEGFR-2%2520as%2520Anti-Breast%2520Cancer%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D118%26spage%3D328%26epage%3D339%26doi%3D10.1016%2Fj.ejmech.2016.04.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cesca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bizzaro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavazzi, R.</span></span> <span> </span><span class="NLM_article-title">Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">259</span>, <span class="refDoi"> DOI: 10.3389/fonc.2013.00259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3389%2Ffonc.2013.00259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24102047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC2cfltlWguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=259&author=M.+Cescaauthor=F.+Bizzaroauthor=M.+Zucchettiauthor=R.+Giavazzi&title=Tumor+Delivery+of+Chemotherapy+Combined+with+Inhibitors+of+Angiogenesis+and+Vascular+Targeting+Agents&doi=10.3389%2Ffonc.2013.00259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents</span></div><div class="casAuthors">Cesca Marta; Bizzaro Francesca; Zucchetti Massimo; Giavazzi Raffaella</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">259</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Numerous angiogenesis-vascular targeting agents have been admitted to the ranks of cancer therapeutics; most are used in polytherapy regimens.  This review looks at recent progress and our own preclinical experience in combining angiogenesis inhibitors, mainly acting on VEGF/VEGFR pathways, and vascular targeting agents with conventional chemotherapy, discussing the factors that determine the outcome of these treatments.  Molecular and morphological modifications of the tumor microenvironment associated with drug distribution and activity are reviewed.  Modalities to improve drug delivery and strategies for optimizing combination therapy are examined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0YQxum6hoa77NkxioyDXTfW6udTcc2eZ1rJCDQcEnrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfltlWguw%253D%253D&md5=18d08759e91e0baf80e6471b7514a115</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00259%26sid%3Dliteratum%253Aachs%26aulast%3DCesca%26aufirst%3DM.%26aulast%3DBizzaro%26aufirst%3DF.%26aulast%3DZucchetti%26aufirst%3DM.%26aulast%3DGiavazzi%26aufirst%3DR.%26atitle%3DTumor%2520Delivery%2520of%2520Chemotherapy%2520Combined%2520with%2520Inhibitors%2520of%2520Angiogenesis%2520and%2520Vascular%2520Targeting%2520Agents%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D259%26doi%3D10.3389%2Ffonc.2013.00259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, D. J.</span></span> <span> </span><span class="NLM_article-title">Combination of Antiangiogenesis with Chemotherapy for More Effective Cancer Treatment</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3670</span>– <span class="NLM_lpage">3684</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-08-0715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1158%2F1535-7163.MCT-08-0715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19074844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2iurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=3670-3684&issue=12&author=J.+Maauthor=D.+J.+Waxman&title=Combination+of+Antiangiogenesis+with+Chemotherapy+for+More+Effective+Cancer+Treatment&doi=10.1158%2F1535-7163.MCT-08-0715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of antiangiogenesis with chemotherapy for more effective cancer treatment</span></div><div class="casAuthors">Ma, Jie; Waxman, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3670-3684</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is a hallmark of tumor development and metastasis and is now a validated target for cancer treatment.  However, the survival benefits of antiangiogenic drugs have thus far been rather modest, stimulating interest in developing more effective ways to combine antiangiogenic drugs with established chemotherapies.  This review discusses recent progress and emerging challenges in this field; interactions between antiangiogenic drugs and conventional chemotherapeutic agents are examd., and strategies for the optimization of combination therapies are discussed.  Antiangiogenic drugs such as the anti-vascular endothelial growth factor antibody bevacizumab can induce a functional normalization of the tumor vasculature that is transient and can potentiate the activity of coadministered chemoradiotherapies.  However, chronic angiogenesis inhibition typically reduces tumor uptake of coadministered chemotherapeutics, indicating a need to explore new approaches, including intermittent treatment schedules and provascular strategies to increase chemotherapeutic drug exposure.  In cases where antiangiogenesis-induced tumor cell starvation augments the intrinsic cytotoxic effects of a conventional chemotherapeutic drug, combination therapy may increase antitumor activity despite a decrease in cytotoxic drug exposure.  As new angiogenesis inhibitors enter the clinic, reliable surrogate markers are needed to monitor the progress of antiangiogenic therapies and to identify responsive patients.  New targets for antiangiogenesis continue to be discovered, increasing the opportunities to interdict tumor angiogenesis and circumvent resistance mechanisms that may emerge with chronic use of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFuKsU4WlEmLVg90H21EOLACvtfcHk0lhOzWVOWfbYEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2iurnN&md5=187b65f71cce4580756ae01973ca758f</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0715%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWaxman%26aufirst%3DD.%2BJ.%26atitle%3DCombination%2520of%2520Antiangiogenesis%2520with%2520Chemotherapy%2520for%2520More%2520Effective%2520Cancer%2520Treatment%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26issue%3D12%26spage%3D3670%26epage%3D3684%26doi%3D10.1158%2F1535-7163.MCT-08-0715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolhouse, M. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chasetopping, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dan, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornell, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilesmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenfell, B. T.</span></span> <span> </span><span class="NLM_article-title">Dynamics of the 2001 UK Foot and Mouth Epidemic: Stochastic Dispersal in a Heterogeneous Landscape</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>294</i></span> (<span class="NLM_issue">5543</span>),  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1126/science.1065973</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1126%2Fscience.1065973" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11679661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotVCitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2001&pages=813-817&issue=5543&author=M.+J.+Keelingauthor=M.+E.+J.+Woolhouseauthor=D.+J.+Shawauthor=L.+Matthewsauthor=M.+Chasetoppingauthor=T.+H.+Danauthor=S.+J.+Cornellauthor=J.+Kappeyauthor=J.+Wilesmithauthor=B.+T.+Grenfell&title=Dynamics+of+the+2001+UK+Foot+and+Mouth+Epidemic%3A+Stochastic+Dispersal+in+a+Heterogeneous+Landscape&doi=10.1126%2Fscience.1065973"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamics of the 2001 UK foot and mouth epidemic: stochastic dispersal in a heterogeneous landscape</span></div><div class="casAuthors">Keeling, Matt J.; Woolhouse, Mark E. J.; Shaw, Darren J.; Matthews, Louise; Chase-Topping, Margo; Haydon, Dan T.; Cornell, Stephen J.; Kappey, Jens; Wilesmith, John; Grenfell, Bryan T.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">5543</span>),
    <span class="NLM_cas:pages">813-817</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Foot-and-mouth is one of the world's most economically important livestock diseases.  We developed an individual farm-based stochastic model of the current UK epidemic.  The fine grain of the epidemiol. data reveals the infection dynamics at an unusually high spatiotemporal resoln.  We show that the spatial distribution, size, and species compn. of farms all influence the obsd. pattern and regional variability of outbreaks.  The other key dynamical component is long-tailed stochastic dispersal of infection, combining frequent local movements with occasional long jumps.  We assess the history and possible duration of the epidemic, the performance of control strategies, and general implications for disease dynamics in space and time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxMSVeBiOn9rVg90H21EOLACvtfcHk0lhOzWVOWfbYEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotVCitLc%253D&md5=13431effc8446e7c510108765616f51b</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1126%2Fscience.1065973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1065973%26sid%3Dliteratum%253Aachs%26aulast%3DKeeling%26aufirst%3DM.%2BJ.%26aulast%3DWoolhouse%26aufirst%3DM.%2BE.%2BJ.%26aulast%3DShaw%26aufirst%3DD.%2BJ.%26aulast%3DMatthews%26aufirst%3DL.%26aulast%3DChasetopping%26aufirst%3DM.%26aulast%3DDan%26aufirst%3DT.%2BH.%26aulast%3DCornell%26aufirst%3DS.%2BJ.%26aulast%3DKappey%26aufirst%3DJ.%26aulast%3DWilesmith%26aufirst%3DJ.%26aulast%3DGrenfell%26aufirst%3DB.%2BT.%26atitle%3DDynamics%2520of%2520the%25202001%2520UK%2520Foot%2520and%2520Mouth%2520Epidemic%253A%2520Stochastic%2520Dispersal%2520in%2520a%2520Heterogeneous%2520Landscape%26jtitle%3DScience%26date%3D2001%26volume%3D294%26issue%3D5543%26spage%3D813%26epage%3D817%26doi%3D10.1126%2Fscience.1065973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnke, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisliuk, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. T.</span></span> <span> </span><span class="NLM_article-title">Novel 5-Substituted, 2,4-Diaminofuro[2,3-D]Pyrimidines as Multireceptor Tyrosine Kinase and Dihydrofolate Reductase Inhibitors with Antiangiogenic and Antitumor Activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5475</span>– <span class="NLM_lpage">5491</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.04.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2005.04.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16039863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnslyjsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=5475-5491&issue=18&author=A.+Gangjeeauthor=Y.+Zengauthor=M.+Ihnatauthor=L.+A.+Warnkeauthor=D.+W.+Greenauthor=R.+L.+Kisliukauthor=F.+T.+Lin&title=Novel+5-Substituted%2C+2%2C4-Diaminofuro%5B2%2C3-D%5DPyrimidines+as+Multireceptor+Tyrosine+Kinase+and+Dihydrofolate+Reductase+Inhibitors+with+Antiangiogenic+and+Antitumor+Activity&doi=10.1016%2Fj.bmc.2005.04.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity</span></div><div class="casAuthors">Gangjee, Aleem; Zeng, Yibin; Ihnat, Michael; Warnke, Linda A.; Green, Dixy W.; Kisliuk, Roy L.; Lin, Fu-Tyan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5475-5491</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent evidence suggests that combination therapy of cancer with receptor tyrosine kinase (RTK) inhibitors, which are usually cytostatic, with conventional chemotherapeutic agents, which are usually cytotoxic, provide an improved treatment option.  The authors have designed, synthesized, and evaluated a series of novel 2,4-diamino-5-substituted furo[2,3-d]pyrimidines with RTK and dihydrofolate reductase (DHFR) inhibitory activity in single mols., as potential cytostatic and cytotoxic agents with antitumor activity.  These compds. were synthesized from 2,4-diamino-5-chloromethyl furo[2,3-d]pyrimidine and aryl Me ketones using the Wittig reaction to afford the C-8-C-9 unsatd. analogs followed by catalytic redn. to the corresponding satd. compds.  The satd. and unsatd. C-8-C-9 bridged compds. were evaluated as inhibitors of vascular endothelial growth factor receptor (VEGFR-2, Flk, KDR), epidermal growth factor receptor, and platelet-derived growth factor receptor-β (PDGFR-β).  Selected analogs were also evaluated as antiangiogenic agents in the chicken embryo chorioallantoic membrane (CAM) assay.  The compds. were also evaluated as inhibitors of human (h) DHFR and Toxoplasma gondii (tg) DHFR.  In each evaluation, a known std. compd. was used as a comparison.  Of the compds. evaluated, compd. (I) was as potent as the std. compds. against VEGFR-2 and PDGFR-β, showing dual inhibitory activity against RTK.  This analog was also highly effective in the CAM assay.  A second analog (II) also demonstrated dual VEGFR-2 and PDGFR-β inhibitory activity as well as potent antiangiogenic activity in the CAM assay.  Four addnl. analogs were also effective against PDGFR-β and in the CAM assay.  An unsatd. C-8-C-9 moiety was necessary for RTK inhibitory activity.  Compd. I also showed inhibitory activity against hDHFR and tgDHFR, illustrating the multitarget inhibitory potential of these analogs.  The biol. activity of these analogs also suggests the necessity of an unsatd. C-8-C-9 bridge for dual RTK and DHFR inhibitory activity.  Compds. II and I were also evaluated in a B16 melanoma mouse model and were found to be more active as antitumor agents than methotrexate.  In addn., both II and I were also active in decreasing lung metastases in a mouse model of B16 melanomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMnkWI8AhnqrVg90H21EOLACvtfcHk0lhOzWVOWfbYEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnslyjsro%253D&md5=055bcb04b9e0e6d6d10e3e65cab44ccd</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.04.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.04.087%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DWarnke%26aufirst%3DL.%2BA.%26aulast%3DGreen%26aufirst%3DD.%2BW.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26aulast%3DLin%26aufirst%3DF.%2BT.%26atitle%3DNovel%25205-Substituted%252C%25202%252C4-Diaminofuro%255B2%252C3-D%255DPyrimidines%2520as%2520Multireceptor%2520Tyrosine%2520Kinase%2520and%2520Dihydrofolate%2520Reductase%2520Inhibitors%2520with%2520Antiangiogenic%2520and%2520Antitumor%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26issue%3D18%26spage%3D5475%26epage%3D5491%26doi%3D10.1016%2Fj.bmc.2005.04.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnke, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cody, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queener, S. F.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and X-Ray Crystal Structures of 2,4-Diaminofuro[2,3-D]Pyrimidines as Multireceptor Tyrosine Kinase and Dihydrofolate Reductase Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">7324</span>– <span class="NLM_lpage">7336</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.08.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2009.08.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19748785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ais7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=7324-7336&issue=20&author=A.+Gangjeeauthor=W.+Liauthor=L.+Linauthor=Y.+Zengauthor=M.+Ihnatauthor=L.+A.+Warnkeauthor=D.+W.+Greenauthor=V.+Codyauthor=J.+Paceauthor=S.+F.+Queener&title=Design%2C+Synthesis%2C+and+X-Ray+Crystal+Structures+of+2%2C4-Diaminofuro%5B2%2C3-D%5DPyrimidines+as+Multireceptor+Tyrosine+Kinase+and+Dihydrofolate+Reductase+Inhibitors&doi=10.1016%2Fj.bmc.2009.08.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors</span></div><div class="casAuthors">Gangjee, Aleem; Li, Wei; Lin, Lu; Zeng, Yibin; Ihnat, Michael; Warnke, Linda A.; Green, Dixy W.; Cody, Vivian; Pace, Jim; Queener, Sherry F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7324-7336</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To optimize dual receptor tyrosine kinase (RTK) and dihydrofolate reductase (DHFR) inhibition, the E- and Z-isomers of 5-[2-(2-methoxyphenyl)prop-1-en-1-yl]furo[2,3-d]pyrimidine-2,4-diamines (I and II) were sepd. by HPLC and the X-ray crystal structures (2.0 and 1.4 Å, resp.) with mouse DHFR and NADPH as well as with human DHFR (1.5 Å) were detd.  The E- and Z-isomers adopt different binding modes when bound to mouse DHFR.  A series of 2,4-diaminofuro[2,3-d]pyrimidines were designed and synthesized using the X-ray crystal structures of I and II with DHFR to increase their DHFR inhibitory activity.  Wittig reactions of appropriate 2-methoxyphenyl ketones with 2,4-diamino-6-chloromethyl furo[2,3-d]pyrimidine afforded the C8-C9 unsatd. compds. and catalytic redn. gave the satd.  Homologation of the C9-Me analog maintains DHFR inhibitory activity.  In addn., inhibition of EGFR and PDGFR-β were discovered for satd. C9-homologated analogs that were absent in the satd. C9-Me analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ_LlusYVT1rVg90H21EOLACvtfcHk0lg9zocjWmI-rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ais7nK&md5=d19a1a3934dff94664163160733695a4</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.08.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.08.044%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DWarnke%26aufirst%3DL.%2BA.%26aulast%3DGreen%26aufirst%3DD.%2BW.%26aulast%3DCody%26aufirst%3DV.%26aulast%3DPace%26aufirst%3DJ.%26aulast%3DQueener%26aufirst%3DS.%2BF.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520X-Ray%2520Crystal%2520Structures%2520of%25202%252C4-Diaminofuro%255B2%252C3-D%255DPyrimidines%2520as%2520Multireceptor%2520Tyrosine%2520Kinase%2520and%2520Dihydrofolate%2520Reductase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26issue%3D20%26spage%3D7324%26epage%3D7336%26doi%3D10.1016%2Fj.bmc.2009.08.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risinger, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Discovery of Water Soluble Microtubule Targeting Agents That Bind to the Colchicine Site on Tubulin and Circumvent Pgp Mediated Resistance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8116</span>– <span class="NLM_lpage">8128</span>, <span class="refDoi"> DOI: 10.1021/jm101010n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101010n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlens77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8116-8128&issue=22&author=A.+Gangjeeauthor=Y.+Zhaoauthor=L.+Linauthor=S.+Raghavanauthor=E.+G.+Robertsauthor=A.+L.+Risingerauthor=E.+Hamelauthor=S.+L.+Mooberry&title=Synthesis+and+Discovery+of+Water+Soluble+Microtubule+Targeting+Agents+That+Bind+to+the+Colchicine+Site+on+Tubulin+and+Circumvent+Pgp+Mediated+Resistance&doi=10.1021%2Fjm101010n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Discovery of Water-Soluble Microtubule Targeting Agents that Bind to the Colchicine Site on Tubulin and Circumvent Pgp Mediated Resistance</span></div><div class="casAuthors">Gangjee, Aleem; Zhao, Ying; Lin, Lu; Raghavan, Sudhir; Roberts, Elizabeth G.; Risinger, April L.; Hamel, Ernest; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8116-8128</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two classes of mols. were designed and synthesized based on a 6-CH3 cyclopenta[d]pyrimidine scaffold and a pyrrolo[2,3-d]pyrimidine scaffold.  The pyrrolo[2,3-d]pyrimidines were synthesized by reacting Et 2-cyano-4,4-diethoxybutanoate and acetamidine, which in turn was chlorinated and reacted with the appropriate anilines to afford pyrrolopyrimidines I (R = Me, H).  The cyclopenta[d]pyrimidines were obtained from 3-methyladapic acid, followed by reaction with acetamidine to afford the cyclopenta[d]pyrimidine scaffold.  Chlorination and reaction with appropriate anilines afforded cyclopentapyrimidines, II (R = 4-MeO, 3-MeO, 2-MeO, H).  Pyrimidines I (R = Me)(III) and II (R = 4-MeO)(IV) had potent antiproliferative activities in the nanomolar range.  Cyclopentapyrimidine IV is significantly more potent than pyrrolopyrimidine III.  Mechanistic studies showed that III and IV cause loss of cellular microtubules, inhibit the polymn. of purified tubulin, and inhibit colchicine binding.  Modeling studies show interactions of these compds. within the colchicine site.  The identification of these new inhibitors that can also overcome clin. relevant mechanisms of drug resistance provides new scaffolds for colchicine site agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc5L05H-4Yj7Vg90H21EOLACvtfcHk0lg9zocjWmI-rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlens77M&md5=8a0bd50260d069a868762389f24d5399</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Fjm101010n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101010n%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DE.%2BG.%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DSynthesis%2520and%2520Discovery%2520of%2520Water%2520Soluble%2520Microtubule%2520Targeting%2520Agents%2520That%2520Bind%2520to%2520the%2520Colchicine%2520Site%2520on%2520Tubulin%2520and%2520Circumvent%2520Pgp%2520Mediated%2520Resistance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D22%26spage%3D8116%26epage%3D8128%26doi%3D10.1021%2Fjm101010n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Activities of (R)- and (S)-N-(4-Methoxy-Phenyl)-N,2,6-Trimethyl-6,7-Dihydro-5h-Cyclopenta[D]Pyrimidin-4-Aminium Chloride as Potent Cytotoxic Antitubulin Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6151</span>– <span class="NLM_lpage">6155</span>, <span class="refDoi"> DOI: 10.1021/jm2007722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVWlsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6151-6155&issue=17&author=A.+Gangjeeauthor=Y.+Zhaoauthor=E.+Hamelauthor=C.+Westbrookauthor=S.+L.+Mooberry&title=Synthesis+and+Biological+Activities+of+%28R%29-+and+%28S%29-N-%284-Methoxy-Phenyl%29-N%2C2%2C6-Trimethyl-6%2C7-Dihydro-5h-Cyclopenta%5BD%5DPyrimidin-4-Aminium+Chloride+as+Potent+Cytotoxic+Antitubulin+Agents&doi=10.1021%2Fjm2007722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium Chloride as Potent Cytotoxic Antitubulin Agents</span></div><div class="casAuthors">Gangjee, Aleem; Zhao, Ying; Hamel, Ernest; Westbrook, Cara; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6151-6155</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(R,S)-I is a potent antimitotic compd.  (R)-I·HCl and (S)-I·HCl were synthesized from (R)- and (S)-3-methyladipic acid.  Both enantiomers were potent inhibitors of cell proliferation and caused cellular microtubule loss and mitotic arrest.  They inhibited purified tubulin assembly and the binding of [3H]colchicine to tubulin, with (S)-I being about twice as potent.  Cytotoxicity against 60 tumor cell lines, however, indicated that the (S)-isomer was 10- to 88-fold more potent than the (R)-isomer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreGCYMkdEFH7Vg90H21EOLACvtfcHk0lgksgCQ3U6Z5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVWlsrk%253D&md5=7a657154e09ef127e57dc648936bcd2b</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Fjm2007722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007722%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DWestbrook%26aufirst%3DC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DSynthesis%2520and%2520Biological%2520Activities%2520of%2520%2528R%2529-%2520and%2520%2528S%2529-N-%25284-Methoxy-Phenyl%2529-N%252C2%252C6-Trimethyl-6%252C7-Dihydro-5h-Cyclopenta%255BD%255DPyrimidin-4-Aminium%2520Chloride%2520as%2520Potent%2520Cytotoxic%2520Antitubulin%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D17%26spage%3D6151%26epage%3D6155%26doi%3D10.1021%2Fjm2007722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span> <span> </span><span class="NLM_article-title">Structure Activity-Relationship and in Vitro and in Vivo Evaluation of the Potent Cytotoxic Anti-Microtubule Agent N-(4-Methoxyphenyl)-N,2,6-Trimethyl-6,7-Dihydro-5h-Cyclopenta[D]Pyrimidin-4-Aminium Chloride and Its Analogues as Antitumor Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6829</span>– <span class="NLM_lpage">6844</span>, <span class="refDoi"> DOI: 10.1021/jm400639z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400639z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOltrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6829-6844&issue=17&author=A.+Gangjeeauthor=Y.+Zhaoauthor=S.+Raghavanauthor=C.+Rohenaauthor=S.+L.+Mooberryauthor=E.+Hamel&title=Structure+Activity-Relationship+and+in+Vitro+and+in+Vivo+Evaluation+of+the+Potent+Cytotoxic+Anti-Microtubule+Agent+N-%284-Methoxyphenyl%29-N%2C2%2C6-Trimethyl-6%2C7-Dihydro-5h-Cyclopenta%5BD%5DPyrimidin-4-Aminium+Chloride+and+Its+Analogues+as+Antitumor+Agents&doi=10.1021%2Fjm400639z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship and in Vitro and in Vivo Evaluation of the Potent Cytotoxic Anti-microtubule Agent N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium Chloride and Its Analogues As Antitumor Agents</span></div><div class="casAuthors">Gangjee, Aleem; Zhao, Ying; Raghavan, Sudhir; Rohena, Cristina C.; Mooberry, Susan L.; Hamel, Ernest</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6829-6844</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 21 substituted cyclopenta-[d]-pyrimidines were synthesized as an extension of authors' discovery of the parent compd. (±)-I·HCl as an anti-microtubule agent.  The structure-activity relationship indicates that the N-Me and a 4N-methoxy groups appear important for potent activity.  In addn., the 6-substituent in the parent analog is not necessary for activity.  The most potent compd. II·HCl was a one to two digit nanomolar inhibitor of most tumor cell proliferations and was up to 7-fold more potent than the parent compd. (±)-I·HCl.  In addn., II·HCl inhibited cancer cell proliferation regardless of Pgp or βIII-tubulin status, both of which are known to cause clin. resistance to several anti-tubulin agents.  In vivo efficacy of II·HCl was demonstrated against a triple neg. breast cancer xenograft mouse model.  Compd. II·HCl is water-sol. and easily synthesized and serves as a lead compd. for further preclin. evaluation as an antitumor agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy75OVrLjyoLVg90H21EOLACvtfcHk0lgksgCQ3U6Z5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOltrjL&md5=22222571e2f3a3a9ddb0b25bdbfc7236</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Fjm400639z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400639z%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DRohena%26aufirst%3DC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DHamel%26aufirst%3DE.%26atitle%3DStructure%2520Activity-Relationship%2520and%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Evaluation%2520of%2520the%2520Potent%2520Cytotoxic%2520Anti-Microtubule%2520Agent%2520N-%25284-Methoxyphenyl%2529-N%252C2%252C6-Trimethyl-6%252C7-Dihydro-5h-Cyclopenta%255BD%255DPyrimidin-4-Aminium%2520Chloride%2520and%2520Its%2520Analogues%2520as%2520Antitumor%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D17%26spage%3D6829%26epage%3D6844%26doi%3D10.1021%2Fjm400639z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey-Downs, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dybdal-Hargreaves, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohena, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">The Design and Discovery of Water Soluble 4-Substituted-2,6-Dimethylfuro[2,3-D]Pyrimidines as Multitargeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3753</span>– <span class="NLM_lpage">3772</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2014.04.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24890652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=3753-3772&issue=14&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=J.+E.+Thorpeauthor=B.+C.+Dischauthor=A.+Bastianauthor=L.+C.+Bailey-Downsauthor=N.+F.+Dybdal-Hargreavesauthor=C.+C.+Rohenaauthor=E.+Hamelauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+Design+and+Discovery+of+Water+Soluble+4-Substituted-2%2C6-Dimethylfuro%5B2%2C3-D%5DPyrimidines+as+Multitargeted+Receptor+Tyrosine+Kinase+Inhibitors+and+Microtubule+Targeting+Antitumor+Agents&doi=10.1016%2Fj.bmc.2014.04.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents</span></div><div class="casAuthors">Zhang, Xin; Raghavan, Sudhir; Ihnat, Michael; Thorpe, Jessica E.; Disch, Bryan C.; Bastian, Anja; Bailey-Downs, Lora C.; Dybdal-Hargreaves, Nicholas F.; Rohena, Cristina C.; Hamel, Ernest; Mooberry, Susan L.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3753-3772</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The design, synthesis and biol. evaluations of fourteen 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines are reported.  Four compds. inhibit vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor β (PDGFR-β), and target tubulin leading to cytotoxicity.  Compd. I has nanomolar potency, comparable to sunitinib and semaxinib, against tumor cell lines overexpressing VEGFR-2 and PDGFR-β.  Further, I binds at the colchicine site on tubulin, depolymerizes cellular microtubules and inhibits purified tubulin assembly and overcomes both βIII-tubulin and P-glycoprotein-mediated drug resistance, and initiates mitotic arrest leading to apoptosis.  In vivo, its HCl salt, I·HCl, reduced tumor size and vascularity in xenograft and allograft murine models and was superior to docetaxel and sunitinib, without overt toxicity.  Thus I·HCl affords potential combination chemotherapy in a single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz0a4q7mfRm7Vg90H21EOLACvtfcHk0lgksgCQ3U6Z5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCns78%253D&md5=b35cd4ed7f053ea14d7ef5ee33828b38</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DDisch%26aufirst%3DB.%2BC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DBailey-Downs%26aufirst%3DL.%2BC.%26aulast%3DDybdal-Hargreaves%26aufirst%3DN.%2BF.%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520Design%2520and%2520Discovery%2520of%2520Water%2520Soluble%25204-Substituted-2%252C6-Dimethylfuro%255B2%252C3-D%255DPyrimidines%2520as%2520Multitargeted%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%2520and%2520Microtubule%2520Targeting%2520Antitumor%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26issue%3D14%26spage%3D3753%26epage%3D3772%26doi%3D10.1016%2Fj.bmc.2014.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zammiello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">The Design, Synthesis and Biological Evaluation of Conformationally Restricted 4-Substituted-2,6-Dimethylfuro[2,3-D]Pyrimidines as Multi-Targeted Receptor Tyrosine Kinase and Microtubule Inhibitors as Potential Antitumor Agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2423</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2015.03.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25882519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1Gmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2408-2423&issue=10&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=E.+Hamelauthor=C.+Zammielloauthor=A.+Bastianauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+Design%2C+Synthesis+and+Biological+Evaluation+of+Conformationally+Restricted+4-Substituted-2%2C6-Dimethylfuro%5B2%2C3-D%5DPyrimidines+as+Multi-Targeted+Receptor+Tyrosine+Kinase+and+Microtubule+Inhibitors+as+Potential+Antitumor+Agents&doi=10.1016%2Fj.bmc.2015.03.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents</span></div><div class="casAuthors">Zhang, Xin; Raghavan, Sudhir; Ihnat, Michael; Hamel, Ernest; Zammiello, Cynthia; Bastian, Anja; Mooberry, Susan L.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2408-2423</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of eleven conformationally restricted, 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines was designed to explore the bioactive conformation required for dual inhibition of microtubule assembly and receptor tyrosine kinases (RTKs), and their biol. activities are reported.  All three rotatable single bonds in the lead compd. were sequentially restricted to address the role of each in SAR for microtubule and RTK inhibitory effects.  Several compds. showed microtubule depolymg. activity comparable to or better than the lead compd., some with nanomolar EC50 values.  One compd. had no effect on microtubules, others showed potent RTK inhibition with nanomolar IC50s.  These compds. confirm that the bioactive conformation for RTK inhibition is different from that for tubulin inhibition.  A tetrahydroquinoline analog showed the most potent dual tubulin inhibitors (i.e., tubulin polymn. inhibitors, microtubule-disrupting agents) and RTK inhibitory activities [i.e., low nanomolar inhibition of epidermal growth factor receptors (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived growth factor receptor β (PDGFR-β)].  The tetrahydroquinoline analog has highly potent activity against many NCI cancer cell lines, including several chemo-resistant cell lines, and could serve as a lead for further preclin. studies.  The synthesis of the target compds. was achieved by a reaction of 4-chloro-2,6-dimethylfuro[2,3-d]pyrimidine with amine derivs., such as benzenamine derivs., benzofuranamine derivs., tetrahydroquinoline derivs., indole derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3IUVQLu9YarVg90H21EOLACvtfcHk0lgw8EYpf9wVtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1Gmu78%253D&md5=4a6d65424606155db3ab4ec5751ad213</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.061%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DZammiello%26aufirst%3DC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520Design%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Conformationally%2520Restricted%25204-Substituted-2%252C6-Dimethylfuro%255B2%252C3-D%255DPyrimidines%2520as%2520Multi-Targeted%2520Receptor%2520Tyrosine%2520Kinase%2520and%2520Microtubule%2520Inhibitors%2520as%2520Potential%2520Antitumor%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26issue%3D10%26spage%3D2408%26epage%3D2423%26doi%3D10.1016%2Fj.bmc.2015.03.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derrick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehrani, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruotolo, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span> <span> </span><span class="NLM_article-title">Structure-Mechanism-Based Engineering of Chemical Regulators Targeting Distinct Pathological Factors in Alzheimer’s Disease</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13115</span>– <span class="NLM_lpage">13127</span>, <span class="refDoi"> DOI: 10.1038/ncomms13115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fncomms13115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27734843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSitb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13115-13127&author=M.+W.+Beckauthor=J.+S.+Derrickauthor=R.+A.+Kerrauthor=S.+B.+Ohauthor=W.+J.+Choauthor=S.+J.+Leeauthor=Y.+Jiauthor=J.+Hanauthor=Z.+A.+Tehraniauthor=N.+Suhauthor=S.+Kimauthor=S.+D.+Larsenauthor=K.+S.+Kimauthor=J.+Y.+Leeauthor=B.+T.+Ruotoloauthor=M.+H.+Lim&title=Structure-Mechanism-Based+Engineering+of+Chemical+Regulators+Targeting+Distinct+Pathological+Factors+in+Alzheimer%E2%80%99s+Disease&doi=10.1038%2Fncomms13115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-mechanism-based engineering of chemical regulators targeting distinct pathological factors in Alzheimer's disease</span></div><div class="casAuthors">Beck, Michael W.; Derrick, Jeffrey S.; Kerr, Richard A.; Oh, Shin Bi; Cho, Woo Jong; Lee, Shin Jung C.; Ji, Yonghwan; Han, Jiyeon; Tehrani, Zahra Aliakbar; Suh, Nayoung; Kim, Sujeong; Larsen, Scott D.; Kim, Kwang S.; Lee, Joo-Yong; Ruotolo, Brandon T.; Lim, Mi Hee</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13115</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The absence of effective therapeutics against Alzheimer's disease (AD) is a result of the limited understanding of its multifaceted etiol.  Because of the lack of chem. tools to identify pathol. factors, investigations into AD pathogenesis have also been insubstantial.  Here we report chem. regulators that demonstrate distinct specificity towards targets linked to AD pathol., including metals, amyloid-β (Aβ), metal-Aβ, reactive oxygen species, and free org. radicals.  We obtained these chem. regulators through a rational structure-mechanism-based design strategy.  We performed structural variations of small mols. for fine-tuning their electronic properties, such as ionization potentials and mechanistic pathways for reactivity towards different targets.  We established in vitro and/or in vivo efficacies of the regulators for modulating their targets' reactivities, ameliorating toxicity, reducing amyloid pathol., and improving cognitive deficits.  Our chem. tools show promise for deciphering AD pathogenesis and discovering effective drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4uSKnEfAtfrVg90H21EOLACvtfcHk0lhWBwA6vp3nrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSitb3P&md5=c92d00abedc661f493e496ba21f20879</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1038%2Fncomms13115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13115%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DM.%2BW.%26aulast%3DDerrick%26aufirst%3DJ.%2BS.%26aulast%3DKerr%26aufirst%3DR.%2BA.%26aulast%3DOh%26aufirst%3DS.%2BB.%26aulast%3DCho%26aufirst%3DW.%2BJ.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DTehrani%26aufirst%3DZ.%2BA.%26aulast%3DSuh%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLarsen%26aufirst%3DS.%2BD.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DRuotolo%26aufirst%3DB.%2BT.%26aulast%3DLim%26aufirst%3DM.%2BH.%26atitle%3DStructure-Mechanism-Based%2520Engineering%2520of%2520Chemical%2520Regulators%2520Targeting%2520Distinct%2520Pathological%2520Factors%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13115%26epage%3D13127%26doi%3D10.1038%2Fncomms13115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derrick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earnest, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozbil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korshavn, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merino, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shearer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruotolo, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span> <span> </span><span class="NLM_article-title">A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates: In Vitro and in Vivo Efficacy and Molecular Mechanisms</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">14785</span>– <span class="NLM_lpage">14797</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b10043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b10043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVGmt7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=14785-14797&issue=46&author=J.+S.+Derrickauthor=R.+A.+Kerrauthor=Y.+Namauthor=S.+B.+Ohauthor=H.+J.+Leeauthor=K.+G.+Earnestauthor=N.+Suhauthor=K.+L.+Peckauthor=M.+Ozbilauthor=K.+J.+Korshavnauthor=A.+Ramamoorthyauthor=R.+Prabhakarauthor=E.+J.+Merinoauthor=J.+Shearerauthor=J.+Y.+Leeauthor=B.+T.+Ruotoloauthor=M.+H.+Lim&title=A+Redox-Active%2C+Compact+Molecule+for+Cross-Linking+Amyloidogenic+Peptides+into+Nontoxic%2C+Off-Pathway+Aggregates%3A+In+Vitro+and+in+Vivo+Efficacy+and+Molecular+Mechanisms&doi=10.1021%2Fjacs.5b10043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates: In Vitro and In Vivo Efficacy and Molecular Mechanisms</span></div><div class="casAuthors">Derrick, Jeffrey S.; Kerr, Richard A.; Nam, Younwoo; Oh, Shin Bi; Lee, Hyuck Jin; Earnest, Kaylin G.; Suh, Nayoung; Peck, Kristy L.; Ozbil, Mehmet; Korshavn, Kyle J.; Ramamoorthy, Ayyalusamy; Prabhakar, Rajeev; Merino, Edward J.; Shearer, Jason; Lee, Joo-Yong; Ruotolo, Brandon T.; Lim, Mi Hee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">14785-14797</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chem. reagents targeting and controlling amyloidogenic peptides have received much attention for helping identify their roles in the pathogenesis of protein-misfolding disorders.  Herein, the authors report a novel strategy for redirecting amyloidogenic peptides into nontoxic, off-pathway aggregates, which utilizes redox properties of a small mol. (DMPD, N,N-dimethyl-p-phenylenediamine) to trigger covalent adduct formation with the peptide.  In addn., for the first time, biochem., biophys., and mol. dynamics simulation studies have been performed to demonstrate a mechanistic understanding for such an interaction between a small mol. (DMPD) and amyloid-β (Aβ) and its subsequent anti-amyloidogenic activity, which, upon its transformation, generates ligand-peptide adducts via primary amine-dependent intramol. crosslinking correlated with structural compaction.  Furthermore, in vivo efficacy of DMPD toward amyloid pathol. and cognitive impairment was evaluated employing 5xFAD mice of Alzheimer's disease (AD).  Such a small mol. (DMPD) is indicated to noticeably reduce the overall cerebral amyloid load of sol. Aβ forms and amyloid deposits as well as significantly improve cognitive defects in the AD mouse model.  Overall, the authors' in vitro and in vivo studies of DMPD toward Aβ with the first mol.-level mechanistic investigations present the feasibility of developing new, innovative approaches that employ redox-active compds. without the structural complexity as next-generation chem. tools for amyloid management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVgBBoRUmXObVg90H21EOLACvtfcHk0lhWBwA6vp3nrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVGmt7fL&md5=f95a3cad02c9a2752ea0389e69820943</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b10043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b10043%26sid%3Dliteratum%253Aachs%26aulast%3DDerrick%26aufirst%3DJ.%2BS.%26aulast%3DKerr%26aufirst%3DR.%2BA.%26aulast%3DNam%26aufirst%3DY.%26aulast%3DOh%26aufirst%3DS.%2BB.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DEarnest%26aufirst%3DK.%2BG.%26aulast%3DSuh%26aufirst%3DN.%26aulast%3DPeck%26aufirst%3DK.%2BL.%26aulast%3DOzbil%26aufirst%3DM.%26aulast%3DKorshavn%26aufirst%3DK.%2BJ.%26aulast%3DRamamoorthy%26aufirst%3DA.%26aulast%3DPrabhakar%26aufirst%3DR.%26aulast%3DMerino%26aufirst%3DE.%2BJ.%26aulast%3DShearer%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DRuotolo%26aufirst%3DB.%2BT.%26aulast%3DLim%26aufirst%3DM.%2BH.%26atitle%3DA%2520Redox-Active%252C%2520Compact%2520Molecule%2520for%2520Cross-Linking%2520Amyloidogenic%2520Peptides%2520into%2520Nontoxic%252C%2520Off-Pathway%2520Aggregates%253A%2520In%2520Vitro%2520and%2520in%2520Vivo%2520Efficacy%2520and%2520Molecular%2520Mechanisms%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26issue%3D46%26spage%3D14785%26epage%3D14797%26doi%3D10.1021%2Fjacs.5b10043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gandini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gonzalez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaldivar-Diez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccheri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petralla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legname, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7640</span>– <span class="NLM_lpage">7656</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00610</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00610" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVChu7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7640-7656&issue=17&author=A.+Gandiniauthor=M.+Bartoliniauthor=D.+Tedescoauthor=L.+Martinez-Gonzalezauthor=C.+Rocaauthor=N.+E.+Campilloauthor=J.+Zaldivar-Diezauthor=C.+Perezauthor=G.+Zuccheriauthor=A.+Mitiauthor=A.+Feoliauthor=S.+Castellanoauthor=S.+Petrallaauthor=B.+Montiauthor=M.+Rossiauthor=F.+Modaauthor=G.+Legnameauthor=A.+Martinezauthor=M.+L.+Bolognesi&title=Tau-Centric+Multitarget+Approach+for+Alzheimer%E2%80%99s+Disease%3A+Development+of+First-in-Class+Dual+Glycogen+Synthase+Kinase+3%CE%B2+and+Tau-Aggregation+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors</span></div><div class="casAuthors">Gandini, Annachiara; Bartolini, Manuela; Tedesco, Daniele; Martinez-Gonzalez, Loreto; Roca, Carlos; Campillo, Nuria E.; Zaldivar-Diez, Josefa; Perez, Concepcion; Zuccheri, Giampaolo; Miti, Andrea; Feoli, Alessandra; Castellano, Sabrina; Petralla, Sabrina; Monti, Barbara; Rossi, Martina; Moda, Fabio; Legname, Giuseppe; Martinez, Ana; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7640-7656</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several findings propose the altered tau protein network as an important target for Alzheimer's disease (AD).  Particularly, two points of pharmacol. intervention can be envisaged: inhibition of phosphorylating tau kinase GSK-3β and tau aggregation process.  On the basis of this consideration and on the authors' interest in multitarget paradigms in AD, the authors report on the discovery of 2,4-thiazolidinedione derivs. endowed with such a profile. 28 and 30 displayed micromolar IC50 values toward GSK-3β, together with the capacity of inhibiting AcPHF6 aggregation of 60% and 80% at 10 μM, resp.  In addn., they showed PAMPA-BBB permeability, together with a suitable cellular safety profile. 30 also displayed inhibition of both K18 and full-length tau aggregations.  Finally, both compds. were able to improve cell viability in an okadaic acid-induced neurodegeneration cell model.  To the best of the authors' knowledge, 28 and 30 are the first balanced, nontoxic, dual-acting compds. hitting tau cascade at two different hubs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6bQV6XoAhyrVg90H21EOLACvtfcHk0lgRjYO8xDpoqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVChu7%252FL&md5=34b7e2f2556f3e96c768dd87fb3f0e6d</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00610%26sid%3Dliteratum%253Aachs%26aulast%3DGandini%26aufirst%3DA.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DTedesco%26aufirst%3DD.%26aulast%3DMartinez-Gonzalez%26aufirst%3DL.%26aulast%3DRoca%26aufirst%3DC.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DZaldivar-Diez%26aufirst%3DJ.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DZuccheri%26aufirst%3DG.%26aulast%3DMiti%26aufirst%3DA.%26aulast%3DFeoli%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DS.%26aulast%3DPetralla%26aufirst%3DS.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DRossi%26aufirst%3DM.%26aulast%3DModa%26aufirst%3DF.%26aulast%3DLegname%26aufirst%3DG.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DTau-Centric%2520Multitarget%2520Approach%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Development%2520of%2520First-in-Class%2520Dual%2520Glycogen%2520Synthase%2520Kinase%25203%25CE%25B2%2520and%2520Tau-Aggregation%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7640%26epage%3D7656%26doi%3D10.1021%2Facs.jmedchem.8b00610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duran-Frigola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siragusa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruppin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruciani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aloy, P.</span></span> <span> </span><span class="NLM_article-title">Detecting Similar Binding Pockets to Enable Systems Polypharmacology</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e1005522</span>, <span class="refDoi"> DOI: 10.1371/journal.pcbi.1005522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1371%2Fjournal.pcbi.1005522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28662117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1agurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=e1005522&issue=6&author=M.+Duran-Frigolaauthor=L.+Siragusaauthor=E.+Ruppinauthor=X.+Barrilauthor=G.+Crucianiauthor=P.+Aloy&title=Detecting+Similar+Binding+Pockets+to+Enable+Systems+Polypharmacology&doi=10.1371%2Fjournal.pcbi.1005522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Detecting similar binding pockets to enable systems polypharmacology</span></div><div class="casAuthors">Duran-Frigola, Miquel; Siragusa, Lydia; Ruppin, Eytan; Barril, Xavier; Cruciani, Gabriele; Aloy, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1005522/1-e1005522/18</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In the era of systems biol., multi-target pharmacol. strategies hold promise for tackling disease-related networks.  In this regard, drug promiscuity may be leveraged to interfere with multiple receptors: the so-called polypharmacol. of drugs can be anticipated by analyzing the similarity of binding sites across the proteome.  Here, we perform a pairwise comparison of 90,000 putative binding pockets detected in 3,700 proteins, and find that 23,000 pairs of proteins have at least one similar cavity that could, in principle, accommodate similar ligands.  By inspecting these pairs, we demonstrate how the detection of similar binding sites expands the space of opportunities for the rational design of drug polypharmacol.  Finally, we illustrate how to leverage these opportunities in protein-protein interaction networks related to several therapeutic classes and tumor types, and in a genome-scale metabolic model of leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrncR4y_CryxbVg90H21EOLACvtfcHk0lgRjYO8xDpoqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1agurnE&md5=568e97aa21976360c76610cdfd4dbfd7</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005522%26sid%3Dliteratum%253Aachs%26aulast%3DDuran-Frigola%26aufirst%3DM.%26aulast%3DSiragusa%26aufirst%3DL.%26aulast%3DRuppin%26aufirst%3DE.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DAloy%26aufirst%3DP.%26atitle%3DDetecting%2520Similar%2520Binding%2520Pockets%2520to%2520Enable%2520Systems%2520Polypharmacology%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D6%26spage%3De1005522%26doi%3D10.1371%2Fjournal.pcbi.1005522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">466</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.3390/molecules21040466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3390%2Fmolecules21040466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27070562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWktLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=466-477&issue=4&author=F.+Pratiauthor=A.+Cavalliauthor=M.+L.+Bolognesi&title=Navigating+the+Chemical+Space+of+Multitarget-Directed+Ligands%3A+From+Hybrids+to+Fragments+in+Alzheimer%E2%80%99s+Disease&doi=10.3390%2Fmolecules21040466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Navigating the chemical space of multitarget-directed ligands: from hybrids to fragments in Alzheimer's disease</span></div><div class="casAuthors">Prati, Federica; Cavalli, Andrea; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">466/1-466/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Multitarget drug discovery is one of the hottest topics and most active fields in the search for new mols. against Alzheimer's disease (AD).  Over the last 20 years, many promising multitarget-directed ligands (MTDLs) have been identified and developed at a pre-clin. level.  However, how to design them in a rational way remains the most fundamental challenge of medicinal chemists.  This is related to the foundational question of achieving an optimized activity towards multiple targets of interest, while preserving drug-like properties.  In this respect, large hybrid mols. and small fragments are poles apart.  In this review article, our aim is to appraise what we have accomplished in the development of both hybrid- and fragment-like mols. directed to diverse AD targets (i.e., acetylcholinesterase, NMDA receptors, metal chelation, BACE-1 and GSK-3β).  In addn., we attempt to highlight what are the persistent needs that deserve to be improved and cared for, with the ultimate goal of moving an MTDL to AD clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAXsoof4raqbVg90H21EOLACvtfcHk0lh5myzGjVs3fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWktLjI&md5=3653a0ef6b41711663e8d2f2d4ae74f6</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21040466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21040466%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DNavigating%2520the%2520Chemical%2520Space%2520of%2520Multitarget-Directed%2520Ligands%253A%2520From%2520Hybrids%2520to%2520Fragments%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26issue%3D4%26spage%3D466%26epage%3D477%26doi%3D10.3390%2Fmolecules21040466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanfar, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaddoumi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Sayed, K. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel GSK-3β Inhibitors with Potent in Vitro and in Vivo Activities and Excellent Brain Permeability Using Combined Ligand- and Structure-Based Virtual Screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">8534</span>– <span class="NLM_lpage">8545</span>, <span class="refDoi"> DOI: 10.1021/jm100941j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100941j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8534-8545&issue=24&author=M.+A.+Khanfarauthor=R.+A.+Hillauthor=A.+Kaddoumiauthor=K.+A.+El+Sayed&title=Discovery+of+Novel+GSK-3%CE%B2+Inhibitors+with+Potent+in+Vitro+and+in+Vivo+Activities+and+Excellent+Brain+Permeability+Using+Combined+Ligand-+and+Structure-Based+Virtual+Screening&doi=10.1021%2Fjm100941j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel GSK-3β Inhibitors with Potent in Vitro and in Vivo Activities and Excellent Brain Permeability Using Combined Ligand- and Structure-Based Virtual Screening</span></div><div class="casAuthors">Khanfar, Mohammad A.; Hill, Ronald A.; Kaddoumi, Amal; El Sayed, Khalid A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8534-8545</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulation of glycogen synthase kinase (GSK-3β) is implicated in the pathophysiol. of many diseases, including type-2 diabetes, stroke, Alzheimer's, and others.  A multistage virtual screening strategy designed to overcome known caveats arising from the considerable flexibility of GSK-3β yielded, from among compds. in our inhouse database and two com. databases, new GSK-3β inhibitors with novel scaffold structures.  The two most potent and selective validated hits, a 2-anilino-5-phenyl-1,3,4-oxadiazole (24) and a phenylmethylene hydantoin (28), both exhibited nanomolar affinity and selectivity over CDK2 and were potent enough for direct in vivo validation.  Both were able to cause significant increases in liver glycogen accumulation in dose-dependent fashion.  One also exhibited excellent blood-brain barrier permeability, the other adequate for a lead compd.  Analogs of the oxadiazole 24 were synthesized to exptl. corroborate or rule out ligand-bound structures arising from docking studies.  SAR results supported one docking study among a no. of alternatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonQs-nSeLYcrVg90H21EOLACvtfcHk0lh5myzGjVs3fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksb%252FF&md5=c58e912dea590063241a5a6554639009</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Fjm100941j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100941j%26sid%3Dliteratum%253Aachs%26aulast%3DKhanfar%26aufirst%3DM.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BA.%26aulast%3DKaddoumi%26aufirst%3DA.%26aulast%3DEl%2BSayed%26aufirst%3DK.%2BA.%26atitle%3DDiscovery%2520of%2520Novel%2520GSK-3%25CE%25B2%2520Inhibitors%2520with%2520Potent%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Activities%2520and%2520Excellent%2520Brain%2520Permeability%2520Using%2520Combined%2520Ligand-%2520and%2520Structure-Based%2520Virtual%2520Screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D24%26spage%3D8534%26epage%3D8545%26doi%3D10.1021%2Fjm100941j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arfeen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborti, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharatam, P. V.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of 5-Benzylidene-2-Iminothiazolidin-4-Ones as Selective GSK-3β Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.04.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2016.04.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27423119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtF2hs7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=727-736&author=M.+Arfeenauthor=S.+Bhagatauthor=R.+Patelauthor=S.+Prasadauthor=I.+Royauthor=A.+K.+Chakrabortiauthor=P.+V.+Bharatam&title=Design%2C+Synthesis+and+Biological+Evaluation+of+5-Benzylidene-2-Iminothiazolidin-4-Ones+as+Selective+GSK-3%CE%B2+Inhibitors&doi=10.1016%2Fj.ejmech.2016.04.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors</span></div><div class="casAuthors">Arfeen, Minhajul; Bhagat, Shweta; Patel, Rahul; Prasad, Shivcharan; Roy, Ipsita; Chakraborti, Asit K.; Bharatam, Prasad V.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">727-736</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, iminothiazolidin-4-one derivs. were explored as selective GSK-3β inhibitors.  Mol. docking anal. was carried to design a series of compds., which were synthesized using substituted thioureas, Et chloroacetate and benzaldehydes.  Out of the twenty five compds. synthesized during this work, the in vitro evaluation against GSK-3 led to the identification of nine compds. with activity in lower nano-molar range (2-85 nM).  Further, in vitro evaluation against CDK-2 showed five compds. to be selective towards GSK-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquv-FRHRtwRbVg90H21EOLACvtfcHk0lh5myzGjVs3fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtF2hs7vJ&md5=fae12d7afdb57bf8512a0f8fbe481056</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.04.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.04.075%26sid%3Dliteratum%253Aachs%26aulast%3DArfeen%26aufirst%3DM.%26aulast%3DBhagat%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DI.%26aulast%3DChakraborti%26aufirst%3DA.%2BK.%26aulast%3DBharatam%26aufirst%3DP.%2BV.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25205-Benzylidene-2-Iminothiazolidin-4-Ones%2520as%2520Selective%2520GSK-3%25CE%25B2%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D727%26epage%3D736%26doi%3D10.1016%2Fj.ejmech.2016.04.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, F. J.</span></span> <span> </span><span class="NLM_article-title">First Non-ATP Competitive Glycogen Synthase Kinase 3β(GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer’s Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1292</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1021/jm011020u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm011020u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFCgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1292-1299&issue=6&author=A.+Martinezauthor=M.+Alonsoauthor=A.+Castroauthor=C.+P%C3%A9rezauthor=F.+J.+Moreno&title=First+Non-ATP+Competitive+Glycogen+Synthase+Kinase+3%CE%B2%28GSK-3%CE%B2%29+Inhibitors%3A+Thiadiazolidinones+%28TDZD%29+as+Potential+Drugs+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fjm011020u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">First Non-ATP Competitive Glycogen Synthase Kinase 3β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Martinez, Ana; Alonso, Mercedes; Castro, Ana; Perez, Concepcion; Moreno, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1292-1299</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3β (GSK-3β) has a central role in Alzheimer's disease (AD).  Selective inhibitors which avoid τ hyperphosphorylation may represent an effective therapeutic approach to the pharmacotherapy of AD and other neurodegenerative disorders.  The synthesis, biol. evaluation, and SAR of some thiadiazolidinones (TDZD) as the first non-ATP competitive inhibitor of GSK-3β.  Their synthesis is based on the reactivity of sulfenyl chlorides.  In GSK-3β assays, TDZD derivs. showed IC50 values in the micromolar range, whereas in other protein kinase assays they were devoid of any inhibitory activity.  SAR studies allowed the identification of the key structural features.  Finally, a possible enzymic binding mode is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofQZkRe2BHh7Vg90H21EOLACvtfcHk0lh5myzGjVs3fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFCgu70%253D&md5=a364133d1035bee183c58ad30ac140f8</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Fjm011020u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm011020u%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DCastro%26aufirst%3DA.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DF.%2BJ.%26atitle%3DFirst%2520Non-ATP%2520Competitive%2520Glycogen%2520Synthase%2520Kinase%25203%25CE%25B2%2528GSK-3%25CE%25B2%2529%2520Inhibitors%253A%2520Thiadiazolidinones%2520%2528TDZD%2529%2520as%2520Potential%2520Drugs%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26issue%3D6%26spage%3D1292%26epage%3D1299%26doi%3D10.1021%2Fjm011020u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palomo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Muela, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Garcia, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Castillo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timchenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span> <span> </span><span class="NLM_article-title">Subtly Modulating Glycogen Synthase Kinase 3β: Allosteric Inhibitors Development and Their Potential for the Treatment of Chronic Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4983</span>– <span class="NLM_lpage">5001</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00395</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00395" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1SgurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4983-5001&issue=12&author=V.+Palomoauthor=D.+I.+P%C3%A9rezauthor=C.+Rocaauthor=C.+Andersonauthor=N.+Rodriguez-Muelaauthor=C.+P%C3%A9rezauthor=J.+A.+Morales-Garciaauthor=J.+A.+Reyesauthor=N.+E.+Campilloauthor=A.+M.+P%C3%A9rez-Castilloauthor=L.+L.+Rubinauthor=L.+Timchenkoauthor=C.+Gilauthor=A.+Martinez&title=Subtly+Modulating+Glycogen+Synthase+Kinase+3%CE%B2%3A+Allosteric+Inhibitors+Development+and+Their+Potential+for+the+Treatment+of+Chronic+Diseases&doi=10.1021%2Facs.jmedchem.7b00395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases</span></div><div class="casAuthors">Palomo, Valle; Perez, Daniel I.; Roca, Carlos; Anderson, Cara; Rodriguez-Muela, Natalia; Perez, Concepcion; Morales-Garcia, Jose A.; Reyes, Julio A.; Campillo, Nuria E.; Perez-Castillo, Ana M.; Rubin, Lee L.; Timchenko, Lubov; Gil, Carmen; Martinez, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4983-5001</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase 3β (GSK-3β) is a central target in several unmet diseases.  To increase the specificity of GSK-3β inhibitors in chronic treatments, we developed small mols. allowing subtle modulation of GSK-3β activity.  Design synthesis, structure-activity relationships, and binding mode of quinoline-3-carbohydrazide derivs. as allosteric modulators of GSK-3β are presented here.  Furthermore, we show how allosteric binders may overcome the β-catenin side effects assocd. with strong GSK-3β inhibition.  The therapeutic potential of some of these modulators has been tested in human samples from patients with congenital myotonic dystrophy type 1 (CDM1) and spinal muscular atrophy (SMA) patients.  We found that compd. I (R1 = 6-Br, R2 = Et, R3 = C11H23) improves delayed myogenesis in CDM1 myoblasts, while compds. I (R1 = H, 6-Br, R2 = Et, R3 = C11H23) have neuroprotective properties in SMA-derived cells.  These findings suggest that the allosteric modulators of GSK-3β may be used for future development of drugs for DM1, SMA, and other chronic diseases where GSK-3β inhibition exhibits therapeutic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGottlg1vBoPw7Vg90H21EOLACvtfcHk0lj4j1n9-MGgeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1SgurY%253D&md5=858ba99deb166b43a488c1141c40ff63</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00395%26sid%3Dliteratum%253Aachs%26aulast%3DPalomo%26aufirst%3DV.%26aulast%3DP%25C3%25A9rez%26aufirst%3DD.%2BI.%26aulast%3DRoca%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DC.%26aulast%3DRodriguez-Muela%26aufirst%3DN.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DMorales-Garcia%26aufirst%3DJ.%2BA.%26aulast%3DReyes%26aufirst%3DJ.%2BA.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DP%25C3%25A9rez-Castillo%26aufirst%3DA.%2BM.%26aulast%3DRubin%26aufirst%3DL.%2BL.%26aulast%3DTimchenko%26aufirst%3DL.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DSubtly%2520Modulating%2520Glycogen%2520Synthase%2520Kinase%25203%25CE%25B2%253A%2520Allosteric%2520Inhibitors%2520Development%2520and%2520Their%2520Potential%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D12%26spage%3D4983%26epage%3D5001%26doi%3D10.1021%2Facs.jmedchem.7b00395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khlistunova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biernat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span> <span> </span><span class="NLM_article-title">Rhodanine-Based Tau Aggregation Inhibitors in Cell Models of Tauopathy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">9215</span>– <span class="NLM_lpage">9219</span>, <span class="refDoi"> DOI: 10.1002/anie.200704051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fanie.200704051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BD2sjjtlSltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=9215-9219&issue=48&author=B.+Bulicauthor=M.+Pickhardtauthor=I.+Khlistunovaauthor=J.+Biernatauthor=E.-M.+Mandelkowauthor=E.+Mandelkowauthor=H.+Waldmann&title=Rhodanine-Based+Tau+Aggregation+Inhibitors+in+Cell+Models+of+Tauopathy&doi=10.1002%2Fanie.200704051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Rhodanine-based tau aggregation inhibitors in cell models of tauopathy</span></div><div class="casAuthors">Bulic Bruno; Pickhardt Marcus; Khlistunova Inna; Biernat Jacek; Mandelkow Eva-Maria; Mandelkow Eckhard; Waldmann Herbert</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">9215-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScsfK7C2PCgf6xYuD7tu2XfW6udTcc2eYeb4NJW82sT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjjtlSltg%253D%253D&md5=9948b3054bae5ce9e52d0ce3d4635788</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1002%2Fanie.200704051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200704051%26sid%3Dliteratum%253Aachs%26aulast%3DBulic%26aufirst%3DB.%26aulast%3DPickhardt%26aufirst%3DM.%26aulast%3DKhlistunova%26aufirst%3DI.%26aulast%3DBiernat%26aufirst%3DJ.%26aulast%3DMandelkow%26aufirst%3DE.-M.%26aulast%3DMandelkow%26aufirst%3DE.%26aulast%3DWaldmann%26aufirst%3DH.%26atitle%3DRhodanine-Based%2520Tau%2520Aggregation%2520Inhibitors%2520in%2520Cell%2520Models%2520of%2520Tauopathy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2007%26volume%3D46%26issue%3D48%26spage%3D9215%26epage%3D9219%26doi%3D10.1002%2Fanie.200704051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendgen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C. D.</span></span> <span> </span><span class="NLM_article-title">Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">743</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1021/jm201243p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201243p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGkt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=743-753&issue=2&author=T.+Mendgenauthor=C.+Steuerauthor=C.+D.+Klein&title=Privileged+Scaffolds+or+Promiscuous+Binders%3A+A+Comparative+Study+on+Rhodanines+and+Related+Heterocycles+in+Medicinal+Chemistry&doi=10.1021%2Fjm201243p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry</span></div><div class="casAuthors">Mendgen, Thomas; Steuer, Christian; Klein, Christian D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">743-753</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rhodanines and related five-membered heterocycles with multiple heteroatoms have recently gained a reputation of being unselective compds. that appear as "frequent hitters" in screening campaigns and therefore have little value in drug discovery.  However, this judgment appears to be based mostly on anecdotal evidence.  Having identified various rhodanines and related compds. in screening campaigns, we decided to perform a systematic study on their promiscuity.  An amt. of 163 rhodanines, hydantoins, thiohydantoins, and thiazolidinediones were synthesized and tested against several targets.  The compds. were also characterized with respect to aggregation and electrophilic reactivity, and the binding modes of rhodanines and related compds. in published x-ray cocrystal structures were analyzed.  The results indicate that the exocyclic, double bonded sulfur atom in rhodanines and thiohydantoins, in addn. to other structural features, offers a particularly high d. of interaction sites for polar interactions and hydrogen bonds.  This causes a promiscuous behavior at concns. in the "screening range" but should not be regarded as a general knockout criterion that excludes such screening hits from further development.  It is suggested that special criteria for target affinity and selectivity are applied to these classes of compds. and that their exceptional and potentially valuable biomol. binding properties are consequently exploited in a useful way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLzna8Pcz1iLVg90H21EOLACvtfcHk0lj4j1n9-MGgeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGkt7nN&md5=6a94d097f44bdbaaec9a56fd6b371521</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Fjm201243p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201243p%26sid%3Dliteratum%253Aachs%26aulast%3DMendgen%26aufirst%3DT.%26aulast%3DSteuer%26aufirst%3DC.%26aulast%3DKlein%26aufirst%3DC.%2BD.%26atitle%3DPrivileged%2520Scaffolds%2520or%2520Promiscuous%2520Binders%253A%2520A%2520Comparative%2520Study%2520on%2520Rhodanines%2520and%2520Related%2520Heterocycles%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D2%26spage%3D743%26epage%3D753%26doi%3D10.1021%2Fjm201243p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J.</span></span> <span> </span><span class="NLM_article-title">Seven Year Itch. Pan-Assay Interference Compounds (Pains) in 2017 - Utility and Limitations</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00903</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00903" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=36-44&issue=1&author=J.+B.+Baellauthor=J.+Nissink&title=Seven+Year+Itch.+Pan-Assay+Interference+Compounds+%28Pains%29+in+2017+-+Utility+and+Limitations&doi=10.1021%2Facschembio.7b00903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations</span></div><div class="casAuthors">Baell, Jonathan B.; Nissink, J. Willem M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on all necessary considerations for the appropriate use of PAINs filters formulated to process hundreds and thousands of compds. in seconds, and identify PAINS in order to exclude them from further anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocZ7E_j7zxfbVg90H21EOLACvtfcHk0lgaNotvqk6ynw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bK&md5=051115704137d6a91b8271702c619682</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00903%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DNissink%26aufirst%3DJ.%26atitle%3DSeven%2520Year%2520Itch.%2520Pan-Assay%2520Interference%2520Compounds%2520%2528Pains%2529%2520in%25202017%2520-%2520Utility%2520and%2520Limitations%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D1%26spage%3D36%26epage%3D44%26doi%3D10.1021%2Facschembio.7b00903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeanmart, S.</span></span> <span> </span><span class="NLM_article-title">Pan Assay Interference Compounds (Pains) and Other Promiscuous Compounds in Antifungal Research</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00361</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00361" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=497-503&issue=2&author=M.+Pouliotauthor=S.+Jeanmart&title=Pan+Assay+Interference+Compounds+%28Pains%29+and+Other+Promiscuous+Compounds+in+Antifungal+Research&doi=10.1021%2Facs.jmedchem.5b00361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research</span></div><div class="casAuthors">Pouliot, Martin; Jeanmart, Stephane</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">497-503</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Every week, articles disclosing new antifungal leads reported as promising starting points for optimization projects are published.  In many cases, the mechanism that accounts for their antifungal activity has not been fully elucidated.  More significantly, the detrimental impact that could result from certain embedded chem. features has been underestimated or even overlooked.  In the course of the authors' research in the agrochem. area, the authors have concluded that in many cases such leads are actually nonoptimizable because they either contain what are now recognized as pan assay interference compds. (PAINS) or other promiscuous groups.  This article is aimed at highlighting the pitfalls the authors have encountered and hopefully to steer other research groups away from them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqURFxdfKNQIbVg90H21EOLACvtfcHk0lgaNotvqk6ynw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7rE&md5=af11fcafd47de435fcc5fdf05080023a</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00361%26sid%3Dliteratum%253Aachs%26aulast%3DPouliot%26aufirst%3DM.%26aulast%3DJeanmart%26aufirst%3DS.%26atitle%3DPan%2520Assay%2520Interference%2520Compounds%2520%2528Pains%2529%2520and%2520Other%2520Promiscuous%2520Compounds%2520in%2520Antifungal%2520Research%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D2%26spage%3D497%26epage%3D503%26doi%3D10.1021%2Facs.jmedchem.5b00361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giacobini, E.</span></span> <span> </span><span class="NLM_article-title">Invited Review Cholinesterase Inhibitors for Alzheimer’s Disease Therapy: From Tacrine to Future Applications</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">5–6</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1016/S0197-0186(97)00124-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0197-0186%2897%2900124-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=9676739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK1cXksFSmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1998&pages=413-419&issue=5%E2%80%936&author=E.+Giacobini&title=Invited+Review+Cholinesterase+Inhibitors+for+Alzheimer%E2%80%99s+Disease+Therapy%3A+From+Tacrine+to+Future+Applications&doi=10.1016%2FS0197-0186%2897%2900124-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications</span></div><div class="casAuthors">Giacobini, Ezio</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">413-419</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with 41 refs., beginning with a historical background of the pharmacol. development of tacrine almost 50 yr ago (1949).  Tacrine was the 1st drug to be tested, clin., on a large scale and to be registered (1993) for treatment of Alzheimer's disease.  Clin. results of four 2nd-generation cholinesterase inhibitors (ChEI) (donepezil, ENA 713, eptastigmine and metrifonate) are reviewed and compared with those of other ChEI such as tacrine, physostigmine and galanthamine.  Data based on >6000 patients show that the 2nd-generation drugs are well tolerated and give evidence of clin. efficacy.  Differences are mainly due to frequency of side effects, no. of dropouts and percentage of improved patients.  These results also demonstrate the presence of clin. efficacy for all ChEI tested so far.  Clin. mechanism of action, levels of efficacy and differences among various ChEI are discussed.  Future potential indications are suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmjB6TkRL8E7Vg90H21EOLACvtfcHk0lgaNotvqk6ynw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksFSmurg%253D&md5=0677cf6d7c497974f146b40fd1602aab</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2FS0197-0186%2897%2900124-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0197-0186%252897%252900124-1%26sid%3Dliteratum%253Aachs%26aulast%3DGiacobini%26aufirst%3DE.%26atitle%3DInvited%2520Review%2520Cholinesterase%2520Inhibitors%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Therapy%253A%2520From%2520Tacrine%2520to%2520Future%2520Applications%26jtitle%3DNeurochem.%2520Int.%26date%3D1998%26volume%3D32%26issue%3D5%25E2%2580%25936%26spage%3D413%26epage%3D419%26doi%3D10.1016%2FS0197-0186%2897%2900124-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolezal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabelova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruba, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedlacek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepovimova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spilovska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musilek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opletalova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepsova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span> <span> </span><span class="NLM_article-title">7-Meota-Donepezil Like Compounds as Cholinesterase Inhibitors: Synthesis, Pharmacological Evaluation, Molecular Modeling and QSAR Studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.05.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2014.05.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24929293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVCqu7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=426-438&author=J.+Korabecnyauthor=R.+Dolezalauthor=P.+Cabelovaauthor=A.+Horovaauthor=E.+Hrubaauthor=J.+Ricnyauthor=L.+Sedlacekauthor=E.+Nepovimovaauthor=K.+Spilovskaauthor=M.+Andrsauthor=K.+Musilekauthor=V.+Opletalovaauthor=V.+Sepsovaauthor=D.+Ripovaauthor=K.+Kuca&title=7-Meota-Donepezil+Like+Compounds+as+Cholinesterase+Inhibitors%3A+Synthesis%2C+Pharmacological+Evaluation%2C+Molecular+Modeling+and+QSAR+Studies&doi=10.1016%2Fj.ejmech.2014.05.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">7-MEOTA-donepezil like compounds as cholinesterase inhibitors: Synthesis, pharmacological evaluation, molecular modeling and QSAR studies</span></div><div class="casAuthors">Korabecny, Jan; Dolezal, Rafael; Cabelova, Pavla; Horova, Anna; Hruba, Eva; Ricny, Jan; Sedlacek, Lukas; Nepovimova, Eugenie; Spilovska, Katarina; Andrs, Martin; Musilek, Kamil; Opletalova, Veronika; Sepsova, Vendula; Ripova, Daniela; Kuca, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">426-438</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Methoxytetrahydroacridinylethylpiperazines I•3 HCl [R = ArCH2, Ph(CH2)n, 1-naphthylmethyl, 2-naphthylmethyl, 2-(1-naphthyl)ethyl, cyclohexylmethyl, HC≡CCH2; Ar = Ph, 4-BrC6H4, 4-MeC6H4, 3,5-Me2C6H3, 4-O2NC6H4, 4-NCC6H4, 4-MeO2CC6H4, 4-F3CC6H4, 3-MeC6H4, 2-MeC6H4, 4-i-PrC6H4, 4-MeSC6H4, 3-BrC6H4, 2-BrC6H4], hybrids of 7-methoxytacrine and donepezil, were prepd. as inhibitors of acetylcholinesterase and butyrylcholinesterase.  I were nonselective inhibitors of cholinesterases of different origins with IC50 values of 0.8->200 μM.  I showed mixed inhibition of both the peripheral and cationic anionic sites of acetylcholinesterase as detd. by kinetic anal.  Mol. modeling and QSAR studies were performed to rationalize the obsd. in vitro activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpisi1Zh6iob7Vg90H21EOLACvtfcHk0lhUQBU33q5R4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVCqu7zI&md5=c7482dac3cf66a61e7dcdf00865fe157</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.05.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.05.066%26sid%3Dliteratum%253Aachs%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DDolezal%26aufirst%3DR.%26aulast%3DCabelova%26aufirst%3DP.%26aulast%3DHorova%26aufirst%3DA.%26aulast%3DHruba%26aufirst%3DE.%26aulast%3DRicny%26aufirst%3DJ.%26aulast%3DSedlacek%26aufirst%3DL.%26aulast%3DNepovimova%26aufirst%3DE.%26aulast%3DSpilovska%26aufirst%3DK.%26aulast%3DAndrs%26aufirst%3DM.%26aulast%3DMusilek%26aufirst%3DK.%26aulast%3DOpletalova%26aufirst%3DV.%26aulast%3DSepsova%26aufirst%3DV.%26aulast%3DRipova%26aufirst%3DD.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3D7-Meota-Donepezil%2520Like%2520Compounds%2520as%2520Cholinesterase%2520Inhibitors%253A%2520Synthesis%252C%2520Pharmacological%2520Evaluation%252C%2520Molecular%2520Modeling%2520and%2520QSAR%2520Studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D82%26spage%3D426%26epage%3D438%26doi%3D10.1016%2Fj.ejmech.2014.05.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeřábek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uliassi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidotti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepsova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabinova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena-Altamira, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petralla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Tacrine-Resveratrol Fused Hybrids as Multi-Target-Directed Ligands against Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.12.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2016.12.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28064079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=250-262&author=J.+Je%C5%99%C3%A1bekauthor=E.+Uliassiauthor=L.+Guidottiauthor=J.+Korabecnyauthor=O.+Soukupauthor=V.+Sepsovaauthor=M.+Hrabinovaauthor=K.+Kucaauthor=M.+Bartoliniauthor=L.+E.+Pena-Altamiraauthor=S.+Petrallaauthor=B.+Montiauthor=M.+Robertiauthor=M.+L.+Bolognesi&title=Tacrine-Resveratrol+Fused+Hybrids+as+Multi-Target-Directed+Ligands+against+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2016.12.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease</span></div><div class="casAuthors">Jerabek, Jakub; Uliassi, Elisa; Guidotti, Laura; Korabecny, Jan; Soukup, Ondrej; Sepsova, Vendula; Hrabinova, Martina; Kuca, Kamil; Bartolini, Manuela; Pena-Altamira, Luis Emiliano; Petralla, Sabrina; Monti, Barbara; Roberti, Marinella; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">250-262</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Multi-target drug discovery is one of the most followed approaches in the active central nervous system (CNS) therapeutic area, esp. in the search for new drugs against Alzheimer's disease (AD).  This is because innovative multi-target-directed ligands (MTDLs) could more adequately address the complexity of this pathol. condition.  In a continuation of our efforts aimed at a new series of anti-AD MTDLs, we combined the structural features of the cholinesterase inhibitor drug tacrine with that of resveratrol, which is known for its purported antioxidant and anti-neuroinflammatory activities.  The most interesting hybrid compds. (5, 8, 9 and 12) inhibited human acetylcholinesterase at micromolar concns. and effectively modulated Aβ self-aggregation in vitro.  In addn., 12 showed intriguing anti-inflammatory and immuno-modulatory properties in neuronal and glial AD cell models.  Importantly, the MTDL profile is accompanied by high-predicted blood-brain barrier permeability, and low cytotoxicity on primary neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHD8lQYiublbVg90H21EOLACvtfcHk0lhUQBU33q5R4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlChug%253D%253D&md5=6ebb19cb71b089213e7e0593c824faa1</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.12.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.12.048%26sid%3Dliteratum%253Aachs%26aulast%3DJe%25C5%2599%25C3%25A1bek%26aufirst%3DJ.%26aulast%3DUliassi%26aufirst%3DE.%26aulast%3DGuidotti%26aufirst%3DL.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DSoukup%26aufirst%3DO.%26aulast%3DSepsova%26aufirst%3DV.%26aulast%3DHrabinova%26aufirst%3DM.%26aulast%3DKuca%26aufirst%3DK.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DPena-Altamira%26aufirst%3DL.%2BE.%26aulast%3DPetralla%26aufirst%3DS.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DTacrine-Resveratrol%2520Fused%2520Hybrids%2520as%2520Multi-Target-Directed%2520Ligands%2520against%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D127%26spage%3D250%26epage%3D262%26doi%3D10.1016%2Fj.ejmech.2016.12.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span> <span> </span><span class="NLM_article-title">Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer’s Disease Drug Discovery</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2gtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=171-176&issue=3&author=X.+Y.+Jiangauthor=T.+K.+Chenauthor=J.+T.+Zhouauthor=S.+Y.+Heauthor=H.+Y.+Yangauthor=Y.+Chenauthor=W.+Quauthor=F.+Fengauthor=H.+P.+Sun&title=Dual+GSK-3%CE%B2%2FAChE+Inhibitors+as+a+New+Strategy+for+Multitargeting+Anti-Alzheimer%E2%80%99s+Disease+Drug+Discovery&doi=10.1021%2Facsmedchemlett.7b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery</span></div><div class="casAuthors">Jiang, Xue-Yang; Chen, Ting-Kai; Zhou, Jun-Ting; He, Si-Yu; Yang, Hong-Yu; Chen, Yao; Qu, Wei; Feng, Feng; Sun, Hao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-176</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget-directed ligands (MTDLs) is considered to be a promising approach to address complex and multifactorial maladies such as Alzheimer's disease (AD).  The concurrent inhibition of the two crucial AD targets, glycogen synthase kinase-3β (GSK-3β) and human acetylcholinesterase (hAChE), might represent a breakthrough in the quest for clin. efficacy.  Thus, a novel family of GSK-3β/AChE dual-target inhibitors was designed and synthesized.  Among these hybrids, I showed the most promising profile as a nanomolar inhibitor on both hAChE (IC50 = 6.5 nM) and hGSK-3β kinase activity (IC50 = 66 nM).  It also showed good inhibitory effect on β-amyloid self-aggregation (inhibitory rate = 46%) at 20 μM.  Western blot anal. revealed that compd. I inhibited hyperphosphorylation of tau protein in mouse neuroblastoma N2a-Tau cells.  In vivo studies confirmed that I significantly ameliorated the cognitive disorders in scopolamine-treated ICR mice and less hepatotoxicity than tacrine.  This study provides new leads for assessment of GSK-3β and AChE pathway dual inhibition as a promising strategy for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq103h9q_6uaLVg90H21EOLACvtfcHk0ljMG4DaWcgPgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2gtrY%253D&md5=8858bb4cbc503c79896ccbc00fb23153</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00463%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DX.%2BY.%26aulast%3DChen%26aufirst%3DT.%2BK.%26aulast%3DZhou%26aufirst%3DJ.%2BT.%26aulast%3DHe%26aufirst%3DS.%2BY.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DH.%2BP.%26atitle%3DDual%2520GSK-3%25CE%25B2%252FAChE%2520Inhibitors%2520as%2520a%2520New%2520Strategy%2520for%2520Multitargeting%2520Anti-Alzheimer%25E2%2580%2599s%2520Disease%2520Drug%2520Discovery%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D3%26spage%3D171%26epage%3D176%26doi%3D10.1021%2Facsmedchemlett.7b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, R. J.</span></span> <span> </span><span class="NLM_article-title">Oxidative Damage in the Central Nervous System: Protection by Melatonin</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1016/S0301-0082(98)00052-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0301-0082%2898%2900052-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=9770244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK1cXmtFKhtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1998&pages=359-384&issue=3&author=R.+J.+Reiter&title=Oxidative+Damage+in+the+Central+Nervous+System%3A+Protection+by+Melatonin&doi=10.1016%2FS0301-0082%2898%2900052-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative damage in the central nervous system: protection by melatonin</span></div><div class="casAuthors">Reiter, Russel J.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">359-384</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with ∼275 refs.  Melatonin was recently reported to be an effective free radical scavenger and antioxidant.  Melatonin is believed to scavenge the highly toxic hydroxyl radical, the peroxynitrite anion, and possibly the peroxyl radical.  Also, secondarily, it reportedly scavenges the superoxide anion radical and it quenches singlet oxygen.  Addnl., it stimulates mRNA levels for superoxide dismutase and the activities of glutathione peroxidase, glutathione reductase and glucose-6-phosphate dehydrogenase (all of which are antioxidative enzymes), thereby increasing its antioxidative capacity.  Also, melatonin, at least at some sites, inhibits nitric oxide synthase, a pro-oxidative enzyme.  In both in vivo and in vitro expts. melatonin has been shown to reduce lipid peroxidn. and oxidative damage to nuclear DNA.  While these effects have been obsd. primarily using pharmacol. doses of melatonin, in a small no. of expts. melatonin has been found to be physiol. relevant as an antioxidant as well.  The efficacy of melatonin in inhibiting oxidative damage has been tested in a variety of neurol. disease models where free radicals have been implicated as being in part causative of the condition.  Thus, melatonin has been shown prophylactically to reduce amyloid β protein toxicity of Alzheimer's disease, to reduce oxidative damage in several models of Parkinson's disease (dopamine auto-oxidn., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine), to protect against glutamate excitotoxicity, to reduce ischemia-reperfusion injury, to lower neural damage due to δ-aminolevulinic acid (porphyria), hyperbaric hyperoxia and a variety of neural toxins.  Since endogenous melatonin levels fall markedly in advanced age, the implication of these findings is that the loss of this antioxidant may contribute to the incidence or severity of some age-assocd. neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbMBfTYQqFtLVg90H21EOLACvtfcHk0ljMG4DaWcgPgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtFKhtbc%253D&md5=2518032c1c106627bdef1151ab5d269f</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2FS0301-0082%2898%2900052-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0301-0082%252898%252900052-5%26sid%3Dliteratum%253Aachs%26aulast%3DReiter%26aufirst%3DR.%2BJ.%26atitle%3DOxidative%2520Damage%2520in%2520the%2520Central%2520Nervous%2520System%253A%2520Protection%2520by%2520Melatonin%26jtitle%3DProg.%2520Neurobiol.%26date%3D1998%26volume%3D56%26issue%3D3%26spage%3D359%26epage%3D384%26doi%3D10.1016%2FS0301-0082%2898%2900052-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. H.</span></span> <span> </span><span class="NLM_article-title">Melatonin Attenuates Amyloid Beta 25–35 -Induced Apoptosis in Mouse Microglial BV2 Cells</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2005.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.neulet.2005.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15854745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1Ght78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2005&pages=26-31&issue=1&author=M.+H.+Jangauthor=S.+B.+Jungauthor=M.+H.+Leeauthor=C.+J.+Kimauthor=Y.+T.+Ohauthor=I.+Kangauthor=J.+Kimauthor=E.+H.+Kim&title=Melatonin+Attenuates+Amyloid+Beta+25%E2%80%9335+-Induced+Apoptosis+in+Mouse+Microglial+BV2+Cells&doi=10.1016%2Fj.neulet.2005.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells</span></div><div class="casAuthors">Jang, Mi-Hyeon; Jung, Sae-Bin; Lee, Myoung-Hwa; Kim, Chang-Ju; Oh, Young-Taek; Kang, Insug; Kim, Jeongseon; Kim, Ee-Hwa</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">26-31</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Melatonin has been reported to possess strong antioxidant actions, and is able to directly scavenge a variety of reactive oxygen species (ROS).  The present study investigated whether melatonin possesses protective effects against Aβ-induced cytotoxicity in microglial cells.  Cells treated with Aβ exhibited several characteristic features of apoptosis, while cells pre-treated with melatonin prior to exposure to Aβ showed a decrease in the occurrence of such apoptotic features.  Several previous studies have demonstrated the involvement of ROS in Aβ-induced neurotoxicity, and ROS generated by Aβ have been reported to lead to the activation of nuclear factor-kappa B (NF-κB), a transcription factor; pretreatment with melatonin in the present study reduced the level of Aβ-induced intracellular ROS generation, inhibited NF-κB activation, and suppressed the Aβ-induced increase in caspase-3 enzyme activity.  In addn., it was found that pretreatment with melatonin inhibits Aβ-induced increase in the levels of bax mRNA and that it enhances the level of bcl-2 expression.  Based on these findings, the authors speculate that melatonin may provide an effective means of treatment for Alzheimer's disease through attenuation of Aβ-induced apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsKTq5KqS4qbVg90H21EOLACvtfcHk0ljMG4DaWcgPgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1Ght78%253D&md5=6a18f6b44c7544fa4e2dda66e6c1d607</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2005.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2005.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DM.%2BH.%26aulast%3DJung%26aufirst%3DS.%2BB.%26aulast%3DLee%26aufirst%3DM.%2BH.%26aulast%3DKim%26aufirst%3DC.%2BJ.%26aulast%3DOh%26aufirst%3DY.%2BT.%26aulast%3DKang%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DE.%2BH.%26atitle%3DMelatonin%2520Attenuates%2520Amyloid%2520Beta%252025%25E2%2580%259335%2520-Induced%2520Apoptosis%2520in%2520Mouse%2520Microglial%2520BV2%2520Cells%26jtitle%3DNeurosci.%2520Lett.%26date%3D2005%26volume%3D380%26issue%3D1%26spage%3D26%26epage%3D31%26doi%3D10.1016%2Fj.neulet.2005.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baydas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Özer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuzcu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koz, S. T.</span></span> <span> </span><span class="NLM_article-title">Melatonin Improves Learning and Memory Performances Impaired by Hyperhomocysteinemia in Rats</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1046</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2005.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.brainres.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15882843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVOltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1046&publication_year=2005&pages=187-194&issue=1&author=G.+Baydasauthor=M.+%C3%96zerauthor=A.+Yasarauthor=M.+Tuzcuauthor=S.+T.+Koz&title=Melatonin+Improves+Learning+and+Memory+Performances+Impaired+by+Hyperhomocysteinemia+in+Rats&doi=10.1016%2Fj.brainres.2005.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin improves learning and memory performances impaired by hyperhomocysteinemia in rats</span></div><div class="casAuthors">Baydas, Giyasettin; Oezer, Mehmet; Yasar, Abdullah; Tuzcu, Mehmet; Koz, Sema T.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1046</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">187-194</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Oxidative stress has been proposed as a possible mechanism underlying many neurodegenerative diseases assocd. with hyperhomocysteinemia.  In the present study, the authors investigated the possible link between oxidative stress, expression of neural cell adhesion mols. and spatial learning deficits induced by chronic hyperhomocysteinemia.  Furthermore, the effectiveness of antioxidant melatonin against homocysteine neurotoxicity was also examd.  Male Wistar rats were treated with either saline or methionine to induce hyperhomocysteinemia and half of methionine-treated rats administered daily melatonin in a dose of 10 mg/kg.  The authors obsd. that chronic administration of melatonin significantly reduced the lipid peroxidn. and restored the decreased glutathione levels induced by chronic hyperhomocysteinemia.  Chronic hyperhomocysteinemia significantly impaired learning and memory performance in the passive avoidance test and Morris water maze task.  The authors also found that these cognitive deficits were reversed by chronic treatment with antioxidant melatonin.  Furthermore, melatonin administration was able to modulate the expression pattern of neural cell adhesion mols. in hippocampus.  The results provide evidence that homocysteine induces long-lasting behavioral deficits, which are possibly caused by oxygen reactive species generation, and by changing in synaptic plasticity and also suggest that melatonin treatment has the ability to prevent nervous system against homocysteine toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSieXYnsI0G7Vg90H21EOLACvtfcHk0lidWra8nvR9pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVOltrk%253D&md5=ab68e7d4f9090f43495bd0ce32d653fd</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DBaydas%26aufirst%3DG.%26aulast%3D%25C3%2596zer%26aufirst%3DM.%26aulast%3DYasar%26aufirst%3DA.%26aulast%3DTuzcu%26aufirst%3DM.%26aulast%3DKoz%26aufirst%3DS.%2BT.%26atitle%3DMelatonin%2520Improves%2520Learning%2520and%2520Memory%2520Performances%2520Impaired%2520by%2520Hyperhomocysteinemia%2520in%2520Rats%26jtitle%3DBrain%2520Res.%26date%3D2005%26volume%3D1046%26issue%3D1%26spage%3D187%26epage%3D194%26doi%3D10.1016%2Fj.brainres.2005.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Franco, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Bachiller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Ledesma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolome, B.</span></span> <span> </span><span class="NLM_article-title">Novel Tacrine-Melatonin Hybrids as Dual-Acting Drugs for Alzheimer Disease, with Improved Acetylcholinesterase Inhibitory and Antioxidant Properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1021/jm050746d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050746d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlWmurfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=459-462&issue=2&author=M.+I.+Rodriguez-Francoauthor=M.+Fernandez-Bachillerauthor=C.+Perezauthor=B.+Hernandez-Ledesmaauthor=B.+Bartolome&title=Novel+Tacrine-Melatonin+Hybrids+as+Dual-Acting+Drugs+for+Alzheimer+Disease%2C+with+Improved+Acetylcholinesterase+Inhibitory+and+Antioxidant+Properties&doi=10.1021%2Fjm050746d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Tacrine-Melatonin Hybrids as Dual-Acting Drugs for Alzheimer Disease, with Improved Acetylcholinesterase Inhibitory and Antioxidant Properties</span></div><div class="casAuthors">Rodriguez-Franco, Maria Isabel; Fernandez-Bachiller, Maria Isabel; Perez, Concepcion; Hernandez-Ledesma, Blanca; Bartolome, Begona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">459-462</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tacrine and melatonin are well-known drugs with activities as an acetylcholinesterase (AChE) inhibitor and free radical scavenger, resp.  In this work, the authors report new hybrids of both drugs that display higher in vitro properties than the sum of their parts.  As selective inhibitors of human AChE, their IC50 values range from sub-nanomolar to picomolar.  They exhibit a higher oxygen radical absorbance capacity than does melatonin and are predicted to be able to cross the blood-brain barrier to reach their targets in the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJx8cNT0dPfrVg90H21EOLACvtfcHk0lidWra8nvR9pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlWmurfM&md5=ee924cb63a2f3263853a6449e40cb69f</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Fjm050746d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050746d%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez-Franco%26aufirst%3DM.%2BI.%26aulast%3DFernandez-Bachiller%26aufirst%3DM.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DHernandez-Ledesma%26aufirst%3DB.%26aulast%3DBartolome%26aufirst%3DB.%26atitle%3DNovel%2520Tacrine-Melatonin%2520Hybrids%2520as%2520Dual-Acting%2520Drugs%2520for%2520Alzheimer%2520Disease%252C%2520with%2520Improved%2520Acetylcholinesterase%2520Inhibitory%2520and%2520Antioxidant%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D2%26spage%3D459%26epage%3D462%26doi%3D10.1021%2Fjm050746d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. J.</span></span> <span> </span><span class="NLM_article-title">Interactions of Nitrogen-Containing Xenobiotics with Monoamine Oxidase (MAO) Isozymes A and B: SAR Studies on MAO Substrates and Inhibitors</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1162</span>, <span class="refDoi"> DOI: 10.1021/tx010073b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx010073b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Orsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=1139-1162&issue=9&author=A.+S.+Kalgutkarauthor=D.+K.+Dalvieauthor=N.+Castagnoliauthor=T.+J.+Taylor&title=Interactions+of+Nitrogen-Containing+Xenobiotics+with+Monoamine+Oxidase+%28MAO%29+Isozymes+A+and+B%3A+SAR+Studies+on+MAO+Substrates+and+Inhibitors&doi=10.1021%2Ftx010073b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors</span></div><div class="casAuthors">Kalgutkar, Amit S.; Dalvie, Deepak K.; Castagnoli, Neal, Jr.; Taylor, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1139-1162</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 302 refs.  MAO inhibitors have been targets for therapeutic agents for many years.  However, inhibition and modulation of this enzyme system can result in undesirable elevations in plasma concns. of MAO substrates and, in some instances, cytochrome P 450 substrates.  The recent development of a new generation of highly selective, reversible MAO inhibitors has led to a renewed interest in the therapeutic potential of these compds.  The primary objective of this review is to summarize the interactions of amine-contg. xenobiotics with MAO, with particular emphasis on the structure-activity requirements for substrate and inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVbjk3FPJan7Vg90H21EOLACvtfcHk0lidWra8nvR9pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Orsb8%253D&md5=73fb2537f94f7dd8ac47be1953803264</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1021%2Ftx010073b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx010073b%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DT.%2BJ.%26atitle%3DInteractions%2520of%2520Nitrogen-Containing%2520Xenobiotics%2520with%2520Monoamine%2520Oxidase%2520%2528MAO%2529%2520Isozymes%2520A%2520and%2520B%253A%2520SAR%2520Studies%2520on%2520MAO%2520Substrates%2520and%2520Inhibitors%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2001%26volume%3D14%26issue%3D9%26spage%3D1139%26epage%3D1162%26doi%3D10.1021%2Ftx010073b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baram, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinreb, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandel, S.</span></span> <span> </span><span class="NLM_article-title">Propargylamine Containing Compounds as Modulators of Proteolytic Cleavage of Amyloid-β Protein Precursor: Involvement of MAPK and PKC Activation</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.3233/JAD-2010-100150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3233%2FJAD-2010-100150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20555137" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=361-371&issue=2&author=O.+Baramauthor=T.+Amitauthor=O.+Weinrebauthor=M.+B.+Youdimauthor=S.+Mandel&title=Propargylamine+Containing+Compounds+as+Modulators+of+Proteolytic+Cleavage+of+Amyloid-%CE%B2+Protein+Precursor%3A+Involvement+of+MAPK+and+PKC+Activation&doi=10.3233%2FJAD-2010-100150"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.3233%2FJAD-2010-100150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2010-100150%26sid%3Dliteratum%253Aachs%26aulast%3DBaram%26aufirst%3DO.%26aulast%3DAmit%26aufirst%3DT.%26aulast%3DWeinreb%26aufirst%3DO.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DMandel%26aufirst%3DS.%26atitle%3DPropargylamine%2520Containing%2520Compounds%2520as%2520Modulators%2520of%2520Proteolytic%2520Cleavage%2520of%2520Amyloid-%25CE%25B2%2520Protein%2520Precursor%253A%2520Involvement%2520of%2520MAPK%2520and%2520PKC%2520Activation%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2010%26volume%3D21%26issue%3D2%26spage%3D361%26epage%3D371%26doi%3D10.3233%2FJAD-2010-100150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">A Novel Series of Tacrine-Selegiline Hybrids with Cholinesterase and Monoamine Oxidase Inhibition Activities for the Treatment of Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2013.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23454517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslWgu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=745-753&author=C.+Luauthor=Q.+Zhouauthor=J.+Yanauthor=Z.+Duauthor=L.+Huangauthor=X.+Li&title=A+Novel+Series+of+Tacrine-Selegiline+Hybrids+with+Cholinesterase+and+Monoamine+Oxidase+Inhibition+Activities+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2013.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Lu, Chuanjun; Zhou, Qi; Yan, Jun; Du, Zhiyun; Huang, Ling; Li, Xingshu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">745-753</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of tacrine-selegiline hybrids was synthesized and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B).  The results demonstrate that most of the synthesized compds. exhibit high inhibitory activity.  Among these compds., compd. I provided a good balance of activity towards all targets (with IC50 values of 22.6 nM, 9.37 nM, 0.3724 μM, and 0.1810 μM for AChE, BuChE, MAO-A and MAO-B, resp.).  These results indicated that I has the potential to be a multi-functional candidate for Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB-OnHqpBtBrVg90H21EOLACvtfcHk0lgIQjceH1l5eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslWgu7g%253D&md5=9e0cfdecbe4e8a2890482f8b32cbf4a4</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DA%2520Novel%2520Series%2520of%2520Tacrine-Selegiline%2520Hybrids%2520with%2520Cholinesterase%2520and%2520Monoamine%2520Oxidase%2520Inhibition%2520Activities%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D62%26spage%3D745%26epage%3D753%26doi%3D10.1016%2Fj.ejmech.2013.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendez, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehouse, P. J.</span></span> <span> </span><span class="NLM_article-title">Psychiatric Symptoms Associated with Alzheimer’s Disease</span>. <i>J. Neuropsychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1176/jnp.2.1.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1176%2Fjnp.2.1.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=2136060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADyaK38zjtVeksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1990&pages=28-33&issue=1&author=M.+F.+Mendezauthor=R.+J.+Martinauthor=K.+A.+Smythauthor=P.+J.+Whitehouse&title=Psychiatric+Symptoms+Associated+with+Alzheimer%E2%80%99s+Disease&doi=10.1176%2Fjnp.2.1.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Psychiatric symptoms associated with Alzheimer's disease</span></div><div class="casAuthors">Mendez M F; Martin R J; Smyth K A; Whitehouse P J</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of neuropsychiatry and clinical neurosciences</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-33</span>
        ISSN:<span class="NLM_cas:issn">0895-0172</span>.
    </div><div class="casAbstract">A retrospective chart review was undertaken to assess the prevalence of specifically defined psychiatric symptoms in 217 outpatients with clinically probable Alzheimer's disease.  A weak but significant correlation was found between Alzheimer's disease and suspiciousness and paranoia (reported by 35.5% of patients), delusions (30%), and formed visual hallucinations (18.4%).  Mild depressive symptoms, such as sad affect, hopelessness, and helplessness were reported by 40.6% of patients, anxiety and fearfulness by 30.9%, and aggressive acts by 24.9%.  Psychotropic medications used to manage these symptoms included antipsychotics, in 11.5% of patients, anxiolytics, in 9.2%, and antidepressants, in 7.4%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWaEl8pnXR99ts4TFFB11gfW6udTcc2eaQYvOZVRtnErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zjtVeksg%253D%253D&md5=dcd14997fd5783f347efdb10da95b534</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1176%2Fjnp.2.1.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fjnp.2.1.28%26sid%3Dliteratum%253Aachs%26aulast%3DMendez%26aufirst%3DM.%2BF.%26aulast%3DMartin%26aufirst%3DR.%2BJ.%26aulast%3DSmyth%26aufirst%3DK.%2BA.%26aulast%3DWhitehouse%26aufirst%3DP.%2BJ.%26atitle%3DPsychiatric%2520Symptoms%2520Associated%2520with%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Neuropsychiatry%2520Clin.%2520Neurosci.%26date%3D1990%26volume%3D2%26issue%3D1%26spage%3D28%26epage%3D33%26doi%3D10.1176%2Fjnp.2.1.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyketsos, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopunek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabins, P. V.</span></span> <span> </span><span class="NLM_article-title">Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Sertraline in the Treatment of Depression Complicating Alzheimer’s Disease: Initial Results from the Depression in Alzheimer’s Disease Study</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>157</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1686</span>– <span class="NLM_lpage">1689</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.157.10.1686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1176%2Fappi.ajp.157.10.1686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11007727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BD3M%252FgvVOguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2000&pages=1686-1689&issue=10&author=C.+G.+Lyketsosauthor=J.+M.+Sheppardauthor=C.+D.+Steeleauthor=S.+Kopunekauthor=M.+Steinbergauthor=A.+S.+Bakerauthor=J.+Brandtauthor=P.+V.+Rabins&title=Randomized%2C+Placebo-Controlled%2C+Double-Blind+Clinical+Trial+of+Sertraline+in+the+Treatment+of+Depression+Complicating+Alzheimer%E2%80%99s+Disease%3A+Initial+Results+from+the+Depression+in+Alzheimer%E2%80%99s+Disease+Study&doi=10.1176%2Fappi.ajp.157.10.1686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study</span></div><div class="casAuthors">Lyketsos C G; Sheppard J M; Steele C D; Kopunek S; Steinberg M; Baker A S; Brandt J; Rabins P V</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1686-9</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  This study evaluated the efficacy and safety of sertraline in the treatment of major depression in 22 outpatients with Alzheimer's disease.  METHOD:  Twelve of the 22 patients were given sertraline and 10 were given placebo by random group assignment for 12 weeks.  Response to treatment was measured by using the Cornell Scale for Depression in Dementia.  The patients were also assessed with the Hamilton Depression Rating Scale, the activities of daily living subscale of the Psychogeriatric Dependency Rating Scales, and the Mini-Mental State.  RESULTS:  After 12 weeks of double-blind, placebo-controlled treatment, nine of the patients given sertraline and two of those given placebo were at least partial responders.  Patients given sertraline had significantly greater mean declines from baseline in Cornell Scale for Depression in Dementia scores; the bulk of antidepressant response occurred by the third week of treatment.  CONCLUSIONS:  Sertraline is superior to placebo in reducing depression in patients with Alzheimer's disease who also suffer from major depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwuX3CVdo1_eIHSmpohpd0fW6udTcc2eaQYvOZVRtnErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M%252FgvVOguw%253D%253D&md5=90d4a4bf6bae01298fac85a9300f2d3b</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.157.10.1686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.157.10.1686%26sid%3Dliteratum%253Aachs%26aulast%3DLyketsos%26aufirst%3DC.%2BG.%26aulast%3DSheppard%26aufirst%3DJ.%2BM.%26aulast%3DSteele%26aufirst%3DC.%2BD.%26aulast%3DKopunek%26aufirst%3DS.%26aulast%3DSteinberg%26aufirst%3DM.%26aulast%3DBaker%26aufirst%3DA.%2BS.%26aulast%3DBrandt%26aufirst%3DJ.%26aulast%3DRabins%26aufirst%3DP.%2BV.%26atitle%3DRandomized%252C%2520Placebo-Controlled%252C%2520Double-Blind%2520Clinical%2520Trial%2520of%2520Sertraline%2520in%2520the%2520Treatment%2520of%2520Depression%2520Complicating%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Initial%2520Results%2520from%2520the%2520Depression%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Study%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2000%26volume%3D157%26issue%3D10%26spage%3D1686%26epage%3D1689%26doi%3D10.1176%2Fappi.ajp.157.10.1686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velkeniers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaelst, L.</span></span> <span> </span><span class="NLM_article-title">Effect of Fluoxetine, a Serotonin Reuptake Inhibitor, on the Pituitary-Thyroid Axis in Rat</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(83)90471-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2F0014-2999%2883%2990471-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=6413229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaL3sXltlemt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1983&pages=239-243&issue=2&author=J.+Golsteinauthor=S.+Schreiberauthor=B.+Velkeniersauthor=L.+Vanhaelst&title=Effect+of+Fluoxetine%2C+a+Serotonin+Reuptake+Inhibitor%2C+on+the+Pituitary-Thyroid+Axis+in+Rat&doi=10.1016%2F0014-2999%2883%2990471-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of fluoxetine, a serotonin reuptake inhibitor, on the pituitary-thyroid axis in rat</span></div><div class="casAuthors">Golstein, Jacqueline; Schreiber, Serge; Velkeniers, Brigitte; Vanhaelst, Luc</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">239-43</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">Fluoxetine (I)  [54910-89-3], a specific 5-HT  [50-67-9] reuptake inhibitor, was administered i.p. either acutely or chronically (2 and 10 mg doses) and intraventricularly to normal rats.  Basal TSH  [9002-71-5] levels were measured and the pituitary TSH reserve was estd. by direct detn. of pituitary TSH content and(or) by a TRH  [24305-27-9] test.  T4  [51-48-9] and T3  [6893-02-3] serum levels were also measured.  The acute administration elicited only a decrease in T4 levels, whereas the chronic administration resulted in a decrease in both T4 and T3 levels.  The 10-mg acute and chronic administrations induced an increase in basal TSH and in pituitary TSH reserve.  Intraventricular administration only prevented the initial stress-induced decline of serum TSH levels.  The major effect of the drug seems to be stimulation of TSH synthesis and release via the inhibition of T4-mediated thyroid-pituitary feedback.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEyFzgI-z-nrVg90H21EOLACvtfcHk0lgDt_4Eeu7eLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXltlemt7k%253D&md5=fd97905c5eb626ee2abd5da2126a53ec</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2883%2990471-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252883%252990471-5%26sid%3Dliteratum%253Aachs%26aulast%3DGolstein%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DVelkeniers%26aufirst%3DB.%26aulast%3DVanhaelst%26aufirst%3DL.%26atitle%3DEffect%2520of%2520Fluoxetine%252C%2520a%2520Serotonin%2520Reuptake%2520Inhibitor%252C%2520on%2520the%2520Pituitary-Thyroid%2520Axis%2520in%2520Rat%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1983%26volume%3D91%26issue%3D2%26spage%3D239%26epage%3D243%26doi%3D10.1016%2F0014-2999%2883%2990471-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dechant, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clissold, S. P.</span></span> <span> </span><span class="NLM_article-title">Paroxetine</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.2165/00003495-199141020-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2165%2F00003495-199141020-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1709852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK3MXktVSjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1991&pages=225-253&issue=2&author=K.+L.+Dechantauthor=S.+P.+Clissold&title=Paroxetine&doi=10.2165%2F00003495-199141020-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Paroxetine.  A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness</span></div><div class="casAuthors">Dechant, Kerry L.; Clissold, Stephen P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-53</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    </div><div class="casAbstract">A review with 96 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIfBGOQXnem7Vg90H21EOLACvtfcHk0lgDt_4Eeu7eLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXktVSjt7w%253D&md5=5b21e5123820f2d25b4d03147d6d0fe6</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.2165%2F00003495-199141020-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199141020-00007%26sid%3Dliteratum%253Aachs%26aulast%3DDechant%26aufirst%3DK.%2BL.%26aulast%3DClissold%26aufirst%3DS.%2BP.%26atitle%3DParoxetine%26jtitle%3DDrugs%26date%3D1991%26volume%3D41%26issue%3D2%26spage%3D225%26epage%3D253%26doi%3D10.2165%2F00003495-199141020-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogen, H.</span></span> <span> </span><span class="NLM_article-title">Development of an Efficient Therapeutic Agent for Alzheimer’s Disease: Design and Synthesis of Dual Inhibitors of Acetylcholinesterase and Serotonin Transporter</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1248/cpb.58.273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1248%2Fcpb.58.273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20190429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Oitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2010&pages=273-287&issue=3&author=N.+Todaauthor=T.+Kanekoauthor=H.+Kogen&title=Development+of+an+Efficient+Therapeutic+Agent+for+Alzheimer%E2%80%99s+Disease%3A+Design+and+Synthesis+of+Dual+Inhibitors+of+Acetylcholinesterase+and+Serotonin+Transporter&doi=10.1248%2Fcpb.58.273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Development of an efficient therapeutic agent for Alzheimer's disease: Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter</span></div><div class="casAuthors">Toda, Narihiro; Kaneko, Tsugio; Kogen, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A review.  To date, acetylcholinesterase (AChE) inhibitors have been clin. effective drugs for the palliative treatment of Alzheimer's disease, but their clin. efficacy is limited, mainly due to their adverse effects on peripheral organs.  Since patients of Alzheimer's disease often exhibit depression as well as memory impairment, dual inhibitors of AChE and serotonin transporter (SERT) would be a better therapeutic method.  Anti-depressive effects based on SERT inhibition would reduce the dose-related side effects of AChE inhibitors.  Such dual inhibitors were designed by the hybridization of rivastigmine and fluoxetine based on a hypothetical model of the AChE active site.  Various derivs. were synthesized and evaluated for their in vitro inhibition, and then (S)-5j (RS-1259), which possessed balanced inhibitory activities of AChE (IC50 = 101 nM) and SERT (IC50 = 42 nM), was successfully obtained.  An ex vivo expt. in mice indicated that (S)-5j (RS-1259) simultaneously inhibited AChE and SERT in the brain following an oral administration.  The simultaneous elevation of extracellular levels of acetylcholine and serotonin in the rat hippocampus was actually confirmed by microdialysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouvnUUscxWf7Vg90H21EOLACvtfcHk0lgDt_4Eeu7eLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Oitr4%253D&md5=d28037b205bb3052b6a5037da6d2be06</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1248%2Fcpb.58.273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.58.273%26sid%3Dliteratum%253Aachs%26aulast%3DToda%26aufirst%3DN.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DKogen%26aufirst%3DH.%26atitle%3DDevelopment%2520of%2520an%2520Efficient%2520Therapeutic%2520Agent%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Design%2520and%2520Synthesis%2520of%2520Dual%2520Inhibitors%2520of%2520Acetylcholinesterase%2520and%2520Serotonin%2520Transporter%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2010%26volume%3D58%26issue%3D3%26spage%3D273%26epage%3D287%26doi%3D10.1248%2Fcpb.58.273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giacobini, E.</span></span> <span> </span><span class="NLM_article-title">From Molecular Structure to Alzheimer Therapy</span>. <i>Jpn. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1254/jjp.74.225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1254%2Fjjp.74.225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=9268083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK2sXkslWqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1997&pages=225-241&issue=3&author=E.+Giacobini&title=From+Molecular+Structure+to+Alzheimer+Therapy&doi=10.1254%2Fjjp.74.225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">From molecular structure to Alzheimer therapy</span></div><div class="casAuthors">Giacobini, Ezio</div><div class="citationInfo"><span class="NLM_cas:title">Japanese Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-241</span>CODEN:
                <span class="NLM_cas:coden">JJPAAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-5198</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">A review with 87 refs.  Clin. trials in the USA, Japan and Europe have confirmed the hypothesis that a steady state increase of acetylcholine resulting from cholinesterase inhibition in the brain results in an improvement of cognitive function in mild to moderate Alzheimer disease (AD) patients.  During the last decade, a systematic effort to develop a pharmacol. treatment for AD has resulted in two drugs being registered for the first time in the USA and Europe for this specific indication.  Both are cholinesterase inhibitors (ChEI).  Based on these first pos. results, several second generation ChEI are being developed.  An addnl. effect of certain ChEI is to maintain cognitive function at a const. level during a 6 mo to one year period of treatment as compared to placebo.  It is possible that the drug effect is one of slowing down cognitive deterioration.  Comparison of clin. effects of 5 ChEI demonstrates a rather similar magnitude of improvement.  For some drugs, this may represent a limit, while for others it may be possible to increase the benefit further.  To maximize and prolong pos. drug effects, it is important to start early and adjust the dosage during the treatment.  Other strategies may involve combinations with other cholinergic drugs such as muscarinic or nicotinic agonists.  A second important class of drugs which is being developed is that of muscarinic m1 agonists.  However, their clin. use is still limited by side effects.  The increased knowledge and recognition of the beta-amyloid mol. as a central focus of AD pathol. has strongly stimulated research with the hope of finding ways of influencing its processing and deposition.  At this point, no product in this line of development has reached clin. trial level.  Other pharmacol. approaches are related to preventive and neuroprotective interventions (estrogens, anti-oxidants and anti-inflammatories).  In conclusion, given the relatively short time of research in this field, results are encouraging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsL1ZPwM1EtbVg90H21EOLACvtfcHk0lgDt_4Eeu7eLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkslWqs7g%253D&md5=e6dabc8bd0d0862e55d7eda296faaf27</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1254%2Fjjp.74.225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjjp.74.225%26sid%3Dliteratum%253Aachs%26aulast%3DGiacobini%26aufirst%3DE.%26atitle%3DFrom%2520Molecular%2520Structure%2520to%2520Alzheimer%2520Therapy%26jtitle%3DJpn.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D74%26issue%3D3%26spage%3D225%26epage%3D241%26doi%3D10.1254%2Fjjp.74.225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamoorthy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savelieff, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brender, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derrick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span> <span> </span><span class="NLM_article-title">Rational Design of a Structural Framework with Potential Use to Develop Chemical Reagents That Target and Modulate Multiple Facets of Alzheimer’s Disease</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1021/ja409801p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja409801p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVWnsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=299-310&issue=1&author=S.+Leeauthor=X.+Y.+Zhengauthor=J.+Krishnamoorthyauthor=M.+G.+Savelieffauthor=H.+M.+Parkauthor=J.+R.+Brenderauthor=J.+H.+Kimauthor=J.+S.+Derrickauthor=A.+Kochiauthor=H.+J.+Leeauthor=C.+Kimauthor=A.+Ramamoorthyauthor=M.+T.+Bowersauthor=M.+H.+Lim&title=Rational+Design+of+a+Structural+Framework+with+Potential+Use+to+Develop+Chemical+Reagents+That+Target+and+Modulate+Multiple+Facets+of+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fja409801p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of a Structural Framework with Potential Use to Develop Chemical Reagents That Target and Modulate Multiple Facets of Alzheimer's Disease</span></div><div class="casAuthors">Lee, Sanghyun; Zheng, Xueyun; Krishnamoorthy, Janarthanan; Savelieff, Masha G.; Park, Hyun Min; Brender, Jeffrey R.; Kim, Jin Hoon; Derrick, Jeffrey S.; Kochi, Akiko; Lee, Hyuck Jin; Kim, Cheal; Ramamoorthy, Ayyalusamy; Bowers, Michael T.; Lim, Mi Hee</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">299-310</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is characterized by multiple, intertwined pathol. features, including amyloid-β (Aβ) aggregation, metal ion dyshomeostasis, and oxidative stress.  The authors report a novel compd. (ML) prototype of a rationally designed mol. obtained by integrating structural elements for Aβ aggregation control, metal chelation, reactive oxygen species (ROS) regulation, and antioxidant activity within a single mol.  Chem., biochem., ion mobility mass spectrometric, and NMR studies indicate that the compd. ML targets metal-free and metal-bound Aβ (metal-Aβ) species, suppresses Aβ aggregation in vitro, and diminishes toxicity induced by Aβ and metal-treated Aβ in living cells.  Comparison of ML to its structural moieties (i.e., 4-(dimethylamino)-phenol (DAP) and (8-aminoquinolin-2-yl)-methanol ) for reactivity with Aβ and metal-Aβ suggests the synergy of incorporating structural components for both metal chelation and Aβ interaction.  Moreover, ML is water-sol. and potentially brain permeable, as well as regulates the formation and presence of free radicals.  Overall, the authors demonstrate that a rational structure-based design strategy can generate a small mol. that can target and modulate multiple factors, providing a new tool to uncover and address AD complexity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcx8TkzbV9U7Vg90H21EOLACvtfcHk0ljV4Cdr0HJgmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVWnsL3I&md5=808d231c5dca419453c176265d16bfe3</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1021%2Fja409801p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja409801p%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DX.%2BY.%26aulast%3DKrishnamoorthy%26aufirst%3DJ.%26aulast%3DSavelieff%26aufirst%3DM.%2BG.%26aulast%3DPark%26aufirst%3DH.%2BM.%26aulast%3DBrender%26aufirst%3DJ.%2BR.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DDerrick%26aufirst%3DJ.%2BS.%26aulast%3DKochi%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DRamamoorthy%26aufirst%3DA.%26aulast%3DBowers%26aufirst%3DM.%2BT.%26aulast%3DLim%26aufirst%3DM.%2BH.%26atitle%3DRational%2520Design%2520of%2520a%2520Structural%2520Framework%2520with%2520Potential%2520Use%2520to%2520Develop%2520Chemical%2520Reagents%2520That%2520Target%2520and%2520Modulate%2520Multiple%2520Facets%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26issue%3D1%26spage%3D299%26epage%3D310%26doi%3D10.1021%2Fja409801p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savelieff, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detoma, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derrick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span> <span> </span><span class="NLM_article-title">The Ongoing Search for Small Molecules to Study Metal-Associated Amyloid- Species in Alzheimer’s Disease</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2475</span>– <span class="NLM_lpage">2482</span>, <span class="refDoi"> DOI: 10.1021/ar500152x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar500152x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GlurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2014&pages=2475-2482&issue=8&author=M.+G.+Savelieffauthor=A.+S.+Detomaauthor=J.+S.+Derrickauthor=M.+H.+Lim&title=The+Ongoing+Search+for+Small+Molecules+to+Study+Metal-Associated+Amyloid-+Species+in+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Far500152x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">The Ongoing Search for Small Molecules to Study Metal-Associated Amyloid-β Species in Alzheimer's Disease</span></div><div class="casAuthors">Savelieff, Masha G.; DeToma, Alaina S.; Derrick, Jeffrey S.; Lim, Mi Hee</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2475-2482</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of a cure for Alzheimer's disease (AD) has been impeded by an inability to pinpoint the root cause of this disorder.  Although numerous potential pathol. factors have been indicated, acting either individually or mutually, the mol. mechanisms leading to disease onset and progression have not been clear.  Amyloid-β (Aβ), generated from proteolytic processing of the amyloid precursor protein (APP), and its aggregated forms, particularly oligomers, are suggested as key pathol. features in AD-affected brains.  Historically, highly concd. metals are found colocalized within Aβ plaques.  Metal binding to Aβ (metal-Aβ) generates/stabilizes potentially toxic Aβ oligomers, and produces reactive oxygen species (ROS) in vitro (redox active metal ions; plausible contribution to oxidative stress).  Consequently, clarification of the relationship between Aβ, metal ions, and toxicity, including oxidative stress via metal-Aβ, can lead to a deeper understanding of AD development.  To probe the involvement of metal-Aβ in AD pathogenesis, rationally designed and naturally occurring mols. have been examd. as chem. tools to target metal-Aβ species, modulate the interaction between the metal and Aβ, and subsequently redirect their aggregation into nontoxic, off-pathway unstructured aggregates.  These ligands are also capable of attenuating the generation of redox active metal-Aβ-induced ROS to mitigate oxidative stress.  One rational design concept, the incorporation approach, installs a metal binding site into a framework known to interact with Aβ.  This approach affords compds. with the simultaneous ability to chelate metal ions and interact with Aβ.  Natural products capable of Aβ interaction have been investigated for their influence on metal-induced Aβ aggregation and have inspired the construction of synthetic analogs.  Systematic studies of these synthetic or natural mols. could uncover relationships between chem. structures, metal/Aβ/metal-Aβ interactions, and inhibition of Aβ/metal-Aβ reactivity (i.e., aggregation modes of Aβ/metal-Aβ; assocd. ROS prodn.), suggesting mechanisms to refine the design strategy.  Interdisciplinary investigations have demonstrated that the designed mols. and natural products control the aggregation pathways of metal-Aβ species transforming their size/conformation distribution.  The aptitude of these mols. to impact metal-Aβ aggregation pathways, either via inhibition of Aβ aggregate formation, most importantly of oligomers, or disaggregation of preformed fibrils, could originate from their formation of complexes with metal-Aβ.  Potentially, these mols. could direct metal-Aβ size/conformational states into alternative nontoxic unstructured oligomers, and control the geometry at the Aβ-ligated metal center for limited ROS formation to lessen the overall toxicity induced by metal-Aβ.  Complexation between small mols. and Aβ/metal-Aβ has been obsd. by NMR spectroscopy (NMR) and ion mobility-mass spectrometry (IM-MS) pointing to mol. level interactions, validating the design strategy.  In addn., these mols. exhibit other attractive properties, such as antioxidant capacity, prevention of ROS prodn., potential blood-brain barrier (BBB) permeability, and redn. of Aβ-/metal-Aβ-induced cytotoxicity, making them desirable tools for unraveling AD complexity.  In this Account, we summarize the recent development of small mols., via both rational design and the selection and modification of natural products, as tools for investigating metal-Aβ complexes, to advance our understanding of their relation to AD pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonOeVndqFambVg90H21EOLACvtfcHk0ljV4Cdr0HJgmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GlurvF&md5=26cb7b5ff0499e657046f99776f48010</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Far500152x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far500152x%26sid%3Dliteratum%253Aachs%26aulast%3DSavelieff%26aufirst%3DM.%2BG.%26aulast%3DDetoma%26aufirst%3DA.%2BS.%26aulast%3DDerrick%26aufirst%3DJ.%2BS.%26aulast%3DLim%26aufirst%3DM.%2BH.%26atitle%3DThe%2520Ongoing%2520Search%2520for%2520Small%2520Molecules%2520to%2520Study%2520Metal-Associated%2520Amyloid-%2520Species%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2014%26volume%3D47%26issue%3D8%26spage%3D2475%26epage%3D2482%26doi%3D10.1021%2Far500152x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title"><sup>99m</sup>Tc(CO)<sub>3</sub>-Labeled Benzothiazole Derivatives Preferentially Bind Cerebrovascular Amyloid: Potential Use as Imaging Agents for Cerebral Amyloid Angiopathy</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2937</span>– <span class="NLM_lpage">2946</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00209</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00209" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSht7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=2937-2946&issue=8&author=J.+Jiaauthor=M.+Cuiauthor=J.+Daiauthor=B.+Liu&title=99mTc%28CO%293-Labeled+Benzothiazole+Derivatives+Preferentially+Bind+Cerebrovascular+Amyloid%3A+Potential+Use+as+Imaging+Agents+for+Cerebral+Amyloid+Angiopathy&doi=10.1021%2Facs.molpharmaceut.5b00209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">99mTc(CO)3-Labeled Benzothiazole Derivatives Preferentially Bind Cerebrovascular Amyloid: Potential Use as Imaging Agents for Cerebral Amyloid Angiopathy</span></div><div class="casAuthors">Jia, Jianhua; Cui, Mengchao; Dai, Jiapei; Liu, Boli</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2937-2946</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cerebral amyloid angiopathy (CAA) is a disorder affecting the elderly that is characterized by amyloid-β (Aβ) deposition in blood vessel walls of the brain.  A series of 99mTc(CO)3-labeled benzothiazole derivs. as potential SPECT imaging probes for cerebrovascular Aβ deposition is reported.  Rhenium surrogate displayed high affinities to Aβ aggregates with Ki values ranging from 106 to 42 nM, and they strongly stained Aβ deposits in transgenic mice (Tg) and Alzheimer's disease (AD) patients.  In vitro autoradiog. on brain sections of Tg and AD patients confirmed that [99mTc]24 possessed sufficient affinity for Aβ plaques, and [99mTc]24 could only label Aβ deposition in blood vessels but not Aβ plaques in the parenchyma of the brain of AD patients.  Moreover, [99mTc]24 possessed favorable initial uptake (1.21% ID/g) and fast blood washout (blood2 min/blood60 min = 23) in normal mice.  These preliminary results suggest that [99mTc]24 may be used as an Aβ imaging probe for the detection of CAA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozsbiTC_kIl7Vg90H21EOLACvtfcHk0ljV4Cdr0HJgmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSht7nO&md5=3900660dbc9f7fd8291662a882e8cc66</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00209%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3D99mTc%2528CO%25293-Labeled%2520Benzothiazole%2520Derivatives%2520Preferentially%2520Bind%2520Cerebrovascular%2520Amyloid%253A%2520Potential%2520Use%2520as%2520Imaging%2520Agents%2520for%2520Cerebral%2520Amyloid%2520Angiopathy%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26issue%3D8%26spage%3D2937%26epage%3D2946%26doi%3D10.1021%2Facs.molpharmaceut.5b00209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braymer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detoma, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampf, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span> <span> </span><span class="NLM_article-title">Development of Bifunctional Stilbene Derivatives for Targeting and Modulating Metal-Amyloid- Species</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">10724</span>– <span class="NLM_lpage">10734</span>, <span class="refDoi"> DOI: 10.1021/ic2012205</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic2012205" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Cht73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=10724-10734&issue=21&author=J.+J.+Braymerauthor=J.+S.+Choiauthor=A.+S.+Detomaauthor=C.+Wangauthor=K.+Namauthor=J.+W.+Kampfauthor=A.+Ramamoorthyauthor=M.+H.+Lim&title=Development+of+Bifunctional+Stilbene+Derivatives+for+Targeting+and+Modulating+Metal-Amyloid-+Species&doi=10.1021%2Fic2012205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Bifunctional Stilbene Derivatives for Targeting and Modulating Metal-Amyloid-β Species</span></div><div class="casAuthors">Braymer, Joseph J.; Choi, Jung-Suk; DeToma, Alaina S.; Wang, Chen; Nam, Kisoo; Kampf, Jeffrey W.; Ramamoorthy, Ayyalusamy; Lim, Mi Hee</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">10724-10734</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Amyloid-β (Aβ) peptides and their metal-assocd. aggregated states have been implicated in the pathogenesis of Alzheimer's disease (AD).  Although the etiol. of AD remains uncertain, understanding the role of metal-Aβ species could provide insights into the onset and development of the disease.  To unravel this, bifunctional small mols. that can specifically target and modulate metal-Aβ species have been developed, which could serve as suitable chem. tools for investigating metal-Aβ-assocd. events in AD.  Through a rational structure-based design principle involving the incorporation of a metal binding site into the structure of an Aβ interacting mol., we devised stilbene derivs. (L1-a and L1-b) and demonstrated their reactivity toward metal-Aβ species.  In particular, the dual functions of compds. with different structural features (e.g., with or without a dimethylamino group) were explored by UV-vis, X-ray crystallog., high-resoln. 2D NMR, and docking studies.  Enhanced bifunctionality of compds. provided greater effects on metal-induced Aβ aggregation and neurotoxicity in vitro and in living cells.  Mechanistic investigations of the reaction of L1-a and L1-b with Zn2+-Aβ species by UV-vis and 2D NMR suggest that metal chelation with ligand and/or metal-ligand interaction with the Aβ peptide may be driving factors for the obsd. modulation of metal-Aβ aggregation pathways.  Overall, the studies presented herein demonstrate the importance of a structure-interaction-reactivity relationship for designing small mols. to target metal-Aβ species allowing for the modulation of metal-induced Aβ reactivity and neurotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNUiFOBflT-rVg90H21EOLACvtfcHk0lijA3mhuxjrew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Cht73L&md5=6fa2692924456a5d1d281f451a307e3d</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Fic2012205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic2012205%26sid%3Dliteratum%253Aachs%26aulast%3DBraymer%26aufirst%3DJ.%2BJ.%26aulast%3DChoi%26aufirst%3DJ.%2BS.%26aulast%3DDetoma%26aufirst%3DA.%2BS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DNam%26aufirst%3DK.%26aulast%3DKampf%26aufirst%3DJ.%2BW.%26aulast%3DRamamoorthy%26aufirst%3DA.%26aulast%3DLim%26aufirst%3DM.%2BH.%26atitle%3DDevelopment%2520of%2520Bifunctional%2520Stilbene%2520Derivatives%2520for%2520Targeting%2520and%2520Modulating%2520Metal-Amyloid-%2520Species%26jtitle%3DInorg.%2520Chem.%26date%3D2011%26volume%3D50%26issue%3D21%26spage%3D10724%26epage%3D10734%26doi%3D10.1021%2Fic2012205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitcock, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokshagundam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Direct Nitric Oxide Detection in Aqueous Solution by Copper(II) Fluorescein Complexes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">14364</span>– <span class="NLM_lpage">14373</span>, <span class="refDoi"> DOI: 10.1021/ja064955e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja064955e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVKitbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=14364-14373&issue=44&author=M.+H.+Limauthor=B.+A.+Wongauthor=W.+H.+Pitcockauthor=D.+Mokshagundamauthor=M.-H.+Baikauthor=S.+J.+Lippard&title=Direct+Nitric+Oxide+Detection+in+Aqueous+Solution+by+Copper%28II%29+Fluorescein+Complexes&doi=10.1021%2Fja064955e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Direct Nitric Oxide Detection in Aqueous Solution by Copper(II) Fluorescein Complexes</span></div><div class="casAuthors">Lim, Mi Hee; Wong, Brian A.; Pitcock, William H., Jr.; Mokshagundam, Deepa; Baik, Mu-Hyun; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">14364-14373</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of FLn (n = 1-5) ligands, where FLn is a fluorescein modified with a functionalized 8-aminoquinoline group as a copper-binding moiety, were synthesized, and the chem. and photophys. properties of the free ligands and their copper complexes were investigated.  UV-visible spectroscopy revealed a 1:1 binding stoichiometry for the Cu(II) complexes of FL1, FL3, and FL5 in pH 7.0 buffered aq. solns.  The reactions of FL2 or FL4 with CuCl2, however, appear to produce a mixt. of 1:1 and 1:2 complexes, as suggested by Job's plots.  These binding modes were modeled by the synthesis and X-ray crystal structure detn. of Cu(II) complexes of 2-[(quinolin-8-ylamino)methyl]phenol (modL), employed as a surrogate of the FLn ligand family.  Two kinds of crystals, [Cu(modL)2](BF4)2 and [Cu2(modL')2(CH3OH)](BF4)2 (modL' = 2-[(quinolin-8-ylamino)methyl]phenolate), were obtained.  The structures suggest that one oxygen and two nitrogen atoms of the FLn ligands most likely bind to Cu(II).  Introduction of nitric oxide (NO) to pH 7.0 buffered aq. solns. of Cu(FLn) (1 μM CuCl2 and 1 μM FLn) at 37 °C induces an increase in fluorescence.  The fluorescence response of Cu(FLn) to NO is direct and specific, which is a significant improvement over com. available small mol.-based probes that are capable of detecting NO only indirectly.  The NO-triggered fluorescence increase of Cu(FL5) occurs by redn. of Cu(II) to Cu(I) with concomitant dissocn. of the N-nitrosated fluorophore ligand from copper.  Spectroscopic and product analyses of the reaction of the FL5 copper complex with NO indicated that the N-nitrosated fluorescein ligand (FL5-NO) is the species responsible for fluorescence turn-on.  D. functional theory (DFT) calcns. of FL5 vs. FL5-NO reveal how N-nitrosation of the fluorophore ligand brings about the fluorescence increase.  The copper-based probes described in the present work form the basis for real-time detection of nitric oxide prodn. in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHswkywkq-w7Vg90H21EOLACvtfcHk0lijA3mhuxjrew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVKitbbN&md5=3c15b4e002de580f413b4729c148a39a</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Fja064955e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja064955e%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DM.%2BH.%26aulast%3DWong%26aufirst%3DB.%2BA.%26aulast%3DPitcock%26aufirst%3DW.%2BH.%26aulast%3DMokshagundam%26aufirst%3DD.%26aulast%3DBaik%26aufirst%3DM.-H.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DDirect%2520Nitric%2520Oxide%2520Detection%2520in%2520Aqueous%2520Solution%2520by%2520Copper%2528II%2529%2520Fluorescein%2520Complexes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26issue%3D44%26spage%3D14364%26epage%3D14373%26doi%3D10.1021%2Fja064955e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orhan Puskullu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tekiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzen, S.</span></span> <span> </span><span class="NLM_article-title">Recent Studies of Antioxidant Quinoline Derivatives</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.2174/138955713804999793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F138955713804999793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23190035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC3s7ntFGhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=365-372&issue=3&author=P.+M.+Orhan+Puskulluauthor=B.+Tekinerauthor=S.+Suzen&title=Recent+Studies+of+Antioxidant+Quinoline+Derivatives&doi=10.2174%2F138955713804999793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Recent studies of antioxidant quinoline derivatives</span></div><div class="casAuthors">Orhan Puskullu M; Tekiner Betul; Suzen Sibel</div><div class="citationInfo"><span class="NLM_cas:title">Mini reviews in medicinal chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Quinoline derivatives constitute an important class of compounds for new drug development.  As a large number of experimental and theoretical studies have shown that the quinoline ring system is an important structural unit widely existing in alkaloids, therapeutics and synthetic analogues with exciting biological activities.  The present review provides recent antioxidant activities covering in vivo and in vitro studies of natural and synthetic analogues, as well as the proposed mechanisms of action and structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRRBr5FFOk3FWTCLT8lX9SfW6udTcc2eYHrHxz3j-5cLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7ntFGhtw%253D%253D&md5=d01bf474b64896b0250fd54c1e619d4f</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.2174%2F138955713804999793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955713804999793%26sid%3Dliteratum%253Aachs%26aulast%3DOrhan%2BPuskullu%26aufirst%3DP.%2BM.%26aulast%3DTekiner%26aufirst%3DB.%26aulast%3DSuzen%26aufirst%3DS.%26atitle%3DRecent%2520Studies%2520of%2520Antioxidant%2520Quinoline%2520Derivatives%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26issue%3D3%26spage%3D365%26epage%3D372%26doi%3D10.2174%2F138955713804999793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson’s Disease</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">E1010</span>, <span class="refDoi"> DOI: 10.3390/molecules22061010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3390%2Fmolecules22061010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28629145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGgtLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=E1010&issue=6&author=X.+Wangauthor=C.+Hanauthor=Y.+Xuauthor=K.+Wuauthor=S.+Chenauthor=M.+Huauthor=L.+Wangauthor=Y.+Yeauthor=F.+Ye&title=Synthesis+and+Evaluation+of+Phenylxanthine+Derivatives+as+Potential+Dual+A2AR+Antagonists%2FMAO-B+Inhibitors+for+Parkinson%E2%80%99s+Disease&doi=10.3390%2Fmolecules22061010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of phenylxanthine derivatives as potential dual A2AR antagonists/MAO-B inhibitors for Parkinson's disease</span></div><div class="casAuthors">Wang, Xuebao; Han, Chao; Xu, Yong; Wu, Kaiqi; Chen, Shuangya; Hu, Mangsha; Wang, Luyao; Ye, Yun; Ye, Faqing</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1010/1-1010/13</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The aim of this research was to prove the speculation that phenylxanthine (PX) derivs. possess adenosine A2A receptor (A2AR)-blocking properties and to screening and evaluate these PX derivs. as dual A2AR antagonists/MAO-B inhibitors for Parkinson0s disease.  To explore this hypothesis, two series of PX derivs. were prepd. and their antagonism against A2AR and inhibition against MAO-B were detd. in vitro.  In order to evaluate further the antiparkinsonian properties, pharmacokinetic and haloperidol-induced catalepsy expts. were carried out in vivo.  The PX-D and PX-E analogs acted as potent A2AR antagonists with Ki values ranging from 0.27 to 10 μM, and these analogs displayed relatively mild MAO-B inhibition potencies, with inhibitor dissocn. consts. (Ki values) ranging from 0.25 to 10 μM.  Further, the compds. PX-D-P6 and PX-E-P8 displayed efficacious antiparkinsonian properties in haloperidol-induced catalepsy expts., verifying that these two compds. were potent A2AR antagonists and MAO-B inhibitors.  We conclude that PX-D and PX-E analogs are a promising candidate class of dual-acting compds. for treating Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpkdoiOmu87rVg90H21EOLACvtfcHk0lg9UmkCpB6cQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGgtLbJ&md5=9804c51e9ea8302927601323590b65fb</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22061010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22061010%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DF.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520Phenylxanthine%2520Derivatives%2520as%2520Potential%2520Dual%2520A2AR%2520Antagonists%252FMAO-B%2520Inhibitors%2520for%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26issue%3D6%26spage%3DE1010%26doi%3D10.3390%2Fmolecules22061010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyce, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lera Ruiz, M. L.</span></span> <span> </span><span class="NLM_article-title">Histamine H<sub>3</sub> Receptor as a Drug Discovery Target</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1021/jm100064d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100064d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2lsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=26-53&issue=1&author=M.+Berlinauthor=C.+W.+Boyceauthor=M.+L.+de+Lera+Ruiz&title=Histamine+H3+Receptor+as+a+Drug+Discovery+Target&doi=10.1021%2Fjm100064d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H3 Receptor as a Drug Discovery Target</span></div><div class="casAuthors">Berlin, Michael; Boyce, Christopher W.; de Lera Ruiz, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-53</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ever since its pharmacol. discovery in 1983, the histamine H3 receptor has provided a tantalizing target for drug research,.  Connections between the biochem. signaling mechanisms and in vivo effects of the H3 agonists and antagonists, whether hypothetical or clearly supported by data, are contemplated throughout the review.  It seems likely, given the current activity level of research and development, that days of com. H3 drugs are approaching.  Whether a stand-alone treatment or a valuable add-on to an existing therapy, H3 antagonists seem well positioned to soon share in and expand the existing drug class designation of "antihistamines".  Led by the abundant preclin. data, drug companies finally seem to be in a position to probe the putative connections between the H3 mechanism and a no. of human therapeutic conditions.  The pressure is clearly on clin. research to generate convincing proof-of-concept data to support or reject those connections.  Further developments in H3 biol. are to be awaited with much interest and may serve to further substantiate the existing indications and suggest novel therapeutic uses.  Because of the wide spectrum of the potential indications, the need to reconcile and manage as a combination the various expected H3 therapeutic effects (most of which, adding to the level of complexity, are believed to be centrally mediated) may prove a significant challenge in itself.  Ever since its pharmacol. discovery in 1983, the histamine H receptor has provided a tantalizing target for drug research,.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEQYOWZmWyy7Vg90H21EOLACvtfcHk0lg9UmkCpB6cQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2lsb3F&md5=2a68aedccfd5f8887f048ead3c3a7517</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1021%2Fjm100064d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100064d%26sid%3Dliteratum%253Aachs%26aulast%3DBerlin%26aufirst%3DM.%26aulast%3DBoyce%26aufirst%3DC.%2BW.%26aulast%3Dde%2BLera%2BRuiz%26aufirst%3DM.%2BL.%26atitle%3DHistamine%2520H3%2520Receptor%2520as%2520a%2520Drug%2520Discovery%2520Target%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D1%26spage%3D26%26epage%3D53%26doi%3D10.1021%2Fjm100064d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sander, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kottke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Histamine H<sub>3</sub> Receptor Antagonists Go to Clinics</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2163</span>– <span class="NLM_lpage">2181</span>, <span class="refDoi"> DOI: 10.1248/bpb.31.2163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1248%2Fbpb.31.2163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19043195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1Kmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=2163-2181&issue=12&author=K.+Sanderauthor=T.+Kottkeauthor=H.+Stark&title=Histamine+H3+Receptor+Antagonists+Go+to+Clinics&doi=10.1248%2Fbpb.31.2163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Histamine H3 receptor antagonists go to clinics</span></div><div class="casAuthors">Sander, Kerstin; Kottke, Tim; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2163-2181</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A review.  Within the recent years novel lead optimizations for histamine H3 receptor antagonists made their way from bench to bedside.  Structure-activity relationships, cross-affinities and side effects as well as pharmacokinetic profiling will be discussed on selected promising compd. series.  Due to diversity in potential therapeutic applications and in some cases a controversial debate, different indications will be highlighted with the potential and the problems of the test compds., e.g. sleep-wake disorders, attention-deficient hyperactivity disorder, epilepsy, cognitive impairment, schizophrenia, obesity and neuropathic pain.  First data published on clin. trials phase II (IIb) are presented showing proof of concept of H3 receptor antagonists in narcolepsy and photoinduced epilepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJWogrOu3mmbVg90H21EOLACvtfcHk0lg9UmkCpB6cQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1Kmsbs%253D&md5=b816371be0c006bef83d279a426fee45</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1248%2Fbpb.31.2163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.31.2163%26sid%3Dliteratum%253Aachs%26aulast%3DSander%26aufirst%3DK.%26aulast%3DKottke%26aufirst%3DT.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DHistamine%2520H3%2520Receptor%2520Antagonists%2520Go%2520to%2520Clinics%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2008%26volume%3D31%26issue%3D12%26spage%3D2163%26epage%3D2181%26doi%3D10.1248%2Fbpb.31.2163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Affini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zivkovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span> <span> </span><span class="NLM_article-title">Novel Indanone Derivatives as MAO B/H<sub>3</sub>R Dual-Targeting Ligands for Treatment of Parkinson’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2018.02.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29477889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsF2msbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=487-497&author=A.+Affiniauthor=S.+Hagenowauthor=A.+Zivkovicauthor=J.+Marco-Contellesauthor=H.+Stark&title=Novel+Indanone+Derivatives+as+MAO+B%2FH3R+Dual-Targeting+Ligands+for+Treatment+of+Parkinson%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2018.02.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease</span></div><div class="casAuthors">Affini, Anna; Hagenow, Stefanie; Zivkovic, Aleksandra; Marco-Contelles, Jose; Stark, Holger</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">487-497</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders.  As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, the authors synthesized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the treatment of PD.  Three series of compds. were developed by attaching the H3R pharmacophore to indanone-related MAO B motifs, leading to development of MAO B/H3R DTLs.  Among synthesized indanone DTLs, compds. bearing the 2-benzylidene-1-indanone core structure showed MAO B preferring inhibition capabilities along with nanomolar hH3R affinity.  Substitution of C5 and C6 position of the 2-benzylidene-1-indanones with lipophilic substituents revealed three promising candidates exhibiting inhibitory potencies for MAO B with IC50 values ranging from 1931 nM to 276 nM and high affinities at hH3R (Ki < 50 nM).  Compd. 3f ((E)-5-((4-bromobenzyl)oxy)-2-(4-(3-(piperidin-1-yl)propoxy)benzylidene)-2,3-dihydro-1H-inden-1-one, MAO B IC50 = 276 nM, hH3R Ki = 6.5 nM) showed highest preference for MAO B over MAO A (SI > 36).  Interestingly, IC50 detns. after preincubation of enzyme and DTLs revealed also nanomolar MAO B potency for 3e (MAO B IC50 = 232 nM), a structural isomer of 3f, and 3d ((E)-5-fluoro-2-[4-[3-(piperidin-1-yl)propoxy]benzylidene]-2,3-dihydro-1H-inden-1-one) (MAO B IC50 = 541 nM), suggesting time-dependent inhibition modes.  Reversibility of inhibition for all three compds. were confirmed by diln. studies in excess of substrate.  Thus, indanone-substituted derivs. are promising lead structures for the design of MAO B/hH3R DTLs as novel therapeutic approach of PD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozgPusP5M44bVg90H21EOLACvtfcHk0liHYrXbhbR1Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsF2msbY%253D&md5=9b915ce055294d79bfa8e585a19e6466</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DAffini%26aufirst%3DA.%26aulast%3DHagenow%26aufirst%3DS.%26aulast%3DZivkovic%26aufirst%3DA.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DStark%26aufirst%3DH.%26atitle%3DNovel%2520Indanone%2520Derivatives%2520as%2520MAO%2520B%252FH3R%2520Dual-Targeting%2520Ligands%2520for%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D148%26spage%3D487%26epage%3D497%26doi%3D10.1016%2Fj.ejmech.2018.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Monteagudo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordeiro, M. N. D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helguera, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejera, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-y-Mino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera-Sardina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Castillo, Y.</span></span> <span> </span><span class="NLM_article-title">Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.2174/1570159X15666170116145316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F1570159X15666170116145316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28093976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFens7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=1117-1135&issue=8&author=M.+Cruz-Monteagudoauthor=F.+Borgesauthor=M.+N.+D.+S.+Cordeiroauthor=A.+M.+Helgueraauthor=E.+Tejeraauthor=C.+Paz-y-Minoauthor=A.+Sanchez-Rodriguezauthor=Y.+Perera-Sardinaauthor=Y.+Perez-Castillo&title=Chemoinformatics+Profiling+of+the+Chromone+Nucleus+as+a+MAO-B%2FA2AAR+Dual+Binding+Scaffold&doi=10.2174%2F1570159X15666170116145316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold</span></div><div class="casAuthors">Cruz-Monteagudo, Maykel; Borges, Fernanda; S. Cordeiro, M. Natalia D.; Helguera, Aliuska Morales; Tejera, Eduardo; Paz-y-Mino, Cesar; Sanchez-Rodriguez, Aminael; Perera-Sardina, Yunier; Perez-Castillo, Yunierkis</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1117-1135</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: In the context of the current drug discovery efforts to find disease modifying therapies for Parkinson&#39;s disease (PD) the current single target strategy has proved inefficient.  Consequently, the search for multi-potent agents is attracting more and more attention due to the multiple pathogenetic factors implicated in PD.  Multiple evidences points to the dual inhibition of the monoamine oxidase B (MAO-B), as well as adenosine A2A receptor (A2AAR) blockade, as a promising approach to prevent the neurodegeneration involved in PD.  Currently, only two chem. scaffolds has been proposed as potential dual MAO-B inhibitors/A2AAR antagonists (caffeine derivs. and benzothiazinones).  Methods: In this study, we conduct a series of chemoinformatics anal. in order to evaluate and advance the potential of the chromone nucleus as a MAO-B/A2AAR dual binding scaffold.  Results: The information provided by SAR data mining anal. based on network similarity graphs and mol. docking studies support the suitability of the chromone nucleus as a potential MAOB/ A2AAR dual binding scaffold.  Addnl., a virtual screening tool based on a group fusion similarity search approach was developed for the prioritization of potential MAO-B/A2AAR dual binder candidates.  Among several data fusion schemes evaluated, the MEAN-SIM and MIN-RANK GFSS approaches demonstrated to be efficient virtual screening tools.  Then, a combinatorial library potentially enriched with MAO-B/A2AAR dual binding chromone derivs. was assembled and sorted by using the MIN-RANK and then the MEAN-SIM GFSS VS approaches.  Conclusion: The information and tools provided in this work represent valuable decision making elements in the search of novel chromone derivs. with a favorable dual binding profile as MAOB inhibitors and A2AAR antagonists with the potential to act as a disease-modifying therapeutic for Parkinson&#39;s disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoau4sw7FLhUrVg90H21EOLACvtfcHk0liHYrXbhbR1Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFens7zI&md5=f90bd3d2805f7ef2af0410bb48f16877</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.2174%2F1570159X15666170116145316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X15666170116145316%26sid%3Dliteratum%253Aachs%26aulast%3DCruz-Monteagudo%26aufirst%3DM.%26aulast%3DBorges%26aufirst%3DF.%26aulast%3DCordeiro%26aufirst%3DM.%2BN.%2BD.%2BS.%26aulast%3DHelguera%26aufirst%3DA.%2BM.%26aulast%3DTejera%26aufirst%3DE.%26aulast%3DPaz-y-Mino%26aufirst%3DC.%26aulast%3DSanchez-Rodriguez%26aufirst%3DA.%26aulast%3DPerera-Sardina%26aufirst%3DY.%26aulast%3DPerez-Castillo%26aufirst%3DY.%26atitle%3DChemoinformatics%2520Profiling%2520of%2520the%2520Chromone%2520Nucleus%2520as%2520a%2520MAO-B%252FA2AAR%2520Dual%2520Binding%2520Scaffold%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2017%26volume%3D15%26issue%3D8%26spage%3D1117%26epage%3D1135%26doi%3D10.2174%2F1570159X15666170116145316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunschweiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Küppers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title">8-Benzyltetrahydropyrazino[2,1-f]Purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1704</span>– <span class="NLM_lpage">1724</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fcmdc.201402082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24817533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslWku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1704-1724&issue=8&author=A.+Brunschweigerauthor=P.+Kochauthor=M.+Schlenkauthor=F.+Pinedaauthor=P.+K%C3%BCppersauthor=S.+Hinzauthor=M.+K%C3%B6seauthor=S.+Ullrichauthor=J.+Hockemeyerauthor=M.+Wieseauthor=J.+Heerauthor=C.+E.+Muller&title=8-Benzyltetrahydropyrazino%5B2%2C1-f%5DPurinediones%3A+Water-Soluble+Tricyclic+Xanthine+Derivatives+as+Multitarget+Drugs+for+Neurodegenerative+Diseases&doi=10.1002%2Fcmdc.201402082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">8-Benzyltetrahydropyrazino[2,1-f]purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases</span></div><div class="casAuthors">Brunschweiger, Andreas; Koch, Pierre; Schlenk, Miriam; Pineda, Felipe; Kueppers, Petra; Hinz, Sonja; Koese, Meryem; Ullrich, Stefan; Hockemeyer, Joerg; Wiese, Michael; Heer, Jag; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1704-1724</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">8-Benzyl-substituted tetrahydropyrazino[2,1-f]purinediones were designed as tricyclic xanthine derivs. contg. a basic nitrogen atom in the tetrahydropyrazine ring to improve water soly.  A library of 69 derivs. was prepd. and evaluated in radioligand binding studies at adenosine receptor (AR) subtypes and for their ability to inhibit monoamine oxidases (MAO).  Potent dual-target-directed A1/A2A adenosine receptor antagonists were identified.  Several compds. showed triple-target inhibition; one of the best compds. was 8-(2,4-dichloro-5-fluorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4-(1H,3H)-dione (human AR: Ki A1 217 nm, A2A 233 nm; IC50 MAO-B: 508 nm).  Dichlorinated compd. [8-(3,4-dichlorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4-(1H,3H)-dione] was found to be the best triple-target drug in rat (Ki A1 351 nm, A2A 322 nm; IC50 MAO-B: 260 nm), and may serve as a useful tool for preclin. proof-of-principle studies.  Compds. that act at multiple targets relevant for symptomatic as well as disease-modifying treatment of neurodegenerative diseases are expected to show advantages over single-target therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq7_nlMNkyirVg90H21EOLACvtfcHk0ljgnBNV_5xt5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslWku7Y%253D&md5=d9965ddec52ab2304e9b14d4a52b0950</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402082%26sid%3Dliteratum%253Aachs%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DSchlenk%26aufirst%3DM.%26aulast%3DPineda%26aufirst%3DF.%26aulast%3DK%25C3%25BCppers%26aufirst%3DP.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DK%25C3%25B6se%26aufirst%3DM.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DWiese%26aufirst%3DM.%26aulast%3DHeer%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3D8-Benzyltetrahydropyrazino%255B2%252C1-f%255DPurinediones%253A%2520Water-Soluble%2520Tricyclic%2520Xanthine%2520Derivatives%2520as%2520Multitarget%2520Drugs%2520for%2520Neurodegenerative%2520Diseases%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26issue%3D8%26spage%3D1704%26epage%3D1724%26doi%3D10.1002%2Fcmdc.201402082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eskelinen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivipelto, M.</span></span> <span> </span><span class="NLM_article-title">Caffeine as a Protective Factor in Dementia and Alzheimer’s Disease</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">Suppl. 1</span>),  <span class="NLM_fpage">S167</span>– <span class="NLM_lpage">S174</span>, <span class="refDoi"> DOI: 10.3233/JAD-2010-1404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3233%2FJAD-2010-1404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20182054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXls12huro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=S167-S174&issue=Suppl.+1&author=M.+H.+Eskelinenauthor=M.+Kivipelto&title=Caffeine+as+a+Protective+Factor+in+Dementia+and+Alzheimer%E2%80%99s+Disease&doi=10.3233%2FJAD-2010-1404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Caffeine as a Protective Factor in Dementia and Alzheimer's Disease</span></div><div class="casAuthors">Eskelinen, Marjo H.; Kivipelto, Miia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S167-S174</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  Caffeine has well-known short-term stimulating effects on central nervous system, but the long-term impacts on cognition have been less clear.  Dementia and Alzheimer's disease (AD) are rapidly increasing public health problems in ageing populations and at the moment curative treatment is lacking.  Thus, the putative protective effects of caffeine against dementia/AD are of great interest.  Here, we discuss findings from the longitudinal epidemiol. studies about caffeine/coffee/tea and dementia/AD/cognitive functioning with a special emphasis on our recent results from the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) study.  The findings of the previous studies are somewhat inconsistent, but most studies (3 out of 5) support coffee's favorable effects against cognitive decline, dementia or AD.  In addn., two studies had combined coffee and tea drinking and indicated some pos. effects on cognitive functioning.  For tea drinking, protective effects against cognitive decline/dementia are still less evident.  In the CAIDE study, coffee drinking of 3-5 cups per day at midlife was assocd. with a decreased risk of dementia/AD by about 65% at late-life.  In conclusion, coffee drinking may be assocd. with a decreased risk of dementia/AD.  This may be mediated by caffeine and/or other mechanisms like antioxidant capacity and increased insulin sensitivity.  This finding might open possibilities for prevention or postponing the onset of dementia/AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomYnYizfcSebVg90H21EOLACvtfcHk0ljgnBNV_5xt5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXls12huro%253D&md5=52fd6e58bc3ceef5bbb8b86523e16f31</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.3233%2FJAD-2010-1404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2010-1404%26sid%3Dliteratum%253Aachs%26aulast%3DEskelinen%26aufirst%3DM.%2BH.%26aulast%3DKivipelto%26aufirst%3DM.%26atitle%3DCaffeine%2520as%2520a%2520Protective%2520Factor%2520in%2520Dementia%2520and%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2010%26volume%3D20%26issue%3DSuppl.%25201%26spage%3DS167%26epage%3DS174%26doi%3D10.3233%2FJAD-2010-1404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunschweiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Küppers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title">8-Benzyltetrahydropyrazino[2,1-F]Purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1704</span>– <span class="NLM_lpage">1724</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201402082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fcmdc.201402082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24817533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslWku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1704-1724&issue=8&author=A.+Brunschweigerauthor=P.+Kochauthor=M.+Schlenkauthor=F.+Pinedaauthor=P.+K%C3%BCppersauthor=S.+Hinzauthor=M.+K%C3%B6seauthor=S.+Ullrichauthor=J.+Hockemeyerauthor=M.+Wieseauthor=J.+Heerauthor=C.+E.+Muller&title=8-Benzyltetrahydropyrazino%5B2%2C1-F%5DPurinediones%3A+Water-Soluble+Tricyclic+Xanthine+Derivatives+as+Multitarget+Drugs+for+Neurodegenerative+Diseases&doi=10.1002%2Fcmdc.201402082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">8-Benzyltetrahydropyrazino[2,1-f]purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases</span></div><div class="casAuthors">Brunschweiger, Andreas; Koch, Pierre; Schlenk, Miriam; Pineda, Felipe; Kueppers, Petra; Hinz, Sonja; Koese, Meryem; Ullrich, Stefan; Hockemeyer, Joerg; Wiese, Michael; Heer, Jag; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1704-1724</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">8-Benzyl-substituted tetrahydropyrazino[2,1-f]purinediones were designed as tricyclic xanthine derivs. contg. a basic nitrogen atom in the tetrahydropyrazine ring to improve water soly.  A library of 69 derivs. was prepd. and evaluated in radioligand binding studies at adenosine receptor (AR) subtypes and for their ability to inhibit monoamine oxidases (MAO).  Potent dual-target-directed A1/A2A adenosine receptor antagonists were identified.  Several compds. showed triple-target inhibition; one of the best compds. was 8-(2,4-dichloro-5-fluorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4-(1H,3H)-dione (human AR: Ki A1 217 nm, A2A 233 nm; IC50 MAO-B: 508 nm).  Dichlorinated compd. [8-(3,4-dichlorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4-(1H,3H)-dione] was found to be the best triple-target drug in rat (Ki A1 351 nm, A2A 322 nm; IC50 MAO-B: 260 nm), and may serve as a useful tool for preclin. proof-of-principle studies.  Compds. that act at multiple targets relevant for symptomatic as well as disease-modifying treatment of neurodegenerative diseases are expected to show advantages over single-target therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq7_nlMNkyirVg90H21EOLACvtfcHk0ljgnBNV_5xt5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslWku7Y%253D&md5=d9965ddec52ab2304e9b14d4a52b0950</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402082%26sid%3Dliteratum%253Aachs%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DSchlenk%26aufirst%3DM.%26aulast%3DPineda%26aufirst%3DF.%26aulast%3DK%25C3%25BCppers%26aufirst%3DP.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DK%25C3%25B6se%26aufirst%3DM.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DWiese%26aufirst%3DM.%26aulast%3DHeer%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3D8-Benzyltetrahydropyrazino%255B2%252C1-F%255DPurinediones%253A%2520Water-Soluble%2520Tricyclic%2520Xanthine%2520Derivatives%2520as%2520Multitarget%2520Drugs%2520for%2520Neurodegenerative%2520Diseases%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26issue%3D8%26spage%3D1704%26epage%3D1724%26doi%3D10.1002%2Fcmdc.201402082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunschweiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafehi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radjainia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Küppers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denonne, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title">8-Substituted 1,3-Dimethyltetrahydropyrazino[2,1-f]Purinediones: Water-Soluble Adenosine Receptor Antagonists and Monoamine Oxidase B Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">5462</span>– <span class="NLM_lpage">5480</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2016.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27658798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFeqsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=5462-5480&issue=21&author=A.+Brunschweigerauthor=P.+Kochauthor=M.+Schlenkauthor=M.+Rafehiauthor=H.+Radjainiaauthor=P.+K%C3%BCppersauthor=S.+Hinzauthor=F.+Pinedaauthor=M.+Wieseauthor=J.+Hockemeyerauthor=J.+Heerauthor=F.+Denonneauthor=C.+E.+Muller&title=8-Substituted+1%2C3-Dimethyltetrahydropyrazino%5B2%2C1-f%5DPurinediones%3A+Water-Soluble+Adenosine+Receptor+Antagonists+and+Monoamine+Oxidase+B+Inhibitors&doi=10.1016%2Fj.bmc.2016.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors</span></div><div class="casAuthors">Brunschweiger, Andreas; Koch, Pierre; Schlenk, Miriam; Rafehi, Muhammad; Radjainia, Hamid; Kueppers, Petra; Hinz, Sonja; Pineda, Felipe; Wiese, Michael; Hockemeyer, Joerg; Heer, Jag; Denonne, Frederic; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5462-5480</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multitarget approaches, i.e., addressing two or more targets simultaneously with a therapeutic agent, are hypothesized to offer additive therapeutic benefit for the treatment of neurodegenerative diseases.  Validated targets for the treatment of Parkinson's disease are, among others, the A2A adenosine receptor (AR) and the enzyme monoamine oxidase B (MAO-B).  Addnl. blockade of brain A1 ARs may also be beneficial.  We recently described 8-benzyl-substituted tetrahydropyrazino[2,1-f]purinediones as a new lead structure for the development of such multi-target drugs.  We have now designed a new series of tetrahydropyrazino[2,1-f]purinediones to extensively explore their structure-activity-relationships.  Several compds. blocked human and rat A1 and A2AARs at similar concns. representing dual A1/A2A antagonists with high selectivity vs. the other AR subtypes.  Among the best dual A1/A2AAR antagonists were 8-(3-(4-chlorophenyl)propyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (41, Ki human A1: 65.5 nM, A2A: 230 nM; Ki rat A1: 352 nM, A2A: 316 nM) and 1,3-dimethyl-8-((2-(thiophen-2-yl)thiazol-4-yl)methyl)-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (57, Ki human A1: 642 nM, A2A: 203 nM; Ki rat A1: 166 nM, A2A: 121 nM).  Compd. 57 was found to be well water-sol. (0.7 mg/mL) at a physiol. pH value of 7.4.  One of the new compds. showed triple-target inhibition: (R)-1,3-dimethyl-8-(2,1,3,4-tetrahydronaphthalen-1-yl)-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione (49) was about equipotent at A1 and A2AARs and at MAO-B (Ki human A1: 393 nM, human A2A: 595 nM, IC50 human MAO-B: 210 nM) thus allowing future in vivo explorations of the intended multi-target approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBB9CeveG_ObVg90H21EOLACvtfcHk0lgxqdv53oKwbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFeqsr%252FM&md5=1bbbe7bc2d2544f99c2dbcfb3d7d1fbd</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DSchlenk%26aufirst%3DM.%26aulast%3DRafehi%26aufirst%3DM.%26aulast%3DRadjainia%26aufirst%3DH.%26aulast%3DK%25C3%25BCppers%26aufirst%3DP.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DPineda%26aufirst%3DF.%26aulast%3DWiese%26aufirst%3DM.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DHeer%26aufirst%3DJ.%26aulast%3DDenonne%26aufirst%3DF.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3D8-Substituted%25201%252C3-Dimethyltetrahydropyrazino%255B2%252C1-f%255DPurinediones%253A%2520Water-Soluble%2520Adenosine%2520Receptor%2520Antagonists%2520and%2520Monoamine%2520Oxidase%2520B%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D21%26spage%3D5462%26epage%3D5480%26doi%3D10.1016%2Fj.bmc.2016.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whiteford, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhardt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erskine, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlson, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaxman, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, T.</span></span> <span> </span><span class="NLM_article-title">Global Burden of Disease Attributable to Mental and Substance Use Disorders: Findings from the Global Burden of Disease Study 2010</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>382</i></span> (<span class="NLM_issue">9904</span>),  <span class="NLM_fpage">1575</span>– <span class="NLM_lpage">1586</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(13)61611-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0140-6736%2813%2961611-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23993280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC3sbktFKktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2013&pages=1575-1586&issue=9904&author=H.+A.+Whitefordauthor=L.+Degenhardtauthor=J.+Rehmauthor=A.+J.+Baxterauthor=A.+J.+Ferrariauthor=H.+E.+Erskineauthor=F.+J.+Charlsonauthor=R.+E.+Normanauthor=A.+D.+Flaxmanauthor=N.+Johnsauthor=R.+Bursteinauthor=C.+J.+L.+Murrayauthor=T.+Vos&title=Global+Burden+of+Disease+Attributable+to+Mental+and+Substance+Use+Disorders%3A+Findings+from+the+Global+Burden+of+Disease+Study+2010&doi=10.1016%2FS0140-6736%2813%2961611-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010</span></div><div class="casAuthors">Whiteford Harvey A; Degenhardt Louisa; Rehm Jurgen; Baxter Amanda J; Ferrari Alize J; Erskine Holly E; Charlson Fiona J; Norman Rosana E; Flaxman Abraham D; Johns Nicole; Burstein Roy; Murray Christopher J L; Vos Theo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">9904</span>),
    <span class="NLM_cas:pages">1575-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We used data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) to estimate the burden of disease attributable to mental and substance use disorders in terms of disability-adjusted life years (DALYs), years of life lost to premature mortality (YLLs), and years lived with disability (YLDs).  METHODS:  For each of the 20 mental and substance use disorders included in GBD 2010, we systematically reviewed epidemiological data and used a Bayesian meta-regression tool, DisMod-MR, to model prevalence by age, sex, country, region, and year.  We obtained disability weights from representative community surveys and an internet-based survey to calculate YLDs.  We calculated premature mortality as YLLs from cause of death estimates for 1980-2010 for 20 age groups, both sexes, and 187 countries.  We derived DALYs from the sum of YLDs and YLLs.  We adjusted burden estimates for comorbidity and present them with 95% uncertainty intervals.  FINDINGS:  In 2010, mental and substance use disorders accounted for 183·9 million DALYs (95% UI 153·5 million-216·7 million), or 7·4% (6·2-8·6) of all DALYs worldwide.  Such disorders accounted for 8·6 million YLLs (6·5 million-12·1 million; 0·5% [0·4-0·7] of all YLLs) and 175·3 million YLDs (144·5 million-207·8 million; 22·9% [18·6-27·2] of all YLDs).  Mental and substance use disorders were the leading cause of YLDs worldwide.  Depressive disorders accounted for 40·5% (31·7-49·2) of DALYs caused by mental and substance use disorders, with anxiety disorders accounting for 14·6% (11·2-18·4), illicit drug use disorders for 10·9% (8·9-13·2), alcohol use disorders for 9·6% (7·7-11·8), schizophrenia for 7·4% (5·0-9·8), bipolar disorder for 7·0% (4·4-10·3), pervasive developmental disorders for 4·2% (3·2-5·3), childhood behavioural disorders for 3·4% (2·2-4·7), and eating disorders for 1·2% (0·9-1·5).  DALYs varied by age and sex, with the highest proportion of total DALYs occurring in people aged 10-29 years.  The burden of mental and substance use disorders increased by 37·6% between 1990 and 2010, which for most disorders was driven by population growth and ageing.  INTERPRETATION:  Despite the apparently small contribution of YLLs--with deaths in people with mental disorders coded to the physical cause of death and suicide coded to the category of injuries under self-harm--our findings show the striking and growing challenge that these disorders pose for health systems in developed and developing regions.  In view of the magnitude of their contribution, improvement in population health is only possible if countries make the prevention and treatment of mental and substance use disorders a public health priority.  FUNDING:  Queensland Department of Health, National Health and Medical Research Council of Australia, National Drug and Alcohol Research Centre-University of New South Wales, Bill & Melinda Gates Foundation, University of Toronto, Technische Universitat, Ontario Ministry of Health and Long Term Care, and the US National Institute of Alcohol Abuse and Alcoholism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiBNuRCD7D-CO2kE7krGOBfW6udTcc2eYesQ0ttH73hrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbktFKktA%253D%253D&md5=b7b9b2c8428804bbec8c78dc8410454d</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2961611-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252961611-6%26sid%3Dliteratum%253Aachs%26aulast%3DWhiteford%26aufirst%3DH.%2BA.%26aulast%3DDegenhardt%26aufirst%3DL.%26aulast%3DRehm%26aufirst%3DJ.%26aulast%3DBaxter%26aufirst%3DA.%2BJ.%26aulast%3DFerrari%26aufirst%3DA.%2BJ.%26aulast%3DErskine%26aufirst%3DH.%2BE.%26aulast%3DCharlson%26aufirst%3DF.%2BJ.%26aulast%3DNorman%26aufirst%3DR.%2BE.%26aulast%3DFlaxman%26aufirst%3DA.%2BD.%26aulast%3DJohns%26aufirst%3DN.%26aulast%3DBurstein%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%2BJ.%2BL.%26aulast%3DVos%26aufirst%3DT.%26atitle%3DGlobal%2520Burden%2520of%2520Disease%2520Attributable%2520to%2520Mental%2520and%2520Substance%2520Use%2520Disorders%253A%2520Findings%2520from%2520the%2520Global%2520Burden%2520of%2520Disease%2520Study%25202010%26jtitle%3DLancet%26date%3D2013%26volume%3D382%26issue%3D9904%26spage%3D1575%26epage%3D1586%26doi%3D10.1016%2FS0140-6736%2813%2961611-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, G.</span></span> <span> </span><span class="NLM_article-title">Serotonin Reuptake Inhibition: An Update on Current Research Strategies</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.2174/0929867024606795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F0929867024606795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11966445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtlGruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=799-810&issue=8&author=D.+Spinksauthor=G.+Spinks&title=Serotonin+Reuptake+Inhibition%3A+An+Update+on+Current+Research+Strategies&doi=10.2174%2F0929867024606795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin reuptake inhibition: An update on current research strategies</span></div><div class="casAuthors">Spinks, D.; Spinks, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">799-810</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  Selective Serotonin reuptake inhibitors (SSRIs) have contributed to the major advances in the treatment of depression and other psychiatric diseases.  This review is on the current knowledge concerning the SSRI class of drugs and discusses the importance of secondary pharmacol. in the mechanism of action and effectiveness of these drugs.  Particular attention is given to the emerging importance of the SSRI "plus" approach: where the serotonin reuptake receptor inhibition of a drug is supplemented by one or more other receptor interactions either by the same drug or by a combination therapy.  This area of research has shed light on the pharmacol. mechanisms of SSRI therapy and has the therapeutic usefulness of serotonin reuptake inhibition, esp. in the area of depression.  There are many new emerging SSRI "plus" drugs, which address the pharmacol. and pharmacokinetic issues of current therapies and these, are discussed in detail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYTi-h24MOV7Vg90H21EOLACvtfcHk0lheV-JmK3n-AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtlGruro%253D&md5=36c0103adb1891d4bfed6f94787163fb</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.2174%2F0929867024606795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867024606795%26sid%3Dliteratum%253Aachs%26aulast%3DSpinks%26aufirst%3DD.%26aulast%3DSpinks%26aufirst%3DG.%26atitle%3DSerotonin%2520Reuptake%2520Inhibition%253A%2520An%2520Update%2520on%2520Current%2520Research%2520Strategies%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2002%26volume%3D9%26issue%3D8%26spage%3D799%26epage%3D810%26doi%3D10.2174%2F0929867024606795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derubeis, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amsterdam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollon, S. D.</span></span> <span> </span><span class="NLM_article-title">Gains in Employment Status Following Antidepressant Medication or Cognitive Therapy for Depression</span>. <i>Br. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>206</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1192/bjp.bp.113.133694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1192%2Fbjp.bp.113.133694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24925985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC2cfhvVertw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=206&publication_year=2015&pages=332-338&issue=4&author=J.+C.+Fournierauthor=R.+J.+Derubeisauthor=J.+Amsterdamauthor=R.+C.+Sheltonauthor=S.+D.+Hollon&title=Gains+in+Employment+Status+Following+Antidepressant+Medication+or+Cognitive+Therapy+for+Depression&doi=10.1192%2Fbjp.bp.113.133694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Gains in employment status following antidepressant medication or cognitive therapy for depression</span></div><div class="casAuthors">Fournier Jay C; DeRubeis Robert J; Amsterdam Jay; Shelton Richard C; Hollon Steven D</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of psychiatry : the journal of mental science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">206</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Depression can adversely affect employment status.  AIMS:  To examine whether there is a relative advantage of cognitive therapy or antidepressant medication in improving employment status following treatment, using data from a previously reported trial.  METHOD:  Random assignment to cognitive therapy (n = 48) or the selective serotonin reuptake inhibitor paroxetine (n = 93) for 4 months; treatment responders were followed for up to 24 months.  Differential effects of treatment on employment status were examined.  RESULTS:  At the end of 28 months, cognitive therapy led to higher rates of full-time employment (88.9%) than did antidepressant medication among treatment responders (70.8%), χ(2) 1 = 5.78, P = 0.02, odds ratio (OR) = 5.66, 95% CI 1.16-27.69.  In the shorter-term, the main effect of treatment on employment status was not significant following acute treatment (χ(2) 1 = 1.74, P = 0.19, OR = 1.77, 95% CI 0.75-4.17); however, we observed a site×treatment interaction (χ(2) 1 = 6.87, P = 0.009) whereby cognitive therapy led to a higher rate of full-time employment at one site but not at the other.  CONCLUSIONS:  Cognitive therapy may produce greater improvements in employment v. medication, particularly over the longer term.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQ7eaU3K4jhuvW160gIxP_fW6udTcc2eYkdBaU45MPjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfhvVertw%253D%253D&md5=90cd4f0ebeaa01caf4395db444d34ae0</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1192%2Fbjp.bp.113.133694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fbjp.bp.113.133694%26sid%3Dliteratum%253Aachs%26aulast%3DFournier%26aufirst%3DJ.%2BC.%26aulast%3DDerubeis%26aufirst%3DR.%2BJ.%26aulast%3DAmsterdam%26aufirst%3DJ.%26aulast%3DShelton%26aufirst%3DR.%2BC.%26aulast%3DHollon%26aufirst%3DS.%2BD.%26atitle%3DGains%2520in%2520Employment%2520Status%2520Following%2520Antidepressant%2520Medication%2520or%2520Cognitive%2520Therapy%2520for%2520Depression%26jtitle%3DBr.%2520J.%2520Psychiatry%26date%3D2015%26volume%3D206%26issue%3D4%26spage%3D332%26epage%3D338%26doi%3D10.1192%2Fbjp.bp.113.133694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millan, M. J.</span></span> <span> </span><span class="NLM_article-title">Dual- and Triple-Acting Agents for Treating Core and Co-Morbid Symptoms of Major Depression: Novel Concepts, New Drugs</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.nurt.2008.10.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.nurt.2008.10.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19110199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsF2ntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=53-77&issue=1&author=M.+J.+Millan&title=Dual-+and+Triple-Acting+Agents+for+Treating+Core+and+Co-Morbid+Symptoms+of+Major+Depression%3A+Novel+Concepts%2C+New+Drugs&doi=10.1016%2Fj.nurt.2008.10.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs</span></div><div class="casAuthors">Millan, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-77</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1933-7213</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The past decade of efforts to find improved treatment for major depression has been dominated by genome-driven programs of rational drug discovery directed toward highly selective ligands for nonmonoaminergic agents.  Selective drugs may prove beneficial for specific symptoms, for certain patient subpopulations, or both.  However, network analyses of the brain and its dysfunction suggest that agents with multiple and complementary modes of action are more likely to show broad-based efficacy against core and comorbid symptoms of depression.  Strategies for improved multitarget exploitation of monoaminergic mechanisms include triple inhibitors of dopamine, serotonin (5-HT) and noradrenaline reuptake, and drugs interfering with feedback actions of monoamines at inhibitory 5-HT1A, 5-HT1B and possibly 5-HT5A and 5-HT7 receptors.  Specific subsets of postsynaptic 5-HT receptors mediating antidepressant actions are under study (e.g., 5-HT4 and 5-HT6).  Assocn. of a clin. characterized antidepressant mechanism with a nonmonoaminergic component of activity is an attractive strategy.  For example, agomelatine (a melatonin agonist/5-HT2C antagonist) has clin. proven activity in major depression.  Dual neurokinin1 antagonists/5-HT reuptake inhibitors (SRIs) and melanocortin4 antagonists/SRIs should display advantages over their selective counterparts, and histamine H3 antagonists/SRIs, GABAB antagonists/SRIs, glutamatergic/SRIs, and cholinergic agents/SRIs may counter the compromised cognitive function of depression.  Finally, drugs that suppress 5-HT reuptake and blunt hypothalamo-pituitary-adrenocorticotrophic axis overdrive, or that act at intracellular proteins such as GSK-3β, may abrogate the neg. effects of chronic stress on mood and neuronal integrity.  This review discusses the discovery and development of dual- and triple-acting antidepressants, focusing on novel concepts and new drugs disclosed over the last 2 to 3 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHNCBcMgEfc7Vg90H21EOLACvtfcHk0lheV-JmK3n-AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsF2ntb8%253D&md5=547817a97dca367c68416bd852572c0e</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2008.10.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2008.10.039%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DDual-%2520and%2520Triple-Acting%2520Agents%2520for%2520Treating%2520Core%2520and%2520Co-Morbid%2520Symptoms%2520of%2520Major%2520Depression%253A%2520Novel%2520Concepts%252C%2520New%2520Drugs%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26issue%3D1%26spage%3D53%26epage%3D77%26doi%3D10.1016%2Fj.nurt.2008.10.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Artigas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celada, P.</span></span> <span> </span><span class="NLM_article-title">Pindolol Augmentation of Antidepressant Response</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.2174/138945006775515446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F138945006775515446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16475955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Ghsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=139-147&issue=2&author=F.+Artigasauthor=A.+Adellauthor=P.+Celada&title=Pindolol+Augmentation+of+Antidepressant+Response&doi=10.2174%2F138945006775515446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Pindolol augmentation of antidepressant response</span></div><div class="casAuthors">Artigas, Francesc; Adell, Albert; Celada, Pau</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-147</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Pindolol, a partial β-adrenoceptor/5-HT1A receptor antagonist was first used to accelerate the onset of action of antidepressant drugs in 1994.  Since then, it has been used in more than a dozen controlled trials to examine whether it can reduce the lag to clin. improvement, and/or improve the clin. response in treatment-resistant patients.  A recent metaanal. concluded that pindolol accelerates the antidepressant response but does not increase the effectiveness of SSRIs in unresponsive patients.  Several studies have examd. the pharmacol. of pindolol to clarify the neurobiol. basis of its clin. action.  Pindolol was initially used due to its ability to block 5-HT1A receptor-mediated responses and to enhance the neurochem. effects of SSRIs.  In transfected cells, however, pindolol is a weak (20-25%) partial agonist at 5-HT1A receptors and, as such, its actions greatly depend on the system used.  In line with this, other reports have also shown that pindolol can reduce serotonergic cell firing when given alone.  Positron emission tomog. (PET) scan studies have shown that pindolol displays a preferential occupancy of pre- vs. postsynaptic 5-HT1A receptors, although the overall occupancy is lower than desirable, which suggests that higher doses (e.g., 15 mg/day) may be more effective than the currently used 7.5 mg daily dosage.  However, given the complex pharmacol. of pindolol, it is hoped that new developments in this field can proceed through the use of (a) selective and silent 5-HT1A receptor antagonists in combination with SSRIs, or (b) dual action agents (SSRI + 5-HT1A receptor blockers).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnn4ribHJkybVg90H21EOLACvtfcHk0lj15Et_zxwq5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Ghsrw%253D&md5=abcdcbeb45be139d18db5b08342e0848</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.2174%2F138945006775515446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945006775515446%26sid%3Dliteratum%253Aachs%26aulast%3DArtigas%26aufirst%3DF.%26aulast%3DAdell%26aufirst%3DA.%26aulast%3DCelada%26aufirst%3DP.%26atitle%3DPindolol%2520Augmentation%2520of%2520Antidepressant%2520Response%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2006%26volume%3D7%26issue%3D2%26spage%3D139%26epage%3D147%26doi%3D10.2174%2F138945006775515446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vermeulen, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprouse, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrom, H. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grol, C. J.</span></span> <span> </span><span class="NLM_article-title">Characterization of the 5-HT<sub>7</sub> Receptor. Determination of the Pharmacophore for 5-HT<sub>7</sub> Receptor Agonism and CoMFA-Based Modeling of the Agonist Binding Site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">5365</span>– <span class="NLM_lpage">5374</span>, <span class="refDoi"> DOI: 10.1021/jm030826m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030826m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5365-5374&issue=25&author=E.+S.+Vermeulenauthor=A.+W.+Schmidtauthor=J.+S.+Sprouseauthor=H.+K.+V.+Wikstromauthor=C.+J.+Grol&title=Characterization+of+the+5-HT7+Receptor.+Determination+of+the+Pharmacophore+for+5-HT7+Receptor+Agonism+and+CoMFA-Based+Modeling+of+the+Agonist+Binding+Site&doi=10.1021%2Fjm030826m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the 5-HT7 Receptor. Determination of the Pharmacophore for 5-HT7 Receptor Agonism and CoMFA-Based Modeling of the Agonist Binding Site</span></div><div class="casAuthors">Vermeulen, Erik S.; Schmidt, Anne W.; Sprouse, Jeffrey S.; Wikstroem, Haakan V.; Grol, Cor J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">5365-5374</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of a set of 20 diverse 5-HT7 receptor agonists, the pharmacophore for 5-HT7 receptor agonism was detd.  Addnl. two CoMFA models were developed, based on different alignments of the agonists.  Both models show good correlations between exptl. and predictive pKi values and show a high degree of similarity.  The CoMFA fields were subsequently used to map the agonist binding site of the model of the 5-HT7 receptor.  Important roles in ligand binding are attributed to Asp162 of TM3 (interaction with a protonated nitrogen), and Thr244 of TM5 (interaction with a substituent at an arom. moiety).  Amino acid residues of the arom. cluster of TM6 are hypothesized to play an important role in ligand binding as π-π stacking moieties.  Agonists missing a hydrogen-bond-accepting moiety, but possessing an arom. substituent instead, seem to bind the receptor with high affinity as well by occupying a lipophilic pocket hosted by residues of TM5 and TM6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8qchiC4OGerVg90H21EOLACvtfcHk0lj15Et_zxwq5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cit74%253D&md5=22551bbc09658d0b4fa804e9708f297a</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1021%2Fjm030826m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030826m%26sid%3Dliteratum%253Aachs%26aulast%3DVermeulen%26aufirst%3DE.%2BS.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DSprouse%26aufirst%3DJ.%2BS.%26aulast%3DWikstrom%26aufirst%3DH.%2BK.%2BV.%26aulast%3DGrol%26aufirst%3DC.%2BJ.%26atitle%3DCharacterization%2520of%2520the%25205-HT7%2520Receptor.%2520Determination%2520of%2520the%2520Pharmacophore%2520for%25205-HT7%2520Receptor%2520Agonism%2520and%2520CoMFA-Based%2520Modeling%2520of%2520the%2520Agonist%2520Binding%2520Site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D25%26spage%3D5365%26epage%3D5374%26doi%3D10.1021%2Fjm030826m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationship Study on N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-Aryl-1-Piperazinehexanamides, a Class of 5-HT<sub>7</sub> Receptor Agents. 2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4214</span>– <span class="NLM_lpage">4221</span>, <span class="refDoi"> DOI: 10.1021/jm070487n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070487n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotVKht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=4214-4221&issue=17&author=M.+Leopoldoauthor=E.+Lacivitaauthor=M.+Continoauthor=N.+A.+Colabufoauthor=F.+Berardiauthor=R.+Perrone&title=Structure-Activity+Relationship+Study+on+N-%281%2C2%2C3%2C4-Tetrahydronaphthalen-1-yl%29-4-Aryl-1-Piperazinehexanamides%2C+a+Class+of+5-HT7+Receptor+Agents.+2&doi=10.1021%2Fjm070487n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Study on N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a Class of 5-HT7 Receptor Agents. 2</span></div><div class="casAuthors">Leopoldo, Marcello; Lacivita, Enza; Contino, Marialessandra; Colabufo, Nicola A.; Berardi, Francesco; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4214-4221</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here the authors report the synthesis of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides 16-29 that were designed to elucidate both structure-affinity and -activity relations for the 5-HT7 receptor, by targeting the substituent in 2-position of the aryl linked to the piperazine ring.  The affinities of 16-29 for 5-HT7, 5-HT1A, 5-HT2A, and D2 receptors were assessed by radioligand binding assays.  The intrinsic activities at the 5-HT7 receptor of the most potent compds. were detd.  Substituents covering a wide range of electronic, steric, and polar properties were evaluated, revealing a key role on 5-HT7 receptor affinity and intrinsic activity.  Certain lipophilic substituents (SCH3, CHMe2, NMe2, CH3, Ph) led to high-affinity agonists, whereas OH and NHCH3 substituents switched intrinsic activity toward antagonism.  4-[2-(1-Methylethyl)phenyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (19), 4-(2-diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (21), and 4-(2-dimethylaminophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (22) were identified as potent 5-HT7 receptor agonists (Ki = 0.13-1.1 nM, EC50 = 0.90-1.77 μM), showing selectivity over 5-HT1A, 5-HT2A, and D2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1C_BPfXRj5bVg90H21EOLACvtfcHk0lj15Et_zxwq5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotVKht7o%253D&md5=0243631a73c3aea226d83da9b2799329</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1021%2Fjm070487n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070487n%26sid%3Dliteratum%253Aachs%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DStructure-Activity%2520Relationship%2520Study%2520on%2520N-%25281%252C2%252C3%252C4-Tetrahydronaphthalen-1-yl%2529-4-Aryl-1-Piperazinehexanamides%252C%2520a%2520Class%2520of%25205-HT7%2520Receptor%2520Agents.%25202%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D17%26spage%3D4214%26epage%3D4221%26doi%3D10.1021%2Fjm070487n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Giorgio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fracasso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzzetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caccia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Structural Modifications of N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: Influence on Lipophilicity and 5-HT<sub>7</sub> Receptor Activity. Part III</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5813</span>– <span class="NLM_lpage">5822</span>, <span class="refDoi"> DOI: 10.1021/jm800615e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800615e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVChs7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5813-5822&issue=18&author=M.+Leopoldoauthor=E.+Lacivitaauthor=P.+De+Giorgioauthor=C.+Fracassoauthor=S.+Guzzettiauthor=S.+Cacciaauthor=M.+Continoauthor=N.+A.+Colabufoauthor=F.+Berardiauthor=R.+Perrone&title=Structural+Modifications+of+N-%281%2C2%2C3%2C4-Tetrahydronaphthalen-1-yl%29-4-aryl-1-piperazinehexanamides%3A+Influence+on+Lipophilicity+and+5-HT7+Receptor+Activity.+Part+III&doi=10.1021%2Fjm800615e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Modifications of N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-Aryl-1-piperazinehexanamides: Influence on Lipophilicity and 5-HT7 Receptor Activity. Part III</span></div><div class="casAuthors">Leopoldo, Marcello; Lacivita, Enza; De Giorgio, Paola; Fracasso, Claudia; Guzzetti, Sara; Caccia, Silvio; Contino, Marialessandra; Colabufo, Nicola A.; Berardi, Francesco; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5813-5822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from the previously reported 5-HT7 receptor agents 4-7 with N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamide structure, the 1-(2-methylthiophenyl)-, 1-(2-diphenyl)-, 1-(2-isopropylphenyl)-, and 1-(2-methoxyphenyl)piperazine derivs. 8-31 were designed with the primary aim to obtain new compds. endowed with suitable physicochem. properties for rapid and extensive penetration into the brain.  The affinities for 5-HT7, 5-HT1A, and D2 receptors of compds. 8-31 were assessed, and several compds. displayed 5-HT7 receptor affinities in the nanomolar range.  Among these, N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide (25) showed high 5-HT7 receptor affinity (Ki = 0.58 nM), high selectivity over 5-HT1A and D2 receptors (324- and 245-fold, resp.), and agonist properties (maximal effect = 82%, EC50 = 0.60 μM).  After i.p. injection in mice, 25 rapidly reached the systemic circulation and entered the brain.  Its brain concn.-time profile paralleled that in plasma, indicating that 25 rapidly and freely distributes across the blood-brain barrier.  Compd. 25 underwent N-dealkylation to the corresponding 1-arylpiperazine metabolite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobpnnFHb4H1bVg90H21EOLACvtfcHk0lhrC7sx1DRMvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVChs7rJ&md5=035e122d1b4fec52b1ce8258f520b0a9</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1021%2Fjm800615e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800615e%26sid%3Dliteratum%253Aachs%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DDe%2BGiorgio%26aufirst%3DP.%26aulast%3DFracasso%26aufirst%3DC.%26aulast%3DGuzzetti%26aufirst%3DS.%26aulast%3DCaccia%26aufirst%3DS.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DStructural%2520Modifications%2520of%2520N-%25281%252C2%252C3%252C4-Tetrahydronaphthalen-1-yl%2529-4-aryl-1-piperazinehexanamides%253A%2520Influence%2520on%2520Lipophilicity%2520and%25205-HT7%2520Receptor%2520Activity.%2520Part%2520III%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D18%26spage%3D5813%26epage%3D5822%26doi%3D10.1021%2Fjm800615e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patarnello, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caroli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Giorgio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pilato, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svenningsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedlund, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 1-(2-Biphenyl)Piperazine Motif: Identification of New Potent and Selective Ligands for the Serotonin 7 (5-HT<sub>7</sub>) Receptor with Agonist or Antagonist Action in Vitro or ex Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6375</span>– <span class="NLM_lpage">6380</span>, <span class="refDoi"> DOI: 10.1021/jm3003679</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003679" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1Cgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6375-6380&issue=14&author=E.+Lacivitaauthor=D.+Patarnelloauthor=N.+Strothauthor=A.+Caroliauthor=M.+Nisoauthor=M.+Continoauthor=P.+De+Giorgioauthor=P.+Di+Pilatoauthor=N.+A.+Colabufoauthor=F.+Berardiauthor=R.+Perroneauthor=P.+Svenningssonauthor=P.+B.+Hedlundauthor=M.+Leopoldo&title=Investigations+on+the+1-%282-Biphenyl%29Piperazine+Motif%3A+Identification+of+New+Potent+and+Selective+Ligands+for+the+Serotonin+7+%285-HT7%29+Receptor+with+Agonist+or+Antagonist+Action+in+Vitro+or+ex+Vivo&doi=10.1021%2Fjm3003679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 1-(2-Biphenyl)piperazine Motif: Identification of New Potent and Selective Ligands for the Serotonin7 (5-HT7) Receptor with Agonist or Antagonist Action in Vitro or ex Vivo</span></div><div class="casAuthors">Lacivita, Enza; Patarnello, Daniela; Stroth, Nikolas; Caroli, Antonia; Niso, Mauro; Contino, Marialessandra; De Giorgio, Paola; Di Pilato, Pantaleo; Colabufo, Nicola A.; Berardi, Francesco; Perrone, Roberto; Svenningsson, Per; Hedlund, Peter B.; Leopoldo, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6375-6380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the design, synthesis, and 5-HT7 receptor affinity of a set of 1-(3-biphenyl)- and 1-(2-biphenyl)piperazines are reported.  The effect on 5-HT7 affinity of various substituents on the second (distal) Ph ring was analyzed.  Several compds. showed 5-HT7 affinities in the nanomolar range and >100-fold selectivity over 5-HT1A and adrenergic α1 receptors.  1-[2-(4-Methoxyphenyl)phenyl]piperazine showed 5-HT7 agonist properties in a guinea pig ileum assay but blocked 5-HT-mediated cAMP accumulation in 5-HT7-expressing HeLa cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_7UpY3EFLzbVg90H21EOLACvtfcHk0lhrC7sx1DRMvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1Cgt78%253D&md5=2a1fce8eef267844ee7ac08748b001a2</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1021%2Fjm3003679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003679%26sid%3Dliteratum%253Aachs%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DPatarnello%26aufirst%3DD.%26aulast%3DStroth%26aufirst%3DN.%26aulast%3DCaroli%26aufirst%3DA.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DDe%2BGiorgio%26aufirst%3DP.%26aulast%3DDi%2BPilato%26aufirst%3DP.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DSvenningsson%26aufirst%3DP.%26aulast%3DHedlund%26aufirst%3DP.%2BB.%26aulast%3DLeopoldo%26aufirst%3DM.%26atitle%3DInvestigations%2520on%2520the%25201-%25282-Biphenyl%2529Piperazine%2520Motif%253A%2520Identification%2520of%2520New%2520Potent%2520and%2520Selective%2520Ligands%2520for%2520the%2520Serotonin%25207%2520%25285-HT7%2529%2520Receptor%2520with%2520Agonist%2520or%2520Antagonist%2520Action%2520in%2520Vitro%2520or%2520ex%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D14%26spage%3D6375%26epage%3D6380%26doi%3D10.1021%2Fjm3003679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antidepressant-Like Activity of Novel Aralkyl Piperazine Derivatives Targeting SSRI/5-HT<sub>1a</sub> /5-HT<sub>7</sub></span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">701</span>– <span class="NLM_lpage">715</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2017.12.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29291438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=701-715&author=Z.+S.+Guauthor=A.+N.+Zhouauthor=Y.+Xiaoauthor=Q.+W.+Zhangauthor=J.+Q.+Li&title=Synthesis+and+Antidepressant-Like+Activity+of+Novel+Aralkyl+Piperazine+Derivatives+Targeting+SSRI%2F5-HT1a+%2F5-HT7&doi=10.1016%2Fj.ejmech.2017.12.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antidepressant-like activity of novel aralkyl piperazine derivatives targeting SSRI/5-HT1A/5-HT7</span></div><div class="casAuthors">Gu, Zheng-Song; Zhou, Ai-nan; Xiao, Ying; Zhang, Qing-Wei; Li, Jian-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">701-715</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel aralkyl piperazine derivs. I (Ar = benzofuran-3-yl, 5-F-indol-3-yl; R1 = H, OMe, SMe, etc.; R2 = H, 3-F, 4-F, 5-F, 3-Ph; m = 0, 1, or 2) were synthesized, and evaluated for their serotonin reuptake inhibitory and 5-HT1A/5-HT7 receptors affinities activity.  Antidepressant activities in vivo of the compds. were screened using the forced swimming test (FST) and tail suspension test (TST).  The results indicated that compds. I (Ar = 5-F-indol-3-yl; R1 = 3-FC6H4; R2 = 4-F) (RUI, IC50 = 31nM; 5-HT1A, 5-HT7, ki = 62, 12nM) and I (Ar = 5-F-indol-3-yl; R1 = Ph; R2 = 4-F) (RUI, IC50 = 25nM; 5-HT1A, 5-HT7, ki = 28, 3.3nM) exhibited high affinities for the 5-HT1A/5-HT7 receptors coupled with potent serotonin reuptake inhibition.  Specifically, the most promising compd. I (Ar = 5-F-indol-3-yl; R1 = Ph; R2 = 4-F) possessed a good oral pharmacokinetic properties and an acceptable hERG profile, and showed potent antidepressant-like effect in the FST and TST models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSMf00wCn8lLVg90H21EOLACvtfcHk0ljXBB-4hisXAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWntg%253D%253D&md5=7eca8795937fca66aabce7ec1704bc54</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.063%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DZ.%2BS.%26aulast%3DZhou%26aufirst%3DA.%2BN.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DQ.%2BW.%26aulast%3DLi%26aufirst%3DJ.%2BQ.%26atitle%3DSynthesis%2520and%2520Antidepressant-Like%2520Activity%2520of%2520Novel%2520Aralkyl%2520Piperazine%2520Derivatives%2520Targeting%2520SSRI%252F5-HT1a%2520%252F5-HT7%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D701%26epage%3D715%26doi%3D10.1016%2Fj.ejmech.2017.12.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skene, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakken, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giusti-Rodriguez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz-Manchado, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donovan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardiñas, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, J. T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linnarsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lein, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjerling-Leffler, J.</span></span> <span> </span><span class="NLM_article-title">Genetic Identification of Brain Cell Types Underlying Schizophrenia</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">825</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.1038/s41588-018-0129-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fs41588-018-0129-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29785013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVShu73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=825-833&issue=6&author=N.+G.+Skeneauthor=J.+Bryoisauthor=T.+E.+Bakkenauthor=G.+Breenauthor=J.+J.+Crowleyauthor=H.+A.+Gasparauthor=P.+Giusti-Rodriguezauthor=R.+D.+Hodgeauthor=J.+A.+Millerauthor=A.+B.+Mu%C3%B1oz-Manchadoauthor=M.+C.+O%E2%80%99Donovanauthor=M.+J.+Owenauthor=A.+F.+Pardi%C3%B1asauthor=J.+Rygeauthor=J.+T.+R.+Waltersauthor=S.+Linnarssonauthor=E.+S.+Leinauthor=P.+F.+Sullivanauthor=J.+Hjerling-Leffler&title=Genetic+Identification+of+Brain+Cell+Types+Underlying+Schizophrenia&doi=10.1038%2Fs41588-018-0129-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic identification of brain cell types underlying schizophrenia</span></div><div class="casAuthors">Skene, Nathan G.; Bryois, Julien; Bakken, Trygve E.; Breen, Gerome; Crowley, James J.; Gaspar, Helena A.; Giusti-Rodriguez, Paola; Hodge, Rebecca D.; Miller, Jeremy A.; Munoz-Manchado, Ana B.; O'Donovan, Michael C.; Owen, Michael J.; Pardinas, Antonio F.; Ryge, Jesper; Walters, James T. R.; Linnarsson, Sten; Lein, Ed S.; Sullivan, Patrick F.; Hjerling-Leffler, Jens</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">825-833</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">With few exceptions, the marked advances in knowledge about the genetic basis of schizophrenia have not converged on findings that can be confidently used for precise exptl. modeling.  By applying knowledge of the cellular taxonomy of the brain from single-cell RNA sequencing, we evaluated whether the genomic loci implicated in schizophrenia map onto specific brain cell types.  We found that the common-variant genomic results consistently mapped to pyramidal cells, medium spiny neurons (MSNs) and certain interneurons, but far less consistently to embryonic, progenitor or glial cells.  These enrichments were due to sets of genes that were specifically expressed in each of these cell types.  We also found that many of the diverse gene sets previously assocd. with schizophrenia (genes involved in synaptic function, those encoding mRNAs that interact with FMRP, antipsychotic targets, etc.) generally implicated the same brain cell types.  Our results suggest a parsimonious explanation: the common-variant genetic results for schizophrenia point at a limited set of neurons, and the gene sets point to the same cells.  The genetic risk assocd. with MSNs did not overlap with that of glutamatergic pyramidal cells and interneurons, suggesting that different cell types have biol. distinct roles in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkacm1fdPmwbVg90H21EOLACvtfcHk0ljXBB-4hisXAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVShu73K&md5=b6493f76b9fa3fa0311c1decf251271f</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1038%2Fs41588-018-0129-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41588-018-0129-5%26sid%3Dliteratum%253Aachs%26aulast%3DSkene%26aufirst%3DN.%2BG.%26aulast%3DBryois%26aufirst%3DJ.%26aulast%3DBakken%26aufirst%3DT.%2BE.%26aulast%3DBreen%26aufirst%3DG.%26aulast%3DCrowley%26aufirst%3DJ.%2BJ.%26aulast%3DGaspar%26aufirst%3DH.%2BA.%26aulast%3DGiusti-Rodriguez%26aufirst%3DP.%26aulast%3DHodge%26aufirst%3DR.%2BD.%26aulast%3DMiller%26aufirst%3DJ.%2BA.%26aulast%3DMu%25C3%25B1oz-Manchado%26aufirst%3DA.%2BB.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%2BC.%26aulast%3DOwen%26aufirst%3DM.%2BJ.%26aulast%3DPardi%25C3%25B1as%26aufirst%3DA.%2BF.%26aulast%3DRyge%26aufirst%3DJ.%26aulast%3DWalters%26aufirst%3DJ.%2BT.%2BR.%26aulast%3DLinnarsson%26aufirst%3DS.%26aulast%3DLein%26aufirst%3DE.%2BS.%26aulast%3DSullivan%26aufirst%3DP.%2BF.%26aulast%3DHjerling-Leffler%26aufirst%3DJ.%26atitle%3DGenetic%2520Identification%2520of%2520Brain%2520Cell%2520Types%2520Underlying%2520Schizophrenia%26jtitle%3DNat.%2520Genet.%26date%3D2018%26volume%3D50%26issue%3D6%26spage%3D825%26epage%3D833%26doi%3D10.1038%2Fs41588-018-0129-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure of the D<sub>2</sub>Dopamine Receptor Bound to the Atypical Antipsychotic Drug Risperidone</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span> (<span class="NLM_issue">7695</span>),  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1038/nature25758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnature25758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29466326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=269-273&issue=7695&author=S.+Wangauthor=T.+Cheauthor=A.+Levitauthor=B.+K.+Shoichetauthor=D.+Wackerauthor=B.+L.+Roth&title=Structure+of+the+D2Dopamine+Receptor+Bound+to+the+Atypical+Antipsychotic+Drug+Risperidone&doi=10.1038%2Fnature25758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span></div><div class="casAuthors">Wang, Sheng; Che, Tao; Levit, Anat; Shoichet, Brian K.; Wacker, Daniel; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">7695</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metab. and hormonal secretion.  Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such as schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, and nausea and vomiting.  The actions of dopamine are mediated by a family of five G-protein-coupled receptors.  The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.  Unfortunately, many drugs that target DRD2 cause serious and potentially life-threatening side effects due to promiscuous activities against related receptors.  Accordingly, a mol. understanding of the structure and function of DRD2 could provide a template for the design of safer and more effective medications.  Here we report the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone.  The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at DRD2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeo4Ov49kft7Vg90H21EOLACvtfcHk0ljXBB-4hisXAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D&md5=2842adc1893293ea8dbf98ae3270a1b2</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1038%2Fnature25758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25758%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520of%2520the%2520D2Dopamine%2520Receptor%2520Bound%2520to%2520the%2520Atypical%2520Antipsychotic%2520Drug%2520Risperidone%26jtitle%3DNature%26date%3D2018%26volume%3D555%26issue%3D7695%26spage%3D269%26epage%3D273%26doi%3D10.1038%2Fnature25758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span> <span> </span><span class="NLM_article-title">Association of DRD2 Polymorphisms and Chlorpromazine-Induced Extrapyramidal Syndrome in Chinese Schizophrenic Patients</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">966</span>– <span class="NLM_lpage">970</span>, <span class="refDoi"> DOI: 10.1111/j.1745-7254.2006.00355.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1111%2Fj.1745-7254.2006.00355.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16867246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVKhtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=966-970&issue=8&author=S.+N.+Wuauthor=R.+Gaoauthor=Q.+H.+Xingauthor=H.+F.+Liauthor=Y.+F.+Shenauthor=N.+F.+Guauthor=G.+Y.+Fengauthor=L.+He&title=Association+of+DRD2+Polymorphisms+and+Chlorpromazine-Induced+Extrapyramidal+Syndrome+in+Chinese+Schizophrenic+Patients&doi=10.1111%2Fj.1745-7254.2006.00355.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients</span></div><div class="casAuthors">Wu, Sheng-nan; Gao, Rui; Xing, Qing-he; Li, Hua-fang; Shen, Yi-feng; Gu, Niu-fan; Feng, Guo-yin; He, Lin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">966-970</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">Aim: Extrapyramidal syndrome (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor.  Recently, many research groups have reported on the pos. relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression.  In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.  Methods: We identified seven SNP(single nucleotide polymorphism) (-141 Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 wk.  The alleles of all loci were detd. by PCR (polymerase chain reaction).  Results: Polymorphisms TaqID, Ser311Cys and rs6277 were not polymorphic in the population recruited in the present study.  No statistical significance was found in the allele distribution of -141 Cins>del, TaqIB, rs6275 and TaqIA or in the estd. haplotypes (constituted by TaqIB, rs6275 and TaqIA) in linkage disequil. between the two groups.  Conclusion: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia.  Our results confirmed a previous study on the relationship between DRD2 and EPS in Caucasians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkbk0GB1iaMbVg90H21EOLACvtfcHk0lhY1CqU1Sknsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVKhtLc%253D&md5=05808a4c3cf12e2a537884e4c34d123e</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1111%2Fj.1745-7254.2006.00355.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1745-7254.2006.00355.x%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DS.%2BN.%26aulast%3DGao%26aufirst%3DR.%26aulast%3DXing%26aufirst%3DQ.%2BH.%26aulast%3DLi%26aufirst%3DH.%2BF.%26aulast%3DShen%26aufirst%3DY.%2BF.%26aulast%3DGu%26aufirst%3DN.%2BF.%26aulast%3DFeng%26aufirst%3DG.%2BY.%26aulast%3DHe%26aufirst%3DL.%26atitle%3DAssociation%2520of%2520DRD2%2520Polymorphisms%2520and%2520Chlorpromazine-Induced%2520Extrapyramidal%2520Syndrome%2520in%2520Chinese%2520Schizophrenic%2520Patients%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2006%26volume%3D27%26issue%3D8%26spage%3D966%26epage%3D970%26doi%3D10.1111%2Fj.1745-7254.2006.00355.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breier, A.</span></span> <span> </span><span class="NLM_article-title">Fluoxetine Augmentation of Clozapine Treatment in Patients with Schizophrenia</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>153</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1627</span>, <span class="refDoi"> DOI: 10.1176/ajp.153.12.1625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1176%2Fajp.153.12.1625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=8942462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADyaK2s%252Fpsl2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=1996&pages=1625-1627&issue=12&author=R.+W.+Buchananauthor=B.+Kirkpatrickauthor=N.+Bryantauthor=P.+Ballauthor=A.+Breier&title=Fluoxetine+Augmentation+of+Clozapine+Treatment+in+Patients+with+Schizophrenia&doi=10.1176%2Fajp.153.12.1625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Fluoxetine augmentation of clozapine treatment in patients with schizophrenia</span></div><div class="casAuthors">Buchanan R W; Kirkpatrick B; Bryant N; Ball P; Breier A</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1625-7</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The authors examined the efficacy of fluoxetine augmentation of clozapine treatment response in schizophrenic outpatients who, despite adequate treatment with clozapine, continued to exhibit persistent positive or negative symptoms.  METHOD:  Thirty-three patients completed on 8-week, double-blind, parallel-groups comparison of adjunctive fluoxetine and placebo.  RESULTS:  There were no significant differences in positive, negative, depressive, or obsessive-compulsive symptoms between patients given adjunctive fluoxetine or placebo.  CONCLUSIONS:  These results suggest that fluoxetine is not effective in augmenting clozapine treatment response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZRh8mt7jW-ZdYoSR9eyvsfW6udTcc2ebiTFNS_5-1rbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s%252Fpsl2hsw%253D%253D&md5=dd02b14d5073762bbcb2e94e9f7968e4</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1176%2Fajp.153.12.1625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fajp.153.12.1625%26sid%3Dliteratum%253Aachs%26aulast%3DBuchanan%26aufirst%3DR.%2BW.%26aulast%3DKirkpatrick%26aufirst%3DB.%26aulast%3DBryant%26aufirst%3DN.%26aulast%3DBall%26aufirst%3DP.%26aulast%3DBreier%26aufirst%3DA.%26atitle%3DFluoxetine%2520Augmentation%2520of%2520Clozapine%2520Treatment%2520in%2520Patients%2520with%2520Schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1996%26volume%3D153%26issue%3D12%26spage%3D1625%26epage%3D1627%26doi%3D10.1176%2Fajp.153.12.1625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coolen, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keizer, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Moes, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Hartog, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stork, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plekkenpol, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemann, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroomer, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulp, M. Th. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van
Stuivenberg, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCreary, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesselink, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herremans, A. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, C. G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Structure-Activity Relationships, and Biological Properties of 1-Heteroaryl-4-[Omega-(1H-Indol-3-yl)Alkyl]Piperazines, Novel Potential Antipsychotics Combining Potent Dopamine D<sub>2</sub> Receptor Antagonism with Potent Serotonin Reuptake Inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">6855</span>– <span class="NLM_lpage">6869</span>, <span class="refDoi"> DOI: 10.1021/jm050148z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050148z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGqsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6855-6869&issue=22&author=P.+Smidauthor=H.+K.+Coolenauthor=H.+G.+Keizerauthor=R.+van+Hesauthor=J.+P.+de+Moesauthor=A.+P.+den+Hartogauthor=B.+Storkauthor=R.+H.+Plekkenpolauthor=L.+C.+Niemannauthor=C.+N.+Stroomerauthor=M.+Th.+M.+Tulpauthor=H.+H.+van%0AStuivenbergauthor=A.+C.+McCrearyauthor=M.+B.+Hesselinkauthor=A.+H.+J.+Herremansauthor=C.+G.+Kruse&title=Synthesis%2C+Structure-Activity+Relationships%2C+and+Biological+Properties+of+1-Heteroaryl-4-%5BOmega-%281H-Indol-3-yl%29Alkyl%5DPiperazines%2C+Novel+Potential+Antipsychotics+Combining+Potent+Dopamine+D2+Receptor+Antagonism+with+Potent+Serotonin+Reuptake+Inhibition&doi=10.1021%2Fjm050148z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and Biological Properties of 1-Heteroaryl-4-[ω-(1H-indol-3-yl)alkyl]piperazines, Novel Potential Antipsychotics Combining Potent Dopamine D2 Receptor Antagonism with Potent Serotonin Reuptake Inhibition</span></div><div class="casAuthors">Smid, Pieter; Coolen, Hein K. A. C.; Keizer, Hiskias G.; Van Hes, Rolf; De Moes, Jan-Peter; Den Hartog, Arnold P.; Stork, Bob; Plekkenpol, Rob H.; Niemann, Leonarda C.; Stroomer, Cees N. J.; Tulp, Martin Th. M.; Van Stuivenberg, Herman H.; McCreary, Andrew C.; Hesselink, Mayke B.; Herremans, Arnoud H. J.; Kruse, Chris G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6855-6869</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel bicyclic 1-heteroaryl-4-[ω-(1H-indol-3-yl)alkyl]piperazines was synthesized and evaluated on binding to dopamine D2 receptors and serotonin reuptake sites.  This class of compds. proved to be potent in vitro dopamine D2 receptor antagonists and in addn. were highly active as serotonin reuptake inhibitors.  Some key representatives showed potent pharmacol. in vivo activities after oral dosing in both the antagonism of apomorphine-induced climbing and the potentiation of 5-HTP-induced behavior in mice.  On the basis of the preclin. data, 8-{4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazin-1-yl}-4H-benzo[1,4]oxazin-(R)-2-methyl-3-one (I, SLV314) was selected for clin. development.  In vitro and in vivo studies revealed that I has favorable pharmacokinetic properties and a high CNS-plasma ratio.  Mol. modeling studies showed that the bifunctional activity of I can be explained by its ability to adopt two different conformations fitting either the dopamine D2 receptor pharmacophore or the serotonin transporter pharmacophore.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNC21__bpXaLVg90H21EOLACvtfcHk0lhY1CqU1Sknsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGqsr3E&md5=226ab1990d08e2635b716f2f3a01b764</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1021%2Fjm050148z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050148z%26sid%3Dliteratum%253Aachs%26aulast%3DSmid%26aufirst%3DP.%26aulast%3DCoolen%26aufirst%3DH.%2BK.%26aulast%3DKeizer%26aufirst%3DH.%2BG.%26aulast%3Dvan%2BHes%26aufirst%3DR.%26aulast%3Dde%2BMoes%26aufirst%3DJ.%2BP.%26aulast%3Dden%2BHartog%26aufirst%3DA.%2BP.%26aulast%3DStork%26aufirst%3DB.%26aulast%3DPlekkenpol%26aufirst%3DR.%2BH.%26aulast%3DNiemann%26aufirst%3DL.%2BC.%26aulast%3DStroomer%26aufirst%3DC.%2BN.%26aulast%3DTulp%26aufirst%3DM.%2BTh.%2BM.%26aulast%3Dvan%2BStuivenberg%26aufirst%3DH.%2BH.%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26aulast%3DHesselink%26aufirst%3DM.%2BB.%26aulast%3DHerremans%26aufirst%3DA.%2BH.%2BJ.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DSynthesis%252C%2520Structure-Activity%2520Relationships%252C%2520and%2520Biological%2520Properties%2520of%25201-Heteroaryl-4-%255BOmega-%25281H-Indol-3-yl%2529Alkyl%255DPiperazines%252C%2520Novel%2520Potential%2520Antipsychotics%2520Combining%2520Potent%2520Dopamine%2520D2%2520Receptor%2520Antagonism%2520with%2520Potent%2520Serotonin%2520Reuptake%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D22%26spage%3D6855%26epage%3D6869%26doi%3D10.1021%2Fjm050148z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feenstra, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Moes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofma, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuipers, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulp, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Heyden, J. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, C. G.</span></span> <span> </span><span class="NLM_article-title">New 1-Aryl-4-(biarylmethylene)piperazines as Potential Atypical Antipsychotics Sharing Dopamine D<sub>2</sub>-Receptor and Serotonin 5-HT<sub>1a</sub>-Receptor Affinities</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2345</span>– <span class="NLM_lpage">2349</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00425-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2FS0960-894X%2801%2900425-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11527728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmt12jsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=2345-2349&issue=17&author=R.+W.+Feenstraauthor=J.+de+Moesauthor=J.+J.+Hofmaauthor=H.+Klingauthor=W.+Kuipersauthor=S.+K.+Longauthor=M.+T.+Tulpauthor=J.+A.+M.+van+der%0AHeydenauthor=C.+G.+Kruse&title=New+1-Aryl-4-%28biarylmethylene%29piperazines+as+Potential+Atypical+Antipsychotics+Sharing+Dopamine+D2-Receptor+and+Serotonin+5-HT1a-Receptor+Affinities&doi=10.1016%2FS0960-894X%2801%2900425-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1A-receptor affinities</span></div><div class="casAuthors">Feenstra, R. W.; de Moes, J.; Hofma, J. J.; Kling, H.; Kuipers, W.; Long, S. K.; Tulp, M. T. M.; van der Heyden, J. A. M.; Kruse, C. G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2345-2349</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">1-Aryl-4-(biarylmethylene)piperazines were prepd. and their affinity for D2 and 5-HT1A receptors was detd..  A selection of these compds. was evaluated in vivo, resulting in the identification of a drug candidate which is being clin. evaluated as a potential atypical antipsychotic with reduced extrapyrimidal side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIUePqOrsrlbVg90H21EOLACvtfcHk0ljMzKVTGfygmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmt12jsr4%253D&md5=9c8ecd3674e9361a038ecced7a481e5e</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900425-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900425-5%26sid%3Dliteratum%253Aachs%26aulast%3DFeenstra%26aufirst%3DR.%2BW.%26aulast%3Dde%2BMoes%26aufirst%3DJ.%26aulast%3DHofma%26aufirst%3DJ.%2BJ.%26aulast%3DKling%26aufirst%3DH.%26aulast%3DKuipers%26aufirst%3DW.%26aulast%3DLong%26aufirst%3DS.%2BK.%26aulast%3DTulp%26aufirst%3DM.%2BT.%26aulast%3Dvan%2Bder%2BHeyden%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DNew%25201-Aryl-4-%2528biarylmethylene%2529piperazines%2520as%2520Potential%2520Atypical%2520Antipsychotics%2520Sharing%2520Dopamine%2520D2-Receptor%2520and%2520Serotonin%25205-HT1a-Receptor%2520Affinities%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26issue%3D17%26spage%3D2345%26epage%3D2349%26doi%3D10.1016%2FS0960-894X%2801%2900425-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runyon, S. P.</span></span> <span> </span><span class="NLM_article-title">Regulation of the Apelinergic System and Its Potential in Cardiovascular Disease: Peptides and Small Molecules as Tools for Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">7913</span>– <span class="NLM_lpage">7927</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00527</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKit7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7913-7927&issue=20&author=S.+Narayananauthor=D.+L.+Harrisauthor=R.+Maitraauthor=S.+P.+Runyon&title=Regulation+of+the+Apelinergic+System+and+Its+Potential+in+Cardiovascular+Disease%3A+Peptides+and+Small+Molecules+as+Tools+for+Discovery&doi=10.1021%2Facs.jmedchem.5b00527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the Apelinergic System and Its Potential in Cardiovascular Disease: Peptides and Small Molecules as Tools for Discovery</span></div><div class="casAuthors">Narayanan, Sanju; Harris, Danni L.; Maitra, Rangan; Runyon, Scott P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7913-7927</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Apelin peptides and the apelin receptor represent a relatively new therapeutic axis for the potential treatment of cardiovascular disease.  Several reports suggest apelin receptor activation with apelin peptides results in cardioprotection as noted through pos. ionotropy, angiogenesis, redn. of mean arterial blood pressure, and apoptosis.  Considering the potential therapeutic benefit attainable through modulation of the apelinergic system, research is expanding to develop novel therapies that limit the inherent rapid degrdn. of endogenous apelin peptides and produce metabolically stable small mol. agonists and antagonists to more rigorously interrogate the apelin receptor system.  This review details the structure-activity relationships for chem. modified apelin peptides and recent disclosures of small mol. agonists and antagonists and summarizes the peer reviewed and patented literature.  Development of metabolically stable ligands of apelin receptor and their effects in various models over the coming years will hopefully lead to establishment of this receptor as a validated target for cardiovascular indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTIngNdWxX87Vg90H21EOLACvtfcHk0ljMzKVTGfygmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKit7rN&md5=6c116a42d7b523905e811c33c46e256f</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00527%26sid%3Dliteratum%253Aachs%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DD.%2BL.%26aulast%3DMaitra%26aufirst%3DR.%26aulast%3DRunyon%26aufirst%3DS.%2BP.%26atitle%3DRegulation%2520of%2520the%2520Apelinergic%2520System%2520and%2520Its%2520Potential%2520in%2520Cardiovascular%2520Disease%253A%2520Peptides%2520and%2520Small%2520Molecules%2520as%2520Tools%2520for%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D20%26spage%3D7913%26epage%3D7927%26doi%3D10.1021%2Facs.jmedchem.5b00527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katselou, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matralis, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kourounakis, A. P.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Drug Design Approaches for Multifactorial Diseases: From Neurodegenerative to Cardiovascular Applications</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">2743</span>– <span class="NLM_lpage">2787</span>, <span class="refDoi"> DOI: 10.2174/0929867321666140303144625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F0929867321666140303144625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=24606519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOjsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=2743-2787&issue=24&author=M.+G.+Katselouauthor=A.+N.+Matralisauthor=A.+P.+Kourounakis&title=Multi-Target+Drug+Design+Approaches+for+Multifactorial+Diseases%3A+From+Neurodegenerative+to+Cardiovascular+Applications&doi=10.2174%2F0929867321666140303144625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Target Drug Design Approaches for Multifactorial Diseases: From Neurodegenerative to Cardiovascular Applications</span></div><div class="casAuthors">Katselou, M. G.; Matralis, A. N.; Kourounakis, A. P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2743-2787</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In multi-target drug design (MTD) medicinal chem. aims to integrate multiple pharmacophores into a single drug mol. in order to make it active on several mol. biol. mechanisms simultaneously.  Given the fact that most diseases are multifactorial in nature, MTD is being pursued with increasing intensity, which has resulted in improved outcomes in disease models and several compds. have entered clin. trials.  In a wide range of examples we illustrate how various functionalities have been combined within single structures and how this has affected their (pre)clin. outcome.  This review describes the successful application of MTD for disorders such as neurodegenerative, cardiovascular, diabetes, metabolic and inflammatory diseases, esp. focusing on the field of atherosclerosis where multi-target strategies are a promising alternative to the classical "one target-one drug" design approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbQu-xgU1fC7Vg90H21EOLACvtfcHk0ljMzKVTGfygmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOjsrjP&md5=6a13bd9362f7caa1362983ac84e526b0</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.2174%2F0929867321666140303144625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867321666140303144625%26sid%3Dliteratum%253Aachs%26aulast%3DKatselou%26aufirst%3DM.%2BG.%26aulast%3DMatralis%26aufirst%3DA.%2BN.%26aulast%3DKourounakis%26aufirst%3DA.%2BP.%26atitle%3DMulti-Target%2520Drug%2520Design%2520Approaches%2520for%2520Multifactorial%2520Diseases%253A%2520From%2520Neurodegenerative%2520to%2520Cardiovascular%2520Applications%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26issue%3D24%26spage%3D2743%26epage%3D2787%26doi%3D10.2174%2F0929867321666140303144625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dimitropoulos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papakyriakou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalkas, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyroulias, G. A.</span></span> <span> </span><span class="NLM_article-title">A Computational Approach to the Study of the Binding Mode of Dual ACE/NEP Inhibitors</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1021/ci9005047</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci9005047" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFyhsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=388-396&issue=3&author=N.+Dimitropoulosauthor=A.+Papakyriakouauthor=G.+A.+Dalkasauthor=E.+D.+Sturrockauthor=G.+A.+Spyroulias&title=A+Computational+Approach+to+the+Study+of+the+Binding+Mode+of+Dual+ACE%2FNEP+Inhibitors&doi=10.1021%2Fci9005047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">A Computational Approach to the Study of the Binding Mode of Dual ACE/NEP Inhibitors</span></div><div class="casAuthors">Dimitropoulos, Nikolaos; Papakyriakou, Athanasios; Dalkas, Georgios A.; Sturrock, Edward D.; Spyroulias, Georgios A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">388-396</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combined blockade of the renin-angiotensin-aldosterone system (RAAS) is an attractive therapeutic strategy for the treatment of cardiovascular diseases.  Vasopeptidase inhibitors are a group of compds. capable of inhibiting more than one enzyme, which leads to potentiation of natriuretic peptide actions and suppression of the RAAS.  In this study, mol. modeling has been used to elucidate key structural features that govern the binding and/or selectivity of a single compd. toward the zinc catalytic sites of the N- and C-domains of the angiotensin-converting enzyme (ACE) and the neutral endopeptidase (NEP).  Eleven dual inhibitors were categorized in three classes, according to their zinc binding groups.  Anal. of their docked conformers revealed the mol. environment of the catalytic sites and the specific interactions between the inhibitors and amino acid residues that are important for selectivity and cooperativity.  In addn., inhibitors were predicted to bind to the C-domain of the ACE with greater affinity than the N-domain, with an av. difference in the free energy of binding ∼2-3 kcal mol-1.  Residues that were identified to actively participate in the binding and stabilizing of the enzyme-inhibitor complexes were analyzed in a consensus way for both the ACE and the NEP.  These at.-level insights into enzyme-ligand binding can be used to drive new structure-based drug design processes in the quest for more selective and effective vasopeptidase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlmtVNKnY-CbVg90H21EOLACvtfcHk0lgZ3saTgbW4gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFyhsLg%253D&md5=b88dadb9dc6da855a31264c038e51212</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1021%2Fci9005047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci9005047%26sid%3Dliteratum%253Aachs%26aulast%3DDimitropoulos%26aufirst%3DN.%26aulast%3DPapakyriakou%26aufirst%3DA.%26aulast%3DDalkas%26aufirst%3DG.%2BA.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DSpyroulias%26aufirst%3DG.%2BA.%26atitle%3DA%2520Computational%2520Approach%2520to%2520the%2520Study%2520of%2520the%2520Binding%2520Mode%2520of%2520Dual%2520ACE%252FNEP%2520Inhibitors%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26issue%3D3%26spage%3D388%26epage%3D396%26doi%3D10.1021%2Fci9005047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milani, F.</span></span> <span> </span><span class="NLM_article-title">Three Key Proteases - angiotensin-I-Converting Enzyme (ACE), ACE2 and Renin - within and Beyond the Renin-Angiotensin System</span>. <i>Arch. Cardiovasc. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1016/j.acvd.2012.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.acvd.2012.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22800722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BC38fgtlCquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2012&pages=373-385&issue=6&author=C.+Guangauthor=R.+D.+Phillipsauthor=B.+Jiangauthor=F.+Milani&title=Three+Key+Proteases+-+angiotensin-I-Converting+Enzyme+%28ACE%29%2C+ACE2+and+Renin+-+within+and+Beyond+the+Renin-Angiotensin+System&doi=10.1016%2Fj.acvd.2012.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system</span></div><div class="casAuthors">Guang Cuie; Phillips Robert D; Jiang Bo; Milani Franco</div><div class="citationInfo"><span class="NLM_cas:title">Archives of cardiovascular diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">373-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The discovery of angiotensin-I-converting enzyme 2 (ACE2) and a (pro)renin receptor has renewed interest in the physiology of the renin-angiotensin system (RAS).  Through the ACE2/angiotensin-(1-7)/Mas counter-regulatory axis, ACE2 balances the vasoconstrictive, proliferative, fibrotic and proinflammatory effects of the ACE/angiotensin II/AT1 axis.  The (pro)renin receptor system shows an angiotensin-dependent function related to increased generation of angiotensin I, and an angiotensin-independent aspect related to intracellular signalling.  Activation of ACE2 and inhibition of ACE and renin have been at the core of the RAS regulation.  The aim of this review is to discuss the biochemistry and biological functions of ACE, ACE2 and renin within and beyond the RAS, and thus provide a perspective for future bioactives from natural plant and/or food resources related to the three proteases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnsgXqrVfI05SWdIdmEou5fW6udTcc2eYE-MubOLlwX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fgtlCquw%253D%253D&md5=a2d1df6c0259ce6e51e6607cb92a0058</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1016%2Fj.acvd.2012.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.acvd.2012.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DGuang%26aufirst%3DC.%26aulast%3DPhillips%26aufirst%3DR.%2BD.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DMilani%26aufirst%3DF.%26atitle%3DThree%2520Key%2520Proteases%2520-%2520angiotensin-I-Converting%2520Enzyme%2520%2528ACE%2529%252C%2520ACE2%2520and%2520Renin%2520-%2520within%2520and%2520Beyond%2520the%2520Renin-Angiotensin%2520System%26jtitle%3DArch.%2520Cardiovasc.%2520Dis.%26date%3D2012%26volume%3D105%26issue%3D6%26spage%3D373%26epage%3D385%26doi%3D10.1016%2Fj.acvd.2012.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodfriend, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catt, K. J.</span></span> <span> </span><span class="NLM_article-title">Angiotensin Receptors and Their Antagonists</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>334</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">1649</span>– <span class="NLM_lpage">1655</span>, <span class="refDoi"> DOI: 10.1056/NEJM199606203342507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1056%2FNEJM199606203342507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=8628362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1emur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=1996&pages=1649-1655&issue=25&author=T.+L.+Goodfriendauthor=M.+E.+Elliottauthor=K.+J.+Catt&title=Angiotensin+Receptors+and+Their+Antagonists&doi=10.1056%2FNEJM199606203342507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin receptors and their antagonists</span></div><div class="casAuthors">Goodfriend, Theodore L.; Elliott, Mary E.; Catt, Kevin J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1649-1654</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review, with 81 refs., of the major actions of angiotensins, the properties of angiotensin receptors, and some aspects of the action and therapeutic applications of the new angiotensin receptor antagonists.  Specific topics discussed were: nomenclature; actions of angiotensins; angiotensin receptors; signal transduction; regulation of angiotensin receptors and their actions; angiotensin receptors in growth and development; mechanism of action of angiotensin-receptor antagonists; clin. trials of angiotensin-receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAVgAOZHXd2LVg90H21EOLACvtfcHk0lgZ3saTgbW4gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1emur0%253D&md5=40ab7efdeabd677d0729f11f3fd0728c</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1056%2FNEJM199606203342507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199606203342507%26sid%3Dliteratum%253Aachs%26aulast%3DGoodfriend%26aufirst%3DT.%2BL.%26aulast%3DElliott%26aufirst%3DM.%2BE.%26aulast%3DCatt%26aufirst%3DK.%2BJ.%26atitle%3DAngiotensin%2520Receptors%2520and%2520Their%2520Antagonists%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1996%26volume%3D334%26issue%3D25%26spage%3D1649%26epage%3D1655%26doi%3D10.1056%2FNEJM199606203342507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prins, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thenappan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritzker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, S. L.</span></span> <span> </span><span class="NLM_article-title">Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What’s Old Is New Again</span>. <i>J. Am. Heart Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">e011343</span>, <span class="refDoi"> DOI: 10.1161/JAHA.118.011343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1161%2FJAHA.118.011343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=30590974" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=e011343&issue=1&author=K.+W.+Prinsauthor=T.+Thenappanauthor=E.+K.+Weirauthor=R.+Kalraauthor=M.+Pritzkerauthor=S.+L.+Archer&title=Repurposing+Medications+for+Treatment+of+Pulmonary+Arterial+Hypertension%3A+What%E2%80%99s+Old+Is+New+Again&doi=10.1161%2FJAHA.118.011343"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1161%2FJAHA.118.011343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FJAHA.118.011343%26sid%3Dliteratum%253Aachs%26aulast%3DPrins%26aufirst%3DK.%2BW.%26aulast%3DThenappan%26aufirst%3DT.%26aulast%3DWeir%26aufirst%3DE.%2BK.%26aulast%3DKalra%26aufirst%3DR.%26aulast%3DPritzker%26aufirst%3DM.%26aulast%3DArcher%26aufirst%3DS.%2BL.%26atitle%3DRepurposing%2520Medications%2520for%2520Treatment%2520of%2520Pulmonary%2520Arterial%2520Hypertension%253A%2520What%25E2%2580%2599s%2520Old%2520Is%2520New%2520Again%26jtitle%3DJ.%2520Am.%2520Heart%2520Assoc.%26date%3D2019%26volume%3D8%26issue%3D1%26spage%3De011343%26doi%3D10.1161%2FJAHA.118.011343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, N.</span></span> <span> </span><span class="NLM_article-title">Tale of 2 Endothelin Receptor Antagonists in Eisenmenger Syndrome</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>139</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.118.037171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1161%2FCIRCULATIONAHA.118.037171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=30592659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADC%252BB3cnmtlOkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2019&pages=64-66&issue=1&author=D.+Ivyauthor=N.+Wilson&title=Tale+of+2+Endothelin+Receptor+Antagonists+in+Eisenmenger+Syndrome&doi=10.1161%2FCIRCULATIONAHA.118.037171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Tale of 2 Endothelin Receptor Antagonists in Eisenmenger Syndrome</span></div><div class="casAuthors">Ivy Dunbar; Wilson Neil; Ivy Dunbar; Wilson Neil</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-66</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLKk-rFuWa2JPq5LRczm8ffW6udTcc2eYS7HYsuhZrz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnmtlOkuw%253D%253D&md5=507f4e130abefafa928df0435b830230</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.118.037171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.118.037171%26sid%3Dliteratum%253Aachs%26aulast%3DIvy%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DN.%26atitle%3DTale%2520of%25202%2520Endothelin%2520Receptor%2520Antagonists%2520in%2520Eisenmenger%2520Syndrome%26jtitle%3DCirculation%26date%3D2019%26volume%3D139%26issue%3D1%26spage%3D64%26epage%3D66%26doi%3D10.1161%2FCIRCULATIONAHA.118.037171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blixt, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanes, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstrup
Christiansen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warfvinge, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edvinsson, L.</span></span> <span> </span><span class="NLM_article-title">Increased Endothelin-1-Mediated Vasoconstriction after Organ Culture in Rat and Pig Ocular Arteries Can Be Suppressed with MEK/ERK1/2 Inhibitors</span>. <i>Acta Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">5</span>), <span class="NLM_elocation-id">e619</span> <span class="refDoi"> DOI: 10.1111/aos.13651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1111%2Faos.13651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29369532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1KltbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2018&issue=5&author=F.+W.+Blixtauthor=K.+A.+Haanesauthor=L.+Ohlssonauthor=A.+Tolstrup%0AChristiansenauthor=K.+Warfvingeauthor=L.+Edvinsson&title=Increased+Endothelin-1-Mediated+Vasoconstriction+after+Organ+Culture+in+Rat+and+Pig+Ocular+Arteries+Can+Be+Suppressed+with+MEK%2FERK1%2F2+Inhibitors&doi=10.1111%2Faos.13651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Increased endothelin-1-mediated vasoconstriction after organ culture in rat and pig ocular arteries can be suppressed with MEK/ERK1/2 inhibitors</span></div><div class="casAuthors">Blixt, Frank W.; Haanes, Kristian Agmund; Ohlsson, Lena; Tolstrup Christiansen, Anders; Warfvinge, Karin; Edvinsson, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Acta Ophthalmologica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e619-e625</span>CODEN:
                <span class="NLM_cas:coden">AOOUAQ</span>;
        ISSN:<span class="NLM_cas:issn">1755-375X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Purpose : Even though retinal vascular changes following ischemia have been poorly understood, the upregulation of vasoconstrictive endothelin-1 (ET-1) receptors (ETA/ETB) following global cerebral ischemia has been described.  The aim of this study was to investigate whether or not the MEK/ERK1/2 pathway is involved in the obsd. upregulation and whether specific MEK/ERK1/2 inhibitors U0126 and trametinib can prevent it.  Methods : The aim was also to localize ETA and ETB receptors using immunohistochem. in both fresh rat ophthalmic arteries and after 24-h organ culture and study the receptors functionally using myog.  Pig retinal arteries also underwent 24-h organ culture to validate similar responses across species and the retinal vasculature.  Results : Results showed that following organ culture there is a significant increase in ET-1-mediated vasoconstriction, in particular via the ETB receptor.  Furthermore, immunohistochem. revealed a clear increase in pERK in the smooth muscle cells of rat ophthalmic artery.  U0126 and trametinib were successful in attenuating the functional vasoconstriction in both rat and pig, as well as restoring immunofluorescence of pERK to fresh levels and counteracting ETB expression in the smooth muscle cells of the rat ophthalmic artery.  Conclusion : This is the first study to show that the MEK/ERK1/2 pathway in responsible for the increase in functional vasoconstriction via ET-1 receptor in rat ophthalmic and pig retinal arteries.  Furthermore, this study is the first to suggest a way of inhibiting and preventing such an increase.  With these results, we suggest a novel approach in retinal ischemia therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiCekzbMo8JLVg90H21EOLACvtfcHk0lgtd_wLxlTlVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1KltbrP&md5=7e179f617f69c9a24831844771f44120</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1111%2Faos.13651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Faos.13651%26sid%3Dliteratum%253Aachs%26aulast%3DBlixt%26aufirst%3DF.%2BW.%26aulast%3DHaanes%26aufirst%3DK.%2BA.%26aulast%3DOhlsson%26aufirst%3DL.%26aulast%3DTolstrup%2BChristiansen%26aufirst%3DA.%26aulast%3DWarfvinge%26aufirst%3DK.%26aulast%3DEdvinsson%26aufirst%3DL.%26atitle%3DIncreased%2520Endothelin-1-Mediated%2520Vasoconstriction%2520after%2520Organ%2520Culture%2520in%2520Rat%2520and%2520Pig%2520Ocular%2520Arteries%2520Can%2520Be%2520Suppressed%2520with%2520MEK%252FERK1%252F2%2520Inhibitors%26jtitle%3DActa%2520Ophthalmol.%26date%3D2018%26volume%3D96%26issue%3D5%26doi%3D10.1111%2Faos.13651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Pascual, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busnadiego, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagares, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamas, S.</span></span> <span> </span><span class="NLM_article-title">Role of Endothelin in the Cardiovascular System</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2011.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.phrs.2011.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21296157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1Krsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=463-472&issue=6&author=F.+Rodr%C3%ADguez-Pascualauthor=O.+Busnadiegoauthor=D.+Lagaresauthor=S.+Lamas&title=Role+of+Endothelin+in+the+Cardiovascular+System&doi=10.1016%2Fj.phrs.2011.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Role of endothelin in the cardiovascular system</span></div><div class="casAuthors">Rodriguez-Pascual, Fernando; Busnadiego, Oscar; Lagares, David; Lamas, Santiago</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">463-472</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The endothelin (ET) system consists of three peptide ligands (ET-1, ET-2 and ET-3) and two G-protein-coupled receptors, ETA and ETB.  In the cardiovascular system, ETs, particularly ET-1, are expressed in smooth muscle cells, cardiomyocytes, fibroblasts, and notably in vascular endothelial cells.  Intense research over the last 10 years has changed the original view of ET-1 as mainly a vasoconstrictor regulating blood pressure, into a biol. factor regulating processes such as vascular remodeling, angiogenesis or extracellular matrix synthesis.  The advent of specific (and type-selective) ET receptor antagonists has greatly fostered our knowledge of the biol. function of ET-1, and has offered a potential therapeutic approach for numerous diseases including hypertension, atherosclerosis or fibrosis.  In this article, we review the regulation of the expression of vascular ET-1, as well as the contribution of ET-1 to endothelial, smooth muscle and fibroblast cell function, with particular interest in the role of ET-1 in the development of cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqq8yOLna2rbVg90H21EOLACvtfcHk0lgtd_wLxlTlVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1Krsr8%253D&md5=7d2bb6049eab438cd3db0ca460915e91</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2011.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2011.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DRodr%25C3%25ADguez-Pascual%26aufirst%3DF.%26aulast%3DBusnadiego%26aufirst%3DO.%26aulast%3DLagares%26aufirst%3DD.%26aulast%3DLamas%26aufirst%3DS.%26atitle%3DRole%2520of%2520Endothelin%2520in%2520the%2520Cardiovascular%2520System%26jtitle%3DPharmacol.%2520Res.%26date%3D2011%26volume%3D63%26issue%3D6%26spage%3D463%26epage%3D472%26doi%3D10.1016%2Fj.phrs.2011.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benson, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pershadsingh, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittiboyina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pravenec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, T. W.</span></span> <span> </span><span class="NLM_article-title">Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist with Selective Ppargamma-Modulating Activity</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.0000123072.34629.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1161%2F01.HYP.0000123072.34629.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15007034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1GmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=993-1002&issue=5&author=S.+C.+Bensonauthor=H.+A.+Pershadsinghauthor=C.+I.+Hoauthor=A.+Chittiboyinaauthor=P.+Desaiauthor=M.+Pravenecauthor=N.+Qiauthor=J.+Wangauthor=M.+A.+Averyauthor=T.+W.+Kurtz&title=Identification+of+Telmisartan+as+a+Unique+Angiotensin+II+Receptor+Antagonist+with+Selective+Ppargamma-Modulating+Activity&doi=10.1161%2F01.HYP.0000123072.34629.57"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ-Modulating Activity</span></div><div class="casAuthors">Benson, Stephen C.; Pershadsingh, Harrihar A.; Ho, Christopher I.; Chittiboyina, Amar; Desai, Prashant; Pravenec, Michal; Qi, Nianning; Wang, Jiaming; Avery, Mitchell A.; Kurtz, Theodore W.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">993-1002</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes that is characterized by the clustering of insulin resistance, dyslipidemia, and increased blood pressure.  In humans, mutations in the peroxisome proliferator-activated receptor-γ (PPARγ) have been reported to cause the full-blown metabolic syndrome, and drugs that activate PPARγ have proven to be effective agents for the prevention and treatment of insulin resistance and type 2 diabetes.  Here the authors report that telmisartan, a structurally unique angiotensin II receptor antagonist used for the treatment of hypertension, can function as a partial agonist of PPARγ; influence the expression of PPARγ target genes involved in carbohydrate and lipid metab.; and reduce glucose, insulin, and triglyceride levels in rats fed a high-fat, high-carbohydrate diet.  None of the other com. available angiotensin II receptor antagonists appeared to activate PPARγ when tested at concns. typically achieved in plasma with conventional oral dosing.  In contrast to ordinary antihypertensive and antidiabetic agents, mols. that can simultaneously block the angiotensin II receptor and activate PPARγ have the potential to treat both hemodynamic and biochem. features of the metabolic syndrome and could provide unique opportunities for the prevention and treatment of diabetes and cardiovascular disease in high-risk populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVMnSBXhf_gLVg90H21EOLACvtfcHk0lgtd_wLxlTlVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1GmtrY%253D&md5=9f3075e771df41d59ac75d2e78ac304b</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000123072.34629.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000123072.34629.57%26sid%3Dliteratum%253Aachs%26aulast%3DBenson%26aufirst%3DS.%2BC.%26aulast%3DPershadsingh%26aufirst%3DH.%2BA.%26aulast%3DHo%26aufirst%3DC.%2BI.%26aulast%3DChittiboyina%26aufirst%3DA.%26aulast%3DDesai%26aufirst%3DP.%26aulast%3DPravenec%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAvery%26aufirst%3DM.%2BA.%26aulast%3DKurtz%26aufirst%3DT.%2BW.%26atitle%3DIdentification%2520of%2520Telmisartan%2520as%2520a%2520Unique%2520Angiotensin%2520II%2520Receptor%2520Antagonist%2520with%2520Selective%2520Ppargamma-Modulating%2520Activity%26jtitle%3DHypertension%26date%3D2004%26volume%3D43%26issue%3D5%26spage%3D993%26epage%3D1002%26doi%3D10.1161%2F01.HYP.0000123072.34629.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chait, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckel, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. C.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowers, J. R.</span></span> <span> </span><span class="NLM_article-title">Diabetes and Cardiovascular Disease</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1134</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.100.10.1134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1161%2F01.CIR.100.10.1134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10477542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A280%3ADyaK1Mvgs1KjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1999&pages=1134-1146&issue=10&author=S.+M.+Grundyauthor=I.+J.+Benjaminauthor=G.+L.+Burkeauthor=A.+Chaitauthor=R.+H.+Eckelauthor=B.+V.+Howardauthor=W.+Mitchauthor=S.+C.+Smithauthor=J.+R.+Sowers&title=Diabetes+and+Cardiovascular+Disease&doi=10.1161%2F01.CIR.100.10.1134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association</span></div><div class="casAuthors">Grundy S M; Benjamin I J; Burke G L; Chait A; Eckel R H; Howard B V; Mitch W; Smith S C Jr; Sowers J R</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1134-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAXnkBr0-67a-9TkgmBqTqfW6udTcc2ea3XOYeGQhdybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1Mvgs1KjsA%253D%253D&md5=7aaa4b0cddedfc2b7fcae3fb91802b46</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.100.10.1134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.100.10.1134%26sid%3Dliteratum%253Aachs%26aulast%3DGrundy%26aufirst%3DS.%2BM.%26aulast%3DBenjamin%26aufirst%3DI.%2BJ.%26aulast%3DBurke%26aufirst%3DG.%2BL.%26aulast%3DChait%26aufirst%3DA.%26aulast%3DEckel%26aufirst%3DR.%2BH.%26aulast%3DHoward%26aufirst%3DB.%2BV.%26aulast%3DMitch%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DSowers%26aufirst%3DJ.%2BR.%26atitle%3DDiabetes%2520and%2520Cardiovascular%2520Disease%26jtitle%3DCirculation%26date%3D1999%26volume%3D100%26issue%3D10%26spage%3D1134%26epage%3D1146%26doi%3D10.1161%2F01.CIR.100.10.1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filzen, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigge, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmaeil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemstra, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohren, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostroski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaum, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Series of Imidazo[4,5-B]Pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4219</span>– <span class="NLM_lpage">4233</span>, <span class="refDoi"> DOI: 10.1021/jm200409s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200409s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4219-4233&issue=12&author=A.+Casimiro-Garciaauthor=G.+F.+Filzenauthor=D.+Flynnauthor=C.+F.+Biggeauthor=J.+Chenauthor=J.+A.+Davisauthor=D.+A.+Dudleyauthor=J.+J.+Edmundsauthor=N.+Esmaeilauthor=A.+Geyerauthor=R.+J.+Heemstraauthor=M.+Jalaieauthor=J.+F.+Ohrenauthor=R.+Ostroskiauthor=T.+Ellisauthor=R.+P.+Schaumauthor=C.+Stoner&title=Discovery+of+a+Series+of+Imidazo%5B4%2C5-B%5DPyridines+with+Dual+Activity+at+Angiotensin+II+Type+1+Receptor+and+Peroxisome+Proliferator-Activated+Receptor-%CE%B3&doi=10.1021%2Fjm200409s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Series of Imidazo[4,5-b]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ</span></div><div class="casAuthors">Casimiro-Garcia, Agustin; Filzen, Gary F.; Flynn, Declan; Bigge, Christopher F.; Chen, Jing; Davis, Jo Ann; Dudley, Danette A.; Edmunds, Jeremy J.; Esmaeil, Nadia; Geyer, Andrew; Heemstra, Ronald J.; Jalaie, Mehran; Ohren, Jeffrey F.; Ostroski, Robert; Ellis, Teresa; Schaum, Robert P.; Stoner, Chad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4219-4233</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mining of an inhouse collection of angiotensin II type 1 receptor antagonists to identify compds. with activity at the peroxisome proliferator-activated receptor-γ (PPARγ) revealed a new series of imidazo[4,5-b]pyridines 2 possessing activity at these two receptors.  Early availability of the crystal structure of the lead compd. bound to the ligand binding domain of human PPARγ confirmed the mode of interaction of this scaffold to the nuclear receptor and assisted in the optimization of PPARγ activity.  Among the new compds., (S)-3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-5-isobutyl-7-methyl-3H-imidazo[4,5-b]pyridine (I) was identified as a potent angiotensin II type I receptor blocker (IC50 = 1.6 nM) with partial PPARγ agonism (EC50 = 212 nM, 31% max) and oral bioavailability in rat.  The dual pharmacol. of I was demonstrated in animal models of hypertension (SHR) and insulin resistance (ZDF rat).  In the SHR, I was highly efficacious in lowering blood pressure, while robust lowering of glucose and triglycerides was obsd. in the male ZDF rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMdOow5t9CALVg90H21EOLACvtfcHk0lj2NtfCPM5aQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGls78%253D&md5=cd55be8d481fccc319ca10c7a2ca2d8b</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1021%2Fjm200409s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200409s%26sid%3Dliteratum%253Aachs%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DFilzen%26aufirst%3DG.%2BF.%26aulast%3DFlynn%26aufirst%3DD.%26aulast%3DBigge%26aufirst%3DC.%2BF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DEdmunds%26aufirst%3DJ.%2BJ.%26aulast%3DEsmaeil%26aufirst%3DN.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DHeemstra%26aufirst%3DR.%2BJ.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DOstroski%26aufirst%3DR.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DSchaum%26aufirst%3DR.%2BP.%26aulast%3DStoner%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520a%2520Series%2520of%2520Imidazo%255B4%252C5-B%255DPyridines%2520with%2520Dual%2520Activity%2520at%2520Angiotensin%2520II%2520Type%25201%2520Receptor%2520and%2520Peroxisome%2520Proliferator-Activated%2520Receptor-%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D12%26spage%3D4219%26epage%3D4233%26doi%3D10.1021%2Fjm200409s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sowers, J.
R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frohlich, E. D.</span></span> <span> </span><span class="NLM_article-title">Diabetes, Hypertension, and Cardiovascular Disease: An Update</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1053</span>– <span class="NLM_lpage">1–59</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.37.4.1053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1161%2F01.HYP.37.4.1053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=11304502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFejt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=1053-1%E2%80%9359&issue=4&author=J.%0AR.+Sowersauthor=M.+Epsteinauthor=E.+D.+Frohlich&title=Diabetes%2C+Hypertension%2C+and+Cardiovascular+Disease%3A+An+Update&doi=10.1161%2F01.HYP.37.4.1053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetes, hypertension, and cardiovascular disease. An update</span></div><div class="casAuthors">Sowers, James R.; Epstein, Murray; Frohlich, Edward D.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1053-1059</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 60 refs.  Cardiovascular diseases (CVDs) are the major causes of mortality in persons with diabetes, and many factors, including hypertension, contribute to this high prevalence of CVD.  Hypertension is approx. twice as frequent in patients with diabetes compared with patients without the disease.  Conversely, recent data suggest that hypertensive persons are more predisposed to the development of diabetes than are normotensive persons.  Furthermore, up to 75% of CVD in diabetes may be attributable to hypertension, leading to recommendations for more aggressive treatment (ie. reducing blood pressure to < 130/85 mm Hg) in persons with coexistent diabetes and hypertension.  Other important risk factors for CVD in these patients include the following: obesity, atherosclerosis. dyslipidemia, microalbuminuria, endothelial dysfunction, platelet hyperaggregability, coagulation abnormalities, and "diabetic cardiomyopathy." The cardiomyopathy assocd. with diabetes is a unique myopathic state that appears to be independent of macrovascular/ microvascular disease and contributes significantly to CVD morbidity and mortality in diabetic patients, esp. those with coexistent hypertension.  This update reviews the current knowledge regarding these risk factors and their treatment, with special emphasis on the cardiometabolic syndrome, hypertension. microalbuminuria, and diabetic cardiomyopathy.  This update also examines the role of the renin-angiotensin system in the increased risk for CVD in diabetic patients and the impact of interrupting this system on the development of clin. diabetes as well as CVD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSwE2PsyOpSbVg90H21EOLACvtfcHk0lj2NtfCPM5aQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFejt7g%253D&md5=4450a490263d9a54aea57b9377dd297a</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.37.4.1053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.37.4.1053%26sid%3Dliteratum%253Aachs%26aulast%3DSowers%26aufirst%3DJ.%2BR.%26aulast%3DEpstein%26aufirst%3DM.%26aulast%3DFrohlich%26aufirst%3DE.%2BD.%26atitle%3DDiabetes%252C%2520Hypertension%252C%2520and%2520Cardiovascular%2520Disease%253A%2520An%2520Update%26jtitle%3DHypertension%26date%3D2001%26volume%3D37%26issue%3D4%26spage%3D1053%26epage%3D1%25E2%2580%259359%26doi%3D10.1161%2F01.HYP.37.4.1053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gress, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wofford, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancati, F. L.</span></span> <span> </span><span class="NLM_article-title">Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus. Atherosclerosis Risk in Communities Study</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1056/NEJM200003303421301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1056%2FNEJM200003303421301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10738048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFWmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2000&pages=905-912&author=T.+W.+Gressauthor=F.+J.+Nietoauthor=E.+Shaharauthor=M.+R.+Woffordauthor=F.+L.+Brancati&title=Hypertension+and+Antihypertensive+Therapy+as+Risk+Factors+for+Type+2+Diabetes+Mellitus.+Atherosclerosis+Risk+in+Communities+Study&doi=10.1056%2FNEJM200003303421301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus</span></div><div class="casAuthors">Gress, Todd W.; Nieto, F. Javier; Shahar, Eyal; Wofford, Marion R.; Brancati, Frederick L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">905-912</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Previous research has suggested that thiazide diuretics and beta-blockers may promote the development of type 2 diabetes mellitus.  However, the results of these studies have been inconsistent, and many studies have been limited by inadequate data on outcomes and by potential confounding.  Methods: We conducted a prospective study of 12,550 adults 45 to 64 yr old who did not have diabetes.  An extensive health evaluation conducted at base line included assessment of medication use and measurement of blood pressure with a random-zero sphygmomanometer.  The incidence of new cases of diabetes was assessed after three years and after six years by measurement of serum glucose concns. while the subjects were fasting.  Results: After simultaneous adjustment for age, sex, race, education, adiposity, family history with respect to diabetes, phys.-activity level, other health-related behavior, and coexisting illnesses, subjects with hypertension who were taking thiazide diuretics were not at greater risk for the subsequent development of diabetes than were subjects with hypertension who were not receiving any antihypertensive therapy (relative hazard, 0.91; 95 % confidence interval, 0.73 to 1.13).  Likewise, subjects who were taking angiotensin-converting-enzyme inhibitors and calcium-channel antagonists were not at greater risk than those not taking any medication.  In contrast, subjects with hypertension who were taking beta-blockers had a 28 % higher risk of subsequent diabetes (relative hazard, 1.28; 95 % confidence interval, 1.04 to 1.57).  Conclusions: Concern about the risk of diabetes should not discourage physicians from prescribing thiazide diuretics to nondiabetic adults who have hypertension.  The use of beta-blockers appears to increase the risk of diabetes, but this adverse effect must be weighed against the proven benefits of beta-blockers in reducing the risk of cardiovascular events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYtqVQbLAwl7Vg90H21EOLACvtfcHk0liiQjPOLjKJjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFWmt7o%253D&md5=11ed15ef60744770a18f6e4acd3f13dc</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1056%2FNEJM200003303421301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200003303421301%26sid%3Dliteratum%253Aachs%26aulast%3DGress%26aufirst%3DT.%2BW.%26aulast%3DNieto%26aufirst%3DF.%2BJ.%26aulast%3DShahar%26aufirst%3DE.%26aulast%3DWofford%26aufirst%3DM.%2BR.%26aulast%3DBrancati%26aufirst%3DF.%2BL.%26atitle%3DHypertension%2520and%2520Antihypertensive%2520Therapy%2520as%2520Risk%2520Factors%2520for%2520Type%25202%2520Diabetes%2520Mellitus.%2520Atherosclerosis%2520Risk%2520in%2520Communities%2520Study%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2000%26volume%3D342%26spage%3D905%26epage%3D912%26doi%3D10.1056%2FNEJM200003303421301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sattigeri, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayasam, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilla, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadhave, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulasi, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voleti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udupa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cliffe, I. A.</span></span> <span> </span><span class="NLM_article-title">Approaches Towards the Development of Chimeric DPP4/ACE Inhibitors for Treating Metabolic Syndrome</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2313</span>– <span class="NLM_lpage">2318</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmcl.2017.04.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=28442252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsFelu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2313-2318&issue=11&author=J.+A.+Sattigeriauthor=S.+Sethiauthor=J.+A.+Davisauthor=S.+Ahmedauthor=G.+V.+Rayasamauthor=B.+G.+Jadhavauthor=S.+M.+Chillaauthor=D.+Dattaauthor=A.+Gadhaveauthor=V.+K.+Tulasiauthor=T.+Jainauthor=S.+Voletiauthor=B.+Benjaminauthor=S.+Udupaauthor=G.+Jainauthor=Y.+Singhauthor=K.+Srinivasauthor=V.+S.+Bansalauthor=A.+Rayauthor=P.+K.+Bhatnagarauthor=I.+A.+Cliffe&title=Approaches+Towards+the+Development+of+Chimeric+DPP4%2FACE+Inhibitors+for+Treating+Metabolic+Syndrome&doi=10.1016%2Fj.bmcl.2017.04.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome</span></div><div class="casAuthors">Sattigeri, Jitendra A.; Sethi, Sachin; Davis, Joseph A.; Ahmed, Shahadat; Rayasam, Geeta V.; Jadhav, Balasaheb G.; Chilla, Satya M.; Datta, Dhrubajyoti; Gadhave, A.; Tulasi, Vamshi K.; Jain, Tarun; Voleti, Sreedhara; Benjamin, Biju; Udupa, Sunitha; Jain, Garima; Singh, Yogender; Srinivas, Kona; Bansal, Vinay S.; Ray, Abhijit; Bhatnagar, Pradip K.; Cliffe, Ian A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2313-2318</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Designing drug candidates exhibiting polypharmacol. is one of the strategies adopted by medicinal chemists to address multifactorial diseases.  Metabolic disease is one such multifactorial disorder characterized by hyperglycemia, hypertension and dyslipidemia among others.  In this paper we report a new class of mol. framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvhiGzVmag5rVg90H21EOLACvtfcHk0liiQjPOLjKJjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsFelu7s%253D&md5=e163a870ca5ca3fd3d3ea46fbcc3ec3f</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.036%26sid%3Dliteratum%253Aachs%26aulast%3DSattigeri%26aufirst%3DJ.%2BA.%26aulast%3DSethi%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DRayasam%26aufirst%3DG.%2BV.%26aulast%3DJadhav%26aufirst%3DB.%2BG.%26aulast%3DChilla%26aufirst%3DS.%2BM.%26aulast%3DDatta%26aufirst%3DD.%26aulast%3DGadhave%26aufirst%3DA.%26aulast%3DTulasi%26aufirst%3DV.%2BK.%26aulast%3DJain%26aufirst%3DT.%26aulast%3DVoleti%26aufirst%3DS.%26aulast%3DBenjamin%26aufirst%3DB.%26aulast%3DUdupa%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DY.%26aulast%3DSrinivas%26aufirst%3DK.%26aulast%3DBansal%26aufirst%3DV.%2BS.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DBhatnagar%26aufirst%3DP.%2BK.%26aulast%3DCliffe%26aufirst%3DI.%2BA.%26atitle%3DApproaches%2520Towards%2520the%2520Development%2520of%2520Chimeric%2520DPP4%252FACE%2520Inhibitors%2520for%2520Treating%2520Metabolic%2520Syndrome%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2313%26epage%3D2318%26doi%3D10.1016%2Fj.bmcl.2017.04.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Natesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwager, S. L. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Human Angiotensin-Converting Enzyme-Lisinopril Complex</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>421</i></span> (<span class="NLM_issue">6922</span>),  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">554</span>, <span class="refDoi"> DOI: 10.1038/nature01370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnature01370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=12540854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntFSqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=421&publication_year=2003&pages=551-554&issue=6922&author=R.+Nateshauthor=S.+L.+U.+Schwagerauthor=E.+D.+Sturrockauthor=K.+R.+Acharya&title=Crystal+Structure+of+the+Human+Angiotensin-Converting+Enzyme-Lisinopril+Complex&doi=10.1038%2Fnature01370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human angiotensin-converting enzyme-lisinopril complex</span></div><div class="casAuthors">Natesh, Ramanathan; Schwager, Sylva L. U.; Sturrock, Edward D.; Acharya, K. Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">421</span>
        (<span class="NLM_cas:issue">6922</span>),
    <span class="NLM_cas:pages">551-554</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Angiotensin-converting enzyme (ACE) has a crit. role in cardiovascular function by cleaving the carboxy terminal His-Leu dipeptide from angiotensin I to produce a potent vasopressor octapeptide, angiotensin II.  Inhibitors of ACE are a first line of therapy for hypertension, heart failure, myocardial infarction and diabetic nephropathy.  Notably, these inhibitors were developed without knowledge of the structure of human ACE, but were instead designed on the basis of an assumed mechanistic homol. with carboxypeptidase A.  Here we present the x-ray structure of human testicular ACE and its complex with one of the most widely used inhibitors, lisinopril (N2-[(S)-1-carboxy-3-phenylpropyl]-l-lysyl-l-proline; also known as Prinivil or Zestril), at 2.0 Å resoln.  Anal. of the three-dimensional structure of ACE shows that it bears little similarity to that of carboxypeptidase A, but instead resembles neurolysin and Pyrococcus furiosus carboxypeptidase-zinc metallopeptidases with no detectable sequence similarity to ACE.  The structure provides an opportunity to design domain-selective ACE inhibitors that may exhibit new pharmacol. profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxHYbWU8PmP7Vg90H21EOLACvtfcHk0lhyv1zgP5E5Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntFSqtg%253D%253D&md5=84f2f474ac20541b0352691128782b1d</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1038%2Fnature01370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01370%26sid%3Dliteratum%253Aachs%26aulast%3DNatesh%26aufirst%3DR.%26aulast%3DSchwager%26aufirst%3DS.%2BL.%2BU.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Human%2520Angiotensin-Converting%2520Enzyme-Lisinopril%2520Complex%26jtitle%3DNature%26date%3D2003%26volume%3D421%26issue%3D6922%26spage%3D551%26epage%3D554%26doi%3D10.1038%2Fnature01370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Natesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwager, S. L. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturrock, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, K. R.</span></span> <span> </span><span class="NLM_article-title">Structural Details on the Binding of Antihypertensive Drugs Captopril and Enalaprilat to Human Testicular Angiotensin I-Converting Enzyme</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">27</span>),  <span class="NLM_fpage">8718</span>– <span class="NLM_lpage">8724</span>, <span class="refDoi"> DOI: 10.1021/bi049480n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi049480n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFSqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=8718-8724&issue=27&author=R.+Nateshauthor=S.+L.+U.+Schwagerauthor=H.+R.+Evansauthor=E.+D.+Sturrockauthor=K.+R.+Acharya&title=Structural+Details+on+the+Binding+of+Antihypertensive+Drugs+Captopril+and+Enalaprilat+to+Human+Testicular+Angiotensin+I-Converting+Enzyme&doi=10.1021%2Fbi049480n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Details on the Binding of Antihypertensive Drugs Captopril and Enalaprilat to Human Testicular Angiotensin I-Converting Enzyme</span></div><div class="casAuthors">Natesh, Ramanathan; Schwager, Sylva L. U.; Evans, Hazel R.; Sturrock, Edward D.; Acharya, K. Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">8718-8724</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Angiotensin converting enzyme (ACE) plays a crit. role in the circulating or endocrine renin-angiotensin system (RAS) as well as the local regulation that exists in tissues such as the myocardium and skeletal muscle.  Here the authors report the high-resoln. crystal structures of testis ACE (tACE) in complex with the first successfully designed ACE inhibitor captopril and enalaprilat, the Phe-Ala-Pro analog.  The authors have compared these structures with the recently reported structure of a tACE-lisinopril complex [Natesh et al. (2003) Nature 421, 551-554].  The analyses reveal that all three inhibitors make direct interactions with the catalytic Zn2+ ion at the active site of the enzyme: the thiol group of captopril and the carboxylate group of enalaprilat and lisinopril.  Subtle differences are also obsd. at other regions of the binding pocket.  These are compared with N-domain models and discussed with ref. to published biochem. data.  The chloride coordination geometries of the three structures are discussed and compared with other ACE analogs.  It is anticipated that the mol. details provided by these structures will be used to improve the binding and/or the design of new, more potent domain-specific inhibitors of ACE that could serve as new generation antihypertensive drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpbHflOxjd7Vg90H21EOLACvtfcHk0lhyv1zgP5E5Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFSqsLs%253D&md5=3c60917f638eaec862889c14576b9624</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1021%2Fbi049480n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi049480n%26sid%3Dliteratum%253Aachs%26aulast%3DNatesh%26aufirst%3DR.%26aulast%3DSchwager%26aufirst%3DS.%2BL.%2BU.%26aulast%3DEvans%26aufirst%3DH.%2BR.%26aulast%3DSturrock%26aufirst%3DE.%2BD.%26aulast%3DAcharya%26aufirst%3DK.%2BR.%26atitle%3DStructural%2520Details%2520on%2520the%2520Binding%2520of%2520Antihypertensive%2520Drugs%2520Captopril%2520and%2520Enalaprilat%2520to%2520Human%2520Testicular%2520Angiotensin%2520I-Converting%2520Enzyme%26jtitle%3DBiochemistry%26date%3D2004%26volume%3D43%26issue%3D27%26spage%3D8718%26epage%3D8724%26doi%3D10.1021%2Fbi049480n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longenecker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Geldern, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiedeman, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubben, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballaron, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mika, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, D. W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempf-Grote, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madar, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagavatula, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fickes, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pireh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lake, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edalji, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevillyan, J. M.</span></span> <span> </span><span class="NLM_article-title">Discovery, Structure-Activity Relationship, and Pharmacological Evaluation of (5-Substituted-Pyrrolidinyl-2-Carbonyl)-2-Cyanopyrrolidines as Potent Dipeptidyl Peptidase IV Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3520</span>– <span class="NLM_lpage">3535</span>, <span class="refDoi"> DOI: 10.1021/jm051283e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051283e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFKks78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3520-3535&issue=12&author=Z.+Peiauthor=X.+Liauthor=K.+Longeneckerauthor=T.+W.+von+Geldernauthor=P.+E.+Wiedemanauthor=T.+H.+Lubbenauthor=B.+A.+Zinkerauthor=K.+Stewartauthor=S.+J.+Ballaronauthor=M.+A.+Stashkoauthor=A.+K.+Mikaauthor=D.+W.+A.+Benoauthor=M.+Longauthor=H.+Wellsauthor=A.+J.+Kempf-Groteauthor=D.+J.+Madarauthor=T.+S.+McDermottauthor=L.+Bhagavatulaauthor=M.+G.+Fickesauthor=D.+Pirehauthor=L.+R.+Solomonauthor=M.+R.+Lakeauthor=R.+Edaljiauthor=E.+H.+Fryauthor=H.+L.+Shamauthor=J.+M.+Trevillyan&title=Discovery%2C+Structure-Activity+Relationship%2C+and+Pharmacological+Evaluation+of+%285-Substituted-Pyrrolidinyl-2-Carbonyl%29-2-Cyanopyrrolidines+as+Potent+Dipeptidyl+Peptidase+IV+Inhibitors&doi=10.1021%2Fjm051283e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, Structure-Activity Relationship, and Pharmacological Evaluation of (5-Substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as Potent Dipeptidyl Peptidase IV Inhibitors</span></div><div class="casAuthors">Pei, Zhonghua; Li, Xiaofeng; Longenecker, Kenton; Von Geldern, Thomas W.; Wiedeman, Paul E.; Lubben, Thomas H.; Zinker, Bradley A.; Stewart, Kent; Ballaron, Stephen J.; Stashko, Michael A.; Mika, Amanda K.; Beno, David W. A.; Long, Michelle; Wells, Heidi; Kempf-Grote, Anita J.; Madar, David J.; McDermott, Todd S.; Bhagavatula, Lakshmi; Fickes, Michael G.; Pireh, Daisy; Solomon, Larry R.; Lake, Marc R.; Edalji, Rohinton; Fry, Elizabeth H.; Sham, Hing L.; Trevillyan, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3520-3535</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of (5-substituted pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidine (C5-Pro-Pro) analogs was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potential treatment of diabetes and obesity.  X-ray crystallog. data show that these inhibitors bind to the catalytic site of DPPIV with the cyano group forming a covalent bond with the serine residue of DPPIV.  The C5-substituents make various interactions with the enzyme and affect potency, chem. stability, selectivity, and PK properties of the inhibitors.  Optimized analogs are extremely potent with subnanomolar Ki's, are chem. stable, show very little potency decrease in the presence of plasma, and exhibit more than 1,000-fold selectivity against related peptidases.  The best compds. also possess good PK and are efficacious in lowering blood glucose in an oral glucose tolerance test in ZDF rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyvx-xfp8nZ7Vg90H21EOLACvtfcHk0lhyv1zgP5E5Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFKks78%253D&md5=05ed6daf508ea3cb7c3294c4662f61fb</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1021%2Fjm051283e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051283e%26sid%3Dliteratum%253Aachs%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLongenecker%26aufirst%3DK.%26aulast%3Dvon%2BGeldern%26aufirst%3DT.%2BW.%26aulast%3DWiedeman%26aufirst%3DP.%2BE.%26aulast%3DLubben%26aufirst%3DT.%2BH.%26aulast%3DZinker%26aufirst%3DB.%2BA.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DBallaron%26aufirst%3DS.%2BJ.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DMika%26aufirst%3DA.%2BK.%26aulast%3DBeno%26aufirst%3DD.%2BW.%2BA.%26aulast%3DLong%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DH.%26aulast%3DKempf-Grote%26aufirst%3DA.%2BJ.%26aulast%3DMadar%26aufirst%3DD.%2BJ.%26aulast%3DMcDermott%26aufirst%3DT.%2BS.%26aulast%3DBhagavatula%26aufirst%3DL.%26aulast%3DFickes%26aufirst%3DM.%2BG.%26aulast%3DPireh%26aufirst%3DD.%26aulast%3DSolomon%26aufirst%3DL.%2BR.%26aulast%3DLake%26aufirst%3DM.%2BR.%26aulast%3DEdalji%26aufirst%3DR.%26aulast%3DFry%26aufirst%3DE.%2BH.%26aulast%3DSham%26aufirst%3DH.%2BL.%26aulast%3DTrevillyan%26aufirst%3DJ.%2BM.%26atitle%3DDiscovery%252C%2520Structure-Activity%2520Relationship%252C%2520and%2520Pharmacological%2520Evaluation%2520of%2520%25285-Substituted-Pyrrolidinyl-2-Carbonyl%2529-2-Cyanopyrrolidines%2520as%2520Potent%2520Dipeptidyl%2520Peptidase%2520IV%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D12%26spage%3D3520%26epage%3D3535%26doi%3D10.1021%2Fjm051283e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beconi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalchick, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiting, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scapin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyvratt, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornberry, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A. E.</span></span> <span> </span><span class="NLM_article-title">(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1021/jm0493156</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0493156" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOjtrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=141-151&issue=1&author=D.+Kimauthor=L.+Wangauthor=M.+Beconiauthor=G.+J.+Eiermannauthor=M.+H.+Fisherauthor=H.+Heauthor=G.+J.+Hickeyauthor=J.+E.+Kowalchickauthor=B.+Leitingauthor=K.+Lyonsauthor=F.+Marsilioauthor=M.+E.+McCannauthor=R.+A.+Patelauthor=A.+Petrovauthor=G.+Scapinauthor=S.+B.+Patelauthor=R.+S.+Royauthor=J.+K.+Wuauthor=M.+J.+Wyvrattauthor=B.+B.+Zhangauthor=L.+Zhuauthor=N.+A.+Thornberryauthor=A.+E.+Weber&title=%282R%29-4-Oxo-4-%5B3-%28trifluoromethyl%29-5%2C6-dihydro%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyrazin-7%288H%29-yl%5D-1-%282%2C4%2C5-trifluorophenyl%29butan-2-amine%3A+A+Potent%2C+Orally+Active+Dipeptidyl+Peptidase+IV+Inhibitor+for+the+Treatment+of+Type+2+Diabetes&doi=10.1021%2Fjm0493156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">(2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Kim, Dooseop; Wang, Liping; Beconi, Maria; Eiermann, George J.; Fisher, Michael H.; He, Huaibing; Hickey, Gerard J.; Kowalchick, Jennifer E.; Leiting, Barbara; Lyons, Kathryn; Marsilio, Frank; McCann, Margaret E.; Patel, Reshma A.; Petrov, Aleksandr; Scapin, Giovanna; Patel, Sangita B.; Roy, Ranabir Sinha; Wu, Joseph K.; Wyvratt, Matthew J.; Zhang, Bei B.; Zhu, Lan; Thornberry, Nancy A.; Weber, Ann E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-151</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of β-amino amides incorporating fused heterocycles, i.e., triazolopiperazines, were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes.  (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (I) is a potent, orally active DPP-IV inhibitor (IC50 = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclin. species, and in vivo efficacy in animal models.  MK-0431, the phosphate salt of I, was selected for development as a potential new treatment for type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0auDWQGbykLVg90H21EOLACvtfcHk0ljsHPVHHH_QQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOjtrbE&md5=85b8a8f3813d7d3d3949945574a684d4</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1021%2Fjm0493156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0493156%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBeconi%26aufirst%3DM.%26aulast%3DEiermann%26aufirst%3DG.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DHickey%26aufirst%3DG.%2BJ.%26aulast%3DKowalchick%26aufirst%3DJ.%2BE.%26aulast%3DLeiting%26aufirst%3DB.%26aulast%3DLyons%26aufirst%3DK.%26aulast%3DMarsilio%26aufirst%3DF.%26aulast%3DMcCann%26aufirst%3DM.%2BE.%26aulast%3DPatel%26aufirst%3DR.%2BA.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DScapin%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DRoy%26aufirst%3DR.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BK.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DB.%2BB.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3D%25282R%2529-4-Oxo-4-%255B3-%2528trifluoromethyl%2529-5%252C6-dihydro%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyrazin-7%25288H%2529-yl%255D-1-%25282%252C4%252C5-trifluorophenyl%2529butan-2-amine%253A%2520A%2520Potent%252C%2520Orally%2520Active%2520Dipeptidyl%2520Peptidase%2520IV%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D1%26spage%3D141%26epage%3D151%26doi%3D10.1021%2Fjm0493156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Dual Inhibitors of HIV Reverse Transcriptase and Integrase: Introducing a Diketoacid Functionality into Delavirdine</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3587</span>– <span class="NLM_lpage">3595</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2008.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18314335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=3587-3595&issue=7&author=Z.+Wangauthor=R.+Vince&title=Design+and+Synthesis+of+Dual+Inhibitors+of+HIV+Reverse+Transcriptase+and+Integrase%3A+Introducing+a+Diketoacid+Functionality+into+Delavirdine&doi=10.1016%2Fj.bmc.2008.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing a diketoacid functionality into delavirdine</span></div><div class="casAuthors">Wang, Zhengqiang; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3587-3595</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cost and toxicity problems assocd. with highly active antiretroviral therapy (HAART) in HIV/AIDS treatment could be alleviated by using designed multiple ligands (DMLs).  Dual inhibitors of HIV reverse transcriptase (RT) and integrase (IN) were rationally designed by introducing a diketoacid (DKA) functionality into the tolerant C-5 site of RT inhibitor delavirdine.  The resulting compds. all demonstrate good activity against both RT and IN in enzymic assays and HIV in cell-based assay, whereas their C-7 regioisomers are all inactive in these assays.  Balanced activities were obsd. with C-3 halogenated inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8iOAhge6i37Vg90H21EOLACvtfcHk0ljsHPVHHH_QQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gqsrg%253D&md5=3f90483b8bac1ee028a201690e34412c</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Dual%2520Inhibitors%2520of%2520HIV%2520Reverse%2520Transcriptase%2520and%2520Integrase%253A%2520Introducing%2520a%2520Diketoacid%2520Functionality%2520into%2520Delavirdine%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26issue%3D7%26spage%3D3587%26epage%3D3595%26doi%3D10.1016%2Fj.bmc.2008.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Advances in Rationally Designed Dual Inhibitors of HIV-1 Reverse Transcriptase and Integrase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">5007</span>– <span class="NLM_lpage">5016</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2016.09.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27658796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFems77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=5007-5016&issue=21&author=S.+X.+Guauthor=P.+Xueauthor=X.+L.+Juauthor=Y.+Y.+Zhu&title=Advances+in+Rationally+Designed+Dual+Inhibitors+of+HIV-1+Reverse+Transcriptase+and+Integrase&doi=10.1016%2Fj.bmc.2016.09.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase</span></div><div class="casAuthors">Gu, Shuang-Xi; Xue, Ping; Ju, Xiu-Lian; Zhu, Yuan-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5007-5016</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Reverse transcriptase (RT) and integrase (IN) are two indispensable enzymes in human immunodeficiency virus type 1 (HIV-1) replication.  RT is responsible for the transformation of the single-stranded RNA viral genome into double-stranded DNA, and IN catalyzes the integration of viral DNA into the host DNA.  Although highly active antiretroviral therapy (HAART) combining nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) with nonnucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) could suppress successfully HIV viral load and reduce evidently the mortality of HIV infected people, it involves the difficulty of perfect adherence, and other drawbacks such as viral rebound, toxicities and multi-drug resistances.  Recently, rational drug design has become a dominant technique for the development of multi-target drugs.  And the rationally designed dual inhibitors of HIV-1 RT and IN have become a hot topic of anti-HIV research.  In this review, the advances in rationally designed dual inhibitors of HIV-1 RT and IN were summarized, including structurally diverse inhibitors, their structure-activity relationship (SAR) studies as well as binding mode anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfniMsd0mbnrVg90H21EOLACvtfcHk0ljsHPVHHH_QQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFems77L&md5=8bf3cf2c5b9873f60397846288e0fb16</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DS.%2BX.%26aulast%3DXue%26aufirst%3DP.%26aulast%3DJu%26aufirst%3DX.%2BL.%26aulast%3DZhu%26aufirst%3DY.%2BY.%26atitle%3DAdvances%2520in%2520Rationally%2520Designed%2520Dual%2520Inhibitors%2520of%2520HIV-1%2520Reverse%2520Transcriptase%2520and%2520Integrase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D21%26spage%3D5007%26epage%3D5016%26doi%3D10.1016%2Fj.bmc.2016.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Pyrimidine and Quinolone Conjugates as a Scaffold for Dual Inhibitors of HIV Reverse Transcriptase and Integrase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1293</span>– <span class="NLM_lpage">1296</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.01.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmcl.2008.01.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=18226894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlajt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1293-1296&issue=4&author=Z.+Wangauthor=R.+Vince&title=Synthesis+of+Pyrimidine+and+Quinolone+Conjugates+as+a+Scaffold+for+Dual+Inhibitors+of+HIV+Reverse+Transcriptase+and+Integrase&doi=10.1016%2Fj.bmcl.2008.01.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase</span></div><div class="casAuthors">Wang, Zhengqiang; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1293-1296</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Title conjugates I [R = H, Me, Et, CH2CH2OH] were designed and synthesized.  The assay results show that these compds. inhibit both reverse transcriptase and integrase and therefore provide a useful scaffold for identifying inhibitors with balanced dual activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuLdCTF2kgJLVg90H21EOLACvtfcHk0lgRnggBOQ9ZYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlajt7c%253D&md5=0a8143d7ee7ca3aa4511c027d1262f1e</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.01.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.01.025%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520Pyrimidine%2520and%2520Quinolone%2520Conjugates%2520as%2520a%2520Scaffold%2520for%2520Dual%2520Inhibitors%2520of%2520HIV%2520Reverse%2520Transcriptase%2520and%2520Integrase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D4%26spage%3D1293%26epage%3D1296%26doi%3D10.1016%2Fj.bmcl.2008.01.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esnouf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willcox, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. I.</span></span> <span> </span><span class="NLM_article-title">Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1589</span>– <span class="NLM_lpage">1600</span>, <span class="refDoi"> DOI: 10.1021/jm960056x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960056x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK28XhslGqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=1589-1600&issue=8&author=A.+L.+Hopkinsauthor=J.+Renauthor=R.+M.+Esnoufauthor=B.+E.+Willcoxauthor=E.+Y.+Jonesauthor=C.+Rossauthor=T.+Miyasakaauthor=R.+T.+Walkerauthor=H.+Tanakaauthor=D.+K.+Stammersauthor=D.+I.+Stuart&title=Complexes+of+HIV-1+Reverse+Transcriptase+with+Inhibitors+of+the+HEPT+Series+Reveal+Conformational+Changes+Relevant+to+the+Design+of+Potent+Non-Nucleoside+Inhibitors&doi=10.1021%2Fjm960056x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors</span></div><div class="casAuthors">Hopkins, Andrew L.; Ren, Jingshan; Esnouf, Robert M.; Willcox, Benjamin E.; Jones, E. Yvonne; Ross, Carl; Miyasaka, Tadashi; Walker, Richard T.; Tanaka, Hiromichi; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1589-600</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crystal structures of HIV-1 reverse transcriptase (RT) complexed with a range of chem. diverse non-nucleoside inhibitors (NNIs) have shown a single pocket in which the inhibitors bind and details of the inhibitor-protein interactions.  To delineate the structural requirements for an effective inhibitor, the authors have detd. the structures of three closely related NNIs which vary widely in their potencies.  Crystal structures of HIV-1 RT complexed with two very potent inhibitors, MKC-442 and TNK-651, at 2.55 Å resoln. complement the authors previous anal. of the complex with the less effective inhibitor, HEPT.  These structures reveal conformational changes which correlate with changes in potency.  The authors suggest that a major determinant of increased potency in the analogs of HEPT is an improved interaction between residue Tyr181 in the protein and the 6-benzyl ring of the inhibitors which stabilizes the structure of the complex.  This arises through a conformational switching of the protein structure triggered by the steric bulk of the 5-substituent of the inhibitor pyrimidine ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1BU3pXNwf67Vg90H21EOLACvtfcHk0lgRnggBOQ9ZYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhslGqsrc%253D&md5=a279a5fe9e82e231f0e898c3dff5bb66</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1021%2Fjm960056x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960056x%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DEsnouf%26aufirst%3DR.%2BM.%26aulast%3DWillcox%26aufirst%3DB.%2BE.%26aulast%3DJones%26aufirst%3DE.%2BY.%26aulast%3DRoss%26aufirst%3DC.%26aulast%3DMiyasaka%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26atitle%3DComplexes%2520of%2520HIV-1%2520Reverse%2520Transcriptase%2520with%2520Inhibitors%2520of%2520the%2520HEPT%2520Series%2520Reveal%2520Conformational%2520Changes%2520Relevant%2520to%2520the%2520Design%2520of%2520Potent%2520Non-Nucleoside%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26issue%3D8%26spage%3D1589%26epage%3D1600%26doi%3D10.1021%2Fjm960056x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3416</span>– <span class="NLM_lpage">3419</span>, <span class="refDoi"> DOI: 10.1021/jm070512p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070512p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVehtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3416-3419&issue=15&author=Z.+Wangauthor=E.+M.+Bennettauthor=D.+J.+Wilsonauthor=C.+Salomonauthor=R.+Vince&title=Rationally+Designed+Dual+Inhibitors+of+HIV+Reverse+Transcriptase+and+Integrase&doi=10.1021%2Fjm070512p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase</span></div><div class="casAuthors">Wang, Zhengqiang; Bennett, Eric M.; Wilson, Daniel J.; Salomon, Christine; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3416-3419</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bifunctional inhibitors were designed and synthesized based on 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) non-nucleoside reverse transcriptase (RT) inhibitors and diketoacid (DKA) integrase (IN) inhibitors.  Biochem. studies revealed activity against RT and IN at low nanomolar and low micromolar concns., resp.  Exceptionally low IC50 values from a cell-based assay were achieved along with remarkably high therapeutic indexes.  Compd. I was identified as the best compd. of the series (IC50: 24 nM against RT, 4.4 μM against IN, and 10 nM against HIV-1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvKQ5ZDoIQqLVg90H21EOLACvtfcHk0lgRnggBOQ9ZYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVehtbo%253D&md5=021d763f7f62919cc1fe9d010ab56e60</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.1021%2Fjm070512p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070512p%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DWilson%26aufirst%3DD.%2BJ.%26aulast%3DSalomon%26aufirst%3DC.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DRationally%2520Designed%2520Dual%2520Inhibitors%2520of%2520HIV%2520Reverse%2520Transcriptase%2520and%2520Integrase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D15%26spage%3D3416%26epage%3D3419%26doi%3D10.1021%2Fjm070512p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motomura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aramaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamataka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinkai, H.</span></span> <span> </span><span class="NLM_article-title">Quinolone Carboxylic Acids as a Novel Monoketo Acid Class of Human Immunodeficiency Virus Type 1 Integrase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4869</span>– <span class="NLM_lpage">4882</span>, <span class="refDoi"> DOI: 10.1021/jm900460z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900460z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4869-4882&issue=15&author=M.+Satoauthor=H.+Kawakamiauthor=T.+Motomuraauthor=H.+Aramakiauthor=T.+Matsudaauthor=M.+Yamashitaauthor=Y.+Itoauthor=Y.+Matsuzakiauthor=K.+Yamatakaauthor=S.+Ikedaauthor=H.+Shinkai&title=Quinolone+Carboxylic+Acids+as+a+Novel+Monoketo+Acid+Class+of+Human+Immunodeficiency+Virus+Type+1+Integrase+Inhibitors&doi=10.1021%2Fjm900460z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Quinolone Carboxylic Acids as a Novel Monoketo Acid Class of Human Immunodeficiency Virus Type 1 Integrase Inhibitors</span></div><div class="casAuthors">Sato, Motohide; Kawakami, Hiroshi; Motomura, Takahisa; Aramaki, Hisateru; Matsuda, Takashi; Yamashita, Masaki; Ito, Yoshiharu; Matsuzaki, Yuji; Yamataka, Kazunobu; Ikeda, Satoru; Shinkai, Hisashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4869-4882</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and detailed structure-activity relationship of quinolonecarboxylic acids as a novel monoketo acid class of HIV-1 integrase inhibitors was presented.  Compds. I (R = t-Bu), which showed an IC50 of 5.8 nM in the strand transfer assay and an ED50 of 0.6 nM in the antiviral assay, and I (R = i-Pr), which had an IC50 of 7.2 nM and an ED50 of 0.9 nM, were the most potent compds. in this class.  The monoketo acid I (R = i-Pr) was much more potent at inhibiting integrase-catalyzed strand transfer processes than 3'-processing reactions, as is the case with the keto-enol acids.  Elvitegravir I (R = i-Pr) was chosen as a candidate for further studies and was reported as being in phase 3 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozJb9SzajWHbVg90H21EOLACvtfcHk0lj5eSrXGoI25Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGjsr0%253D&md5=2eb5292b5c6e9efa8471f293cc9f6bb0</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1021%2Fjm900460z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900460z%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DM.%26aulast%3DKawakami%26aufirst%3DH.%26aulast%3DMotomura%26aufirst%3DT.%26aulast%3DAramaki%26aufirst%3DH.%26aulast%3DMatsuda%26aufirst%3DT.%26aulast%3DYamashita%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DMatsuzaki%26aufirst%3DY.%26aulast%3DYamataka%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DS.%26aulast%3DShinkai%26aufirst%3DH.%26atitle%3DQuinolone%2520Carboxylic%2520Acids%2520as%2520a%2520Novel%2520Monoketo%2520Acid%2520Class%2520of%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Integrase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D15%26spage%3D4869%26epage%3D4882%26doi%3D10.1021%2Fjm900460z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esnouf, R.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. I.</span></span> <span> </span><span class="NLM_article-title">Unique Features in the Structure of the Complex between HIV-1 Reverse Transcriptase and the Bis(Heteroaryl)Piperazine (BHAP) U-90152 Explain Resistance Mutations for This Nonnucleoside Inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3984</span>– <span class="NLM_lpage">3989</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.8.3984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1073%2Fpnas.94.8.3984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=9108091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADyaK2sXis1ehuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=3984-3989&issue=8&author=R.%0AM.+Esnoufauthor=J.+Renauthor=A.+L.+Hopkinsauthor=C.+K.+Rossauthor=E.+Y.+Jonesauthor=D.+K.+Stammersauthor=D.+I.+Stuart&title=Unique+Features+in+the+Structure+of+the+Complex+between+HIV-1+Reverse+Transcriptase+and+the+Bis%28Heteroaryl%29Piperazine+%28BHAP%29+U-90152+Explain+Resistance+Mutations+for+This+Nonnucleoside+Inhibitor&doi=10.1073%2Fpnas.94.8.3984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor</span></div><div class="casAuthors">Esnouf, Robert M.; Ren, Jingshan; Hopkins, Andrew L.; Ross, Carl K.; Jones, E. Yvonne; Stammers, David K.; Stuart, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3984-3989</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The viral reverse transcriptase (RT) provides an attractive target in the search for anti-HIV therapies.  The nonnucleoside inhibitors (NNIs) are a diverse set of compds. (usually HIV-1 specific) that function by distorting the polymerase active site upon binding in a nearby pocket.  Despite being potent and of generally low toxicity, their clin. use has been limited by rapid selection for resistant viral populations.  The 2.65-Å resoln. structure of the complex between HIV-1 RT and the bis(heteroaryl)piperazine (BHAP) NNI, 1-(5-methanesulfonamido-1H-indol-2-yl-carbonyl)-4-[3-(1-methyl-ethylamino)pyridinyl] piperazine (U-90152), reveals the inhibitor conformation and bound water mols.  The bulky U-90152 mol. occupies the same pocket as other NNIs, but the complex is stabilized quite differently, in particular by hydrogen bonding to the main chain of Lys-103 and extensive hydrophobic contacts with Pro-236.  These interactions rationalize obsd. resistance mutations, notably Pro-236-Leu, which occurs characteristically for BHAPs.  When bound, part of U-90152 protrudes into the solvent creating a channel between Pro-236 and the polypeptide segments 225-226 and 105-106, giving the first clear evidence of the entry mode for NNIs.  The structure allows prediction of binding modes for related inhibitors [(altrylamino)piperidine-BHAPs] and suggests changes to U-90152, such as the addn. of a 6 amino group to the pyridine ring, which may make binding more resilient to mutations in the RT.  The observation of novel hydrogen bonding to the protein main chain may provide lessons for the improvement of quite different inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzQuIdPkm-oLVg90H21EOLACvtfcHk0lj5eSrXGoI25Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1ehuro%253D&md5=d9027e0d3dc8ad612fb84d9e98b7f30e</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.8.3984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.8.3984%26sid%3Dliteratum%253Aachs%26aulast%3DEsnouf%26aufirst%3DR.%2BM.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DRoss%26aufirst%3DC.%2BK.%26aulast%3DJones%26aufirst%3DE.%2BY.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26atitle%3DUnique%2520Features%2520in%2520the%2520Structure%2520of%2520the%2520Complex%2520between%2520HIV-1%2520Reverse%2520Transcriptase%2520and%2520the%2520Bis%2528Heteroaryl%2529Piperazine%2520%2528BHAP%2529%2520U-90152%2520Explain%2520Resistance%2520Mutations%2520for%2520This%2520Nonnucleoside%2520Inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26issue%3D8%26spage%3D3984%26epage%3D3989%26doi%3D10.1073%2Fpnas.94.8.3984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daily, J. P.</span></span> <span> </span><span class="NLM_article-title">Antimalarial Drug Therapy: The Role of Parasite Biology and Drug Resistance</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1487</span>– <span class="NLM_lpage">1497</span>, <span class="refDoi"> DOI: 10.1177/0091270006294276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1177%2F0091270006294276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17101748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlajsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=1487-1497&issue=12&author=J.+P.+Daily&title=Antimalarial+Drug+Therapy%3A+The+Role+of+Parasite+Biology+and+Drug+Resistance&doi=10.1177%2F0091270006294276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Antimalarial drug therapy: the role of parasite biology and drug resistance</span></div><div class="casAuthors">Daily, Johanna P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1487-1497</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Malaria continues to affect public health and economic growth in many regions of the world.  The no. of infections continues to rise and is assocd. with increased mortality, despite basic science and public health efforts.  Drug therapy remains the mainstay of treatment and prevention of this disease.  Plasmodium has a complex life cycle involving an arthropod vector and distinct stages within the human host.  Each parasite stage plays a unique role in transmission, disease, and latency.  These different stages may vary in their response to the various anti-malarial compds.  This article will review antimalarial therapies and drug resistance in the context of the parasites' biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCZpemYeNAXbVg90H21EOLACvtfcHk0lj5eSrXGoI25Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlajsbjP&md5=3b019832c10d60a35955edf6549cd256</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1177%2F0091270006294276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270006294276%26sid%3Dliteratum%253Aachs%26aulast%3DDaily%26aufirst%3DJ.%2BP.%26atitle%3DAntimalarial%2520Drug%2520Therapy%253A%2520The%2520Role%2520of%2520Parasite%2520Biology%2520and%2520Drug%2520Resistance%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D46%26issue%3D12%26spage%3D1487%26epage%3D1497%26doi%3D10.1177%2F0091270006294276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bich, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thien, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kager, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisterkamp, S. H.</span></span> <span> </span><span class="NLM_article-title">Combinations of Artemisinin and Quinine for Uncomplicated Falciparum Malaria: Efficacy and Pharmacodynamics</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1302</span>– <span class="NLM_lpage">1308</span>, <span class="refDoi"> DOI: 10.1128/AAC.44.5.1302-1308.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1128%2FAAC.44.5.1302-1308.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10770766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3cXislKitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=1302-1308&issue=5&author=P.+J.+de+Vriesauthor=N.+N.+Bichauthor=H.+V.+Thienauthor=L.+N.+Hungauthor=T.+K.+Anhauthor=P.+A.+Kagerauthor=S.+H.+Heisterkamp&title=Combinations+of+Artemisinin+and+Quinine+for+Uncomplicated+Falciparum+Malaria%3A+Efficacy+and+Pharmacodynamics&doi=10.1128%2FAAC.44.5.1302-1308.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics</span></div><div class="casAuthors">De Vries, Peter J.; Bich, Nguyen Ngoc; Thien, Huynh Van; Hung, Le Ngoc; Anh, Trinh Kim; Kager, Piet A.; Heisterkamp, Siem H.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1302-1308</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Combinations of artemisinin and quinine for uncomplicated falciparum malaria were studied.  A total of 268 patients were randomized to 7 days of quinine at 10 mg/kg of body wt. three times a day (Q) or to artemisinin at 20 mg/kg of body wt. followed by 3 (AQ3) or 5 (AQ5) days of quinine.  Recrudescence rates were 16, 38, and 15% for the Q, AQ3, and AQ5 groups, resp. (P < 0.001).  Recrudescence was assocd. with shorter parasite clearance time (PCT) and longer treatment after the blood smear had become neg. (eradication time).  However, classification of patients to outcome-recrudescence or radical cure-was correct in only 77% of patients.  The population kinetics of the parasitemia was estd. with nonlinear mixed-effect models.  Several models were tested, but the best model was a monoexponential decline of the parasitemia in which the mean parasite elimination half-life was shorter after artemisinin (5.1 h; 95% confidence interval [CI], 4.9 to 5.2 h) than after quinine (8.0 h [95% CI, 7.5 to 8.3 h]).  Attempts to simulate the initial increase of the parasitemia did not result in better models with a biol. plausible interpretation.  Recrudescence was assocd. with slower parasite clearance and a higher simulated terminal parasitemia (Pterm).  The classification of patients to outcome groups based on Pterm was correct in 78% of patients.  The data suggest that parasite strains with reduced sensitivity to quinine are prevalent in Vietnam, with slower parasite clearance and consequent recrudescence.  A single dose of artemisinin induces rapid parasite redn. and lowers the value of Pterm, but to prevent recrudescence, this should be followed by quinine for at least 3 days after parasite clearance, or 5 days in total.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp2PYp44yE8bVg90H21EOLACvtfcHk0ljlIpWfT1TnVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXislKitro%253D&md5=86c7cdfc671038ca0fafb18d1a9c9cf5</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1128%2FAAC.44.5.1302-1308.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.44.5.1302-1308.2000%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BVries%26aufirst%3DP.%2BJ.%26aulast%3DBich%26aufirst%3DN.%2BN.%26aulast%3DThien%26aufirst%3DH.%2BV.%26aulast%3DHung%26aufirst%3DL.%2BN.%26aulast%3DAnh%26aufirst%3DT.%2BK.%26aulast%3DKager%26aufirst%3DP.%2BA.%26aulast%3DHeisterkamp%26aufirst%3DS.%2BH.%26atitle%3DCombinations%2520of%2520Artemisinin%2520and%2520Quinine%2520for%2520Uncomplicated%2520Falciparum%2520Malaria%253A%2520Efficacy%2520and%2520Pharmacodynamics%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2000%26volume%3D44%26issue%3D5%26spage%3D1302%26epage%3D1308%26doi%3D10.1128%2FAAC.44.5.1302-1308.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heneghan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaynor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, A.</span></span> <span> </span><span class="NLM_article-title">A Novel Artemisinin-Quinine Hybrid with Potent Antimalarial Activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3599</span>– <span class="NLM_lpage">3602</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.04.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmcl.2007.04.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=17482816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFait7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3599-3602&issue=13&author=J.+J.+Walshauthor=D.+Coughlanauthor=N.+Heneghanauthor=C.+Gaynorauthor=A.+Bell&title=A+Novel+Artemisinin-Quinine+Hybrid+with+Potent+Antimalarial+Activity&doi=10.1016%2Fj.bmcl.2007.04.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">A novel artemisinin-quinine hybrid with potent antimalarial activity</span></div><div class="casAuthors">Walsh, John J.; Coughlan, David; Heneghan, Nicola; Gaynor, Caroline; Bell, Angus</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3599-3602</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Artemisinin (I) was reduced to dihydroartemisinin and coupled to a carboxylic acid deriv. of quinine (II) via an ester linkage.  This novel hybrid mol. III had potent activity against the 3D7 and (drug-resistant) FcB1 strains of Plasmodium falciparum in culture.  The activity was superior to that of artemisinin alone, quinine alone, or a 1:1 mixt. of artemisinin and quinine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrjW7iX9xRWbVg90H21EOLACvtfcHk0ljlIpWfT1TnVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFait7Y%253D&md5=4f74e16f4e19e101476a7b623720a2a4</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.04.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.04.054%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DJ.%2BJ.%26aulast%3DCoughlan%26aufirst%3DD.%26aulast%3DHeneghan%26aufirst%3DN.%26aulast%3DGaynor%26aufirst%3DC.%26aulast%3DBell%26aufirst%3DA.%26atitle%3DA%2520Novel%2520Artemisinin-Quinine%2520Hybrid%2520with%2520Potent%2520Antimalarial%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D13%26spage%3D3599%26epage%3D3602%26doi%3D10.1016%2Fj.bmcl.2007.04.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bray, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span> <span> </span><span class="NLM_article-title">Quinolines and Artemisinin: Chemistry, Biology and History</span>. <i>Curr. Top. Microbiol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>295</i></span> (<span class="NLM_issue">295</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1007/3-540-29088-5_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1007%2F3-540-29088-5_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=16265885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtF2jsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2005&pages=3-38&issue=295&author=P.+G.+Brayauthor=S.+A.+Wardauthor=P.+M.+O%E2%80%99Neill&title=Quinolines+and+Artemisinin%3A+Chemistry%2C+Biology+and+History&doi=10.1007%2F3-540-29088-5_1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">Quinolines and artemisinin: chemistry, biology and history</span></div><div class="casAuthors">Bray, P. G.; Ward, S. A.; O'Neill, P. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Microbiology and Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">Malaria</span>),
    <span class="NLM_cas:pages">3-38</span>CODEN:
                <span class="NLM_cas:coden">CTMIA3</span>;
        ISSN:<span class="NLM_cas:issn">0070-217X</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Plasmodium falciparum is the most important parasitic pathogen in humans, causing hundreds of millions of malaria infections and millions of deaths each year.  At present there is no effective malaria vaccine and malaria therapy is totally reliant on the use of drugs.  New drugs are urgently needed because of the rapid evolution and spread of parasite resistance to the current therapies.  Drug resistance is one of the major factors contributing to the resurgence of malaria, esp. resistance to the most affordable drugs such as chloroquine.  We need to fully understand the antimalarial mode of action of the existing drugs and the way that the parasite becomes resistant to them in order to design and develop the new therapies that are so urgently needed.  In respect of the quinolines and artemisinins, great progress has been made recently in studying the mechanisms of drug action and drug resistance in malaria parasites.  Here we summarize from a historical, biol. and chem., perspective the exciting new advances that have been made in the study of these important antimalarial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnLgjzw5hRErVg90H21EOLACvtfcHk0ljlIpWfT1TnVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtF2jsrrP&md5=99d7e17c3a40dc321d6ddc515037a55d</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.1007%2F3-540-29088-5_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F3-540-29088-5_1%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DP.%2BG.%26aulast%3DWard%26aufirst%3DS.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26atitle%3DQuinolines%2520and%2520Artemisinin%253A%2520Chemistry%252C%2520Biology%2520and%2520History%26jtitle%3DCurr.%2520Top.%2520Microbiol.%2520Immunol.%26date%3D2005%26volume%3D295%26issue%3D295%26spage%3D3%26epage%3D38%26doi%3D10.1007%2F3-540-29088-5_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref258"><div class="reference"><strong class="refLabel"><a href="#ref258" class="rightTabRefNumLink">258</a></strong><div class="NLM_citation" id="rightTab-cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koeberle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werz, O.</span></span> <span> </span><span class="NLM_article-title">Multi-Target Approach for Natural Products in Inflammation</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1871</span>– <span class="NLM_lpage">1882</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.drudis.2014.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=25172801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyhtrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1871-1882&issue=12&author=A.+Koeberleauthor=O.+Werz&title=Multi-Target+Approach+for+Natural+Products+in+Inflammation&doi=10.1016%2Fj.drudis.2014.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target approach for natural products in inflammation</span></div><div class="casAuthors">Koeberle, Andreas; Werz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1871-1882</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Although an increasing no. of studies show the (pre)clin. efficiency and safety of multi-target natural products, they are still underrepresented as starting points for multi-target drug discovery.  This article provides an overview about the multi-target drug concept and discusses strategies to use the enormous pharmacol. knowledge of natural products with privileged structures (i.e. curcumin, epigallocatechin-3-gallate, resveratrol, salicylate and quercetin) for developing anti-inflammatory multi-target drugs.  Focus is placed on selecting mol. targets, judging their relevance and estg. safety concerns.  An attractive aim might be to modulate natural product affinity to concrete but multiple mol. targets (based on the current knowledge of inflammation-relevant pathways) while maintaining their apparently beneficial broad target profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSJ77tkJ2UerVg90H21EOLACvtfcHk0ljlIpWfT1TnVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyhtrnL&md5=69bf3f871fc69612a71125834e98ab43</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DKoeberle%26aufirst%3DA.%26aulast%3DWerz%26aufirst%3DO.%26atitle%3DMulti-Target%2520Approach%2520for%2520Natural%2520Products%2520in%2520Inflammation%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26issue%3D12%26spage%3D1871%26epage%3D1882%26doi%3D10.1016%2Fj.drudis.2014.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref259"><div class="reference"><strong class="refLabel"><a href="#ref259" class="rightTabRefNumLink">259</a></strong><div class="NLM_citation" id="rightTab-cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacob P, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manju, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethiraj, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, G.</span></span> <span> </span><span class="NLM_article-title">Safer Anti-Inflammatory Therapy through Dual COX-2/5-LOX Inhibitors: A Structure-Based Approach</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">356</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2018.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejps.2018.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=29883727" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2018&pages=356-381&author=J.+Jacob+Pauthor=S.+L.+Manjuauthor=K.+R.+Ethirajauthor=G.+Elias&title=Safer+Anti-Inflammatory+Therapy+through+Dual+COX-2%2F5-LOX+Inhibitors%3A+A+Structure-Based+Approach&doi=10.1016%2Fj.ejps.2018.06.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2018.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2018.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DJacob%2BP%26aufirst%3DJ.%26aulast%3DManju%26aufirst%3DS.%2BL.%26aulast%3DEthiraj%26aufirst%3DK.%2BR.%26aulast%3DElias%26aufirst%3DG.%26atitle%3DSafer%2520Anti-Inflammatory%2520Therapy%2520through%2520Dual%2520COX-2%252F5-LOX%2520Inhibitors%253A%2520A%2520Structure-Based%2520Approach%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2018%26volume%3D121%26spage%3D356%26epage%3D381%26doi%3D10.1016%2Fj.ejps.2018.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref260"><div class="reference"><strong class="refLabel"><a href="#ref260" class="rightTabRefNumLink">260</a></strong><div class="NLM_citation" id="rightTab-cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eleftheriadis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poelman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leus, N. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honrath, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neochoritis, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, F. J.</span></span> <span> </span><span class="NLM_article-title">Design of a Novel Thiophene Inhibitor of 15-Lipoxygenase-1 with Both Anti-Inflammatory and Neuroprotective Properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">801</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.ejmech.2016.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27477687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1OnsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2016&pages=786-801&author=N.+Eleftheriadisauthor=H.+Poelmanauthor=N.+G.+J.+Leusauthor=B.+Honrathauthor=C.+G.+Neochoritisauthor=A.+Dolgaauthor=A.+D%C3%B6mlingauthor=F.+J.+Dekker&title=Design+of+a+Novel+Thiophene+Inhibitor+of+15-Lipoxygenase-1+with+Both+Anti-Inflammatory+and+Neuroprotective+Properties&doi=10.1016%2Fj.ejmech.2016.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Design of a novel thiophene inhibitor of 15-lipoxygenase-1 with both anti-inflammatory and neuroprotective properties</span></div><div class="casAuthors">Eleftheriadis, Nikolaos; Poelman, Hessel; Leus, Niek G. J.; Honrath, Birgit; Neochoritis, Constantinos G.; Dolga, Amalia; Doemling, Alexander; Dekker, Frank J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">786-801</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The enzyme 15-lipoxygenase-1 (15-LOX-1) plays a dual role in diseases with an inflammatory component.  On one hand 15-LOX-1 plays a role in pro-inflammatory gene expression and on the other hand it has been shown to be involved in central nervous system (CNS) disorders by its ability to mediate oxidative stress and damage of mitochondrial membranes under hypoxic conditions.  In order to further explore applications in the CNS, novel 15-LOX-1 inhibitors with favorable physicochem. properties need to be developed.  Here, we present Substitution Oriented Screening (SOS) in combination with Multi Component Chem. (MCR) as an effective strategy to identify a diversely substituted small heterocyclic inhibitors for 15-LOX-1, denoted ThioLox, with physicochem. properties superior to previously identified inhibitors.  Ex vivo biol. evaluation in precision-cut lung slices (PCLS) showed inhibition of pro-inflammatory gene expression and in vitro studies on neuronal HT-22 cells showed a strong protection against glutamate toxicity for this 15-LOX-1 inhibitor.  This provides a novel approach to identify novel small with favorable physicochem. properties for exploring 15-LOX-1 as a drug target in inflammatory diseases and neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJgitwoMsVk7Vg90H21EOLACvtfcHk0li-MvZxE26Yqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1OnsLbM&md5=931aea61ddecf51462afa126deedc302</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DEleftheriadis%26aufirst%3DN.%26aulast%3DPoelman%26aufirst%3DH.%26aulast%3DLeus%26aufirst%3DN.%2BG.%2BJ.%26aulast%3DHonrath%26aufirst%3DB.%26aulast%3DNeochoritis%26aufirst%3DC.%2BG.%26aulast%3DDolga%26aufirst%3DA.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26aulast%3DDekker%26aufirst%3DF.%2BJ.%26atitle%3DDesign%2520of%2520a%2520Novel%2520Thiophene%2520Inhibitor%2520of%252015-Lipoxygenase-1%2520with%2520Both%2520Anti-Inflammatory%2520and%2520Neuroprotective%2520Properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D122%26spage%3D786%26epage%3D801%26doi%3D10.1016%2Fj.ejmech.2016.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref261"><div class="reference"><strong class="refLabel"><a href="#ref261" class="rightTabRefNumLink">261</a></strong><div class="NLM_citation" id="rightTab-cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vane, J. R.</span></span> <span> </span><span class="NLM_article-title">The Mechanism of Action of Anti-Inflammatory Drugs</span>. <i>Acta Rheumatol. Scand.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">Suppl. 102</span>),  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">21</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1997&pages=9-21&issue=Suppl.+102&author=J.+R.+Vane&title=The+Mechanism+of+Action+of+Anti-Inflammatory+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520Mechanism%2520of%2520Action%2520of%2520Anti-Inflammatory%2520Drugs%26jtitle%3DActa%2520Rheumatol.%2520Scand.%26date%3D1997%26volume%3D25%26issue%3DSuppl.%2520102%26spage%3D9%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref262"><div class="reference"><strong class="refLabel"><a href="#ref262" class="rightTabRefNumLink">262</a></strong><div class="NLM_citation" id="rightTab-cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martel-Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lajeunesse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reboul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J. P.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Role of Dual Inhibitors of 5-LOX and COX, Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1136/ard.62.6.501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1136%2Fard.62.6.501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=12759283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkslKqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2003&pages=501-509&issue=6&author=J.+Martel-Pelletierauthor=D.+Lajeunesseauthor=P.+Reboulauthor=J.+P.+Pelletier&title=Therapeutic+Role+of+Dual+Inhibitors+of+5-LOX+and+COX%2C+Selective+and+Non-Selective+Non-Steroidal+Anti-Inflammatory+Drugs&doi=10.1136%2Fard.62.6.501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs</span></div><div class="casAuthors">Martel-Pelletier, J.; Lajeunesse, D.; Reboul, P.; Pelletier, J.-P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">501-509</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dual 5-LOX/COX inhibitors are potential new drugs to treat inflammation.  They act by blocking the formation of both prostaglandins and leucotrienes but do not affect lipoxin formation.  Such combined inhibition avoids some of the disadvantages of selective COX-2 inhibitors and spares the gastrointestinal mucosa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHAzAjNtkY5LVg90H21EOLACvtfcHk0li-MvZxE26Yqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkslKqu78%253D&md5=abb97e7397cdcfa7e7921d4cbc3771c3</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.1136%2Fard.62.6.501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.62.6.501%26sid%3Dliteratum%253Aachs%26aulast%3DMartel-Pelletier%26aufirst%3DJ.%26aulast%3DLajeunesse%26aufirst%3DD.%26aulast%3DReboul%26aufirst%3DP.%26aulast%3DPelletier%26aufirst%3DJ.%2BP.%26atitle%3DTherapeutic%2520Role%2520of%2520Dual%2520Inhibitors%2520of%25205-LOX%2520and%2520COX%252C%2520Selective%2520and%2520Non-Selective%2520Non-Steroidal%2520Anti-Inflammatory%2520Drugs%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2003%26volume%3D62%26issue%3D6%26spage%3D501%26epage%3D509%26doi%3D10.1136%2Fard.62.6.501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref263"><div class="reference"><strong class="refLabel"><a href="#ref263" class="rightTabRefNumLink">263</a></strong><div class="NLM_citation" id="rightTab-cit263"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blobaum, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marnett, L. J.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Basis of Cyclooxygenase Inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1441</span>, <span class="refDoi"> DOI: 10.1021/jm0613166</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0613166" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFeisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1425-1441&issue=7&author=A.+L.+Blobaumauthor=L.+J.+Marnett&title=Structural+and+Functional+Basis+of+Cyclooxygenase+Inhibition&doi=10.1021%2Fjm0613166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Basis of Cyclooxygenase Inhibition</span></div><div class="casAuthors">Blobaum, Anna L.; Marnett, Lawrence J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1425-1441</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will focus on the structural and functional basis of the inhibition of cyclooxygenase (COX) enzymes by nonselective and COX-2 selective inhibitors.  It will integrate kinetic, mechanistic, and structural information to illustrate not only the range of mols. with COX inhibitory activity but also the diversity of mechanisms by which they act.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8SMg_SRasDLVg90H21EOLACvtfcHk0lhqRHvLUlSsOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFeisL8%253D&md5=b9de2eafa7d2b510c866245b09fba546</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1021%2Fjm0613166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0613166%26sid%3Dliteratum%253Aachs%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26atitle%3DStructural%2520and%2520Functional%2520Basis%2520of%2520Cyclooxygenase%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D7%26spage%3D1425%26epage%3D1441%26doi%3D10.1021%2Fjm0613166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref264"><div class="reference"><strong class="refLabel"><a href="#ref264" class="rightTabRefNumLink">264</a></strong><div class="NLM_citation" id="rightTab-cit264"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geerts, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiros, A.</span></span> <span> </span><span class="NLM_article-title">Assessing the Synergy between Cholinomimetics and Memantine as Augmentation Therapy in Cognitive Impairment in Schizophrenia. A Virtual Human Patient Trial Using Quantitative Systems Pharmacology</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1208</span>– <span class="NLM_lpage">1217</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.3389%2Ffphar.2015.00198" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1208-1217&issue=4&author=H.+Geertsauthor=P.+Robertsauthor=A.+Spiros&title=Assessing+the+Synergy+between+Cholinomimetics+and+Memantine+as+Augmentation+Therapy+in+Cognitive+Impairment+in+Schizophrenia.+A+Virtual+Human+Patient+Trial+Using+Quantitative+Systems+Pharmacology&doi=10.3389%2Ffphar.2015.00198"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00198%26sid%3Dliteratum%253Aachs%26aulast%3DGeerts%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%26aulast%3DSpiros%26aufirst%3DA.%26atitle%3DAssessing%2520the%2520Synergy%2520between%2520Cholinomimetics%2520and%2520Memantine%2520as%2520Augmentation%2520Therapy%2520in%2520Cognitive%2520Impairment%2520in%2520Schizophrenia.%2520A%2520Virtual%2520Human%2520Patient%2520Trial%2520Using%2520Quantitative%2520Systems%2520Pharmacology%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26issue%3D4%26spage%3D1208%26epage%3D1217%26doi%3D10.3389%2Ffphar.2015.00198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref265"><div class="reference"><strong class="refLabel"><a href="#ref265" class="rightTabRefNumLink">265</a></strong><div class="NLM_citation" id="rightTab-cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speck-Planche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleandrova, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordeiro, M. N. D. S.</span></span> <span> </span><span class="NLM_article-title">Rational Drug Design for Anti-Cancer Chemotherapy: Multi-Target QSAR Models for the in Silico Discovery of Anti-Colorectal Cancer Agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4848</span>– <span class="NLM_lpage">4855</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.05.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.bmc.2012.05.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22750007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVyjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=4848-4855&issue=15&author=A.+Speck-Plancheauthor=V.+V.+Kleandrovaauthor=F.+Luanauthor=M.+N.+D.+S.+Cordeiro&title=Rational+Drug+Design+for+Anti-Cancer+Chemotherapy%3A+Multi-Target+QSAR+Models+for+the+in+Silico+Discovery+of+Anti-Colorectal+Cancer+Agents&doi=10.1016%2Fj.bmc.2012.05.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">Rational drug design for anti-cancer chemotherapy: Multi-target QSAR models for the in silico discovery of anti-colorectal cancer agents</span></div><div class="casAuthors">Speck-Planche, Alejandro; Kleandrova, Valeria V.; Luan, Feng; Cordeiro, M. Natalia D. S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4848-4855</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery of new and more potent anti-cancer agents constitutes one of the most active fields of research in chemotherapy.  Colorectal cancer (CRC) is one of the most studied cancers because of its high prevalence and no. of deaths.  In the current pharmaceutical design of more efficient anti-CRC drugs, the use of methodologies based on Chemoinformatics has played a decisive role, including Quant.-Structure-Activity Relationship (QSAR) techniques.  However, until now, there is no methodol. able to predict anti-CRC activity of compds. against more than one CRC cell line, which should constitute the principal goal.  In an attempt to overcome this problem we develop here the first multi-target (mt) approach for the virtual screening and rational in silico discovery of anti-CRC agents against ten cell lines.  Here, two mt-QSAR classification models were constructed using a large and heterogeneous database of compds.  The first model was based on linear discriminant anal. (mt-QSAR-LDA) employing fragment-based descriptors while the second model was obtained using artificial neural networks (mt-QSAR-ANN) with global 2D descriptors.  Both models correctly classified more than 90% of active and inactive compds. in training and prediction sets.  Some fragments were extd. from the mols. and their contributions to anti-CRC activity were calcd. using mt-QSAR-LDA model.  Several fragments were identified as potential substructural features responsible for the anti-CRC activity and new mols. designed from those fragments with pos. contributions were suggested and correctly predicted by the two models as possible potent and versatile anti-CRC agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzYPKmeEc7SrVg90H21EOLACvtfcHk0lhqRHvLUlSsOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVyjurg%253D&md5=ad1fcf5e992a4a4f43caf1a5b470529b</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.05.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.05.071%26sid%3Dliteratum%253Aachs%26aulast%3DSpeck-Planche%26aufirst%3DA.%26aulast%3DKleandrova%26aufirst%3DV.%2BV.%26aulast%3DLuan%26aufirst%3DF.%26aulast%3DCordeiro%26aufirst%3DM.%2BN.%2BD.%2BS.%26atitle%3DRational%2520Drug%2520Design%2520for%2520Anti-Cancer%2520Chemotherapy%253A%2520Multi-Target%2520QSAR%2520Models%2520for%2520the%2520in%2520Silico%2520Discovery%2520of%2520Anti-Colorectal%2520Cancer%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26issue%3D15%26spage%3D4848%26epage%3D4855%26doi%3D10.1016%2Fj.bmc.2012.05.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref266"><div class="reference"><strong class="refLabel"><a href="#ref266" class="rightTabRefNumLink">266</a></strong><div class="NLM_citation" id="rightTab-cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speck-Planche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleandrova, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordeiro, M. N. D. S.</span></span> <span> </span><span class="NLM_article-title">In Silico Discovery and Virtual Screening of Multi-Target Inhibitors for Proteins in Mycobacterium Tuberculosis</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.2174/138620712802650487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.2174%2F138620712802650487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22452349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFGru7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=666-673&issue=8&author=A.+Speck-Plancheauthor=V.+V.+Kleandrovaauthor=F.+Luanauthor=M.+N.+D.+S.+Cordeiro&title=In+Silico+Discovery+and+Virtual+Screening+of+Multi-Target+Inhibitors+for+Proteins+in+Mycobacterium+Tuberculosis&doi=10.2174%2F138620712802650487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis</span></div><div class="casAuthors">Speck-Planche, Alejandro; Kleandrova, Valeria V.; Luan, Feng; Cordeiro, M. Natalia D. S.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">666-673</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis (MTB) is the principal pathogen which causes tuberculosis (TB), a disease that remains as one of the most alarming health problems worldwide.  An active area for the search of new anti-TB therapies is concerned with the use of computational approaches based on Chemoinformatics and/or Bioinformatics toward the discovery of new and potent anti-TB agents.  These approaches consider only small series of structurally related compds. and the studies are generally realized for only one target like a protein.  This fact constitutes an important limitation.  The present work is an effort to overcome this problem.  We introduce here the first chemo-bioinformatic approach by developing a multi-target (mt) QSAR discriminant model, for the in silico design and virtual screening of anti-TB agents against six proteins in MTB.  The mt-QSAR model was developed by employing a large and heterogeneous database of compds. and substructural descriptors.  The model correctly classified more than 90% of active and inactive compds. in both, training and prediction series.  Some fragments were extd. from the mols. and their contributions to anti-TB activity through inhibition of the six proteins, were calcd.  Several fragments were identified as responsible for anti-TB activity and new mol. entities were designed from those fragments with pos. contributions, being suggested as possible anti-TB agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ivBLhLx_DLVg90H21EOLACvtfcHk0lhqRHvLUlSsOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFGru7bO&md5=299fc21b83a8afaa190d943c163f4086</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.2174%2F138620712802650487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620712802650487%26sid%3Dliteratum%253Aachs%26aulast%3DSpeck-Planche%26aufirst%3DA.%26aulast%3DKleandrova%26aufirst%3DV.%2BV.%26aulast%3DLuan%26aufirst%3DF.%26aulast%3DCordeiro%26aufirst%3DM.%2BN.%2BD.%2BS.%26atitle%3DIn%2520Silico%2520Discovery%2520and%2520Virtual%2520Screening%2520of%2520Multi-Target%2520Inhibitors%2520for%2520Proteins%2520in%2520Mycobacterium%2520Tuberculosis%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2012%26volume%3D15%26issue%3D8%26spage%3D666%26epage%3D673%26doi%3D10.2174%2F138620712802650487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref267"><div class="reference"><strong class="refLabel"><a href="#ref267" class="rightTabRefNumLink">267</a></strong><div class="NLM_citation" id="rightTab-cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thangapandian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakkiah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. W.</span></span> <span> </span><span class="NLM_article-title">Molecular Docking and Pharmacophore Filtering in the Discovery of Dual-Inhibitors for Human Leukotriene A4 Hydrolase and Leukotriene C4 Synthase</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1021/ci1002813</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci1002813" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWgtrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=33-44&issue=1&author=S.+Thangapandianauthor=S.+Johnauthor=S.+Sakkiahauthor=K.+W.+Lee&title=Molecular+Docking+and+Pharmacophore+Filtering+in+the+Discovery+of+Dual-Inhibitors+for+Human+Leukotriene+A4+Hydrolase+and+Leukotriene+C4+Synthase&doi=10.1021%2Fci1002813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit267R"><div class="casContent"><span class="casTitleNuber">267</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Docking and Pharmacophore Filtering in the Discovery of Dual-Inhibitors for Human Leukotriene A4 Hydrolase and Leukotriene C4 Synthase</span></div><div class="casAuthors">Thangapandian, Sundarapandian; John, Shalini; Sakkiah, Sugunadevi; Lee, Keun Woo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-44</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combination of drugs for multiple targets has been a std. treatment in treating various diseases.  A single chem. entity that acts upon multiple targets is emerging nowadays because of their predictable pharmacokinetic and pharmacodynamic properties.  We have employed a computer-aided methodol. combining mol. docking and pharmacophore filtering to identify chem. compds. that can simultaneously inhibit the human leukotriene hydrolase (hLTA4H) and the human leukotriene C4 synthase (hLTC4S) enzymes.  These enzymes are the members of arachidonic acid pathway and act upon the same substrate, LTA4, producing different inflammatory products.  A huge set of 4966 druglike compds. from the Maybridge database were docked into the active site of hLTA4H using the GOLD program.  Common feature pharmacophore models were developed from the known inhibitors of both the targets using Accelrys Discovery Studio 2.5.  The hits from the hLTA4H docking were filtered to match the chem. features of both the pharmacophore models.  The compds. that resulted from the pharmacophore filtering were docked into the active site of hLTC4S and the hits those bind well at both the active sites and matched the pharmacophore models were identified as possible dual inhibitors for hLTA4H and hLTC4S enzymes.  Reverse validation was performed to ensure the results of the study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA6jX1D7KbArVg90H21EOLACvtfcHk0lgcnCCOPBdFIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWgtrbN&md5=815b2e9b582ddb109d141114ea32a2fa</span></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1021%2Fci1002813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci1002813%26sid%3Dliteratum%253Aachs%26aulast%3DThangapandian%26aufirst%3DS.%26aulast%3DJohn%26aufirst%3DS.%26aulast%3DSakkiah%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DK.%2BW.%26atitle%3DMolecular%2520Docking%2520and%2520Pharmacophore%2520Filtering%2520in%2520the%2520Discovery%2520of%2520Dual-Inhibitors%2520for%2520Human%2520Leukotriene%2520A4%2520Hydrolase%2520and%2520Leukotriene%2520C4%2520Synthase%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26issue%3D1%26spage%3D33%26epage%3D44%26doi%3D10.1021%2Fci1002813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref268"><div class="reference"><strong class="refLabel"><a href="#ref268" class="rightTabRefNumLink">268</a></strong><div class="NLM_citation" id="rightTab-cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Antibody-Drug Conjugates in Cancer Therapy</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-050311-201823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1146%2Fannurev-med-050311-201823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=23043493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFKls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=15-29&issue=3&author=E.+L.+Sieversauthor=P.+D.+Senter&title=Antibody-Drug+Conjugates+in+Cancer+Therapy&doi=10.1146%2Fannurev-med-050311-201823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit268R"><div class="casContent"><span class="casTitleNuber">268</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug copnjugates in cancer therapy</span></div><div class="casAuthors">Sievers, Eric L.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-29</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  An antibody-drug conjugate (ADC) provides the possibility of selectively ablating cancer cells by combining the specificity of a monoclonal antibody (mAb) for a target antigen with the delivery of a highly potent cytotoxic agent.  ADC target antigens are typically highly expressed on the surface of cancer cells compared to normal cells.  The tumor target, the cytotoxic agent, and the manner in which the agent is attached to the antibody are key determinants of clin. activity and tolerability.  Recently, several clin. trials have demonstrated that ADCs achieve higher clin. response rates than unconjugated mAbs targeting the same cell surface antigen.  Brentuximab vedotin represents one such ADC that has recently been approved for the treatment of relapsed Hodgkin and systemic anaplastic large cell lymphomas-both characterized by high expression of the target antigen, CD30, on the surface of malignant cells.  This review summarizes key characteristics of current, clin. active ADCs and highlights recent clin. data illustrating the benefit of antibody-targeted delivery of cytotoxic agents to cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYUxUWLJwNgbVg90H21EOLACvtfcHk0lgcnCCOPBdFIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFKls7w%253D&md5=17779a142df44c67601d7e9555511ab7</span></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-050311-201823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-050311-201823%26sid%3Dliteratum%253Aachs%26aulast%3DSievers%26aufirst%3DE.%2BL.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DAntibody-Drug%2520Conjugates%2520in%2520Cancer%2520Therapy%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2013%26volume%3D64%26issue%3D3%26spage%3D15%26epage%3D29%26doi%3D10.1146%2Fannurev-med-050311-201823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref269"><div class="reference"><strong class="refLabel"><a href="#ref269" class="rightTabRefNumLink">269</a></strong><div class="NLM_citation" id="rightTab-cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ducry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, B.</span></span> <span> </span><span class="NLM_article-title">Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1021/bc9002019</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc9002019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGiu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=5-13&issue=1&author=L.+Ducryauthor=B.+Stump&title=Antibody-Drug+Conjugates%3A+Linking+Cytotoxic+Payloads+to+Monoclonal+Antibodies&doi=10.1021%2Fbc9002019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies</span></div><div class="casAuthors">Ducry, Laurent; Stump, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-13</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic mols., thereby taking advantage of the best characteristics of both components.  Along with the development of the mAbs and cytotoxins, the design of chem. linkers to covalently bind these building blocks is making rapid progress but remains challenging.  Recent advances have resulted in linkers having increased stability in the bloodstream while allowing efficient payload release within the tumor cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlMw1v5iWdG7Vg90H21EOLACvtfcHk0lgcnCCOPBdFIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGiu77I&md5=bf79ac611e08674604d6b8cc29636abb</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1021%2Fbc9002019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc9002019%26sid%3Dliteratum%253Aachs%26aulast%3DDucry%26aufirst%3DL.%26aulast%3DStump%26aufirst%3DB.%26atitle%3DAntibody-Drug%2520Conjugates%253A%2520Linking%2520Cytotoxic%2520Payloads%2520to%2520Monoclonal%2520Antibodies%26jtitle%3DBioconjugate%2520Chem.%26date%3D2010%26volume%3D21%26issue%3D1%26spage%3D5%26epage%3D13%26doi%3D10.1021%2Fbc9002019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref270"><div class="reference"><strong class="refLabel"><a href="#ref270" class="rightTabRefNumLink">270</a></strong><div class="NLM_citation" id="rightTab-cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis
Phillips, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crocker, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blattler, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, W. L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwall, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenkare-Mitra, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9280</span>– <span class="NLM_lpage">9290</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=19010901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&issue=22&author=G.+D.+Lewis%0APhillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=R.+V.+J.+Chariauthor=R.+J.+Lutzauthor=W.+L.+T.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-Positive+Breast+Cancer+with+Trastuzumab-DM1%2C+an+Antibody-Cytotoxic+Drug+Conjugate&doi=10.1158%2F0008-5472.CAN-08-1776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit270R"><div class="casContent"><span class="casTitleNuber">270</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span></div><div class="casAuthors">Lewis Phillips, Gail D.; Li, Guangmin; Dugger, Debra L.; Crocker, Lisa M.; Parsons, Kathryn L.; Mai, Elaine; Blaettler, Walter A.; Lambert, John M.; Chari, Ravi V. J.; Lutz, Robert J.; Wong, Wai Lee T.; Jacobson, Frederic S.; Koeppen, Hartmut; Schwall, Ralph H.; Kenkare-Mitra, Sara R.; Spencer, Susan D.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9280-9290</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER2 is a validated target in breast cancer therapy.  Two drugs are currently approved for HER2-pos. breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (Tykerb), in 2007.  Despite these advances, some patients progress through therapy and succumb to their disease.  A variation on antibody-targeted therapy is utilization of antibodies to deliver cytotoxic agents specifically to antigen-expressing tumors.  We detd. in vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymg. agents) conjugates using disulfide and thioether linkers.  Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured normal and tumor cells.  In vivo activity was detd. in mouse breast cancer models, and toxicity was assessed in rats as measured by body wt. loss.  Surprisingly, trastuzumab linked to DM1 through a nonreducible thioether linkage (SMCC), displayed superior activity compared with unconjugated trastuzumab or trastuzumab linked to other maytansinoids through disulfide linkers.  Serum concns. of trastuzumab-MCC-DM1 remained elevated compared with other conjugates, and toxicity in rats was negligible compared with free DM1 or trastuzumab linked to DM1 through a reducible linker.  Potent activity was obsd. on all HER2-overexpressing tumor cells, whereas nontransformed cells and tumor cell lines with normal HER2 expression were unaffected.  In addn., trastuzumab-DM1 was active on HER2-overexpressing, trastuzumab-refractory tumors.  In summary, trastuzumab-DM1 shows greater activity compared with nonconjugated trastuzumab while maintaining selectivity for HER2-overexpressing tumor cells.  Because trastuzumab linked to DM1 through a nonreducible linker offers improved efficacy and pharmacokinetics and reduced toxicity over the reducible disulfide linkers evaluated, trastuzumab-MCC-DM1 was selected for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpP5fkJnRorrVg90H21EOLACvtfcHk0li1VZDNAd9lYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK&md5=e86e8687d5f8884f8e28514299dcbbf1</span></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%2BT.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-Positive%2520Breast%2520Cancer%2520with%2520Trastuzumab-DM1%252C%2520an%2520Antibody-Cytotoxic%2520Drug%2520Conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D22%26spage%3D9280%26epage%3D9290%26doi%3D10.1158%2F0008-5472.CAN-08-1776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref271"><div class="reference"><strong class="refLabel"><a href="#ref271" class="rightTabRefNumLink">271</a></strong><div class="NLM_citation" id="rightTab-cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, E. L.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Development of Brentuximab Vedotin for Use in Relapsed Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1038/nbt.2289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnbt.2289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=22781692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFCqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=631-637&issue=7&author=P.+D.+Senterauthor=E.+L.+Sievers&title=The+Discovery+and+Development+of+Brentuximab+Vedotin+for+Use+in+Relapsed+Hodgkin+Lymphoma+and+Systemic+Anaplastic+Large+Cell+Lymphoma&doi=10.1038%2Fnbt.2289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma</span></div><div class="casAuthors">Senter, Peter D.; Sievers, Eric L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">631-637</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Progress was made recently in developing antibody-drug conjugates (ADCs) that can selectively deliver cancer drugs to tumor cells.  In principle, the idea is simple: by attaching drugs to tumor-seeking antibodies, target cells will be killed and nontarget cells will be spared.  In practice, many parameters needed to be addressed to develop safe and effective ADCs, including the expression profiles of tumor vs. normal tissues, the potency of the drug, the linker attaching the drug and placement of the drug on the antibody, and the pharmacokinetic and stability profiles of the resulting ADC.  All these issues had been taken into account in developing brentuximab vedotin (Adcetris), an ADC that recently received accelerated approval by the US Food and Drug Administration for the treatment of relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).  Research is under way to extend the applications of brentuximab vedotin and to advance the field by developing other ADCs with new linker and conjugation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyPib6JxGsSrVg90H21EOLACvtfcHk0li1VZDNAd9lYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFCqtbw%253D&md5=6940eb8178e8c8c150a7b21361e23234</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2289%26sid%3Dliteratum%253Aachs%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DSievers%26aufirst%3DE.%2BL.%26atitle%3DThe%2520Discovery%2520and%2520Development%2520of%2520Brentuximab%2520Vedotin%2520for%2520Use%2520in%2520Relapsed%2520Hodgkin%2520Lymphoma%2520and%2520Systemic%2520Anaplastic%2520Large%2520Cell%2520Lymphoma%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26issue%3D7%26spage%3D631%26epage%3D637%26doi%3D10.1038%2Fnbt.2289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref272"><div class="reference"><strong class="refLabel"><a href="#ref272" class="rightTabRefNumLink">272</a></strong><div class="NLM_citation" id="rightTab-cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T.
K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneekloth, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stulberg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundberg, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holley, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Hydrophobic Tagging-Induced Degradation of Halotag Fusion Proteins</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1038/nchembio.597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnchembio.597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=21725302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlCmtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=538-548&author=T.%0AK.+Neklesaauthor=H.+S.+Taeauthor=A.+R.+Schneeklothauthor=M.+J.+Stulbergauthor=T.+W.+Corsonauthor=T.+B.+Sundbergauthor=K.+Rainaauthor=S.+A.+Holleyauthor=C.+M.+Crews&title=Small-Molecule+Hydrophobic+Tagging-Induced+Degradation+of+Halotag+Fusion+Proteins&doi=10.1038%2Fnchembio.597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit272R"><div class="casContent"><span class="casTitleNuber">272</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins</span></div><div class="casAuthors">Neklesa, Taavi K.; Tae, Hyun Seop; Schneekloth, Ashley R.; Stulberg, Michael J.; Corson, Timothy W.; Sundberg, Thomas B.; Raina, Kanak; Holley, Scott A.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">538-543</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ability to regulate any protein of interest in living systems with small mols. remains a challenge.  The authors hypothesized that appending a hydrophobic moiety to the surface of a protein would mimic the partially denatured state of the protein, thus engaging the cellular quality control machinery to induce its proteasomal degrdn.  The authors designed and synthesized bifunctional small mols. to bind a bacterial dehalogenase (the HaloTag protein) and present a hydrophobic group on its surface.  Hydrophobic tagging of the HaloTag protein with an adamantyl moiety induced the degrdn. of cytosolic, isoprenylated and transmembrane HaloTag fusion proteins in cell culture.  The authors demonstrated the in vivo utility of hydrophobic tagging by degrading proteins expressed in zebrafish embryos and by inhibiting Hras1G12V-driven tumor progression in mice.  Therefore, hydrophobic tagging of HaloTag fusion proteins affords small-mol. control over any protein of interest, making it an ideal system for validating potential drug targets in disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYZYbwqzwXZ7Vg90H21EOLACvtfcHk0lh_BqR2TyKMug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlCmtL0%253D&md5=1f358f7900884f91a1ac6f1a51664952</span></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.597%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DTae%26aufirst%3DH.%2BS.%26aulast%3DSchneekloth%26aufirst%3DA.%2BR.%26aulast%3DStulberg%26aufirst%3DM.%2BJ.%26aulast%3DCorson%26aufirst%3DT.%2BW.%26aulast%3DSundberg%26aufirst%3DT.%2BB.%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DHolley%26aufirst%3DS.%2BA.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DSmall-Molecule%2520Hydrophobic%2520Tagging-Induced%2520Degradation%2520of%2520Halotag%2520Fusion%2520Proteins%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D538%26epage%3D548%26doi%3D10.1038%2Fnchembio.597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref273"><div class="reference"><strong class="refLabel"><a href="#ref273" class="rightTabRefNumLink">273</a></strong><div class="NLM_citation" id="rightTab-cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcdonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for an Unexpected Mode of Serm-Mediated Er Antagonism</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1016%2Fj.molcel.2005.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=15893725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=413-424&issue=4&author=Y.+L.+Wuauthor=X.+Yangauthor=Z.+Renauthor=D.+P.+Mcdonnellauthor=J.+D.+Norrisauthor=T.+M.+Willsonauthor=G.+L.+Greene&title=Structural+Basis+for+an+Unexpected+Mode+of+Serm-Mediated+Er+Antagonism&doi=10.1016%2Fj.molcel.2005.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span></div><div class="casAuthors">Wu, Ya-Ling; Yang, Xiaojing; Ren, Zhong; McDonnell, Donald P.; Norris, John D.; Willson, Timothy M.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-424</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tamoxifen is effective for the prevention and treatment of estrogen-dependent breast cancers, but is assocd. with an increased incidence of endometrial tumors.  The authors report the crystal structure of the estrogen receptor α (ERα) ligand binding domain (LBD) bound to the structurally similar compd. GW5638, which has therapeutic potential and does not stimulate the uterus.  Like tamoxifen, GW5638 relocates the carboxy-terminal helix (H12) to the known coactivator-docking site in the ERα LBD.  However, GW5638 repositions residues in H12 through specific contacts with the N terminus of this helix.  In contrast to tamoxifen, the resulting increase in exposed hydrophobic surface of ERα LBD correlates with a significant destabilization of ERα in MCF-7 cells.  Thus, the GW5638-ERα LBD structure reveals an unexpected mode of SERM-mediated ER antagonism, in which the stability of ERα is decreased through an altered position of H12.  This dual mechanism of antagonism may explain why GW5638 can inhibit tamoxifen-resistant breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBuyhLNSdbQbVg90H21EOLACvtfcHk0lh_BqR2TyKMug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D&md5=c60e01b31b57c07b934da01a34efb255</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DMcdonnell%26aufirst%3DD.%2BP.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DStructural%2520Basis%2520for%2520an%2520Unexpected%2520Mode%2520of%2520Serm-Mediated%2520Er%2520Antagonism%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26issue%3D4%26spage%3D413%26epage%3D424%26doi%3D10.1016%2Fj.molcel.2005.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref274"><div class="reference"><strong class="refLabel"><a href="#ref274" class="rightTabRefNumLink">274</a></strong><div class="NLM_citation" id="rightTab-cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cyrus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">Two-Headed Protac: An Effective New Tool for Targeted Protein Degradation</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1531</span>– <span class="NLM_lpage">1534</span>, <span class="refDoi"> DOI: 10.1002/cbic.201000222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1002%2Fcbic.201000222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=20572252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Cksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1531-1534&issue=11&author=K.+Cyrusauthor=M.+Wehenkelauthor=E.+Y.+Choiauthor=H.+Swansonauthor=K.+B.+Kim&title=Two-Headed+Protac%3A+An+Effective+New+Tool+for+Targeted+Protein+Degradation&doi=10.1002%2Fcbic.201000222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">Two-Headed PROTAC: an Effective New Tool for Targeted Protein Degradation</span></div><div class="casAuthors">Cyrus, Kedra; Wehenkel, Marie; Choi, Eun-Young; Swanson, Hollie; Kim, Kyung-Bo</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1531-1534</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system (UPS) is the principle conduit for protein turnover in all eukaryotic cells.  Exploiting the UPS, the authors and others have developed a novel class of small mols., the PROTACs (proteolysis targeting chimeric) mols., designed to induce ubiquitination and degrdn. of targeted proteins.  A new class of PROTACs reported herein use a chimeric mol. that consists of two estradiol ligands linked to a von Hippel-Lindau (pVHL) E3 ubiquitin ligase-recognition motif-targeting pentapeptide.  Because the PROTAC functions as a bridging mol. that promotes the recruitment of a target protein to an E3 ligase complex, the authors envisioned that the introduction of two ligands might recruit the binding protein to an E3 ubiquitin ligase more effectively than the one-ligand PROTAC system.  The authors' proof-of-concept study clearly showed that the two-headed PROTAC gives superior estrogen receptor (ER) degrdn. to one-headed PROTACs.  The two-headed PROTAC also provides improved binding affinity between the PROTAC and the ER.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqznfcen3kCYbVg90H21EOLACvtfcHk0lh_BqR2TyKMug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Cksr8%253D&md5=ecbb816d417627eacdfdf1fe6a79f4e6</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201000222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201000222%26sid%3Dliteratum%253Aachs%26aulast%3DCyrus%26aufirst%3DK.%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DE.%2BY.%26aulast%3DSwanson%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DTwo-Headed%2520Protac%253A%2520An%2520Effective%2520New%2520Tool%2520for%2520Targeted%2520Protein%2520Degradation%26jtitle%3DChemBioChem%26date%3D2010%26volume%3D11%26issue%3D11%26spage%3D1531%26epage%3D1534%26doi%3D10.1002%2Fcbic.201000222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref275"><div class="reference"><strong class="refLabel"><a href="#ref275" class="rightTabRefNumLink">275</a></strong><div class="NLM_citation" id="rightTab-cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced Protein Degradation: An Emerging Drug Discovery Paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&issue=2&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+Protein+Degradation%3A+An+Emerging+Drug+Discovery+Paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0lhvGjC4Aj4usw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520Protein%2520Degradation%253A%2520An%2520Emerging%2520Drug%2520Discovery%2520Paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D2%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i97"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00017">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_47722"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00017">10.1021/acs.jmedchem.9b00017</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Name, indication, MW, cLogP, PSA, HBA, HBD, RB, number of heteroatoms, and clinical phase of 117 MTDLs on market or in clinical trails (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00017/suppl_file/jm9b00017_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00017/suppl_file/jm9b00017_si_002.pdf">jm9b00017_si_002.pdf (778.3 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00017%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-20%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00017" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667983ab298c2495","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
